École des Hautes Études en Sciences Sociales

École doctorale de l'EHESS

Centre d'Analyse et de Mathématique sociales

Thèse de doctorat
Discipline : Mathématiques et informatique

IMKE MAYER

Causal inference from heterogeneous data with missing data – Application to critical care management

Inférence causale à partir de données hétérogènes avec données manquantes – Application à la prise en charge de patients polytraumatisés graves

Thèse dirigée par : Jean-Pierre Nadal et Julie Josse
Date de soutenance : 20 septembre 2021

Rapporteurs	1	James CARPENTER, London School of Hygiene and Tropical Medicine
	2	Romain PIRRACCHIO, University of California San Francisco
Examinateurs	3	Tobias GAUSS, Hôpitaux Universitaires Paris Nord Val de Seine
	4	Fabrizia MEALLI, Università di Firenze
	5	Raphaël PORCHER, Université de Paris
	6	Elizabeth A. STUART, Johns Hopkins Bloomberg School of Public Health

Remerciements

Comment trouver les mots justes et n'oublier personne pour récapituler ces trois dernières années passées si vite ? Comment exprimer en quelques lignes toute la gratitude que j'ai pour les personnes qui m'ont accompagnée et soutenue de tant de manières ? Voici une tentative de réponse à ces questions :

Mes premiers mots sont évidemment pour Julie, Jean-Pierre et Tobias qui ont initié cette belle aventure. Pour le sujet passionnant que vous avez proposé, pour la confiance que vous m'avez accordée et pour votre complémentarité, merci. Arriver à jongler entre théorie et pratique tout en conciliant trois lieux, trois équipes et trois perspectives différentes peut paraître difficile mais grâce à vous et votre encadrement, vos conseils, cela fut un plaisir et une expérience stimulante tout au long de ces trois années. Julie, je te remercie pour ton encadrement exceptionnel, pour l'enseignement scientifique, pour tes conseils à tous les niveaux, scientifiques et humains. Ta curiosité pour des problèmes statistiques et ton élan pour te lancer dans une multitude de projets appliqués n'ont de cesse de susciter mon admiration. Merci pour ton implication et ta disponibilité constantes, choses qui sont si rares qu'on ne me croyait pas toujours quand je racontais mon expérience doctorale ; je n'ai eu vent de directeurs ou de directrices de thèse plus dévoué·e·s à leurs étudiant·e·s que tu ne l'as été : des rendez-vous à l'X, à l'IHP, à l'EHESS, ou encore sur le chemin entre le plateau de Palaiseau et Denfert. Mais au-delà de ta rigueur scientifique, de ton gout de l'esthétisme et des vins et de ton sens de l'organisation, j'ai été particulièrement touchée par l'attention humaine que tu portes à tes doctorants et doctorantes. Enfin, ta considération pour la cause des femmes et des groupes marginalisés en sciences ainsi que ta vision des interactions entre recherche en entreprise et monde académique ont su créer une atmosphère bienveillante, inspirante et propice au travail. Je n'aurais pu rêver d'un environnement doctoral plus stimulant et je sais que tu y es pour beaucoup. Jean-Pierre, merci d'avoir apporté la dimension des systèmes complexes et des notions difficiles à formaliser mais indispensable à la compréhension et à l'exploitation des données, notamment de la Traumabase. Je reste impressionnée par l'ampleur de ton expérience et tes connaissances à l'interface des diverses disciplines, et surtout par le recul que tu portes sur les problématiques de modélisation mathématique de la données et sa collecte. Je te remercie par ailleurs pour le précieux soutien moral et pratique que tu m'as apporté depuis notre première rencontre (virtuelle, et ce en 2018 !) et qui m'a permis de me sentir au bon endroit dans une école de sciences sociales et humaines, à première vue loin de mon parcours et de mon sujet de thèse. Tobias, enfin, le dernier ingrédient, et non des moindres, du trio d'exception, merci pour ton enthousiasme et ta persévérance pour notre projet et pour avoir suivi nos longs développements statistiques que tu as non seulement pris le temps d'écouter et de comprendre mais que tu as ensuite partagé avec enthousiasme avec tes collègues. Merci pour m'avoir montré la complexité et l'aspect concret et humain derrière les données que j'ai pu analyser encore et encore ces dernières années. Sans ta perspective et celle de tes collègues sur ces données, je n'aurais pu retenir que la dimension méthodologique et l'omniprésence des données manquantes.

Au-delà de ce trio exceptionnel il y a eu tant de personnes qui m'ont soutenue et accompagnée durant ces années de thèse et je m'excuse de l'ordre peut-être erratique dont j'essaie de leur adresser ma reconnaissance.

Je tiens à adresser ma plus sincère gratitude à mes rapporteurs de thèse, Romain Pirracchio et James Carpenter. Romain, je suis très honorée que vous ayiez accepté d'être mon rapporteur, votre expérience ainsi que votre expertise ne pourraient être plus adaptées à mon sujet de thèse. I am very honoured, James, that you have agreed to be my reporter and I sincerely thank you. I would also like to thank Elizabeth Stuart, Fabrizia Mealli, Raphaël Porcher and Tobias Gauss for having agreed to be part of my defense jury. It is an honor to have you all united in my jury. d'avoir accept´e de faire partie de mon jury. Mélanie Prague et Arnak Dalalyan, je vous remercie pour votre engagement en tant que membre de mon comité de suivi de thèse, pour vos encouragements à mi-parcours et votre écoute du début jusqu'à la fin.

Stefan Wager, merci de m'avoir amenée sur le chemin des forêts aléatoires généralisés ; ce premier projet de ma thèse et qui a abouti à ma première publication scientifique m'a appris tellement d'aspects sur le plan théorique et pratique, et ceci aussi grâce à l'engagement de ta femme

Julie Tibshirani qui, en puisant dans son rare temps libre, a su nous donner des conseils pratiques et indispensable à la mise en pratique de notre méthodologie. A few words in English now : Even though global events have thrown a wrench in our plans, I am very grateful to you, Stefan, and to Nigam Shah for your hospitality and your invitation to join your research teams at Stanford for a few months. The two short weeks at Stanford that this venture has turned into have given me a taste of what we may be able to catch up on at a later date ; thank you Alison Callahan and Steve Yadlowsky for welcoming me into Nigam's team and thank you Xinkun Nie for sharing your ideas for future projects on the R-learner with me and thank you Erik Sverdrup for your fast and professional integration of MIA into the grf package ; I hope we will have the opportunity to meet more properly and maybe even work together (again) in the future, at Stanford or elsewhere.

Ma thèse n'aurait eu de contenu important sans l'enjeu et les données du groupe Traumabase et je remercie le comité scientifique pour avoir soutenu les projets que j'ai pu mener sur ce registre riche et complexe, et je remercie tous les médecins et techniciens qui sont à la base de la collecte de ces données précieuses. En particulier, je tiens à remercie Sophie Hamada pour avoir eu cette idée et vision d'un tel registre il y a dix ans maintenant avec Tobias ; Jean-Denis Moyer pour ta patience et ton enthousiasme à m'expliquer encore et encore les phénomènes et hypothèses complexes avec lesquelles vous travaillez jour après jour ; Aliénor Dreyfus pour les longues sessions de travail qui ne paraissaient pas si longues que ça au final et qui nous ont permis de comprendre mutuellement nos recherches doctorales ; Manuel Pichon pour ta double expertise et ton don de traducteur entre les disciplines. Enfin je remercie François-Xavier Ageron et Ian Roberts pour leur motivation à entamer un projet encore plus ambitieux : la combinaison de la Traumabase des des études CRASH ; merci FX pour ta patience à discuter avec nous des enjeux et défis d'une telle étude combinée.

Depuis les premiers mois de mon doctorat j'ai eu la chance de travailler avec Nathalie Vialaneix et Nick Tierney sur le projet R-miss-tastic. Thanks Nick for having initiated this great project together with Julie and for welcoming me into your team. Merci Nathalie pour tous tes conseils, ta disponibilité malgré toutes tes obligations, notamment en 2019 quand tu étais l'organisatrice de useR ! à Toulouse. Merci pour cette immense conférence, ma première grande conférence internationale et dont je garde de très beaux souvenirs. Je tiens aussi à remercier tous les participants et contributeurs au projet R-miss-tastic qui nous ont rejoint en cours de route, François Husson, Pavlo Mozharovskyi, Steffen Moritz et surtout Aude Sportisse, merci d'avoir poussé le projet si loin !

Surtout pendant ma deuxième année de thèse ai-je eu l'occasion de découvrir un environnement de travail bien différent des laboratoires universitaires : les journées passées dans les locaux de Google à travailler avec Jean-Philippe Vert et Félix Raimundo ont été une occasion unique. Merci à vous deux pour l'accueil chaleureux quasi hebdomadaire. Merci JP pour ta patience durant nos longues discussions autour des auto-encodeurs et des confondeurs latents et merci beaucoup pour ton engagement dans le processus de sélection du fellowship, sans ta ténacité je ne me serais certainement pas retrouvée dans les fellows de 2020. Again, back to English now : Shu Yang, I would like to thank you for your wonderful initiative of creating a working group on missing values in causal inference at the SAMSI meeting 2019. It was an honor to work with you and your students and colleagues and without you, our review project wouldn't even have started. Thank you Gaël Varoquaux, Jean-Philippe, Awa Dieng, Ruohong Li, Guanhua Chan and in particular Bénédicte Colnet for such a smooth and enriching collaboration.

Un projet particulier dans un contexte particulier : merci Emilie Sbidian et Étienne Audureau de m'avoir accueillie dans votre projet ambitieux et important sur le HCQ. C'était un honneur pour moi de participer à ce projet intense, de discuter avec vous, avec Marc Lavielle, Guillaume Lemaitre et Gaël des différents enjeux et problématiques à adresser.

Une collaboration qui a été annoncée très tôt dans mon doctorat et qui l'a enrichi : je remercie toute l'équipe du projet Data4Good de Capgemini Invent pour avoir accompagné et poussé le projet TrauMatrix, en particulier merci à Julien Sauvan pour toujours avoir réagi à mes questions et demandes sur la Traumabase depuis le tout début du projet.

Comme dit au tout début déjà, j'ai été accueillie dans plusieurs labos en parallèle et tous me manqueront après ma thèse : merci à toute l'équipe du CAMS, Sandrine Nadal, Nathalie Brusseaux, Francesca Aceto, pour votre gentillesse et flexibilité, notamment à Sandrine qui, tard le soir de chez elle, a trouvé une place dans un des derniers vols de San Francisco en Europe au début

de la pandémie. Merci à François Deloche, Julien Brasseur, Charles Ladmiral, Federico Bertoni, Luca Rossi, Laurent Bonasse-Gahot, Elisa Affili et Elisa Sovrano pour les innombrables déjeuners conviviaux à l'EHESS et aux alentours. Merci à toute l'équipe du CMAP, Nasséra Naar, Alex Noiret, Maud Cadiz-Pena, pour votre accueil même en l'absence prolongée d'une convention formelle d'accueil entre l'X et l'EHESS. Merci aux doctorants et doctorantes du bureau 20.15 avec qui j'ai pu partager des bons moments, à la cantine et pendant les pauses cafés : Aude, Fred Logé, Rémi Besson, Corentin Caillaud et Corentin Houpert. Jaouad Mourtada qui n'était pas dans ce bureau mais que j'ai retrouvé à plusieurs conférences en 2019, merci pour les discussions intéressantes et diverses jusque tard dans la nuit à Nancy et à Fréjus. Merci également aux membres de la commission parité et égalité professionnelle pour les discussions et réflexions importantes et intéressantes. Merci Karim Lounici et Katia Meziani pour l'accueil dans votre équipe d'enseignement du cours de régression, c'était un plaisir et une belle expérience pour moi de faire partie de votre équipe et et de voir à quel point les amitiés du temps du doctorat peuvent être durables et productives. Je n'ai jamais officiellement fait partie de l'équipe Parietal mais je m'y suis toujours sentie bienvenue grâce à Bertrand Thirion, Gaël et Thomas Moreau. Un accueil chaleureux m'a également été donné à l'ESSEC grâce à Olga Klopp, merci pour les invitations à ton séminaire, sans toi je n'aurais pas pu rencontrer Don Rubin en personne.

Tout au long de ma thèse j'avais la chance de faire partie, d'abord du bureau élargi, ensuite du bureau élu, du groupe Jeunes de la SFdS. Merci beaucoup à tous les membres, anciens et actuels, pour les nombreuses réunions et évènements, en présentiel jusqu'en janvier 2020 et virtuel depuis ce temps-là. C'était un énorme plaisir d'organiser les YSP d'abord avec Geneviève Robin, Margaux Brégère et Fred, et ensuite avec Margaux et Marie Chion, malgré tous les défis externes que nous avons rencontrés pendant ces organisations (travaux à l'IHP, grèves, pandémie, ...) ; et l'organisation des déjeuners scientifiques avec Margot Selosse et Arthur Leroy qui était un exercice facile grâce à notre équipe parfaite. En parlant de l'IHP, je souhaite remercie toute l'équipe de la Fondation Sciences Mathématiques de Paris, et en particulier Kevin Ledocq, pour leur effort et soutien pour la candidature et ensuite la gestion de la bourse Google.

Et comme ma dernière année de thèse s'est principalement déroulée en télé-travail, il y a quelques personnes que je n'ai pas pu rencontrer en personne mais avec qui j'ai l'impression d'avoir travaillé déjà depuis longtemps : merci à Michael Blum et Talia Lliteras chez Owkin et à Raphaël Porcher pour l'accueil dans votre équipe d'organisation de votre workshop avec Julie ; merci encore à Raphaël et son équipe à l'Inserm, en particulier François Petit et François Grolleau pour l'initiative du séminaire sur les DTR. Affronter le défi des DTR ensemble a facilité l'entrée dans ce domaine et j'espère que nous arrivons un jour à l'organiser en présentiel à Paris et à nous rencontrer sans avoir besoin d'écrans entre nous.

Un certain nombre de personnes ne m'ont pas directement accompagnée durant ma thèse mais sans elles je ne serais même pas arrivée à entamer cette aventure : merci à tous mes profs, chargés de TD-TP à l'UPMC et en particulier à Arnaud Guyader, Maxime Sangnier et Claire Boyer d'avoir fait naître mon enthousiasme pour la statistique et ma compréhension de la diversité de ses applications, de m'avoir introduit à la recherche et la communauté statistiques parisienne pendant mon stage d'été avec vous, de m'avoir encouragée à poser ma candidature au MVA, chose que je n'aurais pas osé sans vos encouragements. Merci à l'équipe d'enseignement du master MVA et en particulier à René Vidal de m'avoir fait découvrir la richesse de l'ACP généralisée et de m'avoir donné la chance de passer un été passionnant et instructif à la JHU à Baltimore.

En recherche, et notamment au cours d'un doctorat, on se retrouve parfois dans des moments difficiles et frustrants, et c'est surtout dans ces moments-là qu'une équipe solidaire et compréhensive est d'une valeur incommensurable : Geneviève, Wei Jiang, Aude, Nicolas Prost, merci pour l'accueil chaleureux dans l'équipe de Julie et au CMAP ; Bénédicte, ma « research buddy », tu as enrichie l'équipe avec ton enthousiasme pour la recherche et surtout l'inférence causale, ton sens de l'organisation, ton goût pour découvrir et rencontrer de nouvelles aventures, je ne peux pas imaginer ma dernière année de thèse sans toi ; Aymeric Dieuleveut, Erwan Scornet, Marine Le Morvan, Judith Abécassis, Costanza Tortu, merci de votre patience avec nous, les jeunes "graduate students", et de votre ouverture à partager vos expériences et vos conseils avec nous ; Paul Roussel, Margaux Zaffran et Pan Zhao, merci d'avoir eu le courage de rejoindre notre équipe sans aucune

rencontre personnelle, je suis impressionnée par la facilité avec laquelle vous vous êtes lancé dans votre doctorat dans des circonstances aussi difficiles. Sans vous tous, ces trois années et surtout ces derniers mois auraient été tellement plus monotones et difficiles à affronter et j'espère fortement trouver de tels collègues et amis dans le futur.

Tout au long de mon parcours, il n'y a pas que les collègues et les encadrants qui ont eu un rôle important dans ma vie. Je pense avant tout à mon entourage familial, je n'aurais jamais pu faire tout cela sans le soutien de ma famille. La certitude que mes parents et mon frère Hanno me soutiennent dans toutes mes décisions et entreprises et qu'ils m'offrent toutes les possibilités de poursuivre mes rêves est d'une valeur inestimable et m'a confortée dès mon entrée à l'école – et avant ça aussi bien-sûr. Merci pour votre soutien inconditionnel à tout instant. Et j'ai toujours pu compter sur le soutien de ma grande famille élargie au fil des ans, même si je n'ai pas pu les voir aussi souvent que je l'aurais souhaité, aussi à cause de mon travail. Au cours des huit dernières années, il y a eu en particulier Sylvie et Michel, que j'ai pu visiter dans tant de coins du monde, merci pour votre chaleur et votre ouverture. Lori, sans ton aide vers la fin, la lecture de ce manuscrit serait bien moins agréable. Merci d'avoir accepté de lire mon travail de ces dernières années dans un délai aussi court. Et comment aurais-je fait face à toutes ces années sans mes amis, proches ou lointains ? Merci Sara, Marisa, Anastasia, Regina, Maritchu, Luise pour les courts et longs moments d'amitié irremplaçable que nous avons partagés au fil des ans, sur place ou au téléphone. Und jetzt auch noch einmal auf Deutsch : Auf meinem bisherigen Weg haben natürlich nicht nur meine Kollegen und Betreuer eine wichtige Rolle in meinem Leben gespielt. Ich denke da zuallererst an meine Familie, ohne deren Unterstützung ich das alles nicht geschafft hätte. Das Wissen, dass meine Eltern und mein Bruder Hanno mich in all meinen Entscheidungen und Bestrebungen unterstützen und mir alle Möglichkeiten bieten, meine Träume und Ziele zu verfolgen, ist von unschätzbarem Wert für mich und hat mich seit meinem Schuleintritt – und auch schon davor – bestärkt und begleitet. Ich danke Euch für Eure konstante und bedingungslose Unterstützung und Ermutigung. Und auch auf die Unterstützung von meiner größeren Familie konnte ich in all den Jahren immer zählen, auch wenn ich sie in dieser Zeit, auch wegen meiner Arbeit, nicht so oft sehen konnte, wie ich es mir manchmal gewünscht hätte. In den vergangenen fast acht Jahren waren da Sylvie und Michel, die ich in so vielen Ecken der Welt besuchen durfte, danke für eure Herzlichkeit und Offenheit. Lori, ohne deine Hilfe am Ende läse sich dieses Manuskript nur holprig, danke, dass du so kurzfristig die Aufgabe angenommen hast, meine Arbeit der letzten Jahre zu lesen. Und wie hätte ich all die Jahre ohne meine Freunde – nah und fern – überstanden ? Danke Sara, Marisa, Anastasia, Regina, Maritchu, Luise für die kurzen und langen Momente der unersetzbaren Freundschaft in den letzten Jahren, die wir in verschiedensten Formen geteilt haben.

Et enfin, mes derniers mots vont à Victor, tu m'as soutenue et supportée dès le début, dès mon début à Paris, merci pour ta confiance, ton soutien inestimable, les longues heures au téléphone et dans les trains durant ces trois dernières années, merci pour tout ce que nous partageons et qui ne regarde que nous. Avec toi le temps passe si vite et même cette thèse n'était qu'un court chapitre sur notre chemin.

Résumé

Le problème des données manquantes est inévitable dans la pratique statistique, la plupart des méthodes d'analyse ne peuvent être mises en œuvre directement à partir de données incomplètes. Ce domaine est en pleine expansion au sein de la communauté statistique, car le problème des valeurs manquantes est exacerbé par la multiplicité des données collectées, souvent à partir de diverses sources d'information. Il est donc crucial d'identifier des méthodologies efficaces pour effectuer des analyses (causales) en présence de données incomplètes, et de savoir quel degré de confiance accorder aux résultats obtenus à partir de données incomplètes.

L'objectif de cette thèse est de proposer de nouvelles méthodes dans le contexte de l'inférence causale, adaptées à certains des défis des processus modernes de collecte de données, à savoir les données manquantes et l'hétérogénéité ; et de développer des méthodologies pratiques adaptées pour évaluer des questions d'intérêt médical et d'apporter un support à la prise de décision dans un contexte de contraintes de temps et de ressources, comme c'est le cas par exemple dans la prise en charge de patients polytraumatisés graves. Nous adoptons l'approche de l'inférence causale pour relever ces défis. La théorie et les méthodologies d'estimation d'effets de traitement sont bien comprises dans le cas d'études expérimentales, c'est-à-dire dans les essais contrôlés randomisés, l'"étalon-or" pour évaluer des effets de traitement ou d'intervention. Cependant, il existe toujours un manque de résultats et de méthodologies d'inférence causale largement appliqués pour les études observationnelles. Cela peut s'expliquer en partie par le contraste qui subsiste entre les résultats existants et leur applicabilité à des problèmes concrets et à des données provenant de divers domaines. Un facteur clé qui peut expliquer cette sous-représentation des études observationnelles dans les analyses causales est l'écart entre le cadre statistique classique et les données collectées qui ne correspondent pas toujours au premier.

Les contributions de cette thèse se composent de trois parties principales. Dans la première partie, nous considérons le cas des valeurs manquantes dans les études observationnelles et leur impact sur les analyses causales, à savoir les problèmes d'identifiabilité et d'estimation. Nous proposons d'intégrer explicitement les valeurs manquantes dans le cadre classique d'inférence causale, permettant de définir des hypothèses d'identifiabilité d'effets de traitement en présence de valeurs manquantes et nous dérivons une approche d'estimation générique et flexible s'appuyant sur les résultats récents des statistiques semi-paramétriques. Dans la deuxième partie, nous considérons un autre ensemble de problèmes, qui se posent dans le cas de la disponibilité simultanée d'études expérimentales et observationnelles pour la même question d'intérêt ; la question de savoir comment relier ces études et comment tirer parti de leurs avantages respectifs et surmonter leurs inconvénients est un sujet de recherche étudié par divers domaines, des sciences sociales et économiques aux sciences biomédicales et pharmaceutiques, et elle intéresse également la communauté de l'apprentissage machine. Nous passons en revue l'état de l'art sur la question de savoir comment généraliser les résultats des études expérimentales à des populations plus pertinentes. Nous abordons ensuite la question de savoir comment ces résultats et méthodes sont affectés par la présence de valeurs manquantes dans l'une ou l'autre des sources de données et nous proposons des stratégies d'estimation. Enfin, un objectif important de cette thèse étant son application à un contexte médical et à d'autres domaines pertinents, la troisième partie de ce manuscrit se concentre sur l'application concrète et la communication de ces méthodologies et sur leur mise en œuvre, rendue accessible à un large public avec des implémentations et tutoriels open-source.

Mots clé : analyse de données, apprentissage statistique, analyse d'effet de traitement, traumatologie

Abstract

The problem of missing data is unavoidable in statistical practice, most analysis methods cannot be implemented directly from incomplete data. This domain is expanding rapidly within the statistical community, as the problem of missing data is exacerbated by the multiplicity of data collected, often from different sources of information. It is therefore crucial to identify effective methodologies for carrying out (causal) analyses in the presence of incomplete data, and to know how much confidence can be placed in the results obtained from incomplete data.

The subject of this dissertation is to propose new methods in the context of causal inference, adapted to some of the challenges of modern data collection processes, namely missingness and heterogeneity ; and to develop practical methodologies suited to assess questions of medical relevance and support decision making in a context of time and resource constraints, as it is the case for instance in critical care management.

We take the perspective of causal inference and treatment effect estimation to address these challenges. Theory and methodologies for treatment effect estimation are well understood especially in the experimental study case, i.e., in randomized controlled trials, the *gold standard* to assess treatment and intervention effects. However, for observational data causal inference methods and results are not widely applied, the number of successful and accepted examples in applied domains still remain quite low currently and only cover few domains of science. Because classical statistical frameworks can only derive limited causal knowledge from observational data without access to treatment randomization, observational studies are rarely considered acceptable as a valid tool for analyzing causality. Additionally, other challenges that arise in practice, limit the leveraging of observational data. For instance the presence of missing values does not only lead to violations of underlying data generating assumptions, it also leads to practical limitations that make it difficult to (implicitly) ignore such missing values, especially in the era of "big data" and high-dimensional data.

The contributions of this thesis consist of three main parts. The first part covers the case of missing values in observational studies and their impact on causal analyses, namely identifiability and estimation issues. We propose to explicitly integrate the missing values in the classical causal inference framework, allowing to define identifiability assumptions of treatment effects in the presence of missing values and we provide a generic and flexible estimation approach leveraging recent results from semi-parametric statistics. In the second part we consider a different set of problems, arising in the case of simultaneous availability of experimental and observational studies for the same question of interest ; the issue of how to relate such studies, how to leverage their respective advantages and how to overcome their shortcomings is a relevant research topic studied by various fields, ranging from social and economic sciences, to biomedical and pharmaceutical research, as well as among the broad computer science community. We begin by reviewing the current state of the art addressing the question of how to generalize or transport results from experimental studies to more representative and general populations. We then address the question of how these results and methods are altered by the presence of missing values in either data source. To generalize effects of any treatment in such cases, we propose an estimation strategy that is based on multiple imputations. Finally, the third part of this manuscript focuses on utilization : We describe the concrete application, communication and implementation of the developed methodologies to critical care management and other relevant fields. Necessary code resources and instructional tutorials are made available as open source material.

Keywords : data analysis, statistical learning, treatment effect analysis, critical care management

Table des matières
Table of contents

Table des figures

Liste des tableaux

Première partie

L'apport de l'inférence causale pour une meilleure compréhension de données observationnelles

Introduction

La science des données au service de la société

La nécessité d'extraire des informations à partir de données biologiques, cliniques et épidémiologiques dans un contexte de santé publique fut plus que jamais démontrée dans le contexte de la pandémie de COVID-19, encore d'actualité en 2021. Bien qu'elle fussent rare au début de la situation pandémique, les informations fiables sur le virus SARS-CoV-2 restaient essentielles pour les responsables politiques qui devaient prendre des décisions rapides aux niveaux régional, national et international pour contenir la propagation du virus et limiter les dégâts humains et économiques. La fiabilité de ces informations nécessitait une évaluation de la qualité des données sous-jacentes aux preuves présentées ainsi que des plans d'étude et d'autres critères d'évaluation habituels. C'est grâce à de telles évaluations [Park et al., 2021] qu'une multitude d'études ont pu être mises en causes. Il n'entre pas dans le cadre de cette brève introduction de passer en revue ces critères d'évaluation dans toute leur diversité et complexité, mais nous abordons brièvement quelques aspects clés qui ont également motivé le travail qui a conduit à la présente thèse. Par exemple, la concordance entre l'objectif d'une étude, son plan d'analyse et les données analysées constitue un défi pour la réalisation et l'évaluation d'une étude, que ce soit dans un contexte clinique ou en sciences sociales et humaines. Si une problématique scientifique peut être formulée au préalable et que le temps et les ressources (financières) permettent de concevoir un protocole adapté pour la collecte bien surveillée et l'analyse des données, la question d'intérêt formulée en amont peut généralement être adressée sur la base des données collectées [Fisher, 1936, Saporta, 2006]. Cependant, il arrive que des données soient collectées en dehors d'un plan d'étude bien défini. Par exemple, les dossiers médicaux électroniques (ou dans un tout autre contexte, des informations sur les utilisateurs de sites web) sont généralement collectés sans qu'une problématique de recherche précise ne motive directement cette collecte. L'exploitation de telles données, potentiellement riches en informations, présente un défi pour de multiples raisons. En effet, la structure des données peut être complexe de par le fait qu'elle est composée de différents types de données (numériques, textuelles, d'imagerie, etc.). Les données peuvent par ailleurs être incomplètes, en raison d'échecs de collecte ou de différences locales dans le processus de collecte. Enfin, notons que dans ce contexte les données sont analysées *a posteriori* et qu'il est donc nécessaire d'évaluer d'abord si une question de recherche peut trouver une réponse *a posteriori*. S'il ne convient pas de mener une étude rétrospective ad-hoc, alors des ajustements des outils d'analyse ou des manipulations des données sont nécessaires. Cette thèse est motivée par

de telles analyses de données rétrospectives dans le contexte clinique. Malgré les avancées technologiques permettant une collecte de plus en plus systématique de données issues des dossiers médicaux électroniques, les outils d'analyse classiques ne sont pas nécessairement adaptés pour extraire des informations pertinentes de ces données. L'objectif général du projet interdisciplinaire dans lequel s'inscrit cette thèse est donc l'exploration et l'exploitation de l'information riche contenue dans les données collectées dans le domaine de la santé. De tels projets n'ont pas vocation à se substituer à la prise de décision humaine mais à accompagner les cliniciens et les professionnels pour créer une synergie. En effet, l'apport majeur des outils classiques de statistique ou des outils plus avancés et des algorithmes d'apprentissage machine est l'exploration et l'exploitation des données, assistant la prise de décision dans un contexte de santé publique ou de pratique clinique. Si ce manuscrit se focalise sur le contexte de la prise en charge de patients avec un traumatisme grave (voir plus bas pour une définition détaillée), les solutions apportées durant cette thèse sont transposables à d'autres contextes, au-delà des problématiques cliniques. Le projet interdisciplinaire en question, dont les différents sous-projets sont regroupés sous le nom de "TrauMatrix", a pour objectif de développer des solutions intégrant l'expertise du domaine, les données d'un grand registre national, ainsi que le contexte particulier d'un nouveau patient, et qui sont intégrées dans les routine des 24 premières heures de la prise en charge. Le "produit" final, également nommé *TrauMatrix*, sera une plate-forme adaptative de gestion de l'information fournissant une aide à la décision ergonomique et en temps réel à un large éventail de cliniciens. *TrauMatrix* utilisera des outils statistiques avancés et des algorithmes d'apprentissage automatique, dont certains ont été développés au cours de cette thèse, et les articulera avec les recommandations cliniques existantes afin d'améliorer la prise de décision par les cliniciens. La plate-forme rationalisera le processus de soins pour le centrer sur le patient et facilitera le partage d'informations entre tous les professionnels concernés (répartiteurs, infirmières, anesthésistes, radiologues, chirurgiens, spécialistes des banques de sang, etc.). Un aperçu du principe et des étapes d'application de cette plate-forme est donné dans la Figure 1. Les différentes étapes suivent la prise en charge d'un patient avec un traumatisme grave à partir de l'appel aux urgences jusqu'à la prise en charge en soin en réanimation à l'hôpital.



FIGURE 1 – Étapes d'application de la plate-forme de support à la prise de décision en traumatologie, la *TrauMatrix* (figure en anglais). [1].

Les défis de la traumatologie

Un traumatisme grave (ou sévère) est défini comme toute blessure qui met en danger la vie ou l'intégrité fonctionnelle d'une personne. Les traumatismes graves, dans leurs diverses manifestations – des accidents de la route, jusqu'à la violence interpersonnelle, en passant par l'automutilation jusqu'aux chutes –, sont source importante de mortalité et de handicap, et constituent un enjeu majeur de santé publique [Hay et al., 2017]. Une prise en charge efficace des patients est cruciale et c'est pourquoi selon la gravité évaluée sur le lieu de l'accident – par les médecins, les urgentistes, les pompiers, ... –, les patients sont envoyés soit vers un centre spécialisé, l'un des "Trauma Centers", soit un hôpital généraliste. Un tel aiguillage est critique car les conséquences peuvent être extrêmement graves pour un patient envoyé à tort vers un hôpital généraliste où il ne pourra pas être traité efficacement – on parle alors de sous-triage – et devra être renvoyé vers un *Trauma Center*. Inversement, un patient envoyé à tort vers un *Trauma Center* mobilisera toute une équipe médicale pluridisciplinaire et une salle d'opération – il s'agit d'un sur-triage – mettant en attente le patient suivant, le plus grand risque étant alors pour ce dernier. De même, certaines décisions d'interventions médicales sont délicates à prendre, mais doivent être prises dans l'urgence. L'expérience montre qu'une prise en charge rapide de tout traumatisme grave fondée sur des protocoles normalisés améliore les résultats fonctionnels et la survie. Ce résultat est vrai en particulier pour les deux principales causes de décès dans les traumatismes graves, c'est-à-dire les hémorragies et les traumatismes crâniens [Hamada et al., 2015]. Le parcours classique d'un patient traumatisé se déroule en plusieurs étapes : du lieu de l'accident où le patient est pris en charge par l'ambulance, au transfert vers une unité de soins intensifs (USI) pour des interventions immédiates, et enfin aux soins complets à l'hôpital. Or pour

1. Source : Traumabase Group [2012, accessed on 2021-04-07].

être efficaces, les protocoles de gestion des patients exigent des ajustements au contexte individuel du patient et au contexte clinique, d'une part, et au contexte organisationnel et au système de traumatologie, d'autre part [Rice et al., 2012]. Cependant, les statistiques montrent que la prise en charge des patients, même dans les centres de traumatologie les plus en pointe, dépasse souvent les délais acceptables [Hamada et al., 2014] et des écarts par rapport aux soins attendus selon le protocole sont souvent observés [Rice et al., 2012]. Ces écarts entraînent une grande variabilité des soins [Hamada et al., 2015] et sont associés à de mauvais résultats tels qu'un contrôle inadéquat de l'hémorragie ou un retard de transfusion. Deux facteurs principaux expliquent ces observations. D'une part, la prise de décision en traumatologie est particulièrement exigeante, car elle exige des décisions rapides et complexes sous pression temporelle dans un environnement très dynamique et multi-acteurs caractérisé par des niveaux élevés d'incertitude et de stress. D'autre part, le processus de prise en charge impliquant plusieurs acteurs est fragilisé par les risques de pertes d'information ou de malentendus [deMattos et al., 2012].

La Traumabase® : opportunités et défis

La Traumabase® est un registre observationnel français pour les patients souffrant de traumatismes majeurs, initié par les docteurs Sophie Hamada et Tobias Gauss en 2010 [Raux et al., 2012]. Limité à ses débuts aux patients admis dans un seul hôpital (l'hôpital Beaujon, Clichy, France), il s'est rapidement étendu pour devenir un registre multicentrique, comptant tous les centres hospitaliers spécialisés dans l'admission de patients souffrant de traumatismes majeurs ainsi que les centres hospitaliers ordinaires. [2] Tout patient admis dans un centre hospitalier participant et présentant au moins un des critères de gravité suivants est inclus dans la Traumabase® : présence des critères de Vittel, activation des services mobiles d'urgence et de réanimation (*SMUR*), activation d'une équipe de réanimation en traumatologie majeure, traitement en soins intensifs [Hamada, 2019].

La Traumabase® a été initiée pour de multiples raisons, tant d'intérêt sanitaire que scientifique. Comme mentionné dans l'introduction, les traumatismes graves désignent les blessures qui entraînent un handicap permanent ou menacent la vie d'une personne. La difficulté de la gestion des soins critiques des patients souffrant de traumatismes majeurs réside dans la multitude simultanée d'agents impliqués sur différents lieux et de blessures subies, le tout interagissant dans un laps de temps court de quelques heures seulement. Un traumatisé grave est généralement transféré en ambulance du lieu de l'accident vers une unité de soins intensifs (USI). Cette dernière est choisie par un centre de coordination en fonction de la gravité du patient et de la nécessité attendue de ressources spécialisées telles que la neurochirurgie, c'est ce qu'on appelle également le *triage*. Une fois arrivé à l'unité de soins intensifs, l'état du patient est stabilisé par une équipe de réanimation spécialisée (consistant souvent en une transfusion sanguine massive et un contrôle temporaire des hémorragies) et une liste de toutes les blessures est établie à l'aide de l'imagerie médicale. Le défi

2. Dans la terminologie officielle, il s'agit encore d'un *observatoire* et non d'un *registre* national car il attend la validation du comité national des registres français.

réside dans la réduction des délais pour chaque étape : triage, transport, stabilisation et diagnostic, et dans le choix optimal de la prise en charge des différentes blessures. En effet, une mauvaise priorisation peut conduire à la perte du patient ou à un pronostic à long terme aggravé. Dans ce contexte, plusieurs objectifs peuvent être visés pour améliorer la prise en charge des patients victimes de traumatismes graves. Grâce à sa structure et à sa granularité, uniques pour un registre en soins intensifs en Europe, la Traumabase® permet d'aborder diverses questions de soins de santé, de communication entre les centres participants, de surveillance de la santé par les institutions de réglementation sanitaire, et d'intérêt scientifique ; par exemple pour l'évaluation de la qualité et amélioration des pratiques standard dans la gestion des soins intensifs et des soins aux patients [Hamada et al., 2015]). Une multitude d'études cliniques observationnelles ont été réalisées sur ce registre, voir Traumabase Group [2012, accessed on 2021-04-07] pour une liste exhaustive des résultats scientifiques basés sur la Traumabase®. Le registre a également servi à l'établissement de modèles prédictifs aidant les praticiens à évaluer le risque pour un patient de développer un choc hémorragique[3], soit sur la base d'un score "fait à la main" [Hamada et al., 2018], soit à l'aide d'un modèle prédictif automatisé [Jiang et al., 2020].

La Traumabase® offre donc une opportunité unique de recherche et de collaboration transdisciplinaire réunissant des compétences mathématiques, méthodologiques, technologiques, cognitives et médicales afin de concevoir des solutions méthodologiques innovantes pour répondre à des défis complexes et améliorer les soins aux patients.

Cependant, la Traumabase®, comme toute base de données, présente des particularités qui rendent son exploitation et analyse plus difficiles et qui requierent des méthodologies adaptées. Nous allons détailler deux aspects majeurs qui ont été particulièrement étudiés durant cette thèse, soit l'hétérogénéité des sources et des données et les valeurs manquantes. L'ensemble de ces caractéristiques se retrouvent rarement simultanément dans des problèmes d'analyse de données, et la difficulté que représentent les données manquantes est particulièrement importante dans le contexte de cette thèse comme nous allons voir dans les parties suivantes de ce manuscrit.

Données multi-sources et hétérogènes

La Traumabase® est une base de données multi-sources : d'une part, pour chaque patient, les données le concernant sont renseignées par différents acteurs au cours de la prise en charge, d'autre part la base rassemble des collectes issues de différents hôpitaux aux pratiques différentes. De plus, les types d'accidents rencontrés, et les populations couvertes par ces hôpitaux contribuent également à des hétérogénéités dans les données. Enfin, les informations sur le suivi et le traitement, ainsi que les données médicales et épidémiologiques sont de types variés, avec des variables pouvant être qualitatives, catégorielles, quantitatives.

3. Le choc hémorragique est la principale cause de décès précoce évitable en cas de traumatisme grave ; sa définition n'est pas unanime mais il peut être décrit comme une hémorragie grave nécessitant une transfusion sanguine importante [Hamada et al., 2018].

Il est à noter que toutes ces caractéristiques multiples sont susceptibles d'évoluer au cours du temps. Des décalages dans la distribution de ces caractéristiques sont à prendre en compte dans la modélisation de ces données et la formalisation des problèmes d'estimation, un problème abordé plus formellement dans la Partie IV de ce manuscrit.

Données incomplètes

La Traumabase® se caractérise aussi par une fraction importante de données manquantes : certaines données sont absentes alors qu'elles auraient dues être renseignées, d'autres parce que non pertinentes dans le contexte précis du patient considéré. Dans la Figure 2, nous représentons les proportions de valeurs manquantes pour un sous-ensemble des variables de la Traumabase®.



FIGURE 2 – Proportions de valeurs manquantes pour un sous-ensemble de variables de la Traumabase®, les différents encodages des valeurs manquantes sont représentés par des codes couleurs.

Certaines de ces absences sont probablement dues à des absences non informatives, par exemple, l'omission par le personnel médical de renseigner certains chiffres. Toutefois, dans d'autres cas, les valeurs manquantes sont informatives ; les cliniciens qui ont conçu cette base de données ont fait le choix de définir plusieurs "codes" différents pour décrire les valeurs manquantes, allant de "non effectuées" et "non applicables" à "impossibles". Cette dernière dénomination apparaît, par exemple dans le cas de mesures de la pression artérielle de patients en arrêt cardiaque ou avec démembrement, car les premiers intervenants ne peuvent tout simplement pas

mesurer la pression artérielle des patients souffrant de l'une de ces deux conditions. Par ailleurs, les variables indiquant la réponse à un certain médicament, comme la contraction de la pupille après osmothérapie (l'administration d'une solution saline), prennent systématiquement la valeur "non applicable" si le traitement n'a pas été administré (ce dernier est renseigné dans une variable séparée), il s'agit alors d'une valeur qui n'est pas vraiment manquante.

L'importance d'une recherche interdisciplinaire

La complexité du problème qui a motivé la création de la Traumabase® représente également un défi pour ceux et celles qui travaillent sur ces données. En effet, la variété des mesures et des facteurs renseignés, leurs interactions, l'ordre chronologique partiel, etc. contiennent des informations riches mais constituent également un défi lors de l'utilisation et de l'analyse des données de la Traumabase®, à commencer par une appréhension précise de la signification des différentes variables et de leur contexte de collecte. Au cours de la période initiale de cette thèse, nous avons consacré du temps à cette dernière tâche, c'est-à-dire comprendre ce que chaque variable représente en pratique chez le patient et pour les cliniciens, et avec quel degré d'incertitude elle est collectée. Une phase importante dans la période initiale de cette thèse a donc été un stage d'observation de deux jours accompagnant l'équipe d'anesthésie-réanimation de l'hôpital Beaujon. Les acquis de ce stage ainsi que des discussions intenses sur la structure des données de la Traumabase® avec des anesthésistes-réanimateurs de plusieurs hôpitaux de l'AP–HP nous ont permis de construire une représentation graphique de l'ensemble de la structure de la Traumabase®. L'objectif de ce graphique était de créer une vue d'ensemble des informations potentiellement disponibles et une base commune de discussion pour les éventuelles interactions entre variables, confirmées ou à explorer. Cette représentation a été établie en étroite collaboration avec les initiateurs du projet Traumabase®.

Un aperçu de la représentation graphique est fourni dans la Figure 3. Une version lisible sous forme de gros plans consécutifs est donnée en Annexe B (en anglais). Il existe deux types de nœuds dans le graphe, désignant soit des traitements/mesures thérapeutiques, soit des observations/diagnostics. Dans ce dernier cas, deux sous-ensembles liés à la condition de traumatisme crânien et à la condition de choc hémorragique sont mis en évidence (respectivement en bleu et en rouge). Le graphe contient des arêtes dirigées et non dirigées. Les arêtes non dirigées définissent des corrélations connues entre les variables mais sans spécifier de relation causale. Au sein des arêtes dirigées, quatre types sont définis :

— les relations déterministes (par exemple, l'indice de masse corporelle (IMC) est une fonction déterministe de la taille et du poids) ;
— les corrélations temporelles entre les mesures, prises de manière répétée dans le temps (par exemple, la pression artérielle prise dans l'ambulance est corrélée à la pression artérielle prise après l'admission dans la salle de réanimation) ;
— les critères/directives établis qui influencent les décisions de traitement (par exemple, une transfusion de globules rouges est effectuée en cas de suspicion d'hémorragie) ;

— les objectifs du traitement (par exemple, la craniectomie décompressive vise à ramener la pression intracrânienne à un niveau normal).

La Figure 4 contient la légende du graphe, décrivant les différents types d'arêtes.



FIGURE 3 – Aperçu de la représentation graphique de la Traumabase®.



FIGURE 4 – Légende de la représentation graphique de la Traumabase®.

De plus, une chronologie indicative au bas du graphique permet une classification approximative des variables en périodes pré-hospitalière, de réanimation, chirurgicale et de soins intensifs.

Pour une meilleure compréhension des informations encodées dans le graphe, nous fournissons une vue rapprochée de la Figure 3 qui se concentre sur les variables liées aux traumatismes crâniens, le traumatisme d'intérêt particulier dans cette thèse, pendant la phase pré-hospitalière et jusqu'à l'admission à l'hôpital. Tous les types de nœuds et d'arêtes expliqués dans la légende de la Figure 4 sont présents sur cette vue rapprochée montrée dans la Figure 5. Comme nous l'avons dit précédemment, ce graphique ne doit pas être compris comme représentant des structures causales (voir la Section 1.3 du Chapitre 1) mais comme représentant les pratiques courantes et les observations des cliniciens sur les relations entre certains groupes de variables. Par exemple, le nœud *Mydriase* au milieu à gauche de la Figure 5 représente la présence d'une anomalie de la réactivité de la pupille et cette anomalie entre comme critère dans une échelle neurologique qui vise à évaluer la conscience d'une personne, l'échelle de coma de Glasgow. Parallèlement, la mydriase sert d'indicateur pour la nécessité d'un traitement par osmothérapie, représenté sur le graphique par le nœud *Mannitol.SSH* à droite du nœud *Mydriase*. Ce petit exemple illustre le type d'informations encodées dans ce graphe. [4] Il s'agit d'une tentative de résumer une grande quantité

4. Une partie restante qui n'a pas pu être renseignée sur ce graphique est une indication de l'incertitude ou de la marge d'erreur attendue pour chaque variable, en raison des contraintes de temps, des transferts entre différents agents, ou d'autres causes d'incertitude. Une telle information serait très utile, par exemple pour le développement de modèles de prédiction des risques basés sur des données.

d'informations sur la pratique clinique courante et les connaissances scientifiques acquises par le biais d'études cliniques, servant de base à une communication fluide et transparente entre les cliniciens et les statisticiens travaillant avec cet ensemble de données. En effet, tout au long de cette thèse, la communication et collaboration avec les cliniciens a été une composante importante du travail qui a mené aux résultats présentés dans ce manuscrit.



FIGURE 5 – Vue rapprochée de la représentation graphique de la Traumabase®, centrée sur les mesures et traitements pré-hospitaliers jusqu'à l'admission à l'hôpital.

Corrélation et causalité

Une leçon apprise à tout élève suivant un cours de statistique est la phrase suivante : *La corrélation n'est pas de la causalité.* Cette leçon, de par sa simplicité et par son presque-statut de mantra en statistique, est généralement retenue à la fin d'un tel cours. Néanmoins, la simple observation que les êtres humains apprennent et raisonnent en terme de causalité tout au cours de leurs vies, explique peut-être la volonté générale et souvent inconsciente de vouloir interpréter des phénomènes de corrélation comme des preuves de liens causaux [Pearl and Mackenzie, 2018]. Là réside un dilemme constant des statistiques : les cadres et formalisations ont été conçus dans une logique probabiliste, i.e., exploitant des associations entre variables afin d'inférer des charactéristiques de distributions probabilistes. Cependant l'application de ces méthodes est souvent motivée par la volonté de comprendre les mécanismes d'un phénomène (physique, biologique, social, etc.) observé en passant par une modélisation de ce phénomène et ensuite une interprétation des paramètres de ce modèle en terme de vrais mécanismes sous-jacents du phénomène. Tant qu'il ne s'agit que de décrire un système ou phénomène dans son présent état, cette approche est généralement justifiable. En revanche, si l'objectif est d'exploiter cette description afin de prédire des changements ou réaction du système à une intervention, l'approche statistique classique atteint ses limites. La distinction parfois vaguement perçue entre

la notion statistique d'effets causaux et le concept commun intuitif de causalité peut conduire à des interprétations erronées. Il est donc crucial de commencer par formuler clairement la question qui nous intéresse, afin d'établir un plan d'analyse statistique et d'interpréter les résultats en conséquence [Glymour and Hamad, 2018].

En pratique, ces questions "causale" se posent dans de nombreux domaines tels que la socio-économie, la politique, la psychologie, la médecine, etc., et sont de la forme : *"étant donné les circonstances, quelle action devrait être entreprise pour atteindre un certain objectif"*. Répondre à une telle question nécessite une compréhension suffisante du système ou du mécanisme sous-jacent, permettant au décideur d'évaluer l'effet de sa décision sur le système. Ainsi, de telles questions peuvent être reformulées en *"Que se passerait-il si je prenais une action A au lieu d'une action B (ou C) ?"* ou *"comment le système changerait-il si j'intervenais sur une certaine partie de celui-ci ?"*. L'action peut être l'administration d'un médicament et son effet sur la santé du patient, ou une stratégie marketing de placement de produit et son effet sur le comportement d'achat du consommateur, etc. Comme énoncé au début de ce paragraphe, la notion de causalité est souvent évitée par les statisticiens. Ceci n'empêche pas toujours des personnes d'interpréter des résultats d'études statistiques comme causaux même s'il n'y a pas lieu ; ce problème de fausses interprétations d'études non causales en terme de causalité est discuté par Hernán [2018]. Pour être plus concret, donnons l'exemple connu de la corrélation très forte entre la consommation de chocolat et le nombre de lauréats du prix Nobel par pays [Messerli, 2012]. Ce lien est visualisé sur la Figure 6.



FIGURE 6 – Corrélation entre la consommation annuelle de chocolat par habitant et nombre de lauréats du prix Nobel pour 10 millions d'habitants par pays. Cette Figure correspond à la Figure 1 de Messerli [2012].

Malgré cette forte corrélation observée, il est évident que la consommation de chocolat n'a pas d'effet *direct* sur le nombre de lauréats du prix Nobel. Il semble

plus pertinent d'expliquer cette corrélation à travers de facteurs confondants qui expliquent à la fois la quantité de chocolat consommée et les distinctions scientifiques d'un pays, par exemple le niveau de richesse d'un pays, le PIB par habitant, etc. Afin de vérifier s'il y a un lien direct entre la consommation annuelle de chocolat et le nombre de lauréats du prix Nobel, il faudrait avoir un moyen d'intervenir sur la consommation de chocolat de façon à randomiser la quantité consommée, ce qui est évidemment impossible.

La notion de causalité et sa définition plutôt vague peuvent ne pas convenir et sont souvent remplacées par les termes d'inférence causale ou d'estimation de l'effet du traitement [Hernán and Robins, 2020], qui intéressent les statisticiens depuis près d'un siècle maintenant, depuis que Fisher [1936] a formalisé le concept de randomisation du traitement et Splawa-Neyman et al. [1929] le concept de résultats contrefactuels ou potentiels. Le formalisme de l'inférence causale permet d'étudier des questions comme celle présentée ci-dessus comme un problème d'estimation commun. Il faut être prudent lorsqu'on raisonne en termes de causalité, car on peut être capable d'estimer l'effet d'un facteur sur un autre, mais cela n'explique pas la causalité elle-même.

Une fois que nous avons une compréhension des relations causales entre les variables, nous pouvons essayer d'utiliser cette connaissance pour faire des prédictions "stables", par exemple des prescriptions de traitement, par opposition aux prédictions ordinaires obtenues avec des algorithmes d'apprentissage (supervisé) appliqués directement sur les données et qui risquent de tirer parti de relations éphémères pour faire des prédictions [Efron, 2020, Subbaswamy and Saria, 2018]. En effet, l'inférence probabiliste se concentre sur la prédiction des conséquences des observations en modélisant la distribution des données. L'inférence causale modélise le mécanisme qui génère les données et permet de prédire les résultats des interventions. Cependant, Holland [1986] souligne le problème fondamental de l'inférence causale : nous voulons estimer quelque chose que nous n'observons jamais puisque nous ne voyons jamais les contrefactuels pour un même individu à un même moment (induits par différents traitements ou politiques).

Malgré ce problème fondamental, il existe une multitude de méthodes bien étudiées pour estimer de manière efficace et consistante les effets causaux dans différents scénarios, motivées par une longue tradition en économie, épidémiologie et politique publique où des décisions raisonnables et justifiées doivent être prises dans des situations jamais vécues. Dans ce qui suit, nous passerons en revue les approches les plus courantes et les mieux établies, en discutant leurs hypothèses et en soulignant leurs avantages et leurs limites, en théorie et en pratique.

Objectifs et structure de la thèse

L'objectif de cette thèse est double : proposer de nouveaux outils d'analyse de données dans le contexte de l'inférence causale, adaptés à certains des défis des processus modernes de collecte de données, à savoir les manques et l'hétérogénéité ; et développer des méthodologies pratiques adaptées à l'évaluation de questions de pertinence médicale et à l'aide à la prise de décision dans un contexte de contraintes de temps et de ressources, comme c'est le cas par exemple dans la gestion des soins intensifs. Bien que la théorie et les méthodologies existantes en matière d'inférence causale soient abondantes et en plein essor malgré l'âge relativement jeune de cette discipline, un fossé subsiste entre ces résultats et leur utilisation dans de nombreux domaines d'application. Cet écart peut s'expliquer par plusieurs facteurs, par exemple le rythme auquel de nouvelles méthodologies sont développées, en particulier ces dernières années avec le concept de double apprentissage automatique dans les travaux séminaux de Robins et al. [1994] et Chernozhukov et al. [2018a] encourageant l'utilisation de méthodes modernes d'apprentissage statistique plus complexes pour aborder les problèmes de causalité [par exemple, Shi et al., 2019, Louizos et al., 2017, Nie and Wager, 2017]. Cependant, un facteur clé réside dans l'écart entre le(s) cadre(s) statistique(s) classique(s) et les données collectées qui ne correspondent pas toujours - ou seulement partiellement - au premier. Un facteur limitant connexe pour l'utilisation de ces méthodologies concerne les implémentations qui permettent souvent des performances étonnantes sous les hypothèses théoriques correctes sur le processus de génération de données mais qui parfois ne parviennent même pas à produire un résultat sur des données qui divergent légèrement de ces hypothèses ; par exemple la présence de valeurs manquantes produit une erreur d'exécution ou la suppression silencieuse de toutes les observations incomplètes peut conduire à d'autres violations des hypothèses nécessaires.

Les contributions de cette thèse peuvent être regroupées en trois parties principales : (i) de nouvelles méthodologies d'inférence causale pour des données d'observation incomplètes, (ii) des méthodologies d'inférence causale pour des données d'observation et expérimentales combinées, et (iii) l'application et l'implémentation en accès public des méthodes présentées dans deux premières parties pour une dissémination plus large de ces approches dans des domaines variés.

Inférence causale sur données observationnelles incomplètes

L'objectif de la thèse a été, dans un premier temps, de développer une méthodologie dite "doublement robuste" [Robins et al., 1994, Chernozhukov et al., 2018a] adaptée aux données manquantes pour l'estimation de l'effet moyen du traitement. Ce travail, publié dans *The Annals of Applied Statistics*, constitue une contribution théorique et méthodologique aux communautés intéressées par l'inférence causale en raison des impacts de biais importants induits par les analyses de cas complets ou les modèles d'imputation mal spécifiés [Mattei and Mealli, 2009]. En effet, la nouvelle méthodologie, placée dans le cadre des résultats potentiels de Neyman-Rubin [Splawa-Neyman et al., 1929, Rubin, 1974], non seulement étend l'approche

double robuste aux données manquantes, mais permet également de gérer les données manquantes informatives, telles que les "données manquantes non aléatoirement" [MNAR Seaman et al., 2013, Franks et al., 2016]. Une variable est MNAR si la probabilité d'absence de cette variable dépend de la valeur de la variable elle-même. L'exemple classique est l'information sur le "revenu" : les personnes riches sont moins susceptibles de divulguer leur revenu, ce qui entraîne un manque de données sur le revenu des personnes riches. Dans le contexte de la gestion des traumatismes majeurs, il est admis par les praticiens qu'une grande partie des données manquantes est susceptible d'entrer dans cette catégorie de valeurs manquantes.

Inférence causale sur données observationnelles et expérimentales combinées

Une question connexe à celle motivant la première partie de cette thèse et qui s'est posée au cours de cette thèse concerne la disponibilité simultanée de données expérimentales et observationnelles pour estimer un effet de traitement. Il s'agit à la fois d'une opportunité et d'un défi statistique : combiner les informations recueillies à partir des deux données est une voie prometteuse pour tirer parti de la validité interne des essais contrôlés randomisés (ECR) et d'une plus grande validité externe des données d'observation. Mais cela soulève des problèmes méthodologiques, notamment en raison des différents plans d'échantillonnage induisant des changements de distribution. Dans deux travaux, l'un soumis à *Journal of Statistical Science*, l'autre au journal *Statistics in Medicine*, nous nous intéressons à l'objectif de transporter un effet causal estimé sur un ECR sur une population cible décrite par un ensemble de covariables. Nous proposons tout d'abord dans le Chapitre 6 une revue approfondie et une évaluation expérimentale des méthodes existantes telles que la pondération par l'inverse de propension, la g-formule et les méthodes doublement robustes. Cependant, ces méthodes disponibles ne sont pas conçues pour traiter les valeurs manquantes, qui sont pourtant courantes dans les deux données. En plus de coupler les hypothèses pour l'identifiabilité causale et pour le mécanisme des valeurs manquantes et de définir des stratégies appropriées, il faut considérer la structure spécifique des données avec deux sources et le traitement et le résultat uniquement disponibles dans l'ECR. Nous étudions dans le Chapitre 7 différentes approches et leurs hypothèses sous-jacentes, dans le cas de données complètes et dans le cas de données incomplètes, sur les processus de génération de données et la distribution des valeurs manquantes et nous suggérons plusieurs méthodes adaptées, en particulier des stratégies d'imputation multiple. Ces méthodes sont évaluées dans une étude de simulation approfondie et des directives pratiques sont fournies pour différents scénarios.

Ce travail a été motivé par l'analyse de la Traumabase® et de deux ECR multicentriques qui ont étudié l'effet de l'administration d'acide tranexamique sur la mortalité. Les analyses illustrent comment les différentes méthodes examinées se comparent sur des données réelles et comment le traitement des valeurs manquantes peut avoir un impact sur la conclusion concernant l'effet transporté de l'ECR à la population cible.

Application et implémentation en accès public des méthodes développés

Nous avons démontré l'applicabilité des nouvelles méthodologies sur des questions concrètes de recherche médicale ouverte : dans le Chapitre 8, nous abordons une question qui s'est posée lors de la très récente et toujours en cours pandémie COVID-19 appelant à proposer et adapter des politiques de santé publique dans un contexte de preuves limitées et en constante évolution. Dans l'Annexe G, nous présentons une étude destinée à un public médical afin de transmettre les principaux concepts des méthodes développées au cours de cette thèse.

Enfin, puisque nous avons annoncé au début de cette introduction que les méthodes proposées au cours de cette thèse, tout en étant motivées par des questions médicales concrètes, sont plus polyvalentes dans leur applicabilité et nous les avons implémentées de manière complète afin de pouvoir facilement transporter et appliquer ces méthodologies dans d'autres contextes tels que les sciences sociales ou les études économiques. Un tutoriel dans le Chapitre 10 guide à travers les différentes étapes de l'analyse, fournissant des recommandations conceptuelles et pratiques sur la façon de déployer les méthodologies proposées dans la pratique, notamment sur le traitement de données manquantes.

Contributions de cette thèse

Articles dans des revues approuvées par des pairs

— Treatment effect estimation with incomplete attributes, I. Mayer, E. Sverdrup, T. Gauss, J.-D. Moyer, S. Wager and J. Josse, *Annals of Applied Statistics*, 2020.

Articles soumis à des revues approuvées par des pairs

— Causal inference methods for combining randomized trials and observational studies : a review, led by Bénédicte Colnet, and in collaboration with Guanhua Chen, Awa Dieng, Ruohong Li, Gaël Varoquaux, Jean-Philippe Vert, Julie Josse, Shu Yang.

— Transporting treatment effects with incomplete attributes, in collaboration with Julie Josse and the Traumabase® Group.

— R-miss-tastic : a unified platform for missing values methods and workflows, in collaboration with Aude Sportisse, Julie Josse, Nathalie Vialaneix, Nicholas Tierney.

— Machine learning augmented causal inference to estimate the treatment effect of Tranexamic Acid in Traumatic Brain Injury, in collaboration with J.-D. Moyer, A. Dreyfus, M. Boutonnet, P-.J. Cungi, A. Foucrier, A. Harrois, A. James, J.-P. Nadal, J. Josse, T. Gauss.

Rapports techniques

— Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection : a cohort study of 4,642 in-patients in France, in collaboration with E. Sbidian, J. Josse, G. Lemaitre, M. Bernaux, A. Gramfort, N. Lapidus, N. Paris, A. Neuraz, I. Lerner, N. Garcelon, B. Rance, O. Grisel, T. Moreau, A. Bellamine, P. Wolkenstein, G. Varoquaux, E. Caumes, M. Lavielle, A. Mekontso Dessap, E. Audureau.

— MissDeepCausal : Causal Inference from Incomplete Data Using Deep Latent Variable Models, initiated by Jean-Philippe Vert and Julie Josse.

Logiciels

— R online platform R-miss-tastic (2019/2020).

Prix et distinctions

— FSMP pre-doctoral research visit scholarship for four-months visit at Stanford University (2020).

— Google PhD fellowship (2020).

Chapitre 1
Analyse causale de données

L'augmentation des données disponibles pour les analyses statistiques et les modèles pronostiques s'accompagne d'une diversification des types et des sources de données qui posent de nouveaux défis pour extraire des informations significatives de cette multitude de données disponibles. Pour les questions causales, en un mot, on peut distinguer les données expérimentales avec interventions contrôlées et les données observationnelles sans contrôle d'intervention mais souvent avec une meilleure représentativité des cas d'utilisation réels. [1] Cette préoccupation est également appelée *efficacité* versus *efficience* dans les contextes de politique publique et clinique, où l'efficacité vise à mesurer l'effet du traitement dans des circonstances idéales et contrôlées, tandis que l'effectivité soutient l'idée de mesurer l'effet moyen du traitement dans la population réelle visée par le traitement [Flay, 1986]. Un exemple récent et marquant est celui des études cliniques qui ont précédé l'autorisation des différents vaccins COVID-19, suivies de plusieurs études observationnelles menées dans le cadre des campagnes de vaccination, voir par exemple Dagan et al. [2021].

Plus généralement, dans la recherche sur les soins de santé et les sciences sociales, les études observationnelles (prospectives) sont fréquentes, relativement faciles à mettre en place (contrairement aux études expérimentales d'essais randomisés, qui sont parfois même impossibles à réaliser) et peuvent permettre différents types d'analyses ultérieures telles que les inférences causales. L'estimation de l'effet moyen du traitement (*average treatment effect* en anglais, ATE), par exemple, est possible grâce à l'utilisation de scores de propension qui permettent de corriger les biais d'affectation du traitement dus à la confusion, c'est-à-dire à la présence de facteurs liés à la fois à l'affectation du traitement et à la variable d'intérêt [Rosenbaum and Rubin, 1983b, Imbens and Rubin, 2015]. Le terme "causal" doit être compris de manière spécifique et peut ne pas refléter la compréhension commune de la causalité. En effet, en statistique classique, il est habituel de poser un modèle pour la distribution d'un processus de génération de données. Ensuite, en supposant ce processus de génération de données, le but est de modéliser et d'estimer la distribution, par exemple en supposant qu'il s'agit d'une distribution gaussienne avec une certaine moyenne et covariance. Dans l'inférence causale, l'objectif est plus ambitieux dans la mesure où plusieurs objectifs sont fixés avec un même "modèle causal" : le modèle

1. Pour résumer cette observation en une phrase encore plus courte : "Toutes les données ne sont pas égales" [Neill et al., 2009].

doit s'adapter à la distribution observée, mais il doit également permettre de faire des inférences sur la façon dont le système change en cas d'intervention, c'est-à-dire des inférences sur les distributions d'intervention. Ainsi, par "causal", nous entendons l'effet d'une variable, sur laquelle on intervient, sur une autre variable qui est mesurée soit avant et après l'intervention, soit entre des individus avec et sans intervention.

1.1 – Le cadre des réponses potentielles

Definitions Supposons que nous observons n échantillons indépendants et identiquement distribués (i.i.d.) $(X_i, W_i, Y_i) \in \mathcal{X} \times \{0, 1\} \times \mathbb{R}$, où $|\mathcal{X}| = p$ $X_i = [X_{i1}, \ldots, X_{ip}]^T$ est un vecteur d'attributs, W_i un indicateur d'attribution de traitement [2], et Y_i le résultat d'intérêt. Dans ce qui suit, les espérances et les probabilités feront référence à la distribution induite par l'échantillonnage aléatoire de la population ou par l'attribution aléatoire (conditionnelle) du traitement.

Nous définissons un "effet causal" dans le cadre des réponses potentielles de Neyman-Rubin [Splawa-Neyman et al., 1929, Imbens and Rubin, 2015] qui repose sur les quantités suivantes de réponses *potentielles* ou *contrefactuelles*.

Definition 1.1.1 (Réponses potentielles)**.** *Les réponses potentielles sont désignées par* $\{Y_i(0), Y_i(1)\}$ *et sont définies comme la réponse que le* i*ème individu aurait connue si on lui avait attribué le traitement* $W_i = 0$ *ou* 1 *respectivement. Ils prennent des valeurs dans le même espace* $\mathcal{Y}$*, par exemple* $\mathcal{Y} = \mathbb{R}$ *ou* $\mathcal{Y} = \{0, 1\}$*.*

Pour l'attribution de traitement W_i, nous pouvons penser à *traitement contre contrôle* ou *traitement A contre traitement B*, et à leurs réponses potentielles associées, dans certains cas également appelés contrefactuelles, $Y_i(1)$ et $Y_i(0)$, où le résultat observé est le *réponse factuelle* tandis que le résultat non observé est appelée *réponse contrefactuelle*. Dans la suite de cette thèse, nous ferons référence aux individus ayant $W_i = 1$ comme *traité* et à ceux ayant $W_i = 0$ comme *contrôle*.

Afin d'évaluer l'effet d'un traitement, nous nous intéressons à l'effet individuel du traitement.

Definition 1.1.2 (Effet individuel du traitement)**.** *L'effet individuel du traitement pour un individu* i *correspond à la différence de ses réponses potentielles :*

$$\tau_i \triangleq Y_i(1) - Y_i(0). \tag{1.1}$$

Par définition des réponses potentielles, cette quantité n'est jamais observée. Face à cette impossibilité d'observer la quantité d'intérêt τ_i, d'autres quantités substitutives d'intérêt pour évaluer un effet de traitement sont considérées : les moyennes de τ_i sur différents sous-ensembles de l'échantillon ou de la population d'origine, par exemple l'effet de traitement moyen (*average treatment effect* en anglais, ATE).

2. Dans cette thèse, nous ne considérerons que le cas du traitement binaire. Cependant, il existe diverses approches pour traiter les traitements multinomiaux et continus [Hirano and Imbens, 2004].

Definition 1.1.3 (Effet moyen du traitement)**.** *Nous désignons l'effet moyen du traitement(average treatment effect en anglais, ATE) par τ, et nous le définissons par*

$$\tau \triangleq \mathbb{E}[Y_i(1) - Y_i(0)] = \mathbb{E}[\tau_i], \tag{1.2}$$

où les espérances sont calculées par rapport à la distribution jointe de $(X_i, W_i, Y_i(0), Y_i(1))$.

L'effet moyen du traitement correspond à l'effet du passage de tous les individus d'un groupe de traitement à l'autre.

Identifiabilité Afin d'identifier (de manière non paramétrique) τ, c'est-à-dire de l'exprimer en termes d'informations observables uniquement, nous devons faire d'autres hypothèses sur le processus de génération des données : L'hypothèse de *ignorabilité*, *non-confusion* (*unconfoundedness* en anglais) ou *exogénéité* (les termes sont utilisés de manière égale dans la littérature) stipule que tous les facteurs confondants sont mesurés, c'est-à-dire que, conditionnellement à X, l'attribution du traitement est indépendante des réponses potentielles. En d'autres termes, il n'y a pas de variable confondante non observée U dans la Figure 1.2. Nous la définissons formellement comme suit.

Definition 1.1.4 (Ignorabilité)**.** *L'hypothèse d'ignorabilité stipule que*

$$\{Y_i(1), Y_i(0)\} \perp\!\!\!\perp W_i \,|\, X_i \qquad \textit{pour tout } i. \tag{1.3}$$

Cette hypothèse peut être affaiblie et permet toujours d'identifier $\mathbb{E}[Y_i(w)]$, $w \in \{0, 1\}$; en effet, nous pourrions supposer à la place que nous avons seulement

$$\mathbb{E}[Y_i(w) \,|\, W = w, X] = \mathbb{E}[Y_i(w) \,|\, X], \; w \in \{0, 1\}. \tag{1.4}$$

Cette égalité est impliquée par (1.3) et permet également de résoudre le problème inhérent des valeurs de réponses contrefactuelles manquantes. Cette hypothèse est également connue sous le nom de *aucun biais de variable omise* (*no omitted variable bias* en anglais) en sciences sociales.

Une autre hypothèse standard de l'inférence causale dans le cadre de Neyman-Rubin [Imbens and Rubin, 2015] est l'*hypothèse de la stabilité individuelle de valeur de traitement.* (*stable unit treatment value assumption* en anglais, SUTVA, Rubin [1978b], Cox [1958]).

Definition 1.1.5 (Stabilité individuelle de valeur de traitement)**.** *Formellement, cette hypothèse est composée de deux parties :*

$$Y_i = Y_i(W_i) \tag{1.5}$$
$$Y_i = W_i Y_i(1) + (1 - W_i) Y_i(0). \tag{1.6}$$

Cette hypothèse se traduit par deux aspects : la réponse de l'individu i est indépendante de l'attribution du traitement des autres individus et le traitement est stable, c'est-à-dire qu'il n'existe pas de versions multiples du traitement qui

pourraient conduire à des résultats différents. Par exemple, si le traitement est une chirurgie, nous supposons que le résultat de la chirurgie ne varie pas en fonction du chirurgien qui a opéré le patient.

Enfin, une hypothèse importante est celle de l'attribution probabiliste du traitement (*probabilistic treatment assignment* ou *overlap* en anglais).

Definition 1.1.6 (Score de propension et hypothèse de recouvrement (overlap))**.** *Le score de propension est défini par*

$$e(x) \triangleq \mathbb{P}(W_i = 1 \,|\, X_i = x), \tag{1.7}$$

notion introduite par Rosenbaum and Rubin [1983b], Imbens and Rubin [2015]. Afin d'identifier la quantité causale d'intérêt telle que l'effet moyen du traitement, nous avons besoin d'une attribution probabiliste du traitement, également connue sous le nom d'hypothèse de recouvrement :

$$\exists\, c > 0, \;\; \textit{tel que } c < e(x) < 1 - c \quad \textit{pour tout } x \in \mathcal{X}. \tag{1.8}$$

Un résultat bien connu et important lié à l'hypothèse de non-confusion est que si la condition (1.3) est vérifiée, alors nous avons aussi

$$\{Y_i(1), Y_i(0)\} \perp\!\!\!\perp W_i \,|\, e(X_i) \qquad \text{for all } i, \tag{1.9}$$

ce qui implique qu'au lieu de devoir contrôler toutes les covariables X_i on peut se limiter à contrôler $e(X_i)$ [3]. En effet, ce résultat important a été établi par Rosenbaum and Rubin [1983b] qui montrent que le score de propension est un score équilibrant : il équilibre les deux groupes en termes de distribution des covariables.

$$\mathbb{P}(X, W \,|\, e(X)) = \mathbb{P}(X \,|\, e(X))\mathbb{P}(W \,|\, e(X)). \tag{1.10}$$

Intuitivement, ce résultat peut être compris comme suit : le score de propension contient toute l'information nécessaire pour dissocier les covariables X et l'attribution du traitement W et donc pour équilibrer les distributions des covariables pour chaque niveau de W sans qu'il reste de la confusion.

La preuve de ce résultat tient en quelques lignes :

Démonstration. On commence par noter que

$$\mathbb{P}(X, W \,|\, e(X)) = \mathbb{P}(X \,|\, e(X))\mathbb{P}(W \,|\, X, e(X)) = \mathbb{P}(X \,|\, e(X))\mathbb{P}(W \,|\, X)$$

où la première égalité est toujours valable et la deuxième est impliquée par le fait que $e(X)$ est une fonction de X. Ainsi, conditionner par rapport à X est équivalent à conditioning par rapport à $X, e(X)$. Ensuite nous remarquons que par définition $\mathbb{P}(W = 1 \,|\, X) = e(X)$ et $\mathbb{P}(W = 1 \,|\, e(X)) = \mathbb{E}[W \,|\, e(X)] = \mathbb{E}[\mathbb{E}[W \,|\, X] \,|\, e(X)] = \mathbb{E}[e(X) \,|\, e(X)] = e(X)$, ce qui conclut la preuve. □

3. Ce résultat peut être étendu au traitement multivalué, voir Imbens [2000].



FIGURE 1.1 – Modèle de données observationnelles avec des variables observées (donc pas de variables non observées). Nous sommes intéressés par l'estimation du lien entre W et Y. Le score de propension $e(X)$ rompt (ou ferme) le chemin entre les facteurs confondants X et le traitement W.

1.2 – L'étalon-or : l'essai randomisé contrôlé

Nous distinguons deux types de données : *données expérimentales* issues d'essais contrôlés randomisés (ECR) contrôlés (*randomized controlled trial* en anglais, RCT) où les distributions des covariables avant traitement entre les traités et les contrôles sont identiques et où nous connaissons la loi de la variable aléatoire d'attribution du traitement. En général, cette situation est considérée comme le "gold standard" de l'inférence causale [Hernán and Robins, 2020].

La première expérience documentée qui peut se lire comme le premier essai clinique est due à James Lind (1716-1794), médecin écossais et marin de la *Royal Navy* [Lind, 1772, Baron, 2009]. A travers une randomisation de différents traitements dont il suspectait un lien avec le scorbut, il a pu mettre en évidence un caractère guérissant et préventif de la consommation de citron pour le scorbut. A son époque, le scorbut était la cause de mortalité principale pour les marins, loin devant les batailles navales entre nations ennemies. Une traduction de la publication de Lind sur cette découverte décrit son plan d'expérience :

"*Le 20 mai 1747, j'ai sélectionné douze malades du scorbut, à bord du Salisbury en mer. [...] On en ordonna à deux d'entre eux une pinte de cidre par jour. Deux autres ont pris vingt-cinq gouttes d'élixir de vitriol trois fois par jour [...] Deux autres ont pris deux cuillères de vinaigre trois fois par jour [...] Deux des plus mauvais patients ont été mis sur un cours d'eau de mer [...] Deux autres ont eu chacun deux oranges et un citron qui leur ont été donnés chaque jour [... Deux autres patients ont pris [...] un médicament recommandé par un chirurgien de l'hôpital [...] La conséquence est que les effets bénéfiques les plus soudains et les plus visibles ont été perçus par l'utilisation des oranges et des citrons ; l'un de ceux qui les avaient pris était, au bout de six jours, apte au service.*" [Lind, 1772]

Dans son expérience, Lind a réussi à contourner le problème de confusion des données. En effet, il a "cassé" tous les liens indirects entre les traitements et la variable cible en randomisant l'attribution du traitement. C'est cette randomisation du traitement qui rend l'effet (moyen) du traitement identifiable (cf. la section précédente) car la variation qu'on observe dans la variable cible à travers les différents groupes de traitement est attribuable aux différences de traitement uniquement grâce

à la randomisation.

Pour donner un contre-exemple où cette interprétation "causale" des variations observées au niveau de la variable cible n'est pas permise, rappelons l'exemple donné en introduction sur la consommation de chocolat (Figure 6).

L'avantage et le principal intérêt des études expérimentales est donc le contrôle de l'intervention, garantissant que la seule variation entre les groupes traités et non traités réside dans la variable de traitement. Ainsi, la variation observée dans les résultats peut être reliée au traitement. Une violation de cette distinction claire et unique entre les groupes traités peut conduire à des conclusions erronées sur l'effet du traitement, comme l'illustre le problème donné dans la Figure 6. Un autre exemple classique est l'essai de terrain du vaccin de Salk [Salk, 1955, Brownlee, 1955], un essai randomisé contrôlé à grande échelle en double aveugle avec plus d'un million d'enfants inclus. Dans cet essai, le traitement, c'est-à-dire un vaccin contre la poliomyélite mis au point par Jonas Salk, a été administré aux enfants dont les parents avaient donné la permission de participer à l'essai. En raison de la variabilité géographique et saisonnière des épidémies de polio à cette époque, il était nécessaire de concevoir une étude tenant compte de ces variations et de considérations supplémentaires. Deux schémas ont été initialement proposés, l'un sans randomisation où les individus traités étaient choisis parmi une certaine classe d'école (2e) et sous condition du consentement de leurs parents. Les contrôles étaient des individus de la même classe et sans le consentement des parents, ainsi que des enfants de classes voisines (1ère et 3ème). Le second plan consistait à randomiser le traitement parmi les individus éligibles (2ème année scolaire et avec le consentement des parents) et à fournir un placebo aux individus randomisés dans le contrôle, permettant ainsi une étude en double aveugle éliminant divers types de biais. Les deux plans ont été réalisés et, comme prévu par la théorie et par certains groupes de cliniciens critiques à l'époque, le premier plan a conduit à une conclusion défavorable quant à l'efficacité du vaccin, tandis que le second plan a montré un effet protecteur significatif du vaccin contre l'infection par la polio [Brownlee, 1955]. Cette vaste étude, réalisée moins de 10 ans après le premier essai contrôlé randomisé publié [Medical Research Council Streptomycin in Tuberculosis Trials Committee, 1948], est considérée comme une étape importante dans la systématisation des études randomisées en double aveugle contre placebo pour évaluer un (nouveau) traitement chaque fois que cela est possible.

Cependant, même avec une étude de cette envergure respectant la randomisation de l'affectation des traitements et la conception en double aveugle, il est important de souligner que la validité des conclusions d'une telle étude ne vaut généralement que dans le contexte de cette étude particulière. Autrement dit, dans le cadre de la *validité interne*, les résultats de l'étude ne peuvent pas être directement étendus à d'autres individus que ceux de l'étude, à moins que l'échantillon de l'étude ne soit représentatif d'une population plus large. Dans ce dernier cas, les conclusions de l'étude sont également valables pour cette population. Si la population d'intérêt n'est pas représentée par la population étudiée, la question de la validité externe se pose, c'est-à-dire si la généralisation des résultats empiriques à un environnement, un cadre ou une population différents est possible, généralement sur la base de données d'observation auxiliaires qui décrivent ce contexte différent [Colnet et al., 2020].

Notez que dans tous les cas, la validité externe est limitée par la validité interne ; si une conclusion causale tirée au sein d'une étude n'est pas valide, les généralisations de cette inférence à d'autres contextes le seront également. Cette remarque souligne à nouveau l'importance des deux formes de validité et des deux sources de données pour évaluer l'efficacité et l'efficience d'un traitement.

Estimation d'effet de traitement dans un ECR Supposons que nous disposons des données d'un ECR, c'est-à-dire les hypothèses d'identifiabilité (1.3), (1.5) et (1.7) sont satisfaites. Alors la définition de l'effet moyen du traitement τ (1.2) suggère un estimateur naturel, à savoir l'estimateur par différence de moyennes.

Definition 1.2.1 (Estimateur par différence de moyennes)**.** *Supposons que nous disposons de n observations indépendantes et identiquement distribuées (W_i, Y_i) à valeurs dans $\{0,1\} \times \mathcal{Y}$ et qui satisfons les hypothèse (1.3), (1.7) et (1.5). Nous pouvons définir l'estimateur par différence de moyennes*

$$\hat{\tau}_{DM} = \frac{1}{n_1} \sum_{W_i=1} Y_i - \frac{1}{n_0} \sum_{W_i=0} Y_i, \tag{1.11}$$

où $n_w = |\{i : W_i = w\}|$. Cet estimateur est non-biaisé et consistent pour l'effet moyen du traitement τ.

De plus, il est possible de construire pour cet estimateur des intervalles de confiance Gaussiens valides de τ.

Pour conclure, même si les ECR sont considérées comme étant le "gold standard", notamment en médecine, il a été noté à multiples reprises que certaines questions ne peuvent ou ne nécessitent pas de telles expériences pour prouver la présence d'un certain effet de traitement ou d'intervention [Smith and Pell, 2003]. Cette dernière remarque est une motivation supplémentaire pour porter notre attention sur un autre type de données, les données observationnelles comme nous allons voir par la suite.

1.3 – Une alternative : données observationnelles

Nous venons de voir que malgré leur statut inofficiel d'"étalon-or" [4], les ECR ont l'inconvénient de ne pas toujours être réalisable, pour des raisons éthiques ou financières, et en pratique, ils ont des coûts opérationnels élevés (en terme de ressources financières, humaines, etc.). Une solution à ce problème est l'analyse de données observationnelles, qui sont généralement disponibles en plus grandes quantités à cause du processus de collecte de ces données. En effet, dans la plupart des domaines, par exemple en recherche médicale et en sciences sociales, les études observationnelles (prospectives) sont fréquentes, relativement faciles à mettre en place, contrairement aux ECR, qui sont parfois même impossibles à réaliser. L'estimation de l'effet moyen du traitement (ATE), par exemple, est possible à partir de telles

4. En effet, les autorités de régulation telles la *Food and Drug Administration* aux États-Unis ne reconnaissnet que les ECR comme preuve d'efficacité [Van der Laan and Rose, 2011] avec très peu d'exceptions.

données dans certains cas, à condition que le biais de confusion ou d'attribution du traitement puisse être corrigé.

La confusion est quasi systématique dans les données observationnelles : les groupes traités et les groupes contrôles n'ont généralement pas les mêmes caractéristiques pré-tratiement puisque l'attribution du traitement se fait en fonction de ces caractéristiques et en fonction de l'effet attendu du choix de traitement. Autrement dit, l'attribution du traitement W n'est pas indépendante des covariables X et des réponses potentielles $Y(1)$ et $Y(0)$. La notion de *confusion* décrit le fait que l'affectation du traitement n'est pas aléatoire en raison de la présence de facteurs confondants X qui déterminent à la fois l'attribution du traitement et les réponses potentielless, comme l'illustre la Figure 1.2.



FIGURE 1.2 – Modèle de données observationnelles avec des facteurs confondants observés (X) et non observés (U). Nous sommes intéressés par l'estimation du lien entre W et Y. Nous devons prendre en compte les facteurs confondants, c'est-à-dire les causes communes de W et Y.

Nous présentons un exemple qui illustre comment une confusion non prise en compte peut fausser les analyses causales à partir de données observationnelles. L'exemple suivant est tiré de Charig et al. [1986]. Cette étude s'intéresse à la comparaison de deux traitements du calcul rénal, la chirurgie ouverte (traitement A) et la néphrolithotomie percutanée (traitement B). Chacun des 700 patients inclus est affecté à l'un ou l'autre de ces deux traitements, de sorte que les deux groupes de traitement sont de taille égale, à savoir 350 patients chacun. Un traitement est considéré comme réussi et le patient comme guéri si le calcul est éliminé ou réduit à moins de 2 mm. Les résultats de cette étude sont résumés dans la figure 1.3. Une première analyse a permis de conclure que le traitement B réussit mieux à éliminer les calculs rénaux que le traitement A (Figure 1.3a). Cependant, si l'on prend en compte une variable supplémentaire, à savoir la taille du calcul, cette conclusion doit être corrigée. En effet, d'après la Figure 1.3b, nous pouvons lire que le groupe du traitement A est principalement composé de patients ayant de gros calculs, tandis que le groupe du traitement B est formé principalement de patients ayant de petits calculs. En comparant les taux de guérison pour chaque taille de calcul, nous constatons que le traitement A est plus performant tant pour l'élimination des petits calculs que pour celle des gros calculs. Ces résultats apparemment contradictoires sont un exemple du paradoxe de Simpson. En effet, les investigateurs de l'étude notent que les patients n'ont pas été randomisés dans les deux groupes de traitement mais que le médecin traitant a décidé du traitement en fonction de la taille du calcul rénal. Pour les calculs plus gros, une intervention chirurgicale (traitement A) semble avoir

été préférée plus souvent que la néphrolithotomie percutanée, moins invasive, alors que c'est le contraire pour les calculs plus petits. Ceci peut également être formulé différemment : étant donné qu'un patient i a reçu le traitement A, la probabilité que ce patient ait un gros calcul est plus grande que pour un patient j qui a reçu le traitement B, c'est-à-dire, $P(S = grand|W = A) > P(S = grand|W = B)$, en raison de la "règle" de décision des urologues traitants. La taille du calcul est donc un facteur confondant et, dans cet exemple, son omission entraîne un biais important qui va jusqu'à inverser la conclusion finale sur le traitement préférable.



(a) Analyse confondue



(b) Analyse ajustée

FIGURE 1.3 – Illustration du paradoxe de Simpson : dans cette étude, la taille des calculs rénaux confond le taux de rétablissement dans les différents groupes de traitement. La partie hachurée correspond à la proportion de patients avec élimination des calculs rénaux réussie.

Estimation d'effet de traitement Avec cet exemple de confusion non ajustée à l'esprit, nous allons maintenant passer en revue les estimateurs les plus courants qui ont été proposés dans le passé pour estimer l'effet moyen du traitement à partir de données d'observation. Puisque nous sommes intéressés par l'estimation des effets causaux à partir de données observationnelles, nous ne pouvons pas appliquer les mêmes méthodes que dans le cas d'un ECR, car cela conduirait à des estimations inconsistante dues à la confusion. En effet, on pourrait décrire la différence entre le cas d'un traitement randomisé et celui d'un traitement confondu comme un changement d'orientation et d'effort global consacré à la collecte de données "parfaites" au profit de stratégies d'estimation qui permettent de faire face à des données "imparfaites". L'idée de base des méthodes suivantes est d'émuler un ou plusieurs ECR [Hernán and Robins, 2016], c'est-à-dire que pour un $x \in \mathcal{X}$ donné, nous aimerions estimer $\tau(x) = \mathbb{E}[Y(1) - Y(0)|X = x]$ par une simple estimation comme dans le cas d'un ECR. Pour une revue plus détaillée de la littérature existante sur l'estimation de l'effet de traitement, nous nous référons à Imbens [2004], Lunceford and Davidian [2004].

Appariement L'appariement (*matching* en anglais) est probablement la façon la plus intuitive de traiter la confusion dans les données observationnelles. En adoptant la perspective de Ho et al. [2007], les méthodes d'appariement peuvent être considérées comme des méthodes non paramétriques de prétraitement des données, et donc comme une étape préliminaire possible à l'estimation statistique de l'effet du traitement. Le choix de cette dernière peut cependant être impacté par la méthode d'appariement choisie. Nous renvoyons le lecteur à Iacus et al. [2012], Abadie and Imbens [2016] pour un examen détaillé des méthodes d'appariement existantes (par exemple, l'appariement *exact un à un*, *exact*, *approximatif*, *score de propension*, *exact grossier*). En bref, l'objectif de l'appariement est d'établir l'indépendance entre les covariables X et l'affectation du traitement W, en équilibrant les distributions des covariables dans les deux groupes (sans utiliser la variable de réponse Y). Par exemple, on peut adopter une approche du plus proche voisin, c'est-à-dire qu'étant donné une métrique de distance d et une observation X_i du groupe de traitement w, on recherche l'observation la plus proche X_j avec $W_j \neq w$: $\arg_{\substack{j \in \{1,\dots,n\} \setminus \{i\} \\ W_j \neq W_i}} d(X_i, X_j)$.

Quelle que soit la stratégie d'appariement choisie, la qualité de l'équilibre résultant peut être évaluée par différents moyens. Idéalement, on compare la distribution conjointe des covariables dans les deux groupes après l'appariement, mais cela devient difficile dans des contextes hautement dimensionnels. Dans ce cas, la comparaison de statistiques sommaires telles que les différences de moyenne, les rapports de variance ou la CDF empirique ou différents tests (t, F, Kolmogorov-Smirnov) peut fournir des informations sur l'adéquation de la stratégie d'appariement choisie. Une autre possibilité pour mesurer l'équilibre des covariables est d'utiliser le biais standardisé multivarié introduit par Rosenbaum and Rubin [1985], qui est une mesure sommaire du (dés)équilibre entre toutes les covariables.

Stratification Les méthodes de stratification généralisent l'appariement à des sous-populations. Elles permettent d'apparier des sous-populations dans le groupe traité et le groupe contrôle avec des distributions de covariables similaires. La stratification sur les scores de propension permet non seulement d'équilibrer les groupes traités et les groupes contrôles mais, en conséquence du Rosenbaum and Rubin [1984, Théorème 1], elle permet également d'utiliser des F-tests (sur chaque covariable) pour évaluer approximativement l'adéquation du modèle de propension. Cependant, l'un des inconvénients de la stratification est qu'il existe un potentiel d'hétérogénéité résiduelle au sein des strates, ce qui entraîne des estimations biaisées de l'effet de traitement.

Ajustement de régression Une solution plus directe pour estimer τ peut être de le définir comme paramètre d'un modèle de régression : $\mathbb{E}[Y \mid X, W] = \beta_0 + X\beta_1 + \tau W$. Cependant, comme le souligne Rubin [1979], de tels ajustements de régression sont sensibles à une mauvaise spécification du modèle si les deux groupes diffèrent considérablement au niveau des covariables. Dans un tel cas de recouvrement insuffisant entre le groupe traité et le groupe contrôle, la régression implique une extrapolation du groupe traité et du groupe contrôle dans les différentes régions [Lunceford and Davidian, 2004].

Méthodes de pondération Les méthodes de pondération sont utilisées dans les études d'observation pour estimer l'effet d'un traitement ou d'une intervention mais aussi dans les enquêtes pour estimer la moyenne d'une variable de résultat en présence de non-réponse unitaire et il existe une large littérature sur les méthodes de pondération (voir par exemple Imbens and Rubin [2015], Lunceford and Davidian [2004]). L'objectif de la pondération est double : équilibrer les distributions empiriques des covariables observées (pour éliminer les biais dus aux facteurs de confusion observés ou retrouver la structure observée de la population cible) et produire des estimations stables des paramètres d'intérêt (des poids très importants peuvent trop influencer les résultats et des poids très variables produisent des résultats à forte variance [Little and Rubin, 2019]).

Pondération par inverse de propension Proposé à l'origine par Horvitz and Thompson [1952] dans le cadre de la théorie des enquêtes dans des paramètres finis, l'estimateur de pondération par inverse de propension (*inverse probability of treatment weighting*, IPW) a été redéfini dans un contexte plus général par Rosenbaum [1987]. Il est étroitement lié à l'estimateur de la différence des moyennes mais avec la différence principale que les observations sont pondérées par l'inverse du score de propension (1.7), la probabilité de traitement étant donné les covariables.

En supposant que nous ayons accès à un estimateur $\hat{e}$ du vrai score de propension (1.7), nous définissons l'estimateur IPW comme suit

$$\hat{\tau}_{IPW_0} \triangleq \frac{1}{n}\sum_{i=1}^{n}\frac{W_i Y_i}{\hat{e}(X_i)} - \frac{1}{n}\sum_{i=1}^{n}\frac{(1-W_i)Y_i}{1-\hat{e}(X_i)}. \tag{1.12}$$

En supposant que les estimations du score de propension sont consistantes, cet estimateur $\hat{\tau}_{IPW_0}$ est un estimateur sans biais de l'ATE. En effet, il utilise le fait qu'en vertu des hypothèses d'identifiabilité (1.3) et (1.5), nous avons

$$\mathbb{E}\left[\frac{W_i Y_i}{e(X_i)}\right] = \mathbb{E}\left[\frac{W_i Y_i(1)}{e(X_i)}\right] \tag{1.13}$$

$$= \mathbb{E}\left[\mathbb{E}\left[\frac{\mathbb{1}_{\{W_i=1\}} Y_i(1)}{e(X_i)} | X_i, Y_i(1)\right]\right] \tag{1.14}$$

$$= \mathbb{E}\left[\frac{Y_i(1)}{e(X_i)}\mathbb{E}\left[\mathbb{1}_{\{W_i=1\}} | X_i, Y_i(1)\right]\right] \tag{1.15}$$

$$= \mathbb{E}[Y_i(1)]. \tag{1.16}$$

De même, nous obtenons $\mathbb{E}\left[\frac{(1-W_i)Y_i}{1-e(X_i)}\right] = \mathbb{E}[Y_i(0)]$. Cela implique que nous pouvons estimer les réponses potentielles moyennes à partir des données observationnelles, en supposant que les propensions $e(X_i)$ sont connues.

Dans la pratique, une version normalisée de (1.20), dérivée dans le contexte de l'échantillonnage par sondage par Hájek [1971], est utilisée puisque la précision est généralement améliorée si l'on utilise des moyennes pondérées pour les deux groupes comme le souligne Kang et al. [2007], c'est-à-dire,

$$\hat{\tau}_{IPW} \triangleq \left(\sum_{i=1}^{n} \frac{W_i}{\hat{e}(X_i)}\right)^{-1} \sum_{i=1}^{n} \frac{W_i Y_i}{\hat{e}(X_i)} - \left(\sum_{i=1}^{n} \frac{1-W_i}{1-\hat{e}(X_i)}\right)^{-1} \sum_{i=1}^{n} \frac{(1-W_i)Y_i}{1-\hat{e}(X_i)}, \tag{1.17}$$

ce qui est justifié par le fait que $\mathbb{E}\left[\frac{W_i}{e(X_i)}\right] = \mathbb{E}\left[\mathbb{E}\left[\frac{W_i}{e(X_i)} | X_i\right]\right] = \mathbb{E}\left[\frac{e(X_i)}{e(X_i)}\right] = 1$.

Si le score de propension est inconnu, un choix populaire pour l'estimer est d'utiliser un modèle de régression logistique : cette approche permet d'estimer les probabilités de traitement à partir des covariables observées, puis d'inverser ces probabilités pour calculer les poids. Cependant, elle ne vise pas explicitement à équilibrer les covariables ou à limiter la variabilité des poids. Les poids peuvent donc varier de manière substantielle et conduire à une instabilité des estimations : c'est le cas de Robins and Wang [2000a], Kang et al. [2007]. Une difficulté majeure est que l'estimation de l'effet de traitement implique alors de diviser par soit $e^{-X_i\beta}$ soit $1 - e^{-X_i\beta}$. Par conséquent, de petites inexactitudes dans l'estimation de β peuvent avoir des effets importants sur les estimateurs ultérieurs, en particulier lorsque le score de propension $e(x) = \mathbb{P}(W_i = 1 \,|\, X_i = x)$ peut être proche de zéro et de un ; ce problème peut être encore plus important dans des contextes de grande dimension où la séparation parfaite peut conduire à des estimations $\hat{e}(x)$ qui sont exactement égales à zéro ou à un [Hill et al., 2011].

Si le modèle de propension est correctement spécifié, c'est-à-dire le modèle de distribution pour l'attribution du traitement compte tenu des covariables, il est alors correct d'avoir des poids très variables ; cependant, cela est difficile à déterminer en pratique. Cela explique la pratique courante consistant à rogner les poids extrêmes, mais cela est souvent fait de manière arbitraire, ce qui introduit un biais dans les estimations (voir Crump et al. [2009] pour des discussions sur les différentes méthodes et Li et al. [2018] pour une alternative au rognage, les poids de recouvrement, *overlap weights* en anglais).

Une autre solution disponible dans certains contextes est d'apprendre les poids (ou les probabilités de traitement) avec une approche non paramétrique (apprentissage automatique) pour obtenir des poids qui sont moins sensibles à la mauvaise spécification du modèle. Plus précisément, si les propensions sont une fonction plus complexe des covariables que logistiques-linéaires, par exemple impliquant des non-linéarités, l'apprentissage d'un modèle de score de propension plus riche peut être avantageux. Notons qu'indépendamment du choix de l'estimation des scores de propension, si les estimations sont consistantes, l'estimateur ATE résultant est plus efficace que l'estimateur utilisant le véritable score de propension, comme le montre Hirano et al. [2003]. Intuitivement, cela peut s'expliquer par la motivation de l'estimation des scores de propension : elle vise à récupérer la "politique" d'attribution qui a conduit aux échantillons observés et les estimations peuvent tenir compte de la variance supplémentaire dans l'échantillon qui n'est pas prise en compte dans le vrai modèle de propension. Si les prédictions sont trop proches des limites, c'est-à-dire si l'on obtient une séparation (presque) parfaite, même sur certaines données de test exclues, cela suggère fortement que l'hypothèse de recouvrement (ou traitement probabiliste) pourrait ne pas être respectée.

Notons que nous pouvons obtenir l'estimateur IPW normalisé (1.17) par une régression linéaire simple pondérée du résultat sur la variable de traitement, $Y_i \sim W_i$, avec des poids $\frac{W_i}{e(X_i)} + \frac{1-W_i}{1-e(X_i)}$.

Équilibrage et poids de recouvrement Les poids d'équilibrage peuvent être considérés comme une généralisation de la pondération par inverse de propension ci-dessus. Les observations sont pondérées de telle sorte que leur distribution se rapproche de la distribution d'une population cible prédéfinie et les réponses potentielles sont moyennés sur cette distribution cible. Par exemple, dans le cas de la pondération par inverse de propension, la population cible est l'ensemble de la population traitée et de la population contrôle. Les poids de recouvrement tels que définis dans Li et al. [2018] sont un cas particulier de la classe des poids d'équilibrage où chaque unité est pondérée proportionnellement à sa probabilité d'être assignée au groupe opposé. Cette pondération cible la sous-population d'unités qui reçoivent l'un ou l'autre traitement dans des proportions substantielles. Cette nouvelle classe de poids est motivée par la remarque suivante : plutôt que de donner la priorité à un bon équilibre des covariables entre les groupes plutôt qu'à la généralisation à une population cible reconnaissable, on devrait plutôt rechercher la sous-population "optimale" pour laquelle l'effet causal peut être estimé avec la plus petite variance [Crump et al., 2009].

Soit $f(x)$ la densité marginale des covariables X par rapport à une certaine mesure de base μ. Les densités dans chaque groupe, $f_1(x)$ et $f_0(x)$ sont proportionnelles à $f(x)e(x)$ et $f(x)(1-e(x))$ respectivement. Étant donné une distribution cible $f(x)h(x)$, par exemple, la distribution de la population globale ou de la population des personnes traitées, l'idée est d'utiliser les poids $\frac{h(x)}{e(x)}$ et $\frac{h(x)}{1-e(x)}$ qui permettent d'équilibrer les distributions des covariables vers la distribution cible. Dans le cas des poids de recouvrement, $h(x) = e(x)(1-e(x))$ et cela met davantage l'accent sur les unités dont le score de propension est proche de 0,5. Dans un contexte médical,

ces unités peuvent être considérées comme des patients aux profils ambigus, ce qui entraîne une absence de consensus entre les experts. Un aspect intéressant des poids de recouvrement est leur propriété d'équilibre exact sur de petits échantillons. Plus précisément, ils conduisent à un équilibre exact des moyennes de toute covariable entre les groupes traités et les groupes contrôles.

Une autre ligne de recherche pour l'équilibrage des poids peut être trouvée dans Zubizarreta [2015]. L'idée est de formuler le problème de la recherche de poids d'équilibrage avec une petite variance dans un problème d'optimisation convexe avec contraintes.

Imai and Ratkovic [2013] dérivent un *score de propension à équilibrer les covariables* (*covariate balancing propensity score* en anglais, CBPS) en se concentrant sur l'estimation robuste du score de propension (au lieu de l'appariement ou de la pondération robuste du score de propension). Cette approche exploite les deux aspects du score de propension, à savoir la propriété d'équilibrage des covariables et sa définition comme probabilité conditionnelle de traitement.

Méthodes doublement robustes L'estimateur CBPS mentionné précédemment s'accompagne d'une propriété qualifiée de *double robustesse*. En effet, elle peut être considérée comme une approche permettant de traiter les cas où le score de propension est quelque peu difficile à estimer. Les méthodes qui ne reposent uniquement sur le score de propension sont en général dominées par le biais dû à l'erreur d'estimation de $e(\cdot)$, et les méthodes qui modélisent également les résultats Y_i peuvent atteindre une meilleure complexité d'échantillon ; nous nous référons à Athey et al. [2018], Chernozhukov et al. [2018a] et Van der Laan and Rose [2011] pour les références et les résultats récents. Une approche particulièrement réussie pour combiner ces deux approches de modélisation est la pondération augmentée par inverse de propension (*augmented inverse propensity weighting* en anglais, AIPW) [Robins et al., 1994].

Nous supposons que nous avons accès à un estimateur $\hat{e}$ du vrai score de propension (1.7), nous définissons l'estimateur augmenté par inverse de propension comme suit.

$$\hat{\tau}_{AIPW} \triangleq \frac{1}{n}\sum_{i=1}^{n} \hat{\mu}_1(X_i) - \hat{\mu}_0(X_i) + W_i\frac{Y_i - hat\mu_1(X_i)}{\hat{e}(X_i)} - (1-W_i)\frac{Y_i - \hat{\mu}_0(X_i)}{1-\hat{e}(X_i)}, \quad (1.18)$$

où $\mu_{(w)}(x) \triangleq \mathbb{E}\left[Y \,\middle|\, X_i = x,\, W_i = w\right]$ et $\hat{\mu}_{(w)}(x)$ en est une estimation.

Malgré sa dérivation initiale dans le contexte de la régression lorsque certaines des issues sont manquantes, le lien avec l'inférence causale peut être facilement établi en considérant chaque issue potentielle comme un cas distinct de ce problème. Par exemple, les résultats $Y_i(1)$ ne sont observés que pour le traité et non pour le contrôle. La probabilité d'observer $Y_i(1)$ étant donné les covariables X_i est exactement le score de propension pour l'observation i. L'estimation consistante des surfaces de réponse conditionnelles des réponses potentielles $\mathbb{E}[Y_i(1)|X_i]$ et $\mathbb{E}[Y_i(0)|X_i]$ permet alors d'estimer de manière consistante $\tau(x)$.

Une description courante de l'estimateur AIPW est qu'il estime deux composantes de nuisance différentes, à savoir le modèle de réponse et le modèle de propension ; il atteint ensuite la consistance si l'une de ces composantes est elle-même estimée de manière consistante, et l'efficacité si les deux composantes sont estimées à des taux

suffisamment rapides. Afin de montrer la double robustesse de $\hat{\tau}_{AIPW}$, réécrivons-la en réarrangeant les termes :

$$\begin{aligned}\hat{\tau}_{AIPW} &= \frac{1}{n}\sum_{i=1}^{n}\frac{W_iY_i}{\hat{e}(X_i)} - \frac{W_i-\hat{e}(X_i)}{\hat{e}(X_i)}\hat{\mu}_1(X_i) - \frac{1}{n}\sum_{i=1}^{n}\frac{(1-W_i)Y_i}{1-\hat{e}(X_i)} + \frac{W_i-\hat{e}(X_i)}{1-\hat{e}(X_i)}\hat{\mu}_0(X_i)\\ &=: \hat{\mu}_{1,DR} - \hat{\mu}_{0,DR}.\end{aligned}$$

Notons d'abord que d'après la loi des grands nombres, $\hat{\mu}_{1,DR}$ et $\hat{\mu}_{0,DR}$ estiment respectivement $\mathbb{E}[Y_i(1)] + \eta_1$ et $\mathbb{E}[Y_i(0)] + \eta_0$ où η_1 est donné par $\eta_1 \triangleq \mathbb{E}\left[\frac{W_i-e(X_i)}{e(X_i)}(Y_i(1)-\mu_1(X_i))\right]$ and $\eta_0 \triangleq \mathbb{E}\left[\frac{W_i-e(X_i)}{1-e(X_i)}(Y_i(0)-\mu_0(X_i))\right]$. En effet, nous pouvons écrire :

$$\begin{aligned}\mathbb{E}\left[\frac{W_iY_i}{e(X_i)} - \frac{W_i-e(X_i)}{e(X_i)}\mu_1(X_i)\right] &= \mathbb{E}\left[\frac{W_iY_i(1)}{e(X_i)} - \frac{W_i-e(X_i)}{e(X_i)}\mu_1(X_i)\right]\\ &= \mathbb{E}[Y_i(1)] + \mathbb{E}\left[\frac{W_i-e(X_i)}{e(X_i)}(Y_i(1)-\mu_1(X_i))\right],\end{aligned}$$

où la première égalité découle de l'hypothèse (1.5) : $W_iY_i = W_i(W_iY_i(1) + (1-W_i)Y_i(0)) = W_iY_i(1) + W_i(1-W_i)Y_i(0)$. Et un raisonnement analogue donne la dérivation de η_0.

La double robustesse peut être facilement démontrée en considérant ces deux termes :

— Si le modèle de propension $e(x)$ est correctement spécifié mais que le modèle de réponse $(\mu_0(x), \mu_1(x))$ est mal spécifié, nous avons

$$\begin{aligned}\eta_1 &= \mathbb{E}\left[\mathbb{E}\left[\frac{W_i-e(X_i)}{e(X_i)}(Y_i(1)-\mu_1(X_i))\right] \mid Y_i(1), X_i\right]\\ &= \mathbb{E}\left[\frac{\mathbb{E}[W_i \mid Y_i(1), X_i] - e(X_i)}{e(X_i)}(Y_i(1)-\mu_1(X_i))\right]\\ &= \mathbb{E}\left[\frac{\mathbb{E}[W_i \mid X_i] - e(X_i)}{e(X_i)}(Y_i(1)-\mu_1(X_i))\right] = 0.\end{aligned}$$

Nous utilisons l'hypothèse de non-confusion (1.3) pour passer de la deuxième à la troisième ligne et la définition du score de propension pour la dernière égalité.

— Si le modèle de propension $e(x)$ est mal spécifié mais que le modèle de réponse

$(\mu_0(x), \mu_1(x))$ est correctement spécifié, nous avons

$$\begin{aligned}
\eta_1 &= \mathbb{E}\left[\mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}(Y_i(1) - \mu_1(X_i))\right] \mid W_i, X_i\right] \\
&= \mathbb{E}\left[\mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}\left(Y_i(1) - \mathbb{E}[Y_i \mid W_i = 1, X_i]\right) \mid W_i, X_i\right]\right] \\
&= \mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}\left(\mathbb{E}[Y_i(1) \mid W_i, X_i] - \mathbb{E}[Y_i \mid W_i = 1, X_i]\right)\right] \\
&= \mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}\left(\mathbb{E}[Y_i(1) \mid X_i] - \mathbb{E}[Y_i(1) \mid X_i]\right)\right] = 0,
\end{aligned}$$

où l'on utilise les hypothèses SUTVA (1.5) et de non-confusion (1.3) pour passer de la troisième à la quatrième ligne.

De manière analogue, nous obtenons dans les deux cas de mauvaise spécification que $\eta_0 = 0$, prouvant la double robustesse de $\hat{\tau}_{DR}$.

Cet estimateur AIPW et d'autres variantes doublement robustes atteignent la borne d'efficacité semi-paramétrique pour l'estimation ATE. Cette limite de type Cramer-Rao est dérivée dans Hahn [1998] pour l'estimation non paramétrique de l'effet de traitement moyen. Chernozhukov et al. [2018a] détaillent les conditions suffisantes pour une estimation semi-paramétrique consistante de l'ATE, à savoir le recouvrement, la consistance sup-normale, une décroissance du risque $o(n^{-1})$ et l'ajustement croisé (*cross-fitting* en anglais) :

$$\sup_{x \in \mathcal{X}} \left|\hat{\mu}_{(w)}(x) - \mu_{(w)}(x)\right| \xrightarrow{p} 0 \qquad \sup_{x \in \mathcal{X}} |\hat{e}(x) - e(x)| \xrightarrow{p} 0, \tag{1.19}$$

and

$$\mathbb{E}_{\hat{\mu}_{(w)}, X}\left[\left(\hat{\mu}_{(w))}(X) - \mu_{(w)}(X)\right)^2\right] \mathbb{E}_{\hat{e}, X}\left[(\hat{e}(X) - e(X))^2\right] = o_P\left(\frac{1}{n}\right). \tag{1.20}$$

Sous (1.19), (1.20) et l'hypothèse de recouvrement, les estimateurs ATE correspondants sont garantis être $\sqrt{n}$ consistants si $\hat{\mu}_{(w)}$ et $\hat{e}$ sont estimés en utilisant le *cross-fitting* (également appelé découpage d'échantillon, *sample splitting* en anglais). Ce dernier élément clé pour la consistence de tels estimateurs semi-paramétriques a été souligné indépendamment par Athey et al. [2019] et Chernozhukov et al. [2018a].

D'autres approches pour les recommendations personnalisées de traitement

Apprentissage pondéré par les résultats Les méthodes précédentes tentent toutes de récupérer ou de compenser l'information manquante, à savoir la réponse contrefactuelle correspondant associé au niveau de traitement qui n'a pas été choisi. Cependant, il existe d'autres approches qui "contournent" cette étape sur la voie de la définition d'un traitement optimal : l'apprentissage pondéré par les résultats (*outcome-weighted learning* en anglais, OWL) qui vise à classer directement les patients dans le groupe de ceux qui bénéficieraient d'un traitement et de ceux qui n'auraient aucun effet ou des effets indésirables. Ceci est réalisé en estimant une frontière dans l'espace des covariables pour séparer ces deux groupes, ce qui permet de définir une règle de traitement : les patients qui tombent dans la partie "bénéfice" reçoivent le traitement, ceux qui tombent dans le groupe opposé, ne recevront pas le traitement spécifique [Zhang et al., 2012]. Cette approche devient donc également populaire dans le contexte de la médecine personnalisée.

Estimation d'effets de traitement hétérogènes Si l'on soupçonne une hétérogénéité de traitement (dans la population étudiée), la quantité causale typiquement considérée est la fonction CATE $\tau : \mathcal{X} \to \mathbb{R}$ définie par :

$$\begin{aligned} \tau :& \mathcal{X} \to \mathbb{R} \\ & Nx \mapsto \mathbb{E}[Y(1) - Y(0) | X = x] \end{aligned} \tag{1.21}$$

Cette définition suppose que l'hétérogénéité du traitement, c'est-à-dire le fait que le traitement a un effet différent sur différents individus, peut être récupérée en conditionnant les covariables X de prétraitement. covariables de prétraitement X. Dans ce cas, le CATE est défini comme l'effet moyen du traitement conditionnel à un ensemble donné de covariables. Il permet d'estimer les différences d'effets de traitement entre les sujets, en d'autres termes, il estime les effets de traitement hétérogènes, induits par les interactions entre le traitement et les covariables.

Les premiers travaux d'estimation de CATE dans les ECR, en particulier dans les applications médicales, proposent de rechercher des sous-groupes pré-spécifiés qui réagissent différemment à un traitement et sont qualifiés d'*analyse de sous-ensembles* [Byar, 1985, Dixon and Simon, 1991].

Plus récemment, différentes approches, également valables pour les données observationnelles, ont été proposées. Elles peuvent être classées en trois groupes :

— Approches à deux modèles ou *T-learner* [e.g. Shi et al., 2019] : elles utilisent la linéarité de l'espérance pour exprimer $\tau(x)$ comme une différence des surfaces de réponse conditionnelles $\mu_1(x)$ et $\mu_0(x)$ pour tous les $x \in \mathcal{X}$ et pour estimer ces deux fonctions de régression séparément. Cependant, cette estimation indirecte via les surfaces de réponse conditionnelles peut être inefficace si les surfaces de réponse sont plus complexes que la fonction CATE. En outre, le terme d'erreur de la différence de deux fonctions de régression estimées peut être important et difficile à quantifier. Une variante du *T-learner*, qui est préférable en cas de déséquilibre de la taille des groupes de traitement ou lorsque les fonctions de régression correspondant aux deux niveaux de traitement sont de complexité différente, est le *X-learner* [Künzel et al., 2019]. Cette approche tire parti du

G-calcul (*G-computation* en anglais) pour adapter la complexité des fonctions de régression estimées à la taille et à la qualité des données de chaque groupe de traitement.

— Approches à modèle unique ou *S-learner* : Comme son nom l'indique, cette approche repose sur un modèle unique pour le résultat. En général, ces méthodes supposent un modèle de régression avec un effet de traitement additif linéaire et des effets d'interaction $Y = \alpha + \tau_0 W_i + \tau^T X_i W_i + \beta^T X_i + \varepsilon_i$. Bien que ce modèle soit raisonnable en petite dimension, les termes d'interaction entre toutes les variables X et l'indicateur de traitement W augmentent la taille de l'espace des paramètres. Une approche largement utilisée proposée par Hill et al. [2011] est basée sur les arbres de régression additifs bayésiens (BART). Il s'agit de l'analogue des arbres de décision boostés par le gradient (*gradient boosted regression trees* en anglais) qui utilisent l'inférence bayésienne via la méthode de Monte-Carlo par chaîne de Markov (MCMC). En pratique, cette méthode atteint de très bonnes performances dans divers contextes, mais son succès empirique nécessite encore une meilleure compréhension théorique [Dorie et al., 2019].

— Approches d'estimation directe sans modélisation des résultats : Ces approches sont basées sur divers concepts, par exemple les *arbres causaux* (ou *arbres de réponses pollinisés*) redéfinissent le critère de division des arbres aléatoires [CART Breiman, 2001] de manière à maximiser l'hétérogénéité du traitement [Athey and Imbens, 2016]. Ceci peut être réalisé, par exemple, en considérant la réponse transformée $Y_i^{TO} = W_i \frac{Y_i}{e(X_i)} + (1 - W_i) \frac{Y_i}{1-e(X_i)}$ et en utilisant CART sur la moitié des données pour construire un arbre sur cette réponse transformée Y^{TO}. L'hétérogénéité du traitement est ensuite évaluée en estimant l'ATE dans chaque feuille de l'arbre résultant en *pollinisant* l'arbre avec l'autre moitié des données et en définissant l'ATE estimé comme la différence des moyennes dans chaque feuille. Les auteurs proposent les arbres causaux comme une étape complémentaire à l'analyse standard des sous-ensembles, car elle permet aux analystes d'exploiter les données pour découvrir des sous-groupes pertinents tout en préservant la validité des intervalles de confiance construits sur les effets du traitement au sein des sous-groupes. Des généralisations de cette approche ont été proposées depuis son introduction : forêts causales et forêts aléatoires généralisées [Athey et al., 2019, Wager and Athey, 2018], et *bagged causal multivariate adaptive regression splines* [Powers et al., 2018]. Au lieu de définir une réponse transformée, Tian et al. [2014], Knaus et al. [2021] proposent une approche de *covariable modifée* : elle consiste à trouver $\hat{\tau}(\cdot)$ en optimisant la fonction de perte suivante $\text{argmin}_\tau \frac{1}{n} \sum_i (2W_i - 1) \frac{W_i - e(X_i)}{4e(X_i)(1-e(X_i))} (2(2W_i - 1)Y_i - \tau(X_i))^2$. Enfin, une méthode liée aux forêts causales est le *R-learner* [Nie and Wager, 2017]. Ils dérivent une fonction de perte en utilisant une généralisation de la transformation de Robinson pour les modèles linéaires partiels [Robinson, 1988], l'étape dite de *résidualisation*. Il en résulte une fonction de perte, la *R-loss* (empirique) : $\frac{1}{n} \sum_i Y_i - \mathbb{E}[Y|X_i] - (W_i - e(X_i))\tau(X_i) + \Lambda(\tau)$, où Λ est un terme de régularisation contrôlant la complexité de la fonction $\tau(\cdot)$. Cette *R-loss* peut être optimisée avec n'importe quelle méthode de minimisation

des pertes, telle que le boosting ou les réseaux neuronaux, pour obtenir une estimation de la fonction CATE (1.21).

Cette courte revue des principaux estimateurs de l'effet (moyen) de traitement conclut l'introduction à l'inférence causale et nous nous intéresserons dans le chapitre suivant à l'autre aspect principal de cette thèse, les données manquantes en analyse statistique.

Chapitre 2

Le rôle des données manquantes

2.1 – Courte histoire des données manquantes

Avant les travaux précurseurs de Rubin [1976], le fait que des données soient incomplètes exigeait, en pratique, un traitement des valeurs manquantes afin d'analyser les données. Les méthodes les plus courantes avant les années 1970 étaient l'imputation *ad-hoc* ou l'analyse des cas complets [Afifi and Elashoff, 1966]. Pour les problèmes et modèles simples, l'estimation par maximum de vraisemblance basée sur la vraisemblance factorisée était déjà présente [Anderson, 1957]. La généralisation de l'approche du maximum de vraisemblance pour les données incomplètes a ensuite été fournie par Rubin [1976], ainsi que l'idée de modéliser le mécanisme des valeurs manquantes et de définir différentes classes de mécanismes ; et l'avènement de ressources informatiques croissantes ainsi que l'algorithme de maximisation de l'espérance proposé par Dempster et al. [*Expectation-Maximization* en anglais (EM) 1977] ont facilité de nouvelles extensions des dérivations du maximum de vraisemblance pour des problèmes plus complexes [Little and Rubin, 2019]. Au milieu des années 1980, une autre approche généralisée de l'inférence avec des valeurs manquantes est apparue, basée sur des idées issues des statistiques bayésiennes [Tanner and Wong, 1984], et popularisée avec l'introduction du concept d'imputation multiple (*multiple imputation* en anglais, MI), justifié par des concepts bayésiens [Rubin, 1978b, 2004]. La popularité des méthodes de chaînes de Markov Monte Carlo (MCMC) dans les statistiques bayésiennes ainsi que pour l'imputation multiple a favorisé l'utilisation de cette dernière comme alternative à l'approche du maximum de vraisemblance avec de meilleures propriétés pour des échantillons de petite taille (voir par exemple, Little and Rubin [2019]). Dans les années 1990, d'autres approches importantes du traitement des valeurs manquantes ont été proposées, comme la pondération (augmentée) par inverse de probabilité par Robins et al. [1994], basée sur des statistiques semi-paramétriques ainsi que la modélisation bayésienne robuste [Linero and Daniels, 2018]. Ces travaux et leurs extensions améliorent la robustesse aux mauvaises spécifications du mécanisme de données manquantes ou du modèle statistique primaire, par exemple l'estimation d'une moyenne. Enfin, des modèles plus complexes sont étudiés, souvent dans le contexte de l'apprentissage automatique et de la modélisation non paramétrique, comme les modèles de classes latentes pour les données catégorielles

[Audigier et al., 2017] ou les arbres de régression additifs bayésiens (*Bayesian additive regression trees* en anglais (BART), Chipman et al. [2010]).

Après ce très bref aperçu des développements des méthodes des valeurs manquantes au cours des 50 dernières années, nous passons maintenant aux concepts et aux formalisations du travail séminal de Rubin [1976].

2.2 – La taxonomie de Rubin

Dans la taxonomie proposée par Rubin [1976], un mécanisme de données manquantes ignorable est soit *manquant complètement aléatoirement.* (*missing completely at random*, MCAR) ou *manquant aléatoirement* (*missing at random*, MAR). Dans le premier cas, cela signifie que le mécanisme de données manquantes est indépendant des données, tandis que dans le second cas, l'absence ne dépend que des valeurs observées. Plus formellement, pour tout motif de réponses r et $X = (X^{obs(r)}, X^{mis(r)})$ la partition des données en valeurs observées et manquantes réalisées étant donné une réalisation spécifique du motif r, nous définissons

$$(MCAR) \quad \forall r,\ P(R = r|X) = P(R = r) \tag{2.1}$$

$$(MAR) \quad \forall r,\ P(R = r|X) = P(R = r|X^{obs(m)}). \tag{2.2}$$

Si le mécanisme de données manquantes est nonignorable, il est qualifié de *manquant non aléatoirement* (*missing not at random*, MNAR). Plus précisément un mécanisme est MNAR s'il ne satisfait pas (2.1) ou (2.2), en d'autres termes, le caractère manquant peut dépendre des valeurs manquantes elles-mêmes.

Afin de concrétiser un peu ces différents concepts, nous allons considérer un petit exemple qui illustre bien les nuances entre ces trois définitions : supposons que nous disposons d'un échantillon d'individus ayant renseignés leurs âge et revenu. Nous supposons que l'âge est renseigné pour tous les individus, alors que l'information est manquantes pour certains individus. Sur les Figures 2.1a à 2.1c nous distingons les trois cas de mécanismes de données manquantes introduits précédemment.

— Le cas MCAR correspond à la situation où les individus pour lesquels l'information sur le revenu est manquante ont été tirés aléatoirement dans l'échantillon. En d'autres termes, un lancer à pile ou face décide si l'information sur le revenue renseignée ou non. On observe effectivement que les points oranges sont répartis uniformément sur l'ensemble des observations de l'échantillon.

— Le cas MAR décrit le cas où l'information sur le revenu est manquante en fonction de l'âge. Dans cette exemple nous supposons que des personnes plus agées ont plus tendance à ne pas renseigner leur revenu. Donc le revenu est manquant en fonction de l'âge de l'individu.

— Le cas MNAR correspond à la situation où les individus renseignent l'information sur leur revenu en fonction de ce revenu. Il est en effet connu que les individus (très) aisés ont tendance à dissimuler cette information, d'où un manque d'information en fonction du revenu [Atkinson et al., 2011]. Ici nous ne pouvons donc pas exploiter l'information sur l'âge pour inférer l'information manquantes sur le revenu.



(a) MCAR

(b) MAR

(c) MNAR

FIGURE 2.1 – Examples simulés illustrant les différents mécanismes de données manquantes dans la taxonomie de Rubin. L'âge en abscisses est toujours observé, le revenu en ordonnées n'est pas toujours observé. Les observations manquantes sont indiquées en orange, les observations présentes en bleu.

Ce petit exemple simplifié montre déjà que les valeurs manquantes ne peuvent pas être traitées toutes de la même façon car en fonction de leur origine, elles contiennent ou non de l'information et elles sont plus ou moins difficile à reconstruire ou imputer, i.e., à compléter.

Afin de passer en revue les principales approches statistiques de gestion de données manquantes, nous allons désormais formaliser un peu plus les différents mécanismes de données manquantes. Par souci de simplicité, nous supposons que les réalisations $(x_i, r_i)_{1 \leq i \leq n}$, $n \in \mathbb{N}$, sont des observations i.i.d. d'une distribution de la famille $\mathcal{P} \triangleq \{p_\theta(x) q_\phi(r \mid x) \ : \ \theta \in \Theta, \phi \in \Phi\}$. Par conséquent, q_ϕ caractérise le mécanisme de données manquantes. L'inférence statistique consiste généralement à estimer le paramètre θ, une approche possible sous certaines hypothèses de régularité et en supposant les x_i entièrement observés est l'estimation par maximum de vraisemblance : $\hat{\theta} \triangleq \operatorname{argmax}_\theta \mathcal{L}(\theta)$ où $\mathcal{L}(\theta) \triangleq \prod_{i=1}^n p_\theta(x_i)$ est la vraisemblance. Afin d'effectuer une estimation par maximum de vraisemblance sur des données incomplètes x_i, certaines hypothèses sur le mécanisme q_ϕ doivent être faites, comme on peut le voir en écrivant la vraisemblance complète $\mathcal{L}_{full}$, qui est obtenue en intégrant sur les valeurs manquantes :

$$\mathcal{L}_{full}(\theta, \phi) \triangleq \prod_{i=1}^{n} \int_{\mathcal{X}^{mis}} q_\phi(r_i|x_i) p_\theta(x_i) dx_i^{mis} \tag{2.3}$$

Puisque le paramètre ϕ et une modélisation du mécanisme de données manquantes ne sont généralement pas intéressants, une quantité plus pratique, la vraisemblance observée $\mathcal{L}_{obs}$, peut être dérivée, en supposant que le manque est *ignorable* [Little and Rubin, 2019]. L'ignorabilité requiert l'indépendance fonctionnelle des deux paramètres θ et ϕ et que le mécanisme d'absence soit MCAR (2.1) ou MAR (2.2). Avec ces notations plus précises nous donnons des définitions de MCAR et MAR adaptées à ces notations.

Étant donné $r \in \{0,1\}^p$ et $x = (x^{obs}, x^{mis}) \in \mathbb{R}^p$, le mécanisme de données manquantes ϕ est qualifié de

(i) MCAR, si

$$\forall\, \phi,\ \forall\, x' = (x'^{obs}, x'^{mis}),\ q_\phi(r|x') = q_\phi(r|x) = q_\phi(r) \tag{2.4}$$

(ii) MAR, si

$$\forall\, \phi,\ \forall\, x'^{mis} \text{ tel que } x' = (x^{obs}, x'^{mis}),\ q_\phi(r|x') = q_\phi(r|x) \tag{2.5}$$

Dans l'un ou l'autre de ces mécanismes, nous pouvons définir la probabilité observée comme suit :

$$\mathcal{L}_{obs}(\theta) \triangleq \prod_{i=1}^{n} q_\phi(r_i|x_i^{obs}) \int_{\mathcal{X}^{mis}} p_\theta(x_i) dx_i^{mis}. \tag{2.6}$$

Cette réduction à la vraisemblance observée n'est pas possible si le mécanisme d'absence est non-ignorable.

2.3 – Estimation et prédiction avec des données manquantes

Nous avons rappelé dans la sous-section précédente le cadre le plus courant pour modéliser les données manquantes dans des analyses statistiques. Une description détaillée de toutes les méthodes d'estimation qui rentrent dans ce cadre dépasserait le cadre de cette section. Nous nous limitons ici à donner trois catégories majeures de traitement de données manquantes en statistique.

Données manquantes intégrées au modèle d'analyse : algorithme EM La question initiale étant *comment effectuer des analyses statistiques avec des valeurs manquantes* ou plus précisément dans le cadre paramétrique énoncé ci-dessus *comment estimer le paramètre* θ, une première solution consiste à adapter les méthodes statistiques existantes pour prendre en compte la présence de valeurs manquantes. Comme nous l'avons vu plus haut en cas d'ignorabilité du mécanisme, le paramètre θ peut être estimé par une estimation par maximum de vraisemblance observée.

Cependant, étant donné que l'expression de $\mathcal{L}_{obs}$ implique l'intégration de toutes les valeurs manquantes possibles, la maximisation directe de $\mathcal{L}_{obs}$ est généralement difficile, mais une solution bien connue est l'algorithme *Expectation-Maximization* (EM) proposé par Dempster et al. [1977]. Il suppose que la distribution jointe des variables manquantes et observées, $p_\theta(x) = p_\theta(x^{obs}, x^{mis})$ est explicitement connue et il vise à maximiser la log-vraisemblance observée ℓ_{obs},

$$\begin{aligned}\ell_{obs}(\theta) &= \log\left(\prod_{i=1}^{n} q_\phi(r_i|x_i^{obs}) \int_{\mathcal{X}^{mis}} p_\theta(x_i) dx_i^{mis}\right) \\ &= \sum_{i=1}^{n} \log\left(\int_{\mathcal{X}^{mis}} p_\theta(x_i) dx_i^{mis}\right) + \log q_\phi(r_i|x_i^{obs}),\end{aligned} \tag{2.7}$$

où le dernier terme est constant en θ, donc il peut être ignoré pour trouver (ou approximer) la valeur θ qui maximise la log-vraisemblance observée.

L'algorithme EM est un algorithme itératif qui commence à une valeur initiale de $\theta^{(0)} \in \Theta$. En utilisant l'inégalité de Jensen, il consiste à prendre alternativement l'espérance de la log-vraisemblance des données complètes $\ell(\theta; x^{obs}, x^{mis}) \triangleq \log p_\theta(x^{obs}, x^{mis})$ par rapport à la distribution conditionnelle des variables manquantes paramétrées par $\theta^{(t)}$ à l'étape t, puis à trouver $\theta^{(t+1)}$ en maximisant cette espérance dans θ :

$$\begin{aligned}\text{Étape E(xpectation) :} \quad Q(\theta|\theta^{(t)}) &\triangleq \sum_{i=1}^{n} \mathbb{E}[\ell(\theta; x_i^{obs}, x_i^{mis})|X_i^{obs} = x_i^{obs}; \theta^{(t)}] \\ &= \int \ell(\theta; x_i^{obs}, x_i^{mis}) p_{\theta^{(t)}}(x_i^{mis}|x_i^{obs}) dx_i^{mis},\end{aligned} \tag{2.8}$$

$$\text{Étape M(aximization) :} \quad \theta^{(t+1)} \in \operatorname{argmax}_\theta Q(\theta|\theta^{(t)}). \tag{2.9}$$

Une propriété importante de cet algorithme est que la séquence $(\theta^{(t)})_{t\geq 0}$ est garantie pour augmenter la log-vraisemblance observée $\ell_{obs}(\theta^{(t)})$, cependant il n'y a aucune garantie de convergence vers un maximum global.

Un algorithme EM supplémenté (SEM) permet d'estimer la variance de l'estimation du maximum de vraisemblance résultant $\hat{\theta}_{MLE}$ [Meng and Rubin, 1991]. On peut également utiliser la formule de Louis pour estimer $Var(\hat{\theta}_{MLE})$ [Louis, 1982].

Données manquantes traitées en amont de l'analyse : imputation L'un des inconvénients de l'algorithme EM est son manque de généralisation : les étapes E et M doivent être dérivées pour chaque méthode statistique et ces dérivations peuvent impliquer des termes compliqués ou difficiles à résoudre, ce qui entrave la mise en œuvre d'un algorithme d'estimation efficace sur le plan informatique. Comme la plupart des méthodes statistiques existantes sont conçues pour des données complètes, une autre idée consiste à *imputer*, c'est-à-dire à remplir, les valeurs manquantes pour récupérer un ensemble de données complet [Rubin, 2004]. Il existe plusieurs approches pour imputer les données avec des valeurs "plausibles" : en supposant une distribution jointe connue des données, *modélisation jointe* consiste à exploiter cette connaissance pour imputer les valeurs manquantes sur la base des valeurs observées [Little and

Rubin, 2019]. D'autres approches sont basées sur la modélisation à rang faible des données [Hastie et al., 2015, Josse et al., 2011b] ou sur la spécification entièrement conditionnelle (*fully conditional specification* en anglais, FCS) [van Buuren, 2018, Stekhoven and Bühlmann, 2012]. Suivant la tendance de l'apprentissage profond, il existe également des méthodes d'imputation basées sur les réseaux adversariens génératifs (*generative adversarial networks* en anglais, GAN) [Yoon et al., 2018b], les autoencodeurs de débruitage [Gondara and Wang, 2018] et le transport optimal [Muzellec et al., 2020].

Si l'objectif est de réaliser des inférences statistiques, alors une imputation simple, c'est-à-dire le remplacement de chaque valeur manquante par une valeur plausible pour obtenir un seul ensemble de données complété, n'est pas suffisante pour prendre en compte la variabilité supplémentaire due aux valeurs manquantes et c'est pourquoi une stratégie d'imputation multiple (MI) [Rubin, 2004] est adoptée avec les méthodes d'imputation listées ci-dessus. Le principe de MI est de proposer M valeurs différentes (plausibles) pour chaque valeur manquante. La variabilité entre ces imputations reflète la variance de l'imputation des valeurs manquantes. Les analyses statistiques sont ensuite effectuées séparément sur les M ensembles de données imputées résultants et les M estimations $(\theta_m)_{1\leq m\leq M}$ sont combinées selon les règles de Rubin [Rubin, 2004] pour obtenir une seule estimation $\hat{\theta}$ avec une variance bien estimée, c'est-à-dire prenant en compte l'incertitude supplémentaire due aux valeurs manquantes.

Données manquantes dans le contexte de l'apprentissage supervisé Nous avons abordé précédemment les problèmes d'estimation en présence de valeurs manquantes, c'est-à-dire l'estimation d'un paramètre $\theta \in \Theta$. Cependant, si l'objectif est de faire des prédictions sur une variable de réponse y compte tenu des informations x, il existe d'autres approches pour gérer les valeurs manquantes dans x qui ne concernent pas l'imputation précise de x ou la bonne estimation des paramètres. Par exemple, les arbres aléatoires [Breiman et al., 1984] sont des modèles non paramétriques qui visent à estimer des modèles discriminants, permettant de prédire y étant donné x. Une propriété attrayante des modèles basés sur des arbres est leur capacité à traiter des variables semi-continues, ce qui permet de tenir compte des valeurs manquantes dans les données. Une solution qui prend en compte les valeurs manquantes dans l'estimation du modèle discriminatif est le *missing incorporated in attributes* (MIA) [Twala et al., 2008, Josse et al., 2019]. Elle permet des divisions optimales le long des parties observées de X et du modèle de réponse R. Une autre approche, conceptuellement encore plus simple, pour la prédiction avec des données incomplètes est l'imputation moyenne qui est consistante, à condition d'utiliser un algorithme d'apprentissage à capacité d'apprentissage infinie : [Josse et al., 2019].

Le succès surtout empirique des réseaux neuronaux ou profonds pour les tâches d'apprentissage supervisé est évident à la fois en termes d'applications de ces méthodes et de la littérature en forte croissance sur leur comportement empirique, moins sur leurs fondements théoriques. La littérature sur un traitement explicite et consistant des valeurs manquantes dans le contexte de l'apprentissage profond est encore assez rare, mais certains résultats récents fournissent des résultats notables : Le Morvan et al. [2020b] proposent de spécifier la distribution des données contenant des valeurs

manquantes avec des fonctions d'activation ReLU (Rectified Linear Units) pour un ensemble de problèmes linéaires. De plus, Le Morvan et al. [2020a] proposent une nouvelle architecture de principe pour différents mécanismes d'absence, basée sur une approximation en série de Neumann du prédicteur optimal de Bayes, c'est-à-dire une fonction de l'entrée x qui minimise l'erreur de prédiction. Enfin, une autre ligne de travail dans le contexte de l'apprentissage par représentation de graphes s'attaque à la tâche de prédiction sous l'hypothèse plus restrictive du mécanisme d'absence (MCAR) [You et al., 2020].

2.4 – L'impact en inférence causale

Le problème fondamental de l'inférence causale, tel qu'il a été formulé par Rubin [1976], Holland [1986], est un problème de données manquantes en soi : on souhaite estimer une différence de deux quantités qui ne sont jamais observées ensemble. Cela pourrait expliquer pourquoi une grande partie des premiers membres de la "communauté" de l'inférence causale sont également d'importants contributeurs à la "communauté" des données manquantes, l'exemple le plus célèbre de cette remarque étant Donald B. Rubin. Pour une revue systématique de l'inférence causale du point de vue des données manquantes, nous nous référons à Ding and Li [2018].

Plusieurs approches ont été introduites pour traiter soit les problèmes de l'analyse statistique classique avec des valeurs manquantes, soit les problèmes liés à l'inférence causale : [par exemple, Bang and Robins, 2005, Bhattacharya et al., 2019]. Une première étape pour comprendre la proximité intrinsèque entre le cadre des réponses potentielles et celui des données manquantes consiste à revenir à la définition des réponses potentielles (1.1.1). Sur la base de cette définition, nous pouvons considérer les réponses potentielles comme deux variables aléatoires différentes, dont au plus une peut être observée pour chaque individu, en fonction de l'affectation de traitement W. Cette dernière peut donc être interprétée comme l'indicateur de valeurs manquantes pour $Y(1)$ et $Y(0)$, à savoir

$$R^{Y(1)} = 1 \text{ et } R^{Y(0)} = 0, \text{ si } W = 1.$$
$$R^{Y(0)} = 1 \text{ et } R^{Y(1)} = 0, \text{ si } W = 0.$$

En d'autres termes, l'affectation du traitement définit un mécanisme de données manquantes pour les réponses potentielles. Les hypothèses sur l'affectation du traitement, en particulier l'hypothèse de non-confusion ou *unconfoundedness* (1.3) peuvent être comprises comme une hypothèse MAR (2.2) :

$$P(W|Y(1), Y(0), X) = P(W|Y^{obs}, Y^{mis}, X) = P(W|X, Y^{obs}),$$

où nous utilisons la notation en exposant de la sous-section précédente pour désigner les valeurs manquantes et observées. Cette correspondance entre l'hypothèse de non-fondation et cette hypothèse MAR est possible grâce à l'hypothèse SUTVA qui garantit que $Y^{mis} = Y(1 - W)$. De manière analogue, le cas de l'étude randomisée contrôlée (RCT) correspond à un mécanisme MCAR,

$$P(W|Y(1), Y(0), X) = P(W|Y^{obs}, Y^{mis}, X) = P(W),$$

puisque l'affectation du traitement est tirée au hasard et indépendamment de toute covariable X et des réponses potentielles $Y(1), Y(0)$. Enfin, le cas général de l'affectation de traitement avec confusion non mesurée peut être relié au cas du mécanisme MNAR :

$$P(W|Y(1), Y(0), X) = P(W|Y^{obs}, Y^{mis}, X^{obs}, X^{mis}) = P(W|Y^{obs}, X^{obs}, X^{mis}).$$

Dans ce dernier cas, nous avons divisé les covariables X en facteurs confondants observés et manquants afin de rendre explicite la dépendance de W vis-à-vis des informations non observées X^{mis}. De la même manière que pour l'analyse statistique classique avec des valeurs manquantes MNAR, il existe plusieurs travaux sur l'identifiabilité et l'estimation dans le cadre d'une telle confusion cachée (ou non mesurée) [Shpitser and Pearl, 2006, Bhattacharya et al., 2020].

Cependant, la présence simultanée de valeurs (covariables) manquantes et de résultats potentiels manquants dans les données d'observation est légèrement différente et nécessite une modélisation plus poussée que les analogies ci-dessus entre les données manquantes et les problèmes d'inférence causale. Dans le cadre des études randomisées contrôlées, le problème des réponses potentielles manquantes n'est pas préoccupant en raison de la conception du design de l'étude, c'est-à-dire grâce à la randomisation, mais le problème des données manquantes dans les études observationnelles présente un défi et il a été noté par un panel de l'académie nationale de la science américaine (*National Academy of Science* en anglais) que, comme dans d'autres domaines statistiques, la littérature est divisées en deux sur ce sujet : les approches basées sur la vraisemblance maximale et les méthodes d'imputation multiple d'une part et les méthodes de pondération telles que l'inversde de propension ou la pondération de censure d'autre part. Cette question n'a pas été traitée de manière approfondie à ce jour. Parmi les exceptions notables, citons D'Agostino and Rubin [2000], Mattei and Mealli [2009], Qu and Lipkovich [2009], Mitra and Reiter [2011], Seaman and White [2014], Blake et al. [2020] qui se concentrent tous sur l'adaptation des méthodes de pondération des scores d'équilibrage au cas des facteurs confondants incomplets. Une autre branche de recherche considère l'identifiabilité des effets causaux en présence de données (covariables) incomplètes [Karvanen et al., 2020]. Dans le Chapitre 4 nous fournissons une revue détaillée de ce problème, et proposerons une nouvelle approche pour traiter les facteurs de confusion incomplets, et plus généralement les attributs incomplets.

Chapitre 3

L'apprentissage automatique dans le contexte de l'inférence causale

Dans ce chapitre, nous illustrons sur un exemple concret, basée sur la Traumabase®, comment appliquer des techniques d'inférence causale couplées avec de l'apprentissage machine à des données d'observation incomplètes. Nous comparons deux approches dont l'une est justifiée par un fondement théorique plus solide que l'autre.

3.1 – Contexte et motivation de l'étude

Les traumatismes crâniens (*traumatic brain injury* en anglais, TBI) restent un défi majeur de santé publique à l'échelle mondiale. L'incidence mondiale devrait augmenter, en raison de l'augmentation du trafic routier dans les pays en développement et d'une proportion plus élevée de personnes âgées dans toutes les populations [James et al., 2019]. L'essai de référence CRASH-3 a examiné l'utilisation de l'acide tranexamique (TXA) pour relever le défi du TBI avec une rigueur méthodologique exemplaire [Cap, 2019]. L'essai n'a démontré aucune réduction de la mortalité globale liée au traumatisme crânien à 28 jours, mais une réduction dans le sous-groupe pré-spécifié des TBI légers à modérés (GCS 9-13) [1].

Malgré les conclusions de deux études récentes [Rowell et al., 2020, Bossers et al., 2021], dont une randomisée, et d'une méta-analyse intégrant plusieurs autres ECR de faible puissance [Al Lawati et al., 2020], le résultat de CRASH-3 reste la preuve la plus fiable de l'utilisation du TXA dans le TBI avec un rapport bénéfice/risque favorable [Maas et al., 2020].

En revanche, en ce qui concerne l'administration du TXA en cas de TBI, pour de nombreuses questions de recherche, la communauté médicale ne dispose pas et ne disposera pas des résultats d'essais prospectifs et randomisés mais s'appuie uniquement sur des données d'observation. Des alternatives sont nécessaires pour améliorer l'inférence à partir de données observationnelles. L'inférence causale tente de déterminer l'influence indépendante d'un effecteur en tant que composant d'un système complexe. L'inférence causale à partir de données d'observation diffère de l'association en analysant la réponse d'une variable effectrice lorsqu'une cause de la variable effectrice est modifiée. Les méthodes de cette famille d'approches,

1. L'échelle de coma de Glasgow est une échelle neurologique qui vise à évaluer l'état de conscience d'une personne. Plus le score est bas, plus la gravité du traumatisme est élevée.

par exemple la pondération par propension ou l'appariement, ont été appliquées avec succès par la physique, la recherche sur le climat, l'économétrie et les sciences cognitives [Harhay et al., 2014, Dreyfuss, 2005]. L'inférence causale et les techniques connexes semblent plus fiables que la recherche observationnelle et physiopathologique conventionnelle [Lederer et al., 2019] et aident à élaborer des hypothèses plus robustes pour la recherche prospective. L'inférence causale pour les données d'observation n'est pas destinée à devenir un substitut aux essais contrôlés randomisés, mais un ajout utile à l'arsenal méthodologique. Il semble nécessaire d'apprendre et de se familiariser avec ce concept en référence à des preuves de haut niveau telles que celles fournies par l'essai CRASH-3.

Sur la base de ce raisonnement, la présente étude a examiné la capacité de deux approches d'inférence causale (pondération de la propension inverse et méthode doublement robuste) combinées au traitement des données manquantes et à l'interprétation des résultats dans le contexte des preuves cliniques disponibles [Al Lawati et al., 2020]. Selon l'hypothèse, les résultats devraient concorder avec ceux obtenus avec l'essai de référence CRASH-3.

3.2 – Données et méthodes utilisées

Cette étude observationnelle est basée sur les données d'un registre régional multicentrique prospectif de traumatologie, la Traumabase®, décrite plus haut. Ce registre a obtenu l'approbation du Comité de Protection des Personnes (Paris VI et Clermont-Ferrand), du Comité Consultatif pour le Traitement de l'Information en matière de recherche dans le domaine de la santé (CCTIRS, 11.305bis) et de la Commission Nationale de l'Informatique et des Libertés (CNIL, 911461), en renonçant au consentement éclairé. Le registre dispose d'algorithmes d'homogénéité et de cohérence et d'un contrôle professionnel des données. Le suivi des données de la Traumabase® est assuré par le Laboratoire de Biostatistique de Paris 7.

3.2.1 Cohorte et analyse des données

Tous les patients consécutifs admis dans l'un des 14 centres de traumatologie participants ont été sélectionnés pour être inclus. Le tableau G.1 fournit la liste complète des variables qui ont été enregistrées pour chaque patient selon le modèle révisé de traumatisme majeur d'Utstein [Utstein TCD expert panel et al., 2008]. Le système de traumatologie des centres de traumatologie participants a été décrit précédemment [Gauss et al., 2019, Hamada et al., 2014, 2019] ; la prise en charge a été laissée à la discrétion du médecin responsable en fonction du triage national [Riou et al., 2002] et des directives de prise en charge des TBI [Geeraerts et al., 2018]. La liste de contrôle Strobe correspondante est fournie en Annexe H.1.

Le traumatisme crânien a été définie comme une lésion cérébrale identifiée sur un scanner cérébral à l'admission correspondant à un Abbreviated Injury Score > 2. Les patients ont été exclus si leur âge était < 16 ans ou si le patient a été admis dans un centre avec moins de 20 traumatismes crâniens sur toute la période d'inclusion.

L'administration de TXA a suivi le protocole CRASH-2, une dose intraveineuse de 1 gramme sur 10 minutes, suivie immédiatement d'une seconde dose intraveineuse de 1 gramme sur 8 heures. Pour les besoins de l'étude, les auteurs ont considéré que toute administration avait eu lieu dans les trois heures suivant la blessure. Le principal résultat d'intérêt était la mortalité hospitalière toutes causes confondues. Les patients décédés dans les 24 heures ont été retenus dans l'analyse afin de minimiser le biais de survivance.

L'objectif était d'évaluer par inférence causale l'effet du TXA sur la mortalité liée au traumatisme crânien à 30 jours dans une cohorte de patients ayant subi un traumatisme crânien. La cohorte d'étude a été stratifiée en sous-groupes prédéfinis conformément à l'essai CRASH-3 : GCS 9-12 et moins de 8 et anomalie pupillaire. Les autres résultats rapportés sont la mortalité toutes causes confondues à 30 jours et la mortalité toutes causes confondues ainsi que tous les décès liés à un traumatisme crânien pour permettre la comparaison avec d'autres études. Le logiciel statistique R version 3.6.2 [R Core Team, 2020] a été utilisé pour l'ensemble de l'analyse de cette étude.

La mesure de l'impact était l'effet moyen du traitement (ATE) et correspondait à la différence de mortalité entre les patients TBI exposés au TXA par rapport aux patients non exposés. L'ATE et l'intervalle de confiance à 95% (IC 95%) correspondant ont été calculés pour l'ensemble de la cohorte et pour des sous-groupes prédéfinis : Gravité du TBI (légère/modérée, sévère) et réactivité pupillaire (normale, réactive, non réactive). L'ATE correspond à l'estimation de l'effet moyen du traitement pour réduire la mortalité, exprimé en points de % de différence entre les deux groupes (voir Annexe H.2 pour les résultats de CRASH-3 exprimés en ATE). L'estimation a été considérée comme favorable à une relation de cause à effet si l'IC 95% n'incluait pas 0. Tous les 95%CI ont été calculés avec une méthode Bootstrap non paramétrique.

3.2.2 Spécificités de l'analyse causale

Les facteurs confondants potentiels ont été identifiés par un processus Delphi en consultant un groupe de 10 experts en TBI [Dalkey and Helmer, 1963]. Les variables pré-intervention (avant l'administration du TXA) identifiées par le processus Delphi concernaient des facteurs qui influenceraient le clinicien à administrer le TXA (par exemple, une hémorragie, voir Figure 3.1). Dans le modèle final (voir Annexe H.2), toutes les variables associées à la gravité du TBI et à la mortalité hospitalière (par exemple, GCS) ainsi que les critères associés à l'administration du traitement ont été visualisés avec le programme DAGitty [Textor et al., 2011] en un graphe acyclique dirigé (*Directed Acyclic Graph* en anglais, DAG, Figure 3.1) comme recommandé [Lederer et al., 2019].



FIGURE 3.1 – Graphe acyclique dirigé (*Directed Acyclic Graph* en anglais, DAG) : a) Variables pré-intervention associées avec la décision de traitement (en rouge) avec arêtes pointant vers l'administration du TXA ou vers la variable décès. b) Variables explicatives associées uniquement avec le critère de jugement principal (en bleu).

3.2.3 Traitement des valeurs manquantes

Imputation multiple par équations chaînées (MICE) L'imputation multiple par équations chaînées (*multiple imputation with chained equations* en anglais, MICE) exploite la corrélation entre diverses variables et modèles de variables en remplaçant les valeurs manquantes par des valeurs plausibles. Dans notre exemple de la cohorte TBI, les patients ayant un GCS de 3 sont plus susceptibles de présenter une anomalie de la pupille. MICE est une approche probabiliste prenant en compte, dans une certaine mesure, le niveau d'incertitude associé à l'estimation des valeurs manquantes. La figure 3.2 illustre cette approche. Pour chaque valeur manquante représentée par un " ?", cinq valeurs plausibles sont suggérées par un modèle d'imputation exploitant la corrélation des différentes variables. Cinq copies de l'ensemble de données initial sont créées. Dans chaque nouvel ensemble, les valeurs manquantes sont remplacées par des valeurs plausibles. L'ATE (effet de traitement moyen) est ensuite calculé pour chaque ensemble de données complété. L'ATE final correspond à la moyenne de tous les ATE pour chaque ensemble de données imputé. [2]

2. Le nombre cinq est arbitraire ici et pourrait être remplacé par un autre nombre entier positif.



$$\Rightarrow \quad \hat{\tau}_{MI} = \frac{1}{M} \sum_{m=1}^{M} \hat{\tau}^{(m)}$$

FIGURE 3.2 – Illustration du principe de l'imputation multiple imputation.

Missing incorporated in attributes (MIA) La méthode *Missing Incorporated in Attributes* applique une composante dite d'apprentissage machine par apprentissage automatique et ne correspond pas à une technique d'imputation classique. La méthode utilise des algorithmes de forêts aléatoires (une généralisation des arbres de classification et régression de Breiman [2001]) qui exploitent de corrélations et interactions présentes dans l'ensemble des données d'entraînement [Hastie et al., 2009]. Ces modèles sont entraînés de manière répétitive sur de multiples exemples dans l'ensemble de données et fournisses des modèles statistiques prédictifs ; d'où le concept d'apprentissage. Cela peut être vu comme une généralisation de la régression linéaire (multivariée). Par exemple, dans notre cas des données de la Traumabase®, l'algorithme peut identifier des sous-groupes de patients en fonction de leur profil d'hémoglobine capillaire et attribuer à cette valeur un niveau de choc ou d'hémorragie possible compte tenu du profil de données du patient. Si l'hémoglobine capillaire est manquante chez un autre patient, l'algorithme complétera la valeur manquante par la valeur la plus fréquemment rencontrée chez les patients ayant un profil correspondant. La méthode est capable d'intégrer de nombreuses variables et leur interaction. Pour prédire si un patient recevra le traitement, l'algorithme estimera la réponse la plus probable sur la base de l'échantillon de patients de la cohorte et se rapprochera du profil identifié dans la forêt aléatoire (voir Figure 3.3).



FIGURE 3.3 – Illustration du principe de *missing incorporated in attributes* (MIA).

3.3 – Résultats

Entre septembre 2010 et février 2019, un total de 20037 cas de traumatismes distincts ont été incorporés au registre Traumabase® dans 14 centres participants (organigramme en Annexe H.1). Parmi cet échantillon, 8269 correspondaient à la définition du TBI. Au total, 683 ont reçu du TXA et 7565 n'en ont pas reçu. Le Tableau G.1 en Annexe montre que les caractéristiques cliniques des deux groupes avant l'ajustement par le score de propension différaient significativement. Les patients ayant reçu du TXA étaient plus gravement blessés, présentaient des scores SAPS II plus élevés et étaient plus souvent en état de choc ou nécessitaient plus souvent une neurochirurgie et des soins neurocritiques.

Avant ajustement par l'approche d'inférence causale, la mortalité à 30 jours liée au traumatisme crânien observée dans le groupe TXA était de 30% (205/683) contre 15% dans le groupe sans TXA (1102/7565), p<0,001. L'effet moyen du traitement (ATE) indique la différence de mortalité dans le groupe TXA par rapport au groupe sans TXA. L'inférence causale selon la méthode IPW indique un ATE suggérant une association objective avec une mortalité plus élevée liée au traumatisme crânien à 30 jours après l'administration du TXA, indépendamment de l'approche appliquée pour estimer les données manquantes (ATE MICE : 0,10 (IC 95% [0,06, 0,14]) ; ATE MIA : 0,09 (IC 95% [0,03, 0,15])). Les résultats obtenus avec la méthode doublement robuste n'ont montré aucun effet du traitement sur la mortalité liée au traumatisme crânien à 30 jours (ATE MICE : -0,01 (95% IC [-0,05, 0,03]) ; ATE MIA : -0,01 (95% IC [-0,07, 0,05])).

Cette étude a appliqué deux techniques d'inférence causale, la pondération par inverse de propension (IPW) et la méthode doublement robuste (DR), combinées au traitement des données manquantes pour estimer l'effet du TXA sur les patients souffrant d'un traumatisme crânien à partir de données observationnelles. Sur la base de ce grand registre de données observationnelles, l'IPW semble surestimer un effet nocif du TXA sur la mortalité par rapport à la référence CRASH-3. En revanche, l'estimation basée sur la méthode doublement robuste (DR) suggère que

l'administration de TXA après un TBI n'exerce aucun effet sur la mortalité.

Comment ces résultats se rapportent-ils aux preuves disponibles ? Tout d'abord, l'étude actuelle ne se compare pas vraiment aux preuves prospectives disponibles. Toute évaluation entre les résultats présentés et les preuves prospectives, en particulier CRASH-3, sert uniquement à apprécier la performance des techniques statistiques (ou d'analyse) utilisées. Deuxièmement, les études prospectives divergent sur des points cruciaux tels que la puissance, les critères de résultat (mortalité à 28 jours contre mortalité à 30 jours ou toutes causes confondues), l'administration pré-hospitalière ou intra-hospitalière de TXA, l'exclusion de l'hémorragie extra-crânienne, les protocoles d'administration.

Lors de la comparaison de données observationnelles provenant de deux groupes très disparates, les méthodes standard de scores de propension ont tendance à sous-corriger la différence observée, soit en raison d'une mauvaise spécification du modèle (dans le cas de la régression logistique), soit en raison d'une taille d'échantillon insuffisante (dans le cas de la régression par forêt aléatoire). En conséquence, l'estimation de l'effet du traitement devient erronée. Dans le cas présent, l'IPW ne semble pas avoir suffisamment corrigé le biais de traitement, probablement parce qu'il a du mal à contrôler suffisamment les facteurs de confusion. L'IPW et le DR exigent tous deux une connaissance suffisante de tous les facteurs confondants. La méthode DR permet cependant un meilleur contrôle des biais potentiels et une variabilité plus faible que l'IPW, en intégrant à la fois une prédiction de la mortalité et de l'allocation des traitements. Cette double modélisation de la mortalité et de l'allocation des traitements exploite de manière optimale les données disponibles et protège contre une mauvaise spécification de l'un ou l'autre des modèles, ce qui la rend plus robuste que l'IPW. En outre, la flexibilité des forêts aléatoires dans la méthode doublement robuste engendre un modèle plus puissant capturant des relations complexes et adapté à l'application à une grande cohorte. La première conclusion de cette présente étude est donc que, lorsqu'on utilise l'inférence causale, la méthode DR est préférable à la méthode IPW. Cette étude présente également une innovation importante, puisqu'elle est la première à combiner la DR avec deux méthodes avancées pour traiter les données manquantes et les deux génèrent des résultats concordants.

3.4 – Conclusion de l'étude

Les essais menés dans le domaine des soins intensifs au cours des quinze dernières années ont souvent donné des résultats négatifs et étaient régulièrement sous-puissants pour détecter des objectifs de résultats souvent inatteignables [Harhay et al., 2014]. La mortalité, en tant que critère de résultat le plus certifié, ne permet souvent pas de rendre compte des effets hétérogènes d'interventions complexes dans des maladies complexes [Dreyfuss, 2005]. En outre, les ECR consomment de précieuses ressources humaines, financières, organisationnelles et temporelles. Les essais de référence tels que CRASH-3 résultent d'efforts de recherche internationaux exemplaires, qui ne sont pas applicables ou reproductibles pour de nombreuses questions de recherche.

Au-delà des contraintes de ressources, le recrutement nécessaire reste impossible à réaliser dans un délai approprié. Le recrutement n'est pas facilité par les bénéfices marginaux de plus en plus faibles apportés par des interventions de plus en plus complexes. Malgré une justification solide, l'étude CRASH-3 a nécessité plus de 12 000 patients.

L'inférence causale augmentée n'aspire pas à remplacer les essais contrôlés randomisés, mais elle est capable d'améliorer les études observationnelles conventionnelles, en particulier à l'ère du "big data" et de la recherche physiologique, et de fournir de meilleures justifications pour les ECR. L'approche pourrait devenir une référence pour préparer des ECR, explorer l'association de différentes interventions ou de différents groupes dans différents sous-groupes. Cette préparation personnalisée permettrait de canaliser les ressources de recherche vers les ECR les plus prometteurs. Pour cette raison, les résultats de cette étude utilisant l'inférence causale augmentée semblent prometteurs et devraient être explorés plus avant. Une association de données prospectives randomisées et d'inférence causale augmentée parallèle sur un ensemble de données d'observation est réalisée (cf. Chapitre 6).

Chapitre 4
Perspectives

L'objectif de cette thèse était double : proposer de nouveaux outils d'analyse de données dans le contexte de l'inférence causale, adaptés à certains des défis des processus modernes de collecte de données, à savoir les manques et l'hétérogénéité ; et développer des méthodologies pratiques adaptées à l'évaluation de questions de pertinence médicale et à l'aide à la prise de décision dans un contexte de contraintes de temps et de ressources, comme c'est le cas pour l'application choisie de la gestion des soins critiques. De nouvelles méthodologies sont développées à un rythme soutenu dans cette discipline plutôt jeune. Ces dernières années, en particulier, le concept de double apprentissage automatique Chernozhukov et al. [2018a] a encouragé l'utilisation de méthodes modernes d'apprentissage statistique plus complexes pour aborder les problèmes de causalité [par exemple, Shi et al., 2019, Louizos et al., 2017, Nie and Wager, 2017]. Il s'agit maintenant d'utiliser les théories existantes et de les appliquer au potentiel de données abondant parmi les domaines scientifiques. Cependant, un facteur clé réside dans l'écart entre le(s) cadre(s) statistique(s) classique(s) et les données collectées qui ne correspondent pas toujours—ou seulement partiellement—au premier. En outre, un facteur limitant connexe pour l'utilisation de ces méthodologies concerne les mises en œuvre qui permettent souvent des performances étonnantes dans le cadre d'hypothèses théoriques correctes sur le processus de génération de données – mais qui parfois ne parviennent même pas à produire un résultat sur des données qui divergent légèrement de ces hypothèses ; dans ces cas, la présence de valeurs manquantes produit une erreur d'exécution ou peut induire la suppression silencieuse de toutes les observations incomplètes, ce qui, dans les cas défavorables, peut conduire à d'autres violations des hypothèses nécessaires et à des conclusions potentiellement trompeuses.

Dans le contexte de l'inférence causale avec des données d'observation, comme nous l'avons vu dans les sections précédentes, un ensemble supplémentaire d'hypothèses sous-tend presque toutes les méthodologies et les outils d'analyse, garantissant l'identifiabilité de l'estimande causal. Cependant, lorsqu'il s'agit de problèmes concrets, par exemple dans un contexte clinique, la mesure dans laquelle ces hypothèses sont satisfaites par les données disponibles est une question de débat et nécessite des connaissances spécialisées solides pour garantir la validité de l'analyse statistique. En raison de ce niveau important d'incertitude lié à ces hypothèses, et en particulier à l'hypothèse de non-fondabilité, des techniques solides et robustes, à la fois efficaces

et flexibles par rapport aux types d'entrée, deviennent encore plus pertinentes pour divers domaines d'application.

Avec cette motivation, nous avons commencé par le problème de l'estimation de l'effet causal avec des attributs manquants dans les données d'observation, illustré sur l'application clinique dans le Chapitre 3. (voir le Chapitre 4 pour plus de détails). Cette méthode bénéficie de garanties théoriques obtenues en combinant les résultats de consistance pour l'apprentissage supervisé avec valeurs manquantes et pour l'apprentissage automatique double, et elle est conceptuellement et pratiquement facile à utiliser grâce à son intégration dans l'environnement plus large du paquet `grf`. R package environment.

Une catégorie de problèmes que nous n'avons pas abordée dans cette première partie est liée aux questions de généralisation des études et de transportabilité des résultats, en utilisant les forces combinées des études expérimentales et observationnelles. De telles questions se sont posées, par exemple, lors de la très récente et toujours en cours pandémie de COVID-19, qui a nécessité la proposition et l'adaptation de politiques de santé publique dans un contexte de preuves limitées et en constante évolution. Ce contexte, certes unique, a mis en lumière une question qui est cependant d'une pertinence et d'un intérêt plus général, à savoir la question de la combinaison d'études observationnelles et expérimentales de manière à orienter mutuellement les explorations et les expériences ultérieures et à soutenir la prise de décision pour des populations qui sont potentiellement différentes des populations étudiées précédemment. Dans le Chapitre 6, nous proposons un examen systématique de ces méthodes qui tirent parti de la dualité des études expérimentales et observationnelles, en exploitant la validité interne des données expérimentales et la validité externe des données observationnelles. La question associée de la transportabilité ou de la généralisation devient de plus en plus pertinente, notamment dans les applications pharmaceutiques, mais de nombreux problèmes de recherche connexes et intéressants doivent encore être abordés, d'un point de vue théorique, par exemple les questions de variables systématiquement manquantes, mais aussi d'un point de vue pratique, comme la grande variété de types de données et d'encodages qui nécessitent une communication claire entre les différents chercheurs de l'étude pour bien aligner les différentes sources de données. Cette remarque rejoint également un autre aspect important mis en évidence par l'application présentée au Chapitre 3, à savoir une partie complémentaire à la recherche en méthodologie statistique : la collaboration avec des experts du domaine qui est cruciale à chaque étape de l'analyse statistique, de la conception de l'étude, à la modélisation et à l'estimation des données, puis à l'interprétation des résultats. Ainsi, ce travail fournit également un exemple de création de valeur fructueuse et mutuelle tant en statistique qu'en recherche clinique.

Une extension intéressante du travail présenté dans cette thèse serait une formalisation plus précise et une méthodologie sur la façon de combiner l'expertise du domaine et la découverte causale automatisée pour exploiter les données et les connaissances disponibles de manière efficace, tout en quantifiant les niveaux d'incertitude à la fois du côté de l'expert et de l'algorithme. Un tel travail pourrait encore ne pas répondre à un reproche régulier—et compréhensible—adressé aux études observationnelles, à savoir leur talon d'Achille que sont les hypothèses d'identifiabilité

non testables. Des solutions telles que les analyses de sensibilité [Rosenbaum, 2010] et les méthodes à variables instrumentales [Imbens, 2014] pour répondre partiellement à ces préoccupations. Ces dernières sont en effet populaires dans la pratique, en particulier dans les applications économiques ; cependant, la façon dont les valeurs manquantes peuvent avoir un impact sur ces approches à variables instrumentales n'a pas encore été largement étudiée en théorie et en pratique. Une direction intéressante serait donc d'explorer cette classe de méthodes sous l'angle de l'identifiabilité et de l'estimation avec des valeurs (covariables) manquantes.

En conclusion, malgré les avancées majeures réalisées dans le domaine de l'inférence causale depuis les premières formalisations de Rubin [1974] et Pearl [1995], il est important de garder à l'esprit la conclusion de Cochran [1972] qui reste valable à ce jour : "*En conclusion, les études observationnelles sont un domaine intéressant et stimulant qui demande une bonne dose d'humilité, puisque nous ne pouvons prétendre qu'à tâtons vers la vérité.*". Cette remarque ne doit pas être comprise comme un appel à s'abstenir de poursuivre l'étude de problèmes d'inférence causale nouveaux et complexes, mais plutôt comme une note prudente sur ce que nous pouvons ou devons attendre de tels travaux, outre la valeur scientifique de résultats théoriques potentiellement forts.

Enfin, une façon transparente et robuste de répondre à une question en proposant de "bonnes" prédictions suppose également que la méthode est appropriée à la question posée et que la question, ou plus précisément l'estimande, est appropriée au problème d'intérêt. Ainsi, poser la question appropriée et choisir ou développer les outils appropriés pour répondre à ces questions sur la base des données disponibles est une tâche interdisciplinaire qui nécessite un échange continu entre les praticiens et les statisticiens et analystes, et une compréhension mutuelle des défis et limites respectifs. Un tel échange a ouvert la voie à la formulation des questions abordées et des résultats développés au cours de cette thèse et, espérons-le, encourage les collaborations futures, en abordant les questions de décisions de traitement dynamiques et en contribuant à la promotion de l'aide à la décision assistée par les données dans les soins intensifs et d'autres applications.

Part II

Causal analysis of heterogeneous data with missing values

Introduction

Context and motivation

A multi-disciplinary project for critical care management

The work that led to this present thesis has been conducted as part of the "TraumaMatrix" collaboration between the CAMS (CNRS-EHESS), CMAP (CNRS-École Polytechnique) and the Traumabase® group [Traumabase Group, 2012, accessed on 2021-04-07], the latter being initiated within the AP–HP (Assistance Publique – Hôpitaux de Paris). This initiative focuses on the analysis and modeling of critical care management, i.e., the management of major trauma patients. A major (or severe) trauma is defined as any injury that endangers a person's life or functional integrity. Major trauma, in its various manifestations—from road accidents, interpersonal violence, self-harm to falls—is a major source of death and disability, and a major public health issue [Hay et al., 2017]. Efficient patient management is crucial. Depending on the severity assessed at the accident site – by medical doctors, emergency physicians, firefighters, ... – patients are referred either to a specialized center, one of the "Trauma Centers", or to a general hospital. This switch is critical. The consequences can clearly be serious for a patient who is wrongly referred to a general hospital or cannot be treated effectively, and will have to be referred to a Trauma Center. Conversely, a patient wrongly referred to a Trauma Center will mobilize an entire multidisciplinary medical team and an operating room, putting the next patient on hold, the greatest risk then being for the latter. Similarly, some medical intervention decisions are difficult to make, but must be made urgently.

Experience shows that fast management of all major trauma based on standardized protocols improves functional outcomes and survival, particularly for the two leading causes of death in major trauma, i.e., bleeding and head injury. The classical path of a traumatized patient takes place in several stages: from the accident site where the patient is taken care of by the ambulance, to transfer to an intensive care unit (ICU) for immediate interventions, and finally to full care in the hospital. To be effective, patient management protocols require adjustments to the individual patient and clinical context, on the one hand, and to the organizational context and trauma system, on the other hand [Rice et al., 2012]. However, studies show that patient management, even in the most advanced Trauma Centers, often exceeds acceptable timelines [Hamada et al., 2014], and deviations from expected care according to the protocol are often observed [Rice et al., 2012]. These differences lead to high variability of care [Hamada et al., 2015] and are associated with poor outcomes

such as inadequate hemorrhage control or delayed transfusion. Two main factors explain these observations: On the one hand, trauma decision making is particularly challenging because it requires rapid and complex decisions under time pressure in a very dynamic and multi-stakeholder environment characterized by high levels of uncertainty and stress. On the other hand, the care process involves several actors and is thus weakened by the risks of information loss or misunderstandings [deMattos et al., 2012]. To improve decision-making and care processes, the AP–HP has for some years now developed a unique register of clinical data on major trauma patients in France, the "Traumabase". Over 20 French Trauma Centers have already decided to collaborate to collect detailed clinical data, from the first measures taken at the accident site, to the patient's discharge (or death) from hospital. This consortium of hospitals is gradually extending to the entire country [Traumabase Group, 2012, accessed on 2021-04-07]. The Traumabase® currently counts over 30,000 observations on trauma admissions and is continuously updated, with about 4,000 new entries per year. The granularity of the data collected makes this observatory unique in Europe.

The ultimate objective is to develop decision support models for emergency physicians who must help the practitioner to define the best medical strategy. It is also a question of identifying, for all the stages of care, the good or bad practices thanks to statistical analyses of the Traumabase®.

The Traumabase® registry: opportunities and challenges

The data gathered in the Traumabase® is qualified as heterogeneous or mixed - meaning that its variables can be qualitative or quantitative. Quantitative data usually are physical measurement values on a continuum, e.g., for systolic and diastolic blood pressure, (given in Riva-Rocci millimeters of mercury, mmHg). Qualitative data indicate a type of lesion (bleeding, head trauma, shock, etc., coded using a standardized scale [1]), presence of comorbidities, socio-professional status, etc. A large majority of statistical methods, classical or more recent, is suited for quantitative data due to the large spectrum of theoretical guarantees that can be derived from statistical theory. Other methods exist that address qualitative or categorical data.

Approaches that tackle the combination of all these types of data however are less frequently proposed, even though such data are the rule rather than the exception in many applications (see e.g., Murdoch and Detsky [2013], Heeringa et al. [2010]). Furthermore the Traumabase® registry is an aggregation of data coming from different participating Trauma Centers. This leads to another form of heterogeneity in the data, induced by the heterogeneity of trauma care processes which apply existing protocols in different variations and by the heterogeneity of the patient population which can vary from one center to another due to geographical and demographic differences [Hamada et al., 2015]. This induced multilevel structure of the registry represents another challenge for statistical analyses but also a potentially rich pool of information which could allow to compare different treatment strategies and to evaluate the generalizability of results from one patient population to a more or less

1. The Abbreviated Injury Score (AIS) is a clinical score that allows to describe and quantify anatomical injury https://www.aaam.org/abbreviated-injury-scale-ais/.

different patient population. Such multilevel structures are also encountered in data collected in other contexts, for instance through administrative claims, surveys, or (centralized) electronic health records (EHR). The latter often aggregate data from different hospitals, at a municipal, regional or national level and therefore share the challenges that come with the Traumabase® registry [Callahan et al., 2020].

Among these challenges is the often neglected presence of missing values: some data are missing when they should have been filled in, others because they are not relevant to the specific context of the patient concerned. All these characteristics are rarely found simultaneously in rigorously formalized data analysis problems, and the difficulty of missing data is particularly important in the context of critical care management where many observations and decisions are made by multiple actors in a short time-frame, facilitating potential loss of information on the way. Existing analytical methods are not well adapted to such a situation, for instance the literature on treatment effect estimation methods with missing values is scarce [Leyrat et al., 2019]. Complete case analyses – consisting in "throwing away" all observations with at least one missing value – is a default choice in many implementations of statistical methods [Josse and Reiter, 2018], but it dramatically impacts efficiency and power of the analysis and most likely induces biases in all subsequent analyses.

Efficacy and effectiveness, experimental and observational data

The increase of available data for statistical analyses and prognostic models is accompanied by a diversification in data types and sources that pose new challenges for extracting significant information from this multitude of available data. For causal questions, in a nutshell, one can distinguish between experimental data with controlled interventions and observational data without intervention control but often better representativity of real use-cases. [2] This concern is also termed *efficacy* versus *effectiveness* in public policy and clinical contexts, where efficacy aims to measure the treatment effect under ideal and controlled circumstances, while effectiveness supports the idea of measuring the average treatment effect in the real population targeted by the treatment [Flay, 1986]. A recent and prominent example are the clinical studies that preceded the authorization of the different COVID-19 vaccines, followed by several observational studies carried out within the vaccination campaigns, see for instance Dagan et al. [2021].

More generally, in healthcare and social science research, (prospective) observational studies are frequent, relatively easy to set up (unlike experimental studies of randomized trials, which are sometimes even impossible to conduct) and can allow different types of subsequent analyses such as causal inferences. The estimation of the average treatment effect (ATE), for example, is possible through the use of propensity scores that allow to correct treatment assignment biases due to confoundedness, i.e., the presence of factors related to both the treatment assignment and the variable

2. To summarize this observation in an even shorter sentence: "Not all data is created equal" [Neill et al., 2009].

of interest [Rosenbaum and Rubin, 1983b, Imbens and Rubin, 2015]. The term "causal" is to be understood in a specific way and might not reflect the common understanding of causality. Indeed, in classical statistics, a common approach is to posit a distribution model for a data generating process. Under conjecture of this distribution model, the goal is to characterize its features, e.g., data fits a Gaussian distribution with a certain mean and covariance. In causal inference, the goal is more ambitious in that there are several goals that are set with a same "causal model": the model should fit the observed distribution, but it should also allow to make inferences about how the system changes under interventions, i.e., inferences about interventional distributions. Thus, by "causal" we mean the effect of a variable, that is intervened on, on another variable that is measured either before and after the intervention or between individuals with and without intervention. The advantage and main interest of experimental studies is the control over the intervention, ensuring that the only variation between treated and non-treated groups lies in the treatment variable. Thus the observed variation in the outcomes can be related back to the treatment.

A violation of this clear and sole distinction between the treatment groups can lead to false conclusions about the effect of the treatment. The Salk Vaccine Field Trial [Salk, 1955, Brownlee, 1955] is a classical example for such a misguided conclusion. This large-scale randomized controlled double-blinded trial included over a million children who, after parental consent for trial participation, were administered a vaccine against poliomyelitis developed by Jonas Salk. The design of this study required accounting for such variations and additional considerations, due to the geographical and seasonal variability of polio outbreaks in this time. An alternative trial design without randomization had proposed to choose treated individuals among a certain school grade (second grade), conditional on their parents' consent. Controls would be those individuals whose parents hat not consented, as well as neighboring school grades (first and third grade). The second design consisted in randomizing treatment among the eligible individuals (2nd school grade and with parent's consent) and to provide a placebo to the ones randomized into control, allowing for a double-blinded study eliminating various types of biases. Both designs were carried out and, as expected by theory and by some groups of critical clinicians at the time, the first design led to an unfavorable conclusion about the vaccine's efficacy while the second design showed a significant protective effect of the vaccine against polio infection [Brownlee, 1955]. This large study, carried out less than 10 years after the first published randomized controlled trial [Medical Research Council Streptomycin in Tuberculosis Trials Committee, 1948], is considered an important step in the systematization of randomized placebo-controlled double-blinded studies to assess a (new) treatment whenever this is possible.

However, even with such a large study respecting randomization of treatment assignment and double-blinded design, it is important to point out that the validity of the conclusions of such a study generally only hold within the context of this particular study. Put differently, under *internal validity*, the results of the study are not directly extendable to other individuals than the individuals from the study, unless the study sample is representative of a larger population. In this latter case, conclusions from

the study are valid for this population as well. If the population of interest is not represented by the study population, the question of external validity arises, i.e., whether generalizability of the empirical findings to a different environment, setting or population is possible, usually based on auxiliary observational data that describes this different context [Colnet et al., 2020]. Note that in any case, external validity is limited by internal validity; if a causal conclusion drawn within a study is invalid, then generalizations of this inference to other contexts will also be invalid. This remark highlights again the importance of both forms of validity and both sources of data for assessing the efficacy and effectiveness of a treatment.

Finally, the evoked issues and examples give a hint of the complexity of the theoretical and methodological challenges and indeed we will go into more details and contextualize them in the broader framework presented in Part IV.

The role of missing values in theory and in practice

A major problem with large observational studies is their complexity and often incompleteness: covariates are often taken at different levels and stages, they can be heterogeneous – categorical, discrete, continuous – and almost inevitably contain missing values. Although the problem of missing data is unavoidable in statistical practice, most methods of analysis, in causal inference as in other fields, cannot be implemented directly from incomplete data. This domain is expanding rapidly within the statistical community, as the problem of missing data is exacerbated by the multiplicity of data collected, often from different sources of information [e.g., Josse and Reiter, 2018, Mayer et al., 2019]. It is therefore crucial to identify effective methodologies for carrying out (causal) analyses in the presence of incomplete data, and especially to know how much confidence can be placed in the results obtained from incomplete data.

The problem of missing values in causal inference has long been ignored and only recently gained some attention due to the non-negligible impacts in terms of bias induced by complete case analyses and mis-specified imputation models. In Part III, we discuss conditions under which causal inference can be possible despite missing confounder values, namely unconfoundedness on the observed values; we propose two several alternative ATE estimators which directly account for the missing values, the first is built on logistic-linear specification and observed likelihood, appropriate for data *missing at random*, the second uses semi-parametric estimation based on random forests with the great advantage of handling data *missing not at random*, and the third is based on latent confounding modeling. We compare these three estimators to different methods proposed in the past to deal with missing confounder values. In Chapter 4 and Appendix H we assess the performance of our estimators on the large prospective Traumabase® registry containing detailed information about over 30,000 severely traumatized patients in France. Using the proposed ATE estimators and this database we study the effect on mortality of tranexamic acid administration to patients with traumatic brain injury in the context of critical care management.

Summary of contributions of this thesis

Causal inference on incomplete observational data

The objective of the thesis has been, in a first step, to develop a so-called "doubly robust" methodology [Robins et al., 1994, Chernozhukov et al., 2018a] adapted to missing data for the estimation of the average treatment effect [Mayer et al., 2020]. This work, published in *The Annals of Applied Statistics*, is a theoretical and methodological contribution to communities whose interest in causal inference is motivated by the significant bias impact that is induced by complete case analyses or poorly specified imputation models [Mattei and Mealli, 2009]. Indeed, the new methodology, placed in the Neyman-Rubin potential outcome framework [Splawa-Neyman et al., 1929, Rubin, 1974], not only extends the robust dual approach to missing data, but also makes it possible to manage missing data that is informative, such as "missing not at random" [MNAR Seaman et al., 2013, Franks et al., 2016]. A variable is MNAR if the probability of missingness on this variable depends on unobserved information, e.g., the value of the variable itself. The classic example is information on the "income": rich people are less likely to disclose their income, resulting in a lack of income data for wealthy people [Atkinson et al., 2011]. In the context of the management of major trauma, it is admitted by practitioners that much of the missing data is likely to fall into this category of missing values. The methodology developed during the thesis has been applied to a concrete question emerging in the context of major trauma: *is there an effect of tranexamic acid on the mortality of patients with head injury?* This question has very recently been the subject of a large randomized controlled study CRASH-3 [Dewan et al., 2012]. The results of estimating the average effect with the proposed doubly robust methodology on the observational Traumabase® data are consistent with the results concerning the primary outcome of interest of the CRASH-3 study [Cap, 2019]. This result is a first empirical evidence for the feasibility of the proposed methodology. Another study carried out in the context of the current COVID-19 pandemic also deployed this new methodology to assess the effectiveness of a specific candidate treatment (see Chapter 8 for this study).

Causal inference for combining observational and experimental data

A related issue which has arisen during this thesis concerns the simultaneous availability of experimental and observational data to estimate a treatment effect. This represents both an opportunity and a statistical challenge: combining the information gathered from both data is a promising avenue to build upon the internal validity of randomized controlled trials (RCTs) and a greater external validity of observational data, but it raises methodological issues, especially due to different sampling designs inducing distributional shifts. In two works, one submitted to *Statistical Science*, the other to *Statistics in Medicine*, we focus on the aim of transporting a causal effect estimated on an RCT onto a target population described

by a set of covariates. We first propose a thorough review and experimental assessment of existing methods such as inverse propensity weighting, g-formula and doubly robust methods. While missing values are common in both data neither of these available methods are designed to handle them. After coupling the assumptions for both the causal identifiability and the missing values mechanism, as well as defining appropriate strategies, one has to consider the specific structure of the data with two sources and treatment and outcome only available in the RCT. We study different approaches and their underlying assumptions, in the full data and in the incomplete data case, on the data generating processes and distribution of missing values and suggest several adapted methods, in particular multiple imputation strategies. These methods are assessed in an extensive simulation study and practical guidelines are provided for different scenarios.

This work has been motivated by the analysis of a large registry of over 30,000 major trauma patients and two multi-centered RCTs studying the effect of tranexamic acid administration on mortality. The analyses illustrate how the different reviewed methods compare on real data and how the missing values handling can impact the conclusion about the effect transported from the RCT to the target population.

Outline of the thesis

We begin with an introduction to causal inference in Chapter 1, laying out the main concepts, notions and results of this discipline, which will facilitate the understanding of the remainder of the thesis. In Chapter 2 we discuss the role of missing values in general statistical problems and in particular in causal inference. This is followed by the short Chapter 3 about the main data analyzed in this thesis. The main methodological and theoretical contributions of this thesis are detailed Chapters 4, 5, 6 and 7. These are completed by a concrete medical study in Chapter 8 and an illustration of the implementations and practical conclusions accompanying these contributions in Chapters 9 and 10.

Chapter 1
Causal inference: an introductory overview

Through sheer existence, you know what a causal effect is, understand the difference between association and causation, and you have used this knowledge consistently throughout your life. Had you not, you'd be dead.

— Miguel A. Hernán, James M. Robins, *Causal Inference: What if?*

Table of contents
Table des matières

1.1 – What do we mean by "causal"?

Causal inference questions arise in many domains such as socio-economics, politics, psychology, medicine, etc., and are of the form *"given the circumstances, what action should be taken to achieve a certain goal"*. An answer to such question requires a sufficient understanding of the system or underlying mechanism, enabling the decision-maker to evaluate the effect of her decision on the system. Thus, such questions can be reformulated to *"what would happen if I took action A instead of action B (or C)?"* or *"how would the system change if I intervened on a certain part of it?"* The action could be the administration of a drug and its effect on a patient's health, or a marketing strategy for product placement and its effect on a consumer's purchase behavior, etc. The notion of causality is often avoided by statisticians and this manifests, for instance, in the famous phrase "correlation is no causation", taught to generations of young scholars taking introductory or advanced statistics courses. Indeed the notion of causality and its rather vague definition may not be suited and are often replaced by the terms of causal inference or treatment effect

estimation [Hernán and Robins, 2020], which have been of interest to statisticians for almost a century now, since Fisher [1936] formalized the concept of treatment randomization and Splawa-Neyman et al. [1929] the concept of counterfactual or potential outcomes. The causal inference formalism allows one to study questions like the one given above as a common estimation problem. Caution is required when reasoning in terms of causality, since we may be able to estimate an effect of one factor on another but this does not explain the causality itself.

The sometimes vaguely perceived distinction between the statistical notion of causal effects and the intuitive common concept of causality can lead to misinterpretations [Messerli, 2012]. It is thus crucial to first clearly articulate the causal question of interest, in order to lay out a statistical analysis plan and interpret the results accordingly [Glymour and Hamad, 2018]. Another important preliminary question to consider is whether the data allows to discover causal relations and has to be assessed after the question has been formulated. It is commonly admitted that the gold standard for treatment effect estimation are randomized controlled trials (RCT) that allow to estimate the average effect of a treatment, an intervention or a policy on a well defined population of interest. For instance, in pharmaceutical and medical research, RCTs are compulsory for the authorization of new drugs or other treatments. [1] However RCTs are generally very expensive in terms of time, human resources, and financial costs [Concato and Horwitz, 2004], and in recent years many RCTs led to inconclusive results despite large and expensive trial design [Hwang et al., 2016, Fogel, 2018]. Furthermore in some areas such as economics or political sciences, it is often impossible to implement an RCT to assess the effectiveness of a given intervention or policy, for instance the impact of a minimum wage policy on employment, with few exceptions carried out for instance by Duflo et al. [2012].

Once we have an understanding of causal relations between variables we can attempt to use this knowledge to make "stable" predictions, for instance treatment prescriptions, as opposed to ordinary predictions obtained with (supervised) learning algorithms applied directly on the data and which risk to leverage ephemeral relations to make predictions [Efron, 2020, Subbaswamy and Saria, 2018]. Indeed probabilistic inference focuses on predicting consequences of observations by modeling the data distribution. Causal inference models the mechanism that generates the data and allows to predict results of interventions. But, as pointed out as the fundamental problem of causal inference by Holland [1986], we want to estimate something that we never observe since we never see the counterfactuals for a same individual at a same time (induced by different treatments or policies).

Despite this fundamental problem, there exists a multitude of well studied methods to consistently and efficiently estimate causal effects in different scenarios, motivated by a long tradition in economics, epidemiology and public policy where reasonable and justified decisions have to be made in never experienced situations. In the following, we will review the most common and well established approaches, discussing their underlying assumptions and highlighting their advantages and limits, in theory and in practice.

1. With a few notable exceptions which will shortly be discussed in Part IV.

1.2 – The potential outcomes framework

1.2.1 Definitions

Suppose we observe n independent and identically distributed (i.i.d.) samples $(X_i, W_i, Y_i) \in \mathcal{X} \times \{0, 1\} \times \mathbb{R}$, where $|\mathcal{X}| = p$, $X_i = [X_{i1}, \ldots, X_{ip}]^T$ is a vector of attributes, W_i the treatment assignment indicator [2], and Y_i the outcome of interest. Depending on the context, the covariates for observation i will either be denoted by X^i or $X_{i,\cdot}$ (the i-th row from the covariate matrix $\boldsymbol{X} = [X_1, \ldots, X_p] \in \mathcal{X}^{n \times p}$) [3]. In the following, expectations and probabilities will refer to the distribution induced by the random sampling from the population, or by the (conditional) random assignment of the treatment.

We define "causal effects" under the Neyman-Rubin potential outcomes framework [Splawa-Neyman et al., 1929, Imbens and Rubin, 2015] which relies on the following quantities of *potential* or *counterfactual* outcomes.

Definition 1.2.1 (Potential outcomes)**.** ***Potential outcomes*** *are denoted by* $\{Y_i(0), Y_i(1)\}$ *and defined as the outcome the* i*-th individual would have experienced had she been assigned treatment* $W_i = 0$ *or* 1 *respectively. They take values in the same space, usually in* $\mathbb{R}$*.*

For the treatment assignment W_i, we can think of *treatment vs. control* or *treatment A vs. treatment B*, and their associated potential outcomes, in some cases also referred to as counterfactuals, $Y_i(1)$ and $Y_i(0)$, where the observed outcome is the *factual outcome* while the unobserved is called *counterfactual outcome*. In the remainder of this thesis, we will refer to individuals with $W_i = 1$ as *treated* and to those having $W_i = 0$ as *controls*.

To assess the effect of a treatment we are interested in the individual treatment effect.

Definition 1.2.2 (Individual treatment effect)**.** *The* ***individual treatment effect*** *for individual* i *is the difference of his potential outcomes*

$$\tau_i \triangleq Y_i(1) - Y_i(0). \tag{1.1}$$

By definition of the potential outcomes, this quantity is never observed. Faced with this impossibility to observe the quantity of interest τ_i, other substitute quantities of interest to evaluate a treatment effect are considered: averages of τ_i over different subsets of the original sample or population, for instance the (population) average treatment effect (ATE).

Definition 1.2.3 (Average treatment effect)**.** *We denote the* ***average treatment effect*** *(ATE) by* τ*, and define it as*

$$\tau \triangleq \mathbb{E}[Y_i(1) - Y_i(0)] = \mathbb{E}[\tau_i], \tag{1.2}$$

2. Throughout this thesis we will only consider the binary treatment case. However there exist various approaches to dealing with multinomial and continuous treatments [Hirano and Imbens, 2004].

3. Note that here $\mathcal{X}$ is a generic notation for the covariate space of dimension p.

where the expectation is taken over the joint distribution of $(X_i, W_i, Y_i(0), Y_i(1))$.

The average treatment effect corresponds to the effect of switching every individual from one group to the other.[4] There exist similar quantities of interest such as the average treatment effect on the treated (ATT) or on the controls (ATC):

$$\tau^{ATT} \triangleq \mathbb{E}[Y_i(1) - Y_i(0) \mid W_i = 1] = \mathbb{E}[\tau_i \mid W_i = 1] \tag{1.3}$$
$$\tau^{ATC} \triangleq \mathbb{E}[Y_i(1) - Y_i(0) \mid W_i = 0] = \mathbb{E}[\tau_i \mid W_i = 0] \tag{1.4}$$

As their names indicate, these estimands are defined over different (sub)sets of the entire population. For instance, the ATT can be rephrased as the difference of the expected outcome of the treated under treatment and the expected outcome of the treated had they not been treated. This focus on the effect on the group of individuals who actually received the treatment is more meaningful and useful in certain cases. For instance in oncology, chemotherapy is usually given to all eligible cancer patients, while it is never given to patients who do not suffer from cancer. The question of interest is therefore to determine the average effect of chemotherapy on cancer patients – as it is irrelevant to estimate the effect for the patient subpopulation that does not have cancer. Similarly, the ATC can be of interest in other contexts, where the focus is on the individuals who are not treated (one could think of treatment or intervention that is inaccessible due to systemic or monetary barriers or due to regulatory counter-indications). These two estimands are identifiable under slightly less restrictive assumptions as those that we will see below.

Finally, we note that there exist other possible estimates to quantify a treatment effect such as the relative risk or the odds ratio:

$$\tau^{RR} \triangleq \frac{\mathbb{E}[Y_i(1)]}{\mathbb{E}[Y_i(0)]}$$
$$\tau^{OR} \triangleq \frac{\mathbb{E}[Y_i(1)]/(1 - \mathbb{E}[Y_i(1)])}{\mathbb{E}[Y_i(0)]/(1 - \mathbb{E}[Y_i(0)])},$$

which, in some cases, are preferred over the ATE, depending on the studied phenomenon and context [Yadlowsky et al., 2019]. The relative risk or risk ratio is the ratio of risks of the treated and the control group. For instance, assuming a binary outcome where $Y = 1$ indicates an adverse event, a value $\tau^{RR} = 0.76$ indicates that treated individuals have a lower risk of an adverse event than control patients and that the treatment induces a 24% decrease in the risk of such an adverse outcome. The relative risk is interpretable on a proportional scale, and it is therefore generally

4. Sometimes it is necessary to distinguish between the sample ATE (SATE) and the population ATE (PATE). The difference between the variances of SATE and PATE is exactly the variance of the treatment effect. In the definition of the PATE, $\tau^{PATE} = \mathbb{E}[Y_i(1) - Y_i(0)]$, the potential outcomes are assumed to be random variables drawn from a super-population; the SATE definition, $\tau^{SATE} = \widehat{\mathbb{E}}_n[Y_i(1) - Y_i(0)] = \frac{1}{n}\sum_{i=1}^{n} Y_i(1) - Y_i(0)$, considers all potential outcomes as fixed values, put differently, all inferences are conditional on the vectors of the potential outcomes [Ding and Li, 2018]. Note that in RCTs the target estimand is usually τ^{SATE}, while in observational studies it is often τ^{PATE}. And under the random sampling assumption, we have $\mathbb{E}(SATE) = PATE$. Since we consider this case here, we will therefore drop the distinction between the two.

recommended to use it as a relative effect measures for summarizing the evidence, while absolute measures, such as the ATE, are more meaningful for application to a concrete clinical or public health case [Schechtman, 2002]. The odds ratio is the ratio between the odds of the treated and the odds of the control group (where odds can be interpreted as the number of events relative to the number of nonevents). For instance, assuming we have a binary outcome Y, where $Y = 1$ denotes the event of interest and assuming $\tau^{OR} < 1$, this can be interpreted as the risk of the event being lower in treated individuals than in control individuals and conversely for $\tau^{OR} > 1$. To provide a more concrete interpretation, assume again a binary outcome and an odds ratio of 1.7 – corresponding to the odds of $Y = 1$ (instead of $Y = 0$) being 70% higher in treated patients than in the control patients. The odds ratio is also a proportional measure of effect, however it is less intuitive to interpret and presents certain drawbacks [see e.g. Yadlowsky et al., 2019] and the relative risk should be preferred over the odds ratio when the initial risk (i.e., without treatment) is high [Davies et al., 1998]. For more examples and details on these estimands we refer to Schechtman [2002]

1.2.2 Identifiability

In order to (non-parametrically) identify τ, i.e. to express it in terms of solely observable information, we need to make further assumptions about the data generating process: The *ignorability*, *unconfoundedness* or *exogeneity* assumption (the terms are equally used in the literature) states that all confounding factors are measured, i.e., conditionally on X, the treatment assignment is independent of the potential outcomes. In other words, there is no unobserved confounding variable U in Figure 1.3. Formally we define it as follows.

Definition 1.2.4 (Unconfoundedness)**.** *The* ***unconfoundedness*** *assumption states that*

$$\{Y_i(1), Y_i(0)\} \perp\!\!\!\perp W_i \,|\, X_i \qquad \textit{for all } i. \tag{1.5}$$

This assumption can be weakened and still allow to identify $\mathbb{E}[Y_i(w)]$, $w \in \{0, 1\}$; indeed we could assume instead that we only have

$$\mathbb{E}[Y_i(w) \,|\, W = w, X] = \mathbb{E}[Y_i(w) \,|\, X], \; w \in \{0, 1\}. \tag{1.6}$$

This equality is implied by (1.5) and also allows to tackle inherent problem of missing outcome values due to counterfactuals.

Another standard assumption in the causal inference in the Neyman-Rubin framework [Imbens and Rubin, 2015] is the *Stable Unit Treatment Value Assumption* (SUTVA, Rubin [1978b], Cox [1958]).

Definition 1.2.5 (Stable Unit Treatment Value Assumption)**.** *Formally, the* ***SUTVA*** *assumption is composed of two parts:*

$$Y_i = Y_i(W_i) \tag{1.7}$$
$$Y_i = W_i Y_i(1) + (1 - W_i) Y_i(0). \tag{1.8}$$

This assumption translates into two aspects: the outcome of unit i is independent of the treatment assignment of other units and the treatment is stable, i.e., there are no multiple versions of the treatment which could lead to different outcomes. For instance if the treatment is *surgery* then we assume that the result of the surgery does not depend on the surgeon who operated the patient.

Finally, an important assumption is that of *probabilistic treatment assignment* or *overlap*[5].

Definition 1.2.6 (Propensity score and overlap assumptions)**.** *The* ***propensity score*** *is defined by*

$$e(x) \triangleq P(W_i = 1 \,|\, X_i = x), \tag{1.9}$$

following [Rosenbaum and Rubin, 1983b, Imbens and Rubin, 2015]. In order to identify the causal estimand such as the ATE, we require probabilistic treatment assignment, also known as ***overlap*** *assumption:*

$$\exists\, c > 0, \;\; \textit{such that } c < e(x) < 1 - c \quad \textit{for all } x \in \mathcal{X}. \tag{1.10}$$

A well known and important result related to the unconfoundedness assumption is that if condition (1.5) holds, then we also have

$$\{Y_i(1), Y_i(0)\} \perp\!\!\!\perp W_i \,|\, e(X_i) \qquad \text{for all } i. \tag{1.11}$$

This implies that instead of having to control for all covariates X_i one can limit oneself to controlling for $e(X_i)$[6]. Indeed this important result has been established by Rosenbaum and Rubin [1983b] who show that the propensity score is a balancing score: it balances the two groups in terms of covariate distribution.

$$P(X, W \,|\, e(X)) = P(X \,|\, e(X))\mathbb{P}(W \,|\, e(X)). \tag{1.12}$$

More specifically, this result can be understood as follows: the propensity score contains all the information required to disentangle the covariates X and the treatment assignment W and thus to balance the covariate distributions for each level of W without any remaining confounding.

The proof for this result holds in a couple of lines:

Proof. We have $P(X, W \,|\, e(X)) = P(X \,|\, e(X))P(W \,|\, X, e(X)) = P(X \,|\, e(X))P(W \,|\, X)$ where the first equality always holds and the second one is given by the fact that $e(X)$ is a function of X, therefore conditioning on X is equivalent to conditioning on $X, e(X)$. Next we note that $P(W = 1 \,|\, X) = e(X)$ by definition and $P(W = 1 \,|\, e(X)) = \mathbb{E}[W \,|\, e(X)] = \mathbb{E}[\mathbb{E}[W \,|\, X] \,|\, e(X)] = \mathbb{E}[e(X) \,|\, e(X)] = e(X)$, which concludes the proof. □

5. Note that the coupling of probabilistic assignment and unconfoundedness assumptions is also referred to as *strongly ignorability* assumption [Rosenbaum and Rubin, 1983b].

6. This result can be extended to multivalued treatment, see Imbens [2000].



Figure 1.1 – Observational data model with observed (and without unobserved) factors. We are interested in estimating the link between W and Y. The propensity score $e(X)$ breaks (or closes) the path between confounders X and treatment W.

An additional assumption which is made implicitly in many works on causal inference consists of *perfect compliance* or *adherence*, i.e., every individual assigned to a group effectively belongs to this group. Note that this condition is not always true – where e.g. social sciences rely on self-assessments this perfect compliance assumption is often found to be violated. However, there exist methods to handle cases of non-compliance: instead of only considering the treatment assignment variable W, we define the assigned treatment Z and the received treatment W; assuming that perfect compliance does *not hold* using only the variable Z for treatment assignment, the target estimand will measure the effect of assigning participants to being treated with Z, this is referred to as the *intention-to-treat effect*. We refer to Hernán and Robins [2020, Chapter 9] for more details on this aspect.

1.3 – An alternative framework: Structural Causal Models

Although this thesis is mainly based on the Neyman-Rubin potential outcomes framework introduced above, it is important to point out that there exist other widely used approaches to causal inference than this framework, the most prominent examples being the structural causal models (SCM) framework and, to a lesser extent, causal Bayesian networks. The former is based on seminal work by Pearl [1995] and has since been developed by many well known figures mostly from the machine learning community: P. Bühlmann, B. Schölkopf, P. Spirtes, J. Mooij, M. Maathuis, and many others.

We briefly recall the main concepts and results of the SCM framework which leverages results from probabilistic inference theory, in particular probabilistic graphical modeling, by alternating between causal graphs and subsumed probabilistic graphs underlying the observed and interventional distributions. In this framework, causal reasoning refers to the process of drawing conclusions from a causal model, similar to the way probability theory is the basis for reasoning about random processes. However, because causal models contain more information than probabilistic models, they are richer, and enable the analysis of the effect of interventions or changes in distribution. In the same way that statistical learning poses the inverse problem of probability theory, the SCM framework asks how to infer causal structures from their

empirical implications. The data used may be purely observational, but may also include results obtained from interventions (e.g., randomized trials). The Figure 1.2, which corresponds to Figure 1.1 in Peters et al. [2017], summarizes the relationships between causal reasoning and probabilistic inference theory. A probabilistic model allows to describe and reason about (random) processes. Given data, with statistical learning we aim to infer a parameter of an assumed underlying probabilistic model. With an infinite amount of data, the inference problem is solved. With a causal model, we are able to make statements about observations and changes following interventions. Inversely, with data we can infer a causal structure that fits the observed and interventional distributions. But even with an infinite amount of data, the problem of estimating the underlying causal structure can remain impossible in some cases, i.e., the causal model can be unidentifiable. We also refer to Peters et al. [2017] for a detailed introduction and overview of the SCM framework and recent developments. [7] These developments evolve around a list of open research questions and subtleties which have only been answered partially and for specific cases: *How does the causal model work?*, *What if there are hidden variables or treatment-confounder feedback?*, *What is the best graphical representation, especially in case of hidden variables or feedback?*, *Can we test counterfactual statements?*, *Can we infer the graph structure from data?*, *Is causality useful, even in classical ML/statistics settings?*



Figure 1.2 – Terminology used in the SCM framework to distinguish and relate probabilistic inference problems and causal inference problems. This graph reproduces the Figure 1.1 from Peters et al. [2017].

Definitions and notations Probabilistic graphs are at the center of the SCM framework and we first give a brief series of definitions required to state the main results under the SCM framework: Consider a finite number of random variables

7. The following section is also inspired by a related short course given by Jonas Peters at the MIT Broad Institute in 2017.

$X \triangleq (X_1, \ldots, X_p)$ with joint distribution f, and a set of *nodes* (or *vertices*) $V \triangleq \{1, \ldots, p\}$. A graph $\mathcal{G} \triangleq (V, \mathcal{E})$ is composed for a finite number of nodes V and edges $\mathcal{E} \subseteq V \times V$ such that $(v, v) \notin \mathcal{E}$, i.e., there are no edges from a node to itself. We can associate the random variables X to the nodes V of the graph, i.e., node i represents the random variable X_i. Sets of nodes represent sets of random variables: if $A \subseteq V$, then $X_A \triangleq \{X_i : i \in A\}$.

A node i is a *parent* of node j if $(i, j) \in \mathcal{E}$ and $(j, i) \notin \mathcal{E}$. In this case, j is called a *child* of i. The set of parents of node j is denoted by $pa(j)$, or by $pa(X_j)$ when reasoning in terms of the associated random variables. An edge between two adjacent nodes (i.e., two nodes i and j such that $(i, j) \in \mathcal{E}$ or $(j, i) \in \mathcal{E}$) is qualified as *directed* if it informs a direction from one node to the other; assuming that $(i, j) \in \mathcal{E}$, we then write $i \to j$ to denote this direction. A graph that only contains directed edges is called a *directed graph*. A *path* in the graph $\mathcal{G}$ is defined as a sequence of at least two distinct nodes $i_1, \ldots, i_l$, such that there exists an edge between i_k and i_{k+1} for all $k \in \{1, \ldots, l-1\}$. If there is a directed path from i to j, then i is an *ancestor* of j and j is a *descendant* of j. A directed graph $\mathcal{G}$ is called a *directed acyclic graph* (DAG) if it contains no directed cycle, i.e., there exists no pair $(k, l) \in V \times V$ such that there is a path from k to l and from l to k.

We can connect a distribution P with density p (with respect to the Lebesgue measure μ) to a DAG by noting the following: the density p of the distribution P over the set of random variables X can always be factorized using the *probability chain rule*: $p(x_1, \ldots, x_p) = p(x_1)p(x_2|x_1) \ldots p(x_p|x_1, \ldots, x_{p-1})$. A set of variables $X_{pa(j)}$ is said to be *Markovian parents* of X_j, if it is a minimal subset of $\{X_1, \ldots, X_{j-1}\}$ such that $p(x_j|x_1, \ldots, x_{j-1}) = p(x_j|x_{pa(j)})$. Using the notion of Markovian parents, we can factorize p as follows: $p(x_1, \ldots, x_p) = \prod_{j=1}^{p} p(x_j|x_{pa(j)})$. And using the above definition of parents and children, we can draw a corresponding DAG for this factorization of f. We can then define a *DAG model* (or *Bayesian network*) as a combination $(\mathcal{G}, P)$, where $\mathcal{G}$ is a DAG and P is a distribution with density p that factorizes according to $\mathcal{G}$, i.e.,

$$p(x) = \prod_{i \in V} p(x_i|x_{pa(i)}), \quad \forall x.$$

Note that a distribution can factorize according to several DAGs. DAG models are also used in other contexts than causal inference, for instance for estimating the joint density from low order conditional densities [see, e.g., sum-product message passing Pearl, 1982].

Definition 1.3.1 (d-separation, Pearl [1995])**.** *In a DAG $\mathcal{G} = (V, \mathcal{E})$,*

1. *a path between two nodes $i_1 \in V$ and $i_l \in V$ is **blocked** by a set $C \subseteq V \backslash \{i_1, i_l\}$ if there exists a node i_k on this path such that either one of the following two conditions is satisfied:*
   - *(i) $i_k \in C$ and ($i_{k-1} \to i_k \to i_{k+1}$ or $i_{k-1} \leftarrow i_k \leftarrow i_{k+1}$ or $i_{k-1} \leftarrow i_k \to i_{k+1}$);*
   - *(ii) neither i_k nor any of its descendants is in the set C and $i_{k-1} \to i_k \leftarrow i_{k+1}$ (i_k is qualified as a **collider** on the path between i_1 and i_l).*

2. *two disjoint subsets A and B of $\mathcal{E}$ are **d-separated** by a set $C \subseteq V \backslash \{A, B\}$ if every path between a node $a \in A$ and a node $b \in B$ is blocked by the set C. This is denoted as $A \perp_{\mathcal{G}} B \mid C$.*

If a distribution P over the associated random variables of a DAG $\mathcal{G}$ factorizes according to $\mathcal{G}$, then all d-separations in $\mathcal{G}$ imply conditional independencies in P.

Definition 1.3.2 (Global Markov property)**.** *A distribution P satisfies the **global Markov property** with respect to a DAG $\mathcal{G}$ if:*

$$A \text{ and } B \text{ are d-separated by } C \text{ in } \mathcal{G} \Rightarrow X_A \perp\!\!\!\perp X_B \mid X_C \text{ in } P.$$

This property allows to read off some of the conditional dependencies and independencies of P from the DAG $\mathcal{G}$, but generally not all conditional dependencies.

Definition 1.3.3 (Faithfulness)**.** *A distribution P is **faithful** with respect to a DAG $\mathcal{G}$ if*

$$X_A \perp\!\!\!\perp X_B \mid X_C \text{ in } P \Rightarrow \ A \text{ and } B \text{ are d-separated by } C \text{ in } \mathcal{G}.$$

This assumption ensures that all conditional dependencies of P are encoded in the DAG.

With these basic notions and results from graph terminology, we are now ready to review their role for structural causal models and structure learning.

1.3.1 Structural learning

The idea behind structural learning in the context of causality is that directed graphs encode some "causal structure". Ideally, the goal would be to infer the true underlying DAG from observed data, but this is in general impossible with solely observational data. More precisely, if we assume a true DAG $\mathcal{G}$ and the data-generating distribution P which allows a recursive factorization with respect to $\mathcal{G}$, and if we assume that we observe n i.i.d. samples of $X_1, \ldots, X_p \sim P$, then we cannot identify $\mathcal{G}$, i.e., there are several DAGs $\mathcal{G}' \neq \mathcal{G}$ such that P factorizes according to $\mathcal{G}'$. It is however possible to infer the Markov equivalence class of DAGs with minimal number of edges: $\mathcal{D}_{minimal\, I-MAP}(P) \triangleq \{\text{DAG } \mathcal{G} : P \text{ factorized w.r.t. } \mathcal{G}, \text{ and } \mathcal{G} \text{ has minimal number of edges}\}$ [Van de Geer et al., 2013]. Verma and Pearl [1990] derive a graphical criterion to decide whether two DAGs are in the same equivalence class $\mathcal{D}_{minimal\, I-MAP}(P)$. Based on this criterion, several popular structure learning algorithms have been proposed to estimate this Markov equivalence class from observational data: constraint-based methods (PC-algorithm, Spirtes and Glymour [1991]; Inductive Causation, Pearl and Verma [1992]; FCI-algorithm Spirtes et al. [2000]) which rely on inferring conditional dependencies from the data and select the DAG(s) that correspond(s) to these dependencies; score-based methods which use penalties such as Gaussian likelihood penalization [Van de Geer et al., 2013] or the Greedy Equivalence Search algorithm [Chickering, 2002].

1.3.2 Structural causal models

Informally, a structural causal model has two components, a "causal influence diagram" that encodes direct causes by directed edges and a quantitative model on this diagram that describes the quantitative behavior of the system. The exact definition is given below:

Definition 1.3.4 (Structural Causal Model)**.** *A **structural causal model** (SCM), or **structural equation model** (SEM), $\mathcal{C} \triangleq (S, P_p^N)$ with DAG $\mathcal{G}$ (where is sometimes called the causal graph), consists of a set S of structural equations and a set of noise distributions such that*

$$X_j \leftarrow f(X_{pa(j)}, N_j),$$

where $N_i \perp\!\!\!\perp N_j$ for all $i, j = 1, \ldots, p$, for every node j of the DAG $\mathcal{G}$.[8]

An SCM entails a joint distribution P over all variables $X_1, \ldots, X_p$. And if P has a continuous density, then the global Markov property holds. This implies that the previous methods seen for structural learning can thus be applied to infer the model underlying the observed data and making predictions about interventions. In the SCM framework, an important notion to reason about interventions and identifiability of causal structures is the $do-$operator from Pearl [1995]. A $do-$intervention on a variable X_i in an SCM corresponds to altering the structural equation of X_i by setting X_i to a certain value, for instance to x. This writes as $do(X_j = x)$ and the structural equation is changed from $X_i \leftarrow f(X_{pa(i)}, N_i)$ to $X_i \leftarrow x$. The rest of the SCM remains unchanged. This change in the SCM naturally induces a change in the associated joint distribution which is then called "interventional distribution" due to the intervention on X_j. A key observation in the SCM framework which relates interventional and observational distributions is based on adjustment sets:

Definition 1.3.5 (Valid adjustment set)**.** *Given an SCM over $(W, Y, \boldsymbol{X})$. We call $\boldsymbol{Z} \subset X$ a **valid adjustment set** for (W, Y) if*

$$p_{do(W:=w)}(y) = \sum_z p(y \mid w, z)p(z) \tag{1.13}$$

This definition allows to compute an interventional distribution solely from observational distributions. And the following result allows to derive actionable approaches to both infer causal structures and make "causal predictions", i.e., predictions using the interventional distribution instead of the observational distribution.

Proposition 1.3.1 (Parent adjustment)**.** *Assume that $Y \notin pa(W)$. Then $pa(W)$ is a valid adjustment set for (W, Y).*

Finally, in this SCM framework, we have seen that causal structures and entailed observational and interventional distributions are at the core of identifiability and estimation questions. The issue of estimating causal effects is related to this and thus there exists a definition of causal effects in this framework as well.

8. Note the notation $\leftarrow$ instead of an equality sign that emphasizes the structural assumption of relative definitions of the different variables.

Definition 1.3.6 (Causal effect, Peters et al. [2017])**.** *Given an SCM, there is a* ***total causal effect*** *from W to Y if they satisfy the following:*

$$W \not\perp\!\!\!\perp Y \text{ in } P_{do(W=N_W)} \text{ for some random variable } N_W,$$

where $\not\perp\!\!\!\perp$ stands for any statistical dependence.

Note that other equivalent definitions of a causal effect in this SCM framework also exist.

1.3.3 Link with the potential outcomes framework

A counterfactual SCM for the original SCM $\mathcal{C} = (S, N_p)$ is obtained from a given observation $X = x$ by conditioning the noise distribution on the observation, $(S, P_p^{N|W=a})$. Counterfactuals then correspond to $do-$statements in this new counterfactual SCM. Indeed, conditioning the noise distribution of the treatment variable W corresponds to asking a question of the type *What would have happened to the patient had he gotten treatment $W = a$ instead of another treatment $W = b$?* Everything in the SCM is kept fixed, in particular the patient's state does not change, and only the treatment variable is intervened on in the new SCM. For a more detailed review of the relationship between the PO and the SCM framework, we refer to Richardson and Robins [2013].

Finally, various works exist which infer causal effects under the SCM framework, for instance invariant causal predictions [Peters et al., 2016, Heinze-Deml et al., 2018]. This concludes the short review of the alternative SCM framework. In the following sections and chapters we will remain with the PO framework, however, where pertinent, we will also draw some connections between the PO and the SCM framework.

1.4 – The randomized treatment case

We distinguish two cases of data settings: *experimental data* from randomized controlled trials (RCT) and *observational data*. In the former, the pre-treatment covariate distributions between treated and control are identical and we know the law of the treatment assignment random variable. In general this is considered to be the gold standard for causal inference [Hernán and Robins, 2020]. However, in practice, such RCTs can come at high operational costs or can even be impossible in some domains such as social or political sciences.

Using the notions of the SCM framework, the randomized treatment case corresponds to the the $do-$intervention on the treatment variable W, "cutting off" all incoming edges into this variable, while leaving the rest of the causal model unchanged. This allows to consider solely the observations of the treatment assignment and the observed outcomes to infer the treatment effect of W on Y. Put differently, the randomization of treatment assignment ensures the unconfoundedness assumption with the empty set as set of confounders:

$$W \perp\!\!\!\perp \{Y(0), Y(1)\}.$$

Additionally, by definition, all included individuals in an RCT are eligible for treatment and thus have a non-zero probability of ending up in either the treatment or the control group, this ensures that the overlap assumption (1.10) is satisfied. The following results are partly borrowed from Wager [2020].

Under these RCT conditions, the definition of the ATE τ and the satisfied identifiability assumptions suggest a natural estimator, namely the difference-in-means estimator.

Definition 1.4.1 (Difference in means estimator)**.** *Assume we have n i.i.d. observations (W_i, Y_i) taking values in $\{0,1\}\times\mathbb{R}$ and that satisfy the identifiability assumptions 1.2.4, 1.2.5 and 1.2.6. The* ***difference in means estimator*** *is defined as*

$$\hat{\tau}_{DM} \triangleq \frac{1}{n_1}\sum_{W_i=1} Y_i - \frac{1}{n_0}\sum_{W_i=0} Y_i, \tag{1.14}$$

where $n_w \triangleq |\{i : W_i = w\}|$.

Proposition 1.4.1. *Under the same assumptions as in the previous definition, the difference in means estimator (1.14) is unbiased and consistent for the average treatment effect τ.*

Proof. We note that for $w \in \{0,1\}$, we have

$$\begin{aligned}
\mathbb{E}\left[\tfrac{1}{n_w}\textstyle\sum_{W_i=w} Y_i\right] &= \mathbb{E}\left[Y_i \mid W_i = w\right] && \text{(i.i.d.)}\\
&= \mathbb{E}\left[Y_i(w) \mid W_i = w\right] && \text{(SUTVA, Def. 1.2.5)}\\
&= \mathbb{E}\left[Y_i(w)\right] && \text{(random assignment).}
\end{aligned}$$

Thus $\mathbb{E}[\hat{\tau}_{DM}] = \mathbb{E}[Y_i(1)] - \mathbb{E}[Y_i(0)] = \tau$ is unbiased. Moreover, the variance of $\hat{\tau}_{DM}$ can be written as

$$\mathrm{Var}\left[\hat{\tau}_{DM}\right] = \frac{1}{n_0}\mathrm{Var}\left[Y_i(0)\right] + \frac{1}{n_1}\mathrm{Var}\left[Y_i(1)\right],$$

as shown for instance by Imbens and Rubin [2015]. They show as well that a standard central limit theorem can be applied to prove that

$$\sqrt{n}\left(\hat{\tau}_{DM} - \tau\right) \to \mathcal{N}\left(0, V_{DM}\right),$$

where we have $V_{DM} \triangleq \mathrm{Var}\left[Y_i(0)\right]/P\left[W_i = 0\right] + \mathrm{Var}\left[Y_i(1)\right]/P\left[W_i = 1\right]$. □

Moreover, using the above results, it is possible to build valid Gaussian confidence intervals for τ by estimating the asymptotic variance V_{DM} with standard plug-in estimators.

While this estimator is conceptually very simple and comes with sound theoretical guarantees that allow for valid inferences, it raises the question of efficiency since in Section 1.2 we introduced i.i.d. observations (X_i, W_i, Y_i), i.e., along the treatment assignment W_i and the outcome Y_i, we also have access to additional information X_i. The latter is not used by the difference-in-means estimator and we will now see how the information in X_i can improve the estimation of τ in terms of efficiency.

Linear case We begin by assuming a linear specification for the potential outcomes, i.e., we assume that the potential outcomes are generated under the following model

$$Y_i(w) = c_{(w)} + X_i\beta_{(w)} + \varepsilon_i(w), \quad \mathbb{E}\left[\varepsilon_i(w) \mid X_i\right] = 0, \quad \mathrm{Var}\left(\varepsilon_i(w) \mid X_i\right) = \sigma^2. \tag{1.15}$$

Without loss of generality, we can assume a balanced randomized trial, i.e., $P(W_i = 1) = P(W_i = 0) = \frac{1}{2}$, and that $\mathbb{E}[X] = 0$. Let us denote $A \triangleq Var(X)$ and for any $v \in \mathbb{R}^p$, $\|v\|_A^2 \triangleq v^T A v$.

Under this model, we can rewrite the ATE as follows:

$$\tau = \mathbb{E}[Y(1) - Y(0)] = c_{(1)} - c_{(0)} + \mathbb{E}[X]\left(\beta_{(1)} - \beta_{(0)}\right),$$

which naturally suggests an ordinary least squares estimator (OLS).

Definition 1.4.2 (Ordinary least squares estimator)**.** *Under the model* (1.15)*, we can define the following* ***ordinary least squares estimator*** *for* τ*:*

$$\hat{\tau}_{OLS} \triangleq \hat{c}_{(1)} - \hat{c}_{(0)} + \bar{X}\left(\hat{\beta}_{(1)} - \hat{\beta}_{(0)}\right),$$

where $\bar{X} \triangleq \frac{1}{n}\sum_{i=1}^n X_i$ *and* $\left(c_{(w)}, \beta_{(w)}\right)$ *are estimated via OLS applied on the individuals in the group* $W = w$*.*

Using standard results from OLS regression, it is possible to prove that $\hat{\tau}_{OLS} - \tau$ can be decomposed as follows [9]:

$$\begin{aligned}\hat{\tau}_{OLS} - \tau = &\left[\overline{Y_{(1)}} - (c_{(1)} + \overline{X_{(1)}}\beta_{(1)})\right] - \left[\overline{Y_{(0)}} - (c_{(0)} + \overline{X_{(0)}}\beta_{(0)})\right] \\ &- (\overline{X_{(1)}} - \overline{X_{(0)}})\left(\frac{n_0}{n}(\hat{\beta}_{(1)} - \beta_{(1)}) + \frac{n_1}{n}(\hat{\beta}_{(0)} - \beta_{(0)})\right) \\ &+ \left(\frac{n_1}{n}\overline{X_{(1)}} + \frac{n_0}{n}\overline{X_{(0)}}\right)(\beta_{(1)} - \beta_{(0)}),\end{aligned}$$

and using standard results for i.i.d. observations, we can show that $\hat{\tau}_{OLS}$ is asymptotically normal:

$$\sqrt{n}\left(\hat{\tau}_{OLS} - \tau\right) \to \mathcal{N}\left(0, V_{OLS}\right),$$

where $V_{OLS} \triangleq 4\sigma^2 + \left\|\beta_{(0)} - \beta_{(1)}\right\|_A^2$.

If we now notice that while $\hat{\tau}_{DM}$ does not use the variables X_i, we can still characterize its behavior in terms of the distribution of these variables under the linear model specification, then we can write the following:

$$\begin{aligned}V_{DM} &= \mathrm{Var}\left(Y_i(0)\right)/P\left(W_i = 0\right) + \mathrm{Var}\left(Y_i(1)\right)/P\left(W_i = 1\right) && (1.16)\\ &= 2\left(\mathrm{Var}\left(X_i\beta_{(0)}\right) + \sigma^2\right) + 2\left(\mathrm{Var}\left(X_i\beta_{(1)}\right) + \sigma^2\right) && (1.17)\\ &= 4\sigma^2 + 2\left\|\beta_{(0)}\right\|_A^2 + 2\left\|\beta_{(1)}\right\|_A^2 && (1.18)\\ &= 4\sigma^2 + \left\|\beta_{(0)} + \beta_{(1)}\right\|_A^2 + \left\|\beta_{(0)} - \beta_{(1)}\right\|_A^2, && (1.19)\end{aligned}$$

9. We refer to Appendix A for the omitted proofs of this section.

which allows us to conclude that $V_{DM} = V_{OLS} + \left\|\beta_{(0)} + \beta_{(1)}\right\|_A^2$, i.e., $\hat{\tau}_{OLS}$ has smaller asymptotic variance than $\hat{\tau}_{DM}$.

Before turning to the general case, we note that it is possible to obtain an equivalent OLS estimator for τ, $\hat{\tau}_{OLS'}$ by regressing the outcome vector $Y = (Y_1, \ldots, Y_n)^T$ on the matrix $[\mathbf{1} \quad W \quad X - \overline{X} \quad W(X - \overline{X})]$, i.e., using a linear regression model with centered covariates, the treatment assignment and an interaction between them. The proof of this result is given in Appendix A.

General case The previous result encourages the use of the OLS estimator $\hat{\tau}_{OLS}$ instead of the difference-in-means estimator $\hat{\tau}_{DM}$ in the case of linear model specification. However, there is more to add to this former estimator because it has been shown that even in case of model mis-specification, i.e., if the potential outcomes are not linearly related to the covariates X, the use of $\hat{\tau}_{OLS}$ performs at least as well as $\hat{\tau}_{DM}$. Indeed, it is possible to prove that under the generic model assumption

$$Y_i(w) = \mu_{(w)}(X_i) + \varepsilon_i(w), \quad \mathbb{E}[\varepsilon_i(w) \mid X_i] = 0, \quad \mathrm{Var}[\varepsilon_i(w) \mid X_i] = \sigma^2,$$

with arbitrary functions $\mu_{(w)}(x)$, we can apply a central limit theorem to obtain

$$\sqrt{n}\,(\hat{\tau}_{OLS} - \tau) \to \mathcal{N}(0, V_{OLS}),$$

with a similar expression for V_{OLS} as in the linear case, namely $V_{OLS} = V_{DM} - \left\|\beta^*_{(0)} + \beta^*_{(1)}\right\|_A^2$, where $\beta^*_{(w)}$ is taken from the solution of the minimization of the expected mean-squared error of any linear model relating $Y(w)$ to X:

$$\left(c^*_{(w)}, \beta^*_{(w)}\right) = \mathrm{argmin}_{c,\beta}\left\{\mathbb{E}\left[(Y_i(w) - X_i\beta - c)^2\right]\right\}.$$

For more details on this more general result which relies on a Huber-White analysis of linear regression, we refer to Lin et al. [2013], Wager [2020].

Finally, note that in this section we have only introduced the core aspects of treatment effect identifiability and estimation in this randomized treatment case and that there exist many other issues such as handling of non-compliance, stratified and cluster randomization that are addressed by a broad body of research work.

1.5 – The confounded treatment case

Confounding or confoundedness generally arises in *observational data*: treated and control groups do not necessarily have the same distribution (before treatment) since the treatment assignment is not independent of the covariates and the potential outcomes. The notion of *confoundedness* describes the fact that treatment assignment is not random due to the presence of confounding factors X that drive both treatment assignment and potential outcomes as illustrated in Figure 1.3.



Figure 1.3 – Observational data model with observed (X) and unobserved (U) confounding factors. We are interested in estimating the link between W and Y. We need to take into account the confounders, i.e., the common causes of W and Y.

Before diving into the variety of treatment effect estimators that have been developed for observational data, we give an example of how unaddressed confounding can distort causal analyses from observational data. The following example is taken from Charig et al. [1986]. This study is interested in comparing two renal calculi treatments, open surgery (treatment A) and percutaneous nephrolithotomy (treatment B). Each of the 700 included patients is affected to either one of these two treatments, such that both treatment groups are of equal size, namely 350 patients each. A treatment is considered successful and the patient considered to have recovered if either the stone is eliminated or reduced to less then 2mm. The results of this study are summarized in Figure 1.4. From a first analysis, it could be concluded that treatment B is more successful in eliminating renal calculi than treatment A (Figure 1.4a). However, if taking into account an additional variable, namely the size of the stone, the conclusion needs to be corrected. Indeed, from Figure 1.4b we read that the treatment A group is mostly composed of patients with large stones, while the treatment B group is formed of mostly patients with small stones. When comparing recovery rates for each stone size, we see that treatment A is more successful both for eliminating small stones and large stones. These seemingly contradicting results are an example of the Simpson's paradox [Simpson, 1951]. Indeed, the study investigators note that the patients have not been randomized into the two treatment groups but the treating physician decided upon treatment depending on the size of the renal stone. For larger stones, a surgery (treatment A) seems to have been preferred more often over the less invasive percutaneous nephrolithotomy, while it has been the opposite for smaller stones. This can be formulated differently as well: given that a patient i got treatment A, the probability that this patient has a large stone is larger than for a patient j who got treatment B, i.e., $P(S = large|W = A) > P(S = large|W = B)$, due to the "decision rule" of the treating urologists. The size of the stone is therefore a confounder and in this example, its omission leads to a large bias which even inverts the final conclusion about which treatment is preferable. In the language of the SCM framework, the authors were interested in the overall better treatment, i.e., in the conditional interventional distribution $P_{do(W=w)}(Y = recovery|W)$ but used the conditional observational distribution $P(Y = recovery|W = w)$ which is not the same. However, when also conditioning on the size of the stone, due to the practitioners' way of attributing the treatments, we have indeed $P_{do(W=w)}(Y = recovery|W, S) = P(Y = recovery|W, S)$. And assuming we know the marginal distribution of the variable S, the size of

the kidney stones, $P(S)$, the target of interest $P_{do(W=w)}(Y = recovery)$ is indeed identifiable. For ease of readability, we assume that $Y = 1$ means recovery, and $Y = 0$ failure of the intervention. We can now write the recovery rate under treatment A as follows:

$$\begin{aligned}
\mathbb{E}_{do(W=A)}[Y] &= P_{do(W=A)}(Y = 1) \\
&\sum sP_{do(W=A)}(Y = 1, S = s, W = A) \\
&\sum sP_{do(W=A)}(Y = 1 \mid S = s, W = A)P_{do(W=A)}(S = s, W = A) \\
&\sum sP_{do(W=A)}(Y = 1 \mid S = s, W = A)P_{do(W=A)}(S = s) \\
&\sum sP(Y = 1 \mid S = s, W = A)P(S = s) \\
&= 0.832,
\end{aligned}$$

which is different from the observed recovery rate under treatment A in the study $P(Y = 1|W = A) = 0.78$. And analogously for treatment B we obtain $\mathbb{E}_{do(W=B)}[Y] = P_{do(W=B)}(Y = 1) = \cdots = 0.782$.

1.5.1 Classical estimators

For the remainder of this chapter, we focus on the ATE estimand and present different estimators that have been proposed in the past to estimate this quantity of interest. Since we are interested in estimating the causal effects from observational data, we cannot apply the same methods as in the RCT case since this would lead to inconsistent estimates due to confounding. Indeed, one could describe the difference between the randomized and the confounded treatment case as a shift of focus and overall effort put in collecting "perfect" data to the focus on estimation strategies that allow to cope with "imperfect" data. The basic idea behind the following methods is to emulate one or several RCTs [Hernán and Robins, 2016], i.e., for a given $x \in \mathcal{X}$ we would like to estimate $\tau(x) = \mathbb{E}[Y(1) - Y(0)|X = x]$ by a simple estimate as in the RCT case. For a more detailed review of existing literature on treatment effect estimation we refer to Imbens [2004], Lunceford and Davidian [2004].

1.5.1.1 Matching

Matching might be the most intuitive way to handle confounding in observational data. A first rough description of matching could state that for every individual in the sample, we search for at least one individual in the opposite treatment group that "looks" similar in terms of baseline characteristics. Adopting the perspective of Ho et al. [2007], matching methods can be considered as non-parametric data pre-processing methods, and therefore a possible preliminary step to statistical treatment effect estimation. The choice of the latter can however be impacted by the chosen matching method. We refer the reader to Iacus et al. [2012], Abadie and Imbens [2016] for detailed reviews of existing matching methods (e.g. *one-to-one exact*, *exact matching*, *approximate*, *propensity score*, *coarsened exact* matching). In a nutshell, the aim of matching is to establish independence between the covariates X and treatment



(a) Confounded analysis



(b) Deconfounded analysis

Figure 1.4 – Example of Simpson's paradox: in the study, the size of the stone confounds the recovery rate in the treatment groups. The hatched area corresponds to the proportion of patients with successful renal stone elimination.

assignment W, by balancing the covariate distributions in both groups (without using the outcome variable Y). For instance, one can adopt a nearest neighbor approach, i.e., given a distance metric d and an observation X_i of treatment group w, search for the nearest observation X_j with $W_j \neq w$: $\underset{\substack{j \in \{1,\dots,n\} \setminus \{i\} \\ W_j \neq W_i}}{\operatorname{argmin}} d(X_i, X_j)$.

Whatever matching strategy is chosen, the resulting balance quality can be assessed by different means. Ideally one compares the joint covariate distribution in

both groups after matching but this becomes challenging in high-dimensional settings. In this case comparing summary statistics such as mean differences, variance ratios or empirical CDF or different tests (t, F, Kolmogorov-Smirnov) can provide some information on the adequacy of the chosen matching strategy. Another possibility to measure covariate balance is to use the multivariate standardized bias introduced by Rosenbaum and Rubin [1985] which is a summary measure of (im)balance across all covariates.

1.5.1.2 Stratification

In a nutshell, stratification methods generalize matching to subpopulations. Stratification allows to "match" subpopulations in treated and control with similar covariate distributions. Stratification on the propensity scores allows not only to balance treated and control groups but, as a consequence of Rosenbaum and Rubin [1984, Theorem 1], it also allows to use F tests (on each covariate) to approximately assess the adequacy of the propensity model. However drawbacks of stratification are that there is potential for remaining heterogeneity within strata leading to biased treatment effect estimations, and the reduced sample size in each stratum.

1.5.1.3 Regression adjustment

A more direct solution to estimate τ can be to define it as parameter of a regression model: $\mathbb{E}[Y \mid X, W] = \beta_0 + X\beta_1 + \tau W$. However, as pointed out by Rubin [1979], such regression adjustments are sensitive to model mis-specification if the two groups differ considerably in the covariates. In such a case of insufficient overlap between treated and control the regression involves extrapolation of treated and control in the different regions [Lunceford and Davidian, 2004]. Note that while the difference in conditional means estimator with regression adjustment using a linear model specification is consistent on experimental data even in the case of model mis-specification, this property is valid for observational data.

1.5.1.4 Weighting methods

Weighting methods are used in observational studies for estimating the effect of a treatment or an intervention but also in surveys for estimating the mean of an outcome variable in the presence of unit nonresponse and there exists a broad literature on weighting methods (see for instance Imbens and Rubin [2015], Lunceford and Davidian [2004]). The goal of weighting is twofold: to balance the empirical distributions of the observed covariates (to remove biases due to observed confounders or recover the observed structure of the target population) and to yield stable estimates of the parameters of interest (very large weights may overly influence the results and highly variable weights produce results with high variance [Little and Rubin, 2019]).

Inverse probability of treatment weighting (IPW) Originally proposed by Horvitz and Thompson [1952] in the context of survey theory in finite settings, the IPW estimator has been re-defined in a more general context by Rosenbaum

[1987]. It is closely related to the difference in means estimator (Definition 1.4.1) but with the main difference that the observations are weighted by the inverse of the propensity score, the probability of treatment given the covariates.

Definition 1.5.1 (Inverse probability of treatment weighting or inverse propensity weighting estimator (IPW))**.** *Assuming we have access to an estimator $\hat{e}$ of the true propensity score* (1.9)*, we define the* ***inverse probability of treatment estimator*** *as*

$$\hat{\tau}_{IPW_0} \triangleq \frac{1}{n}\sum_{i=1}^{n}\frac{W_i Y_i}{\hat{e}(X_i)} - \frac{1}{n}\sum_{i=1}^{n}\frac{(1-W_i)Y_i}{1-\hat{e}(X_i)}. \tag{1.20}$$

Assuming consistent propensity score estimations, this estimator $\hat{\tau}_{IPW_0}$ is an unbiased estimator of the ATE. Indeed it uses the fact that under SUTVA and unconfoundedness we have

$$\begin{aligned}
\mathbb{E}\left[\frac{W_i Y_i}{e(X_i)}\right] &= \mathbb{E}\left[\frac{W_i Y_i(1)}{e(X_i)}\right] && (1.21)\\
&= \mathbb{E}\left[\mathbb{E}\left[\frac{\mathbb{1}_{\{W_i=1\}}Y_i(1)}{e(X_i)}|X_i, Y_i(1)\right]\right] && (1.22)\\
&= \mathbb{E}\left[\frac{Y_i(1)}{e(X_i)}\mathbb{E}\left[\mathbb{1}_{\{W_i=1\}}|X_i, Y_i(1)\right]\right] && (1.23)\\
&= \mathbb{E}[Y_i(1)]. && (1.24)
\end{aligned}$$

And similarly we also get $\mathbb{E}\left[\frac{(1-W_i)Y_i}{1-e(X_i)}\right] = \mathbb{E}[Y_i(0)]$. This implies that we can estimate the expected potential outcomes from the observational data, assuming the propensities $e(X_i)$ known.

In practice a normalized version of (1.20), derived in the context of survey sampling by Hájek [1971], is used since precision is generally enhanced if using weighted averages for the two groups as pointed out by Kang et al. [2007], i.e.,

$$\hat{\tau}_{IPW} \triangleq \left(\sum_{i=1}^{n}\frac{W_i}{\hat{e}(X_i)}\right)^{-1}\sum_{i=1}^{n}\frac{W_i Y_i}{\hat{e}(X_i)} - \left(\sum_{i=1}^{n}\frac{1-W_i}{1-\hat{e}(X_i)}\right)^{-1}\sum_{i=1}^{n}\frac{(1-W_i)Y_i}{1-\hat{e}(X_i)}, \tag{1.25}$$

which is justified by the fact that $\mathbb{E}\left[\frac{W_i}{e(X_i)}\right] = \mathbb{E}\left[\mathbb{E}\left[\frac{W_i}{e(X_i)}|X_i\right]\right] = \mathbb{E}\left[\frac{e(X_i)}{e(X_i)}\right] = 1$.

If the propensity score is unknown, a popular choice for estimating it is to use a logistic regression model: this approach allows to estimate the probabilities of treatment from the observed covariates and then one inverts these probabilities to calculate the weights. However it does not aim explicitly at covariate balance or at restraining the variability of the weights. Weights can therefore vary substantially and lead to instability in the estimates [Kang et al., 2007, Robins and Wang, 2000b]. A key difficulty is that estimating the treatment effect then involves dividing by either $e^{-X_i\beta}$ or $1-e^{-X_i\beta}$. Hence small inaccuracies in the estimation of β can have large effects on the subsequent estimators, especially when the propensity score $e(\cdot)$ (Definition 1.2.6) can be close to the boundaries; this problem can be even more important in high-dimensional settings where perfect separation can lead to estimates $\hat{e}(\cdot)$ that are exactly zero or one [Hill et al., 2011].

If the propensity model is correctly specified, i.e., the distribution model for treatment assignment given the covariates, then it is correct to have highly variable weights; however this is hard to determine in practice. This explains the common practice of trimming extreme weights, but this is often done in an arbitrary way that introduces bias in the estimates (see Crump et al. [2009] for discussions of different methods and Li et al. [2018] for an alternative to trimming, *overlap weights*).

Another solution that is available in certain settings is to learn the weights (or the probabilities of treatment) with a non-parametric (machine learning) approach to obtain weights that are less sensitive to model mis-specification. More specifically if the propensities are a more complex function of the covariates than a logistic regression model, for instance involving non-linearities, then learning a richer propensity score model can be advantageous. Note that independently of the choice for estimating the propensity scores, if the estimations are consistent then the resulting ATE estimator is more efficient than the estimator using the true propensity score as shown by Hirano et al. [2003]. Intuitively this can be explained by the motivation of estimating the propensity scores: it aims at recovering the assignment "policy" which lead to the observed samples and the estimations might account for additional variance in the sample which is not accounted for in the true propensity model. If the predictions are too close to the borders, i.e., if one achieves (almost) perfect separation, even on some held out test data, then this strongly suggests that the probabilistic treatment assumption might not be satisfied.

Note that we can obtain the normalized IPW estimator (1.25) by a weighted simple linear regression of the outcome on the treatment variable, $Y_i \sim W_i$, with weights $\frac{W_i}{e(X_i)} + \frac{1-W_i}{1-e(X_i)}$.

Proof. Consider the weighted simple linear regression of $Y = [Y_1, \dots, Y_n]^T$ on binary $W = [W_1, \dots, W_n]^T$ with weights $\omega_i = \frac{W_i}{e(X_i)} + \frac{1-W_i}{1-e(X_i)}$. We note $\overline{Y}_\omega = \frac{\sum_{i=1}^n \omega_i Y_i}{\sum_{i=1}^n \omega_i}$ and $\overline{W}_\omega = \frac{\sum_{i=1}^n \omega_i Y_i}{\sum_{i=1}^n \omega_i}$ the weighted means of Y and W.

We denote by $\beta = [\beta_0, \beta_1]^T$ the regression coefficients of our weighted linear regression. We have

$$\hat{\beta}_1 = \frac{\sum_{i=1}^n \omega_i (W_i - \overline{W}_\omega)(Y_i - \overline{Y}_\omega)}{\sum_{j=1}^n \omega_j (W_j - \overline{W}_\omega)^2} = \sum_{i=1}^n \frac{\omega_i (W_i - \overline{W}_\omega)}{\sum_{j=1}^n \omega_j (W_j - \overline{W}_\omega)^2} Y_i = \frac{A}{B},$$

where

$$A \triangleq \sum_{i=1}^n a_i Y_i - \left((a_i + b_i) \frac{\sum_j a_j}{\sum_k a_k + b_k} \right) Y_i = \sum_i a_i Y_i - \frac{\Sigma_a}{\Sigma_a + \Sigma_b} \sum a_i Y_i - \frac{\Sigma_a}{\Sigma_a + \Sigma_b} \sum_i b_i Y_i,$$

$$B \triangleq \sum_i a_i + (a_i + b_i) \left(\frac{\sum_j a_j}{\sum_k a_k + b_k} \right)^2 - 2 a_i \frac{\sum_j a_j}{\sum_k a_k + b_k} = \Sigma_a - \frac{\Sigma_a^2}{\Sigma_a + \Sigma_b},$$

with $a_i \triangleq \frac{W_i}{e(X_i)}$, $b_i \triangleq \frac{1-W_i}{1-e(X_i)}$, $\Sigma_a \triangleq \sum_{i=1}^n a_i$, $\Sigma_b \triangleq \sum_{i=1}^n b_i$.

Finally, after simplifications, $\hat{\beta}_1 = \frac{A}{B} = \frac{\sum_{i=1}^n a_i Y_i}{\Sigma_a} - \frac{\sum_{i=1}^n b_i Y_i}{\Sigma_b} = \tau_{IPW}$.

□

Balancing and overlap weights Balancing weights can be viewed as a generalization of the above inverse propensity weighting. Observations are weighted such that their distribution approximates the distribution of a predefined target population and the potential outcomes are averaged over this target distribution. For instance in the case of inverse propensity weighting the target population is the entire population of treated and control. Overlap weights as defined in Li et al. [2018] are a special case of the class of balancing weights where each unit is weighted proportionally to its probability of being assigned to the opposite group. This weighting targets the subpopulation of units which receive either treatment in substantial proportions. This new class of weights is motivated by the remark that rather than prioritizing good covariate balance between groups over generalizability to a recognizable target population one should rather investigate the "optimal" subpopulation for which the causal effect can be estimated with smallest variance [Crump et al., 2009].

Let $f(x)$ be the marginal density of the covariates X w.r.t. some base measure μ. The densities in each group, $f_1(x)$ and $f_0(x)$ are proportional to $f(x)e(x)$ and $f(x)(1-e(x))$ respectively. Given a target distribution $f(x)h(x)$, e.g., the distribution of the overall population or of the population of the treated, the idea is to use the weights $\frac{h(x)}{e(x)}$ and $\frac{h(x)}{1-e(x)}$ that allow to balance the covariate distributions towards the target distribution. In case of the overlap weights, $h(x) = e(x)(1 - e(x))$ and this places more emphasis on units with propensity score close to 0.5. In a medical context these units could be seen as patients with ambiguous profiles which lead to an absence of consensus between experts. An attractive aspect of overlap weights is their small-sample exact balance property. More precisely they lead to exact balance in the means of any covariate between treated and control groups.

Another line of research for balancing weights can be found in Zubizarreta [2015]. The idea is to formulate the problem of finding balancing weights with small variance in a convex constrained optimization problem.

Imai and Ratkovic [2013] derive a *covariate balancing propensity score* (CBPS) by focussing on robust propensity score estimation (instead of robust propensity score matching or weighting). This approach exploits both aspects of the propensity score, namely the covariate balancing property and its definition as conditional probability of treatment.

1.5.1.5 Doubly robust methods

The previously mentioned CBPS comes along with a property qualified as *double robustness*. Indeed it can be seen as a one approach to handle cases where the propensity score is somewhat difficult to estimate. Methods that only rely on the propensity score are in general dominated by bias due to estimation error in $\hat{e}(\cdot)$, and methods that also model the outcomes Y_i can yield a better sample complexity; see Athey et al. [2018], Chernozhukov et al. [2018a] and Van der Laan and Rose [2011] for references and recent results. One particularly successful approach to combining these two approaches to modeling is via augmented inverse propensity weighting (AIPW) [Robins et al., 1994].

Definition 1.5.2 (Augmented inverse-propensity weighting estimator (AIPW))**.** *We*

assume we have access to an estimator $\hat{e}$ of the true propensity score (1.9)*, we define the augmented inverse propensity weighting estimator as*

$$\hat{\tau}_{AIPW} \triangleq \frac{1}{n}\sum_{i=1}^{n} \hat{\mu}_1(X_i) - \hat{\mu}_0(X_i) + W_i\frac{Y_i - \hat{\mu}_1(X_i)}{\hat{e}(X_i)} - (1-W_i)\frac{Y_i - \hat{\mu}_0(X_i)}{1-\hat{e}(X_i)}, \quad (1.26)$$

where $\mu_{(w)}(x) \triangleq \mathbb{E}\left[Y \,\middle|\, X_i = x,\, W_i = w\right]$ and $\hat{\mu}_{(w)}(x)$ is an estimate thereof.

Despite its initial derivation in the context of regression when some of the outcomes are missing, the link to causal inference can be easily established by viewing each potential outcome as a separate case of this problem. For instance the outcomes $Y_i(1)$ are only observed for the treated and not for the control. The probability of observing $Y_i(1)$ given the covariates X_i is exactly the propensity score for observation i. Then consistently estimating the conditional response surfaces of the potential outcomes $\mathbb{E}[Y_i(1)|X_i]$ and $\mathbb{E}[Y_i(0)|X_i]$ allows to consistently estimate $\tau(x)$.

A common description of the AIPW estimator is that it estimates two different nuisance components, i.e., the outcome model and the propensity model; it then achieves consistency if either of these components is itself estimated consistently, and efficiency if both components are estimated at fast enough rates. In order to show the double robustness of $\hat{\tau}_{AIPW}$, let us rewrite it by rearranging the terms:

$$\begin{aligned}\hat{\tau}_{AIPW} &= \frac{1}{n}\sum_{i=1}^{n} \frac{W_iY_i}{\hat{e}(X_i)} - \frac{W_i - \hat{e}(X_i)}{\hat{e}(X_i)}\hat{\mu}_1(X_i) - \frac{1}{n}\sum_{i=1}^{n}\frac{(1-W_i)Y_i}{1-\hat{e}(X_i)} + \frac{W_i - \hat{e}(X_i)}{1-\hat{e}(X_i)}\hat{\mu}_0(X_i)\\ &= \hat{\mu}_{1,DR} - \hat{\mu}_{0,DR}.\end{aligned}$$

First note that by the law of large numbers, $\hat{\mu}_{1,DR}$ and $\hat{\mu}_{0,DR}$ respectively estimate $\mathbb{E}[Y_i(1)] + \eta_1$ and $\mathbb{E}[Y_i(0)] + \eta_0$ where η_1 is given by $\eta_1 \triangleq \mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}(Y_i(1) - \mu_1(X_i))\right]$ and $\eta_0 \triangleq \mathbb{E}\left[\frac{W_i - e(X_i)}{1-e(X_i)}(Y_i(0) - \mu_0(X_i))\right]$. Indeed we have that

$$\begin{aligned}\mathbb{E}\left[\frac{W_iY_i}{e(X_i)} - \frac{W_i - e(X_i)}{e(X_i)}\mu_1(X_i)\right] &= \mathbb{E}\left[\frac{W_iY_i(1)}{e(X_i)} - \frac{W_i - e(X_i)}{e(X_i)}\mu_1(X_i)\right]\\ &= \mathbb{E}[Y_i(1)] + \mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}(Y_i(1) - \mu_1(X_i))\right],\end{aligned}$$

where the first equality results from SUTVA: $W_iY_i = W_i(W_iY_i(1) + (1-W_i)Y_i(0)) = W_iY_i(1) + W_i(1-W_i)Y_i(0)$. And similar for the derivation of η_0.

The double robustness can easily be shown by considering these two terms:

— If the propensity model $e(x)$ is correctly specified but the outcome model $(\mu_0(x), \mu_1(x))$ is mis-specified we have

$$\begin{aligned}\eta_1 &= \mathbb{E}\left[\mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}(Y_i(1) - \mu_1(X_i))\right] \,|\, Y_i(1), X_i\right]\\ &= \mathbb{E}\left[\frac{\mathbb{E}[W_i \,|\, Y_i(1), X_i] - e(X_i)}{e(X_i)}(Y_i(1) - \mu_1(X_i))\right]\\ &= \mathbb{E}\left[\frac{\mathbb{E}[W_i \,|\, X_i] - e(X_i)}{e(X_i)}(Y_i(1) - \mu_1(X_i))\right] = 0.\end{aligned}$$

We use the unconfoundedness assumption to go from the second to the third line and the definition of the propensity score for the last equality.

— If the propensity model $e(x)$ is mis-specified but the outcome model $(\mu_0(x), \mu_1(x))$ is correctly specified we have

$$\begin{aligned}
\eta_1 &= \mathbb{E}\left[\mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}(Y_i(1) - \mu_1(X_i))\right] \mid W_i, X_i\right] \\
&= \mathbb{E}\left[\mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}\left(Y_i(1) - \mathbb{E}[Y_i \mid W_i = 1, X_i]\right) \mid W_i, X_i\right]\right] \\
&= \mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}\left(\mathbb{E}[Y_i(1) \mid W_i, X_i] - \mathbb{E}[Y_i \mid W_i = 1, X_i]\right)\right] \\
&= \mathbb{E}\left[\frac{W_i - e(X_i)}{e(X_i)}\left(\mathbb{E}[Y_i(1) \mid X_i] - \mathbb{E}[Y_i(1) \mid X_i]\right)\right] = 0,
\end{aligned}$$

where we use SUTVA and unconfoundedness to go from the third to the fourth line.

Analogously we obtain in both cases of mis-specification that $\eta_0 = 0$, proving the double robustness of $\hat{\tau}_{DR}$.

This AIPW estimator and other doubly robust variants attain the semi-parametric efficiency bound for ATE estimation. This Cramer-Rao type bound is derived in Hahn [1998] for non-parametric average treatment effect estimation. Chernozhukov et al. [2018a] detail the sufficient conditions for consistent semi-parametric ATE estimation, namely overlap, sup-norm consistency, a $o(n^{-1})$ risk decay and cross-fitting:

$$\sup_{x \in \mathcal{X}} \left|\hat{\mu}_{(w)}(x) - \mu_{(w)}(x)\right| \xrightarrow{p} 0 \qquad \sup_{x \in \mathcal{X}} |\hat{e}(x) - e(x)| \xrightarrow{p} 0, \tag{1.27}$$

and

$$\mathbb{E}_{\hat{\mu}_{(w)}, X}\left[\left(\hat{\mu}_{(w))}(X) - \mu_{(w)}(X)\right)^2\right] \mathbb{E}_{\hat{e}, X}\left[(\hat{e}(X) - e(X))^2\right] = o_P\left(\frac{1}{n}\right). \tag{1.28}$$

Under (1.27), (1.28) and the overlap assumption introduced earlier, the corresponding ATE estimators are guaranteed to be $\sqrt{n}$-consistent if $\hat{\mu}_{(w)}$ and $\hat{e}$ are estimated using *cross-fitting* (also called *sample splitting*). This last key element for consistency of such semi-parametric estimators has been pointed out independently by Athey et al. [2019] and Chernozhukov et al. [2018a].

1.5.1.6 Other approaches for personalized treatment recommendations

Outcome-weighted learning The previous methods all attempt to recover or compensate for the missing information, namely the counterfactual outcome associated with the treatment level which has not been chosen. However, there exist other approaches which "bypass" this step on the way to define an optimal treatment: outcome-weighted learning (OWL) which aims at directly classifying patients into the group of those who would benefit from a treatment and those who would have either no or undesirable effects. This is achieved by estimating a boundary in the covariate space to separate these two groups, allowing to define a treatment rule: patients who fall into the "benefit" part are given the treatment, those who fall into the opposite group, will not receive the specific treatment [Zhang et al., 2012]. This approach is therefore also becoming popular in the context of personalized medicine [Zhao et al., 2012].

Heterogeneous treatment effect estimation If one suspects treatment heterogeneity (in the study population), then the standard considered target estimand is the CATE function.

Definition 1.5.3 (Conditional Average Treatment Effect)**.** *The* ***conditional average treatment effect*** *(CATE) is a function of $x \in \mathcal{X}$ given by:*

$$\begin{aligned} \tau : \mathcal{X} &\to \mathbb{R} \\ x &\mapsto \mathbb{E}[Y(1) - Y(0) | X = x] \end{aligned} \tag{1.29}$$

This definition assumes that the treatment heterogeneity, i.e., the fact that the treatment has a different effect on different individuals, can be recovered by conditioning on the pre-treatment covariates X. In this case the CATE is defined as the average treatment effect conditional on a given set of covariates. It allows to estimate the differences in treatment effects across subjects, in other words it estimates heterogeneous treatment effects, induced by treatment-covariate interactions.

Early works for CATE estimation in RCTs, especially in medical applications, propose to search for pre-specified subgroups that react differently to a treatment and are qualified as *subset analysis* [Byar, 1985, Dixon and Simon, 1991].

More recently, different approaches that are also valid for observational data have been proposed. They can be classified into three groups:

— Two-model approaches or *T-learner* [e.g. Shi et al., 2019]: they use the linearity of the expectation to express $\tau(x)$ as a difference of conditional response surfaces $\mu_1(x)$ and $\mu_0(x)$ for all $x \in \mathcal{X}$ and to estimate these two regression functions separately. However, this indirect estimation via the conditional response surfaces can be inefficient if the response surfaces are more complex than the CATE function. Furthermore, the error term of the difference of two estimated regression functions can be large and difficult to quantify. A variant of the T-learner, that is preferable in case of unbalanced treatment group sizes or when the regression functions corresponding to the two treatment levels are of different complexity, is the *X-learner* [Künzel et al., 2019]. This approach

leverages G-computation to adapt the complexity of the estimated regression functions to the size and quality of the data in each treatment group.

— Single-model approaches or *S-learner*: As the name indicates, this approach relies on a single model for the outcome. Generally, these methods assume a regression model with linear additive treatment effect and interaction effects $Y = \alpha + \tau_0 W_i + \tau^T X_i W_i + \beta^T X_i + \varepsilon_i$. While this model is reasonable in low dimensions, the interaction terms between all variables X and the treatment indicator W increase the size of the parameter space. A widely used approach proposed by Hill et al. [2011] is based on Bayesian Additive Regression Trees (BART). It is the analogue of gradient boosted decision trees using Bayesian inference via Markov Chain Monte Carlo (MCMC). In practice, this method achieves very good performances in various settings, but its empirical success still requires further theoretical understanding [Dorie et al., 2019].

— Direct estimation approaches without outcome modeling: These approaches are based on various concepts, for instance *causal trees* (or *pollienated outcome trees*) redefine the splitting criterion of random trees [CART Breiman, 2001] such as to maximize treatment heterogeneity [Athey and Imbens, 2016]. This can be achieved for instance, by considering the transformed outcome $Y_i^{TO} \triangleq W_i \frac{Y_i}{e(X_i)} + (1 - W_i) \frac{Y_i}{1-e(X_i)}$ and using CART on half of the data to build a tree on this transformed outcome Y^{TO}. The treatment heterogeneity is then assessed by estimating the ATE in each leaf of the resulting tree by *pollienating* the tree with the other half of the data and defining the estimated ATE as the difference in means in each leaf. The authors propose causal trees as a complementary step to the standard subset analysis, since it enables analysts to leverage the data for discovering relevant subgroups while preserving the validity of confidence intervals constructed on treatment effects within subgroups. Generalizations of this approach have been proposed since its introduction: causal forests and generalized random forests [Athey et al., 2019, Wager and Athey, 2018], and bagged causal multivariate adaptive regression splines [Powers et al., 2018]. Instead of defining a transformed outcome, Tian et al. [2014], Knaus et al. [2021] propose a *modified covariate* approach: it consists in finding $\hat{\tau}(\cdot)$ by optimizing the following loss function

$$\text{argmin}_\tau \frac{1}{n} \sum_i (2W_i - 1) \frac{W_i - e(X_i)}{4e(X_i)(1 - e(X_i))} (2(2W_i - 1)Y_i - \tau(X_i))^2.$$

Finally, a method related to causal forests is the *R-learner* [Nie and Wager, 2017]. They derive a loss function using a generalization of Robinson's transformation for partial linear models [Robinson, 1988], the so-called *residualization* step. This results in an (empirical) *R-loss*:

$$\frac{1}{n} \sum_i Y_i - \mathbb{E}[Y|X_i] - (W_i - e(X_i))\tau(X_i) + \Lambda(\tau),$$

where Λ is a regularization term controlling the complexity of the function $\tau(\cdot)$. This *R-loss* can be optimized with any loss-minimization method, such

as boosting or neural networks, to obtain an estimation of the CATE function (1.29).

We will see in Subsection 1.6.5 how these heterogeneous treatment effect estimation techniques are related to policy learning and reinforcement learning which are more dominant in the domain of machine learning.

1.5.2 Instrumental variables

A key ingredient for all the above methods is the unconfoundedness assumption (1.5) which states that there are no unmeasured confounders for the studied problem. However, this is a strong and untestable assumption and in practice it is often unclear to what extent it holds. A popular method, especially in economics, which circumvents this unconfoundedness assumption, at least in the linear context, by relying on a different set of assumptions is called *instrumental variables (IV) inference* [Angrist et al., 1996, Imbens, 2014]. Informally, an instrumental variable is defined as a variable that influences the treatment variable but that has no impact on the outcome conditionally on the treatment. For a detailed review of instrumental variables we refer the reader to Angrist et al. [1996] and Imbens [2014].

An example of instance of the simplified causal graph from Figure 1.5 is the widely discussed tobacco-lung cancer example from Cochrane et al. [1972]. The first study that established a strong association between tobacco consumption and lung cancer [Doll and Hill, 1950] has been criticized for its lack of control for hidden confounders such as genetic predisposition. A plausible instrument which could be used to cope with this argument is the level of the tobacco tax. Indeed higher taxes are likely to reduce the consumption of tobacco and if there was an effect of tobacco consumption on lung cancer, the tax would indirectly influence lung cancer, while the unobserved confounders remain unchanged.



Figure 1.5 – Observational data model with hidden confounding factors U and observed instrumental variable I. The instrument I allows to estimate the link between W and Y despite the unobserved confounders U.

Assuming the model is linear in all is components, we obtain the following:

$$\begin{aligned} Y &= \tau W + \beta U + \varepsilon_Y \\ W &= \alpha U + \delta I + \varepsilon_W \\ \Rightarrow Y &= (\alpha + \beta)U + \tau\delta I + \varepsilon_Y + \tau\varepsilon_W, \end{aligned}$$

where the $\varepsilon_\cdot$ denote exogenous random variables.

These expressions invoke a natural two-stage estimation approach:

1. Regress W on I. This gives an unbiased estimate of δ. Use the fitted values for W which approximately correspond to δI.
2. Regress Y on the fitted values $\hat{W} = \hat{\delta} I$. This gives an unbiased estimate of τ since I is by definition independent of U and the noise variables ε_W and ε_Y.

This approach is known as *two stages least squares* (TSLS) or *indirected least squares* (ILS) approach. The key for success of this method consists of two parts: the instrumental variable needs to satisfy the conditions of a valid instrument and the linearity in all components, i.e., a linear model relating Y to W and H and a linear model relating W to H and I.

Furthermore, if the true δ is small, i.e., the relationship between I and W is weak, then its estimation is more difficult in the sense that the estimator will have larger variance which then also leads to a larger variance in the fitted values. The final estimate of τ will still be unbiased but will potentially have large variance.

Note that if the treatment variable W is one-dimensional, a single instrument is sufficient for this approach. More generally, this method requires the instrument to be of the dimension as the treatment.

A shortcoming of IV methods is the task of identifying and justifying an instrumental variable for a specific context and causal question of interest. Indeed, some argue that most IVs are not really random and could affect the outcome other than through its effect on the treatment [see e.g., Baiocchi et al., 2014]. Furthermore, instrumental variables can also be confounded by unobserved confounders. Thus, sensitivity analysis approaches have also been derived for assessing the sensitivity of IV models [Cinelli and Hazlett, 2020]. Finally, IV methods have mostly been derived for the linear case and only few results exist for non-parametric settings. This aspect also limits the use of IV methods, especially in cases where the studied phenomena are more complex and likely not well approximated using linear specifications.

1.5.3 Sensitivity analysis

In most applications, the main criticism of causal analysis on observational data consists in the strong dependence on the identifiability assumptions, especially the untestable unconfoundedness assumption. Indeed, as stated already earlier in this chapter, one can never prove that there is no hidden confounding, i.e., at least one unobserved variable that drives both treatment assignment and potential outcomes [Cochrane et al., 1972, Pearl, 2009c, Imbens and Rubin, 2015, Hernán and Robins, 2020]. If there is an unobserved variable that is a confounder, then the induced bias on the treatment effect can change completely the final conclusion about the treatment effectiveness.

This issue is partially addressed by sensitivity analysis that attempts to assess how much the main analysis and conclusion, for instance the estimated value of the ATE, would change if an underlying model or method assumptions were altered, for

instance the presence of a hidden confounder [10]. The first proposal of sensitivity analysis for causal inference dates back to a widely discussed study on the effect of smoking on lung cancer [Cornfield et al., 1959]; this specific sensitivity analysis considers a binary unobserved confounder and its impact on the final estimate. Since then, various results have been derived for parametric settings [Rosenbaum and Rubin, 1983a, Imbens, 2003, Rosenbaum, 2005, Ichino et al., 2008, Cinelli and Hazlett, 2020], as well as for semi-parametric cases [Yadlowsky et al., 2018, Franks et al., 2019, Zhang and Tchetgen, 2019, Veitch and Zaveri, 2020]. Typically, the analysis translates expert judgement into a mathematical expression of how much the confounding affects treatment assignment and the outcome, and finally how much the treatment effect estimate is biased. In practice the expert must usually provide the so-called *sensitivity parameters* that reflect plausible properties of the missing confounder. Classic sensitivity analysis, dedicated to ATE estimation from observational data, use as sensitivity parameters the *impact of the missing covariate on treatment assignment probability* along with the *strength on the outcome* of the missing confounder.

To convey an idea of how sensitivity analysis can help addressing the issue of the untestable unconfoundedness assumption, we provide three examples, illustrating different approaches to tackle the problem of hidden confounding bias. For a more detailed review of this topic we refer to Rosenbaum [2010].

1.5.3.1 Point identification with sensitivity parameters

The first work that proposes using a sensitivity model to achieve point estimation is given by Rosenbaum and Rubin [1983a]. They consider a parametric setting with stratified individuals described by their stratum S taking values in $\{1, \dots, J\}$, $J > 0$. The outcome as well as the treatment are binary and modeled using logistic regression models. They assume the existence of a binary unobserved confounder U taking values in $\{0, 1\}$. They introduce two quantities: (1) the probability to be in one of the strata $\phi_s \triangleq P(S_i = s)$ such that $\sum_{s=1}^{J} \phi_s = 1$; (2) the probability that $U_i = 0$ if $S_i = s$, $\pi_s \triangleq P(U_i = 0 \mid S_i = s), \quad s = 1, \dots, J$.

The propensity score defined on all confounders, i.e., observed and unobserved, is defined as follows:

$$P(W = 0 \mid U = u, S = s) = [1 + \exp(\gamma_s + u\alpha_s)]^{-1}, \quad s = 1, \dots, J; \quad u = 0, 1$$

And conditional outcome model conditionally on all confounders is defined as

$$P(Y(w) = 0 \mid U = u, S = s) = [1 + \exp(\beta_{sw} + u\delta_{sw})]^{-1}, \quad s = 1, \dots, J; \quad w = 0, 1.$$

Under these assumptions and models, the ATE would be identifiable had we

10. Note that more generally, sensitivity analysis in statistics can be described the study of how the uncertainty in the output of a mathematical model can be affected by the inputs.

access to all confounders:

$$\begin{aligned}\mathbb{E}[Y(1) - Y(0)] &= P(Y(1) = 1) - P(Y(0) = 1) \\ &= \sum_{s=1}^{J} \phi_s \left[(1 - \pi_s) \frac{\exp(\beta_{s1} + \delta_{s1})}{1 + \exp(\beta_{s1} + \delta_{s1})} + \pi_s \frac{\exp(\beta_{s1})}{1 + \exp(\beta_{s1})} \right] \\ &\quad - \sum_{s=1}^{J} \phi_s \left[(1 - \pi_s) \frac{\exp(\beta_{s0} + \delta_{s0})}{1 + \exp(\beta_{s0} + \delta_{s0})} + \pi_s \frac{\exp(\beta_{s0})}{1 + \exp(\beta_{s0})} \right].\end{aligned}$$

The maximum likelihood estimate of the treatment effect can be computed from the maximum likelihood estimates of ϕ_s and β_{sw} corresponding to fixed values of the sensitivity parameters π_s, α_s and δ_{st}.

But since π_s as well as the parameters β_{sw} and δ_{sw} cannot be computed from the observed data, i.e., without the knowledge of U, we cannot directly use the above expression. But they propose to use this expression to derive a maximum likelihood estimate of τ with fixed maximum likelihood estimates of ϕ_s and β_{sw} which correspond to fixed values of the sensitivity parameters π_s, α_s and δ_{sw}. Such an approach, where different ranges of possible values for these sensitivity parameters are chosen to assess how the estimate of τ varies, allows to make empirical statements about the amount of variability of the estimated treatment effects for different combinations of $(\alpha_s, \delta_{s1}, \delta_{s0}, \pi_s)$.

Various solutions that aim at point identification with sensitivity parameters have been proposed since this first proposal by Rosenbaum and Rubin [1983a], see for instance Imbens [2003], Dorie et al. [2016], Zhang and Tchetgen [2019], Franks et al. [2019].

1.5.3.2 Bounding the hidden confounder bias using sensitivity parameters

The most common approach to perform sensitivity analysis in causal inference relies on the framework proposed by Rosenbaum [2005]. It aims to quantify how severely the causal conclusions would change, for instance whether there would still by a statistically significant treatment effect, if there was hidden confounding and subsequent confounding bias. Rosenbaum [2005] considers the propensity score $e(\cdot)$ and argues that for two individuals with observed covariates $X_{i\cdot}$ and $X_{j\cdot}$ it is possible to have $e(X_{i\cdot}) = e(X_{j\cdot})$, while there exists an unobserved confounder U such that $e(X_{i\cdot}, U_i) \neq e(X_{j\cdot}, U_j)$. This can be interpreted as two individuals who seem comparable in terms of observed covariates $X_{i\cdot}$ and $X_{j\cdot}$ may differ in terms of unobserved covariates U_i and U_j. The impact of a covariate U on the treatment assignment can be more or less important. And the parameter that quantifies this impact is denoted Γ. More precisely, Rosenbaum [2005] proposes to bound the following propensity score ratio using Γ and its inverse:

$$\frac{1}{\Gamma} \leq \frac{e(X_{i\cdot}, U_i)}{e(X_{j\cdot})} \leq \Gamma$$

The interpretation of these bounds is as follows: if we have $\Gamma = 1$, then there is no hidden confounder bias, since it is possible to perfectly balance the treatment

groups based on the propensity score. However, if $\Gamma \geq 1$ then it implies a hidden bias. In practice, varying the range of possible values for Γ, the treatment effect can become no longer statistically significant, and the practical question is then up to which value of Γ, the final conclusion about the treatment effect remains the same. This is sometimes referred to as *regulatory* or *statistical agreement* [Dahabreh et al., 2020]. With this approach, it is possible to compute Fisher (exact) p-values under the null hypothesis of no treatment effect [Fisher, 1936] [11], and to assess the sensitivity of the conclusion with respect to the unconfoundedness assumption. More specifically, for $\Gamma > 1$, an interval of p-values is obtained and for increasing values of Γ these associated p-values eventually become inconclusive, allowing to determine a threshold Γ_{th} up to which the hidden confounding bias does not alter the final conclusion. The associated sensitivity model can be summarized as follows:

— Assume that there exists an unobserved confounder U that summarizes all confounding, i.e., $W \perp\!\!\!\perp \{Y(0), Y(1)\} \mid X, U$

— Let $e(x, u) = P(W = 1 \mid X = x, U = u)$

— Use the quantity

$$\mathcal{R}(\Gamma) \triangleq \left\{ e(x,u) : \frac{1}{\Gamma} \leq \text{OR}\left(e\left(x,u_1\right), e\left(x,u_2\right)\right) \leq \Gamma, \forall x \in \mathcal{X}, u_1, u_2 \right\},$$

where OR denotes the odds ratio, to determine values of Γ such that the associated treatment effect estimations remain consistent with the initial estimation.

Many other works propose alternative ways to bound the bias of the estimated treatment effect using different sensitivity parameters [Yadlowsky et al., 2018, Shen et al., 2011, Zhao et al., 2017, Luedtke et al., 2015, Bonvini and Kennedy, 2021].

1.5.3.3 Austen plots: a graphical tool for sensitivity analysis

Especially in applied research, it is important to convey results and uncertainty about data and analyses as explicitly as possible. Visual representations are especially helpful when exchanging results with domain experts. Veitch and Zaveri [2020] propose to develop Austen plots, a graphic tool introduced by Imbens [2003] that aims to relate a level of bias (strength of the confounder) to the induced bias on the causal estimate. This approach is agnostic of the estimation strategy, and can be seen as a tool for posthoc analysis. While the approach to estimate the causal estimand [12] is unaffected by the sensitivity analysis, the latter requires certain assumptions to establish a link between the observed data and the unobserved confounder(s). Similarly to Imbens [2003], Veitch and Zaveri [2020] make the following assumptions:

$$\text{logit}\, \text{P}(W = 1 \mid x, u) = h(x) + \alpha u;$$

$$\mathbb{E}[Y \mid w, x, u] = l(w, x) + \delta u,$$

11. The Fisher exact p-values allow to test a sharp null hypothesis of no individual treatment effect.

12. For simplicity, we assume the estimand to be τ.

for some parameters α and δ and some functions h and l. As we can see from these expressions, there is no assumption added concerning only the observed data, but on the link between the observations, the propensity score, and the conditional response surface. By rearranging these expressions to solve for u this gives:

$$\mathbb{E}[Y \mid w, x, u] = \tilde{l}(w, x) + \tilde{\delta} \operatorname{logit} \mathrm{P}(W = 1 \mid x, u).$$

With this expression, Veitch and Zaveri [2020] posit a sensitivity model by defining a distribution on the true propensity score $\tilde{e}(X, U)$, from the propensity score that is estimated in practice $e(X)$:

$$\tilde{e}(X, U) \mid X \sim \mathrm{Beta}(e(X)(1/\alpha - 1), (1 - e(X))(1/\alpha - 1))$$

Similarly to the original work by Imbens [2003], the parameter α characterizes the strength of the unobserved confounder in the treatment assignment. If α is close to 0 then $\tilde{e} \approx e$. Conversely if α is close to 1, then the knowledge of U gives precise prediction of the treatment assignment. A similar derivation is provided for the parameter δ which characterizes the outcome-confounder strength.

In Figure 1.6, we provide an example of such an Austen plot as given by Veitch and Zaveri [2020] to illustrate how this approach allows to communicate the results of the sensitivity analysis. The bias in this example is chosen to be equal to the nominal average treatment effect estimated from the data. The curve shows all values of treatment and outcome influence that would induce a bias of 2. The colored dots show the influence strength of (groups of) observed covariates, given all other covariates. For example, an unobserved confounder with as much influence as the patient's age might induce a bias of about 2.



Figure 1.6 – Austen plot showing how strong an unobserved confounder would need to be to induce a bias of 2 in an observational study of the effect of combination blood pressure medications on diastolic blood pressure [Dorie et al., 2016]. This figure reproduces the Figure 1 from Veitch and Zaveri [2020].

To get an idea of the level of possible unconfoundedness in practice, Veitch and Zaveri [2020] propose to measure the influence of every observed covariate or

groups of observed covariates, performing the analysis with and without these single covariates or groups of covariates it to assess the amount of induced bias.

1.6 – Other research fields of causal inference

This introductory chapter, while aiming to provide a broad overview of key notions and results of causal inference, especially under the potential outcomes framework, cannot cover all existing research topics of causal inference that have received attention in the past decades. We briefly name a few domains which are related to the previously discussed approaches and results but which tackle more or less different issues related to the type of data and the modeling of causal effects.

1.6.1 Mediation analysis

While the main objective in many applications is to assess the effect of a treatment or an intervention on a target variable, the outcome, another important question concerns the causal mechanisms, or *mediators*, through which a treatment affects the outcome variable. More specifically, mediation analysis, formalized by Robins and Greenland [1992], aims at disentangling the effects of a treatment on an outcome through alternative causal mechanisms and has become a popular practice in biomedical and social science applications [Imai et al., 2010]. As appealing as this aim might seem, it is an ambitious task even in the randomized treatment case. Indeed, even if the treatment is assigned at random, the mediators, i.e., variables that lie on a path from the treatment variable to the main outcome and that can be seen as intermediate outcomes, are not randomized. This evokes the question of confounding between these mediators and the main outcome, since the mediators can also be seen as intermediate treatment variables but without randomization of the assignment. The literature on identifying causal mechanisms by mediation analysis is growing and we provide a few notable examples of works: the idea for causal mediation analysis has first been mentioned by Cochran [1957] in the context of linear models. Subsequent works further develop this linear case, [e.g., Judd and Kenny, 1981, Baron and Kenny, 1986]. In the semi-parametric setting, the focus is on the correction for the selection on observables or confounding of the mediators [e.g., Pearl, 2001, Robins, 2003, Petersen et al., 2006, Imai et al., 2010, VanderWeele, 2009, Vansteelandt et al., 2012, Tchetgen and Shpitser, 2012].

1.6.2 Targeted learning

The targeted learning framework has been pioneered by Mark van der Laan [Van Der Laan and Rubin, 2006, Van der Laan and Rose, 2011] and its scope goes beyond causal inference, covering many other aspects of statistical analyses. It proposes to resolve seemingly irreconcilable model-based approaches and model-agnostic approaches, trying to address concerns about model mis-specification and trade-offs between interpretable and correct models (summarized under *Occam's dilemma* [Breiman, 2001]). In a nutshell, targeted learning consists in targeting the analysis to the primary scientific question at hand, for instance about a treatment effect, in a way that incorporates flexible modeling, while still allowing for valid inferences. In this section, we will briefly review the key concepts and results of this framework, presented here in the context of causal inference and thus omitting more general result formulations.

In order to avoid interpretability and mis-specification issues of certain model parameters, in targeted learning it is proposed to specify a model-free estimand prior to any modeling of the data. An example of this is the average treatment effect τ as defined in Section 1.2. To simplify notations in this section, we will focus on only one part of the definition of τ, namely $\mathbb{E}[Y(1)]$. This target quantity does not rely on any model. Under the (non-parametric) identifiability assumptions from Subsection 1.2.2, we can rewrite this as

$$\mathbb{E}[Y(1)] = \mathbb{E}\left[\mathbb{E}[Y|W=1,X]\right] = \mathbb{E}[Q_0(X)],$$

where $Q_0(X)$ denotes the response surface over the treated. We define $\theta \triangleq \mathbb{E}[Y(1)]$ as the model-free estimand of interest.

As we saw in Section 1.5, regression adjustment or inverse propensity weighting allow flexible and data-adaptive modeling for estimation of θ, using plug-in estimators. However, depending on the complexity of the conditional response surface $Q_0(X)$, data-adaptive estimators might have complex distributions and variability that are difficult to quantify. Thus, standard error estimation and valid inferences using the final estimator's distribution are not straightforward. Another concern is plug-in bias which can be assessed for predictive tasks where all outcomes are observed, but is problematic in causal inference where we generally do not have access to the ground truth.

To remedy the shortcomings of these plug-in estimators, Van Der Laan and Rubin [2006] leverages ideas from semi-parametric theory (we refer to Tsiatis [2007] for a general introduction to semi-parametric theory) and the key concept of *efficient influence functions*. An efficient influence function characterizes the sensitivity of an estimand θ to small changes in the observed data distribution and thus also impacts how sensitive an estimator $\hat{\theta}$ of θ will be. The influence function is a mean zero function $\phi_P(O)$ of the observed data O and their distribution P and its derivation is specific for each estimand. This function, and more specifically its empirical counterpart $\frac{1}{n}\sum_{i=1}^{n}\phi_{\hat{P}_n}(O_i)$ quantifies the previously mentioned plug-in bias.

With the targeted maximum likelihood estimator (TMLE) Van Der Laan and Rubin [2006] then propose to build a parametric model around the initial data-adaptive estimate, for instance a regression adjustment estimator $\overline{Q}_{0,n}(X)$ for the

response surface $Q_0(X)$, such that the bias term $\frac{1}{n}\sum_{i=1}^{n}\phi_{\hat{P}_n}(O_i)$ is forced to be zero. The resulting estimator benefits from the well understood behavior of the parametric model based estimator for valid inference and from plug-in bias removal due to the use of the influence function term.

In practice, a popular generalization of this TMLE is the *super learner* [Polley and Van der Laan, 2010] which extends this estimator to include complex data-adaptive methods such as penalized or tree-based regression as well as kernel based methods (see the R package `SuperLearner` for a concrete implementation of this approach [Polley et al., 2019]).

This very brief introduction to targeted learning only aims to provide an intuition of this approach as an alternative class of methods to estimate causal effects; we refer to Van der Laan and Rose [2011] for a complete review of this still growing domain of research.

1.6.3 Causal survival analysis

An important domain in epidemiology and other related fields is *survival analysis*. It tackles the issue of analyzing *time-to-event* data and the distribution of the survival outcome. The key challenge with such data is the general presence of censoring which can occur for various reasons: studies are generally of limited duration and thus the outcome may not be achieved for some participants by the end of the study (administrative censoring); subjects may drop out of a study and are lost to follow-up before the event of interest is ascertained. In some cases, the presence of *competing risks* may prevent the observation of the outcome, e.g., death by a road accident while the outcome is recovery from a certain disease. Thus, the observed time for individuals with censoring is the time up to the censoring event while for other individuals it is the time until the outcome of interest is observed. Important quantities of interest in survival analysis are the *survival function* S which corresponds to the probability of survival up to a time point $u \geq 0$: $S(u) \triangleq P(T > u)$, where T is a nonnegative random variable (the potential event time), and the *hazard function* $\lambda(u) \triangleq \lim_{du \to 0} \frac{P(u \leq T < u+d | T \geq u)}{du}$, such that $\lambda(u)du$ can be interpreted as the probability that an individual at time u experiences the event of interest at the next instant of time. The aim in survival analysis is to estimate these survival and hazard functions in the presence of censoring, i.e., the random variable T is not always observed [Klein and Moeschberger, 2003].

More recently, there have been works bridging the gap between causal inference and survival analysis by asking questions of the form: *how do the survival and hazard functions change under different treatments?* The resulting "hybrid" methods are qualified as *causal survival analysis* methods. These methods tackle the issues of censoring and those arising in causal inference, namely confounding and the unobserved counterfactual outcomes. Early works focus on parametric cases and unconfounded data, proposing variants of the Kaplan-Meier estimator [Kaplan and Meier, 1958] combined with inverse probability of censoring weighting [Robins and Rotnitzky, 1992, Robins and Finkelstein, 2000, Howe et al., 2016]; doubly robust alternatives have been proposed as well [Ozenne et al., 2020]; and a growing literature

on semi-parametric results for treatment effect estimation with time-to-event data can be found as well [Zhao et al., 2015, Yadlowsky et al., 2019, Cui et al., 2020].

1.6.4 Causal inference with panel data

Another type of data where time plays an explicit role is panel data (or longitudinal data). However, as opposed to the previous case of survival data, in panel data we consider that an outcome of interest is measured for every individual at multiple time points $\{1, \dots, T\}$, for instance a monthly or yearly measurement. In parallel, the treatment assignment (and possibly also other variables such as some baseline measures X) is also measured at these same time points, so that the considered data consists of measurements for individuals $i \in \{1, \dots, n\}$ taken at each $t \in \{1, \dots, T\}$. Such data is frequent in economic applications and the aim generally is to evaluate effects of interventions or policy changes (such as introducing or changing minimum wage or introducing wider access to public health services) that affect entire regions, states or nations and that are difficult to measure with classical treatment effect tools.

Assuming a simple model with constant treatment effect τ across individuals and across time and without treatment dynamics, i.e., the outcome Y_{it} of individual i at time t is only affected by the treatment level of this individual at this time point, W_{it}, a simple approach to estimate such a treatment effect is to define a two-way additive fixed effect regression model with a fixed effect for each individual and each time point:

$$Y_{it} = \alpha_i + \beta_t + W_{it}\tau + \varepsilon_{it}, \text{ such that } \mathbb{E}[\varepsilon|\alpha, \beta, W] = 0.$$

A resulting estimator from this modeling is called the *difference-in-differences* estimator [Card and Krueger, 1994].

A generalization of this simplistic modeling of such data consists in allowing for interaction terms

$$Y_{it} = A_{i\cdot}B_{t\cdot}^T + W_{it}\tau + \varepsilon_{it}, \text{ such that } \mathbb{E}[\varepsilon|A, B, W] = 0, \text{ and } A \in \mathbb{R}^{n\times k}, B \in \mathbb{R}^{T\times k},$$

for some parameter $k > 0$. This model covers a variety of scenarios, for instance, as opposed to the above two-way model, it does not assume parallel trends between individuals [Abadie et al., 2010]. Several methods exist that allow to estimate τ from panel data under this model, *synthetic controls* [Abadie et al., 2010] and *synthetic difference-in-differences* [Arkhangelsky et al., 2019]. The former are popular among policy makers for their clear interpretability. This approach adopts a block assignment set-up, i.e., individuals are not treated in the beginning, and at some time time point t a group of individuals gets treated and keeps the treated status until the final time point T [13]. Other set-ups exist as well, for instance, a recent work considers *staggered adoption* where the treatment can be given to different individuals at

13. Note that this assumption only allows for a single change of treatment level, from untreated to treated, at a single time-point in the study. A different case considering varying treatment levels is addressed by the dynamic treatment regimes framework, see the following section.

different time points instead of a single onset [Athey et al., 2021]. The approach from Abadie et al. [2010] consists in re-weighting the control observations such that their weighted average trend matches (approximately) the average trend of the treated up to treatment onset. The rationale behind this weighting is that the differences observed between the treated and the synthetic control after treatment should be attributable to the treatment. The proposal of Arkhangelsky et al. [2019] proceeds differently, by combining three different approaches to model the data: vertical regression [Doudchenko and Imbens, 2016] that assumes there is a relation between different individuals that is stable over time, horizontal regression [Imbens, 2004] that assumes there is a relation between outcomes under treatment and outcomes during pretreatment periods that is the same for all individuals, and the two-way fixed effect model.

The study of panel data, with and without treatment effect estimation, is an entire research field and the examples provided above only cover a small part of it. For a detailed introduction to panel data and different associated statistical problems we refer to Wooldridge [2010] and references therein.

1.6.5 Policy learning and dynamic treatment regimes

A natural continuation of the previous setting of panel data and of the previously discussed heterogeneous treatment effect estimation methods is to consider dynamic treatment regimes and policies. Indeed, causal inference and policy learning are closely related in terms of their high-level aim: quantifying treatment or intervention effects or expected rewards to guide future decisions. However, while causal inference attempts to exploit the data *a posteriori* to estimate efficiently the contrasts of potential outcomes from the perspective of guiding decisions in the future based on the estimated efficacy or effectiveness of one or several treatments, policy learning directly aims at learning optimal treatment assignment rules and exploits the data either offline, i.e., *a posteriori*, or online, i.e., during the data collection process.

Estimating the value of a personalized policy is related to estimating the ATE (this corresponds to comparing the "treat all"-policy to the "treat none"-policy) and to estimating the CATE; certain results from causal inference can be extended to provide tightened bounds on the regret, i.e., the gap between the optimal policy and the estimated policy [Athey and Wager, 2021].

More formally, if using the notation from the previous sections, the framework for policy learning can be summarized as follows: the goal consists in seeking a policy $\pi : \mathcal{X} \to \{0, 1\}$, i.e., a mapping from the covariates to the treatment decision. The value of a policy π is defined as $V(\pi) \triangleq \mathbb{E}[Y_i(\pi(X_i))]$ and consequently, the optimal policy is defined by $\pi^* \triangleq \text{argmax}\{V(\pi') : \pi' \in \Pi\}$, where Π is the space of possible policies. With these definitions, the regret of a policy π can be formalized as

$$R(\pi) \triangleq \sup\{V(\pi') : \pi' \in \Pi\} - V(\pi).$$

Policy learning can be viewed as learning a policy π with guaranteed bounds on the regret. A large variety of strategies exist to learn a policy π in this context, but they generally all consist of two elements: exploration and exploitation. These can

be consecutive stages of the strategy, namely learning a first policy $\hat{\pi}$ on a training sample $(X_i, W_i, Y_i)_{i \in n_{train}}$ and then applying the policy $W_i = \hat{\pi}(X_i)$ to compute the value $V(\hat{\pi})$, or they are applied simultaneously (this class of strategies as called multi-armed contextual bandit models, initially introduced by Thompson [1933]; for a complete review of these models we refer to Lattimore and Szepesvári [2020]).

In certain contexts, it is necessary to also model the temporal aspect in the treatment assignment process, since certain covariates vary across time and due to prior treatment decisions. This problem is called *dynamic policy learning*. The objective remains the same, namely to learn a policy that can be applied to choose a treatment or action at each stage; however the context changes with respect to the previous static case. Indeed the final outcome Y_i at final time-point T corresponds to $Y_i = Y(W_{i_{1:T}})$ with 2^T associated potential outcomes for the different possible treatment sequences.

For each time-point t, the policy maps time-t observables to an action or treatment assignment, $\pi : (X_1, W_1, \ldots, X_t) \mapsto \{0, 1\}$, and the value function thus also changes:

$$V_T(\pi) \triangleq \mathbb{E}\left[Y_i\left(\pi_1\left(X_1\right), \pi_2\left(X_1, \pi_1\left(X_1\right), X_2\left(\pi_1\left(X_1\right)\right)\right), \ldots\right)\right].$$

This dynamic policy problem addressed primarily in a computer science context actually rejoins another field, rooted in the biomedical context, and which also studies treatment assignments as a dynamic decision process in order to provide decision support systems: dynamic treatment regimes (DTR), a notion pioneered by Susan Murphy and James Robins [Murphy et al., 2001, Murphy, 2003]. A DTR is defined as a sequence of decision rules, one per stage of the intervention, mapping the individual patient's history, which is evolving over time after each decision, and current response to the previous intervention to a feasible treatment option. Broadly speaking, a DTR π is considered to be optimal if it optimizes the mean long-term outcome, i.e., $\pi^* = \text{argmax}\{V_T(\pi') : \pi' \in \Pi\}$. Note however that for a given individual, an optimal regime is not necessarily the optimal sequence of treatment. But on population level, it is, by definition, the optimal regime.

For a complete introduction to DTR and overview of existing results and applications we refer to Tsiatis et al. [2019] and references therein.

Chapter 2

The role of missing values

> Causal inference is [...] fundamentally a missing data problem and, as in all missing data problems, a key role is played by the mechanism that determines which data values are observed and which are missing.
>
> — Guido W. Imbens, Donald B. Rubin, *Causal Inference for Statistics, Social, and Biomedical Sciences*

Abstract

While the issue of missing data is an inevitable part of statistical practice, most analytical methods are not directly applicable to incomplete data. Since the seminal work of Rubin [1976], the topic has grown steadily within the statistical community; and more recently, the problem of missing data is exacerbated even more by the growing multiplicity and variety of data collected, often from different sources of information. It is then crucial to have effective methodologies for conducting analyses in the presence of incomplete data, and especially to know how much confidence can be placed in the results obtained from partial data. To understand the possibilities and challenges that come with missing data, it is crucial to have a solid understanding of their impact on classical statistical analysis and to dispose of a common framework that formalizes missing values problems [Rubin, 1976]. In this chapter, we will first present this general framework and briefly discuss the main methods that allow statistical analysis with missing values; second, we will focus on the role of missing values in causal inference.

Table of contents
Table des matières

2.1 – Missing values in general statistical context

2.1.1 A short history of missing values in statistics

Prior to the seminal work of Rubin [1976], the practical fact of incomplete data even back then required missing values handling in practice. The most common methods before the 1970s were either ad-hoc imputation or complete case analysis [Afifi and Elashoff, 1966]. For simple problems and models, maximum likelihood estimation based on the factorized likelihood was already present [Anderson, 1957]. The generalization of the maximum likelihood approach for incomplete data was then provided by Rubin [1976], together with the idea of modeling the missing values mechanism and defining different classes of mechanisms; and the advent of increasing computational resources as well as the Expectation Maximization algorithm proposed by Dempster et al. [1977] facilitated further extensions of maximum likelihood derivations for more complex problems [Little and Rubin, 2019]. In the mid 1980s, another generalized approach to inference with missing values has emerged, based on ideas from Bayesian statistics [Tanner and Wong, 1984], and popularized with the introduction of the concept of multiple imputation (MI) [Rubin, 1978b, 2004]. The popularity of Monte Carlo Markov Chains (MCMC) methods in Bayesian statistics as well as for MI promoted the use of the latter as an alternative to the maximum likelihood approach with better small sample properties (see e.g., Little and Rubin [2019]). In the 1990s, other important approaches to missing values handling have been proposed, such as augmented inverse probability weighting by Robins et al. [1994], based on semi-parametric statistics as well as robust Bayesian modeling [Linero and Daniels, 2018]. These works and following extensions improve on robustness to mis-specifications of the missingness mechanism or the statistical model of interest. Finally, more complex models are studied, often in the context of machine learning and non-parametric modeling, such as latent class models for

categorical data [Audigier et al., 2017] or Bayesian Additive Regression Trees (BART, Chipman et al. [2010]).

After this very short overview over the developments of missing values methods of the past 50 years, we now go over to the concepts and formalizations of Rubin [1976]'s seminal work.

2.1.2 Concepts and Rubin's taxonomy of missing values mechanisms

The definitions of missing values mechanisms proposed by Rubin [1976] are based on (n) realizations $x_{i\cdot}$ of random variables $X_{i\cdot}$ with support in $\mathbb{R}^p$. However, a more recent formulation considers all possible values that can be taken by the variables X_i [Seaman et al., 2013, Little and Rubin, 2019]. Several other works draw a complete picture of available formalizations, concepts and methods for handling missing values [Schafer, 1997, Kim and Haziza, 2013, Molenberghs et al., 2014, van Buuren, 2018].

Response (or equivalently missingness) information is encoded in binary variables $R_i \in \{0,1\}^p$.

Definition 2.1.1 (Response pattern)**.** *The response pattern $R \in \{0,1\}^{n\times p}$ is a (random) binary matrix, such that its realized values are*

$$\forall\, i \in \{1,\dots,n\},\ \forall\, j \in \{1,\dots,p\}, \quad r_{ij} \triangleq \begin{cases} 1 & \text{if } x_{ij} \text{ is observed} \\ 0 & \text{otherwise.} \end{cases} \tag{2.1}$$

Additionally we denote by x_i^{obs} and x_i^{mis} the observed and the missing values of x_i. For simplicity, we will assume that the realizations $(x_i, r_i)_{1\leq i\leq n}$, $n \in \mathbb{N}$, are i.i.d. samples from a distribution in the family $\mathcal{P} \triangleq \{p_\theta(x)q_\phi(r \mid x) : \theta \in \Theta, \phi \in \Phi\}$. Hence q_ϕ characterizes the missingness mechanism. Statistical inference is generally about estimating the parameter θ, a possible approach under some regularity assumptions and assuming fully observed x_i is maximum likelihood estimation: $\hat{\theta} \triangleq \operatorname{argmax}_\theta \mathcal{L}(\theta)$ where $\mathcal{L}(\theta) \triangleq \prod_{i=1}^n p_\theta(x_i)$ is the likelihood. In order to perform maximum likelihood estimation on incomplete data x_i, some assumptions on the mechanism q_ϕ have to be made as can be seen when writing out the full likelihood $\mathcal{L}_{full}$, which is obtained by integrating over the missing values:

$$\mathcal{L}_{full}(\theta,\phi) \triangleq \prod_{i=1}^n \int_{\mathcal{X}^{mis}} q_\phi(r_i|x_i)p_\theta(x_i)dx_i^{mis} \tag{2.2}$$

Since the parameter ϕ and a modeling of the missingness mechanism are generally not of primary interest, a more common quantity, the observed likelihood $\mathcal{L}_{obs}$, can be derived, assuming that the missingness is *ignorable* [Little and Rubin, 2019]. Ignorability requires functional independence of the two parameters θ and ϕ and that the missingness mechanism is either *missing completely at random* (MCAR) or *missing at random* (MAR). The former means that the missingness mechanism is independent of the data x, whereas the latter states that the missingness only depends on the observed values x^{obs}. More formally, we have the following definitions:

Definition 2.1.2 (Missingness mechanism)**.** *Given* $r \in \{0,1\}^p$ *and* $x = (x^{obs}, x^{mis}) \in \mathbb{R}^p$*, the missingness mechanism* ϕ *is qualified as*

(i) missing completely at random (MCAR), if

$$\forall\, \phi,\ \forall\, x' = (x'^{obs}, x'^{mis}),\ q_\phi(r|x') = q_\phi(r|x) = q_\phi(r) \tag{2.3}$$

(ii) missing at random (MAR), if

$$\forall\, \phi,\ \forall\, x'^{mis} \text{ such that } x' = (x^{obs}, x'^{mis}),\ q_\phi(r|x') = q_\phi(r|x) \tag{2.4}$$

Under either one of these mechanisms, we can define the observed likelihood as follows:

$$\mathcal{L}_{obs}(\theta) \triangleq \prod_{i=1}^{n} q_\phi(r_i|x_i^{obs}) \int_{\mathcal{X}^{mis}} p_\theta(x_i) dx_i^{mis}. \tag{2.5}$$

This reduction to the observed likelihood is not possible if the missingness mechanism is non-ignorable. In this case the mechanism is qualified as *missing not at random* (MNAR) and it formally states that the mechanism does not satisfy (2.3) or (2.4), in other words the missingness is allowed to depend on the missing values themselves. In the remainder of this work, we will equivalently designate this case as *general* missingness or MNAR. A classical example that illustrates this case is the well known fact that very wealthy – but also very poor – people tend to keep their earnings secret, so in a survey they would leave out questions related to their earnings leading to missing values that are therefore missing not at random [Atkinson et al., 2011].

2.1.3 Missing values handled in the analysis: EM

The initial question being *how to perform statistical analyses with missing values?* or more precisely in the parametric setting stated above *how to estimate the parameter* θ*?*, a first solution is to adapt existing statistical methods to take into account the presence of missing values. As seen above under ignorability, the parameter θ can be estimated by maximum observed likelihood estimation. However, since the expression of $\mathcal{L}_{obs}$ involves integrating over all possible missing values, a direct maximization of $\mathcal{L}_{obs}$ is generally intractable but a well known solution to this is the *Expectation-Maximization* algorithm (EM) proposed by Dempster et al. [1977]. It assumes that the joint distribution of missing and observed variables, $p_\theta(x) = p_\theta(x^{obs}, x^{mis})$ is explicitly known and it aims at maximizing the observed log-likelihood ℓ_{obs},

$$\begin{aligned} \ell_{obs}(\theta) &\triangleq \log\left(\prod_{i=1}^{n} q_\phi(r_i|x_i^{obs}) \int_{\mathcal{X}^{mis}} p_\theta(x_i) dx_i^{mis}\right) \\ &= \sum_{i=1}^{n} \log\left(\int_{\mathcal{X}^{mis}} p_\theta(x_i) dx_i^{mis}\right) + \log q_\phi(r_i|x_i^{obs}), \end{aligned} \tag{2.6}$$

where the last term is constant in θ, hence it can be dropped for finding (or approximating) the value θ that maximizes the observed log-likelihood.

The EM algorithm is an iterative algorithm starting at some initial $\theta^{(0)} \in \Theta$. Using Jensen's inequality, it consists in alternately taking the expectation of the complete-data log-likelihood $\ell(\theta; x^{obs}, x^{mis}) \triangleq \log p_\theta(x^{obs}, x^{mis})$ with respect to the conditional distribution of missing covariates parametrized by $\theta^{(t)}$ at step t and then finding $\theta^{(t+1)}$ by maximizing this expectation in θ:

$$\begin{aligned} \text{E(xpectation) step:} \quad Q(\theta|\theta^{(t)}) &\triangleq \sum_{i=1}^{n} \mathbb{E}[\ell(\theta; x_i^{obs}, x_i^{mis})|X_i^{obs} = x_i^{obs}; \theta^{(t)}] \\ &= \int \ell(\theta; x_i^{obs}, x_i^{mis}) p_{\theta^{(t)}}(x_i^{mis}|x_i^{obs}) dx_i^{mis}, \end{aligned} \tag{2.7}$$

$$\text{M(aximization) step:} \quad \theta^{(t+1)} \in \operatorname{argmax}_\theta Q(\theta|\theta^{(t)}). \tag{2.8}$$

An important property of this algorithm is that the sequence $(\theta^{(t)})_{t\geq 0}$ is guaranteed to increase the observed log-likelihood $\ell_{obs}(\theta^{(t)})$, however there is no guarantee for convergence towards a global maximum.

A supplemented EM algorithm (SEM) allows to estimate the variance of the resulting maximum likelihood estimate $\hat{\theta}_{MLE}$ [Meng and Rubin, 1991]. Alternatively one can use Louis' formula to estimate $Var(\hat{\theta}_{MLE})$ [Louis, 1982].

2.1.4 Missing values handled in pre-processing: imputation

A drawback of the expectation-maximization algorithm is its lack of generalizability: the E and M steps have to be derived for every statistical method and these derivations can involve complicated or intractable terms hindering the implementation of a computationally efficient estimation algorithm. Since most of the existing statistical methods are designed for complete data, another idea consists in *imputing*, i.e., filling in, the missing values to recover a complete dataset [Rubin, 2004]. There exist several approaches to impute the data with "plausible" values: assuming a known joint distribution of the data, *joint modeling* consists in exploiting this knowledge to impute the missing values based on the observed values [Little and Rubin, 2019]. Other approaches are based on low-rank modeling of the data [Hastie et al., 2015, Josse et al., 2011b] or on fully conditional specification (FCS) [van Buuren, 2018, Stekhoven and Bühlmann, 2012]. Following the trend of deep learning now there also exist imputation methods based on generative adversarial networks [Yoon et al., 2018b], denoising autoencoders [Gondara and Wang, 2018], and optimal transport [Muzellec et al., 2020].

If the goal is to perform statistical inferences, then a single imputation, i.e., replacing each missing value with one plausible value to get a single completed dataset, is not sufficient to take into account the additional variability due to missing values and therefore a multiple imputation (MI) strategy [Rubin, 2004] is adopted with the imputation methods listed above. The principle of MI is proposing M different (plausible) values for each missing value. The variability across these imputations reflects the variance of the imputation of the missing values. Statistical analyses are then carried out separately over the M resulting imputed datasets and the M estimations $(\theta_m)_{1\leq m\leq M}$ are combined according to Rubin's rules [Rubin, 2004]

to obtain a single estimate $\hat{\theta}$ with a well estimated variance, i.e., taking into account the additional uncertainty due to the missing values.

2.1.5 Missing values in the context of supervised learning

Previously we discussed estimation problems in the presence of missing values, i.e., the estimation of some parameter $\theta \in \Theta$. However, if the goal is to make predictions about a response variable y given the information x, there exist other approaches to handle missing values in x that are not about accurate imputation of x or good parameter estimation. For instance, random trees [Breiman et al., 1984] are non-parametric models that aim at estimating discriminative models, allowing to predict y given x. An appealing property of tree-based models is their ability to handle semi-continuous variables, therefore allowing for missing values in the data. One solution that takes into account the missingness in the discriminative model estimation is *missing incorporated in attributes* (MIA) [Twala et al., 2008, Josse et al., 2019]. It allows optimal splits along the observed parts of X and the response pattern R. Another, conceptually even simpler approach for prediction with incomplete data is mean imputation which is consistent, provided that one uses a learning algorithm with infinite learning capacity [Josse et al., 2019]. The mostly empirical success of neural or deep networks for supervised learning tasks is apparent both in terms of applications of these methods and the fast growing literature on their empirical behavior, less so on their theoretical foundations. And the literature on explicit and consistent handling of missing values in the context of deep learning is still rather scarce, but some recent works provide notable results: Le Morvan et al. [2020b] propose to specify the distribution of data containing missing values with Rectified Linear Units (ReLU) activation functions for a set of linear problems. Additionally, Le Morvan et al. [2020a] propose a new principled architecture for different missingness mechanisms, based on a Neumann-series approximation of the Bayes-optimal predictor, i.e., a function of the input x that minimizes the prediction error. Finally, another line of work in the context of graph representation learning tackles the prediction task under the more restrictive assumption on the missingness mechanism (MCAR) [You et al., 2020].

2.2 – Missing values in causal inference

The fundamental problem in causal inference, as formulated by Rubin [1976], Holland [1986], is a missing values problem in itself: one wishes to estimate a difference of two quantities that are never observed together, as we have already seen in Chapter 1. This might explain why a large part of the early members of the causal inference community are also important contributors to the missing values community, the most famous example for this being Donald B. Rubin. For a systematic review of causal inference from a missing data perspective we refer to Ding and Li [2018].

Several approaches have been introduced to address either problems from classical statistical analysis with missing values or problems related to causal inference [e.g.,

Bang and Robins, 2005, Bhattacharya et al., 2019]. A first step to understanding the intrinsic proximity between the potential outcomes and missing data framework is to go back to Definition 1.2.1 of potential outcomes: Based on this definition, we can consider the potential outcomes as two different random variables, of which at most one can be observed for each individual, depending on the treatment assignment W. The latter can thus be interpreted as the missing values indicator for $Y(1)$ and $Y(0)$, namely

$$R^{Y(1)} = 1 \text{ and } R^{Y(0)} = 0, \text{ if } W = 1$$
$$R^{Y(0)} = 1 \text{ and } R^{Y(1)} = 0, \text{ if } W = 0.$$

In other words, the treatment assignment defines a missing data mechanism for the potential outcomes. The assumptions on the treatment assignment, in particular the unconfoundedness assumption (1.5) can be understood as a MAR assumption (Definition 2.1.2):

$$P(W|Y(1), Y(0), X) = P(W|Y^{obs}, Y^{mis}, X) = P(W|X, Y^{obs}),$$

where we use the superscript notation from the previous section to denote the missing and observed (outcome) values. This correspondence between the unconfoundedness assumption and this MAR assumption is possible due to the SUTVA assumption that guarantees that $Y^{mis} = Y(1-W)$. Analogously, the randomized treatment case (RCT) corresponds to a MCAR mechanism,

$$P(W|Y(1), Y(0), X) = P(W|Y^{obs}, Y^{mis}, X) = P(W),$$

since the treatment assignment is drawn at random and independently from any covariate X and potential outcomes $Y(1), Y(0)$. [1] Finally, the general case of treatment assignment with unmeasured confounding can be related to the case of MNAR mechanism:

$$P(W|Y(1), Y(0), X) = P(W|Y^{obs}, Y^{mis}, X^{obs}, X^{mis}) = P(W|Y^{obs}, X^{obs}, X^{mis}).$$

In this last case we have split the covariates X into observed and missing confounders to make the dependence of W on unobserved information X^{mis} explicit. Similarly to classical statistical analysis with MNAR missing values, there exist several works on identifiability and estimation under such hidden (or unmeasured) confounding [Shpitser and Pearl, 2006, Bhattacharya et al., 2020].

However, the simultaneous presence of missing (covariate) values and missing potential outcomes in observational data is slightly different and requires further modeling than the above analogies between missing data and causal inference problems. [2] This issue has not been extensively addressed to date. Notable exceptions

1. For simplicity of this analogy we omit the case of stratified experiments where the randomization is preceded by a stratification step based on certain baseline covariates.

2. In experimental data, the missing potential outcomes problem is not of concern due to the randomization design, however the missing data problem in RCTs is a challenge and it has been noted by a panel of the National Academy of Science that, like in other statistical domains, the literature is twofold: maximum-likelihood-based approaches and multiple imputation methods on the one hand and weighting methods such as inverse probability of missing or censoring weighting on the other hand [Van der Laan and Rose, 2011].

include D'Agostino and Rubin [2000], Mattei and Mealli [2009], Qu and Lipkovich [2009], Mitra and Reiter [2011], Seaman and White [2014], Blake et al. [2020] who all focus on adapting balancing score weighting methods to the case of incomplete confounders. Other lines of work consider identifiability of causal effects in the presence of incomplete (covariate) data [Karvanen et al., 2020], and latent variable modeling to handle incomplete covariates [Kallus et al., 2018a]. In Part III, we will provide a detailed review of this problem, and propose a novel approach to handle incomplete confounders, and more generally incomplete attributes.

Chapter 3
The Traumabase® registry

> [B]ehind every data point there is a human story, there is a family, and there is suffering.
>
> — Nick Jewell, *Statistics for Epidemiology*

Abstract

Major trauma is defined as any injury that endangers the life or the functional integrity of a person. The Global Burden of Disease working group of the WHO has recently shown that major trauma in its various manifestations, from road traffic accidents, interpersonal violence, self-harm to falls, remains a public health challenge and major source of mortality and handicap around the world. Hopefully, it has also been shown that management of major trauma based on standardized and protocol based care improves prognosis of patients especially for the two main causes of death in major trauma i.e., hemorrhage and traumatic brain injury.

With the objective of evaluating and improving the care of trauma patients, 23 French Trauma centers have decided to collaborate to collect detailed, high quality clinical data from the scene of the accident to discharge from the hospital. The resulting database, the Traumabase® has prospectively gathered more than 30,000 trauma admissions data, and new cases are permanently recruited. The granularity of the collected data makes this observatory unique in Europe. A multidisciplinary consortium of clinicians, statisticians, and mathematicians takes strategic advantage of an unrestricted access to this database to propose an innovative response to the public health challenge of major trauma. The objectives of this consortium are manifold: to develop and design an interactive, real-time, probabilistic decision-support and information management platform; to adopt and develop new methods to eliminate preventable deaths and disabilities, leveraging the large amounts of data for diagnosis, decision-support and treatment; to propose innovative methods to tackle the important scientific challenge of handling highly heterogeneous data, with a large number of missing data. Indeed, despite the high quality of the Traumabase®, certain issues arise with these data. Data collection is carried out by multiple actors and summarized by data technicians, thus there are many possible sources for missing

values to occur (impossibility to make the measurement for technical issues or because of the patient's state, no time to record the measure, etc.).

The Traumabase® provides thus a unique opportunity for trans-disciplinary research and collaboration bringing together mathematical, methodological, technological, cognitive and medical expertise to design innovative methodological solutions to respond to complex challenges and improve patient care.

Table of contents
Table des matières

3.1 – Motivation and implementation

The Traumabase® is a French observational registry for major trauma patients, initiated by MDs Sophie Hamada and Tobias Gauss in 2010 [Raux et al., 2012]. In its beginning it was a limited to patients admitted in a single hospital (Beaujon hospital, Clichy, France), but it has soon been extended to become a multi-centered registry, counting all hospital centers specialized in admitting major trauma patients as well as regular hospital centers. [1] Every patient who is admitted to a participating hospital center and who presents at least one of the following criteria of severity is included in the Traumabase®: presence of Vittel criteria, activation of the mobile emergency and intensive care services (*SMUR* in French), activation of a major trauma resuscitation team, treatment in intensive care [Hamada, 2019].

The Traumabase® has been initiated for multiple reasons, both of sanitary and scientific interest. As mentioned in the introduction, major trauma refers to injuries that result in permanent disability or threaten a person's life. The difficulty in critical care management of major trauma patients is the simultaneous multitude of implicated agents at different scenes and of sustained injuries, all interacting in a short time-frame of only several hours. A major trauma patients is generally transferred with an ambulance from the scene of the accident to an intensive care unit (ICU). The latter is chosen by a coordinating center according to the patient's severity and expected need for specialized resources such as neurosurgery, this is also known as *triage*. Once arrived at the ICU, the patient's state is stabilized by a specialized resuscitation team (consisting often of massive blood transfusion and of temporary hemorrhage control) and a list of all injuries is established using medical imaging. The challenge lies in the shortening the delays for each step, triage, transport, stabilization and diagnosis, and in the optimal choice of dealing with the different injuries. Indeed, a wrong priorization can lead to can increase the mortality rate or worsen the long term prognosis. In this context, several objectives can be targeted for improving major trauma patient care. With its structure and granularity, unique for a registry in critical care in Europe, the Traumabase® allows to tackle

1. In the official terminology, it is still an *observatory* and not a national *registry* because it awaits validation by the French national committee of registries.

various questions of health care (quality evaluation and improvement of standard practices in critical care management and patient care, see, e.g., Hamada et al. [2015]), of communication between participating centers, of health monitoring by health regulatory institutions, and of scientific interest. A multitude of observational clinical studies has been carried out on this registry, see Traumabase Group [2012, accessed on 2021-04-07] for an extensive list of scientific findings based on the Traumabase®. It has also served for the establishment of predictive models assisting practitioners in assessing a patient's risk of developing a hemorrhagic shock [2], either based on a "hand-crafted" score [Hamada et al., 2018] or using an automated predictive model [Jiang et al., 2020].

3.2 – Structure and data

The Traumabase® is a tabular registry composed of continuous, categorical and textual variables, a total of 195 items can be informed for each patient. The data is collected by technical clinical research staff in a prospective-retrospective manner, the first data acquisition taking place within the first 24h of the patient's hospital admission, and completions being recorded until the patient's discharge from hospital or death. The recorded variables describe epidemiological and geographic aspects, the type and severity of occurred injuries, medical and therapeutic decisions, as well as diagnoses and prognoses.

The variety of informed variables and the partial chronological order contain rich information but also come as a challenge when using and analyzing the data. During the initiation period for this thesis, it has thus been attempted to build a graphical representation of the entire structure of the Traumabase®, aiming at creating a comprehensive overview of potentially available information and a common base of discussion for possible variable interactions, either confirmed or to be explored. This representation has been established in close collaboration with the initiators of the Traumabase® project.

A preview of the graphical representation is provided in Figure 3.1. A readable version in forms of consecutive close-ups is given in the Appendix B. There exist two types of nodes in the graph, designating either treatment/therapeutic measures or observations/diagnoses. Within the latter, two subsets related to the traumatic brain injury condition and the hemorrhagic shock condition are highlighted (respectively in blue and red). The graph contains both directed and undirected edges. The undirected edges define known correlations between variables but without specification of a causal relationship. Within the directed edges, four types are defined:

— deterministic relationships (e.g., the body mass index (BMI) is a deterministic function of height and weight);

— temporal correlations between measurements, taken repeatedly over time (e.g., the blood pressure taken in the ambulance is correlated to the blood pressure

2. Hemorrhagic shock is the leading cause of early preventable death in severe trauma; its definition is not unanimous but it can be described as severe hemorrhage necessitating important blood transfusion [Hamada et al., 2018].

taken after admission to the resuscitation room);

— established criteria/guidelines that influence treatment decisions (e.g., red blood cell transfusion is given in case of suspected hemorrhage);

— treatment targets (e.g., decompressive craniectomy aims at reducing the intracranial pressure to a normal level).

Figure 3.2 contains the legend of the graph, depicting the different types of edges.



Figure 3.1 – Preview of entire Traumabase® graph.



Figure 3.2 – Legend for the Traumabase® graph.

Additionally, an indicative timeline at the bottom of the graph provides an approximate classification of the variables into pre-hospital, resuscitation, surgical and intensive care periods.

For a better understanding of the information encoded in the graph, we provide a close-up view of Figure 3.1 that focuses on variables related to traumatic brain injury, the major trauma of special interest in this thesis, during the pre-hospital phase and up until hospital admission. All types of nodes and edges explained in the legend from Figure 3.2 are present on this close-up view shown in Figure 3.3. As said previously, this graph is not to be understood as representing causal structures (see Section 1.3 of Chapter 1) but to represent common practices and clinicians' observations on relationships between certain groups of variables. For instance, the *Mydriasis* node on the left of Figure 3.3 represents the presence of an anomaly of pupil reactivity and this anomaly enters as a criterion into a neurological scale which aims to assess a person's consciousness, the Glasgow Coma Scale. At the same time, mydriasis serves as an indicator for the need for osmotherapy treatment, represented on the graph by the *Osmotherapy.ph* node to the right of the *Mydriasis* node. This small example illustrates the type of information encoded in this graph. This is an attempt to summarize a large amount of information about common clinical practice and scientific knowledge acquired through clinical studies, serving as a basis for

smooth and transparent communication between clinicians and statisticians working with this dataset.



Figure 3.3 – Close-up view of the Traumabase® graph, focus on pre-hospital measurements and treatments up until hospital admission.

A remaining part that could not be informed on this graph is an indication of the uncertainty or expected error margin for each variable, due to time constraints, handovers between different agents, or other causes of uncertainty. Such information would be of much value, for instance in the development of data-driven risk prediction models.

Part III

Causal inference from incomplete observational data

Chapter 4

Doubly robust treatment effect estimation with missing attributes

This chapter corresponds to the paper Doubly robust treatment effect estimation with missing attributes, published in the *Annals of Applied Statistics*, 2020, written with Erik Sverdrup, Tobias Gauss, Jean-Denis Moyer, Stefan Wager and Julie Josse.

Abstract

Missing attributes are ubiquitous in causal inference, as they are in most applied statistical work. In this chapter, we consider various sets of assumptions under which causal inference is possible despite missing attributes and discuss corresponding approaches to average treatment effect estimation, including generalized propensity score methods and multiple imputation. Across an extensive simulation study, we show that no single method systematically out-performs others. We find, however, that doubly robust modifications of standard methods for average treatment effect estimation with missing data repeatedly perform better than their non-doubly robust baselines; for example, doubly robust generalized propensity score methods beat inverse-weighting with the generalized propensity score. This finding is reinforced in an analysis of an observational study on the effect on mortality of tranexamic acid administration among patients with traumatic brain injury in the context of critical care management. Here, doubly robust estimators recover confidence intervals that are consistent with evidence from randomized trials, whereas non-doubly robust estimators do not.

Table of contents
Table des matières

4.1 – Introduction

4.1.1 Hemorrhagic shock and traumatic brain injury in critical care management

Our work is motivated by a prospective observational study of the causal effect of tranexamic acid (TA), an antifibrinolytic agent that limits excessive bleeding, on mortality among traumatic brain injury patients during their stay at the hospital (from admission to ICU and regular care units). The beneficial effect of TA on mortality has been shown in a large randomized placebo-controlled study [Shakur-Still et al., 2009]. Our interest in developing observational study methods for assessing the effect of TA is twofold: In the long run, observational studies will be able to incorporate data on a larger and more diverse set of patients, thus allowing us to get a better understanding of when and for whom TA works; and treatment effect estimation on such observational studies can serve as a precursor for future randomized placebo-controlled studies, namely by helping defining the most interesting or promising target population beforehand and the associated inclusion rules.

Our study is built on top of the Traumabase® database, which currently indexes around 30,000 major trauma patients.[1] For each patient, 244 measurements are collected both before and during the hospital stay, including both quantitative and categorical variables. As shown in Table 4.1, TA was administered to roughly 8% of traumatic brain injury patients, and among all patients 20% died before the end of their hospital stay. We also see that mortality was much higher among patients who received TA than those who did not (46% vs. 18%). This apparent reversal of the expected causal effect is a standard example of confounding bias (also known as Simpson's paradox): The effect arises because patients who appeared to be in more severe state were more likely to be administered TA and were also more likely to die with or without the treatment.

Table 4.1 – Occurrence and frequency table for traumatic brain injury patients (total number: 8,248).

	survived	died
TA not administered	6,238 (76%)	1,327 (16%)
TA administered	367 (4%)	316 (4%)

The goal of our observational study design is to use a subset of 37 auxiliary covariates collected by the Traumabase® Group to control for confounding and identify the causal effect of TA on mortality. This "unconfoundedness" or "selection on observables" strategy is justified if the treatment of interest (i.e., administration of TA) is as good as random after conditioning on covariates [Imbens and Rubin, 2015, Rosenbaum and Rubin, 1983b]. In general, such an unconfoundedness assumption

1. Major trauma is defined as any injury that potentially causes prolonged disability or death and it is a public health challenge and a major source of mortality and handicap around the world [Hay et al., 2017].

cannot be validated from data, and needs to be built into the observational study design.

In order to make unconfoundedness as plausible as possible, the Traumabase® Group chose which covariates among the total of 244 collected covariates to incorporate in our study by soliciting feedback from a number experts using the Delphi method [Dalkey and Helmer, 1963, Jones and Hunter, 1995]. The focus of the Delphi survey was in understanding which factors were important for understanding health trajectories of major trauma patients. Because the decision whether or not to administer TA was performed by health professionals, it is likely that this same set of variables is also relevant to understanding which patients were more likely than others to be selected for treatment. A detailed list of the confounders and predictors of the outcome, in-ICU mortality, that were chosen via the Delphi method is given in the Appendix C.

As discussed further in the following section, the statistics of treatment effect estimation under unconfoundedness are by now well understood, with literature covering a range of topics from identification [Imbens and Rubin, 2015, Rosenbaum and Rubin, 1983b] and simple weighted estimators [Abadie and Imbens, 2016, Rosenbaum and Rubin, 1984, Zubizarreta, 2012] to semi-parametrically efficient estimation in potentially high-dimensional settings [Athey et al., 2018, Chernozhukov et al., 2018a, Robins et al., 1994, Van der Laan and Rose, 2011] and optimal treatment personalization [Athey and Wager, 2017, Kitagawa and Tetenov, 2018, Luedtke and Van Der Laan, 2016, Zhao et al., 2012].



Figure 4.1 – Percentage of missing values for a subset of variables relevant for traumatic brain injury. Different encodings of missing values: *NA* (not available), *not informed*, *not made*, *not applicable*, *impossible*.

In the case of the Traumabase® dataset, however, we have an additional com-

plication whereby, in Figure 4.1, many of the variables have missing entries. Some of the missingness is presumably due to non-informative missingness, e.g., medical staff simply forgetting to log some numbers, but in other cases the missingness is clearly informative; and in fact the analysts compiling the dataset used many different phrases to describe missing measurements, ranging from "not made" and "not applicable" to "impossible". The last denomination arises, for example, in the case of blood pressure measurements for patients in cardiac arrest or with dismemberment, as first responders simply cannot measure blood pressure for patients suffering from one of these two conditions. Meanwhile, variables indicating the response to a certain drug, such as the pupil contraction after the administration of a saline solution, systematically take on the value "not applicable" if the treatment has not been administered (the latter is informed in a separate variable).

There are a handful of popular strategies for working with missing values in the context of treatment effect estimation under unconfoundedness, ranging from generalized propensity score methods [D'Agostino and Rubin, 2000, Rosenbaum and Rubin, 1984] to multiple imputation [Little and Rubin, 2019, Rubin, 1976, 2004]. However, the methodology for treatment effect estimation with missingness is not as thoroughly fleshed out as corresponding methods without missing data. In particular, although doubly robust and semi-parametrically efficient methods have shown considerable promise in cases without missingness [Athey et al., 2018, Chernozhukov et al., 2018a, Robins et al., 1994, Van der Laan and Rose, 2011], we are not aware of a study of doubly robust treatment effect methods with missing covariates.

4.1.2 Summary of contributions and outline

In this chapter, we consider several popular methods for treatment effect estimation with missing covariates that rely on various unconfoundedness assumptions or assumptions about the missingness mechanism. We then discuss natural doubly robust generalizations of these methods, and compare them in numerical experiments. We find considerable variability in which methods perform best in our experiments. Sometimes methods that start from generalized propensity scores do better, while other times multiple imputation with parametric methods fit via the EM algorithm [Dempster et al., 1977] are better whereas other times non-parametric estimators do better; overall, the performance of each method strongly depends on the underlying confounding mechanism. However, we systematically find our doubly robust modifications of standard methods to outperform their baselines.

In the case of the Traumabase® study, all doubly robust estimators give confidence intervals that cover 0, indicating that we need to collect more data before we can use the observational study to guide clinical choices around administration of TA in the context of traumatic brain injury. In contrast, all baseline methods result in confidence intervals that do not cover 0, and find significantly harmful effects of TA on mortality. It thus appears that using doubly robust estimators is needed to eliminate the selection bias seen in Table 4.1.

4.2 – Treatment Effect Estimation with Missing Attributes

Since we have reviewed in Chapter 1 methods that are widely used in the complete data case, i.e., the case without missingness in the data, we can now go directly into the more difficult task where the analyst cannot always observe the full attribute vector. Rather, we assume that there is a "mask" $R_i \in \{1, \text{NA}\}^p$ such that the analyst observes $X_i^* \triangleq R_i \odot X_i \in \{\mathbb{R} \cup \text{NA}\}^p$. Here, $\odot$ denotes an element-wise product, such that $X_{ij}^* = X_{ij}$ if $R_{ij} = 1$ and $X_{ij}^* = \text{NA}$ if $R_{ij} = \text{NA}$. [2]

In current empirical practice, there are several approaches to treatment effect estimation with missing attributes; but the literature studying this problem is rather scarce and most such approaches focus on IPW-form estimators as in (1.20) [Rosenbaum and Rubin, 1984, D'Agostino and Rubin, 2000, Seaman and White, 2014, Mattei and Mealli, 2009, Leyrat et al., 2019].

The main contributions of this work consist in (1) a dyadic classification of possible approaches to treatment effect estimation with missing attributes, the first class relying on a variant of the unconfoundedness assumption while the second uses the classical missing values mechanism taxonomy; (2) the proposal of two new estimators in the first class, a parametric and non-parametric estimator, both in an IPW and an AIPW form; (3) the extension of previously introduced IPW estimators to the AIPW form in the second class; and (4) an extensive comparison of these estimators. As preliminaries, below we review some paradigms for treatment effect estimation with missing attributes.

4.2.1 Unconfoundedness despite missingness

Perhaps the simplest way to work with missing attributes is to assume that the missingness mechanism does not break unconfoundedness (1.5), i.e., that [Rosenbaum and Rubin, 1984]

$$\{Y_i(0), Y_i(1)\} \perp\!\!\!\perp W_i \,\big|\, X_i^*. \tag{4.1}$$

In this setting, D'Agostino and Rubin [2000] show that matching on the generalized propensity score

$$e^*(x^*) \triangleq PW_i = 1 \,\big|\, X_i^* = x^* \tag{4.2}$$

is consistent for τ. In general, the simplest way to verify (4.1) is to pair (1.5) together with one of the two assumptions below [Blake et al., 2020, Mattei and Mealli, 2009]

$$\begin{cases} \text{CIT:} & W_i \perp\!\!\!\perp X_i \,|\, X_i^*, R_i \\ \textbf{or} & \\ \text{CIO:} & Y_i(w) \perp\!\!\!\perp X_i \,|\, X_i^*, R_i \quad \text{for } w \in \{0, 1\}, \end{cases} \tag{4.3}$$

where CIT and CIO stand for *conditional independence of treatment* and *conditional independence of outcome* respectively. Given these assumptions, (4.1) can be directly

2. This representation of the incomplete data where the missing values are treated as a special category is chosen in view of the random forest approach handling this type of data.

derived from the causal graphs shown in Figure 4.2 [Pearl, 1995, Richardson and Robins, 2013].

Figure 4.2 – Causal graph depicting the assumptions (4.3).



We note that fitting (4.2) may appear difficult from the perspective of classical parametric statistics; e.g., in order to run logistic regression, one needs to fit a separate parameter vector for each mask r. However, many modern machine learning methods, including tree ensembles and neural networks, can readily handle missing data and enable (4.2) to be fit directly [Josse et al., 2019].

4.2.2 Missing values mechanisms

Another choice is to make assumptions about the missingness mechanism R_i. The most popular approach is to take the missingness mechanism to be random (MAR) [Little and Rubin, 2019, Rubin, 1976], i.e., for each possible mask $r \in \{1, \text{NA}\}^p$,

$$P(R_i = r \,\big|\, X_i = x, W_i, Y_i) = P(R_i = r \,\big|\, (X_i)_r = x_r, W_i, Y_i), \tag{4.4}$$

where X_r is the subset of entries of X indexed by $\{j : r_j = 1\}$. Under these assumptions, multiple imputation [Rubin, 2004, van Buuren, 2018] is a popular approach to treatment effect estimation [Qu and Lipkovich, 2009, Robins and Wang, 2000b, Rubin, 1978a, 2004, Seaman and White, 2014]. Under the condition that this imputation is "proper", i.e., that the missing attributes are simulated from the correct conditional distribution, and correct model specification for the outcome and treatment, this method is consistent for IPW estimators [Seaman and White, 2014]. Note that multiple imputation does not rely on the assumption (4.1) or the generalized propensity score, but it only requires the data to be MAR as in (4.4).

A stronger variant of the missing-at-random assumption (4.4) is to assume missingness to be completely at random (MCAR),

$$P(R_i = r \,\big|\, X_i, W_i, Y_i) = P(R_i = r),$$

or equivalently

$$R_i \perp\!\!\!\perp \{X_i, Y_i, W_i\}.$$

Under this assumption, further methods become available. First, we can consistently estimate τ using only the subset of the data with no missingness, i.e., $X_i = X_i^*$. Of course, using only a subset of the data results in a loss of efficiency; however, this approach is simple and consistent. We emphasize that complete case analysis is not

valid under the weaker assumption (4.4); in that case, ignoring observations with missingness will result in bias [Little and Rubin, 2019].

Another algorithm that has been studied under the MCAR assumption is based on matrix completion [Kallus et al., 2018a]. Write X and X^* for the matrices with rows X_i and X_i^* respectively. Then, assuming that X is a potentially noisy realization of a low rank matrix U and that unconfoundedness (1.5) holds with X_i replaced by U_i, we can approximate U from X^* using methods for low-rank matrix factorization [e.g., Candès and Plan, 2010], and then apply complete-data methods on the recovered $\hat{U}_i$. In cases where both MCAR and the low-rank assumption hold, matrix factorization may be more efficient than complete case analysis and simpler than multiple imputation.

4.2.3 Discussion: The Traumabase® study

In light of the previous discussion on the underlying (additional) assumptions required in the case of missing attributes, we argue that the Traumabase® data is more likely to fall under the *unconfoundedness despite missingness* assumption from Section 4.2.1 than the MAR assumption from Section 4.2.2. Indeed, the administration of TA in the context of major trauma generally takes place under time pressure – the more blood a patient looses, the more complications can occur – and the medical staff cannot wait too long to collect a lot of information before deciding on the treatment. Therefore, if a value such as the evolution of the shock index level between arrival of the MICU [3] and arrival at the ICU, is not available because at least one measurement is missing – for instance, due to transmission problems, the decision on the treatment will not depend on this feature. Another example could be information about the pre-hospital hemoglobin level: if the patient is in a severe state and immediate measures (such as resuscitation) are prioritized, then this measurement might not be made, however the consequently missing value is informative in the sense that it is due to the severe state of the patient, which might not necessarily be recorded explicitly in other observed features. These examples point in favor of the *unconfoundedness despite missingness* assumption as they suggest that the missing values are not only missing for the analyst but have already been missing for the physician at the time of treatment administration.

On the contrary, the MAR assumption seems plausible only for a subset of covariates. For instance, if the binary variable *Cardiac.arrest.ph* indicates that the patient needed to be resuscitated, then this can explain the missing values for the blood pressure and heart rate during pre-hospital phase. And there are other incomplete variables such as the total quantity of volume expanders used in pre-hospital phase for which the missing values depend on several other recorded variables describing the need for volume expansion. But overall—due to the multitude of agents collecting the data in different circumstances and under important time constraints—such statements about the plausibility of MAR are difficult to assess on the whole of the registry.

3. *Mobile intensive care unit*, enhanced medical care team that takes care of the patient at the scene of the accident.

4.3 – IPW and augmented IPW with Missing Attributes

The previously discussed assumptions lead to two families of methods for treatment effect estimation with missing attributes. We now propose two IPW and AIPW estimators in the family derived from the *unconfoundedness despite missingness* assumption (Section 4.2.1). In the other family that relies on classical assumptions on the *missingness mechanism* (Section 4.2.2), we extend the existing multiple imputation IPW estimator to a doubly robust AIPW version. For the former family, we only present details for the AIPW estimators, their IPW counterparts can almost directly be read off the AIPW formulation below.

4.3.1 Unconfoundedness despite missingness

Under assumption (4.1), the generalization to incomplete attributes is direct. First, estimate the generalized propensity score $e^*(x^*)$ from (4.2) and similarly the generalized outcome model $\mu^*_{(w)}(x^*)$, and then form the AIPW estimator

$$\begin{aligned}\hat{\tau}_{AIPW^*} \triangleq \frac{1}{n}\sum_{i=1}^{n}\Bigg(&\hat{\mu}^*_{(1)}(X_i^*) - \hat{\mu}^*_{(0)}(X_i^*) \\ &+ \frac{W_i}{\hat{e}^*(X_i^*)}\left(Y_i - \hat{\mu}^*_{(1)}(X_i^*)\right) - \frac{(1-W_i)}{1-\hat{e}^*(X_i^*)}\left(Y_i - \hat{\mu}^*_{(0)}(X_i^*)\right)\Bigg).\end{aligned} \tag{4.5}$$

There are general results about AIPW that immediately guarantee that the above estimator $\hat{\tau}_{AIPW^*}$ is $\sqrt{n}$-consistent and asymptotically normal around τ given only weak regularity conditions provided the product of the root-mean squared errors of the nuisance component estimates decay as $o(n^{-1/2})$ [Chernozhukov et al., 2018a], and these results extend directly to the case where the X_i may contain missing values. Specifically, in order to get such results for $\hat{\tau}_{AIPW^*}$, it suffices to assume that

$$\begin{aligned}\mathbb{E}\left[\left(\frac{1}{\hat{e}^*(X_i^*)\left(1-\hat{e}^*(X_i^*)\right)} - \frac{1}{e^*(X_i^*)\left(1-e^*(X_i^*)\right)}\right)^2\right]^{\frac{1}{2}} \times \\ \mathbb{E}\left[\left(\hat{\mu}^*_{(W)}(X_i^*) - \mu^*_{(W)}(X_i^*)\right)^2\right]^{\frac{1}{2}} = o\left(\frac{1}{\sqrt{n}}\right),\end{aligned} \tag{4.6}$$

i.e., that $\hat{\mu}^*_w(x^*)$ and $\hat{e}^*(x^*)$ are good approximations to the best predictors we could have using on the partially observed predictors x^*. Below, we instantiate the approach (4.5) via both a parametric approach based on logistic regression, and a non-parametric approach based on random forests.

4.3.1.1 Parametric estimation of nuisance components

For the parametric approach, we build on work by Jiang et al. [2020] and Schafer [1997] and logistic and linear forms respectively for the generalized propensity score and outcome using the *complete* covariates x. The functions μ^* and e^* that take in incomplete covariates x^* are then estimated via EM [Dempster et al., 1977]. The exact description of this parametric procedure for the AIPW estimator is outlined in Procedure 1; the resulting IPW and AIPW estimators will be denoted $\hat{\tau}_{EM}$.

A major limitation of this approach is that, in order to justify use of the EM algorithm, one typically needs to make further assumptions on the missing value mechanism; in particular, it is common to make the missing at random assumption (4.4). In other words, although we did not require the missing at random assumption to identify τ, this assumption is used for consistent parametric estimation of $e^*(x^*)$ and $\mu^*_{(w)}(x^*)$. Below, we describe non-parametric alternative that only needs the identifying assumption (4.1) to get consistency for τ.

Procedure 1: parametric AIPW with generalized propensity score and generalized response surfaces. This algorithm provides an estimation for the average treatment effect τ via logistic and linear regressions, given incomplete covariates X^*, observed treatment assignment W and outcome Y. We assume unconfoundedness despite missingness (4.1) and MAR (4.4).

1. Fit a logistic model on (W, X^*) using the stochastic approximation EM algorithm to obtain predictions for the generalized propensity score $e^*(X^*_i)$.
2. Fit two separate linear models on $(Y_{i:\,W_i=1}, X^*_{i:\,W_i=1})$ and on $(Y_{i:\,W_i=0}, X^*_{i:\,W_i=0})$ respectively via an EM algorithm to obtain predictions for $\mu^*_{(1)}(X^*_i)$ and $\mu^*_{(0)}(X^*_i)$ respectively.
3. Combine the predictions following (4.5) to obtain a doubly robust estimation of τ.

4.3.1.2 Non-parametric estimation of nuisance components

As an alternative to fitting parametric models via EM as discussed above, one can also directly estimate the functions $e^*(x^*)$ and $\mu^*_{(w)}(x^*)$ non-parametric. This task may appear somewhat unusual, as the features x^* take values in the augmented space $\{\mathbb{R} \cup \text{NA}\}^p$. However, many popular machine learning methods—including decision trees, kernels and neural networks—can be adapted to this context, and standard arguments still arguments for verifying consistency of these methods still apply [Josse et al., 2019]. Then, once we have estimates of $e^*(x^*)$ and $\mu^*_{(w)}(x^*)$, we can proceed to estimate the treatment effect using the AIPW estimator (4.5) or the analogous IPW estimator.

In this chapter, we focus on non-parametric nuisance component estimation via (generalized) random forests [Breiman, 2001, Athey et al., 2019], with missing data handled using the *missing incorporated in attributes* (MIA) method of Twala et al.

[2008]. The main idea of the MIA approach is give each split additional flexibility, such that missing values may be sent on either side of the split independently of where the split occurred. More specifically, as outlined by Twala et al. [2008], consider splitting on the j-th attribute and assume that for some individuals, the value of X_j is missing. MIA treats the missing values as a separate category or code and the considers the following splits:

— $\{i : X_{ij} \leq t$ or X_{ij} is missing$\}$ vs. $\{i : X_{ij} > t\}$

— $\{i : X_{ij} \leq t\}$ vs. $\{i : X_{ij} > t$ or X_{ij} is missing$\}$

— $\{X_{ij}$ is missing$\}$ vs. $\{X_{ij}$ is observed$\}$,

for some threshold t. The MIA approach does not seek to model why some features are unobserved; instead, it simply tries to use information about missingness to make the best possible splits for modeling the desired outcome. Thus the MIA strategy work with arbitrary missingness mechanisms and does not require the missing data to be MAR. [4]

In order to estimate the average treatment effect, we use the estimator (4.5) with nuisance components extracted from a variant of the causal forests of Athey et al. [2019] that use MIA splitting to handle missing values. [5] To do so, we have added the MIA splitting rule to the `causal_forest` function in `grf` [Tibshirani et al., 2020], and our proposed estimator can be computed by simply calling the function `average_treatment_effect` on a trained causal forest.

Procedure 2: non-parametric AIPW with generalized propensity score and generalized response surfaces. This algorithm provides an estimation for the average treatment effect τ via random forests with MIA splitting rule, given incomplete covariates X^*, observed treatment assignment W and outcome Y. We assume unconfoundedness despite missingness (4.1).

1. Train a causal forest on the potentially incomplete features X^* using MIA splitting.
2. Extract out-of-bag estimates $\hat{\mu}^*_{(w)}(X^*_i)$ and $\hat{e}^*(X^*_i)$ from the causal forest.
3. Combine the predictions as in (4.5) to obtain a doubly robust estimate $\hat{\tau}$ for τ.

4. We conjecture that consistency proofs for random forests following, e.g., Scornet et al. [2015] or Wager and Walther [2015] extend to the case of MIA splitting and missing covariates. However, formal results of this type are not currently available.

5. We refer to Section 2.1 of Athey and Wager [2019] for a detailed discussion of how the doubly robust scores used in (4.5) can be extracted from a causal forest.

4.3.2 Standard unconfoundedness and missingness mechanisms

As discussed in Section 4.2.2, multiple imputation is a solution if the missingness mechanism is MAR as defined by (4.4). We propose to augment the multiple imputation approach to obtain an AIPW estimator: we proceed similarly to Mattei and Mealli [2009], i.e., we do multiple imputation using fully conditional equation (FCE) where we draw missing values from a joint distribution which is implicitly defined by the set of conditional distributions, proper imputation is ensured using a Bootstrap approach to reflect the sampling variability of the imputation models parameters. Then, on each imputed data set $m \in \{1, \dots, M\}$, we compute an AIPW estimate $\hat{\tau}^{(m)}_{AIPW}$ given in (1.26) instead of the IPW estimate $\hat{\tau}^{(m)}_{IPW}$ given in (1.20). This approach is outlined in Procedure 3. We note that this method relies on the performance of the multiple imputation strategy; for instance in the case of FCE, the method requires correct specification of the conditional models which can be hard to assess in practice. We refer to Carpenter and Kenward [2013] for a discussion on imputation strategies.

Another recent solution is based on matrix factorization [Kallus et al., 2018a] as outlined in Procedure 4 in the Appendix C. Note that, unlike with multiple imputation, we only impute each datapoint once and consistency guarantees are only given under MCAR.

4.4 – Simulation study

We assess the performance of the previously introduced treatment effect estimators in different scenarios, modifying the data generating process, the confounders' relationship structure, the unconfoundedness hypothesis, the missingness mechanism, the percentage of missing values, the sample size. The comparisons are twofold: (1) comparisons between IPW-baseline and AIPW-type estimators, (2) comparisons w.r.t. the assumptions on the underlying unconfoundedness and the missingness mechanism. Note that in all simulations, we only consider the well-specified case, i.e., we do not study the (parametric) estimators' performances in case of model mis-specification. More specifically, $e(x) = \sigma(\alpha_0 + \alpha^T x + \epsilon_e)$ and $\mu_{(w)}(x) = \beta_0 + \beta^T x + w\tau + \epsilon_\mu$, where ϵ_e and ϵ_μ are zero mean and independent noise terms. All simulations are implemented in R [R Core Team, 2020]. [6]

6. The code for reproducing the experiments presented in this work is available at this GitHub repository: https://github.com/imkemayer/causal-inference-missing.

Procedure 3: AIPW with multiple imputation. This algorithm provides an estimation for the average treatment effect τ using multiple imputation, given incomplete covariates X^*, observed treatment assignment W and outcome Y. We assume unconfoundedness (1.5) and MAR (4.4).

1. Choose number of imputations M, for instance $M = 20$. Choose an imputation method. Impute the initial data X^* using an M times with the chosen imputation method to obtain M complete data matrices $(X^{(1)}, \ldots, X^{(M)})$.
2. For every imputed data matrix $X^{(m)}$, $m \in \{1, \ldots, M\}$:

   Option 1 non-parametric regression.

   (a) Train a causal forest on the imputed features $X^{(m)}$.

   (b) Extract out-of-bag estimates $\hat{\mu}_{(w)}(X_i^{(m)})$ and $\hat{e}(X_i^{(m)})$ from the causal forest.

   (c) Combine the predictions following (1.26) to obtain a doubly robust estimation $\hat{\tau}$ for τ.

   Option 2 Parametric regression (we additionally assume logistic-linear model specification for $(e, \mu_{(0)}, \mu_{(1)})$).

   (a) Fit a logistic model to obtain predictions for the propensity score $e(X_i^{(m)})$

   (b) Fit two separate linear models on $(Y_{i:W_i=1}, X^{(m)}_{i:W_i=1})$ and on $(Y_{i:W_i=0}, X^{(m)}_{i:W_i=0})$ respectively to obtain predictions for $\mu_{(1)}(X_i^{(m)})$ and $\mu_{(0)}(X_i^{(m)})$ respectively.

   (c) Combine the predictions following (1.26) to obtain a doubly robust estimation $\hat{\tau}^{(m)}$ for τ.
3. Aggregate the M estimations $(\hat{\tau}^{(1)}, \ldots, \hat{\tau}^{(M)})$: $\hat{\tau} = \frac{1}{M} \sum_{m=1}^{M} \hat{\tau}^{(m)}$.

4.4.1 Methods overview

We compare our approaches $\hat{\tau}_{EM}$ and $\hat{\tau}_{MIA}$, denoted *saem* and *grf* in the experiments [7], to the following methods, where we summarize their assumptions in Table 4.2:

— *mice*: Procedure 3 (and its IPW analogue detailed in the Appendix C) with Option 2; we use the R package `mice` [van Buuren and Groothuis-Oudshoorn, 2011] and default options.

— *mf*: Procedure 4 (and its IPW analogue detailed in the Appendix C) with Option 2; we adapt the implementation [8] of Kallus et al. [2018a] based on the R package `softImpute` [Hastie and Mazumder, 2015].

7. These abbreviations refer to the algorithms used for the estimation of the nuisance parameters in the presence of missing values. For instance *saem* stands for (stochastic approximation) EM algorithm.

8. For details on the implementation of this last method, see https://github.com/udellgroup/causal_mf_code.

Table 4.2 – Methods and their assumptions on the underlying data generating process. (✓indicates cases that can be handled by a method, whereas ✗marks cases where a method is not applicable in theory; (✗) indicates cases without theoretical guarantees but with heuristic solutions.)

	Confounders & Covariates		Missingness		Unconfoundedness		Models for (W, Y)	
	multivariate normal	general	M(C)AR	general	(1.5)	(4.1)	logistic-linear	non-param.
saem	✓	✗	✓	✗	✗	✓	✓	✗
grf	✓	✓	✓	✓	✗	✓	✓	✓
mice	✓	✓	✓	✗	✓	✓	✓	(✗)
mf	✓	✗	✓	✗	✓ (on U)	✗	✓	(✗)
mean.loglin	✗	✗	✗	✗	✗	✗	✗	✗

— *mean.loglin*: Imputation by the mean for the missing values and estimate e with logistic regression on the mean imputed covariates and the two $\mu_{(w)}$ with two separate linear regressions.

For the parametric $\hat{\tau}_{EM}$ we use the R package `misaem` [Jiang, 2019]. We grow forests with missingness via the the MIA method; then, the estimator (4.5) is implemented in the command `average_treatment_effect`. Note that it is common to concatenate the initial or imputed data matrix X and the binary mask R for estimation or prediction and it is admitted that this addition can sometimes improve the analysis and generally does not deteriorate the result. Hence, in this work we only report results obtained by adding R.

In all cases, we consider inference using the bootstrap (i.e., we bootstrap the original data and repeat the whole process).

4.4.2 Data generation

We define different models for the generation of the confounders, covariates, missing values, treatment assignment and outcome.

4.4.2.1 Confounders and covariates

Model 1: Multivariate normally distributed confounders We generate normally distributed confounders $X_{i\cdot} = [X_{i1} \ \dots \ X_{ip}]^T \sim \mathcal{N}(\mathbf{1}, \Sigma)$, $i \in \{1, \dots, n\}$, for $p = 10$, where $\Sigma = I - 0.6 \times (I - 1)$, $\mathbf{X} = [X_{1\cdot} \ \dots \ X_{p\cdot}]^T \in \mathbb{R}^{n \times p}$.

Model 2: Latent classes model We consider a Gaussian mixture model, i.e., we first generate class labels C from a multinomial distribution with three categories. Then the confounders of observation i, $X_{i\cdot}$, are sampled from the corresponding class distribution, i.e., $X_{i\cdot} \sim \mathcal{N}(\mu(c_i), \Sigma(c_i)) \,|\, C_i = c_i$.

Treatment and outcome are defined using the logistic-linear model in the following way: we define $\text{logit}(e^*(X^*_{i\cdot})) = (\alpha(C_i))^T X^*_{i\cdot}$. This allows us to add an additional

interaction between treatment and the latent class. Analogously, the outcome is defined as $Y_i \sim \mathcal{N}((\beta(C_i))^T X^*_{i\cdot} + \tau W_i, \sigma^2)$.

Model 3: Low rank matrix factorization We adapt the simulation framework from Kallus et al. [2018a] by generating $U_{i\cdot} = [U_{i1} \ \dots \ U_{id}]^T \sim \mathcal{N}(0, I_d)$ and defining $X = UV^T$ for some fixed matrix $V \in \mathbb{R}^{p\times d}$, with $d = 3$.

Model 4: Hierarchical data-generating model An alternative to defining a Gaussian mixture model, is to use a simplified shallow version of a *deep latent variable model* (DLVM, Kingma and Welling [2014b]): the codes C are sampled from a normal distribution $\mathcal{N}_d(0, 1)$. Covariates X_i are then sampled from $\mathcal{N}_p(\mu(c), \Sigma(c)) \,|\, C_i = c$, where

$$(\mu(c), \Sigma(c)) = (V \tanh(Wc + a) + b, \exp(\gamma^T(Wc + a) + \delta)I_p),$$

and the weights in $V \in \mathbb{R}^{p\times 5}$ and $W \in \mathbb{R}^{5\times d}$ are respectively sampled from a standard normal and a uniform distribution (and similarly for the offsets a and b). We fix $d = 3$. Results for this model are reported in the Appendix C.

4.4.2.2 Missing values

We generate missing values either under MCAR (i.e., $P(R_{ij} = 1) = 1 - \mathcal{B}(\eta)$ such that on average we have ηnp missing values) or as informative [9] missing values (missing values in $X_{\cdot,1:5}$ are generated depending on the quantiles of $X_{\cdot,1:5}$ such that there are about $\eta np/2$ missing values). In the results presented here we fix $\eta = 0.3$.

4.4.2.3 Treatment assignment and outcome

For models 1, 3 and 4, treatment assignment and outcome are defined under either of the unconfoundedness assumptions.

Unconfoundedness despite missingness We define $\text{logit}(e^*(X^*_{i\cdot})) = \alpha_0 + \alpha^T X^*_{i\cdot}$. Analogously, the outcome is defined as $Y_i \sim \mathcal{N}(\beta_0 + \beta^T X^*_{i\cdot} + \tau W_i, \sigma^2)$.

Complete data unconfoundedness We define $\text{logit}(e(X_{i\cdot})) = \alpha_0 + \alpha^T X_{i\cdot}$. Analogously, the outcome is defined as $Y_i \sim \mathcal{N}(\beta_0 + \beta^T X_{i\cdot} + \tau W_i, \sigma^2)$.

For model 2, treatment assignment and outcome are defined under unconfoundedness on the latent factors U as follows: $\text{logit}(e(U_{i\cdot})) = \alpha_0 + \alpha^T U_{i\cdot}$. Analogously, the outcome is defined as $Y_i \sim \mathcal{N}(\beta_0 + \beta^T U_{i\cdot} + \tau W_i, \sigma^2)$

We refer to the Appendix C for details on how to simulate treatment and outcome under assumption (4.1) (or rather (1.5) and (4.3)).

9. By informative we designate all non-ignorable missingness mechanisms, where the probability of observing missing values depends on the missing values.

4.4.3 Results

We report the estimations for a fixed average treatment effect using the previously described estimation methods. All figures in this study are generated from 100 simulations for sample sizes $n \in \{100, 500, 1000, 5000\}$, we fix the proportion of missing values at 30% throughout all experiments; and the true treatment effect τ is reported as black solid line. The *standard unconfoundedness* setting corresponds to assumption (1.5), while *unconfoundedness despite missingness* corresponds to (4.1).

4.4.4 Take-home message from the simulation study

The results from this first simulation study can be summarized in several general observations:

— Augmented IPW outperform their IPW equivalents throughout all scenarios (both in terms of variability and of bias), this behavior is analogous to the behavior in the well understood complete data setting.

— All methods perform well if their assumptions on the underlying data generating process are met (see Table 4.2).

— For multiple imputation (*mice*) there is a small remaining bias, even for large sample sizes. In some cases, when the assumptions for this method are met, based on the theorem from Seaman and White [2014] on multiple imputation with $M = \infty$ imputations, it is expected that an increase of the number of imputations should decrease this remaining bias in these cases.

— The tree-based estimation using the MIA splitting rule (*grf*) generally performs at least as well as multiple imputation but yields unbiased results if "unconfoundedness despite missingness" (4.1) holds.

— Mean imputation coupled with concatenation of the imputed data with the mask and parametric estimation empirically performs well, provided that (4.1) holds. However, the concatenation of the mask R appears necessary, since otherwise this approach is biased as soon as (4.1) is violated, and in this case it is outperformed by competing methods.

— The EM-based estimator (*saem*) performs well under correct specification (multivariate Gaussian confounders, logistic treatment assignment, linear outcome, M(C)AR missing data mechanism, (4.1) satisfied) and adding the mask to the initial data matrix yields unbiased estimates even if the missing data mechanism is not ignorable. It fails however in the cases where the data is not i.i.d. Gaussian.

In conclusion, the type of unconfoundedness assumption is important for the choice of the estimation strategy. Once the type is fixed, the choices between simple and doubly robust and between parametric and non-parametric estimation depend on the *a priori* on the data generating processes. However, in general, we recommend privileging the doubly robust strategy.

For a more detailed discussion of the simulation results, we refer to the Appendix C.



(a) MCAR (with 30% missing values in $X_{\cdot,1:10}$)



(b) Informative missing values (with 30% missing values in $X_{\cdot,1:5}$)

Figure 4.3 – Model 1. IPW and AIPW estimations across simulation designs described in Section 4.4.2. We report results for all combinations of $n \in \{100, 500, 1000, 5000\}$, missing values mechanism $\in$ {MCAR, general} and unconfoundedness $\in \{\cdot$ despite missingness, complete data $\cdot\}$. Results are displayed for 100 runs of every setting.

4.5 – Application on observational critical care management data

As announced in the introduction we apply our methods to clinical data from a French observational database on major trauma patients. The medical question



(a) MCAR (with 30% missing values in $X_{\cdot,1:10}$)



(b) Informative missing values (with 30% missing values in $X_{\cdot,1:5}$)

Figure 4.4 – Model 2. IPW and AIPW estimations across simulation designs described in Section 4.4.2. We report results for all combinations of $n \in \{100, 500, 1000, 5000\}$, missing values mechanism $\in$ {MCAR, general} and unconfoundedness $\in \{\cdot$ despite missingness, complete data $\cdot\}$. Results are displayed for 100 runs of every setting.

we aim to answer is whether administrating the drug TA has an effect on in-ICU mortality for patients with traumatic brain injury.



(a) MCAR (with 30% missing values in $X_{\cdot,1:10}$)



(b) Informative missing values (with 30% missing values in $X_{\cdot,1:5}$)

Figure 4.5 – Model 3. IPW and AIPW estimations across simulation designs described in Section 4.4.2. We report results for all combinations of $n \in \{100, 500, 1000, 5000\}$ and missing values mechanism $\in \{\text{MCAR}, \text{ general}\}$. Results are displayed for 100 runs of every setting.

4.5.1 Data and causal DAG

For our analysis we used 20,037 of the currently available validated patient records, validated by the medical expert team after a first pre-treatment. The pre-treatment consisted in identifying outliers clearly due to erroneous inputs and recoding missing values that are not really missing (for instance the variable informing previous pregnancies is evidently consistently missing, or ideally set to false, for male patients,

etc.).[10] Out of these 20,047 patients, 8,269 are identified as having a traumatic brain injury (defined by the medical expert team as either the presence of a brain lesion visible on the first computed tomography (CT) scan—which is generally taken within the first three hours after the accident—or as a head AIS score[11] greater or equal 2). Additionally, we excluded a total of 21 patients among this group coming from Trauma centers with too few observations, having joined the registry group several years after the majority of all other Trauma centers.

The treatment of interest, TA, is an antifibrinolytic agent limiting excessive bleeding and it is currently used in patients suspected of developing an hemorrhagic shock, a state in which the body is no longer able to provide vital organs with sufficient quantities of dioxygen to sustain them. The average cost of a dose of TA lies below 10€ and the drug is generally available immediately after the arrival of the medical first responders team at the place of the accident. It is now recommended to administer this drug to patients at risk of developing an hemorrhagic shock.

In order to clarify the previously raised causal question given the data, we first establish a causal graph in order to summarize the a priori on existing confounding and to highlight the causal question, as suggested, for instance, by Lederer et al. [2019], Blake et al. [2020]. The causal graph in Figure 4.6 is the result of a two-step Delphi procedure in which six anesthetists and resuscitators specialized in critical care first selected covariates related to either treatment or outcome or both and second classified these covariates into confounders and predictors of only treatment or outcome. The absence of an exact timestamp for the drug administration is compensated by the fact that it is always given within the first three hours from the accident and that the treatment does not have an immediate effect on variables such as blood pressure, hemoglobin level or the Glasgow Coma Scale (GCS) which are measured at various moments within the first three hours.

From this graph it becomes clear as well that a method that incorporates a model of the outcome as a function of the identified potential predictors might achieve more precise results than a method that uses the observed outcome directly. The large number of predictors of the outcome is due both to the medical complexity of traumatic brain injury and to the ambiguous treatment target: the assignment is made in the context of hemorrhagic shock but recently there is some evidence that there might also be a beneficial effect in the context of traumatic brain injury [Hijazi et al., 2015].

10. The code for pre-treatment and for estimating the treatment effect on this data are available at this GitHub repository: https://github.com/imkemayer/causal-inference-missing.

11. The head Abbreviated Injury Score indicates, on a scale from one to six, the severity of the most severe observed brain lesion. This score is defined in the context of the Abbreviated Injury Scale proposed by the American Association for Automotive Medicine. See the Appendix C or https://www.aaam.org/abbreviated-injury-scale-ais/ for more information.



Figure 4.6 – Causal graph representing treatment, outcome, confounders and other predictors of outcome (Figure generated using DAGitty [Textor et al., 2011]; `NAs` indicates variables that still have missing values after pre-treatment).

4.5.2 Results

First, we recall the estimand we aim at estimating in this context: we are interested in the average treatment effect of the treatment on mortality among traumatic brain injury patients. When adjusting for confounding using the identified confounders (nodes with two outgoing arcs on the graph in Figure 4.6), using additional predictors for the outcome model (nodes with one outgoing arc pointing to the outcome node on the graph in Figure 4.6), we obtain the following estimations in Figure 4.7 of the direct causal effect of TA on in-ICU mortality among traumatic brain injury patients.

Unlike the simulations of the previous paragraph, the real-world medical data is more complicated and some concessions have to be made to apply the previously discussed method. For instance, due to an important number of outliers in the variable *Medcare.time.ph* that are related with inconsistent units of the recorded values and with patient transfers from one hospital to another, we chose to drop this variable in our analyses since, according to the practitioners, its predictive power does not outweigh the potential issues related to inconsistent recording of this variable.

Note that apart from the issue with the variable *Medcare.time.ph*, the estimation via random forest with MIA splitting rule does not require any pre-processing of the data and is therefore straightforward when using the *grf* package.

Here, we only consider three pairs of methods: *grf* and *mice*. We do not test *saem* and *mf* since currently both these methods have not been derived for heterogeneous

12. Values on the x-axis are multiplied by 100 for better readability. The results can be read as difference in percentage points between mortality rate in the treatment groups.



Figure 4.7 – ATE estimations on Traumabase® data (solid: doubly robust estimates; dotted: IPW estimates; dashed vertical line: without adjustment; x-axis: $\hat{\tau}$ and bootstrap confidence intervals [12]). *Note:* Positive ATE ≡ increase of mortality.

data. [13] A first observation on the results reported in Figure 4.7 is the concordance of the two estimators: none of the AIPW-type estimation strategies allows to reject the null hypothesis of no treatment effect. As discussed in Section 4.2.3, it can be argued which family of methods has more plausible underlying assumptions on the Traumabase® data, but in our opinion the *unconfoundedness despite missingness*—and therefore the *grf* estimations—are most suited for our specific application. When comparing covariate balance for both methods in terms of standardized mean differences, we note that both methods achieve similar balance on the observed values (see results reported in the Appendix C) but, as expected, only GRF additionally achieves balance on the response pattern (Figure 4.8). Since there is consensus by the medical experts that certain missing values are not missing at random, achieving balance on the response pattern is a relevant feature for interpreting the estimation results. A remaining issue might consist in the overlap assumption which is generally difficult to assess in most medical applications and which might be slightly violated due in part to the heterogeneity of patient profiles and it could be argued that for certain patients the probability of receiving the treatment is zero. However, the lack of a standardized protocol for tranexamic acid administration favors the overlap assumption even for this group of patients. A solution to handle weak overlap is the use of overlap weights [Li et al., 2018] and we give the results using this alternative to inverse propensity weights in the Appendix C.

We notice a large difference between the IPW and the AIPW estimations. The AIPW estimations seem more reasonable for two reasons: first, the medical experts

13. Concatenating the mask with the data matrix does not lead to major changes in the estimations, therefore we only report results obtained when including the mask.



(a) GRF (b) MICE

Figure 4.8 – Absolute difference in proportion for observed and missing values; circles: before adjustment, triangles: after adjustment.

have noticed beneficial effects of TA for some of their TBI patients in practice and a previous clinical trial, focusing on a slightly different patient group, has also exhibited a potential benefit from the drug for patients with TBI; moreover, the results of the clinical trial studying the effect of the drug on all TBI patients indicate that on average there is neither benefit nor harm in prescribing the drug [Cap, 2019]; second, for the AIPW estimators, we incorporate much more available information, namely all identified features that are strongly related to the outcome Y according to the expert panel (see Figure 4.6). Finally, the compared estimates have similar standard errors and asymptotic confidence intervals which are also close to the estimated bootstrap confidence intervals (the latter are not reported in Figure 4.7).

4.6 – Discussion and perspectives

4.6.1 Two families of treatment effect estimators handling missing attributes

We have stressed the dyadic classification of previously exposed methods that allow treatment effect estimation with missing attributes, both in theory and in practice. The class of methods that relies on assumptions about the missingness mechanisms for treatment effect identifiability is currently often used, in combination with IPW-type estimators. We have also proposed an AIPW formulation for the most popular method from the first class, namely multiple imputation. However, methods of this first class have limited applicability in practice, most importantly they exclude informative missing data; this is a drawback of all developed methods in this class. The second class, relying on the generalized propensity score and a different

unconfoundedness assumption, can handle arbitrary missingness mechanisms, in particular the case where MAR does not hold, but to the best of our knowledge, implementable and versatile methods in this class have not been proposed so far.

In practice, if one can exclude smooth regression functions for the treatment assignment and the outcome model, such as logistic and linear models, and if the "unconfoundedness despite missingness" assumption is likely to hold—for more details on this, we refer to Blake et al. [2020]—we advocate our tree-based estimator $\hat{\tau}_{MIA}$ in its AIPW-form and its mean-imputation variant. If one is willing to make stronger (parametric) assumptions about the structure of X and its relationship with W and Y, then our second estimator $\hat{\tau}_{EM}$ can also be considered as an alternative.

4.6.2 Heterogeneous treatment effects and policy learning

Instead of estimating the average treatment effect τ, one could be interested in the conditional average treatment effect function (Definition 1.5.3) for several reasons. For instance one might be interested in estimating how treatment effects vary across sub-populations, or assessing whether there is heterogeneity in the population w.r.t. a given treatment. Such questions anticipate problems of learning decision rules that exploit treatment effect heterogeneity [Athey and Wager, 2017].

In light of our medical application, heterogeneous treatment effect estimation is of particular interest because of the known existing heterogeneity among traumatic brain injury patients in terms of clinical presentation, patho-physiology and outcome. It is even more relevant since to this date there is no general classification of patients with traumatic brain injury. Hence a causal inference approach allowing classification w.r.t. treatment heterogeneity for any given treatment is of interest for practitioners in critical care management.

4.6.3 Weighted Treatment Effects

Throughout this chapter, we have focused on cases with overlap (1.10), i.e., where all units have a realistic chance of being randomized to both treatment and control. In some cases, however, there may be subjects who are quasi-deterministically assigned to one of the two treatment arms—in which case the methods developed here may be unstable and/or have very large variance. When this happens, it is common to shift focus away from the average treatment effect, and towards alternative weighted estimands that are more robust to lack of overlap. For example, if some units are quasi-deterministically assigned to control (but no units are quasi-deterministically assigned to treatment, i.e., propensity scores are uniformly bounded below 1), then estimating the average treatment effect on the treatment is a popular way to avoid overlap problems [Imbens, 2004]. Crump et al. [2009] and Li et al. [2018] discuss other weighted estimands that can be used when overlap problems get more severe and propensity scores may get arbitrarily close to both 0 and 1.

Although we do not discuss it here, the arguments developed in this chapter can be applied directly to estimators of other weighted treatment effects. We implement

extensions of the random forest based estimator described in 4.3.1.2 for estimating both the average treatment effect and the overlap-weighted treatment effect of Li et al. [2018] in the `R` package `grf` [Tibshirani et al., 2020].

4.6.4 Further identification strategies

Although the two lines of approaches studied here for identification of average treatment effects with missing attributes are the most prevalent in applied work, they are far from exhaustive. For example, Yang et al. [2019] consider a setting with outcome-independent missingness, $Y_i \perp\!\!\!\perp R_i \,\big|\, \{X_i, W_i\}$, and find that τ can be identified via a set of integral equations. We expect the area of methods development for causal inference with missing attributes to be a fruitful research area for years to come.

Acknowledgement We thank Jean-Pierre Nadal for fruitful discussion, Helen Blake and Julie Tibshirani for their suggestions for the simulation study, and the Delphi expert committee for the medical insight and advice on traumatic brain injury and hemorrhagic shock.

Chapter 5

MissDeepCausal: Causal Inference from Incomplete Data Using Deep Latent Variable Models

This chapter corresponds to a more recent version of the paper MissDeepCausal: Causal Inference from Incomplete Data Using Deep Latent Variable Models, written with Jean-Philippe Vert and Julie Josse.

Abstract

Inferring causal effects of a treatment, intervention or policy from observational data is central to many applications. However, state-of-the-art methods for causal inference seldom consider the possibility that covariates have missing values, which is ubiquitous in many real-world analyses. Missing data greatly complicate causal inference procedures as they require an adapted unconfoundedness hypothesis which can be difficult to justify in practice. We circumvent this issue by considering latent confounders whose distribution is learned through variational autoencoders adapted to missing values. They can be used either as a pre-processing step prior to causal inference but we also suggest to embed them in a multiple imputation strategy to take into account the variability due to missing values. Numerical experiments demonstrate the effectiveness of the proposed methodology especially for non-linear models compared to competitors.

Table of contents
Table des matières

5.1 – Introduction

Many methods have been developed to estimate the causal effect of an intervention, such as the administration of a treatment, on an outcome such as survival, from observational data, i.e., data that is potentially confounded by selection bias due to the absence of randomization. Classical ones include matching [Iacus et al., 2012], inverse propensity weighting [IPW, Horvitz and Thompson, 1952, Rosenbaum and Rubin, 1983b] and doubly robust methods [Robins et al., 1994, Chernozhukov et al., 2018a, Wager and Athey, 2018, Athey et al., 2019, Künzel et al., 2019]. More recent proposals use deep learning methods that ensure balance of the population at the level of representation [Johansson et al., 2016, Shalit et al., 2017], infer the joint

distribution of latent and observed confounders, the treatment and the outcome [Louizos et al., 2017] or predict the counterfactuals with specific network architectures exploiting overlap [Shi et al., 2019] or using GANs [Yoon et al., 2018a]. For a detailed review of existing literature on treatment effect estimation we refer to Imbens [2004], Lunceford and Davidian [2004] and Guo et al. [2019].

However, state-of-the-art methods still suffer from important shortcomings. In particular, they seldom consider the possibility that covariates have missing values, which is ubiquitous in many real-world situations [Josse and Reiter, 2018] and has been widely discussed in different contexts [Little and Rubin, 2019, van Buuren, 2018, Mayer et al., 2019]. Although this question of missing attributes in the context of treatment effect estimation has been raised early in the development of causal inference [Rosenbaum and Rubin, 1984], there is still a lack of effective and consistent solutions addressing this problem.

In Chapter 4, in addition to suggesting doubly robust estimators with missing data, we classified the existing approaches into two classes. In the first one, identifiability of the causal effect with missing values is ensured by adapting the causal inference assumptions to the missing values setting with an *unconfoundedness with missing values* assumption [Rosenbaum and Rubin, 1984], that can be difficult to assess in practice. Then, estimation requires or not some hypothesis on the missing values mechanisms [Rubin, 1976]. In the second class, the classical *unconfoundedness* assumption is kept, but most of the methods require missing (completely) at random (M(C)AR) assumptions [Mattei and Mealli, 2009, Seaman and White, 2014]. In addition, consistent estimation is demonstrated under strong parametric assumptions about the outcome, treatment and covariates models. Yang et al. [2019] derived identifiability conditions under specific missing non at random (MNAR) settings via sets of integral equations and also provide an estimator of the average treatment effect based on these integral equations.

Additionally, a third class of models and methods can be defined that considers a *latent unconfoundedness* assumption [Kallus et al., 2018a, Louizos et al., 2017]. Louizos et al. [2017] consider covariates with missing values that are noisy proxies of the true latent confounders and base their estimation on a low-rank model with MCAR missing values. With this model they provide an asymptotically unbiased estimator for the causal parameter defined via a linear regression model.

In this work we focus on this third class of models, namely latent unconfoundedness, and propose the following contribution: we suggest a non-linear model with deep-latent variables [Kingma and Welling, 2014a, Rezende et al., 2014] and MAR data. We provide heuristics for the recoverability of the latent confounders and subsequent estimation of the causal effect in the non-linear case and illustrate these claims with empirical findings.

In the remainder of this article we first introduce the problem framework and recall existing work for handling missing values in causal inference in Section 5.2. In Section 5.3 we discuss identifiability in the non-parametric setting. In Section 5.4 we propose our variational autoencoder based estimation strategy. Finally we compare our proposals empirically with several state-of-the-art methods on simulated data in Section 5.5.

5.2 – Notations and related works

In this chapter, we use the same framework as in Chapter 4, namely the potential outcomes framework [Rubin, 1974, Imbens and Rubin, 2015] and the corresponding notations introduced in Chapter 1. Thus, here we also consider we have a sample of n independent and identically distributed (i.i.d.) 4-tuples $(Y_i(0), Y_i(1), W_i, X_i)_{i=1,\dots,n}$, with $W_i \in \{0, 1\}$ a binary treatment, $X_i = (X_{i1}, \dots, X_{ip})^\top \in \mathbb{R}^p$ a vector of covariates, and $(Y_i(0), Y_i(1)) \in \mathbb{R}^2$ the outcomes we would have observed had we assigned control or treatment to the i-th sample, respectively. Throughout this chapter we are interested in estimating the ATE (1.2) defined in Chapter 1.

We also recall the *unconfoundedness* and *overlap* assumptions. The former states that all confounding factors C are measured, i.e., conditionally on C, the treatment assignment is independent of the potential outcomes:

$$\{Y_i(1), Y_i(0)\} \perp\!\!\!\perp W_i \,|\, C_i, \qquad \text{for all } i; \tag{5.1}$$

and the latter assumes the existence of some $\eta > 0$ such that $\eta < e(c) < 1 - \eta$, for all $c \in \mathcal{C}$.

We now consider an extension to account for possible missing entries in the covariates. For that purpose, we borrow the notation X^* from the previous chapter, namely: we denote the response pattern of the i-th sample as $R_i \in \{0, 1\}^p$ such that $R_{ij} = 1$ if X_{ij} is observed and $R_{ij} = 0$ otherwise. The rows of the matrix of observed covariates can be written with $X_i^\star \triangleq X_i \odot R_i + \texttt{NA} \odot (\mathbf{1} - R_i)$. We model R_i as a random vector and the (conditional) distribution of $1 - R_i$ is known as the missing values mechanism.

As mentioned in the introduction, methods for causal inference with missing covariates can be classified into three categories according to assumptions made on both part.

5.2.1 Unconfoundedness with missing values and no assumptions on the missingness mechanism

This case corresponds to the main setting of the previous chapter and we briefly recall it for ease of reading. Rosenbaum and Rubin [1984] extend the unconfoundedness hypothesis (5.1) to missing values as

$$\{Y_i(1), Y_i(0)\} \perp\!\!\!\perp W_i \,|\, X_i^\star, \qquad \text{for all } i, \tag{5.2}$$

i.e., here we have $C = X^*$. This implies the assumption, illustrated in Figure 5.1, that if a covariate is not observed, it is not a confounder. In particular, observations can have different confounders depending on their pattern of missing data. They define the generalized propensity score as:

$$\forall x^\star \in \mathcal{X}^\star, \quad e^\star(x^\star) \triangleq \mathbb{P}(W_i = 1 \,|\, X_i^\star = x^\star)\,, \tag{5.3}$$

which is a balancing score under (5.2). Consequently, an IPW estimator formed with estimators of $e^\star$ can be an unbiased estimator of the ATE with missing values.

Nevertheless, this method relies both on the fact that the covariates X are the appropriate set of confounders, which can be questioned without missing data [Kallus et al., 2018a], and requires certain expert input and reasoning to verify that for each observation, treatment assignment and/or outcome values depend only on observed values of the confounders (Blake et al. [2020] and Chapter 4). Note in particular, that it is not because the missing data in the covariates are completely at random (MCAR), i.e., $R \perp\!\!\!\perp X$, that (5.2) is met. In practice, in addition, a difficulty with this approach is that estimating (5.3) requires fitting one model per pattern of missing values, which is unrealistic with classical tools [Miettinen, 1985, D'Agostino and Rubin, 2000, D'Agostino et al., 2001, Blake et al., 2020]; In Chapter 4 we have shown how to address this problem using random forests adapted to covariates with missing values.



Figure 5.1 – Unconfoundedness with missing values. X represents the complete covariates, and R (or $1 - R$) a missing data mechanism, X^* represents the observed incomplete covariates, confounding the treatment assignment. The formalism of Pearl [1995] and Richardson and Robins [2013] is used.

5.2.2 Classical unconfoundedness with assumptions on the missingness mechanism

Seaman and White [2014] show that when assuming (i) identifiability of the ATE in the complete case, i.e., including classical unconfoundedness assumptions as in equation (5.1), (ii) missing at random (MAR) values given W and Y, (iii) correct specification of the propensity score with logistic regression and of the Gaussian distribution of covariates, then multiple imputation [Little and Rubin, 2019, van Buuren, 2018] gives a consistent estimate for the ATE estimated with IPW. An extension to doubly robust estimation has been proposed in Chapter 4.

Even though the assumption of MAR missing values is prevalent in applied work for causal inference with missing values – as it allows simple estimation strategies –, Yang et al. [2019] consider a setting with outcome-independent missingness, $Y_i \perp\!\!\!\perp R_i | \{X_i, W_i\}$, which can be seen as a special case of MNAR missingness mechanism. Methods proposed to handle such cases are sometimes hard to implement in practice, even in small dimensions and particularly in high-dimensional settings. However, Yang et al. [2019] find that τ can be identified via a set of integral equations and also provide an estimator for τ based on these integral equations.

5.2.3 Latent unconfoundedness assumption

Kallus et al. [2018a] consider that the p observed covariates $X = [X_1, \ldots, X_p]$ are noisy and/or incomplete *proxies* of the d true latent confounders $Z = [Z_1, \ldots, Z_d]$, as illustrated in Figure 5.2. This is known as a case of "*surrogate*-rich" setting or multiple proxies. They assume a factor analysis model for the covariates and estimate the latent variables $\hat{Z}$ from the incomplete covariates X^* using matrix completion methods [Hastie et al., 2015, Josse et al., 2016b].



Figure 5.2 – Latent confounding with observed proxy variables. Z represents the unobserved latent confounders of the treatment W and the effect Y. X represents a proxy for the confounders, and R a missing data mechanism; X^* represents the observed incomplete covariates.

Then, under the linear regression model

$$Y_i = Z_i^T \alpha + \tau W_i + \varepsilon_i, \tag{5.4}$$

with MCAR values in X^*, and some other additional assumptions, they prove that regressing Y on $\hat{Z}$ and W leads to an asymptotically consistent ATE estimator (as n and p tend to infinity but with $n >> p$ and assuming $d^5(d \vee \log(n \vee p))n \log n/[\#obs]$ tends to 0, with $[\#obs]$ the number of observed cells). The convergence rate of this estimator also depends on the principal angle between the true and the estimated column space of the confounders matrix, in other words on the quality of estimation of the true latent confounders from the noisy (and incomplete) covariates. Despite the strong model assumptions, they show empirically that their approach performs well in many other settings including plug-in $\hat{Z}$ in AIPW estimators, as long as the underlying latent factors assumption is met approximately.

5.2.4 Identifiability in latent variable models

Even without missing values, identification is generally difficult in the case of latent confounding, where the true confounders Z are unobserved but instead we assume access to surrogate or proxy variables in X. Only a few results have been shown so far, relying on strong assumptions about the dimension, type, and relationship between the latent confounders and the proxies. Kuroki and Pearl [2014] assume that the proxies only depend on the latent confounders, an assumption often called *nondifferential error* in measurement error modeling [Carroll et al., 2006]. Furthermore they assume that (a) both the proxy and the latent confounder are discrete variables with a given finite number of categories k and either (b.1) X is univariate and the distribution $p_{X|Z}$ is available or (b.2) $p_{X|Z}$ is non-parametrically identifiable which requires that $X = (X_1, X_2)^T$ where X_1 and X_2 are conditionally

independent of each other given Z. These assumptions, together with additional assumptions of invertibility of $p_{X_2|X_1,w}$ and $p_{Y,X_2|X_1,w}$ for all w, allow them to apply a matrix adjustment method [Rothman et al., 2008] to recover the joint distribution $p_{Z,W,Y}$ from the observable information and thus to identify the causal effect of W on Y. Miao et al. [2018] tackle the identification problem differently, without requiring identifiability of $p_{X|Z}$. They establish identifiability conditions for the model given in Figure 5.3. In the case where all variables (Z, X_1, X_2) are discrete, they require invertibility of the matrix $p_{X_2|X_1,w}$ for all w. [1] They also provide identifiability results in the case where Z as well as X_1 and X_2 are continuous, assuming two completeness conditions on the conditional distributions of these three variables, satisfied for instance by exponential families. Together with regularity conditions, they prove identifiability of the causal effect via existence of a certain Fredholm integral equation. They note however that non-parametric inference from these results is not straightforward and thus left for future work.



Figure 5.3 – Latent confounder with observed two proxy variables. X_1 can be a negative control exposure ($Y(w, x_1) = Y(w)$) and X_2 a negative control outcome ($X_2(w, x_1) = X_2$).

Shi et al. [2020] establish non-parametric identification of the ATE under weaker conditions than Kuroki and Pearl [2014], Miao et al. [2018] in the case where Z, X_1, X_2 are all categorical and both proxies have at least as many categories as Z. With additional completeness assumptions (involving the rank of the matrices specifying the conditional distributions $p_{X_2|Z}$ and $p_{Z|X_1,w}$), they show that the causal effect can be non-parametrically identified.

Louizos et al. [2017] consider the same causal model as in Figure 5.2, i.e., a surrogate-rich or multiple proxies problem, but without the missing values in X. In addition, they do not consider that the relationships are linear between the proxies and the latent variables but can potentially be much more complex. Then, they first provide an identification result for the ATE in their problem, assuming identifiability of the joint distribution $p_{Z,X,W,Y}$, and second leverage recent advances from variational autoencoding (VAE) to estimate the joint distribution $p_{Z,X,W,Y}$ from the data (X, W, Y).

Their work is built on the following theorem: [2]

Theorem 5.2.1 (Louizos et al. [2017, Theorem 1]). *If we can recover the joint*

1. The authors note that this is equivalent to having $p_{X_2|Z}$ and $p_{Z|X_1,w}$ invertible for all values of w.

2. This theorem uses Pearl's *do*-operator [Pearl, 2009c] which has not been introduced in this work and we cite the theorem and its proof without formally introducing it.

distribution $p_{Z,X,W,Y}$*, then we can recover the ATE* $\tau = \mathbb{E}[\mathbb{E}[Y_i|X_i, do(W_i = 1)] - \mathbb{E}[Y_i|X_i, do(W_i = 0)]]$ *under model 5.2.*

Proof. They prove that $p_{Y|X,do(W=1)}$ is identifiable under the premise of the theorem. The case for $w = 0$ is identical, and the expectations in the definition of ITE, $ITE(x) := \mathbb{E}[Y \mid X = x, do(W = 1)] - \mathbb{E}[Y \mid X = x, do(W = 0)]$ readily recovered from the probability function. ATE, $ATE = \mathbb{E}[ITE(X)]$, is identified if ITE is identified. They note that:

$$\begin{aligned} p_{Y|X,do(W=1)}(y \mid x, do(w = 1)) &= \int_{\mathcal{Z}} p_{Y|X,do(W=1),Z}(y \mid x, do(w = 1), z) \\ &\qquad p_{Z|X,do(W=1)}(z \mid x, do(w = 1))dz \qquad (5.5) \\ &\overset{(i)}{=} \int_{\mathcal{Z}} p_{Y|X,W=1,Z}(y \mid x, w = 1, z)p_{Z|X}(z \mid x)dz \end{aligned}$$

where equality (i) is by the rules of *do*-calculus applied to the causal graph in Figure 5.2. This completes the proof since the quantities in the final expression of (5.5) can be identified from the distribution $p_{Z,X,W,Y}$ which is known by the theorem's premise. □

In other words, identifiability of the joint distribution over (Z, X, W, Y) induces identifiability of the causal parameter under model 5.2. Evoking recent advances in the field of generative networks and in particular VAEs, they assume that their VAE approximates sufficiently well the true joint distribution $p_{Z,X,W,Y}$ from the observed variables (X, W, Y). The variational lower bound of their model is

$$\begin{aligned} \mathcal{L}_{CEVAE} \triangleq \sum_{i=1}^{N} \mathbb{E}_{q(Z_i|X_i,W_i,Y_i)} [\, &\log p\,(X_i, W_i \mid Z_i) + \log p\,(Y_i \mid W_i, Z_i) \\ &+ \log p\,(Z_i) - \log q\,(Z_i \mid X_i, W_i, Y_i)\,]\,. \end{aligned}$$

To compute $p(y|x, do(w = 1))$ and $p(y|x, do(w = 0))$, they sample from the approximate posterior $q(z|x) = \sum_w \int q(z|w, y, x)q(y|w, x)q(w|x)dy$. While there is no theoretical guarantee that the VAE estimate of $p_{Z,X,W,Y}$ convergences to the true joint distribution, despite recent encouraging identifiability results for VAEs [Khemakhem et al., 2020], the authors show empirically that the resulting method is promising.

A related literature based on the *the deconfounder* approach of Wang and Blei [2019], Wang and Blei focuses on handling unmeasured confounders. For that purpose, they consider a multi-cause causal inference problem and their approach consists in a two step procedure that first applies a dimension reduction on the multiple causes A to obtain an approximation $\hat{Z}$ of the unobserved multi-cause confounders Z, and second regresses the outcome Y on the causes A and approximated $\hat{Z}$. This line of work has given rise to a significant amount of work and has further highlighted the difficulty of managing latent confounding factors and obtaining plausible conditions of identifiability (see D'Amour [2019], Grimmer et al. [2020] and references therein).

For instance, it has been pointed out by Grimmer et al. [2020] that the deconfounder approach does not improve upon simple regression on the multiple causes.

Put differently, the additional step that extracts information from A on the confounding does not improve the regression upon directly using this information implicitly by regressing only on A.

Finally, it can be noted that the problem of latent confounders is related to the identifiability problems of MNAR missing data models, approached by graphical modeling [Saadati and Tian, 2019, Bhattacharya et al., 2019].

5.3 – ATE with latent confounders with incomplete proxy variables

In this section, we propose methods that rely on the latent unconfoundedness model with missing values in the proxy variables as represented in Figure 5.2. We assume that the relationship between the confounders Z and their observed and potentially incomplete proxies X^*, can be complex, i.e., that it cannot be captured by simple models such as matrix factorization, going beyond the linear case proposed by Kallus et al. [2018a].

5.3.1 Multiple imputation strategy

Under the model represented in Figure (5.2), the unconfoundedness hypothesis (5.2) does *not* hold, thus a standard treatment effect estimator using X^* as covariates would be biased. On the other hand, we can express the treatment effect conditioned on X^* as follows:

$$\begin{aligned}\mathbb{E}[Y(1) - Y(0) \,|\, X^*] &= \mathbb{E}[\mathbb{E}[Y(1) - Y(0) \,|\, Z, X^*] \,|\, X^*] \\ &= \mathbb{E}[\mathbb{E}[Y(1) - Y(0) \,|\, Z] \,|\, X^*] \,.\end{aligned}$$

We recall that we denote as in Bennett and Kallus [2019]:

$$\begin{aligned}f(z) &= \mathbb{E}[Y(1) - Y(0) | Z = z], \\ \mu_w(z) &= \mathbb{E}[Y(w) | Z = z] \\ \rho_w(x^*) &= \mathbb{E}[\mu_w(Z) | X^* = x^*] = \mathbb{E}[Y(w) | X^* = x^*]\end{aligned}$$

Consequently, if we had an unbiased estimator of the treatment effect conditioned on Z, $\hat{f}(Z)$ of f (or equivalently unbiased estimators $\{\hat{\mu}_w(Z)\}_w$), and if we knew $P_{Z \,|\, X^*}$, the conditional distribution of Z given X^*, then we could estimate the treatment effect conditioned on X^*, $\rho_1(X^*) - \rho_0(X^*)$, by

$$\hat{g}(X^\star) \triangleq \mathbb{E}[\hat{f}(Z) | X^\star] \,. \tag{5.6}$$

Furthermore, by expressing the ATE as

$$\tau = \mathbb{E}[Y(1) - Y(0)] = \mathbb{E}[\mathbb{E}[Y(1) - Y(0) \,|\, X^*]] \,,$$

we can form an estimate of the ATE by $\mathbb{E}[\hat{g}(X^\star)]$. We describe an estimator in Section 5.4.2 based on this approach, which is reminiscent of multiple imputation techniques in the field of missing value imputation [Rubin, 2004].

5.3.2 Pre-processing strategy

Another strategy, closest to the one of Kallus et al. [2018a] and described in 5.4.3, is to consider latent variables estimation as a pre-processing step prior to causal inference by computing

$$h(X^\star) \triangleq f(\mathbb{E}[Z|X^\star]). \tag{5.7}$$

5.3.3 In which conditions, such approaches are reasonable

We propose to estimate the joint distribution of (Z, X) from $X^\star$ using a variational autoencoder (VAE) with missing data [Mattei and Frellsen, 2019], as will be detailed in Section 5.4. If the latent confounders are "sufficiently well" inferred from the data $X^\star$, the estimation of the causal parameter is possible. Such a postulate is plausible considering an adaptation from the *substitute confounder* assumption of Wang and Blei that states a pinpointing relationship between the observed X^* and the latent confounders Z.

Assumption 5.3.1. *There are no confounding factors which cannot be inferred from the proxies X^*. In other words, we assume that there exists a deterministic function l of X^* defined by*

$$\mathrm{P}\left(Z \mid X_1^*, \ldots, X_p^*\right) = \delta_{l\left(X_1^*, \ldots, X_p^*\right)} \tag{5.8}$$

Thus if we knew l perfectly, we could deconfound the data using only X^* with the assumption $\{Y(0), Y(1)\} \perp\!\!\!\perp W|l(X^*)$, i.e., all information about the true confounders Z is captured in X^*. Assuming a certain degree of regularity of this function l, we could define an estimator $\hat{Z}$ via an approximation of this function l estimated from the data. Note however that in the multi-cause problem of Wang and Blei, for finite number of observations and covariates, even for an accurate approximation of this function from the observed data, Imai and Jiang [2019] point out that the associated $\hat{Z}$ still depends on the choice of the factor model and if $\hat{Z}$ is taken to be the posterior mean, $\hat{Z} = \mathbb{E}[Z|X^*]$, this expectation is taken with respect to the fitted factor model, which does not guarantee convergence (in probability) of $\hat{Z}$ to the true confounder Z. Finally, we can note that a possible graphical model that is in agreement with this assumption is a fully connected graph as illustrated in Figure 5.4.



Figure 5.4 – Latent confounding with observed proxy variables. $(Z_1, \ldots, Z_d)$ represent the unobserved latent confounders of the treatment W and the effect Y. $(X_1, \ldots, X_p)$ represent proxies, and R a missing data mechanism; $(X_1^*, \ldots, X_p^*)$ represent the observed incomplete covariates.

Such a framework excludes the case where Z and X^* are independent i.e., cases where the proxies are simple noise and contain no information about Z. It also implies that there are no unobserved variables Z_j that are related to X^* but that are not confounding factors.

Following D'Amour [2019] and Grimmer et al. [2020], we can note that in the non-parametric case, Assumption 5.3.1 requires an infinity of proxies X^* to identify all information about the confounders Z from the proxies X^*. In our setting of multiple proxies, we postulate that as the number of observations increases and for increasing number of observed covariates, the posterior distribution $p_{Z|X^*}$ concentrates in the true confounders, which in turn justifies the two strategies proposed previously. This statement will be illustrated with numerical experiments in Section 5.5.2.

5.4 – MissDeepCausal

As we saw in Section 5.3, the proposed strategies require sampling from the posterior distribution $P_{Z|X^\star}$. Consequently, we first describe in Section 5.4.1 how to learn the joint distribution of (Z, X) from $X^\star$ using a variational autoencoder (VAE) with missing data, before turning to the details of each strategy.

5.4.1 Deep latent variable models with missing values

Deep latent variable models can be defined as follows. Let $(X_i,\, Z_i)_{1\leq i\leq n}$ be n i.i.d. random variables such that

$$\begin{cases} Z_i \sim P(Z_i)\,, \\ X_i \sim P_\theta(X_i|Z_i) = \Phi\left(X_i|f_\theta(Z_i)\right)\,. \end{cases}$$

The prior distribution of the latent variables or *codes* $Z_i \in \mathbb{R}^d$ is often isotropic Gaussian $Z_i \sim \mathcal{N}(0_d, I_d)$. The function $f_\theta : \mathbb{R}^d \to H$ is a (deep) neural network called the *decoder* and $\Phi(\cdot|\eta)_{\eta\in H}$ is a parametric observation model, which we take

to be multivariate Gaussian. The inference of deep latent variable models can be achieved by maximizing evidence lower bounds of the likelihood, such as the variational autoencoder bounds.

With missing values, the appropriate quantity to target for inference on θ, when the missing values mechanism, parametrized by ξ, can be ignored (see Section 5.2 and Rubin [1976], Little and Rubin [2019]), is the observed log-likelihood. Using Rubin [1976]'s notations, we define $X_i = (X_i^{obs}, X_i^{mis})$ the partition of the data in realized observed and missing values given a specific realization of the pattern [3], and we start by writing the full likelihood:
$\mathcal{L}_{full}(\theta, \xi) \triangleq \prod_{i=1}^{n} \int p_\theta \left(X_i^{obs}, X_i^{mis}\right) p_\xi \left(R_i \mid X_i^{obs}, X_i^{mis}\right) \mathrm{d}X_i^{mis}$. The observed log-likelihood writes as

$$\begin{aligned}\ell(\theta) \triangleq \log(\mathcal{L}(\theta)) &= \sum_{i=1}^{n} \log p_\theta \left(X_i^{obs}\right) \\ &= \sum_{i=1}^{n} \log \int p_\theta \left(X_i^{obs} | Z_i\right) p(Z_i) dZ_i,\end{aligned}$$

where $\mathcal{L}$ is the observed likelihood. Using the following theorem, the parameter of interest θ can be inferred by maximizing this observed likelihood rather than the full likelihood:

Theorem 5.4.1. *[Rubin, 1976, Thereom 1] Given ξ such that for all $1 \leq i \leq n$, $p_\xi(R_i|X_i) > 0$, assume (a) MAR, (b) $\Omega_{\theta,\xi} = \Theta \times \Xi$, $\mathcal{L}(\theta)$ is proportional to $\mathcal{L}_{full}(\theta, \xi)$ with respect to θ, so that the inference for θ can be obtained by maximizing the likelihood $\mathcal{L}$ which ignores the mechanism parametrized by ξ.*

The evidence lower bound (ELBO) corresponding to the observed log-likelihood is:

$$\begin{aligned}\mathcal{L}(\theta; \gamma) \triangleq \sum_{i=1}^{n} &\mathbb{E}_{Q_\gamma} \left[\ln P_\theta \left(X_i^{obs} | Z_i\right)\right] \\ &- KL \left(Q_\gamma \left(Z_i | X_i^{obs}\right) || \, P_\theta \left(Z_i\right)\right),\end{aligned}$$

with KL for the Kullback-Leibler divergence and the variational distribution

$$Q_\gamma \left(Z | X^{obs}\right) \triangleq \Psi \left(Z | g_\gamma(X^{obs})\right),$$

with $\Psi(\cdot)$ the (parametric) variational distribution over $\mathbb{R}^d$. The function $g_\gamma : \mathcal{X} \to \mathcal{K}$, called the *encoder*, is parametrized by a (deep) neural network whose weights are stored in $\gamma \in \Gamma$.

To take into account missing values in deep latent variable models, Mattei and Frellsen [2019] suggest the missing data importance weight autoencoder bound (MIWAE) approach. They use a simple variational family where they impute the missing entries with a constant and show that using this class of distributions, it

3. To lighten notations, when there is no ambiguity, we remove the explicit dependence in the pattern m.

maximizes a lower bound of the observed log-likelihood. Specifically, they replace Q_γ with

$$Q_\gamma\left(Z|X^{obs}\right) = \Psi\left(Z|g_\gamma\left(\iota\left(X^{obs}\right)\right)\right),$$

where ι is an imputation function chosen beforehand that transforms X^{obs} into a complete input vector $\iota\left(X^{obs}\right) \in \mathcal{X}$.

Self-normalized importance sampling In the MIWAE approach, the variational distribution $Q_\gamma(Z|X^\star)$ plays a central role but is not necessarily a good surrogate for the posterior distribution $P_\theta(Z|X^\star)$. To sample from the true posterior distribution, we resort to importance sampling techniques using the variational distribution Q_γ for proposal. More precisely, we can define, for any measurable function s,

$$\begin{aligned}\mathbb{E}[s(Z)|X^\star] &= \int s(Z)p_\theta(Z|X^\star)dZ \\ &= \frac{1}{p(X^\star)}\int s(Z)\frac{p_\theta(X^\star|Z)p(Z)}{q_\gamma(Z|X^\star)}q_\gamma(Z|X^\star)dZ.\end{aligned}$$

This quantity can be estimated using self-normalized importance sampling with:

$$\begin{aligned}&\mathbb{E}[s(Z)|X^\star] \approx \sum_{l=1}^{L} w_l s(Z^{(l)}), \\ &\text{where } w_l \triangleq \frac{r_l}{r_1+\cdots+r_L}, \text{ with } r_l \triangleq \frac{p_\theta(X^\star|Z^{(l)})p(Z^{(l)})}{q_\gamma(Z^{(l)}|X^\star)}.\end{aligned} \tag{5.9}$$

Equation (5.9) is used in our second strategy described in Section 5.4.3, while for our first strategy (described in Section 5.4.2) we sample L samples $Z^{(1)},\ldots,Z^{(L)}$ according to $Q_\gamma(Z|X^\star)$, compute the weights as in (5.9) and re-sample $B << L$ with probability proportional to the weights.

5.4.2 MissDeepCausal with multiple imputation (MDC-MI)

MDC-MI uses the importance sampling strategy presented in Subsection 5.4.1, to compute an approximation of (5.6) by Monte-Carlo as follows. First, we draw B i.i.d. samples $(Z^{(j)})_{1\leq j\leq B} \in \mathbb{R}^{n\times d}$ from the posterior distribution $P_{Z|X^\star}$. On each sample, we evaluate the function f and aggregate the results: $\hat{g}^{(B)}(X^\star) = \frac{1}{B}\sum_{j=1}^{B} f(Z^{(j)})$. This approach can be viewed as a multiple imputation method, which consists in generating different imputed data sets by drawing the missing values from their posterior distribution given observed values, then estimating the parameters of interest on each imputed data set and aggregating the results according to Rubin's rules [Rubin, 2004] to obtain a final estimate for the quantity of interest. Take for instance the simple regression estimator: we regress the observed outcome Y on every sample $Z^{(j)}$ of the confounders, $j = 1,\ldots,B$, and on the treatment assignment vector, to obtain an estimate $\hat{\tau}^{(j)}$ (corresponding to the regression coefficient of W).

The final estimate for the causal effect by computing the mean of the estimators i.e. $\hat{\tau} = \frac{1}{B}\sum_{j=1}^{B}\hat{\tau}^{(j)}$.

Alternatively, we could apply the AIPW estimator (1.26) (from Chapter 1) on each table $Z^{(j)}$:

$$\begin{aligned}\hat{\tau}^{(j)} =& \frac{1}{n}\sum_{i=1}^{n}\Big(\hat{\mu}_1^{(j)}(Z_i^{(j)}) - \hat{\mu}_0^{(j)}(Z_i^{(j)}) \\ &+ W_i\frac{Y_i - \hat{\mu}_1^{(j)}(Z_i^{(j)})}{\hat{e}^{(j)}(Z_i^{(j)})} \\ &- (1-W_i)\frac{Y_i - \hat{\mu}_0^{(j)}(Z_i^{(j)})}{1-\hat{e}^{(j)}(Z_i^{(j)})}\Big),\end{aligned} \tag{5.10}$$

and get the final estimate for the causal effect by taking the average of the intermediate estimations as before. Aggregation rules for multiple imputation [Rubin, 2004] are valid when the estimator is distributed according to a Gaussian distribution. This is the case asymptotically for the estimator in Equation 1.26 [Wager and Athey, 2018] which motivates this heuristic strategy. Note also that for this latter estimator, we can write

$$\begin{aligned}\hat{\tau} = f(Z) =& \mathbb{E}_{X^\star}[g(X^\star)] \\ =& \mathbb{E}_{X^\star}\left[\int_{\mathcal{Z}} f(z)p(z|X^\star)dz\right] \\ \approx& \frac{1}{nB}\sum_{j=1}^{B}\sum_{i=1}^{n}\hat{\mu}_1^{(j)}(Z_i^{(j)}) - \hat{\mu}_0^{(j)}(Z_i^{(j)}) \\ &+ W_i\frac{Y_i - \hat{\mu}_1^{(j)}(Z_i^{(j)})}{\hat{e}^{(j)}(Z_i^{(j)})} - (1-W_i)\frac{Y_i - \hat{\mu}_0^{(j)}(Z_i^{(j)})}{1-\hat{e}^{(j)}(Z_i^{(j)})},\end{aligned}$$

where the nuisance parameters e, μ_w are estimated separately on every sample $j = 1, \ldots, B$. Note that this multiple imputation strategy additionally allows to reflect the variability due to the missing values in the variance estimation of the estimator $\hat{\tau}$.

5.4.3 MissDeepCausal with latent variables estimation as a pre-processing step (MDC-process)

We also propose MDC-process as a non-linear extension of Kallus et al. [2018a], where we estimate $h(X^\star)$ defined in (5.7). For that purpose, we first approximate the expectation of the posterior distribution

$$\hat{Z}(x^\star) \triangleq \mathbb{E}[Z|X^\star = x^\star] \tag{5.11}$$

to obtain estimates for the latent confounders. In a second step, we use them under the regression model (5.4) and accordingly regress the observed outcome Y on the estimated latent factors $\hat{Z}(x^\star)$ and the treatment assignment W to obtain an estimation of the treatment effect. This strategy is a heuristic extension of Kallus

et al. [2018a] to a non-linear case in the sense that the latent variables encode non-linear relationship between covariates.

An alternative, still heuristic, approach is to use the estimated latent confounders from (5.11) as inputs for standard techniques to estimate the average treatment effect. More precisely, for the AIPW estimator (1.26), we replace the estimates for the propensity score with estimates for

$$\tilde{e}(z) = \mathbb{P}(W_i = 1 \,|\, \hat{Z}_i(x^\star) = z),$$

and similarly for the conditional response surfaces.

5.5 – Simulation study

5.5.1 Settings

Under the latent confounding assumption (corresponding to the graphical model in Figure 5.2), we generate covariates according to two models:

— LRMF: The covariates are generated from a low-rank matrix factorization model as in Kallus et al. [2018a].

— DLVM: The covariates are generated from a deep latent variable model as in as in Kingma and Welling [2014a] with homoscedastic noise. $Z_i \sim \mathcal{N}_d(0, 1)$, covariates X_i are sampled from $\mathcal{N}_p(\mu_{(Z)}, \sigma^2 I)$, where $\mu_{(Z)} = V \tanh(UZ + a) + b$ with $U \in \mathbb{R}^{h\times d}, V \in \mathbb{R}^{p\times h}, a \in \mathbb{R}^h, b \in \mathbb{R}^p$ drawn from standard Gaussian distributions (V, b) and uniform distributions (U, a). We fix $\sigma^2 = 0.001$ throughout the experiments for confounders recovery. [4] [5]

We define treatment and outcome models with a logistic-linear model as follows: $\text{logit}(e(Z_{i\cdot})) = \alpha^T Z_{i\cdot}$ and $Y_i \sim \mathcal{N}((\beta^T Z_i + \tau W_i, \sigma^2)$. We add an additive noise term in the outcome model such that the SNR ($SNR = \frac{\mu_Y}{\sigma_Y}$) is set to 10. Missing values are generated under the MCAR mechanism, i.e., $P(R_{ij} = 0) = \rho, \forall\, i, \forall\, j$, with $\rho \in \{0, 0.3, 0.5\ 0.9\}$. Finally, we consider the following problem dimensions: $n \in \{1\,000, 10\,000\}$, $p \in \{10, 100, 1\,000\}$, and $d \in \{2, 10\}$. Results are averaged over 30 replicates for each setting. We only report results for $n = 10,000$, experiments with other choices of parameters are reported in the Supplementary Material.

4. Note that for the experiments in Section 5.5.4 we use a slightly different model, where instead the covariance of X depends on Z, namely $\text{Var}(X_i) = \Sigma_{(Z_i)} = \text{diag}\{\exp(\eta^T \tanh(UZ + a) + \delta)\}$ with $\delta \in \mathbb{R}$ following a uniform distribution and $\eta \in \mathbb{R}^h$ drawn from a standard Gaussian distribution.

5. Details about the different choices for the constants can be found in the implementation available under https://github.com/imkemayer/MissDeepCausal.

5.5.2 Latent confounders recovery

Our heuristics about ATE estimation rely on the assumption that the posterior distribution $p_{Z|X^*}$ obtained by our proposed strategy, namely MIWAE/VAE+importance sampling, converges to the Dirac in the true latent confounders (see Section 5.3.3). To illustrate this behavior, we consider simulations in the complete case with a univariate latent confounder.

Figure 5.5 shows the estimated posterior distribution for a given observation i, $Z_i|X_i$ when the sample size increases. The realization z_i is considered as the target (black solid line). The estimated posterior distribution and its mean $\hat{Z}_i$ are represented by the gray histogram and the dashed line respectively. Additionally, we add the "true" posterior distribution and its mean (in blue), obtained by rejection sampling with the target distribution proportional to $p(X^*|Z)p(Z)$. One observes that as the number of observations n increases the bias decreases and the posterior distribution converges to the true posterior.

Figure 5.6 summarizes this result for an entire sample of n observations: on the left the mean squared errors (MSE) between $\hat{Z} = [\hat{Z}_1, \dots \hat{Z}_n]^T$ and Z that are averaged across repetitions for increasing n. For a fixed p, as n increases the error decreases towards the error obtained with the true posterior mean (dashed line). On the right, the averaged variances of the posterior distributions are displayed in the same settings. As expected, the posterior variance, both the true and the estimated, decrease with increasing values of p. It remains to understand why either for larger $p \in \{50, 100\}$ or for small $(n, p) = (1000, 10)$, we underestimate the variance of the posterior distribution.

Additionally, the strength of the initial signal, in our case the (near) orthogonality of the noise in the ambient space to the signal in the latent space impacts the convergence rate. Note that this is naturally linked to the behavior for increasing p.



Figure 5.5 – Example, for a given realization z_i, of concentration of the posterior in the true confounder value (with model parameters $(d, p) = (1, 10)$). The true posterior mean is approximated by rejection sampling.

This first set of experiments motivates the following steps where we exploit the posterior distribution obtained by MIWAE+importance sampling to estimate the ATE.



(a) MSE of $\hat{Z} = \mathbb{E}[Z|X^*]$ from fitted VAE for estimating Z.

(b) Average variance of posterior $p_{Z|X^*}$ from fitted VAE.

Figure 5.6 – Approximation of univariate confounder for increasing $n \in \{1000, 5000, 10000\}$ and $p \in \{10, 50, 100\}$.

5.5.3 Methods

We compare the following methods to handle missing values (the following acronyms are identical to the method labels used in Figures 5.7–5.9):

— MissDeepCausal:

  — `MDC.process`: using the estimations of the latent variables either in a regression adjustment estimator or in an AIPW-like estimator as presented in Section 5.4.3;

  — `MDC.mi`: using the AIPW estimator MDC-mi Section 5.4.2.

  We extended the publicly available code of Mattei and Frellsen [2019] to implement both methods. Throughout all experiments, we fix $L = 10,000$ for the importance sampling weights. We choose hyperparameters, σ^2_{prior} (variance of the prior on Z) and d_{miwae} (dimension of estimated latent space), by cross-validation. We vary the number of draws B from the posterior for the `MDC.mi` approach from 50 to 500 (results only reported for $B = 500$).

— `MI`: the multiple imputation approach as suggested in Mattei and Mealli [2009] and Seaman and White [2014]. We generate 20 imputations, using the python implementation in the scikit-learn [Pedregosa et al., 2011].

— `MF`: the matrix factorization approach of Kallus et al. [2018a] based on nuclear norm penalty (python implementation inspired by the R package `softImpute` [Hastie and Mazumder, 2015]). The dimension of the latent space is chosen via cross-validation on the nuclear norm penalty parameter.

— `GRF.MIA`: the doubly robust random forest based approach estimates the generalized scores $e^*(\cdot), \mu^*_w(\cdot)$ and handle missing values using the semi-discrete structure of the observed proxies X^* (see Chapter 4).

5.5.4 Results

5.5.4.1 Regression adjustment

First, we assess the quality of our heuristic described in Section 5.4.3 concerning the non-linear extension of Kallus et al. [2018a]. An estimation of τ is obtained by regressing the observed outcomes Y on the estimations of the latent factors Z (for `MDC.process`, `MF`) and on the imputed data X_{imp} (for `MI`).

Figure 5.7 show that our proposed method, `MDC.process` tends to slightly outperform all other methods when the covariates are generated according to a DLVM model. As expected the performances of all the methods decrease when the percentage of missing values increase.

Additionally we find that when the data is generated under the LRMF model, then our method performs as well as the initial proposal of Kallus et al. [2018a] (results are reported in the Supplementary Material).



Figure 5.7 – Estimated ATE via regression adjustment for varying amount of missing values; covariates generated from a DLVM, (logistic-)linear model specification for (e, μ_0, μ_1); results with `Z` results are obtained using the true confounders Z. $(n, p, d) = (10\,000,\ 100,\ 2)$.

5.5.4.2 Weighting-based estimation

Now we turn to the more flexible framework which does not assume linear relationships (5.4) between the outcome and the confounders. We consider the AIPW estimator (1.26) with the (imputed) covariates X for `MI` and with the estimation of the latent variables Z for `MF` and `MDC`.

To estimate the regression surfaces (μ_1, μ_0) and the propensity score e required for the AIPW estimator (1.26), we use a logistic-linear model, either with or without additional ℓ_2 regularization.

Figure 5.8 [6] illustrates that even when the latent variables are generated from matrix factorization, our approaches based on the VAE with missing values lead to unbiased estimates. We note as well that all methods perform similarly, independently

6. The multiple imputation approach fails due to memory saturation. We only report results for replications that did not fail due to memory constraints.

of the number of observed covariates p (results for the other values of p are in the Supplementary Material).

Figure 5.9 [7] show that as expected, due to the flexibility of MissDeepCausal, the suggested approaches better handle highly non-linear relationships between the latent confounders and the observed (incomplete) covariates. MDC methods are the only ones achieving no bias or small bias under this non-linear model.



Figure 5.8 – Estimated ATE via parametric AIPW estimation for varying amount of missing values; covariates generated from a LRMF, (logistic-)linear model specification for (e, μ_0, μ_1); results with `Z` are obtained using the true confounders Z. $(n, p, d) = (10\,000,\ 1\,000,\ 2)$.



Figure 5.9 – Estimated ATE via parametric AIPW estimation for varying amount of missing values; covariates generated from a DLVM, (logistic-)linear model specification for (e, μ_0, μ_1); results with `Z` are obtained using the true confounders Z. $(n, p, d) = (10\,000,\ 1\,000,\ 2)$.

7. Again the multiple imputation approach fail due to memory saturation.

5.5.5 IHDP data

We assess our methodology on the Infant Health and Development Program (IHDP) benchmark data [Hill, 2011]. The original data comes from a randomized control trial where the aim was to assess the impact of visits by specialists on children's test scores. There are six quantitative and 19 binary variables, recorded for 985 individuals. Hill [2011] transformed the original experimental data into observational data by selecting a nonrandom subset among the treated, stratified along an ethnicity variable, which leads to two unbalanced treatment groups. In total there are 139 treated and 608 control observations in the new data set. Then, keeping fixed the treatment variable, simulated data are obtained by generating new potential outcomes. More precisely, we follow the scenario "B" of Hill [2011] , i.e., $Y(0) \sim \mathcal{N}(\mu_0, 1)$ and $Y(1) \sim \mathcal{N}(\mu_1, 1)$, with $(\mu_0, \mu_1) = (\exp(X + W)\beta,\ X\beta - \omega)$ where ω is chosen to get an average treatment effect τ equal to 4. [8] After simulating the outcomes, we add missing values to the 25 covariates, assuming an MCAR mechanism. For the MIWAE part of our MDC methods, we select the parameters σ_{prior} and d_{miwae} by 5-fold cross-validation.

In addition to comparing the estimators considered in this chapter that handle missing data, we also add two other approaches: the CEVAE estimator detailed in Louizos et al. [2017] as a baseline and the MIA.GRF estimator proposed in Chapter 4. Note that CEVAE does not deal with missing values so that we replace the missing values by the mean of the variables. The CEVAE estimator is based on the difference between the two conditional expectations. The MIA.GRF estimator targets (10.3) and the generalized response surface analogue. It is based on estimation using random forests where missing values are encoded with *missing incorporated in attributes* such that the splitting rules in the random forests exploit the missingness pattern [Twala et al., 2008, Josse et al., 2019]. We use the R package `grf` [Tibshirani et al., 2020] for the complete case and the implementation from Chapter 4 for the incomplete case [9].

Finally, we additionally apply a non-parametric doubly robust estimator, denoted by DR_{rf}, on the approximated confounders (resp. imputed covariates) based on (generalized) random forests [Athey et al., 2019]. For this part we use the implementation of the R package `grf` [Tibshirani et al., 2020].

For comparability with previous experiments on these data, we report the in-sample mean absolute error, i.e. the mean absolute difference between the estimated ATE and the sample ATE (by construction of the data we know the exact values of $\mu_{(1)}(X_i)$ and $\mu_{(0)}(X_i)$ for all i): $\Delta = \left|\hat{\tau} - \frac{1}{n}\sum \mu_{(1)}(X_i) - \mu_{(0)}(X_i)\right|$.

8. We use and adapt the corresponding code from V. Dorie: https://github.com/vdorie/npci/.
9. https://github.com/imkemayer/causal-inference-missing

Table 5.1 – Methods on the IHDP benchmark data. Mean absolute error Δ (with standard error) across simulations on all the data points (in-sample error). OLS corresponds to the estimator obtained by regression and DR to the doubly robust estimator(s).

% NA	Method	Δ		
		OLS	$\text{DR}_{log-lin}$	DR_{rf}
0	X (complete data)	0.72 ± 0.02	0.13 ± 0.00	0.20 ± 0.01
	MF	0.56 ± 0.03	0.14 ± 0.01	0.16 ± 0.01
	$MDC.process$	0.51 ± 0.03	0.15 ± 0.01	0.19 ± 0.03
	$MDC.mi$	0.47 ± 0.03	0.16 ± 0.01	0.14 ± 0.02
	$CEVAE(X)$	0.34 ± 0.02		
10	MI	0.85 ± 0.02	0.16 ± 0.00	0.24 ± 0.01
	$MIA.GRF$	–	–	0.23 ± 0.01
	MF	0.50 ± 0.03	0.15 ± 0.01	0.15 ± 0.01
	$MDC.process$	0.42 ± 0.02	0.15 ± 0.01	0.16 ± 0.02
	$MDC.mi$	0.35 ± 0.02	0.17 ± 0.01	0.13 ± 0.02
	$CEVAE(X_{imp})$	0.31 ± 0.01		
30	MI	1.20 ± 0.02	0.30 ± 0.00	0.32 ± 0.01
	$MIA.GRF$	–	–	0.17 ± 0.01
	MF	0.39 ± 0.02	0.16 ± 0.01	0.17 ± 0.01
	$MDC.process$	0.37 ± 0.02	0.16 ± 0.01	0.15 ± 0.02
	$MDC.mi$	0.30 ± 0.02	0.18 ± 0.01	0.13 ± 0.01
	$CEVAE(X_{imp})$	0.38 ± 0.02		
50	MI	1.54 ± 0.03	0.46 ± 0.01	0.42 ± 0.01
	$MIA.GRF$	–	–	0.19 ± 0.01
	MF	0.28 ± 0.01	0.20 ± 0.01	0.21 ± 0.02
	$MDC.process$	0.24 ± 0.01	0.20 ± 0.01	0.21 ± 0.02
	$MDC.mi$	0.18 ± 0.01	0.22 ± 0.01	0.22 ± 0.03
	$CEVAE(X_{imp})$	0.38 ± 0.02		

Table 5.1 shows that the more sophisticated estimators (either in the parametric regression, $DR_{log-lin}$, or the random forest form DR_{rf}) systematically outperform the corresponding OLS estimator which highlights that the linear model is not appropriate, at least that it is not linear in the covariates X. Indeed, we know that the outcome is simulated as a non-linear function of the (complete) covariates X, whereas the treatment assignment is taken from the (de-randomized) experiment and can therefore well depend on latent variables. The results of MissDeepCausal are competitive with other approaches and greatly improve on CEVAE and MI. Its performances when used with the double robust estimators are stable with respect to the percentage of missing values.

5.6 – Conclusion

In this chapter we have investigated the problem of treatment effect estimation with incomplete covariates and latent unconfoundedness. This problem of missing values is highly relevant for modern causal inference as it is exacerbated with high dimensional data. Yet most causal inference techniques do not address this issue; and complete case analysis, in addition to leading to potentially inconsistent causal effects estimators, is not an option anymore. We have proposed MissDeepCausal which borrows the strength of deep latent variable models to retrieve the latent confounders from incomplete covariates encoding complex non-linear relationships. We use a modular approach in the style of Bayesian propensity based methods for treatment

effect estimation [Zigler, 2016], where the latent variables are used as inputs for standard complete data estimators. We suggest a multiple imputation strategy that allows to fully exploit the posterior distribution of the latent variables. Numerical results are very encouraging insofar as we obtain best relative performance in terms of bias and MSE whether the underlying model is well or badly specified compared to current state of the art. However we have also highlighted some theoretical challenges that are evoked by this (non-parametric) latent unconfoundedness problem and that have also been discussed in other recent works [D'Amour, 2019, Grimmer et al., 2020]. Other open challenges include heterogeneous treatment effect estimation with missing values as well as the ambitious task of handling missing not at random type data.

Acknowledgments

Part of this work was performed while JJ was visiting Google Brain. We thank Pierre-Alexandre Mattei for interesting discussion around deep latent variable models and we thank the anonymous referees for their valuable feedback on earlier versions of this work.

Part IV

Causal inference from combined experimental and observational data

Chapter 6

Causal inference methods for combining randomized trials and observational studies: a review

This chapter corresponds to the paper under review at the *Journal of Statistical Science* Causal inference methods for combining randomized trials and observational studies: a review, led by Bénédicte Colnet, carried out in collaboration with Guanhua Chen, Awa Dieng, Ruohong Li, Gaël Varoquaux, Jean-Philippe Vert, Julie Josse, and Shu Yang.

Abstract

With increasing data availability, causal treatment effects can be evaluated across different datasets, both randomized controlled trials (RCTs) and observational studies. RCTs isolate the effect of the treatment from that of unwanted (confounding) co-occurring effects. But they may struggle with inclusion bias, and thus lack external validity. On the opposite, large observational samples are often more representative of the target population but can conflate confounding effects with the treatment of interest. In this chapter, we review the growing literature on methods for causal inference on combined RCTs and observational studies, striving for the best of both worlds. We first discuss identification and estimation methods that improve generalizability of RCTs using the representativeness of observational data. Classical estimators include weighting, difference between conditional outcome models, and doubly robust estimators. We then discuss methods that combine RCTs and observational data to improve the (conditional) average treatment effect estimation, handling possible unmeasured confounding in the observational data. We also connect and contrast works developed in both the potential outcomes framework and the structural causal models framework. Finally, we compare the main methods using a simulation study and real world data to analyze the effect of tranexamic acid on mortality in major trauma patients. Code to implement many of the methods is provided.

Table of contents
Table des matières

6.1 – Introduction

Experimental data, collected through carefully designed experimental protocols, are usually considered the gold standard approach for assessing the causal effect of an intervention or a treatment on an outcome of interest. Randomized interventions are widely used in many domains such as economics, social sciences and medicine. In particular, the intensive use of randomized controlled trials (RCTs) in the medical area pertains to the so-called "evidence-based medicine", a keystone of modern medicine. Given that the treatment allocation in an RCT is under control, and that the distribution of covariates for treated and control individuals is generally *balanced* for a binary treatment, simple estimators such as the difference in mean effect between the treated and control individuals can be used to consistently estimate the treatment effect [Imbens and Rubin, 2015]. However, RCTs can come with drawbacks: First,

RCTs can be expensive, take a long time to set up, and be compromised by insufficient sample size due to either recruitment difficulties or restrictive inclusion/exclusion criteria. Second, these criteria for participant eligibility can lead to a narrowly defined trial sample that differs markedly from the population potentially eligible for the treatment. Therefore, the findings from RCTs can lack generalizability to a target population of interest. This concern is related to the aim of *external validity*, central in medical research [Concato et al., 2000, Rothwell, 2005, Green and Glasgow, 2006, Frieden, 2017], with the recent example of the COVID-19 vaccine effectiveness [Kim et al., 2021], policy research [Martel Garcia and Wantchekon, 2010, Deaton and Cartwright, 2018, Deaton et al., 2019], and other fields such as advertising [Gordon et al., 2019]. Note that this concern about the need for generalizability is not shared by all, as discussed by Rothman et al. [2013].

In contrast, there is an abundance of *observational data*, collected without systematically designed interventions. Such data can come from different sources. For example, they can be collected from research sources such as disease registries, cohorts, biobanks, epidemiological studies, or they can be routinely collected through electronic health records, insurance claims, administrative databases, etc. In that sense, observational data can be readily available, include large samples that are representative of the target populations, and be less cost-intensive than RCTs. In order to leverage observational data for causal effect analysis in health domains, the U.S. Food and Drug Administration (FDA) has proposed a framework that distinguishes two types of information levels: *Real World Data* (RWD) and *Real World Evidence* (RWE). On the one hand, RWD are data related to individuals' health status or the delivery of health care routinely collected from a variety of sources. On the other hand, RWE is the clinical evidence derived from analysis of RWD. However, there are often concerns about the quality of these "big data", given that the lack of a controlled experimental intervention opens the door to *confounding bias*. In the absence of unknown confounders, there exist many methods to consistently estimate a causal treatment effect from observational data such as matching, inverse propensity weighting (IPW), or augmented IPW (AIPW) [Imbens and Rubin, 2015], see also Chapter 1 for more details. When a confounder is unobserved, solutions exist and methods have been developed such as the *front-door criterion* [Pearl, 1993], instrumental variables [Angrist et al., 1996, Hernán and Robins, 2006, Imbens, 2014], robust causal structure learning [Frot et al., 2017], anchor regression [Rothenhäusler et al., 2021], negative controls [Kuroki and Pearl, 2014, Shi et al., 2020], sensitivity analysis [Cornfield et al., 1959, Rosenbaum and Rubin, 1983a, Imbens, 2003], and multiple causes analysis [Wang and Blei, 2019, Kong et al., 2021].

However, the *internal validity* of causal claims built from observational data remains challenging since it relies on modeling assumptions difficult to validate. Combining the information gathered from experimental and observational data is a promising avenue to build upon the internal validity of RCTs and a greater external validity of the real-world data. In what follows, we provide three examples of potential benefits in real world applications.

Using RCTs and observational data to generalize the treatment effect to a target patient population The FDA has recently greenlighted the extended usage of a certain drug (Ibrance) to men with breast cancer, even though clinical trials performed for authorization on the market were performed on a female population. Breast cancer in men is a rare disease, and therefore fewer trials were conducted to include male patients. The approval of the extension to the male population was based on the post-market health record and claims data, which cited the real-world usage of Ibrance on men. Authorizing such an extension can be a solution to reduce approval time of a drug for patients who could benefit from it. But such approaches are also accompanied by several concerns, especially in cases where the target population is very different from the RCT cohort. Method development and validation is needed to better navigate the risk-benefit trade-off.

Comparing RCTs and observational data to validate observational methods. There are many research questions for which it is impossible to conduct an RCT, e.g., for ethical reasons. Thus, researchers and clinicians remain compelled to take decisions based on observational data. Having at disposal the two sources of data can be useful to benchmark and validate observational studies as there is still concern that the new methods developed to analyze observational data could weaken standards. The Women's Health Initiative (WHI) is a widely cited example to illustrate potential inconsistencies between conclusions derived from RCTs and RWD. This extensive project was launched to assess whether hormone replacement therapy for healthy women could prevent the appearance of menopausal symptoms. Two out of four interventions of the RCT ended earlier than expected when evidence had accumulated that the health risks exceeded the benefits for this study population [Prentice and Anderson, 2008], whereas observational data first showed a benefit of the hormone replacement therapy. There were many discussions to understand whether the discrepancies between the studies were due to external validity issues of the RCT or internal validity issues of the observational data [Cole and Stuart, 2010, Shadish et al., 2002]. This debate led to a renewed analysis of the data which showed that the observational data carried the same message as the RCT, and that the differences observed were due to discrepancies in timing of start of treatment and effect over the time [Vandenbroucke, 2009, Frieden, 2017]. Following a specific analysis protocol can help avoid such apparent contradictions, by ensuring comparable analyses and a well-stated causal question. More precisely, such a protocol requires first to specify what *target trial* could answer the precise causal question we are interested in, while the observational data is used in a second step to emulate this target trial. The third part of the procedure is to perform sensitivity analysis to investigate remaining discrepancies [Hernán et al., 2016, Hernán, 2018, Lodi et al., 2019].

Integrating the complementary features of RCTs and observational data to better estimate treatment effects. The COVID-19 health crisis is a timely example of a public health context where a very rapid response is needed to assess the efficacy of various candidate treatments. In the beginning of the outbreak, there

are generally far more observational data than clinical trials. Knowing how to best combine these two sources of information can be crucial, in particular to better estimate heterogeneous treatment effects as RCTs are known to be under-powered in such settings.

There is an abundant literature on the problem of bridging the findings from an experimental study to the target population and combining both sources of information. Similar problems have been termed as *generalizability* [Cole and Stuart, 2010, Stuart et al., 2011, Hernán and VanderWeele, 2011, Tipton, 2013, O'Muircheartaigh and Hedges, 2014, Stuart et al., 2015, Keiding and Louis, 2016, Dahabreh and Hernán, 2019, Dahabreh et al., 2019c, Buchanan et al., 2018], *representativeness* [Campbell, 1957], *external validity* [Rothwell, 2005, Stuart et al., 2018, Westreich et al., 2018], *transportability* [Pearl and Bareinboim, 2011, Rudolph and van der Laan, 2017, Westreich et al., 2017], and also *data fusion* [Bareinboim and Pearl, 2016]. They have connections to the covariate shift problem in machine learning [Sugiyama and Kawanabe, 2012]. This problem of data integration is tackled in the two main frameworks for causal inference, namely the potential outcomes (PO) framework [Splawa-Neyman et al., 1929, Rubin, 1974], associated with the work by Donald Rubin and collaborators, and the work on structural causal models (SCM) using directed acyclic graphs (DAGs), much of it associated with work by Judea Pearl [Pearl, 1995] and his collaborators. Note that the DAGs are intuitive tools to clinicians and can be used to easily incorporate the domain knowledge.

The present chapter reviews available works on combining experimental data (RCTs) and observational data (RWD). It is organized as follows: In the next section, we introduce the notations from the PO framework, as well as the design setting. The review then starts by considering in Section 6.3 the case where the available data on the RCT are covariates (also known as baseline covariates when measured at inclusion of the patient), treatment, and outcome, while on observational data, only covariates are available. The aim is to generalize RCT findings to the target population. In this perspective, we give the identifiability assumptions and present the main estimation methods, i.e., inverse probability of sampling weighting (IPSW) and stratification, g-formula, doubly robust estimators, that have been suggested to account for distributional shifts. In Section 6.4, we consider the case where observational data also contain treatment and outcome data. We consider estimators for estimating the conditional average treatment effect using the two data sources while handling potentially unmeasured confounders. In Section 6.5, we present the SCM point of view which can be used to achieve identification in the presence of many variables. The SCM and PO frameworks use different notions and languages to formulate causal effects, they come with different strengths discussed in Imbens [2019] and share many aspects [Richardson and Robins, 2013]. In Section 6.6, we present available implementations and software, which we apply on simulated data using also new implementations, to simulated data. In Section 6.7, we apply the different methods on a medical application involving major trauma patients where the aim is to assess the effect of the drug tranexamic acid on mortality in head trauma patients and where both an RCT (the CRASH-3 trial) and an observational

database (the Traumabase® registry) are available. In this section, we also review methods for addressing data quality issues such as missing values.

6.2 – Problem setting

6.2.1 Notations, in the PO framework

We model each patient in the RCT or observational population as described by a random tuple $(X, Y(0), Y(1), W, S)$ drawn from a distribution $\mathcal{P}$, where X is a p-dimensional vector of covariates, W denotes the binary treatment assignment (with $W = 0$ for the control and $W = 1$ for the treated patients), $Y(w)$ is the binary or continuous outcome had the subject been given treatment w (for $w \in \{0, 1\}$), and S is a binary indicator for RCT eligibility (i.e., meet the RCT inclusion criteria) and willingness to participate if being invited to the trial ($S = 1$ if eligible and also willing to participate if being invited to the trial, $S = 0$ otherwise) [1].

Assuming *consistency of potential outcomes*, we also denote by $Y = WY(1) + (1 - W)Y(0)$ the outcome realized under treatment W. We model the patients belonging to an RCT sample of size n and to an observational data sample of size m by $n + m$ independent random tuples: $\{X_i, Y_i(0), Y_i(1), W_i, S_i\}_{i=1}^{n+m}$, where the RCT samples $i = 1, \ldots, n$ are identically distributed according to $\mathcal{P}(X, Y(0), Y(1), W, S \mid S = 1)$, and the observational data samples $i = n + 1, \ldots, n + m$ are identically distributed according to $\mathcal{P}(X, Y(0), Y(1), W, S)$. For simplicity of exposition, we also denote $\mathcal{R} = \{1, \ldots, n\}$ the index set of units observed in the RCT study, and $\mathcal{O} = \{n + 1, \ldots, n + m\}$ the index set of units observed in the observational study. For each RCT sample $i \in \mathcal{R}$, we observe $(X_i, W_i, Y_i, S_i = 1)$, while for observational data $i \in \mathcal{O}$, we consider two settings:

i. we only observe the covariates X_i,

ii. we also observe the treatment and outcome (X_i, W_i, Y_i).

The former case will be discussed in the next section while the latter will be detailed in Section 6.4. For ease of reading, we recall the conditional average treatment effect (CATE):

$$\forall x \in \mathbb{R}^p\,, \quad \tau(x) \triangleq \mathbb{E}[Y(1) - Y(0) \mid X = x]\,,$$

and the RCT CATE as

$$\forall x \in^p\,, \quad \tau_1(x) = \mathbb{E}_{Y(1)-Y(0)|X=x,S=1}\,[\,]\,.$$

We also define the population average treatment effect (ATE):

$$\tau \triangleq \mathbb{E}[Y(1) - Y(0)] = \mathbb{E}[\tau(X)]\,,$$

1. Note that depending on the context, S can have a slightly different meaning, for example other works use two indicators, one for participation and one for eligibility [Nguyen et al., a, Dahabreh et al., 2019c]. In such situations $S = 1$ denotes individuals who are eligible **and** participating in the trial, while $S = 0$ denotes ineligible or eligible but necessarily non-participating individuals.

introduced in Chapter 1. The ATE is different from the RCT ATE:

$$\tau \neq \tau_1, \quad \tau_1 \triangleq \mathbb{E}[Y(1) - Y(0) \mid S = 1] \,.$$

We denote respectively by $e(x)$ and $e_1(x)$ the propensity score in the observational population and in the RCT population:

$$e(x) \triangleq P(W = 1 \mid X = x) \,, \quad e_1(x) \triangleq P(W = 1 \mid X = x, S = 1) \,.$$

We also denote by $\mu_w(x)$ and $\mu_{w,1}(x)$ the conditional mean outcome under treatment $w \in \{0, 1\}$ in the observational population and in the RCT population, respectively:

$$\mu_w(x) \triangleq \mathbb{E}[Y(w) \mid X = x] \,, \quad \mu_{w,1}(x) \triangleq \mathbb{E}[Y(w) \mid X = x, S = 1] \,,$$

and by $\pi_S(x)$ the selection score [2]:

$$\pi_S(x) \triangleq P(S = 1 \mid X = x) \,.$$

Note that $\pi_S(x)$ is the probability of being *eligible* for selection in the RCT given covariates x. It is different from the probability that an individual with covariates x known to be in the blended study (RCT or observational population) is selected into the RCT:

$$\pi_S(x) \neq \pi_{\mathcal{R}}(x), \quad \pi_{\mathcal{R}}(x) \triangleq P(\exists i \in \mathcal{R}, X_i = x \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x) \,.$$

We similarly define

$$\pi_{\mathcal{O}}(x) \triangleq P(\exists i \in \mathcal{O}, X_i = x \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x) = 1 - \pi_{\mathcal{R}}(x) \,.$$

Finally, we denote by $\alpha(x)$ the conditional odds that an individual with covariates x is in the RCT or in the observational cohort:

$$\alpha(x) \triangleq \frac{P(i \in \mathcal{R} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)}{P(i \in \mathcal{O} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)} = \frac{\pi_{\mathcal{R}}(x)}{\pi_{\mathcal{O}}(x)} = \frac{\pi_{\mathcal{R}}(x)}{1 - \pi_{\mathcal{R}}(x)} \,.$$

Table 6.2 summarizes the notations for convenience, and Table 6.1 illustrates the considered type of data.

Table 6.1 – Illustration of data structure of RCT data (Set $\mathcal{R}$) and observational data (Set $\mathcal{O}$) with covariates X, trial eligibility S, binary treatment W and outcome Y. Left: with observed outcomes, Right: with potential outcomes.

			Covariates			Treatment	Outcome
	S	Set	X_1	X_2	X_3	W	Y
1	1	$\mathcal{R}$	1.1	20	F	1	1
	1	$\mathcal{R}$	-6	45	F	0	1
n	1	$\mathcal{R}$	0	15	M	1	0
$n+1$	0	$\mathcal{O}$		...		...	...
	0	$\mathcal{O}$	-2	52	M	0	1
	1	$\mathcal{O}$	-1	35	M	1	1
$n+m$	0	$\mathcal{O}$	-2	22	M	0	0

			Covariates			Treatment	Outcome(s)	
	S	Set	X_1	X_2	X_3	W	$Y(0)$	$Y(1)$
1	$\mathcal{R}$	1.1	20	F	1	NA	1
1	$\mathcal{R}$	-6	45	F	0	1	NA
1	$\mathcal{R}$	0	15	M	1	NA	1
0	$\mathcal{O}$		...		...	...	...
0	$\mathcal{O}$	-2	52	M	0	1	NA
1	$\mathcal{O}$	-1	35	M	1	NA	1
0	$\mathcal{O}$	-2	22	M	0	0	NA

2. Also named sampling propensity score in Tipton [2013].

Table 6.2 – List of notations.

Symbol	Description
X	Covariates (also known as baseline covariates when measured at inclusion of the patient)
W	Treatment indicator ($W = 1$ for treatment, $W = 0$ for control)
Y	Outcome of interest
S	Trial eligibility and willingness to participate if invited to ($S = 1$ for eligibility, $S = 0$ for non-eligibility)
n	Size of the RCT study
m	Size of the observational study
$\mathcal{R}$	Index set of units observed in the RCT study; $\mathcal{R} \triangleq \{1, \ldots, n\}$
$\mathcal{O}$	Index set of units observed in the observational study; $\mathcal{O} \triangleq \{n+1, \ldots, n+m\}$
$\pi_{\mathcal{R}}(x)$	Probability that a unit in $\mathcal{R} \cup \mathcal{O}$ with covariate x is in $\mathcal{R}$
$\pi_{\mathcal{O}}(x)$	Probability that a unit in $\mathcal{R} \cup \mathcal{O}$ with covariate x is in $\mathcal{O}$
$\alpha(x)$	Conditional odds $\alpha(x) \triangleq \pi_{\mathcal{R}}(x)/\pi_{\mathcal{O}}(x)$
τ	Population average treatment effect (ATE) defined as $\tau \triangleq \mathbb{E}[Y(1) - Y(0)]$
τ_1	Trial (or sample) average treatment effect defined as $\tau_1 \triangleq \mathbb{E}[Y(1) - Y(0) \mid S = 1]$
$\tau(x)$	Conditional average treatment effect (CATE) defined as $\tau(x) \triangleq \mathbb{E}[Y(1) - Y(0) \mid X = x]$
$\tau_1(x)$	Trial conditional average treatment effect defined as $\tau_1(x) \triangleq \mathbb{E}[Y(1) - Y(0) \mid X = x, S = 1]$
$e(x)$	Propensity score defined as $e(x) \triangleq P(W = 1 \mid X = x)$
$e_1(x)$	Propensity score in the trial defined as $e_1(x) \triangleq P(W = 1 \mid X = x, S = 1)$, known by design
$\mu_w(x)$	Outcome mean defined as $\mu_w(x) \triangleq \mathbb{E}[Y(w) \mid X = x]$ for $w = 0, 1$
$\mu_{w,1}(x)$	Outcome mean in the trial defined as $\mu_{w,1}(x) \triangleq \mathbb{E}[Y(w) \mid X = x, S = 1]$ for $w = 0, 1$
$\pi_S(x)$	Selection score defined as $\pi_S(x) \triangleq P(S = 1 \mid X = x)$
$f(X)$	Covariates distribution in the target population
$f(X\|S = 1)$	Covariates distribution conditional to trial-eligible individuals ($S = 1$)

6.2.2 Study designs

6.2.2.1 Transportability or generalizability?

Several terms are present in the literature to describe the issue of assessing the validity of a causal treatment effect from one population to another. In particular, generalization and transportability are two commonly used denominations, but they encompass design differences we believe should be made explicit. Subtle differences in the definitions can be found in the literature, but the following cover a broad range of proposed works:

— **Generalizability**: generalize the study result to *its* larger population. Mathematically, one considers the population distribution $P(X, Y(0), Y(1))$, then selects the trial sample ($S = 1$) from the population according to $P(S = 1|X)$. Generalizability supposes to use the trial sample to draw conclusions for the population, i.e., the estimand is a functional of $P(X, Y(0), Y(1))$.

— **Transportability**: extend the study result to a different external population. Mathematically, one is supposed to have access to two studies[3] following $P^1(X, Y(0), Y(1))$ and $P^2(X, Y(0), Y(1))$. The transportability problem supposes to transport some feature of $P^1(X, Y(0), Y(1))$ to $P^2(X, Y(0), Y(1))$. In this case, we can use the conditional odds ratio without referring to $P(S = 1|X)$. In some cases, the term transportability is used to refer to an *external* population, and may implicitly suppose different covariate support; however we will not consider this latter case in the present review.

According to the above definitions, this chapter focuses on both generalizability and transportability, because they coincide when $P^2(X, Y(0), Y(1)) = P(X, Y(0), Y(1))$. Also, in this review we use the terminology *selected* or *sampled* throughout the review for simplicity and coherence with existing research work, although for transportability subjects are not directly sampled into the study from the target population as pointed out in Degtiar and Rose [2021].

6.2.2.2 Nested or non-nested?

Following Dahabreh et al. [2019a] and Dahabreh and Hernán [2019], the study design to obtain the trial and observational samples can be categorized into two types: *nested* study designs and *non-nested* study designs as illustrated on Figure 6.1. Designs imply different identifiability conditions and therefore different estimators.

— **Non-nested trial design** involves separate sampling mechanisms for the RCT and the observational samples. The trial sample and the observational sample are obtained separately from the target population(s). For example, the trial study and the observational study are conducted by different researchers at different times or in different regions – with smallno time-specific or regional effects so that the underlying study populations are assumed to follow the same distribution. Note the difference between S and the sets $\mathcal{R}$ and $\mathcal{O}$, where in the observational sample we can have both $S = 1$ and $S = 0$ (Figure 6.1). In this review, we consider the case where the observational data set is a random *i.i.d* sample from the target population. Note that the choice of the proper target population can in itself be a challenging task [Westreich et al., 2018], and an implicit assumption is that the target population of interest is the study sample itself [Lesko et al., 2017].

— **Nested trial design** involves a two-stage sampling mechanism. First, a large sample is selected from the target population, and then the trial sample is selected from and nested in this sample. The rest of the sample constitutes the observational study. It corresponds to a real medical situation, such as designs for a pragmatic trial embedded in a broader health system. For example, in the Women Health Initiative (WHI), after the end of the initial trial period, a cohort of study participants are followed to measure their long-term outcomes. Olschewski and Scheurlen [1985] introduce the comprehensive cohort

3. But note that we do not necessarily have to define a superpopulation $P(X, Y(0), Y(1))$ and neither $P(S = 1|X)$ in this case.

study (CCS) design for evaluating competing treatments in which clinically eligible participants are first asked to enroll in a randomized trial and, if they refuse, are then asked to enroll in a parallel observational study in which they can choose treatments according to their own preference, leading to the observational data. Note that in this design, even the causal quantity of interest can be different from the non-nested design, as we may want to transport $\tau_1(x)$ to the observational population such that the causal quantity of interest is $\mathbb{E}[Y(1) - Y(0) \mid S = 0]$ rather than $\mathbb{E}[Y(1) - Y(0)]$ in the non-nested design.



Figure 6.1 – Schematics of the nested (left) and non-nested (right) designs; a similar schematic can be found in Josey et al. [2021] referring to generalizability (left) and transportability (right).

This design difference is also related to generalizability and transportability, where the latter necessarily corresponds to a non-nested design and the former can correspond either one of these designs [Josey et al., 2021]. In this chapter we focus on the **non-nested** design in the main part but we detail identifiability and estimators for the nested case in Appendix D.2.

6.3 – When observational data have no treatment and outcome information

We start by considering the case where only the distribution of the covariates from the observational study is available or used. Note that we consider the observational data as a random sample from the target population. In other words, the problem that we tackle in this section is the generalizability issue, i.e., how to use both data to estimate the target population ATE. Generalizability is of growing importance in medical research and beyond. For example, in trials for non-small-cell lung cancer, inclusion of elderly patients is often limited and thus the trial population cannot

represent the real-world patient population. In this case, the covariate information from a larger population based disease registry (e.g., national cancer database) can be used for generalization of trial findings [Dong et al., 2020]. For other examples of applied work (using the IPSW estimator introduced below) we refer the reader to Lesko et al. [2016], Tipton et al. [2016], Li et al. [2021]. He et al. [2020] review current practice, and reveal that generalization is gaining interest with an acceleration since 2015, but with very few quantitative assessments in practice. Another recent review on generalization methods has also been proposed by Degtiar and Rose [2021].

6.3.1 Assumptions needed to identify the ATE on the target population

A fundamental problem in causal inference is that we can observe at most one of the potential outcomes for an individual subject. In order to identify nonetheless the ATE from RCT and observational covariate data, we require some of the following assumptions.

6.3.1.1 Internal validity of the RCT

Assumption 6.3.1 (Consistency)**.** $Y = W\,Y(1) + (1 - W)\,Y(0)$.

Assumption 6.3.1 implies that the observed outcome is the potential outcome under the actual assigned treatment.

Assumption 6.3.2 (Randomization)**.** $Y(w) \perp\!\!\!\perp W \mid (X, S = 1)$ *for all* $w = 0, 1$.

Assumption 6.3.2 corresponds to internal validity. It holds by design in a completely randomized experiment, where the treatment is independent of all the potential outcomes and covariates, i.e., $\{Y(0), Y(1)\} \perp\!\!\!\perp W \mid S = 1$. It also holds by design in a stratified randomized trial based on a discrete X, where the treatment is independent of all the potential outcomes within each stratum of X. The more general case of conditional randomization is assumed throughout this chapter.

If Assumptions 6.3.1 and 6.3.2 hold, then the RCT is said to be compliant. In addition, in an RCT, it is common that the probability of treatment assignment (also called the propensity score), $e_1(x)$, is known. In a complete randomized trial, the propensity score is fixed as a constant, e.g., $e_1(x) = 0.5$ for all x.

6.3.1.2 Generalizability of the RCT to the target population

Different assumptions on the generalizability of the RCT to the target population are proposed in the literature, ranging from weak to stringent conditions. We now describe these assumptions and their implications.

Assumption 6.3.3 (Transportability of the CATE)**.** $\tau_1(x) = \tau(x)$ *for all* x*.*

Assumption 6.3.3 requires that the CATE function is transportable from the RCT to the target population, which is plausible if X captures all the *treatment effect modifiers* and there is no trial encouragement. It means that the invitation to participate in the trial and trial participation itself do not affect the outcome except through treatment assignment [Dahabreh and Hernán, 2019].

Assumption 6.3.4 (Mean exchangeability)**.**

$$\mathbb{E}[Y(w) \mid X = x, S = 1, W = w] = \mathbb{E}[Y(w) \mid X = x, S = 1]$$

(mean exchangeability over treatment assignment), and

$$\mathbb{E}[Y(w) \mid X = x, S = 1] = \mathbb{E}[Y(w) \mid X = x]$$

(mean exchangeability over trial participation), for all x *and* $w = 0, 1$ *[Dahabreh et al., 2019c].*

Assumption 6.3.5 (Ignorability assumption on trial participation)**.**

$$\{Y(0), Y(1)\} \perp\!\!\!\perp S \mid X,$$

[Stuart et al., 2011, Buchanan et al., 2018].

Assumption 6.3.5 states that the covariates X we require for generalization correspond to covariates that are both related to potential outcomes and subject to a distributional shift between the RCT sample and the target population. A parallel can be made with the *ignorability assumption* on treatment assignment in causal inference with observational data (see Definition 1.2.4 from Chapter 1), but with the sample selection. Still, note that those assumptions are similar from a formal point of view, however from a practical point of view the transportability problem faces additional challenges compared to those of identification of causal effects in a single population, e.g., because the proper covariates to capture the shift in causal effect are often missing Hernán and Robins [2020] (see p.46).

It is worth discussing the relationships among Assumptions 6.3.3 – 6.3.5, ranging from weak to strong conditions. Assumption 6.3.3, *transportability of the CATE*, is implied by, but does not imply, the stronger conditions in Assumption 6.3.4. The *mean exchangeability over treatment assignment* of Assumption 6.3.4 is implied by, but does not imply, Assumption 6.3.2. In the same way, *mean exchangeability over trial participation* of Assumption 6.3.4, also known as *mean generalizability* (from trial participants to the target population), is implied by, but does not imply, the stronger condition $Y(w) \perp\!\!\!\perp S \mid X$ in Assumption 6.3.5 (participation in the RCT is randomized within levels of X).

Assumption 6.3.6 (Positivity of trial participation)**.** *There exists a constant c such that, for almost all x, with probability 1, $\pi_S(x) \geq c > 0$; and $0 < P(W = w \mid X = x, S = 1) < 1$ for all w and for all x such that $P(S = 1 \mid X = x) > 0$.*

Assumption 6.3.6 means that we require adequate overlap of the covariate distribution between the trial sample and the target population (in other words, all members of the target population have nonzero probability of being selected into the trial), and also between the treatment groups over the trial sample. The positivity of treatment assignment in the trial given covariates, related to the assumption required for causal inference in confounded settings, is expected to hold by design in the RCT.

6.3.1.3 Towards identification formula

Under Assumptions 6.3.1, 6.3.4 (or 6.3.5), and 6.3.6 (for the regression formulation), and under Assumptions 6.3.1, 6.3.3 (or 6.3.4 or 6.3.5), and 6.3.6 (for the reweighting formulation), the ATE can be identified based on the following formulas (proved in Appendix D.1):

1. Reweighting formulation:

$$\tau = \mathbb{E}\left[\frac{n}{m\alpha(X)}\tau_1(X) \mid S = 1\right] = \mathbb{E}\left[\frac{n}{m\alpha(X)}\left\{\frac{W}{e_1(X)} - \frac{1-W}{1-e_1(X)}\right\}Y \mid S = 1\right]. \tag{6.1}$$

   In a fully randomized RCT where $e_1(x) = 0.5$ for all x, this formula further simplifies to

$$\tau = \mathbb{E}\left[\frac{2n}{m\alpha(X)}(2W - 1)Y \mid S = 1\right].$$

2. Regression formulation:

$$\tau = \mathbb{E}[\mu_{1,1}(X) - \mu_{0,1}(X)]. \tag{6.2}$$

Different identification formulas motivate different estimating strategies as discussed in the next subsection.

6.3.2 Estimation methods to improve generalizability of RCT analysis

As the RCT assigns treatment at random to the participants, the CATE $\tau_1(x) = \tau(x)$ is identifiable (under assumptions 6.3.1 and 6.3.2) and can be estimated by standard estimators, such as the difference in means solely from the RCT (see Chapter 1). However, in general, the covariate distribution of the RCT sample $f(X \mid S = 1)$ differs from that of the target population $f(X)$; therefore, τ_1 is different from τ in general, and an RCT ATE estimator using only trial data is biased for the ATE of interest. All along this review, estimators are denoted with the number of used observations in index, for example $\hat{\tau}_n$ if the estimator depends only on the RCT individuals, or $\hat{\tau}_{n,m}$ if it depends on both datasets.

6.3.2.1 IPSW and stratification: modeling the probability of trial participation

To overcome this bias, most existing methods rely on direct modeling of the selection score previously introduced. The selection score adjustments methods include inverse probability of sampling weighting (IPSW; Cole and Stuart, 2010, Stuart et al., 2011, Buchanan et al., 2018) and stratification [Stuart et al., 2011, Tipton, 2013, O'Muircheartaigh and Hedges, 2014]. For an example of an applied work using IPSW we refer the reader to Lesko et al. [2016], Tipton et al. [2016]. Note that some works only compute weights to assess how much the trial population differs from the target population without estimating the target population treatment effect [Susukida et al., 2016].

Inverse probability of sampling weighting (IPSW) The IPSW approach can be seen as the counterpart of inverse propensity weighting (IPW) methods for estimating the ATE from observational studies by controlling for confounding (see Chapter 1 for details). Based on the identification formula (Equation 6.1), the IPSW estimator of the ATE is defined as the weighted difference of average outcomes between the treated and control group in the trial. The observations are weighted by the inverse odds $1/\alpha(x) = \pi_{\mathcal{O}}(x)/\pi_{\mathcal{R}}(x)$ to account for the shift of the covariate distribution from the RCT sample to the target population. The larger $\pi_{\mathcal{R}}$, the smaller the weight of the observation. The form of the IPSW estimator is slightly different from the expression of the IPW estimator. In the latter, each observation is weighted by the inverse of the probability to be treated whereas in the former it is weighted by the inverse of the odds of the probability to be selected into the trial sample. This is due to the non-nested sampling design (see the IPSW estimator for the nested design (D.1)), as mentioned by Kern et al. [2016] and Nguyen et al. [a]. The IPSW estimator can be written as follows:

$$\widehat{\tau}_{\text{IPSW},n,m} \triangleq \frac{1}{n}\sum_{i=1}^{n} \frac{Y_i}{\widehat{\alpha}_{n,m}(X_i)} \left(\frac{W_i}{e_1(X_i)} - \frac{1-W_i}{1-e_1(X_i)} \right), \tag{6.3}$$

where $\widehat{\alpha}_{n,m}$ is an estimate of α. In a standard RCT with $e_1(x) = 0.5$ being fixed, this further simplifies to

$$\widehat{\tau}_{\text{IPSW},n,m} = \frac{1}{m}\sum_{i=1}^{n} \frac{2Y_i(2W_i - 1)}{\widehat{\alpha}_{n,m}(X_i)}.$$

The IPSW estimator is consistent if the quantity α is consistently estimated by $\widehat{\alpha}$. The most common method for estimating the selection score is to define it as $\widehat{\alpha}(x) \triangleq \widehat{\pi}_{\mathcal{R}}(x)/(1 - \widehat{\pi}_{\mathcal{R}}(x))$, where $\widehat{\pi}_{\mathcal{R}}$ is estimated by logistic regression trained to discriminate RCT from observational samples [Stuart, 2010], while recent works also use other methods such as random forest and Gradient boosting [Kern et al., 2016]. Similar to IPW estimators, IPSW estimators are known to be highly unstable, especially when the selection scores are extreme. This can occur if the trial study contains units with very small probabilities of being selected into the trial. Normalized weights can be used to overcome this issue [Dahabreh and Hernán, 2019]. Still, the major challenge remains that IPSW estimators require a correct model specification

of the selection score. Avoiding this problem requires either very strong domain expertise or turning to doubly robust methods (Subsubsection 6.3.2.4). Finally, Dahabreh et al. [2019c] propose the use of sandwich-type variance estimators (for both nested and non-nested designs) or non-parametric bootstrap approaches, and note that the latter may be preferable in practice.

Stratification The stratification approach – or subclassification – is introduced by Cochran [1968], and further detailed by Stuart et al. [2011], Tipton [2013], and O'Muircheartaigh and Hedges [2014]. It is proposed as a solution to mitigate the risks of extreme weights in the IPSW approach. The principle is to define L strata based on the covariate values via the selection score, which, in practice, consists in grouping observations for which values of $\widehat{\alpha}_{n,m}$ are similar. Then, in each stratum l, the average treatment effect is estimated as $\overline{Y(1)}_l - \overline{Y(0)}_l$, where $\overline{Y(w)}_l$ denotes the average value of the outcome for units with treatment w in stratum l in the RCT. Finally, the ATE estimator is the weighted sum of the difference between means in each stratum:

$$\widehat{\tau}_{\text{strat},n,m} \triangleq \sum_{l=1}^{L} \frac{m_l}{m} \left\{ \overline{Y(1)}_l - \overline{Y(0)}_l \right\}, \tag{6.4}$$

where m_l/m is the proportion of cases in the stratum l in the observational study. Kang et al. [2007] assess the performance of the stratification as opposed to the IPSW, and show that stratification is less effective than IPSW at removing bias, but that IPSW struggle more than stratification when the selection scores are small.

6.3.2.2 G-formula estimators: modeling the conditional outcome in the trial

An alternative to IPSW for generalizing RCT findings to a target population consists in leveraging the regression formulation Equation 6.2. The corresponding estimators, known as *g-formula* estimators, fit a model of the conditional outcome among trial participants, instead of fitting a model for the probability of trial participation. Applying these models to the covariates in the target population, i.e., marginalizing over the empirical covariate distribution of the target population, gives the corresponding expected outcome [Robins, 1986]. This outcome model-based estimator is then defined as:

$$\widehat{\tau}_{G,n,m} \triangleq \frac{1}{m} \sum_{i=n+1}^{n+m} \left(\widehat{\mu}_{1,1,n}(X_i) - \widehat{\mu}_{0,1,n}(X_i) \right), \tag{6.5}$$

where $\widehat{\mu}_{w,1,n}(X_i)$ is an estimator of $\mu_{w,1}(X_i)$ fitted on the RCT data. In the simplest case, one can assume a linear regression model for each treatment level w, estimate it by standard ordinary least squares (OLS), on the trial sample and apply it on the observational sample. If the model is correctly specified, the estimator is consistent. Kern et al. [2016] suggest using Bayesian additive regression trees [BART, Hill, 2011, Hahn et al., 2020] to learn the regression functions. Simulations illustrating the g-formula can be found in Lesko et al. [2017], Dahabreh et al. [2019c], Dong et al. [2020]. Dahabreh et al. [2019b] show that g-estimators are equivalent to specific IP

weighting estimators where the probability of treatment among trial participants is also modeled and when all models are estimated by non-parametric frequency (non-smooth) estimators. Nevertheless, in practice, their method encounters difficulties in practice, especially in high-dimensional settings, so that they suggest resorting to doubly robust estimators (Subsubsection 6.3.2.4).

6.3.2.3 Calibration weighting: balancing covariates

Beyond propensity scores, other schemes use sample reweighting. Dong et al. [2020] propose a calibration weighting approach, which is similar to the idea of entropy balancing weights introduced by Hainmueller [2012]. They calibrate subjects in the RCT samples in such a way that after calibration, the covariate distribution of the RCT sample empirically matches the target population. Let $\boldsymbol{g}(X)$ be a vector of functions of X to be calibrated, e.g., the moments, interactions, and non-linear transformations of components of X. In order to calibrate, they assign a weight ξ_i to each subject i in the RCT sample by solving the optimization problem:

$$\begin{aligned} &\min_{\xi_1,\ldots,\xi_n} \sum_{i=1}^{n} \xi_i \log \xi_i, \\ \text{subject to} \quad &\xi_i \geq 0, \text{ for all } i, \\ &\sum_{i=1}^{n} \xi_i = 1, \sum_{i=1}^{n} \xi_i \, \boldsymbol{g}(X_i) = \widetilde{\boldsymbol{g}}, \text{ (the balancing constraint)} \end{aligned} \tag{6.6}$$

where $\widetilde{\boldsymbol{g}} = m^{-1} \sum_{i=n+1}^{m+n} \boldsymbol{g}(X_i)$ is a consistent estimator of $\mathbb{E}[\boldsymbol{g}(X)]$ from the observational sample. The balancing constraint calibrates the covariate distribution of the RCT sample to the target population in terms of $\boldsymbol{g}(X)$. The objective function in (6.6) is the negative entropy of the calibration weights; thus, minimizing this criterion ensures that the empirical distribution of calibration weights are not too far away from the uniform distribution, such that it minimizes the variability due to heterogeneous weights. This optimization problem can be solved using convex optimization (with Lagrange multipliers). For an intuitive understanding of the calibration weighting framework, consider $\boldsymbol{g}(X) = X$. In such a setting, the balancing constraint is forcing the means of the observational data and RCT to be equal after reweighting. More complex constraints can enforce balance on higher-order moments. The calibration algorithm is inherently imposing a log-linear model of the sampling propensity score and solving the corresponding parameters by a set of estimating equations induced by covariate balance. This equivalence provides insights into using the penalized estimating equation approach to select important variables for balancing.

Based on the calibration weights, the CW estimator is then

$$\widehat{\tau}_{\mathrm{CW},n,m} \triangleq \sum_{i=1}^{n} \widehat{\xi}_{n,m}(X_i) Y_i \left\{ \frac{W_i}{e_1(X_i)} - \frac{1 - W_i}{1 - e_1(X_i)} \right\}, \tag{6.7}$$

where $\widehat{\xi}_{n,m}(X_i)$ corresponds to the approximation of ξ_i from the optimization problem (6.6). The CW estimator $\widehat{\tau}_{\mathrm{CW},n,m}$ is doubly robust in that it is a consistent estimator

for τ if the selection score of RCT participation follows a log-linear model, i.e., $\pi_S(X) = \exp\{\boldsymbol{\eta}_0^\top \boldsymbol{g}(X)\}$ for some $\boldsymbol{\eta}_0$, or if the CATE is linear in $\boldsymbol{g}(X)$, i.e., $\tau(X) = \boldsymbol{\gamma}_0^\top \boldsymbol{g}(X)$, though not necessarily both. The authors suggest a bootstrap approach to estimate its variance.

6.3.2.4 Doubly-robust estimators

The model for the expectation of the outcomes among randomized individuals (used for the g-estimator in Equation 6.5) and the model for the probability of trial participation (used in IPSW estimators in Equation 6.3) can be combined to form an Augmented IPSW estimator (AIPSW):

$$\widehat{\tau}_{\text{AIPSW},n,m} \triangleq \frac{1}{n}\sum_{i=1}^{n} \frac{1}{\widehat{\alpha}_{n,m}(X_i)} \left[\frac{W_i\left\{Y_i - \widehat{\mu}_{1,1,n}(X_i)\right\}}{e_1(X_i)} - \frac{(1-W_i)\left\{Y_i - \widehat{\mu}_{0,1,n}(X_i)\right\}}{1-e_1(X_i)}\right] + \frac{1}{m}\sum_{i=n+1}^{n+m}\left\{\widehat{\mu}_{1,1,n}(X_i) - \widehat{\mu}_{0,1,n}(X_i)\right\}.$$

It can be shown to be doubly robust, i.e., consistent and asymptotically normal when either one of the two models for $\widehat{\alpha}_{n,m}(\cdot)$ and $\widehat{\mu}_{w,1,n}(\cdot)$ $(w = 0, 1)$ is correctly specified, as demonstrated by Dahabreh and Hernán [2019, supplementary material] for both the nested and non-nested designs.

More recently, Dong et al. [2020] propose an augmented calibration weighting (ACW) estimator, given by

$$\widehat{\tau}_{\text{ACW},n,m} \triangleq \sum_{i=1}^{n} \widehat{\xi}_{n,m}(X_i) \left[\frac{W_i\left\{Y_i - \widehat{\mu}_{1,1,n}(X_i)\right\}}{e_1(X_i)} - \frac{(1-W_i)\left\{Y_i - \widehat{\mu}_{0,1,n}(X_i)\right\}}{1-e_1(X_i)}\right] + \frac{1}{m}\sum_{i=n+1}^{m+n}\left\{\widehat{\mu}_{1,1,n}(X_i) - \widehat{\mu}_{0,1,n}(X_i)\right\}. \tag{6.8}$$

They show that $\widehat{\tau}_{\text{ACW},n,m}$ achieves double robustness and local efficiency, i.e., its asymptotic variance achieves the semi-parametric efficiency bound (the variance is smaller than the asymptotic variance of $\widehat{\tau}_{\text{CW},n,m}$ in Equation 6.7). Moreover, the ACW estimator enables the use of double machine learning estimation of nuisance functions (estimates of both) while preserving the $\sqrt{n}$-consistency of the ACW estimator. Other doubly robust estimators include targeted maximum likelihood estimators (TMLE) [Rudolph and van der Laan, 2017]. They provide a semi-parametric efficiency score for transporting the ATE from one study site to another, where one site is regarded as a population. Chernozhukov et al. [2018a] propose double/debiased machine learning methods to consistently estimate the ATE by using flexible machine learning methods for the nuisance parameters estimation to avoid model mis-specification. Their approach uses Neyman-orthogonal scores to reduce sensitivity of ATE estimation with respect to approximation errors of nuisance parameters. In addition, they use cross-fitting [Zheng and van der Laan, 2011, Chernozhukov et al., 2018a] to provide an efficient and unbiased form of data-splitting.

Dahabreh et al. [2020] perform a simulation study when all hypotheses are met to compare IPSW, g-estimators and doubly robust approaches. This study confirms that

when all models are correctly specified all estimators are approximately unbiased, with the outcome-model based estimator (6.5) showing the lowest variance. Note that they do not explicitly simulate examples under model mis-specification.

Note that when the overlap assumption between RCT and observational distributions does not hold, we may have to select a sub-population of the observational data for generalization. In particular, similarly to the propensity score trimming idea by Crump et al. [2009] for dealing with limited overlap between treated and control groups, Chen et al. [2021] propose a generalizability score, a function of participation probability and propensity score, to select sub-populations of observational data for causal generalization when the overlap between the RCT and observational distributions is limited.

Finally, we point out an important caveat that all methods assume the transportability condition: given the covariates x, the conditional treatment effect must be the same in the observational data as in the trial. This assumption could be violated if some treatment effect modifiers are not captured in the data. However, if the observational data provide additional treatment and outcome information, some key assumptions may be testable. In the next section, we review methods developed in the context of combining RCT and full observational data.

6.4 – When observational data contain treatment and outcome information

In Section 6.3, we have studied the use of the covariate distribution of the observational sample to adjust for selection bias of the RCT sample. Now we consider the setting where we have access to additional treatment and outcome information (Y, W) from the observational sample. Many studies involve both RCT and observational data with comparable information, e.g., the study we detail in Section 6.7 with the Traumabase® and the CRASH-3 datasets. In this context, the question of interest becomes how to leverage both data sources for efficient estimation of the ATE and CATE.

6.4.1 Causal inference on observational data

Under classical identifiability assumptions, it is possible to estimate the ATE and CATE based only on the observational data. For ease of reading, we recall these classical assumptions defined already in Chapter 1.

Assumption 6.4.1 (Unconfoundedness)**.** $Y(w) \perp\!\!\!\perp W \mid X$ *for* $w = 0, 1$.

Assumption 6.4.1 (also called *ignorability* assumption) states that treatment assignment is as good as random conditionally on the attributes X. In other words, all confounding factors are measured. Unlike the RCT, in observational studies, its plausibility relies on whether or not the observed covariates X include all the confounders that affect the treatment as well as the outcome.

Assumption 6.4.2 (Overlap)**.** *There exists a constant $\eta > 0$ such that for almost all x, $\eta < e(x) < 1 - \eta$.*

Assumption 6.4.2 (also called *positivity* assumption) states that the propensity score $e(\cdot)$ is bounded away from 0 and 1 almost surely.

Under Assumptions 6.4.1 and 6.4.2, the ATE can be identified based on the following formula from the observational data:

1. Reweighting formulation:

$$\tau = \mathbb{E}\left[\frac{WY}{e(X)} - \frac{(1-W)Y}{1-e(X)}\right]; \tag{6.9}$$

2. Regression formulation:

$$\tau = \mathbb{E}[\tau(X)] = \mathbb{E}[\mu_1(X) - \mu_0(X)]. \tag{6.10}$$

The identification formulas motivate inverse propensity weighted estimators, regression estimators or doubly robust estimators based solely on the observational data. There are many methods also available to estimate the CATE $\tau(\cdot)$ based on the observational data such as causal forests [Wager and Athey, 2018], causal BART [Hill, 2011, Hahn et al., 2020], causal boosting [Powers et al., 2018], or causal multivariate adaptive regression splines (MARS) [Powers et al., 2018]. In Chapter 1, we have seen that there are also meta-learners such as the S-Learner [Künzel et al., 2018], T-learner [Künzel et al., 2018], X-Learner [Künzel et al., 2019], MO-Learner [Rubin and van der Laan, 2007, Künzel et al., 2018], modified covariate method (MCM) [Tian et al., 2014, Chen et al., 2017], modified covariate method with efficiency augmentation (MCM-EA), and R-learner [Nie and Wager, 2017], which build upon any base learners for regression or supervised classification such as random forests [Breiman, 2001] and BART [Hill, 2011]. Among these methods, IPW, MO-Learner, S-Learner, T-Learner, X-Learner, MCM, MCM-EA, R-Learner, causal forests, and causal BART were proved to be unbiased under appropriate conditions; MCM-EA and R-Learner are efficient under appropriate conditions; MO-Learner has doubly robustness property, and all of them have been implemented in R. Knaus et al. [2021] and Powers et al. [2018] conduct comprehensive simulation studies to compare these methods, and the general conclusion is that none of these methods is overall best performing across all settings.

6.4.2 Dealing with unmeasured confounders in observational data

The ATE is useful to inform about the treatment effect over a target population on average. Alternatively, the CATE informs how treatment effects vary over individual characteristics. Under Assumptions 6.3.5 and 6.4.1, the CATE can be estimated based on the RCT and observational study, and therefore the two data sources can be pooled to improve estimation efficiency. In this case, the covariate shift problem

for the RCT does not bias the estimator of the CATE; furthermore, we do not require the covariate distribution to overlap between the RCT and observational samples. In practice, observational data may violate the desirable assumption for combining, e.g., that there are no unmeasured confounders. The design benefit of RCTs can be used to overcome this lack of internal validity. A recent applied example on the COVID-19 vaccine shows a situation where the covariate adjustment is empirically found to ensure unconfoundedness because the survival data in the first days following the injection in the RCT are similar to the ones in the adjusted observational sample [Dagan et al., 2021]. Hence, the next questions are whether we should include observational data into our analysis and if so, how we should use it. At a general level, we face a case where we want to combine an unbiased but high-variance estimator (due to the small sample size of the RCT) and a biased but low-variance estimator from the observational study.

To answer the first question, Yang et al. [2020a] derive a statistical test to gauge the reliability of the observational data compared to the gold-standard RCT data. The test outcome determines whether or not to use the observational data in an integrative analysis. Their strategy leads to an elastic test-based integrative estimator that uses the optimal combining rule for estimation if the violation test is not significant and retains only the RCT counterpart if the violation test is significant. This guarantees the consistency of the CATE estimator regardless of whether or not the observational data meet the criteria for combining. The elastic integrative estimator gains efficiency over the RCT alone estimator and gains robustness to unmeasured confounding over the naive combining estimator.

Other approaches exist to handle unmeasured confounders. Kallus et al. [2018b] consider a setting where the ignorability on the trial assumption (Assumption 6.3.5) holds but where the observational data does not fully overlap with the RCT. They suggest the following estimation strategy. First, using confounded observational data $\{(X_j, W_j, Y_j) : \ j \in \mathcal{O}\}$, they estimate the conditional treatment effect with classical methods such as causal forest [Wager and Athey, 2018], denoted by $\widehat{\tau}_m^{\mathcal{O}}(x)$. Due to possible unmeasured confounding, $\widehat{\tau}_m^{\mathcal{O}}(x)$ may be biased for $\tau(x)$. To correct for this bias, they write the bias as $\eta(x) \triangleq \tau(x) - \mathbb{E}[\widehat{\tau}_m^{\mathcal{O}}(x)]$. Given that $\hat{\tau}_m^{\mathcal{O}}(x)$ is obtained from the observational data, one can learn the bias term η using the unconfounded RCT data, $\{(X_i, W_i, Y_i, S_i = 1) : \ i \in \mathcal{R}\}$. Furthermore, they assume that the bias can be well approximated by a function with low complexities, e.g., a linear function of the covariates x: $\eta(x) = \theta^T x$. This assumption guarantees the validity of the framework even if the observational data does not fully overlap with the experimental data as the bias can be well estimated by extrapolation. A lack of overlap could be an issue if the bias was approximated using non-parametric models such as random forests because their ability to extrapolate may be weak. Kallus et al. [2018b] then use the transformed outcome $Y_i^* \triangleq [e(X_i)^{-1}W_i - \{1 - e(X_i)\}^{-1}(1 - W_i)]Y_i$, which satisfies $\mathbb{E}[Y_i^* \mid X_i] = \tau(X_i)$, and estimate the bias as $\widehat{\eta}_{n,m}(x) = \widehat{\theta}_{n,m}^T x$ where:

$$\widehat{\theta}_{n,m} \triangleq \operatorname{argmin}_\theta \sum_{\mathrm{i}=1}^{\mathrm{n}} \left\{ \mathrm{Y}_\mathrm{i}^* - \widehat{\tau}_\mathrm{m}^{\mathcal{O}}(\mathrm{X}_\mathrm{i}) + \theta^{\mathrm{T}} \mathrm{X}_\mathrm{i} \right\}^2 .$$

Finally, $\widehat{\tau}_{n,m}(x) = \widehat{\tau}_m^{\mathcal{O}}(x) + \widehat{\eta}(x)$ is the estimated conditional average treatment

effect. They prove that under conditions of parametric identification of η, $\widehat{\tau}_{n,m}(x)$ is a consistent estimate of $\tau(x)$ which converges at a rate governed by the rate of estimating $\mathbb{E}[\widehat{\tau}_m^{\mathcal{O}}(x)]$ by $\widehat{\tau}_m^{\mathcal{O}}(x)$.

In clinical settings, parametric models for the CATE are desirable due to their easy interpretations. Yang et al. [2020b] consider a structural model assumption for the CATE, e.g., for continuous outcomes, a linear CATE function of the form $\tau_{\varphi_0}(x) \triangleq x^T\varphi_0$ with $\varphi \in \mathbb{R}^{p_1}$, and for binary outcomes, a CATE function of the form $\tau_{\varphi_0}(x) \triangleq \{\exp(x^T\varphi_0) - 1\}/\{\exp(x^T\varphi_0) + 1\}$ ranging from -1 to 1. Furthermore, to accommodate the possible unmeasured confounders in the observational data, they assume that a confounding function summarizes the impact of unmeasured confounders on the difference in the potential outcome between the treated and untreated groups, accounting for the observed covariates. In particular, they consider

$$\lambda(x) \triangleq \mathbb{E}[Y(0) \mid W = 1, X = x] - \mathbb{E}[Y(0) \mid W = 0, X = x]$$

for the observational data. In the absence of unmeasured confounding $\lambda(x) = 0$ for any $x \in \mathbb{R}^{p_1}$, while if there is unmeasured confounding, $\lambda(x) \neq 0$ for some x. Similar to the CATE, Yang et al. [2020b] impose a structural model assumption for $\lambda(x) = \lambda_{\phi_0}(x)$ with $\phi \in \mathbb{R}^{p_2}$ The confounding function is unidentifiable based only on the observational data. Coupling the RCT and observational data, Yang et al. [2020b] show that the CATE and confounding function are identifiable. The key insight is to define the random variable

$$H_{\psi_0} \triangleq Y - \tau_{\varphi_0}(X)W - (1 - S)\lambda_{\phi_0}(X)\{W - e(X)\}\,, \tag{6.11}$$

where $\psi_0 = (\varphi_0^{\mathrm{T}}, \phi_0^{\mathrm{T}})^{\mathrm{T}} \in \mathbb{R}^p$ $(p = p_1 + p_2)$ is the full vector of model parameters in the CATE and confounding function. By separating the treatment effect $\tau_{\varphi_0}(X)W$ and $(1 - S)\lambda_{\phi_0}(X)\{W - e(X)\}$ from the observed Y, H_{ψ_0} mimics the potential outcome $Y(0)$. They then derive the semi-parametric efficient score of ψ_0:

$$S_{\psi_0}(V) \triangleq \begin{pmatrix} \frac{\partial \tau_{\varphi_0}(X)}{\partial \varphi_0} \\ \frac{\partial \lambda_{\phi_0}(X)}{\partial \phi_0}(1 - S) \end{pmatrix} \{\sigma_S^2(X)\}^{-1}(H_{\psi_0} - \mathbb{E}[H_{\psi_0} \mid X, S])\{W - e(X)\}\,, \tag{6.12}$$

where $\sigma_S^2(X) = \mathrm{Var}[Y(0) \mid X, S]$. A semi-parametric efficient estimator of ψ_0 can be obtained by solving the estimating equation based on (6.12). If the predictors in $\tau_{\varphi_0}(X)$ and $\lambda_{\phi_0}(X)$ are not linearly dependent, they show that the integrative estimator of the CATE is strictly more efficient than the RCT estimator. As a by-product, this framework can be used to generalize the ATEs from the RCT to a target population without requiring an overlap covariate distribution assumption between the RCT and observational data.

The methods mentioned above are applicable to general cases of integrative analysis, other approaches have been tailored for special applications. Peysakhovich and Lada [2016] propose a method for integrative analysis when observational data are time series. First, one can use observational time series data to estimate a mapping from observed treatments to unit-level effects. This estimate is biased due to potential unobserved confounders. Then, one can use experimental data to identify a monotonic transformation from biased estimates to real treatment effects. To use

this method, unit-level time series data are needed for the first step and assume the bias preserves unit-level relative rank ordering. Athey et al. [2020a] combine RCT and observational data to obtain credible estimates of the causal effect on a primary outcome in a setting where both observational and RCT samples contain treatment, features, and a secondary (often short-term) outcome, but the primary outcome is observed only in the non-randomized sample, the rational being that the treatment effect on the secondary outcome and that on the primary outcome should be similar. If this is not the case, they assume that it is because of unobserved confounders in the observational sample. Their method consists in adjusting the estimates of the treatment effects on the primary outcome using the differences observed on the secondary outcome. They suggest three methods, namely, *i)* imputing the missing primary outcome in the RCT, *ii)* weighting the units in the observational sample to remove biases and *iii)* using control function methods. The key assumption for identifiability is a latent unconfoundedness $Y^{1^{st}}(w) \perp\!\!\!\perp W \mid Y^{2^{nd}}(w), X$, for $w = 0, 1$, where $Y^{1^{st}}(w)$ and $Y^{2^{nd}}(w)$ refer respectively to a primary and secondary potential outcome under treatment w. In other words, unobserved confounders that affect both treatment assignment and the secondary outcome in the observational study are the same unobserved confounders that affect both the treatment assignment and primary outcome. Their assumptions also imply that the missing data in the potential outcomes are missing at random [Rubin, 1976].

6.4.3 Other use cases

Beyond generalizability or experimental grounding to overcome confounding, there are other purposes for combining experimental and observational data. Detailing all these methods would be beyond the scope of this review. Still, for the reader interested in other methods dedicated to combining data, we provide a non exhaustive list of other purposes and methodologies.

Using hybrid controls A hybrid control arm is a control arm constructed from a combination of randomized patients and real-world data on patients receiving usual care in standard clinical practice, as introduced by Pocock [1976] and pursued by [Hobbs et al., 2012, Schmidli et al., 2014]. Recently the FDA detailed their usage in the regulatory purposes [FDA, 2018]. Using hybrid controls has the potential to decrease the cost of randomized trials, and to diminish ethic constraints on control groups.

Surrogates The use of surrogates outcomes is increasing, for example in cancer disease or because long-term outcome (for example in economy) are complicate to observe. Sometimes the use of intermediate outcomes as surrogates is proposed, but there is always a fear that it dos not mediate the full effect of the treatment. Athey et al. [2020b] propose a method that relies on two data samples, one experimental and one observational, to handle the surrogate and the primary outcome. Their method combines an RCT containing data about the treatment indicator and the surrogates but not the long-term outcome, and an observational sample containing

information about the surrogates and the primary (long-term) outcome, but not on the treatment.

Case-control studies In certain applications, e.g., in epidemiology, the observational data at hand comes from a case-control study where the selection of observations is driven by the outcome of interest Y. Thus, the RCT and observational data differ in terms of the outcome distribution, for instance, if we consider a binary outcome as indicator of a certain event, the occurrence of the outcome event in the observational data is impacted by the selection process. Several solutions have been proposed to handle this type of selection bias induced by preferential selection on the outcome for the observational dataset. Robins [2000] and Hernán et al. [2005] propose marginal structural model approaches to eliminate this bias by assuming sufficient knowledge of the selection model given treatment. More recently, Guo et al. [2021] propose a control variates technique [Tan, 2006, Yang and Ding, 2019] to eliminate outcome selection bias by identifying and estimating an estimand that is sufficiently correlated with the target estimand of interest for the observational cohort.

6.5 – Structural causal models and transportability

The SCM framework [Pearl, 1995, 2009c] is a general model for causal inference, different from the PO framework that we discussed in the previous sections. It provides interesting answers to the transportability problem, as summarized by Bareinboim and Pearl [2016].

The structural causal model framework. Let us first briefly introduce the SCM framework, using as much as possible the notations of Subsection 6.2.1 that we introduced for the PO framework (Appendix D.3 gives a more general primer on the SCM framework). The covariates X, treatment W, and response Y are modeled in the SCM framework as random variables with joint distribution $P(X, W, Y)$. Each intervention, such as setting W to $w = 0$ or $w = 1$, defines an alternative distribution over (X, W, Y) that can be systematically deduced from the no-intervention (or observational) distribution P using the SCM model, and which is written $P(X, W, Y \,|\, do(W = w))$. In this framework, the CATE then becomes:

$$\tau(x) = \mathbb{E}[Y \,|\, do(W = 1), X = x] - \mathbb{E}[Y \,|\, do(W = 0), X = x];$$

and the ATE:

$$\tau = \mathbb{E}[Y \,|\, do(W = 1)] - \mathbb{E}[Y \,|\, do(W = 0)].$$

These expressions look similar to the corresponding expressions in the PO framework (Table 6.2) when one identifies the variable $Y(w)$ in the PO framework to the variable Y under the intervention $do(W = w)$ in the SCM framework, namely when we set $P(Y(w), X) = P(Y, X \,|\, do(W = w))$. In fact this analogy is valid in the sense that

any theorem that holds for SCM counterfactuals holds in the PO framework, and vice-versa (Pearl, 2009c, Chapter 7; Pearl, 2009b, Chapter 4).

In spite of this formal equivalence, the two frameworks differ in how they allow practitioners to express causal assumptions, and to derive corresponding estimands of causal effects. The SCM framework provides a convenient graphical representation known as causal diagram to encode potentially complex causal assumptions between variables, and provides a complete language known as *do*-calculus to express causal effects (i.e., some expectation under the $do(W = w)$ probability) as a function of observational data (i.e., some expectation under the no-intervention distribution) [Pearl, 1995, 2009c]. When this reduction is possible, the causal effect is called *identifiable*. In addition, the *do*-calculus is complete in the sense that a causal effect is identifiable if and only if it can be reduced to a function of observational data using *do*-calculus [Huang and Valtorta, 2006, Shpitser and Pearl, 2006]. Interestingly, this provides a variety of formulas to correctly infer causal effects even in the presence of unmeasured confounders, which cannot be handled by the PO framework (without additional structural and modeling assumptions), such as the front-door adjustment formula [Pearl, 1995].

Formulating transportability in the SCM framework. The SCM framework and *do*-calculus naturally cover the problem of generalizing an RCT experiment to a different target population. Following our notations in the PO setting (Subsection 6.2.1), we again denote by S a binary random variable that indicates which individuals can be in the RCT, and assume given an SCM model for (X, Y, W, S). The RCT population then follows the distribution $P(X, Y, W \mid S = 1)$, and by design the RCT allows estimating the conditional distributions $P(Y \mid do(W = w), X, S = 1)$ for $w = 0, 1$. The problem of generalization to the target population in this setting is then to deduce the distributions of $P(Y \mid do(W = w), X)$ for $w = 0, 1$ from these two distributions and the observed distribution of the covariates $P(X)$ in the target distribution (as in Section 6.3), or of the covariates, treatments and responses $P(X, W, Y)$ in the target population (as in Section 6.4). If this deduction (using *do*-calculus) is possible, then the causal effect on the target population is identifiable, and the deduction provides a formula for the causal effect that can then be estimated from a finite population using some consistent estimator.

Interestingly, this formalism covers two important situations: (i) the *sample selection bias* problem, when the RCT population is a subset of the target population that fulfills some eligibility criterion [4] , and (ii) the *transportability* problem, where the RCT population differs more drastically from the target, e.g., when one wants to generalize an RCT conducted in one country to a population in another country [Pearl, 2015]. To model sample selection bias, on the one hand, one typically adds a node S with incoming edges to a causal graph in order to capture the eligibility conditions that may depend on pre- or post-treatment variables. It is then possible to derive conditions under which one can recover from selection bias when the probability of selection is available [Cooper, 1995, Lauritzen and Richardson, 2008, Geneletti et al.,

4. This setting has been termed as *generalizability* in the introduction of the different study designs in Subsection 6.2.2.

2008] or when no quantitative knowledge is available about probability of selection [Didelez et al., 2010, Bareinboim and Pearl, 2012a]. We provide examples of such conditions in Appendix D.3.1.2. To model transportability to a different population, on the other hand, the node S has typically no incoming edge, and instead points to variables that differ between the RCT and the target population, either in their functional dependency to their parents in the causal graph, or in the distribution of their exogenous variables. The resulting graph is called a *selection diagram* and allows to encode graphically detailed assumptions about the differences between populations [Pearl and Bareinboim, 2011, Bareinboim and Pearl, 2012b, Pearl and Bareinboim, 2014, Bareinboim and Pearl, 2013].

Note that even if the two situations imply different causal diagrams, the problem of selection bias "*has some unique features, but can also be viewed as a nuance of the transportability problem, thus inheriting all the theoretical results of transportability*" [Pearl, 2015]; this remark is connected to the discussion from Subsection 6.2.2.

The SCM approach thus provides a powerful machinery to generalize causal effect across populations, and entails a detailed description of the causal assumptions between variables in the selection diagram, including the selection variable S. The two selection diagrams of Figure 6.2 represent for example transportability problems with a distributional change of covariates X between the RCT and target populations (with an arrow from S to X), and where the interventional nature of the RCT versus the target population is also represented with an arrow from S to W.



Figure 6.2 – Illustration of selection diagrams depicting differences between source and target populations: In (a) and (b), the two populations differ by covariate distributions (indicated by S pointing to X) and the two populations differ in their interventional nature (S pointing to W). Assumption 6.3.3 (transportability assumption) is assumed on (b), but not on (a) (since S points to Y in (a)). These two examples are inspired by Pearl and Bareinboim [2011].

In addition, in Figure 6.2(a) the arrow from S to Y indicates that the conditional distribution of Y given X and W differs between the two populations, which in general prevents any transportability of causal effect, while the lack of arrow from S to W in Figure 6.2(b) encodes the independence assumption $P(Y \mid X, W) = P(Y \mid X, W, S = 1)$, which implies the transportability assumption $P(Y \mid do(W = w), X, S = 1) = P(Y \mid do(W = w), X)$ (which itself implies Assumption 6.3.3 in the PO framework). In that case, one easily deduces by simple conditioning on X that

the distribution of Y under intervention on the whole population is given by

$$P(Y \mid do(W = w)) = \sum_x \underbrace{P(Y \mid do(W = w), X = x, S = 1)}_{RCT} \underbrace{P(X = x)}_{Obs.} . \tag{6.13}$$

This transport formula, also known as *re-calibration*, *re-weighting* or *post-stratification* formula [Pearl, 2015], thus combines experimental results obtained in the RCT population and the observational description of the target population to estimate the causal effect in the target population. In particular, we easily deduce the ATE on the target population by integrating (6.13) in Y to get

$$\tau = \sum_x \underbrace{\tau_1(x)}_{RCT} \underbrace{P(X = x)}_{Obs.}, \tag{6.14}$$

where $\tau_1(x)$ is by design identifiable by conditioning on treatment in the RCT population. This formula (6.14) is equivalent to the regression formula (6.10) in the PO framework, which is valid under Assumption 6.3.3. Interestingly, Pearl and Bareinboim [2011] show that the transport formula (6.13) holds more generally as soon as X is a set of pre-treatment variables which is *S-admissible*, i.e., if $S \perp\!\!\!\perp Y \mid X, do(W = w)$ for $w = 0, 1$. Graphically, S-admissibility holds whenever X blocks all paths from S to Y after deleting from the graph all incoming arrows into W. We note that S-admissibility implies the mean exchangeability assumption (Assumption 6.3.4) and is equivalent to the S-ignorability assumption $S \perp\!\!\!\perp Y(w) \mid X$ (Assumption 6.3.5) used in the PO framework when X and S are pre-treatment variables, and entails similar transport formula in that situation. However, the two notions differ for treatment-dependent selection and covariates, as discussed by Pearl [2015], where several examples illustrate how the S-admissibility assumption can lead to different transport formulas when both pre- and post-treatment variables are leveraged. Such an example is presented in Figure 6.3, where the covariate X is a post-treatment variable, for example a biomarker, believed to mediate between treatment and outcome.



Figure 6.3 – Post-treatment covariate adjustment: On this selection diagram the arrow from S to X indicates the assumption of different effect of W on X in the two populations. Here, X is S-admissible but not S-ignorable, and the corresponding transport formula is

$$P(Y \mid do(W = w)) = \sum_x P(Y \mid do(W = w), X = x, S = 1) P(X = x \mid W = w),$$

where it invokes an unconventional average of the CATE weighted by a conditional probability in the target population. This example is taken from Pearl [2015].

Finally, it is worth mentioning that the transportation problem discussed so far, to export a causal effect estimated in an RCT to a general population is only one specific instance of the more general problem of *data fusion* [Pearl and Bareinboim, 2011, Bareinboim and Pearl, 2012b, 2016, Hünermund and Bareinboim, 2019, Lee et al., 2020], which simultaneously accounts for confounding issues of observational data, sample selection issues, as well as extrapolation of causal claims across heterogeneous environments. The SCM framework, with its elegant way of formalizing the problem, helps practitioners formulate and discuss causal assumptions across variables and environments. In particular, subject to a good knowledge of the graph, it helps selecting sets of variables that are sufficient to establish identifiability and exclude variables that would bias the analysis. As we will see in Section 6.7, already in the early phase of a study, the causal and selection diagrams offer a very convenient tool to discuss with clinicians and explicitly lay out conditional independence assumptions. Once a diagram encodes assumptions about a system, algorithmic solutions implementing the *do*-calculus are available to determine whether non-parametric identifiability holds, and to provide correct formula if it holds [Correa et al., 2018, Tikka et al., 2019].

While the SCM framework provides a powerful and versatile set of concepts and tools to *identify* causal effects, there are still challenges in their applicability on real data to *estimate* causal effects, due to the finiteness of the samples, and practical estimators with publicly available implementations and detailed consistency, convergence rates or robustness results are still scarce. Some recent work has proposed solutions for this estimation task in the context of either experimental or observational data by extending weighting-based methods developed for the back-door case to more general settings [Jung et al., 2020b,a], or extending the double/debiased machine learning (DML) approach proposed by Chernozhukov et al. [2018a] under ignorability assumption to any identifiable causal effect [Jung et al., 2020b]. In the same spirit, Karvanen et al. [2020] propose combination of data from a survey and a meta-analysis of 34 trials, where identifiability and transport formula are the output of the algorithm `do-search` (see Section 6.6), and estimation is performed with the real data at hand. Additionally, even if a causal effect is not identifiable, partial-identifiability techniques have been proposed for deriving bounds for the causal effect [Tian and Pearl, 2000, Dawid et al., 2019]. Cinelli and Pearl [2020] give an example illustrating partial identifiability on real data, with experiments assessing the effect of the Vitamin A supplementation. In this setting the existence of experimental data from one source population leads to identify bounds on the transported causal effect, but the availability of two trials instead of one leads to a point estimate. Finally, Dahabreh et al. [2019c, 2020] propose an alternative approach for generalizability and integrative analyses of trials and observational studies using structural equation models under weaker error assumptions and represented using single world intervention graphs [Richardson and Robins, 2013].

6.6 – Software for combining RCT and observational data

6.6.1 Review of available implementations

A decisive point to bridge the gap between theory and practice is the availability of software. Practitioners use the methods with easily-available implementations, even when these methods have some shortcomings. In recent years, there have been more and more solutions for users interested in causal inference and causation, see Tikka and Karvanen [2017], Guo et al. [2019], Yao et al. [2020a] for surveys. One can mention the toolboxes doWhy [Sharma et al., 2019], econML [Microsoft Research, 2019], causalToolbox [Künzel et al., 2018]. There are also many standalone packages. However, one can regret that many implementations are 'one-shots', i.e., associated with a single article and not pushed further.

Regarding the specific topic of this chapter, we present in Table 6.3 the implementations available about both identifiability and estimators. The implementations found are mostly research-dedicated tools made public rather than user-friendly packages. Note that no implementation of stratification (6.4) was found. Most implementations do not handle categorical variables, or handle only continuous outcomes for example. In addition, the available implementations are often dedicated to specific sampling designs and estimators are different from nested and non-nested framework. As a consequence, a new user has to pay attention to all of these practical – but fundamental – details.

6.6.2 Example of usage

In this part we detail an identifiability question. Implementation examples for the nested case are presented in examples D.2.3.1 and D.2.3.2 in Appendix D.2.

Identifiability queries The R packages `causaleffect` [Tikka and Karvanen, 2017] and `dosearch` [Tikka et al., 2019] can be used for causal effect identification, with the latter handling transportability, selection bias and missing values (bivariates) issues simultaneously. In this package, the `dosearch` function takes the observable distributions, a query, and a semi-Markovian causal graph as input and outputs a formula for the query over the input distributions, or decides that it is not identifiable. It is based on a search algorithm that directly applies the rules of *do*-calculus. Their general identification procedure is not necessary complete given an arbitrary query and an arbitrary set of input distributions. In order to retrieve the backdoor criterion from Pearl [2009a], one can write:

```
data <- "P(Y, X,Z)"
query <- "P(Y|do(X))"
graph <- "X -> Y
          Z -> X
          Z -> Y"
dosearch(data, query, graph)
```

Table 6.3 – Inventory of publicly available code for generalization (top: software for identification; bottom: software for estimation).

Name	Method - Setting	Source & Reference
Identification		
causaleffect	Identification and transportation of causal effects, e.g., conditional causal effect identification algorithm	R package on CRAN, Tikka and Karvanen [2017]
dosearch	Identification of causal effects from arbitrary observational and experimental probability distributions via *do*-calculus	R package on CRAN, Tikka et al. [2019]
Causal Fusion	Identifiability in data fusion framework (Section 6.5)	Browser beta version upon request Bareinboim and Pearl [2016]
Estimation		
ExtendingInferences	IPWS equation (6.3), g-formula equation (D.3) – Nested AIPSW (D.5) - Nested Continuous outcome	R code on GitHub, Dahabreh et al. [2020]
generalize	IPSW equation (6.3), TMLE (Section 6.3.2.4)	R package on GitHub Ackerman et al. [2020]
genRCT	IPSW equation (D.1) – Nested, calibration weighting (Section 6.3.2.4) Continuous and binary outcome	R package available upon request Dong et al. [2020]
IntegrativeHTE	Integrative HTE (Section 6.4.2)	R package on GitHub, Yang et al. [2020a]
IntegrativeHTEcf	Includes confounding functions (Section 6.4.2)	R package on GitHub, Yang et al. [2020a]
generalizing	SCM with probabilistic graphical model for Bayesian inference Binary outcome	R package on GitHub, Cinelli and Pearl [2020]
RemovingHidden Confounding	Unmeasured confounder (Section 6.4.2)	R package on GitHub, Kallus et al. [2018b]

```
$identifiable
[1] TRUE
$formula
[1] "[sum_{Z} [p(Z)*p(Y|X,Z)]]"
```

Beta version of `causalfusion` The beta version of `causalfusion` [Bareinboim and Pearl, 2016] can be used, with a user-friendly interface requiring no coding

skills. For example, if uploading the selection diagrams from Figure 6.2 onto this interface, it will state that diagram (a) is not transportable, while (b) is transportable along with the correct transport formula. The authors also propose to load onto the interface their diagrams from previous publications and research works, some of which have been discussed in this review.

6.6.3 Simulation study of the main approaches

This part presents simulation results to illustrate the different estimators introduced and their behavior under several mis-specification patterns. The code to reproduce the results is available on Gitlab [5]. Note that except for the calibration weighting, all the estimators are implemented by the authors to correspond exactly to the formulas introduced in the review (IPSW and IPSW.norm (6.3), stratification (6.4), g-formula (6.5), and AIPSW (6.8)).

Well-specified models We consider the framework of Section 6.3 where the observational study contains neither outcome nor treatment and the aim is to estimate the causal effect on the target population. We use similar simulations as in Dong et al. [2020], where four covariates are generated independently as with $X_j \sim \mathcal{N}(1,1)$ for each $j = 1,\dots,4$. The trial selection scores are defined using a logistic regression model:

$$\text{logit}\left\{\pi_S(X)\right\} = -2.5 - 0.5\,X_1 - 0.3\,X_2 - 0.5\,X_3 - 0.4\,X_4. \tag{6.15}$$

The outcome is generated according to a linear model:

$$Y(w) = -100 + 27.4\,w\,X_1 + 13.7\,X_2 + 13.7\,X_3 + 13.7\,X_4 + \epsilon \text{ with } \epsilon \sim \mathcal{N}(0,1). \tag{6.16}$$

This outcome model implies a target population ATE of $\tau = 27.4\,\mathbb{E}[X_1] = 27.4$. Note that the sample selection ($S = 1$) in (6.15) is biased toward lower values of X_1 and consequently toward lower treatment effect.

To generate a non-nested trial, we proceed as follows. First a sample of size $50,000$ is drawn from the covariate distribution. From this sample, the selection model (6.15) is applied which leads to an RCT sample of size $n \sim 1000$. Then, the treatment is generated according to a Bernoulli distribution with probability equals to 0.5, $e_1(x) = e_1 = 0.5$. Finally the outcome is generated according to (6.16). The observational sample is obtained by drawing a new sample of size $m = 10,000$ from the distribution of the covariates.

Figure 6.4 presents estimated ATEs with the inverse propensity of sampling weighting with and without weights normalization (IPSW and IPSW.norm; Section 6.3.2.1), stratification (with 10 strata; Section 6.3.2.1), g-formula (Section 6.3.2.2), calibration weighting (CW; Section 6.3.2.3), and augmented IPSW (AIPSW; Section 6.3.2.4) over 100 simulations. All estimators are implemented by the authors, except for the CW implementation which comes from Dong et al. [2020]. The true ATE is represented with a dashed line. The ATE estimated only with the RCT sample is

5. `https://gitlab.inria.fr/misscausal/combine-rct-rwd-review`



Figure 6.4 – Well-specified model. Estimated ATE with the inverse propensity of sampling weighting with and without weights normalization (IPSW and IPSW.norm; Section 6.3.2.1), stratification (with 10 strata; Section 6.3.2.1), g-formula (Section 6.3.2.2), calibration weighting (CW; Section 6.3.2.3), and augmented IPSW (AIPSW; Section 6.3.2.4) over 100 simulations.

also displayed as a baseline. As expected it is biased downward (its mean is equal to 14.24) as the distribution of the covariates and in particular the treatment effect modifiers such as X_1 is not the same in the trial sample and in the population (as illustrated in Table D.5 in Appendix D.4). Note that all the estimators are unbiased which is expected. The variability of the two IPSW estimators is larger than for the others. The number of strata in the stratification estimator plays an important role. As shown in Figure D.6, the results in this study are biased when the number of strata is smaller than 10.

Mis-specification of sampling propensity score or outcome model To study the impact of mis-specification of the sampling propensity score model, we generate the RCT selection according to the model

$$\text{logit}\left\{\pi_S(X)\right\} = -2.5 - 0.5\, e^{X_1} - 0.3\, e^{X_2} - 0.5\, e^{X_3} - 0.4\, e^{X_4} + 3,$$

and outcome according to the model

$$Y(w) = -100 + 27.4\, w\, X_1 X_2 + 13.7\, X_2 + 13.7\, X_3 + 13.7\, X_4 + \epsilon.$$

The analysis is then performed using classical logistic and linear estimators. As shown in Figure 6.5, when the sampling propensity score model is mis-specified,



Figure 6.5 – Mis-specified models. Estimated ATE when RCT and/or outcome models are mis-specified. Estimators used being IPSW (IPSW and IPSW.norm), stratification (with 10 strata), g-formula, calibration weighting (CW), and augmented IPSW (AIPSW) over 100 simulations.

the IPSW estimators are biased; whereas when the outcome model is mis-specified, the g-estimator is biased. In both settings, the double robust estimator (AIPSW) is unbiased and robust to mis-specification. In the case where both models are mis-specified, all estimators are biased except the CW estimator. This demonstrates some robust properties of calibration against slight model mis-specification.

Stronger distributional shift The above sampling propensity score model implies a weak covariate shift between the RCT sample and the observational sample. A stronger shift can be obtained, at least on covariate X_1, swapping the coefficient $-0.5X_1$ with $-1.5X_1$. Figure 6.6 shows that the variance of the weighted and CW estimators have increased in the setting with a stronger covariate shift. Figure 6.6(a) illustrates the different strength of the distributional shifts, and Figure 6.6(b) presents estimated ATE if the RCT sample is either weakly or strongly shifted w.r.t. the target population distribution.



(a) Distributional shift on X_1



(b) Simulation results

Figure 6.6 – Weak versus strong distributional shift between experimental and observational data. Estimators used being IPSW (IPSW and IPSW.norm), stratification (with 10 strata), g-formula, calibration weighting (CW), and augmented IPSW (AIPSW) over 100 simulations.

Impact of the treatment-effect modifiers In this part, we consider a heterogeneous treatment effect setting where X_1 impacts the RCT sampling while also being a treatment effect modifier. We consider the IPSW estimator and its variations without using X_1 (labeled as IPSW.without.X1) and using only X_1 (labeled as IPSW.X1). As shown in Figure 6.7, IPSW.X1 is still unbiased when using only X_1 in the sampling propensity score estimation, as it is the only covariate being the treatment effect modifier. However, if X_1 is missing, the resulting estimator IPSW.without.X1 is strongly biased. Therefore, it is important to include all variables that affect both sampling and outcome to adjust for bias. We also conjecture that including outcome predictors that do not affect sampling may increase the efficiency of the estimator.

Note also that if the treatment effect was homogeneous (does not depend on X_1), then the estimated ATE on the RCT would be unbiased (as shown in Figure D.7 in Appendix D.4.3) so in this setting there is no need to use the observational data and associated methods to transport the ATE from the trial to the target population.



Figure 6.7 – Impact of treatment-effect modifiers. Estimated ATE when IPSW estimator includes all covariates, only X_1, or all covariates except X_1, with g-formula presented as a control, over 100 simulations. Simulations are still performed with (6.15) for RCT eligibility and (6.16) for outcome modeling.

6.6.4 Practical summary of reviewed estimators

While simulation studies are helpful to get a better understanding of the different estimators and their relative performance under different simulation settings, in practice, it often remains challenging to choose an appropriate (set of) estimators for a given problem. In Table 6.4 we provide a compressed summary of the different estimators' properties to guide the choice of an appropriate estimator depending on the concrete problem and data.

Note that the complete proofs of consistency for the non-parametric case can be found in Colnet et al. [2021].

6.7 – Application: Effect of Tranexamic Acid

To illustrate the methodological question of combining experimental and observational data and demonstrate how to apply some of the previously discussed methods, we consider a currently open medical question about major trauma patients. We focus again on trauma patients suffering from a traumatic brain injury (TBI) and the drug tranexamic acid (TXA) which is an antifibrinolytic agent that limits excessive bleeding, commonly given to surgical patients. Previous clinical trials showed that TXA decreases mortality in patients with traumatic *extracranial* bleeding [Shakur-Still et al., 2009]. Such prior result raises the possibility that it might also be effective in TBI, because *intracranial* hemorrhage is common in TBI patients. Therefore the question here is to assess the potential decrease of mortality in patients with intracranial bleeding when using TXA.

To answer this question, we have at disposal both a RCT, named CRASH-3, and the previously introduced observational Traumabase® registry. Both data have previously been analyzed separately in Cap [2019] (for the RCT) and in Chapter 4 (for the observational study) and the medical teams of both studies want to share their

Table 6.4 – Summary table of reviewed estimators for the the generalization task (see Section 6.3).

	Consistency	(Local) efficiency	Double robustness	Missing values/variables	Implementation	Advantages	Inconveniences
IPSW (6.3)	✓	✗	✗	✗	✓	Sandwich-type variance estimators or non-parametric bootstrap variance estimators exist. Normalized weights can be used to overcome the variability issue.	Requires correct model specification of π_s; very unstable and high variability when the selection scores are extreme (when the trial study contains units with very small probabilities of being in the trial).
Stratification (6.4)	✓	✗	✗	✗	✓	Preferable over IPSW in case of small selection scores	Less effective in reducing bias than IPSW Kang et al. [2007].
G-formula (6.5)	✓	✗	✗	✗	✓	Possible use of BART [Kern et al., 2016]; empirically lowest variance among all other estimators in case of correct model specification [Dahabreh et al., 2019b]	In practice not well performing for high-dimensional data.
CW (6.7)	✓	✗	✓	✗	✓	Bootstrap procedure proposed by Dong et al. [2020] to estimate the estimator's variance.	Requires either loglinear selection score or a CATE that is linear in the CW
ACW (6.8)	✓	✓	✓	✗	✓	Allows the use of non-parametric nuisance parameters	Sensitivity to unmeasured covariates in observational dataset not studied yet.
AIPSW (6.8)	✓	✓	✓	✗	✓	Easily implementable and existing sandwich-type variance estimators.	Can have bad performances in terms of bias and variance in case of double mis-specification [Kern et al., 2016].
TMLE [Rudolph and van der Laan, 2017]	✓	✓	✓	✗	✓	Empirically good finite sample performance; recommended for high-dimensional covariate space; variance estimation through efficient influence curve.	Sensitive to positivity violations
BART [Kern et al., 2016]	✗	✗	✗	✗	✓	Empirically good performances in terms of bias and RMSE [Kern et al., 2016], recommended in case of suspected treatment covariate interactions and treatment effect heterogeneity.	Lack of theoretical guarantees for this approach.

respective data to answer both medical and methodological questions. Such initiatives allow to confront and combine the evidence obtained from the observational data set using causal inference estimators with the evidence obtained from the CRASH-3 randomized controlled trial. In particular it allows to:

— Benchmark the observational study with the RCT. As the treatment effect was estimated with a recent doubly robust estimator handling missing data, its adoption by the community could be reinforced using the RCT's result to validate the estimated effect.

— Assess the generalizability and transportability methods, considering the Traumabase® as the target population, and confront the estimators presented in this review to a real situation.

We will first present the two data sources, treatment effect analyses and findings from these, before turning to the combined analysis in Section 6.7.3. The code to reproduce all analyses for this application is available on GitLab [6], even if the medical data cannot be publicly shared for privacy reasons.

6.7.1 The observational data: Traumabase

To improve decisions and patient care in emergency departments, the Traumabase® group, which comprises 23 French Trauma centers, collects detailed clinical data from the scene of the accident to the release from the hospital. We refer to Chapter 3 for a detailed introduction of this project. At the moment of the presented study, the Traumabase® registry contained around 8,270 patients suffering from TBI. A first study was performed to assess the effect of TXA on mortality for traumatic brain injury patients from this observational registry (see Chapter 4 and Appendix G). More precisely, the treatment variable is the administration of TXA during pre-hospital care or on admission to a Trauma Center [7] and considered to have occurred within three hours of the initial trauma. In these used Traumabase® data, TXA is administered to roughly 8.2% of patients suffering from TBI, and 20% die before the end of their hospital stay. Notably, mortality is much higher among patients who receive TXA than those who do not (30% vs. 14%). This situation is a classical example of confounding bias: the effect arises because patients who appear to be in more severe state are more likely to be administered TXA and are also more likely to die, with or without the treatment.

Before turning to the causal analysis on these data, we first discuss an important practical aspect, namely missing values, and how we handle them in the subsequent analyses.

6. `https://gitlab.inria.fr/misscausal/combine-rct-rwd-review`

7. More precisely, to the resuscitation room of a hospital equipped to treat major trauma patients.

6.7.1.1 Missing values

The problem of missing values is ubiquitous in data-analysis practice and particularly present with observational data, as they are not necessarily collected for research purposes. The Traumabase® is a high-quality dataset but, nevertheless, missing values occur as it has been discussed intensively in Chapter 4, see e.g., the proportions of missing values in a subset of relevant variables reported on Figure 4.1.

6.7.1.2 Covariate adjustment

Since the Traumabase® is an observational registry, straightforward treatment effect estimation on these data is not possible due to confounding. The causal graph from Figure 4.6 is the result of a two-stage Delphi method [Dalkey and Helmer, 1963] in which six anesthetists and resuscitators specialized in critical care—and therefore familiar with the allocation process for TXA—first selected covariates related to either treatment or outcome or both, and second classified these covariates into confounders and predictors of only treatment or outcome. Even though it is not possible to test for unobserved confounding, this Delphi procedure is an attempt to gather as much expert knowledge about the studied question as possible to manually identify possible confounders and qualitatively assess the plausibility of the unconfoundedness assumption. Note that this approach is an explicit example where we leverage the advantages of the SCM and PO frameworks: the causal graph helps to select relevant variables during the conception phase of the study, and the treatment effect analysis uses different estimation methods from the PO framework.

6.7.1.3 Results

We adjust for confounding using the identified confounders and use additional predictors for the outcome model (see Figure 4.6 from Chapter 4), to estimate the direct causal effect of TXA on 28-day intra-hospital TBI-related mortality and on all cause intra-hospital mortality among traumatic brain injury patients (for the latter see results of Chapter 4). The two methods presented here for handling missing values are multiple imputation via chained equations (MICE) [van Buuren, 2018] and missing incorporated in attributes (MIA) [Twala et al., 2008]; the treatment effect estimation is then performed using either logistic regressions or generalized random forests [Athey et al., 2019], denoted respectively by *GLM* and *GRF* in Table 6.5.[8] The doubly robust results (AIPW) in Table 6.5 show that from this study there is no evidence for an effect of TXA on mortality of TBI patients. However, when considering the IPW estimations, the conclusion differs in that they indicate a deleterious effect of the drug for almost all subgroups considered, for both definitions of the outcome. These findings might be due to inaccurate estimations of the propensity scores used for the reweighting, for instance due to possible model mis-specification for the parametric approach and to insufficient sample sizes or

8. Note that another method for handling the missing values could theoretically be used, namely EM for logistic regression [Jiang et al., 2020]. In this application however, this method is not (yet) adapted due to the large number of mixed covariates.

machine learning regulation bias for the non-parametric random forest approach. In the non-parametric case, the doubly robust approach can compensate the slow convergence of the non-parametric propensity model estimations with the outcome model estimations and correct for the regularization bias that comes from fitting predictive models using machine learning, while there is no such bias correction for the IPW approach and in case of insufficient the latter would also require additional samples to estimate the propensity scores sufficiently well. Additionally, note the large variability of the parametric IPW and AIPW estimators (*GLM*) which could also support the remark on possible model mis-specification. [9] In such a situation, the possibility to transport the treatment effect from the RCT is also a step to comfort the results.

The AIPW findings on the data—obtained prior to the publication of CRASH-3—are consistent with the main conclusion of the CRASH-3 study (no effect). Results are presented in Table 6.5). As patients can be stratified based on trauma severity, analyses on sub-strata can also be performed, but are only reported in the Appendix D.5.

Table 6.5 – ATE estimations from the Traumabase® for TBI-related 28-day mortality. Red cells conclude on deteriorating effect, white cells conclude on no effect. Additional results can be found in Table D.1 in Appendix D.5.

	Multiple imputation (MICE)				MIA		Unadjusted ATE $\times 10^2$
	IPW (95% CI) $\times 10^2$		AIPW (95% CI) $\times 10^2$		IPW (95% CI) $\times 10^2$	AIPW (95% CI) $\times 10^2$	
	GLM	GRF	GLM	GRF			
Total ($n = 8,248$)	15 (6.8, 23)	11 (6.0, 16)	3.4 (-9.0, 16)	-0.1 (-4.7, 4.4)	9.3 (4.0, 15)	-0.4 (-5.2, 4.4)	16

6.7.2 The RCT: CRASH-3

A total of 175 hospitals in 29 different countries participated to the randomized and placebo-controlled trial, called CRASH-3 [Dewan et al., 2012], where adults with TBI suffering only from intracranial bleeding, i.e., without major extracranial bleeding, were randomly administrated TXA [Cap, 2019]. The inclusion criteria of the trial are patients with a Glasgow Coma Scale (GCS) [10] score of 12 or lower or any intracranial bleeding on CT scan, and no major extracranial bleeding, leading to 9202 patients (which is uncommonly large for a medical RCT). We provide a DAG summarizing the trial selection and addition regressors present in CRASH-3 of the outcome in Figure 6.8.

The primary outcome studied is head-injury-related death (not simply death) in hospital within 28 days of injury in patients treated within 3 hours of injury. Six

9. Larger variance of the IPW is often observed when comparing to AIPW, independently of the nuisance parameter approach.

10. The Glasgow Coma Scale (GCS) is a neurological scale which aims to assess a person's consciousness. The lower the score, the higher the severity of the trauma.



Figure 6.8 – Causal graph for the CRASH-3 trial representing treatment, outcome, inclusion criteria with S and other predictors of outcome (Figure generated using the Causal Fusion software presented in Section 6.6 from Bareinboim and Pearl [2016]).

covariates are present at baseline, with age, sex, time since injury, systolic blood pressure, Glasgow Coma Scale score (GCS), and pupil reaction. The study concludes that the risk of head-injury-related death was 18.5% in the TXA group versus 19.8% in the placebo group (855 vs 892 events; risk ratio [RR] 0.94 [95% CI 0.86 - 1.02]), i.e, there is no effect of TXA on mortality when considering the total sample. The rest of the data analysis focuses on the effect on the total sample as well.

6.7.3 Transporting the ATE on the observational data

With the two separate analyses in mind, we are now ready to tackle the combined analysis, namely the generalization from the RCT results to the target population defined by the observational Traumabase® data.

6.7.3.1 Common covariates description

In the following, we discuss common variables definition, outcome, treatment, and designs in order to leverage both sources of information. We recall the causal question of interest: "What is the effect of the TXA on brain-injury death on patients suffering from TBI?" This part is important for the harmonization of the study protocol.

Treatment exposure The treatment protocol of CRASH-3 frames the timing and mean of administration precisely (a first dose given by intravenous injection shortly after randomization, i.e., within 8 (resp. 3) hours of the accident, and a maintenance dose given afterwards [Dewan et al., 2012]). For consistency with the original CRASH-3 study described above, we also only keep observations from the RCT with administration within 3 hours. The Traumabase® study being a retrospective analysis, this level of granularity concerning TXA is not available. Neither the exact timing, nor the type of administration are specified for patients who received the drug. However, the expert committee agreed that the assumption of

treatment within 3 hours of the accident is very likely since this drug is administered in pre-hospital phase or within the first 30 minutes at the hospital.

Outcome of interest The CRASH-3 trial defined its primary outcome as head injury-related death in hospital within 28 days of injury. For the Traumabase® data we also look at death in hospital within 28 days but with a wider range of possible causes of death, namely TBI, brain death, multiple organ failure, brain death, or withdrawal of life-sustaining therapy. This slightly different definition for the Traumabase® outcome allows to obtain medically similar outcomes despite different data collection processes.

Multi-centered design Both studies are multi-centered, but while the Traumabase® is a French registry with 20 participating Trauma Centers, the CRASH-3 trial enrolled patients in various countries on different continents. While this large spectrum of participating centers is likely to contribute to external validity of the CRASH-3 trial, it should be noted that more than 65% of the patients included were from developing countries; regions of the world that differ from developed countries by a prolonged pre-hospital care period, limited access to brain imaging tests and neurosurgery within short periods of time, and the absence of expert centers for heavy trauma and neuro-intensive care. Thus, on top of the restrictive inclusion criteria of the RCT, this aspect of large heterogeneity in the participating Trauma centers motivates the combination both studies to estimate the effect for a population with access to a specific high level of care, here represented by the French Trauma centers.

Covariates accounting for trial eligibility In total, four criteria depending on five variables determined inclusion in the CRASH-3 trial: age (only adults were eligible), presence of TBI (defined as presence of intracranial bleeding on the CT scan, or a GCS of less than 13 in the case of no available CT scan), absence of major extracranial bleeding (defined explicitly in CRASH-3 and defined via the number of packed red blood cells transfused in the first 6 hours of admission or by colloid injection in the Traumabase), and delay of less than 8 hours (later reduced to 3 hours) between the injury and the randomization. The necessary variables are also available in the Traumabase®, either exactly or in form of proxies, which allows the estimation of the trial inclusion model on the combined data.

Additional covariates Note that other covariates are available in both data sets, while not responsible of trial inclusion according to CRASH-3 investigators. But as this could still be covariates moderating the outcome and treatment effect, we included them. According to the two data sets, we could add three of them: sex (binary), systolic blood pressure (continuous), and pupils reactivity (categorical, ranging from 0 to 2, being the number of active pupils). Note that this three covariates are all mentioned in the baseline of CRASH3 results [Cap, 2019], arguing that they should impact the outcome.

6.7.3.2 Descriptive analyses

Missing values First, note that the RCT contains almost no missing values, whereas the variables for determining eligibility in the observational data contains important fractions of missing values, as shown in Table 6.6, while the sample sizes of the two data are similar, see Table 6.7. This requires a modification of the methods introduced in this review and illustrated in the simulations section in order to account for these missing values. For correctly estimating the trial inclusion model and the outcome models (Section 6.3.2), we need to handle the missing values in the covariates, especially in the observational data.[11] This modification consists in two alternative estimation strategies for fitting the trial inclusion and outcome models:

— Logistic regression with incomplete covariates using an expectation maximization algorithm [Dempster et al., 1977]. A computationally efficient variant of this method using stochastic approximation is implemented in the R package `misaem` [Jiang et al., 2020].

— Generalized regression forest with missing incorporated in attributes [Twala et al., 2008, Josse et al., 2019]. This method is implemented in the R package `grf` [Tibshirani et al., 2020].

Table 6.6 – Percentage of missing values in each covariate for the Traumabase® and CRASH-3.

	Major Extracranial	Age	Glasgow initial	SystolicBlood Pressure	Sex	Pupil Reactivity
CRASH-3	0	0	0.69	0.25	<0.1	<0.1
Traumabase	0	0.27	2.0	29	0.76	2.0

Table 6.7 – Sample sizes for both studies.

	Traumabase			CRASH-3		
	m	#treated	#death	n	#treated	#death
Total (within 3 hours)	8248	683	1411	9168	4632	1745

Distribution shift There are different ways of assessing the shift between the distributions of the two studies, for instance by univariate comparisons. We provide a simplified comparison of the means of the covariates between the treatment groups of the two studies in Figure 6.9. This graph illustrates again the fundamental difference between the two studies, namely the treatment bias in the observational study and the balanced treatment groups in the RCT. Another representation of the distribution shift is presented in the Appendix D.5 with histograms (Figures D.8 –D.12).

11. If we assumed the missing values being missing completely at random (MCAR), we could "throw away" the incomplete observations and perform the analyses on the complete observations, but this would reduce the total sample size by 917. And as explained in Chapter 4, the MCAR assumption is not plausible for the present observational data, thus such a *complete case analysis* would be biased.



Figure 6.9 – Distributional shift and difference in terms of univariate means of the trial inclusion criteria (red: group mean greater than overall mean, blue: group mean less than overall mean, white: no significant difference with overall mean, numeric values: group mean (resp. proportion for binary variables). Graph obtained with the `catdes` function of the `FactoMineR` package [Lê et al., 2008].

6.7.3.3 Analyses

Notations and estimator details We use two consistent ATE estimators from the solely CRASH-3 data:

— `Difference_in_mean`: the difference in mean estimator (see Definition 1.4.1, Chapter 1);

— `Difference_in_condmean_ols` the difference in conditional mean fitting an outcome model with an OLS (see Definition 1.4.2, Chapter 1).

To transport the ATE to the target population, we apply the estimators discussed in this review (with the additional handling of the missing values as outlined in the previous section), namely:

— IPSW (6.3): with sampling propensities estimated via logistic regression (`EM_IPSW_glm`) or via generalized random forest (`MIA_IPSW_grf`);

— normalized IPSW (6.3): with sampling propensities estimated via logistic regression (`EM_IPSW.norm_glm`) or via generalized random forest (`MIA_IPSW.norm_grf`);

— G-formula (6.5): with outcome models estimated via logistic regression (`EM_G-formula_glm`) or via generalized random forest (`MIA_G-formula_grf`);

— AIPSW (6.8): with sampling propensities and outcome models estimated via logistic regression (`EM_AIPSW_glm`) or via generalized random forest (`MIA_AIPSW_grf`).

The confidence intervals of these estimators are computed with a stratified bootstrap in the RCT and the observational data set in order to maintain the ratio of relative sizes of the two studies (with 100 bootstrap samples). Note that the

Calibration Weighting (CW) estimators are not used in this analysis as it would require a specific adaptation in the case of the missing values. Propensity score methods and outcome modeling methods are more straightforward to adapt to the missing data situation with off-the-shelf computational tools. Since this topic combines missing data assumptions with the specific assumptions for the goal of generalization, the specific validity domain for each estimator remains an open-research work.

We also present the estimators for the observational study applied solely on the Traumabase® data. For details about the derivation and properties of these estimators applied on incomplete observations we refer to Section 4:

— AIPW with nuisance parameters via logistic regression (`AIPW_glm`),

— AIPW with nuisance parameters via generalized random forest (`AIPW_grf`).

Since AIPW combined with either missing incorporated in attributes (`MIA`) or multiple imputation (`MICE`) is recommended when analyzing observational data, these are the estimators kept in this analysis. These estimators are built upon the unconfoundedness assumption and as outlined in Section 6.7.1, the list of identified confounders comprises 17 variables, complemented with 21 variables predictive of the outcome but not related to the treatment. Hence the results of the observational study depend on these 38 variables while the generalization results are using a different set of variables, namely three of the five variables that determine treatment eligibility [12] and the additional three baseline covariates susceptible to moderate outcome and treatment effect.

Final results As we can observe on Figure 6.10, the generalization from the RCT to the target population using all the observations from both data sets, presents certain discrepancies with respect to the two previous studies. On the one hand, half the generalization estimators support the CRASH-3 conclusion about the treatment effect: no significant effect. On the other hand, some estimators support a deleterious treatment effect (corresponding to a positive ATE). Note that the AIPW ATE estimations from the solely Traumabase® data do not reject the null hypothesis of no treatment effect. The analysis can also be performed on a imputed Traumabase® data set, the corresponding results are presented in appendix on Figure D.17. Note that these results are to be interpreted carefully due to the potential impact of missingness on the performance of the chosen estimators. For instance, note the large confidence intervals for the `GRF` estimators that are likely to be due to the imbalanced proportions of missing values in the RCT and the observational data.

Here we present the results transported onto the total TBI Traumabase® population, but the CRASH-3 study focuses on subgroups of patients (mild and moderate patients) for which a positive effect of the tranexamic acid is measured. The generalization of the CRASH-3 findings onto this subgroup in the Traumabase® raises multiple methodological issues that still need to be addressed in future works and that we detail in the Appendix D.5.

12. We filter the CRASH-3 population using the remaining two variables, TBI and delay between injury and randomization, therefore these variables are removed for the remainder of the analysis.



Figure 6.10 – Juxtaposition of different estimation results with ATE estimators computed on the Traumabase® (observational data set), on the CRASH-3 trial (RCT), and transported from CRASH-3 to the Traumabase® target population. All the observations are used. Number of variables used in each context is given in the legend.

Overall this data analysis highlights practical limitations that can be encountered when combining two different data sets: the need for a good understanding of the common covariates, exposure, and outcome of interest before combining the data sets, different missing data patterns, and poor overlap when considering specific target (sub-)populations.

6.8 – Summary, recommendations, and shortcomings

Combining observational data and RCTs can improve many aspects of causal inference, from increased statistical power to better external validity. Questions on external validity arise as soon as there are heterogeneities in the populations under study, whether these be heterogeneities of a treatment effect or simply heterogeneities of outcome. And yet, most effects of interest have some form of heterogeneity: mortality rates increase with age, different populations are exposed to different risks, have different comorbidities, etc. Generalization challenges may arise even for homogeneous treatment effects, as developed by Cinelli and Pearl [2020] in a thought experiment on the Russian Roulette: its treatment is homogeneous –for every game, there is one chance out of six of dying– but the average treatment effect may differ across populations since the chances of dying of other independent reasons

differ. To come to clear conclusions, an RCT is often run on a more homogeneous subpopulation. The definition of the corresponding inclusion criteria is then crucial. Observational data can help defining these inclusion criteria, and the methods reviewed in the present chapter, combining the RCT and observational data, can extrapolate the results of the RCT to different populations, supplementing other RCTs with different inclusion criteria. These statistical methods are crucial to explore potential heterogeneities left aside in the RCT. A plethora of settings is associated with a variety of identifiability criteria and estimators. Yet, whether in the potential-outcomes or in the structural causal models framework, the number of methods for combining experimental and observational data with treatment and outcome is still limited.

Identifiability: which data to answer our question? Domain expertise can be used to postulate a causal graph: a directed acyclic graph representing the mechanisms (as Figure 6.8). The SCM framework is then convenient to see whether the question at hand can be formulated in an identifiable way. It offers a principled way of selecting variables needed for identification of the causal effect and to avoid biased causal effects, such as conditioning on the wrong covariates.

Without such an approach, identifiability claims are limited and the recommendation is often to include as many as possible to be sure to avoid violation of any assumption: "it is probably best to include as many outcome predictors as possible in regression models for the expectation of the outcome or the probability of trial participation" [Dahabreh and Hernán, 2019].

Selecting a small number of covariate can help reducing the variance of estimators. Some developments in the broad settings of causal inference –and not dedicated to fusion of experimental and observational data– use causal graphs to select between different adjustment sets to get estimators with smaller variance [Rotnitzky and Smucler, 2019, Witte et al., 2020, Guo and Perković, 2020].

Challenges in the SCM framework A challenge in the use of the SCM framework is that, to fully exploit its potential, it requires a graph, much more detailed than the one we could establish for the Traumabase® analysis. The consortium of clinicians managed to formulate groups of variables to identify confounders but not the precise links between all (or a set of) these variables.

Also, the current developments of the SCM framework mention neither treatment effect heterogeneity nor explicitly state the differences between nested and non-nested designs. Finally, the corresponding literature is typically useful to the practitioner for variable selection, but lacks estimators that can be readily instantiated on the data –with the notable exception of Cinelli and Pearl [2020] in a Bayesian setting.

Estimation: what are the treatment effects in wider populations? For causal effects on a combination of experimental and observational data, available estimators mostly lie in the potential outcome framework. Estimation typically relies on a propensity score –modeling trial participation– or outcome-regression models. Weakly-parametric models such as machine-learning estimators or estimators coping

with missing values can be used both, enabling a large class of functional forms. A different approach is that of calibration weighting, which rather relies on balancing the functions of the covariates. Theoretical properties of different estimators, and their behavior in our experimental study, outline practical recommendations. Calibration weighting and doubly-robust methods (AIPSW) are more robust to mis-specification. Calibration weighting is more robust than doubly-robust methods which break down if both the propensity-score and the outcome regression model are mis-specified (Figure 6.5). But, on the other hand, calibration weighting suffers more variance in case of large shifts of the causal effect between the RCT and the observational data (Figure 6.6) and is expected to break down with large dimension of covariates when there is no natural function to match. Modeling the probability of trial participation via stratification can help if this probability takes very high or very low value; however definition of the strata –in particular their number– can be important. If chosen too small, results are biased towards the RCT (Figure D.6), akin to a typical bias-variance compromise. Any model of trial participation must correctly capture the treatment-effect modifiers, in the sense of heterogeneous treatment effect (Figure 6.7). As a consequence, the data collection and modeling should focus of on covariates likely to modulate the treatment effect. For reliable causal conclusions, a good knowledge of the data and the mechanisms at hand is crucial. Indeed, not only is it important to formulate good models of the response or the selection biases, but also different settings, i.e, the nested and non nested design, lead to different estimators (this is often implicit in the publications). A few estimators are readily available, but they must be used for the particular design they were conceived for.

Challenges to handle missing values We have seen the need to account for missing values. Missing values occur more often in observational data since RCT typically deploy significant efforts to avoid them, but they are not immune to participants missing scheduled visits or completely dropping out from the study. The literature for RCT mainly focuses on missing outcome data and calls for sensitivity analysis giving that available strategies (weighting, multiple imputation) rely on untestable assumptions on the missing values mechanism [Carpenter and Kenward, 2007, National Research Council, 2010, Kenward, 2013, O'Kelly and Ratitch, 2014, Li and Stuart, 2019, Cro et al., 2020]. In observational studies, many methods are available relying on different assumptions either on the missing values mechanism or on the identifiability conditions of the causal effect (see Chapter 4).

Missing values may lead to subtle biases in the inferences, as they are seldom uniformly distributed across both datasets—missing more in one than in the other. We will consider this issue in the next chapter and propose solutions for ensuring identifiability and estimation of generalized treatment effects.

An extreme case of missing information arises from the fact that observational data and clinical trials are seldom collected to be analyzed jointly. As such, they typically measure different covariates. The common practice to analyze these data jointly consists in only considering the covariates present in both data. However, throwing away covariates leads to lost opportunities to characterize better confounding effects and variables responsible for trial eligibility. Nguyen et al. [b] and Nguyen et al.

[a] use extra covariates present in the experimental data to assess the sensitivity of the estimated treatment effect to an unobserved treatment effect moderator that interacts with treatment in influencing the outcome when generalizing from an RCT to a target population.

Discrepancies between RCTs and observational data The analysis of real-world data allows to apply the methods and to assess their feasibility. This analysis is pointing towards moderate external validity of the RCT since the results where the ATE is generalized are not entirely concordant with the RCT. Notably, the study using only the observational data supports the results from the RCT. Which analysis to trust depends on the assumptions we are willing to make, either the transportability assumptions or the unconfoundedness assumptions and whether the variables have been selected appropriately. However, caution is needed when interpreting the presented results, since the impact of the missing values when combing RCT and observational data requires further research as mentioned above. In addition, the fact that outcome, treatment and covariates are comparable is of major importance [Lodi et al., 2019] and remains a challenging question when it comes to data fusion. The observed discrepancies support a possible deleterious effect of the treatment, and as soon as the treatment effect depends on the timing, another explanation of the difference could come from slightly different time-to-treatment in both data sets. Such considerations, beyond others, have to be investigated jointly with the clinicians. Finally, the results are presented for the total population but in this application, the clinicians are more interested in assessing treatment effects on specific strata (see Appendix D.5 for more details). However, there are issues to be solved before answering their request. Indeed, when considering certain strata in our application we are facing the issue of violated positivity, which leads to a non-transportable treatment effect on the strata of interest: mild and moderate patients. Therefore, further discussions and analyses with the medical expert committee are necessary to re-define a target population of interest on which generalization is possible and medically relevant. As it is generally the case, beyond methodological and theoretical guarantees, a major step before applying a set of methods is to clearly state the causal question and estimand(s) and the associated identifiability requirements.

Acknowledgment This work is initiated by a SAMSI working group jointly led by JJ and SY in the 2020 causal inference program. We would like to acknowledge the helpful discussions during the SAMSI working group meetings. We also would like to acknowledge the discussions and insights from the Traumabase® group and physicians, in particular Drs. François-Xavier Ageron, Tobias Gauss, and Jean-Denis Moyer. In addition, none of the data analysis part could have been done without the help of Dr. Ian Roberts and the CRASH-3 group, who shared with us the clinical trial data. Part of this work was performed while JJ was a visiting researcher at Google Brain Paris. Finally, we would like to warmly thank Issa Dahabreh for his comments, suggestions of additional references, and insightful discussions.

Chapter 7

Missing values in combined data

This chapter corresponds to the paper *Generalizing treatment effects with incomplete covariates*, under review at *Biometrical Journal*, written with Julie Josse and the Traumabase® group.

Abstract

We focus on the problem of generalizing a causal effect estimated on a randomized controlled trial (RCT) to a target population described by a set of covariates from observational data. Available methods such as inverse propensity weighting are not designed to handle missing values, which are however common in both data sources. In addition to coupling the assumptions for causal effect identifiability and for the missing values mechanism and to defining appropriate estimation strategies, one difficulty is to consider the specific structure of the data with two sources and treatment and outcome only available in the RCT. We propose and compare three multiple imputation strategies (separate imputation, joint imputation with fixed effect, joint imputation without source information), as well as a technique that uses estimators that can handle missing values directly without imputing them. These methods are assessed in an extensive simulation study, showing the empirical superiority of fixed effect multiple imputation followed with any complete data generalizing estimators. This work is motivated by the analysis of a large registry of over 20,000 major trauma patients and a RCT studying the effect of tranexamic acid administration on mortality. The analysis illustrates how the missing values handling can impact the conclusion about the effect generalized from the RCT to the target population.

Table of contents
Table des matières

7.1 – Introduction

Observational and clinical trial data can provide different perspectives when evaluating an intervention or a medical treatment. Combining the information gathered from experimental and observational data is a promising avenue for medical research, because the knowledge that can be acquired from integrative analyses would not be possible from any single-source analysis alone. Such integrative analyses can be used for example to predict a treatment effect on a specific target population using the one estimated from the RCT, to validate methods, especially applied to observational data by emulating a trial, to better estimate heterogeneous effects (which generally cannot be estimated from experimental data due to underpowered studies). Here, we are interested in the former case, where the experimental data

or randomized controlled trial (RCT) is considered as a biased sample of a target population and we would like to estimate the treatment effect on the target population represented by an observational study. More precisely, the effect is estimated on a RCT composed of covariates, treatment and outcome while the observational study is composed only of covariates. A detailed review of the existing works on data integration of RCTs and observational data to estimate causal effects, also called treatment effects, has been given in Chapter 6. For complementary reading we also refer to Degtiar and Rose [2021]. But all these methods do not consider the problem of missing data which is ubiquitous in data analysis practice [Josse and Reiter, 2018]. We emphasize here that we focus on incomplete covariates in both studies, while the outcome and treatment (available in the RCT) are assumed to be fully observed.

In certain cases, naive approaches such as complete-case analysis can yield unbiased treatment effect estimates [Bartlett et al., 2015]; however, in many settings, especially for observational data, the estimations are known to be biased since the complete-case observations are generally not a representative subsample of the population of interest [Little and Rubin, 2019]. Furthermore, this approach is sometimes not even possible since in high-dimensional settings the probability of having complete observations decreases rapidly Zhu et al. [2019]. There exists a multitude of methods to handle missing values [Little and Rubin, 2019, van Buuren, 2018, Mayer et al., 2020], such as maximum likelihood estimation or multiple imputations with the aim of estimating as well as possible a parameter and its variance. These methods make assumptions on the mechanism that generated the missing values. More recent works also consider the question of supervised learning with missing values which is a different problem from statistical inference of model parameters [Josse et al., 2019, Le Morvan et al., 2020a]. In the context of causal inference there exist several recent works that address missing data [Mattei and Mealli, 2009, Seaman and White, 2014, Yang et al., 2019, Kallus et al., 2018a, Mayer et al., 2020]. One difficulty in the context of causal inference, is that one has to couple identifiability assumptions for the causal parameter with assumptions on the missing values mechanisms to define an appropriate strategy. Recalling the approach from Chapter 4, identifiability of the causal effect with missing values is ensured by adapting the causal inference assumptions to the missing values setting with an *unconfoundedness despite missing values* (UDM) assumption [Rosenbaum and Rubin, 1984]. However, these works only consider the case of a single dataset—or potentially multiple datasets with the same data distribution, i.e., sampled from the same population of interest—and do not treat the case of transporting or generalizing a treatment effect from an RCT to a target distribution defined through an observational dataset; the RCT representing a "distorted" population due to sampling or selection bias (generally defined via eligibility criteria). In practice, the observed distributions between the observational data and the RCT do not only differ due to the selection bias but may also differ in terms of missing values patterns. Another field that explicitly studies data integration and missing values therein is meta-analysis. Burgess et al. [2013] study a multiple imputation approach in the context of meta-analysis where missing values can occur in different data sources.

In this paper we propose to revisit the standard identifiability assumptions

and estimators for generalizing a treatment effect from one to the other under the perspective of identifying the impact of missing values and suggesting appropriate strategies to handle missing values according to the different assumptions, such as the missing values mechanisms. Indeed, to the best of our knowledge, there exists no directly applicable method for this setting nor guidelines for a correct handling of missing values in either of or both data sources. Our main contributions are:

— we define several multiple imputation strategies adapted for the aforementioned data integration problem in Section 7.3;

— we propose alternative identifiability assumptions which can be seen as an an extension of the *unconfoundedness despite missingness* (UDM) assumption from the observational data case (see Chapter 4) and suggest adapted estimators in Section 7.4;

— we assess the performance of the proposed estimators and naive complete case estimators in an extensive simulation study in Section 7.5;

— we present a real-world data analysis which has motivated this work in Section 7.6.

For simplicity, we will assume that the relevant covariates that allow for adjustment of the sampling bias are observed both in the RCT and the observational dataset, and we focus on the case of different missing values mechanisms for these covariates.

Before diving into the statistical aspects of the problem of treatment effect generalization, we briefly motivate this work with the same medical question about major trauma patients as in the previous chapters and that has been addressed in various studies over the past few years.

We focus again on trauma patients suffering from a traumatic brain injury (TBI) and on the treatment with tranexamic acid (TXA) which is an antifibrinolytic agent that limits excessive bleeding, commonly given to surgical patients. Previous clinical trials showed that TXA decreases mortality in patients with traumatic *extracranial* bleeding [Shakur-Still et al., 2009]. Such a result raises the possibility that it might also be effective in TBI, because *intracranial* hemorrhage is common in TBI patients. Therefore the question here is to assess the potential decrease of mortality in patients with intracranial bleeding when using TXA.

To answer this question, we have at disposal two data sources: “CRASH-2”, a multi-center international RCT, and “Traumabase”, an observational national registry. The details about these data are provided in Section 7.6, as well as the analysis results for generalizing the treatment effect from the CRASH-2 study to the Traumabase registry.

7.2 – Background and notations

For ease of readability, we first recall the notations, standard assumptions and estimators in the complete case from Chapter 6 which also apply in this section.

7.2.1 Notations

The general case consists in assuming that each patient from the two populations is fully characterized by a random tuple $(X, Y(0), Y(1), W, S)$, where $X \in \mathcal{X}$ is a p-dimensional vector of covariates, W denotes the binary treatment assignment, $Y(w)$ is the potential outcome for treatment level w, $w \in \{0, 1\}$ and S indicates RCT participation [1]. The data considered is composed of $n+m$ independent random tuples: $(X_i, Y_i(0), Y_i(1), W_i, S_i)_{i=1,\dots,n+m}$. For simplicity of exposition, we introduce an additional indicator variable Q that allows to distinguish between observations from the RCT (indexed by the set $Set_{\mathcal{R}} \triangleq \{1, \dots, n\}$) and from the observational cohort (indexed by $Set_{\mathcal{O}} \triangleq \{n+1, \dots, n+m\}$). Thus $Q_i \triangleq \begin{cases} \mathcal{R} & \text{if } i \in Set_{\mathcal{R}} \\ \mathcal{O} & \text{if } i \in Set_{\mathcal{O}} \end{cases}$. Note that (i) $P(Q = \mathcal{R} | S = 1) = 1$, and we assume that conditionally on $S = 0$, Q is independent of all other variables considered in this setting. In this paper, we consider the case where for each RCT sample i such that $Q_i = \mathcal{R}$, we observe $(X_i, W_i, Y_i, S_i = 1)$, while for observational data i such that $Q_i = \mathcal{O}$, we consider that we only observe the covariates X_i, more precisely:

— the RCT samples $i = 1, \dots, n$ are identically distributed according to $\mathcal{P}(X, Y(0), Y(1), W, S \mid S = 1)$,

— and the observational data samples $i = n+1, \dots, n+m$ are identically distributed following $\mathcal{P}(X, S)$.

An illustration of the data we consider in this work is provided in Figure 7.1.

	Q	Covariates			Treatment	Outcome under W=0	Outcome under W=1
		X_1	X_2	X_3	W	$Y(0)$	$Y(1)$
1	$\mathcal{R}$	1.1	20	5.4	1	23.4	24.1
...	$\mathcal{R}$		...		...	...	...
$n-1$	$\mathcal{R}$	-6	45	8.3	0	26.3	27.6
n	$\mathcal{R}$	0	15	6.2	1	28.1	23.5
$n+1$	$\mathcal{O}$	-2	52	7.1	NA	NA	NA
$n+2$	$\mathcal{O}$	-1	35	2.4	NA	NA	NA
...	$\mathcal{O}$		...		NA	NA	NA
$n+m$	$\mathcal{O}$	-2	22	3.4	NA	NA	NA

	Q	Covariates			Treatment	Outcome under W
		X_1	X_2	X_3	W	Y
1	$\mathcal{R}$	1.1	20	5.4	1	24.1
...	$\mathcal{R}$		...		...	...
$n-1$	$\mathcal{R}$	-6	45	8.3	0	26.3
n	$\mathcal{R}$	0	15	6.2	1	23.5
$n+1$	$\mathcal{O}$	-2	52	7.1	NA	NA
$n+2$	$\mathcal{O}$	-1	35	2.4	NA	NA
...	$\mathcal{O}$		...		NA	NA
$n+m$	$\mathcal{O}$	-2	22	3.4	NA	NA

Figure 7.1 – Example of data structure in the full data problem setting. Left: complete underlying data with potential outcomes in the RCT. Right: observed data with factual outcomes.

We define the conditional average treatment effect (CATE):

$$\forall x \in \mathcal{X}\,, \quad \tau(x) = \mathbb{E}[Y(1) - Y(0) \mid X = x]\,, \tag{7.1}$$

1. This indicator S comprises several components: eligibility, selection into the trial and willingness to participate.

and the population average treatment effect (ATE):

$$\tau = \mathbb{E}[Y(1) - Y(0)] = \mathbb{E}[\tau(X)]\,,$$

while we define the RCT (or sample) average treatment effect as

$$\tau_1 = \mathbb{E}[Y(1) - Y(0) \mid S = 1].$$

We denote by $\mu_w(x)$ and $\mu_{w,1}(x)$ the conditional response surfaces under treatment $w \in \{0, 1\}$ in the general and in the RCT population, respectively:

$$\mu_w(x) = \mathbb{E}\left[Y(w) \mid X = x\right]\,, \quad \mu_{w,1}(x) = \mathbb{E}\left[Y(w) \mid X = x, S = 1\right]\,,$$

and by $\pi_S(x)$ the selection score:

$$\pi_S(x) = P(S = 1 \mid X = x)\,.$$

Note that $\pi_S(x)$ is the probability of being eligible for selection in the RCT and of being willing to participate given covariate values x. It is different from the probability that an individual with covariates x, known to be in the study (RCT or observational population), is selected in the RCT:

$$\pi_S(x) \neq \pi_{\mathcal{R}}(x), \quad \pi_{\mathcal{R}}(x) = P(\exists i, Q_i = \mathcal{R}, X_i = x \mid \exists i \in Set_{\mathcal{R}} \cup Set_{\mathcal{O}}, X_i = x)\,.$$

We similarly note

$$\pi_{\mathcal{O}}(x) = P(\exists i, Q_i = \mathcal{O}, X_i = x \mid \exists i \in Set_{\mathcal{R}} \cup Set_{\mathcal{O}}, X_i = x) = 1 - \pi_{\mathcal{R}}(x)\,.$$

Finally, we denote by $\alpha(x)$ the conditional odds that an individual with covariates x is in the RCT or in the observational cohort: [2]

$$\alpha(x) = \frac{P(i \in \mathcal{R} \mid \exists i \in Set_{\mathcal{R}} \cup Set_{\mathcal{O}}, X_i = x)}{P(i \in \mathcal{O} \mid \exists i \in Set_{\mathcal{R}} \cup Set_{\mathcal{O}}, X_i = x)} = \frac{\pi_{\mathcal{R}}(x)}{\pi_{\mathcal{O}}(x)} = \frac{\pi_{\mathcal{R}}(x)}{1 - \pi_{\mathcal{R}}(x)}\,.$$

This quantity arises in several approaches that have been proposed to generalize a treatment effect from an RCT to a target population, see for example Westreich et al. [2017]. As we will see in the following, this conditional odds is identifiable under certain assumptions and can be used instead of the selection score π_S to generalize a treatment effect. Indeed the latter is only identifiable in the case of a nested trial design [Dahabreh et al., 2019a] which we do not cover in this chapter.

2. In the statistical and econometric literature, this term is sometimes also referred to as *conditional odds* even though, by definition, it is an odds and not a ratio of odds.

7.2.2 Assumptions for identifiability of the ATE on the target population in the full data case

The main identifiability assumptions that allow for generalizing an ATE from the RCT onto a target population are as follows:

- Internal validity of the RCT: consistency of potential outcomes, treatment randomization.
  - Consistency of potential outcomes

$$Y = W\,Y(1) + (1 - W)\,Y(0).$$

  - Treatment randomization

$$Y(w) \perp\!\!\!\perp (W, X) \mid S = 1 \text{ for all } X \text{ and } w = 0, 1.$$

- Generalizability of the RCT to the target population:
  - Ignorability on trial participation

$$\{Y(0), Y(1)\} \perp\!\!\!\perp S \mid X. \tag{7.2}$$

  - Positivity of trial participation

$$\begin{aligned} &\exists\, c \text{ such that for all } x,\ P(\pi_S(x) \geq c > 0) = 1, \\ &\text{and } 0 < P(W = w \mid X = x, S = 1) < 1 \text{ for all } w \\ &\text{and for all } x \text{ such that } P(S = 1 \mid X = x) > 0 \end{aligned} \tag{7.3}$$

Assumption Equation 7.2 implies that we have measured all variables related to the trial eligibility indicator S that are treatment effect modifiers. In other words, participation in the RCT is randomized within levels of X. This is analogous to the *ignorability assumption* on treatment assignment in causal inference with observational data. With Assumption (7.3) we require adequate overlap of the covariate distribution between the trial sample and the target population, as well as between the treatment groups in the trial.

7.2.3 Estimators in the full data case

The covariate distribution of the RCT sample is generally different from that of the target population; therefore, τ_1 is different from τ, and an estimator based solely on the RCT is biased for the ATE of interest τ. Under the previous identifiability assumptions, different estimators are available to estimate the ATE τ: one proposes to reweight the RCT sample so that it "resembles" the target population with respect to the observed shifted covariates and treatment effect modifiers. Another proposes to model the conditional outcomes with and without treatment in the RCT, and then to apply the model to the target population of interest. Doubly robust approaches are combinations of the former two, improving the robustness and efficacy. For simplicity, we assume a standard RCT with a constant propensity score of 0.5 for all individuals.

Inverse probability of sampling weighting (IPSW). This estimator is defined as the weighted difference of average outcomes between the treated and control groups in the trial. The observations are weighted by the inverse odds $1/\alpha(x) = \pi_{\mathcal{O}}(x)/\pi_{\mathcal{R}}(x)$ to account for the shift of the covariate distribution from the RCT sample to the target population. The IPSW estimator can be written as follows:

$$\widehat{\tau}_{IPSW,n,m} = \frac{2}{n}\sum_{i=1}^{n} \frac{Y_i\,(2W_i - 1)}{\widehat{\alpha}_{n,m}(X_i)}\,, \tag{7.4}$$

where $\widehat{\alpha}_{n,m}$ is an estimate of α. The IPSW estimator is consistent as soon as α is consistently estimated by $\widehat{\alpha}_{n,m}$. In practice, analysts often rely on logistic regression.

Conditional outcome-based estimation. It fits models of the conditional response surfaces among trial participants. Applying these models to the covariates of the observational data, gives the corresponding expected outcome [Robins, 1986]. This outcome-model-based estimator, also called g-formula estimator, is then defined as:

$$\widehat{\tau}_{CO,n,m} = \frac{1}{m}\sum_{i=n+1}^{n+m} \left(\widehat{\mu}_{1,1,n}(X_i) - \widehat{\mu}_{0,1,n}(X_i)\right), \tag{7.5}$$

where $\widehat{\mu}_{w,1,n}(X_i)$ is an estimator of $\mu_{w,1}(X_i)$. If the model is correctly specified, then the estimator is consistent. Note that in the previous chapter, we denoted this estimator by $\widehat{\tau}_{G,n,m}$.

Doubly robust estimators The selection score and outcome models used in the first two estimators can be combined to form an augmented IPSW estimator (AIPSW):

$$\widehat{\tau}_{\text{AIPSW},n,m} = \frac{2}{n}\sum_{i=1}^{n} \frac{1}{\widehat{\alpha}_{n,m}(X_i)} \left[W_i\left\{Y_i - \widehat{\mu}_{1,1,n}(X_i)\right\} - (1-W_i)\left\{Y_i - \widehat{\mu}_{0,1,n}(X_i)\right\}\right] + \frac{1}{m}\sum_{i=n+1}^{m+n} \left\{\widehat{\mu}_{1,1,n}(X_i) - \widehat{\mu}_{0,1,n}(X_i)\right\}.$$

It is doubly robust, i.e., consistent and asymptotically normal when either one of the two models for $\widehat{\alpha}_{n,m}$ and $\widehat{\mu}_{w,1,n}(X)$ $(w = 0, 1)$ is consistent.

Calibration weighting. It is well known that IPSW is likely to be unstable as soon as some of the estimated odds are very small. To resolve the instability of IPSW calibration weighting [Dong et al., 2020] have been proposed. They calibrate, i.e. weight subjects in the RCT sample in such a way that afterwards, the covariates are balanced between the RCT sample and the target population: usually the balance is enforced on the first and second moments of the covariates $X_1, \ldots, X_p$ such that the weighting mean and variance for each variable in the RCT match the ones in the observational data. More precisely, in order to calibrate, they assign an entropy-balancing weight ω_i to each subject i in the RCT sample obtained by solving an

optimization problem:

$$\min_{\omega_1,\ldots,\omega_n} \sum_{i=1}^{n} \omega_i \log \omega_i, \tag{7.6}$$

$$\text{subject to} \quad \omega_i \geq 0, \text{ for all } i, \tag{7.7}$$

$$\sum_{i=1}^{n} \omega_i = 1, \quad \sum_{i=1}^{n} \omega_i \, \mathbf{g}(X_i) = \widetilde{\mathbf{g}}, \tag{7.8}$$

where $\widetilde{\mathbf{g}} = m^{-1} \sum_{i=n+1}^{m+n} \mathbf{g}(X_i)$ is a consistent estimator of $\mathbb{E}[\mathbf{g}(X)]$ from the observational sample. The balancing constraint calibrates the covariate distribution of the RCT sample to the target population in terms of $\mathbf{g}(X)$. The objective function in (7.6) is the negative entropy of the calibration weights; thus, minimizing this criterion ensures that the empirical distribution of calibration weights are not too far away from the uniform, such that it minimizes the variability due to heterogeneous weights. Based on the calibration weights, the CW estimator is then defined as

$$\widehat{\tau}_{\mathrm{CW},n,m} = 2 \sum_{i=1}^{n} \widehat{\xi}_i Y_i (2W_i - 1). \tag{7.9}$$

This estimator is doubly robust in that it is a consistent estimator for τ if either the selection score follows a log-linear model, or if the CATE (7.1) is linear in the calibration constraint.

7.2.4 Missing values mechanisms

In Chapter 2, we have already recalled Rubin [1976]'s taxonomy of missing values mechanisms. We have seen that an ignorable missingness mechanism is either *missing completely at random* (MCAR) or *missing at random* (MAR). The former means that the missingness mechanism is independent of the data, whereas the latter states that the missingness only depends on the observed values. In a nutshell, ignorable missingness means that the missing data mechanism can be "ignored" when doing inference for the parameter in the data likelihood function since the two are separable in the full data likelihood function, whereas non-ignorable missingness complicates analyses more significantly.

More formally, we denote the response pattern of the i-th sample as $R_i \in \{0,1\}^p$ such that $R_{ij} = 1$ if X_{ij} is observed and $R_{ij} = 0$ otherwise. We model $1 - R_i$ as a random vector and its (conditional) distribution is known as the missing values mechanism. Additionally, for our problem, for all response patterns r and $X = (X^{obs(r)}, X^{mis(r)})$ the partition of the data in realized observed and missing values given a specific realization of the pattern,

$$(MCAR) \quad \forall r,\ P(R = r|X, S, Q, W, Y) = P(R = r) \tag{7.10}$$

$$(MAR) \quad \forall r,\ P(R = r|X, S, Q, W, Y) = P(R = r|X^{obs(r)}, Q, W, Y) \tag{7.11}$$

If the missingness mechanism is non-ignorable, it is qualified as *missing not at random* (MNAR) and it formally states that the mechanism does not satisfy (7.10)

or (7.11), in other words the missingness is allowed to depend on the missing values themselves.

In Figure 7.2 we provide an example of observed incomplete data and recall the underlying data for our problem.

	Q	Covariates			Treatment	Outcome under W=0	Outcome under W=1
		X_1	X_2	X_3	W	$Y(0)$	$Y(1)$
1	$\mathcal{R}$	1.1	20	5.4	1	23.4	24.1
...	$\mathcal{R}$		...		...	...	...
$n-1$	$\mathcal{R}$	-6	45	8.3	0	26.3	27.6
n	$\mathcal{R}$	0	15	6.2	1	28.1	23.5
$n+1$	$\mathcal{O}$	-2	52	7.1	NA	NA	NA
$n+2$	$\mathcal{O}$	-1	35	2.4	NA	NA	NA
...	$\mathcal{O}$		...		NA	NA	NA
$n+m$	$\mathcal{O}$	-2	22	3.4	NA	NA	NA

	Q	Covariates			Treatment	Outcome under W
		X_1^*	X_2^*	X_3^*	W	Y
1	$\mathcal{R}$	1.1	20	NA	1	24.1
...	$\mathcal{R}$		...		...	...
$n-1$	$\mathcal{R}$	-6	NA	8.3	0	26.3
n	$\mathcal{R}$	0	15	6.2	1	23.5
$n+1$	$\mathcal{O}$	-2	52	NA	NA	NA
$n+2$	$\mathcal{O}$	-1	NA	2.4	NA	NA
...	$\mathcal{O}$		...		NA	NA
$n+m$	$\mathcal{O}$	NA	NA	3.4	NA	NA

Figure 7.2 – Example of data structure in the incomplete data problem setting. Left: complete underlying data with potential outcomes in the RCT. Right: observed incomplete data with factual outcomes.

7.3 – Multiple imputation

7.3.1 General concept

Multiple imputation (MI) is one of the most powerful approaches to estimate parameters and their variance from incomplete data [Little and Rubin, 2019, Kim and Shao, 2013, Schafer, 1997]. In a nutshell, for a single dataset, it consists in generating M plausible values for each missing entry, which leads to M completed datasets. Then, an analysis is performed on each imputed data set $m = 1, \ldots, M$, to get an estimate for the parameter of interest, say θ as $\widehat{\theta}^m$ and an estimate of its variance $\widehat{V}^m(\widehat{\theta}^m)$ and the results are combined using Rubin [2004]'s rules to get correct inference with missing values, namely confidence intervals with the appropriate coverage.

7.3.2 Adapted multiple imputation for multiple data sources with different data design

For our problem, there are multiple possibilities to derive a multiple imputation strategy to generalize a treatment effect. This is due to the multi-source structure of the data and the fact that there is an additional complication due to the number of variables are not the same in the RCT and in the observational study. Indeed, we assume that the observational study does not include treatment and outcome but only covariates. We stress again that we assume missing values only occur in the covariates of both data. We suggest and describe three strategies to tackle this problem:

1. Within-study multiple imputation, see also Figure 7.3 (a):

   (a) Multiple imputation of the RCT: Impute M times the covariates of the RCT using $(X_i, W_i, Y_i)_{i:\, Q_i=\mathcal{R}}$.
   (b) Multiple imputation of the observational data: Impute M times the covariates of the observational data using only the covariates $(X_i)_{i:\, Q_i=\mathcal{O}}$.
   (c) Create $M \times M$ complete tables by concatenating all possible combinations of imputed RCT and observational data. Estimate the treatment effect on every combination using any complete case estimator as in Section 7.2 and aggregate these estimations using Rubin's rules.
2. Ad-hoc joint covariates multiple imputation, ignoring the group variable, see also Figure 7.3 (b):
   (a) Impute M times the joint datasets (the concatenation of the covariates from the RCT and the ones from the observational study) with covariates X and ignore the "source" indicator variable Q during the imputation.
   (b) Concatenate the outcome Y and treatment W for each imputed RCT.
   (c) Compute the M treatment effect estimators using any complete case estimator as in Section 7.2 and aggregate them using Rubin's rules.
3. Joint covariates multiple imputation, modeling the group variable as a fixed effect, i.e. keep the indicator variable Q indicating the corresponding "group"/"source" during the imputation, see also Figure 7.3 (c):
   (a) Impute M times the joint datasets with covariates X and model the source indicator variable Q as a fixed effect during the imputation.
   (b) Concatenate the outcome Y and treatment W for each imputed RCT.
   (c) Compute the M treatment effect estimators using any complete case estimator as in Section 7.2 and aggregate them using Rubin's rules.

The first strategy has the advantage that it takes into account the outcome Y and treatment W which are dependent variables of the covariates X, when imputing the covariates of the RCT as suggested by Leyrat et al. [2019], Seaman and White [2014], Mattei and Mealli [2009] as it models the entire joint distribution. The other strategies only consider the covariates X. The second strategy solely relies on the relationships between the covariates X and the assumption that these are stable across the data sources, i.e., $Cov(X) = Cov(X|S = 1)$. The third strategy allows to additionally take into differences between both sources when imputing by modeling the source as a fixed effect. Strategy 3 can thus be seen as a fixed effect method, where the variable Q is included as a variable in the imputation model which allows, e.g., in case of multiple imputation with conditional regression models, to impute according to an analysis of covariance model. A drawback of this approach is that it generally inflates the between-group variability [Andridge, 2011].

In the case of several observational data sources, a fourth strategy could be considered, namely a multilevel multiple imputation approach, adding random effects into the model for each (observational) data source. Indeed, multilevel multiple imputation is specifically designed for cases of hierarchical or clustered observations, allows for a random intercept between groups (or, in our case, data sources) [van

Buuren, 2018, Burgess et al., 2013, Audigier et al., 2018]. It could be also appropriate when the observational data consists of patient records coming from different hospitals. It is indeed useful to encode the clustered structure of these records to account for between-hospital variability in terms of patient population and treatment practices. For a broader overview of multilevel imputation, we refer to Audigier et al. [2018], van Buuren [2018].

All three strategies can be implemented easily using the R package mice [van Buuren, 2018] which uses conditional models such as linear and logistic regressions to perform multiple imputation. The sketched fourth strategy could be implemented using the `micemd` R package [Audigier et al., 2018].



(a) Within-study multiple imputation.



(b) Ad-hoc joint covariates multiple imputation.



(c) Joint covariates multiple imputation, modeling the source variable as fixed effect.

Figure 7.3 – Schematic illustrations of different multiple imputation strategies.

Multiple imputation is suited if the missing values are ignorable as described in Subsection 7.2.4 and if the identifiability assumptions of the ATE τ in the full data case are met, namely Assumptions (7.2) and (7.3).

Note that for the considered imputation strategies, increasing the number of imputations does not improve (significantly) the final result. There exists no clear

rule about the number of multiple imputations to achieve good performances, however an accepted rule of thumb is to choose the number of imputations to be similar to the percentage of incomplete cases [Hippel, 2009] or to the average percentage of missing data [van Buuren, 2018].

7.4 – Missing incorporated in attributes under adapted ignorability assumption

Multiple imputation makes classical identifiability assumptions of the causal effect and ignorability assumptions of the missing values mechanism [Seaman and White, 2014, Leyrat et al., 2019]. An alternative to handle missing covariates values consists in modifying the identifiability assumptions so that they directly handle missing values but do not necessarily require assumptions on the missing values mechanism. This can be seen as an advantage as it possibly allows for MNAR data, but the new identifiability assumptions may be more difficult to satisfy than in the full data case. More precisely, we extend the work from Chapter 4 where we have adapted the unconfoundedness assumption to the incomplete covariates in order to identify the (average) treatment effect in the observational data case. In the following we lay out the modified assumptions for generalizability of the RCT to the target population we make to achieve a similar identifiability in the case of missing values in the RCT and the observational data.[3] We then explain how to generalize treatment effects under these assumptions. First, we recall the notation introduced in Chapter 4, required for the following approach. The matrix of observed covariates can be written with $X_i^* \triangleq X_i \odot R_i + \texttt{NA} \odot (\mathbf{1} - R_i)$, with $\odot$ the element-wise multiplication and $\mathbf{1}$ the matrix filled with 1, so that X_i^* takes its value in the half discrete space $\mathcal{X}^* \triangleq \underset{1 \leq j \leq |\mathcal{X}|}{\times} \{\mathcal{X}_j \cup \{\texttt{NA}\}\}$. And, similar to D'Agostino and Rubin [2000] and the proposal of Chapter 4, we define the generalized conditional response surfaces μ_a^* and $\mu_{a,1}^*$ as follows:

$$\begin{aligned} \mu_w^*(x^*) &= \mathbb{E}(Y(w) \mid X^* = x^*), \\ \mu_{w,1}^*(x^*) &= \mathbb{E}(Y(w) \mid X^* = x^*, S = 1), \end{aligned} \tag{7.12}$$

The possibility to infer causal effects and to generalize the effect(s) from the RCT to another (broader) target population in the presence of missing data, i.e., using observations $(X_i^*, W_i, Y_i, S_i = 1)_{i=1,\dots,n}$ and $(X_i^*)_{i=n+1,\dots,n+m}$, depends on the following additional assumptions on the joint law of $(X_i, W_i, Y_i(0), Y_i(1), S_i = 1, R_i)_{i=1,\dots,n}$ and $(X_i, R_i)_{i=n+1,\dots,n+m}$.

— **Ignorability on trial participation, conditionally independent selection (CIS)**

$$\text{Assumption (7.2) and } \{Y(0), Y(1)\} \perp\!\!\!\perp S \mid X^*. \tag{7.13}$$

3. Note that the assumptions for internal validity of the RCT are the same as in the full data case.

— **Positivity of trial participation**

$$\begin{aligned}&\text{Assumption (7.3) and } \exists\, c^* \text{ such that for all } x^*, P(\pi_S(x^*) \geq c > 0) = 1,\\ &\text{and } 0 < P(W = w \mid X^* = x^*, S = 1) < 1 \text{ for all } w\\ &\text{and for all } x^* \text{ such that } P(S = 1 \mid X^* = x^*) > 0.\end{aligned} \tag{7.14}$$

Assumption (7.13) means that being eligible to the RCT does not affect the potential outcomes conditionally on the covariates X^*.

The intuition behind these additions is to assume that instead of requiring conditional independence of potential outcomes and trial eligibility conditionally on all covariates, we only require conditional independence conditionally on the *observed* information, meaning the observed values and the pattern of missing values. Taking the example given in Figure 7.2, for observation 1, only X_1 and X_2 and the fact that X_3 is unobserved are decisive for trial eligibility, while for observation 2, only X_1 and X_3 and the fact that X_2 is missing decide upon trial eligibility, etc. A possible scenario could be the existence of a list of sufficient but not necessary trial eligibility criteria. In other words, one could imagine a "check list" of L conditions and it is necessary to fulfill at least $l < L$ of these to be eligible.

Similar to the UDM assumption in Chapter 4, Assumption 7.13 can be replaced by two sufficient assumptions: Equation 7.2 and $S \perp\!\!\!\perp X \mid X^*$, thus the term *conditionally independent selection* (CIS).

7.4.1 Generalized nuisance parameters and estimators

Since the conditional response surfaces μ_w^* and $\mu_{w,1}^*$ now depend on X^* rather than X and thus depends on the pattern of missing values, the estimators that involve an estimation of these quantities require an adaptation. Analogously to the generalized response surfaces, on can also define the generalized conditional odds α^*, following the same logic.

$$\mu_w^*(x^*) = \mathbb{E}\left[Y(w) \mid X^* = x^*\right], \qquad \mu_{w,1}^*(x^*) = \mathbb{E}\left[Y(w) \mid X^* = x^*,\, S = 1\right]. \tag{7.15}$$

The resulting estimators are then formed analogously to the estimators in the full data case, by substituting the corresponding nuisance or intermediary parameters with their generalized counterparts. More explicitly, the outcome-model-based estimator defined by (7.5) becomes

$$\widehat{\tau}_{CO,n,m}^* = \frac{1}{m} \sum_{i=n+1}^{n+m} \left(\widehat{\mu}_{1,1,n}^*(X_i^*) - \widehat{\mu}_{0,1,n}^*(X_i^*)\right). \tag{7.16}$$

Fitting the new nuisance or intermediary parameters (7.15) is not straightforward, since these require to fit a separate regression model for each possible pattern r of missing values. For example, if we have three incomplete covariates X_1, X_2, X_3, this means we need to fit a separate regression on $\{X_1, X_2, X_3\}$, on $\{X_1, X_2\}$, on

$\{X_2, X_3\}$, on $\{X_1\}$, etc. We can see from this example that this is not possible in moderate and high dimensions with classical regression methods. This is why we propose to use random forests with a splitting criterion adapted to missing data. Indeed, as noted already by Athey et al. [2019], and discussed in Chapter 4, many modern machine learning methods, including tree ensembles and neural networks, can be adapted to this context and thus readily handle missing data and enable direct fitting of the generalized models above [Josse et al., 2019].

Nonparametric estimation. As an example of such a modern nonparametric estimation approach, we propose to estimate the generalized parameters via random forests [Breiman, 2001, Athey et al., 2019], with missing data handled using the *missing incorporated in attributes* (MIA) method of Twala et al. [2008]. The resulting IPSW, CO and AIPSW estimators will be denoted by $\hat{\tau}^{*,MIA}_{IPSW,n,m}$, $\hat{\tau}^{*,MIA}_{CO,n,m}$, and $\hat{\tau}^{*,MIA}_{AIPSW,n,m}$ respectively.

For ease of reading, we recall what we have already seen in Chapter 4: In random trees, the MIA approach extends the classical splitting rules such that missing values are incorporated in the splitting criterion. More specifically, consider splitting on the j-th attribute and assume that for some individuals, the value of X_j is missing, MIA treats the missing values as a separate category or code and considers the following splits:

— $\{i : X_{ij} \leq t$ or X_{ij} is missing$\}$ vs. $\{i : X_{ij} > t\}$

— $\{i : X_{ij} \leq t\}$ vs. $\{i : X_{ij} > t$ or X_{ij} is missing$\}$

— $\{X_{ij}$ is missing$\}$ vs. $\{X_{ij}$ is observed$\}$,

for some threshold t. The MIA approach does not seek to model why some features are unobserved; instead, it simply tries to use information about missingness to make the best possible splits for modeling the desired outcome. Thus the MIA strategy works with arbitrary missingness mechanisms and does not require the missing data to follow a specific mechanism. This MIA approach for (generalized) random forests is implemented in the R package `grf` [Tibshirani et al., 2020] which is also used in the simulation part of this work presented in Section 7.5.

Parametric alternative. Parametric estimation is however possible in the case of logistic and linear regression models. This is based on work by Jiang et al. [2020] and Schafer [1997] for logistic and linear regressions with missing covariates. The functions μ^* and α^* that take in incomplete covariates x^* are estimated via EM [Dempster et al., 1977]. The resulting IPSW, CO and AIPSW estimators will be denoted by $\hat{\tau}^{*,EM}_{IPSW,n,m}$, $\hat{\tau}^{*,EM}_{CO,n,m}$, and $\hat{\tau}^{*,EM}_{AIPSW,n,m}$ respectively.

The details of this approach are given in the Appendix E.1.

However, a major limitation of this approach is that, in addition to the modified identifiability assumptions (7.13) and (7.14), in order to justify the use of the EM algorithm, one typically needs to make further assumptions on the missing value mechanism; in particular, this approach assumes the MAR mechanism (7.11). In other words, although we did not require the missing at random assumption to identify

τ, this assumption is used for consistent parametric estimation of the generalized conditional models α^* and $\mu^*_{w,1}$.

7.5 – Simulations

We conduct a detailed simulation study to assess the performance of the previously introduced estimators to handle missing values. This controlled study allows to quantify the impact of different missing values mechanisms and identifiability assumptions on the final estimate for the ATE τ. The code to reproduce the results is available on GitHub. [4]

7.5.1 Data generation

7.5.1.1 Classical assumptions for identifiability in treatment effect generalization and on missing values mechanisms

We consider the selection model generated as a logistic model as follows

$$\text{logit}\left\{\pi_S(X)\right\} = -2.5 - 0.5X_1 - 0.3X_2 - 0.5X_3 - 0.4X_4, \tag{7.17}$$

where every X is drawn from a multivariate normal distribution with mean 1 and covariance matrix Σ such that $\Sigma_{ij} = \begin{cases} 1 & \text{if } i = j \\ 0.6 & \text{if } i \neq j \end{cases}$ to have correlated covariates. The outcome is generated according to the linear model below such that X_1 is a treatment effect modifier and the true ATE τ is set to 27.4.

$$Y(w) = -100 + 27.4wX_1 + 13.7X_2 + 13.7X_3 + 13.7X_4 + \epsilon \quad \text{with } \epsilon \sim \mathcal{N}(0,1). \tag{7.18}$$

We do not modify the treatment assignment mechanism since by assumption it is independent of the rest and in standard RCT design it is constant for all individuals. Missing values in the covariates are generated as follows, defining different models for the response indicator R (see Subsection 7.2.4):

- Missing values can occur in all four covariates.
- Proportion of missing values in each incomplete covariate: 20%.
- The missing values mechanism can be one out of the following and is implemented in the `produce_NA` function (see Chapter 9):
  - MCAR where the probability to have missing values does not depend on any variable:

$$P(R_{i\cdot} = r | X_i, S_i, Q_i, Y_i, W_i) = P(R_{i\cdot} = r) \tag{7.19}$$

  We choose $P(R_{ij} = 0) = 0.2$ for all $i \in \{1, \ldots, n+m\}$, and $j \in \{1, 2, 3, 4\}$.

4. https://github.com/imkemayer/combined-incomplete-data

— MAR:

$$P(R_{i\cdot} = r|X_i, S_i, Q_i, Y_i, W_i) = f(X_{obs(r)}), \tag{7.20}$$

for some function $f : \mathcal{X} \to [0, 1]$, for all $i \in \{1, \ldots, n + m\}$. For example, missing values in X_1 are introduced for observation i using a logistic model on X_2, X_3, X_4, assuming these three variables are observed for observation i.

— MNAR:

$$P(R_{ij} = 0|X_i, S_i, Q_i, Y_i, W_i) = g(X_{ij}), \tag{7.21}$$

for some function $g : \mathcal{X}_j \to [0, 1]$, for all j and $i \in \{1, \ldots, n + m\}$. In this study, we use a self-masking MNAR mechanism, i.e., the missingness of a variable depends on its value alone. More precisely, we use an upper quantile censorship approach. The quantile level q is chosen such that when missing values are generated on the q-quantile at random, the requested proportion of missing values is achieved. For more details about this chosen approach, we refer to the documentation of the `produce_NA` function [5].

We assume that the trial selection, randomization and potential outcomes are completely independent from the missing values. The simulation design is summarized by Algorithm 1.

Algorithm 1: Steps for simulation design under the standard assumption.

Input : Population size $N > 0$, RCT size $n < N$, observational study $m < N$, number of covariates p, missing values mechanism, proportion of missing values.

Output: Joint data table X^* of RCT and observational data and additional variables W, Y for the RCT.

1 Sample $N >> n$ observations $X_1, \ldots, X_N$ from the target population $\mathcal{P}(X)$;
2 Sample S according to the logistic model (7.17) on X;
3 Keep the $\{S = 1\}$ indexed observations $X_{\mathcal{R}} \leftarrow X_{\{i:\, S_i=1\}}$ as the RCT data;
4 Sample W according to a Bernoulli distribution $\mathcal{B}(0.5)$ (coin flip);
5 Sample Y according to the linear model (7.18) on $X_{\mathcal{R}}$;
6 Sample m observations $X_{\mathcal{O}}$ from the target population $\mathcal{P}(X)$ as the observational data;
7 Concatenate the datasets: $X \leftarrow [X_{\mathcal{R}}^T\,,\, X_{\mathcal{O}}^T]^T$ and append the indicator Q to the data ($X \leftarrow [X\,,\, Q]$);
8 Sample missing values for the $n + m$ observations according to either (7.19), (7.20) or (7.21);

For ease of comparison with the alternative simulation scenario, we provide the expression of the joint distribution over (X, R, W, Y, S, Q) factorized according to the underlying generative model:

5. https://rmisstastic.netlify.app/how-to/generate/missSimul.pdf

$$\begin{aligned} p(X, R, W, Y, S, Q) &\propto p(R|S, Q, X, W, Y)p(S, Q, Y|X, W)p(W|X)p(X) \\ &\propto p(R|S, Q, X, W, Y)p(Q|S)p(S|X, W)p(Y|X, W)p(W|X)p(X) \end{aligned} \tag{7.22}$$

In the MCAR case (7.10), this factorization simplifies as follows:

$$p(X, R, W, Y, S, Q) \propto p(R)p(Q|S)p(S, Y|X, W)p(W|X)p(X).$$

7.5.1.2 Modified assumptions on treatment effect generalization

We also generate data according where the CIS assumption (7.13) is met. In such scenarios, we expect that the methods described in Section 7.4 will work best.

The main difference with the previous setting of simulation, lies in the definition of the selection model, the outcome model remaining unchanged. To relate this setting to the previous one, we begin by giving the expression of the factorization of the joint distribution under these assumptions on the data generating process.

$$\begin{aligned} p(X, R, W, Y, S, Q) &\propto p(S, Q|X, R, W, Y)p(R|X, W, Y)p(Y|X, W)p(W|X)p(X) \\ &\propto p(Q|S)p(S|X, R, W, Y)p(R|X)p(Y|X, W)p(W|X)p(X) \end{aligned} \tag{7.23}$$

Note that we can see from this factorization, that the difference w.r.t. the previous case induced by the modified transportability assumptions, and in particular the modified ignorability (7.13) which induces a (conditional) dependence between R and $\{S, Q\}$ by assumption.

In order to simulate data under the CIS assumption (7.13), we need to modify the definition of π_S such that it becomes pattern-dependent.

$$\text{logit}\left\{\pi_S(X)\right\} = -2.5 - 0.5X_1 \odot R_1 - 0.3X_2 \odot R_2 - 0.5X_3 \odot R_3 - 0.4X_4 \odot R_4, \tag{7.24}$$

The simulation design and the adapted CIS ignorability assumption is summarized

in Algorithm 2 and is different from the one described in Algorithm 1.

Algorithm 2: Steps for simulation design under the CIS assumption.

Input : Population size $N > 0$, RCT size $n < N$, observational study $m < N$, number of covariates p, missing values mechanism, proportion of missing values.

Output: Joint data table X of RCT and observational data and additional variables W, Y for the RCT.

Sample $N >> n$ observations $X_1, \ldots, X_N$ from the target population $\mathcal{P}(X)$;
Sample missing values for the N observations according to either (7.19), (7.20) or (7.21);
Sample S according to pattern-dependent logistic model on X;
Keep the $\{S = 1\}$ indexed observations $X_{\mathcal{R}} \leftarrow X_{\{i:\, S_i=1\}}$;
Sample W according to a Bernoulli distribution $\mathcal{B}(0.5)$ (coin flip);
Sample Y according to the linear model (7.18) on $X_{\mathcal{R}}$;
Sample m observations $X_{\mathcal{O}}$ from the target population;
Sample missing values for the m observations $X_{\mathcal{O}}$ using the same mechanism as before but possibly with different proportions;
Concatenate $X_{\mathcal{R}}$ and $X_{\mathcal{O}}$ ($X \leftarrow [X_{\mathcal{R}}^T\,,\, X_{\mathcal{O}}^T]^T$), and append the indicator Q to the data ($X \leftarrow [X\,,\, Q]$);

7.5.2 Estimation methods

We consider different scenarios of data generating processes by varying the type of missing values (MCAR, MAR, MNAR), ignorability assumption (standard or CIS), as well as the number of observations.

We compare the following methods to handle missing values (the following acronyms are identical to the method labels used in Figures 7.4 –7.5:

— Full data: we apply the standard full data estimators from Section 7.2 on the full data before introducing missing values (this would serve as a reference).

— Complete cases (CC): we apply the standard full data estimators from Section 7.2 on the complete observations extracted from the incomplete data (by deleting observations with missing values). [6]

— EM (see Subsection 7.4.1): we use EM to fit logistic and linear regression models of α^* and $\mu^*_{w,1}$ on the incomplete data using the R package `misaem` [Jiang et al., 2020].

— MIA (see Subsection 7.4.1): we use generalized random forests with MIA splitting criterion to estimate the generalized models α^* and $\mu^*_{w,1}$ on the incomplete data, using the R package `grf` [Athey et al., 2019].

— Multiple imputation (MI, see Section 7.3): we apply the standard full data estimators from Section 7.2 on the imputed data (5-10 imputations obtained using the R package `mice`) where we use either

  — within-study multiple imputation (WI-MI), or

6. Note that this approach is the most common default option in many implementations.

— ad-hoc multiple imputation (AH-MI), or

— fixed effect multiple imputation (FE-MI).

We do not assess the random effect multiple imputation (i.e., the joint covariates multiple imputation with a 2-level model accounting for the multiple data sources, sketched Strategy 4 from Section 7.3) in this simulation study because this does not correspond to our motivating data example from the introduction.

Note that for the EM and MIA approach, we only compute the IPSW, CO and AIPSW estimators (see Subsection 7.2.3) since the calibration weighting estimator in its current form is not applicable on incomplete data and future work is required to adapt this estimator to incomplete data.

7.5.3 Results

Due to the large number of different scenarios we consider in this simulation study, we first provide a summary of the expected behaviors of the different estimators in various cases before we report results of our experiments.

7.5.3.1 Summary of expected and empirical results

In Table 7.1 we summarize the expected results in terms of consistency of the different approaches, depending on the mechanisms that generate the data. For example, the MIA approach being suited for the modified ignorability assumption CIS (7.13), we expect it to perform well under CIS, independently of the missingness mechanism. In contrast, we do not expect it to be consistent under the standard ignorability assumption (7.2), whereas multiple imputation should be consistent under this standard assumption, provided the missingness is either MCAR or MAR.

Table 7.1 – Expected behavior under different assumptions about the data generating process and used estimation approach. Color code: blue=no bias; red=bias.

			Full data	Complete cases	EM	MIA	Multiple imputation
$\rho = 0.6$	MCAR	CIS (Assmpt. 7.13)					
		I (Assmpt. 7.2)					
	MAR	CIS (Assmpt. 7.13))					
		I (Assmpt. 7.2)					
	MNAR	CIS (Assmpt. 7.13)					
		I (Assmpt. 7.2)					

This Table 7.1 is based on the Table 7.2 that summarizes the required assumptions for each method.

Some simulations results are in agreement with what is expected but there are also some gaps between the expected and empirical behavior in the chosen simulation settings. Indeed, in Figure 7.4 and Figure 7.5 we report the empirical bias with at 95% Monte Carlo confidence interval (based on a Monte Carlo standard error) of the estimated generalized ATE $\hat{\tau}$ relative to the true value $\tau = 27.4$, using $n_{sim} = 100$

Table 7.2 – Methods for handling incomplete observations in treatment effect transport and their assumptions on the underlying data generating process. (✓indicates cases that can be handled by a method, whereas ✗marks cases where a method is not applicable in theory; (✗) indicates cases without theoretical guarantees but with good empirical performance.)

	Covariates		Missingness			Identifiability of transported τ		Models for (S, Y)	
	multivariate normal	other	MCAR	MAR	general	I (≡ (7.2) & (7.3))	CIS (≡ (7.13) & (7.14))	Generalized linear models	Non-parametric models
CC	✓	✓	✓	✗	✗	✓	✗	✓	✓
EM	✓	✗	✓	✓	✗	✗	✓	✓	✗
MIA	✓	✓	✓	✓	✓	✗	✓	✓	✓
MI	✓	✓	✓	✓	✗	✓	✓	✓	(✗)

repetitions of each scenario. We define the empirical bias and its Monte Carlo standard error respectively by

$$\widehat{B}_{\hat{\tau}} = \widehat{Bias}(\hat{\tau}) = \frac{1}{n_{sim}} \sum_{i=1}^{n_{sim}} \hat{\tau}_i - \tau$$

$$\widehat{SE}(\widehat{B}_{\hat{\tau}}) = \sqrt{\frac{1}{n_{sim}(n_{sim}-1)} \sum_{i=1}^{n_{sim}} (\hat{\tau}_i - \overline{\tau})^2},$$

where $\overline{\tau} = \sum_{i=1}^{n_{sim}} \hat{\tau}_i$, following Morris et al. [2019].

— As expected, in Figure 7.4 we note that the full-data estimations are unbiased in all scenarios under the standard ignorability assumption (7.2). Under the CIS assumption, only the full-data estimators that (partly) rely on the outcome model, namely CO, AIPSW, and CW are unbiased, whereas the parametric IPSW estimator fails under CIS. Surprisingly, the nonparametric full-data IPSW estimator recovers the true value in the MAR and MNAR case (see Figure 7.5).

— The complete case estimations are, unsurprisingly, unbiased only in the MCAR case.

— The behavior of the EM estimations is as expected: all estimators are unbiased under CIS under MCAR and MAR. However the AIPSW estimator performs better than the IPSW and the CO. In the MNAR case, the algorithm fails to converge.

— The MIA estimations overall have either small or no bias under CIS, especially the AIPSW estimator. Furthermore, under the CIS assumption, the AIPSW estimator always performs at least as well as the simple estimators (IPSW and CO). Under the standard ignorability assumption, the behavior is heterogeneous and tends toward biased results for all missingness mechanisms.

— Surprisingly, the within-study MI IPSW estimator is biased in all cases except the CIS+MCAR, and CIS+MNAR cases. This behavior is not expected and it remains to be investigated whether this is due to the simulation design.

— The joint fixed effect MI estimator (FE-MI) comes closer to the expected behavior of the multiple imputation approach than the ad-hoc MI (AH-MI) and the within-study MI (WI-MI) estimator as it has small or no bias under the standard ignorability and ignorable missingness (I+MCAR and I+MAR), but all three fail in the MNAR case (as expected).

Note that for the full data case, the choice of the estimator, namely parametric (in our case, generalized linear models) or non-parametric (here generalized random forests), has an impact on the bias, especially for the single-model estimators IPSW and CO. This is not surprising given the linear specification of the conditional odds and outcome models from (7.17) and (7.18) and the rather slow convergence of the chosen non-parametric method, random forest (`grf`), for linear models. [7]

In view of the results, if one has to recommend a method, it is preferable, from the present empirical evidence, to choose the MIA-AIPSW estimator or the joint multiple imputation coupled with the CW estimator. The MIA approach is simple to use in R thanks to the `grf` package which directly handles incomplete variables with the MIA splitting criterion for random forests. However, in terms of computational costs, this approach can be more expensive due to (automatic) parameter tuning. The joint multiple imputation approaches are easy to implement (with the `mice` package) but the relative computational running time is of similar magnitude as the MIA approach.

7. The random forest approach would require a lot of data to estimate linear regression functions; random forests are however known for their good performance in the presence of non-linearities and high order interaction terms [Breiman, 2001].



Figure 7.4 – Empirical bias of generalizing ATE estimators under the *standard ignorability assumption*, 95% Monte Carlo confidence intervals, $n = 1000$.



Figure 7.5 – Empirical bias of generalizing ATE estimators under the *conditionally independent ignorability (CIS) assumption*, 95% Monte Carlo confidence intervals, $n = 1000$.

7.5.3.2 Impact of different proportions of missing values in the RCT and observational data

It is common that the RCT presents significantly less missing values than the observational study due to a more systematic monitoring of the data collection process. This invokes the question of how the above studied methods behave in the case of unbalanced proportions of missing values or different missing values mechanisms in the different data sources.

Extending the previous simulation study by such a case, we summarize in Figure 7.6 the performance of the different estimators under different scenarios of varying proportions of missing values in the RCT and the observational data when the data is MAR given S (or equivalently, we say it is MCAR in each data set). Note that this implies a slightly different factorization of the joint distribution over all variables than the one in the standard MCAR case (8):

$$\begin{aligned} p(X, R, W, Y, S, Q) &\propto p(R|S, Q, X, W, Y)p(S, Q, Y|X, W)p(W|X)p(X) \\ &\propto p(R|S, Q, X, W, Y)p(S, Q|X, W)p(Y|X, W)p(W|X)p(X) \\ &\propto p(R|Q)p(Q|S)p(S|X, W)p(Y|X, W)p(W|X)p(X) \end{aligned}$$

As expected, the complete case estimators are unbiased in this special case since conditionally on S, the data is MCAR. The doubly robust multiple imputation

estimators can cope with very different proportions of missing values, either 10%, 50% in RCT and observational data respectively, or 5% and 22% respectively.

These results are supporting our claim that the previous results and methods apply as well to the likely case of different proportions of missing values in the two studies. Indeed the following data analysis in Section 7.6 is an example of this case.



Figure 7.6 – Bias estimates of generalized ATE under *standard ignorability* where missing values are **"study-wise MCAR"** (≡ MAR given S). For $n \in \{1000, 5000\}$, $n_{sim} = 20$ repetitions. Case A={m=$10 \times n$, RCT=10% NA, Obs=50% NA}; case B={$m = 10 \times n$, RCT=5% NA, Obs=22% NA}.

7.6 – Application on critical care data

In this part, we come back to the medical question introduced in the beginning of this chapter about the potential effect of tranexamic acid (TXA) on mortality in patients with intracranial bleeding. We recall that, in order to answer this question, we have at disposal two data sources: (1) CRASH-2, a multi-center international RCT, (2) Traumabase®, the observational national registry.

A detailed data analysis of the observational registry to address the above medical question has been presented in Chapter 4. We thus refer to this previous analysis for a detailed description of the observational registry as well as their findings. In a nutshell, leveraging only the observational registry does not provide evidence towards a beneficial (or detrimental) effect of TXA on trauma patients with TBI in terms of head-injury-related mortality.

We will first recall a summary of the findings of the original CRASH-2 study [Shakur-Still et al., 2009] before turning to focus on how the handling of missing values in the RCT and the observational registry impacts the final estimations of the population average treatment effect.

7.6.1 Findings of the CRASH-2 RCT

The CRASH-2 (Clinical Randomisation of Antifibrinolytic in Significant Haemorrhage) trial enrolled 20,211 patients in 274 hospitals in 40 countries between May 2005 and 2009 [Shakur-Still et al., 2009].

The aim of this trial was to study the effect of tranexamic acid in adult trauma patients with ongoing significant hemorrhage or at risk of significant hemorrhage, within 8 hours of injury (inclusion criteria), except those for whom antifibrinolytic agents were thought to be clearly indicated or clearly counter-indicated (exclusion criteria). [8].

More precisely, eligible patients were defined as trauma patients within 8 hours of the injury, of age at least 16 years:

— with ongoing significant hemorrhage (systolic blood pressure less than 90 mmHg and/or heart rate more than 110 beats per minute)

— or who are considered to be at risk of significant hemorrhage.

The inclusion criteria and other baseline regressors are summarized in the graph of Figure 7.7.



Figure 7.7 – Causal graph of CRASH-2 trial representing treatment, outcome, inclusion criteria with S and other predictors of outcome (Figure generated using the Causal Fusion software by Bareinboim and Pearl [2016]).

The results of the CRASH-2 study are reported in Shakur-Still et al. [2009] and show a beneficial effect of TXA on the trial population for the primary outcome of interest (all-cause 28 day death).

8. Extract from the study protocol available at https://www.thelancet.com/protocol-reviews/05PRT-1.

7.6.2 Integration of the CRASH-2 trial and the Traumabase® registry

In the following, we discuss common variables definition, outcome, treatment, and designs in order to leverage both sources of information. We recall the causal question of interest: "What is the effect of the TXA on brain-injury death on patients suffering from TBI?" This part is important for the harmonization of the study protocol.

Treatment exposure The treatment protocol of CRASH-2 frames the timing and mean of administration precisely (a first dose given by intravenous injection shortly after randomization, i.e., within 8 hours of the accident, and a maintenance dose given afterwards [Shakur-Still et al., 2009]). The Traumabase® study being a retrospective analysis, this level of granularity concerning TXA is unfortunately not available. Neither the exact timing, nor the type of administration are specified for patients who received the drug. However, the expert committee agreed that the assumption of treatment within 3 hours of the accident is very likely since this drug is administered in pre-hospital phase or within the first 30 minutes at the hospital (see Chapter 4).

Outcome of interest The CRASH-2 trial defined primary outcome as any-cause death in hospital within 28 days of injury. This outcome is also available in the Traumabase®.

Covariates accounting for trial eligibility For the CRASH-2 trial, four criteria determined inclusion: age (patients of at least 16 years old were eligible), ongoing or risk of significant hemorrhage (defined as systolic blood pressure below 90 mmHg or heart rate above 110 beats per minute, or clinicians evaluation of a risk), within 8 hours of injury and absence of a clear indication or counter-indication of antifibrinolytic agents. The necessary variables are also available in the Traumabase®, either exactly or in form of proxies, which allows the estimation of the trial inclusion model on the combined data.

Additional covariates Note that other covariates are (partially) available in both data sets, while not responsible of trial inclusion according to CRASH-2 investigators. But as this could still be covariates moderating the outcome and treatment effect, we include them in the outcome models used for instance in the CO and AIPSW estimators (7.5) and (7.6). According to the two data sets, we could add three of them: sex (binary), type of injury (categorical, 1 =blunt, 2 = penetrating, 3 = blunt and penetrating), and initial Glasgow coma scale (numeric, integers from 3 to 15). Note that this three covariates are all mentioned in the baseline of CRASH-2 results [Shakur-Still et al., 2009], arguing that they should impact the outcome. The variables *central capillary refill time* and *respiratory rate* are also mentioned but are not available in the Traumabase®, we thus omit them from this joint study.

Missing values First, note that the RCT contain almost no missing values, whereas the variables for determining eligibility in the observational data contains important fractions of missing values, as shown in Table 7.8, while the sample sizes of the data sets are similar, see Table 7.3.



Figure 7.8 – Percentages of missing values in each covariate for the Traumabase® and CRASH-2 RCT.

Table 7.3 – Sample sizes for the two studies.

	m	n	#treated	#all-cause 28d death
Traumabase	8248	–	686	1648
CRASH-2	–	3727	1866	1176

While the MCAR assumption is admitted for the RCT [Shakur-Still et al., 2009], the missing values in the observational Traumabase® are more complex and, according to the medical experts monitoring the collection process, partly non-ignorable. For instance, the pre-hospital systolic blood pressure (SBP) is likely to be missing for patients with severe ongoing bleeding. Since the latter is informed in the *hemorrhage risk* variable, we could admit the missing values in the SBP variable as being MAR. A similar reasoning can be applied for the delay between the accident and treatment administration. However, there remains uncertainty as to whether the observed variables allow to fully explain the missingness in this variable.

Distribution shift There are different ways of assessing the shift between the distributions of the two studies, for instance by univariate comparisons. We provide a simplified comparison of the means of the covariates between the treatment groups of the two studies in Figure 7.9. This graph illustrates again the fundamental difference between the two studies, namely the treatment bias in the observational study and the balanced treatment groups in the RCT, but also a covariate shift between the two studies. For instance, the average patient age in the RCT is 7-9 years below the

average age in the observational study; and there are only 16% of female patients in the RCT while there are over 20% in the observational study.



Figure 7.9 – Distributional shift and difference in terms of univariate means of the trial inclusion criteria (red: group mean greater than overall mean, blue: group mean less than overall mean, white: no significant difference with overall mean, numeric values: group mean (resp. proportion for binary variables). Graph obtained with the `catdes` function of the `FactoMineR` package [Lê et al., 2008].

Ignorability Due to the design of the CRASH-2 study, namely the eligibility criteria which all need to be informed to decide upon trial eligibility, the modified ignorability assumption CIS (7.13) is less plausible to hold in this case and we rather consider the standard assumptions (7.2) and (7.3) to be satisfied by the CRASH-2 and Traumabase® studies. The additional assumptions concerning the missing values mechanism(s) have been outlined above and we consider that the assumptions for the multiple imputation strategy to be applicable are sufficiently plausible in this real-world example.

The distribution of the estimated selection scores are given in Figure 7.10 (a) (logistic regression via EM), Figure 7.10 (b) (generalized random forest with MIA), and Figure 7.10 (c) (logistic regression on joint fixed effect multiple imputations, MI). We notice that the scores obtained using EM and MI are similar and suggest that the positivity assumption is satisfied since we observe a good degree of overlap between the distributions of the scores for the two data sets. The scores estimated via MIA however concentrate around 0 and 1 for the observational and RCT observations respectively, suggesting poor overlap under this model. In Appendix E.2, we provide further comparisons of the estimated selection scores, pointing towards the multiple imputation strategy as the suited approach in this case.

These results provide an additional argument in favor of the multiple imputation strategy which appears to be more adapted to the handling of missing values in this analysis; in particular we will apply a joint fixed effect multiple imputation strategy since it outperforms the other multiple imputation strategies in the simulation study of Section 7.5.



(a) EM. Obtained with the `misaem` R package.

(b) MIA. Obtained with the `grf` R package.



(c) Joint fixed effect MI. Obtained with the `mice` R package.

Figure 7.10 – Estimated densities of the fitted selection scores.

7.6.3 Final results when transporting the ATE from the CRASH-2 trial onto the observational study population

We now apply the estimators presented in this work and implemented first for the simulation study of Section 7.5. The confidence intervals for the corresponding point estimators are computed via non-parametric stratified bootstrap [Efron and Tibshirani, 1994] using 100 bootstrap samples (using stratified sampling to preserve the study-specific sample sizes).

We additionally report two consistent ATE estimators from the solely CRASH-2 data:

— `Difference_in_mean`: the difference in mean estimator (classical estimator for RCT, see Definition 1.4.1);

— `Difference_in_condmean_ols` the difference in conditional means where the we assume linear-logistic outcome models for $Y(1)$ and $Y(0)$ (estimator for

RCT with smaller variance, see Definition 1.4.2).

The former only involves treatment assignment W and outcome Y and thus requires no additional handling of the incomplete covariates; the latter is obtained using an EM algorithm for logistic regression with ignorable missing values in the covariates [Jiang et al., 2020].

And we present the AIPW estimators [Robins et al., 1994] for the observational study applied solely on the Traumabase® data. The derivation and properties of these estimators applied on incomplete observations have been provided in Chapter 4:

— Nuisance parameters via generalized random forest after multiple imputation (`MI_AIPW`),

— Nuisance parameters via generalized random forest using MIA splitting criterion (`MIA_AIPW`).

Since AIPW combined with either missing incorporated in attributes (`MIA`) or multiple imputation (`MI`) is recommended in the conclusion of Chapter 4 when analyzing observational data, these are the estimators kept in this analysis.

When summarizing the results from the separate analyses on the RCT and the observational data respectively and the results from the joint analysis of both studies, we observe on Figure 7.11 a discrepancy between the different results. The only approach with consistent estimations throughout all estimators is the EM approach that points towards a beneficial effect of TXA on all-cause mortality. The joint fixed effect multiple imputation IPSW and AIPSW estimators (`MI_IPSW` and `MI_AIPSW`) also conclude on a beneficial effect of the treatment. However, the calibration weighting estimator (`MI_CW`) does not find a significant effect.

The large confidence intervals could be partly explained by the measurement noise in the administration delay variable in the Traumabase®: contrary to the RCT, the Traumabase® does not encode the exact delay of treatment administration, but is defined by a noisy proxy (delay between accident and admission to the resuscitation bay). However there exists evidence that administration delay is a treatment modifier for TXA and that only early administration has a beneficial effect [Hijazi et al., 2015, CRASH-2 Collaborators et al., 2011]. This remark and the discrepancies between the findings, especially the different conclusions of the joint fixed effect multiple imputation estimators call for additional attempts to further refine the administration delay proxy variable in the Traumabase® and potentially for additional analyses with supplementary data such as the CRASH-3 study [Cap, 2019] which describes another slightly different TBI patient population.



Figure 7.11 – Separate and joint ATE estimators and 95% confidence computed on the Traumabase® (observational data set; purple), on the CRASH-2 trial (RCT; cyan), and generalized from CRASH-2 to the Traumabase® target population (red). Number of variables used in each context is given in the legend. The confidence intervals obtained on the observational data set and on the joint data sets are obtained via nonparametric bootstrap.

7.7 – Conclusion

In this work we have shown that missing values in multiple data sources require additional assumptions either on the mechanism that generated the missing values or on the data generating processes of both data sources to ensure generalizability (or transportability) of the treatment effect. We have proposed several estimators that are suited for generalizing a treatment effect from an RCT to a different target population described by observational covariate data. Which of the proposed methods is preferable depends on the underlying identifiability assumptions for generalizing the treatment effect. If the identifiability assumptions on the full data case are kept and only assumptions on the missingness mechanism are added, we recommend a joint multiple imputation that models the data source as fixed effect as long as the missing values are ignorable. If the identifiability assumptions are altered to account for informative missing values implicated in the selection process, then estimators involving generalized conditional models are suited. These estimators

rely on strong assumptions about the form of ignorability that is imposed, and we note that in many common examples in medicine or epidemiology it does not appear to be the most plausible one. The approach(es) that only imply additional assumptions on the missing values mechanism seem both closer to real application contexts and methodologically more feasible. Indeed, the presented data analysis on a treatment administered in critical care falls into this latter case and the results obtained with the proposed estimators from the two different presented approaches do not come to the same conclusion. This illustrates again the importance of choosing adequate assumptions for identifiability with missing covariate values and corresponding estimation strategies.

On the methodological side, for all considered approaches and simulation settings, the question of varying missing values mechanisms across data sources remains to be addressed in more detail. Note as well that we have focused on missing values in both data sets, but the recommendations extend to the case where there are only missing values in the observational data and not the RCT due to different levels of systematic data collection.

Finally, the problem of incomplete observations addressed here is different from the problem of inconsistent variable sets between an RCT and an observational dataset, e.g., one variable is completely missing in one set, which is a challenging problem of a different kind that is left for future work. We note that this latter problem may cause issues of identifiability and is thus more related to the problem of unobserved confounding and a recent work proposes sensitivity analysis to address this issue [Colnet et al., 2021].

Acknowledgements

We would like to thank Shu Yang for fruitful discussions and her valuable feedback on our work. We thank Tobias Gauss, Jean-Denis Moyer and François-Xavier Ageron for their medical insights and interpretation of our data analysis; finally we thank the CRASH-2 trial investigators for sharing the trial data with us.

Part V

Applications and implementations

Chapter 8

Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection

This chapter presents a work led by Emilie Sbidian, Etienne Audureau and Julie Josse in collaboration with researchers from AP–HP, INSERM, and Inria. I have contributed to the data analysis, an application of the methodology proposed in Chapter 4; the medical considerations and interpretations have been led by Emilie Sbidian and Etienne Audureau.

Abstract

Background

Several publications have raised the question of hydroxychloroquine (HCQ) efficacy for COVID- 19 infection. We aimed to assess the clinical effectiveness of oral HCQ in preventing death or allowing to hospital discharge using a non-selected population.

Methods

Retrospective cohort study from the 39 public hospitals in France. All adult inpatients with COVID-19-documented infection between February 1st and April 6th, 2020 were eligible. Patients were classified into 3 groups: (i) HCQ alone, (ii) HCQ together with AZI, and (iii) neither HCQ nor AZI. Outcomes were all-cause 28-day mortality and discharge home. Multivariable analyses relied on augmented inverse probability of treatment weighted (AIPTW) estimates of the average treatment effect (ATE) on the whole population.

Results

A total of 4,642 patients (mean age: 66.1 ± 18; males: 2,738 (59%)) were included, of whom 623 (13.4%) received HCQ alone, 227 (5.9%) HCQ plus AZI, and 3,792 (81.7%) neither drug. After accounting for confounding, no statistically significant difference was observed between the 'HCQ' and 'Neither drug' groups for 28-day mortality: AIPTW ratio in ATE 1.05 (0.77 to 1.33). 28-day discharge rates were statistically significantly higher in the 'HCQ' group: AIPTW ratio in ATE (1.25 [1.07 to 1.42]). As for the 'HCQ+AZI' vs neither drug, trends for significant ratios in AIPTW ATE were found suggesting higher mortality rates in the former group.

Conclusions

No evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality was found. Significantly higher rates of discharge home were observed in patients treated by HCQ, a finding warranting further confirmation in replicative studies.

Table of contents
Table des matières

8.1 – Introduction

The COVID-19 pandemic due to the SARS-CoV-2 coronavirus started in Wuhan, China last December, 2019 [Guan et al., 2020]. The COVID-19 epidemic is a worldwide pandemic with more than 16 million cases reported up to July 26, 2020, of whom more than 645,000 have died. Because effective treatments are urgently needed, more than 600 clinical trials are currently ongoing in a worldwide effort to fight the coronavirus. The 4-aminoquinolines chloroquine (CQ) and hydroxychloroquine (HCQ) are synthetic antimalarials drugs (AMD). The use of HCQ or HCQ with azithromycin (AZI) has arisen as a promising treatment or combination of treatment for COVID-19 infection. First, in vitro data have shown the effectiveness of HCQ

(and to a lesser extent CQ) in reducing the viral load of cells infected with SARS-CoV-2 [Yao et al., 2020b]. Then, a Chinese clinical trial showed that CQ had a significant effect, including a better clinical outcome, when compared to control groups [Chen et al., 2020]. A French research team suggested that HCQ, at a dose of 600 mg/day, was associated with viral load reduction in twenty COVID-19 patients and its effect was strengthened by AZI [Gautret et al., 2020a]. These preliminary results were further backed up by two prospective cohorts from the same team of 80 and 1,061 participants, suggesting good clinical outcomes in 65 (81%) and 973 (92%) patients, respectively, with lower frequency of aggressive clinical course requiring oxygen therapy, fewer transfers to the intensive care unit (ICU), or death after at least 3 days of treatment and a viral load reduction at day 6 [Gautret et al., 2020b, Million et al., 2020]. In multivariate analysis, hydroxychloroquine use was associated with a lower risk of in-hospital death among 6,493 patients with COVID-19 who were seen in 8 different hospitals and 400 ambulatory practices in the New York City metropolitan area [Mikami et al., 2021]. Several published or preprint publications have raised the question of HCQ efficacy for COVID- 19 infection. Four observational studies with diverse cohort sizes (81, 368, 1,376, and 1,438 participants) failed to find a difference between HCQ and no-HCQ groups in terms of risk of death or need for mechanical ventilation [Mahévas et al., 2020, Magagnoli et al., 2020, Geleris et al., 2020, Rosenberg et al., 2020]. Preliminary results from the UK RECOVERY randomized trial have been communicated concluding that there was no beneficial effect of HCQ on 28-day mortality in hospitalized patients with COVID-19 [Torjesen, 2020 (cited on 2020-06-16, Horby et al., 2020]. Data from large health care databases provide a unique opportunity to assess the potential effectiveness and harm of HCQ in a real-world setting, including unselected population. Because some variation has been reported between studies, replicated analyses minimizing selection and confounding biases are crucially needed to disentangle current evidence on the actual risks and benefits of HCQ-based treatments. We consequently aimed to assess the clinical effectiveness of oral HCQ in preventing death or allowing to hospital discharge using a large, exhaustive, non- selected population of in-patients hospitalized for COVID-19 infection in 39 hospitals in France, accounting in detail for patients characteristics.

8.2 – Methods

8.2.1 Study Design

We performed a retrospective cohort study using the Corona OMOP database, which combines electronic medical records and administrative claim data from the Greater Paris Public Hospitals (Assistance Publique - Hôpitaux de Paris (AP-HP) data warehouse, called ‘Entrepôt de Données de Santé’ (EDS). This study was approved by the French data protection agency Commission Nationale de l’Informatique et des Libertés (regulatory decision DE-2017-013), IRB00011591.

8.2.2 Data sources

The EDS currently collects data on more than 11 million patients treated in the 39 hospitals of the AP-HP, Ile-de-France, France. The warehouse contains medico-administrative data from the Medical Information System Program (PMSI), the French national hospital database which gathers information from standardized discharge reports on diagnoses and procedures performed in all medical units involved in patient management during his/her hospital stay. Primary and associated diagnoses are recorded using the International Classification of Diseases, 10^{th} edition (ICD-10) and therapeutic procedures using a national standardized classification system (Classification Commune des Actes Médicaux, CCAM, 11^{th} edition).

In addition to PMSI data, the EDS gathers information from multiple electronic health record databases, including biology and imaging results, drug prescriptions (stored within the ORBIS medication database and coded according to the international Anatomical Therapeutic Chemical (ATC) classification system) and medical text reports associated with hospital visits, including emergency department data and outpatient visits. EDS data were part of a European collaborative project which aimed to capture the trajectory of COVID-19 disease in patients and their response to interventions [Brat et al., 2020 (cited on 2020-07-17].

8.2.3 Data acquisition

PMSI information was not available for patients being still hospitalized or for whom discharge reports were not yet processed at the time of analysis. Consequently, data acquisition for the present study relied on both structured data (i.e. PMSI pertaining to past hospitalizations, if any, biological results, ORBIS medication system) and unstructured data (i.e. medical text records). For the latter, we used artificial intelligence algorithms based on Natural Language Processing (NLP), to extract information on patients diagnoses (including comorbidities, see below) and drugs prescriptions (including HCQ+/−AZI), considering contexts where mentions of drugs by name do not correspond to actual prescriptions (i.e. when the drug is mentioned in a negative context) [Hamon and Grabar, 2010], and considering both International non-proprietary name (INN) and trade-marks.

8.2.4 Study population

All adult ($\geq$ 18 years of age) inpatients with at least one polymerase chain reaction-documented SARS-CoV-2 RNA from a nasopharyngeal sample between February 1^{st} , 2020 and April 6^{th} , 2020 were eligible for the present analysis. The date of inclusion in the study cohort (index date) was defined as the date of admission. We excluded patients having received specific COVID-19 treatments, i.e. treatments assessed in ongoing trials: remdesivir, lopinavir-ritonavir (ATC J05AR10), favipiravir (J05AX27), anti-interleukin 1 - i.e., anakinra (ATC L04AC03), canakinumab (ATC L04AC038) - anti-interleukin 6 - i.e., tocilizumab (ATC L04AC037), sarilumab (ATC L04AC14). When patients were transferred between hospitals for the same stay, several discharge reports were available which were analyzed as a single hospital stay

until first discharge home. Patients who died or were discharged within 24 hours following their admission were excluded. The end of follow-up was defined by the time of death, discharge home, day 28 (D28) after admission, whichever occurred first, or administrative censoring on May 4, 2020. Patients transferred to hospitals outside AP-HP or to follow-up care and rehabilitation services before day 28 were considered as censored.

8.2.5 Outcomes

The study's primary outcome was all-cause 28-day mortality, assessed as a time-to-event endpoint under a competing risks survival analysis framework. For patients discharged home before day 28, we looked at subsequent re-admissions to determine vital status on day 28. The secondary outcome was 28-day discharge home, also assessed as a time-to-event endpoint.

8.2.6 Drug exposures

While there was no overarching recommendation regarding HCQ+/−AZI prescription at the AP- HP level, guidelines were nonetheless proposed at local level in several individual hospitals, suggesting hydroxychloroquine to physicians as a therapeutic option for patients with moderate- to-severe COVID-19 infection, i.e. requiring oxygen. The suggested HCQ regimen was a loading dose of 600 mg on day 1, followed by 400 mg daily for 9 additional days. AZI at a dose of 500 mg on day 1 and then 250 mg daily for 4 more days in combination with HCQ was an additional suggested therapeutic option. Prescription of HCQ or HCQ together with AZI was at the discretion of the physicians.

Using data acquisition procedures previously detailed, we identified patients with a prescription of HCQ (ATC P01BA02), AZI (ATC J01FA10), steroids (ATC H02AB), and antithrombotic agents (heparin group, ATC B01AB) usually used for acute respiratory distress syndrome [Villar et al., 2020, Camprubí-Rimblas et al., 2018]. Exposure to a HCQ/AZI combination was defined as a simultaneous prescription of the two treatments (within one day). Based on previous possible combinations, patients were further classified into three groups: (i) receiving HCQ alone, (ii) receiving HCQ together with AZI, and (iii) receiving neither HCQ nor AZI. Patients receiving AZI alone were excluded, in accordance with our objective to assess clinical effectiveness of HCQ with or without AZI vs. neither specific treatment.

8.2.7 Covariates

For each patient, age, sex, hospital-admission location, ICU admission, ICU stay length and hospital stay length were recorded. Co-morbidities and risk factors (smoker status, obesity, hypertension, diabetes, dyslipidemia, ischaemic or rhythmic heart diseases, heart failure, renal disease, presence of chronic respiratory insufficiency or asthma or cystic fibrosis, and cancer) were recorded for the two-year period before the index date. Clinical severity features within 24h after admission were also recorded: ICU transfer within the first 24h, oxygen saturation, partial pressure of oxygen (PaO_2 mmHg), and carbon dioxyde (PCO_2). Lastly, biologic values were also recorded at the index date using their LOINC (Logical Observation Identifiers Names and Codes). Biological values were recorded for neutrophils, lymphocytes, C reactive protein, D-Dimer, prothrombin time, creatine, and lacticodesydrogenase. Detailed definitions of the covariates are available in Supplemental Table F.1.

8.2.8 Statistical analysis

All analyses were performed considering the three main treatment modalities of interest, as previously described (HCQ/HCQ+AZI/Neither drug), in the entire population or after stratifying by the level of severity of COVID-19 at admission, considering (i) early ICU admission as defined as occurring within the first 24 hours of admission or (ii) not. Descriptive statistics are detailed in Appendix F.

8.2.8.1 Causal inference modeling

Due to the influence on treatment assignment of baseline characteristics of patients included in non-randomized observational studies, it is essential to account for such differences when estimating treatment effects to address bias arising from confounding [Austin, 2011]. To do so, we used two complementary analytical approaches, both relying on propensity-score estimation. First, causal inference modeling was conducted based on the computation of the average treatment effect (ATE) of HCQ+/−AZI on the whole population, under assumptions of unconfoundedness (i.e., potential outcomes are independent of the treatment assignment conditionally on a vector of covariates) [Rosenbaum and Rubin, 1983b] and its extension in the presence of missing values [Rosenbaum and Rubin, 1984, Wendling et al., 2018]. This calculation relied on doubly robust estimators combining an outcome regression with a model for the treatment (i.e., propensity score) to derive augmented inverse probability of treatment weighting (AIPTW) estimators, a more effective approach in minimizing bias due to model mis-specification than only IPTW [Funk et al., 2011]. Second, average treatment effect for the treated (ATT) population was estimated using a propensitymatched analysis. Matching between treated (i.e. HCQ+/−AZI) and controls (i.e. neither drug) was performed with 1 : 1 ratio, using the nearest neighbor matching method with exact matching on the gender.

The selection of the relevant covariates to be used in causal inference modeling was based on available published data at the time of analysis [Goyal et al., 2020] and expert *a priori* knowledge on key prognostic factors and determinants of treatment

assignment, including patients' demographics, co-morbidities, hospital and time period of admission. Supplemental Figure F.1 generated using DAGitty [Textor et al., 2011],Textor et al. [2011] shows the causal inference model we applied, differentiating between variables assessed as predictors of the treatment assignment, unrelated to the outcome (brown), predictors of the outcome, unrelated to the treatment assignment (blue), predictors of both treatment and outcome (violet).

As the primary analysis, we constructed cause-specific Cox proportional hazards regression models to account for the competing risk between all-cause death and hospital discharge. For ATE computation on the whole population, doubly-robust estimation equations were derived based on regression models for the outcome and the censoring (using Cox modeling), and the treatment distribution (using a generalized linear model with a logit link function), conditional on baseline covariates [Ozenne et al., 2020]. ATEs were calculated as the ratios in the standardized absolute risks, Benichou and Gail [1990] along with their 95% confidence intervals (95% CI). For ATT computation on the propensity-matched population, hazard ratios and 95% CI were computed from the cause-specific Cox models using robust variance estimators.

8.2.8.2 Sensitivity analyses and missing data handling

We conducted several sensitivity analyses to check the stability of our results under varying approaches. First, we assessed 28-day mortality as a binary endpoint, considering patients discharged home before day 28 as alive at that date and excluding patients transferred to hospitals outside AP-HP or to follow-up care and rehabilitation services before day 28. To do so, we used the causal forest implementation based on the generalized random forests (GRF) method [Athey et al., 2019] to compute forest-based weighting functions and derive AIPTW estimates for doubly robust inference of the average treatment effect (ATE). Second, conventional multivariable and IPT-weighted analyses ('singly robust') using cause specific Cox models and Fine-Gray competing risks analyses were also performed, computing IPT-weighted and adjusted hazard ratios (HR) and subhazard ratios (SHR), respectively, and plotting raw and adjusted cumulative incidence curves to illustrate the associations.

For all IPT-weighting and propensity-matched population based analyses, standardized differences of the means were computed before and after IPTW or matching to assess imbalance of the covariates between treatment groups. Standardized differences less than 10% were considered negligible following common practice when using IPTW to estimate causal treatment effects in observational studies [Austin and Stuart, 2015].

To account for the potential influence of missing data on causal inference procedures, we used single imputation with a (regularized) iterative Factorial Analysis for Mixed Data model (FAMD) [Audigier et al., 2016], accounting for similarities between both individuals and relationships between covariates, treatment assignment and the outcome. Variables showing departure from normality using graphical methods and kurtosis/skewness statistics were log-transformed prior to imputation. For the GRF method, the GRF-MIA approach which enables the computation of ATE without any imputation of the data was used for missing data handling.

A two-tailed p-value of less than 0.05 was considered significant. Statistical analyses were performed using R v3.6.4 (R Foundation for Statistical Computing, Vienna, Austria; packages *grf, riskRegression* [Ozenne et al., 2020, Tibshirani et al., 2020]).

8.3 – Results

8.3.1 Study population

From February 1st to April 6, 2020, 5,556 adult patients were hospitalized at AP-HP for a Covid19 infection and did not receive specific COVID-19 treatments other than HCQ or AZI. Patients who died (n = 91) or who were discharged (n = 196) within 24 hours after their admission were excluded, as well as patients receiving AZI alone (n = 582) or patients who did not initiate HCQ and AZI the same day (more or less 24 hours, n = 45). Thus, a total of 4,642 patients (mean age: 66.1 ± 18; males: 2,738(59%)) were included in the study population, of whom 623(13.4%) received HCQ alone, 227(5.9%) received HCQ plus AZI, and 3,792(81.7%) neither HCQ nor HCS plus AZI (Figure 8.1). In the 'HCQ alone' and 'HCQ plus AZI' groups, median timing of the first dose of HCQ after the admission was 0.42 days, IQR (0 to 2.3).



Figure 8.1 – Flow chart of the study population.

8.3.2 Descriptive results

The main characteristics of the study population are summarized in Table 8.1. Patients receiving 'HCQ alone' or 'HCQ plus AZI' were more likely younger, males, current smokers and overall presented with slightly more co-morbidities (obesity, diabetes, any chronic pulmonary diseases, liver diseases) than the 'Neither drug' group, while no major difference was apparent in biological parameters. Supplemental Table F.2 shows the main characteristics of the study population after imputation of missing data using the FAMD methodology, as previously described.

Table 8.1 – Patient characteristics by treatment group.

	Missing data	**HCQ alone,** n=623	**HCQ plus AZI,** n=227	**Neither drug,** n=3792
Demographic characteristics				
Age years, median (IQR)		63 (53 – 74)	61 (53 – 72)	69 (54 – 82)
Male sex, n (%)		413 (66.3)	158 (69.6)	2167 (57.1)
Comorbidities, n(%)				
Current smoker	156(3.3)	178(28.6)	65(28.6)	913(24.1)
Obesity	156(3.3)	121(19.4)	59(26)	467(12.3)
Hypertension	156(3.3)	30(4.8)	8(3.5)	229(6)
Diabetes	156(3.3)	243(39)	89(39.2)	1229(32.4)
Dyslipidemia	156(3.3)	141(22.6)	50(22)	761(20.1)
Ischaemic heart disease	156(3.3)	1643(26.2)	47(20.7)	924(24.4)
Rhythmic heart diseases	156(3.3)	60(9.6)	23(10.1)	488(12.9)
Chronic renal failure & Chronic end-stage kidney failure	156(3.3)	142(22.8)	26(11.5)	770(20.3)
Asthma	156(3.3)	45(7.2)	30(13.2)	280(7.4)
Chronic obstructive pulmonary diseases	156(3.3)	27(4.3)	19(8.4)	173(4.6)
Other chronic respiratory failure	156(3.3)	19(3.0)	8(3.5)	87(2.3)
Hepatic Failure	156(3.3)	35(5.6)	25(11)	160(4.2)
Cancer	156(3.3)	117(18.8)	50(22)	822(21.7)
Hemopathies	156(3.3)	35(5.6)	15(6.6)	210(5.5)
Chemotherapy	156(3.3)	96(15.4)	42(18.5)	679(17.9)
Current steroid use		106(17)	43(18.9)	400(10.5)
Biological parameters at baseline				
Oxygen saturation (%), median (IQR)	2114 (45.1)	95 (92.3 – 97)	95.2 (92.7 – 97)	95 (92 – 97.3)
Partial pressure of oxygen (mmHg), median (IQR)	2032 (43.3)	75.1 (64 – 90.2)	73.1 (62 – 87.5)	73.5 (59 – 91.5)
Partial pressure of carbon dioxide (mmHg), median (IQR)	2007 (42.8)	35.2 (31.9 – 39.1)	35.6 (30.8 – 39.2)	35 (30.2 – 39.6)
Neutrophil count per mm^3, median (IQR)	652 (13.9)	4.64 (3.41 – 6.71)	4.6 (3.5 – 6.6)	4.82 (3.28 – 7.08)
Lymphocyte count per mm^3, median (IQR)	660 (14.1)	0.94 (0.64 – 1.28)	1 (0.7 – 1.3)	0.96 (0.69 – 1.3)
Prothrombin time (%), median (IQR)	1155 (24.6)	86 (76 – 96)	81 (72 – 89)	86 (75 – 96)
D-Dimer (μ g/L), median (IQR)	2883 (61.5)	847 (577 – 1458)	720 (486 – 1274)	1110 (630 – 2066)
Creatine (mg/dL), median (IQR)	221 (4.7)	84 (68.5 – 110)	80.2 (65.5 – 99.5)	83 (65 – 113)
C reactive protein (mg/L), median (IQR)	546 (11.6)	77.3 (42.7 – 135)	85.5 (45 – 136)	65 (23.3 – 103)
Lacticodeshydrogenase (U/L), median (IQR)	2174 (46.4)	371 (292 – 290)	402 (314 – 554)	367 (265 – 527)

IQR: interquartile range.

Table 8.2 shows unadjusted clinical outcomes by treatment group. Raw 28 -day

mortality rates statistically differed between the three groups (number of deaths: 111(17.8%), 54(23.8%) and 830 (21.9%) for 'HCQ alone', 'HCQ plus AZI' and 'Neither drug' groups, respectively; $p < 0.001$). Of the 4,642 patients, 777 (16.7%) were transferred to ICU within $24h$ after the admission, more markedly so in the 'HCQ plus AZI' group (27.3%; $p < 0.001$). Groups main characteristics stratified by early ICU transfer are summarized in Supplemental Tables F.3 and F.4.

Table 8.2 – Unadjusted clinical outcomes by treatment group.

	HCQ alone, n=623	**HCQ plus AZI,** n=227	**Neither drug,** n=3792	**p-values**			
				*Overall**	*HCQ vs. HCQ+AZI***	*HCQ vs. neither drug***	*HCQ+AZI vs. neither drug***
ICU transfer							
Early (<1 day)	94 (15.1)	62 (27.3 %)	621 (16.4)				
Later ≥1 day)	112 (18)	35 (15.4 %)	17 2(4.5)				
Concurrent with treatment initiation	50 (44.6)	26 (54.2)	–				
After treatment initiation	62 (55.4)	22 (45.8)	–				
Time to ICU transfer, days, median (IQR)	1.18 [0.15 ; 3.49]	0.37 [0.07 ; 2.26]	0.16 [0.00 ; 0.80]	**<0.001**	**0.004**	**<0.001**	**0.001**
Mortality							
Overall mortality rate n (%)	126 (20.2 %)	56 (24.7 %)	865 (22.8 %)	0.264	0.289	0.289	0.572
28-day mortality rate, n (%)	111 (17.8 %)	54 (23.8 %)	830 (21.9 %)	**<0.001**	**0.002**	**<0.001**	0.795
Time to death, days, median (IQR)	8.66 [4.72 ; 15.4]	7.30 [4.46 ; 11.7]	7.54 [3.94 ; 13.0]	0.104	0.227	0.112	0.797
Hospital discharge							
Overall discharge rate, n (%)	363 (58.3 %)	117 (51.5 %)	1545 (40.7 %)	**<0.001**	0.095	**<0.001**	**0.003**
28-day discharge rate, n (%)	351 (56.3 %)	114 (50.2 %)	1507 (39.7 %)	**<0.001**	0.055	**<0.001**	**0.011**
Time to discharge, days, median (IQR)	8.90 [6.02 ; 13.4]	8.75 [5.99 ; 13.2]	5.99 [3.15 ; 11.1]	**<0.001**	0.994	**<0.001**	**<0.001**
Length of stay among those alive, days, median (IQR)	10.2 [6.73 ; 17.5]	9.83 [6.91 ; 17.6]	10.9 [4.74 ; 31.9]	0.974	0.984	0.984	0.984
Length of stay among those alive, days, mean (SD)	15.0(12.7)	14.7(12.0)	17.6(15.7)	**<0.001**	0.976	**0.002**	0.056

* Based on overall between-groups comparisons, using Chi^2 or Kruskal-Wallis tests for categorical and continuous variables, respectively.
** Based on pairwise between-groups comparisons, using Chi^2 or Mann-Whitney tests with Benjamini-Hochberg correction for test multiplicity.
Bolded results are statistically significant at the $p < 0.05$ level

8.3.3 Average treatment effects on the whole population

Results from competing risks multivariable analyses for the average treatment effect of HCQ+/AZI on 28 -day mortality and hospital discharge are displayed in Table 8.3, showing both raw unadjusted estimates and AIPTW results from double robust estimation accounting for confounders for the outcome and the treatment allocation. In the whole population, the raw ratio in average treatment effect on 28-day mortality for the 'HCQ' versus 'neither drug' comparison was 0.78 (0.64 to 0.91). After accounting for confounding, no significant difference was observed between the 'HCQ alone' and 'Neither drug' groups with a AIPTW ratio in ATE of 1.05 (0.77 to 1.33; $p = 0.723$). Regarding 28 -day discharge rates, a statistically significant difference was found for the ratio in AIPTW ATE in favor of 'HCQ alone' (1.25 [1.07 to 1.42; $p = 0.006$]). For the 'HCQ plus AZI' vs. 'Neither drug' comparison, a trend was found towards higher mortality rates in the former group, though not reaching statistical significance (ratio in ATE 1.40 [0.98 to 1.81]; $p = 0.062$). Results from subgroup analyses according to early ICU transfer, age ($<$ vs. ≥ 65 years), period ($<$ March 20^{th} , March $20^{\text{th}} - 30^{\text{th}}$, $>$ March 30^{th}) are detailed in Table 8.3, notably

showing varying results regarding 28 -day mortality for the HCQ+AZI vs neither drug comparison according to age (with a statistically significant unfavourable HR found in older patients) and period (with an increasingly worsening association with time), while results varied regarding 28-day discharge according to age for the HCQ vs neither drug comparison (with a statistically significant relationship being only found in younger patients), and period for the HCQ+AZI vs neither drug comparison (with highly contrasted results depending on the period).

Table 8.3 – Adjusted clinical outcomes according to treatment groups: results from weighted analyses on the whole population.

		HCQ alone vs neither drug		**HCQ plus AZI vs neither drug**	
		Raw Estimate (95% CI)	Adjusted Estimate* (95% CI)	Raw Estimate (95% CI)	Adjusted Estimate* (95% CI)
28-day mortality					
Whole population		**0.78 (0.64-0.91)**	1.05 (0.77-1.33)	1.05 (0.80-1.30)	1.40 (0.98-1.81)
Transfer to ICU within the first 24 hours	Yes	0.84 (0.53-1.14)	0.75 (0.20-1.30)	0.99 (0.59-1.38)	1.20 (0.77-1.63)
	No	**0.77 (0.62-0.93)**	1.13 (0.82-1.44)	1.02 (0.72-1.32)	1.41 (0.82-2.00)
Age	< 65 years	0.81 (0.47-1.15)	0.82 (0.41-1.22)	0.82 (0.29-1.35)	1.49 (0.00-3.68)
	≥ 65 years	0.91 (0.75-1.08)	1.20 (0.87-1.54)	**1.40 (1.10-1.70)**	**1.51 (1.03-2.00)**
Period	Before March 20th	0.76 (0.42-1.09)	1.08 (0.30-1.86)	0.74 (0.07-1.41)	0.59 (0.00-2.93)
	March 20th - March 30th	**0.80 (0.62-0.98)**	0.90 (0.65-1.16)	0.98 (0.68-1.27)	1.24 (0.77-1.71)
	After March 30th	**0.71 (0.44-0.98)**	1.20 (0.62-1.79)	1.33 (0.78-1.88)	**1.96 (1.28-2.64)**
28-day hospital discharge					
Whole population		**1.37 (1.27-1.48)**	**1.25 (1.07-1.42)**	**1.28 (1.11-1.44)**	1.00 (0.77-1.23)
Transfer to ICU within the first 24 hours	Yes	**1.51 (1.09-1.93)**	1.03 (0.42-1.64)	**1.64 (1.13-2.15)**	1.09 (0.76-1.42)
	No	**1.35 (1.24-1.45)**	1.16 (0.98-1.33)	**1.27 (1.09-1.45)**	1.01 (0.74-1.28)
Age	< 65 years	**1.21 (1.12-1.31)**	**1.24 (1.09-1.38)**	**1.22 (1.08-1.37)**	1.12 (0.92-1.33)
	≥ 65 years	**1.43 (1.22-1.65)**	1.04 (0.70-1.37)	1.04 (0.71-1.36)	0.85 (0.42-1.27)
Period	Before March 20th	1.15 (0.95-1.35)	1.23 (0.81-1.65)	1.00 (0.62-1.39)	0.77 (0.00-3.24)
	March 20th - March 30th	**1.41 (1.26-1.57)**	**1.26 (1.06-1.46)**	**1.45 (1.23-1.68)**	**1.26 (1.04-1.47)**
	After March 30th	**1.55 (1.33-1.77)**	**1.32 (1.02-1.63)**	1.14 (0.79-1.48)	**0.69 (0.44-0.94)**

All results are ratios in average treatment effect
** AIPTW: Augmented inverse probability of treatment weight estimator for doubly robust inference of the average treatment effect conditional on baseline covariates, derived from cause specific Cox proportional hazards modeling; 95% CI: 95% confidence interval*
Baseline covariables considered for adjustment were sex, age, current smoker, diabetes, obesity, hypertension, dyslipidemia, Ischaemic heart disease, rhythmic heart diseases, Chronic renal failure & Chronic end-stage kidney

Results from double robust analyses considering 28-day mortality as a binary endpoint analyzed at a fixed timepoint are shown in Supplemental Table F.5, confirming those obtained in the competing risk analysis. Results from multivariable analyses using conventional adjustment and/or IPT weighting are shown in Figure 8.1 for the cause specific Cox proportional hazards models, with balance statistics before/after IPT weighting being shown in Supplemental Table F.6 (HCQ) and F.7 (HCQ+AZI). Using these approaches, results essentially confirmed those obtained from double robust estimates, illustrating for the 'HCQ alone' vs. 'Neither drug' comparison (Figure 8.1A) the influence of confounders on estimations as indicated by the progressive alignment of death incidence curves according to treatment after adjustment and/or IPT weighting, and the persistence of statistically significant differences in discharge rates after adjustment, but not when using IPT weighting ($p = 0.073$) or combining both approaches ($p = 0.116$). Regarding the 'HCQ plus AZI' vs. 'Neither drug' comparison (Figure 8.1B), a trend for a statistically significant difference was found for mortality after multiple adjustment and IPT weighting ($HR = 1.53; p = 0.057$), but not for discharge ($HR = 0.98; p = 0.923$). Results from Fine-Gray models identified similar but not significant trends for the excess risk of mortality in the

'HCQ plus AZI' group. (Supplemental Figures F.2 and F.2).



Figure 8.2 – Death and discharge cumulative incidence curves: results from cause specific Cox competing risks analyses.
Panel A - HCQ vs. Neither drug; Panel B - HCQ+AZI vs. Neither drug; Adjusted results are based on the adjustment strategy for the outcome detailed in Figure F.1.

8.3.4 Average treatment effects for the treated on the propensity-matched population

Results from the propensity-matched analyses are shown in Table 8.4 and Figure 8.3, with balance statistics before/after matching being shown in Supplemental Table F.6 (HCQ) and F.7 (HCQ+AZI). In the whole population, HR on 28-day mortality for the 'HCQ' versus 'neither drug' comparison was 0.87(0.68 to 1.13), and 0.93(0.70 to 1.23) after further adjustment. Regarding 28-day discharge rates, a statistically significant difference in favor of 'HCQ alone' (HR = 1.27[1.08 to 1.49]; adjusted HR = 1.34[1.13 to 1.59]). For the 'HCQ plus AZI' vs. 'Neither drug' comparison, a trend was again found towards higher mortality rates in the former group, though not reaching statistical significance (adjusted HR = 1.44[0.93 to 2.23]; p = 0.099), while a significant favorable association was found regarding 28-day discharge (adjusted HR = 1.47[1.07 to 2.03]). Results from subgroup analyses are detailed in Table 8.4, notably showing varying results regarding 28 -day discharge according to age for both the HCQ and HCQ+AZI vs neither drug comparisons (with statistically significant relationships being only found in younger patients),

and period for the HCQ vs neither drug comparison (with increasingly stronger associations with time).

Table 8.4 – Adjusted clinical outcomes according to treatment groups: results from propensity-matched analyses.

		HCQ alone vs neither drug		**HCQ plus AZI vs neither drug**	
		Raw Estimate (95% CI)	Adjusted Estimate* (95% CI)	Raw Estimate (95% CI)	Adjusted Estimate* (95% CI)
28-day mortality					
Whole population		0.87 (0.68-1.13)	0.93 (0.70-1.23)	1.33 (0.89-1.99)	1.44 (0.93-2.23)
Transfer to ICU within the first 24 hours	Yes	0.99 (0.60-1.65)	0.84 (0.43-1.61)	1.66 (0.79-3.49)	1.64 (0.51-5.31)
	No	0.84 (0.63-1.13)	0.90 (0.64-1.27)	1.19 (0.74-1.93)	1.04 (0.58-1.88)
Age	< 65 years	0.85 (0.49-1.47)	0.79 (0.38-1.65)	1.18 (0.49-2.85)	1.83 (0.30-11.21)
	≥ 65 years	0.88 (0.66-1.17)	0.86 (0.63-1.18)	1.29 (0.83-2.02)	1.43 (0.84-2.45)
Period	Before March 20th	0.61 (0.34-1.12)	0.75 (0.41-1.36)	0.84 (0.22-3.21)	1.02 (0.18-5.66)
	March 20th - March 30th	0.90 (0.65-1.25)	0.86 (0.59-1.25)	1.20 (0.73-1.97)	1.80 (0.99-3.29)
	After March 30th	0.98 (0.55-1.75)	1.72 (0.69-4.29)	2.02 (0.91-4.51)	1.57 (0.21-11.76)
28-day hospital discharge					
Whole population		**1.27 (1.08-1.49)**	**1.34 (1.13-1.59)**	**1.46 (1.10-1.95)**	**1.47 (1.07-2.03)**
Transfer to ICU within the first 24 hours	Yes	1.37 (0.89-2.12)	1.04 (0.62-1.73)	**2.01 (1.08-3.75)**	1.30 (0.52-3.21)
	No	1.15 (0.97-1.37)	1.23 (1.02-1.50)	1.34 (0.97-1.85)	**1.56 (1.09-2.21)**
Age	< 65 years	**1.35 (1.10-1.65)**	**1.42 (1.14-1.77)**	**1.65 (1.17-2.31)**	**1.65 (1.11-2.44)**
	≥ 65 years	1.13 (0.86-1.48)	1.16 (0.86-1.56)	1.13 (0.65-1.95)	1.27 (0.62-2.61)
Period	Before March 20th	0.86 (0.61-1.22)	0.85 (0.59-1.22)	1.11 (0.47-2.62)	1.05 (0.40-2.74)
	March 20th - March 30th	**1.34 (1.08-1.67)**	**1.53 (1.22-1.93)**	**1.42 (1.01-2.00)**	1.46 (0.97-2.21)
	After March 30th	**1.59 (1.13-2.24)**	**1.59 (1.07-2.34)**	1.79 (0.92-3.45)	1.28 (0.45-3.64)

** AIPTW: Augmented inverse probability of treatment weight estimator for doubly robust inference of the average treatment effect conditional on baseline covariates, derived from cause specific Cox proportional hazards modeling; 95% CI: 95% confidence interval.*



Figure 8.3 – Death and discharge cumulative incidence curves: results from propensity-matched analyses.
Panel A - HCQ vs. Neither drug; Panel B - HCQ+AZI vs. Neither drug; Adjusted results are based on the adjustment strategy for the outcome detailed in Figure F.1.

8.4 – Discussion

Using a large non-selected population of 4,642 hospitalized for COVID-19 infection in 39 hospitals in France, we found no evidence for efficacy of HCQ or HCQ combined with AZI on 28 -day mortality. Our findings suggest that patients treated by association of HCQ and AZI are at greater risk of mortality compared with the 'Neither drug' group. Significantly higher rates of discharge home were observed in patients treated by HCQ when using competing risks survival analyses, a finding whose statistical significance persisted after multivariable adjustment and propensity-score weighting. These results were found to be robust to a variety of methodological approaches conducted regarding missing data handling and causal inference modeling to properly account for potential confounders.

The absence of difference on mortality between hospitalized patients receiving HCQ and those receiving neither drug is consistent with previous observational studies led in hospitalized patients after accounting for confounding by multivariable analyses potentially combined with propensity score weighting, matching or adjustment methods ($8-11$), as well as with preprint results from the Recovery trial [Horby et al., 2020]. It should be stressed out that findings from these reports pertain to hospitalized patients and do not provide information on the efficacy of either drug when administered in earlier forms of the disease.

Regarding the association of HCQ and AZI, our findings indicate a trend towards higher risk of death for the 'HCQ plus AZI' group compared with the 'Neither drug' group (ratio in ATE at 1.40 [0.98 to 1.81]; adjusted HR at 1.44[0.93 to 2.23] in propensity-matched analysis). This finding is consistent with the results from the Rosenberg et al. [2020] study (adjusted HR for mortality 1.35[0.76 to 2.40]). Because of a limited sample size for this subgroup in our study, our results should be taken with caution. However, among possible hypotheses that could be discussed, an increased risk of serious adverse events such as arrhythmia has been advocated in several studies. [11,28] Among 90 consecutively included patients receiving HCQ for Covid-19 infection in Israel, Mercuro et al. [2020 (cited on 2020-05-26] detected change in QTc in 21 patients (23%), and more evidently so in the 'HCQ plus AZI' subgroup. HCQ is already known to inhibit voltage-gated sodium and potassium channels, prolonging the QT interval and increasing the risk of torsades de pointes, syncope and sudden cardiac death [Roden, 2004]. Azithromycin has also been implicated in QTc prolongation and proarrhythmic events [Roden, 2004]. In addition to HCQ and AZI interaction, patients hospitalized with severe COVID-19 pneumonia are also at risk to present clinical characteristics leading to QT prolongation such as hypokalemia or congestive heart failure.

In our study, we identified increased discharge rates at day-28 in the HCQ group, corresponding to a ratio in average treatment effect of 1.28 in favor of HCQ, with corresponding predicted day-28 discharge rates of 56% [HCQ] vs. 45% [neither drug] in the whole study population, with similarly statistically significant associations in the propensity-matched analysis for both HCQ and HCQ+AZI. Importantly, subgroup analyses revealed that these associations were only found in younger patients, and also depended somewhat on the period of inclusion, indicating increasingly apparent effects

over time. This latter result could relate to the organizational nature of the discharge endpoint, as increasing numbers in patients accrual were concomitantly recorded in the participating AP-HP hospitals over that same period. To our knowledge, this is the first report from a large observational study specifically addressing this issue in addition to mortality and ICU-related outcomes, [8–11] whereas a similar endpoint was used for the Recovery randomized controlled trial [Horby et al., 2020]. In this trial, patients allocated to HCQ were less likely to be discharged from hospital alive within 28 days (60.3% vs. 62.8%; rate ratio 0.92; 95% CI 0.85-0.99 [Horby et al., 2020]. Of note, no subgroup analysis was performed for discharge according to age, while differences were apparent regarding mortality in subgroup analyses suggesting worse outcomes in patients older than 70 years. While there was no significant difference in the frequency of adverse effects related to HCQ, those were collected only in 45% of the study population, thus we can not exclude that the higher risk of hospital stay for HCQ group was not related to adverse events. Finally, discussion and comparison of potential differences in the severity of patients at baseline between HCQ/standard of care and the study groups observed in our study is hampered by the lack of details on the severity of COVID19 infection at baseline in the Recovery preprint.

Among the strengths of our study is the use of advanced causal inference approaches both considering time-to-event survival analyses and binary endpoints at a single timepoint. Because inappropriately accounting for confounders can drastically modify results, we performed several sensitivity analyses to check the stability of our results under varying approaches, including so called double robust estimations relying on both multivariable modeling of the outcome and of the treatment (including propensity score-based approaches), which offer better robustness to model mis-specification, and use of varying missing data imputation techniques confirming the stability of our findings. Other strengths of this work include the assessment of a large, representative sample study population in the Greater Paris area from 39 hospitals. Study's limitations include the absence of direct, clinical information on regimen duration and dosages, and respiratory parameters of COVID-19 infection, including oxygen requirement, non-invasive or mechanical ventilation, which are potential confounders. However, we used biological parameters proxy to assess the severity of the COVID-19 infection including creatine, lymphocyte count and inflammatory markers (D-Dimer and C-Reactive protein) well known to be associated with severity of COVID- 19 [Goyal et al., 2020]. Yet, causal interpretation of our findings relying on retrospective evaluation of medical records should remain cautious considering the observational nature of the study design.

8.4.1 Conclusion

Using a large non-selected population of inpatients hospitalized for COVID-19 infection in 39 hospitals in France and robust methodological approaches, we found neither evidence for reduced or excess risk of 28 -day mortality with the use of HCQ alone. Our findings suggest a possible higher risk of death for patients receiving HCQ combined with AZI. Significantly higher rates of discharge home were observed in younger patients treated by HCQ, more apparently so at the peak of the crisis, a finding warranting further confirmation in replicative studies.

8.5 – Declarations

8.5.1 Ethical approval

This study was approved by the French data protection agency Commission Nationale de l'Informatique et des Libertés (regulatory decision DE-2017-013), IRB00011591.

8.5.2 Availability of data and materials

The datasets used and/or analysed during the current study are available from ES on reasonable request.

8.5.3 Authors' contributions

Contributors: ES, JJ, GL, IM, MB, AG, GV, ML and EA conceived and designed the experiments. JJ, IM, ML and EA performed the experiments. ES, JJ, GL, IM, MB, AG, GV, ML and EA analysed the data. ES, JJ, PW, EC, ML, AMD and EA interpreted the results. ES and EA wrote the first draft of the manuscript. All the authors contributed to the writing of the manuscript. All the authors agreed with the results and conclusions of the manuscript. All authors have read, and confirm that they meet, ICMJE criteria for authorship. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. ES is the guarantor

8.5.4 Acknowledgments

We thank Susan Wilkinson for editorial assistance. Data used in preparation of this article were obtained from the AP-HP Covid CDR Initiative database. A complete listing of ECAI members can be found at https://eds.aphp.fr/covid-19.

Chapter 9

Missing values and the R-miss-tastic platform

This chapter is a work submitted to *The Journal of Statistical Software* and which has been carried out in collaboration with Aude Sportisse, Julie Josse, Nathalie Vialaneix and Nicholas Tierney. I have built the main components of the platform, the workflows part has been significantly contributed by Aude Sportisse.

Abstract

Missing values are unavoidable when working with data. Their occurrence is exacerbated as more data from different sources become available. However, most statistical models and visualization methods require complete data, and improper handling of missing data results in information loss, or biased analyses. Since the seminal work of Rubin (1976), a burgeoning literature on missing values has arisen, with heterogeneous aims and motivations. This led to the development of various methods, formalizations, and tools. For practitioners, it remains nevertheless challenging to decide which method is most suited for their problem, partially due to a lack of systematic covering of this topic in statistics or data science curricula.

To help address this challenge, we have launched the "R-miss-tastic" platform, which aims to provide an overview of standard missing values problems, methods, and relevant implementations of methodologies. The objective of this work goes beyond comprehensively organizing materials, also covering the development of standardized analysis workflows, and providing a common reference for different communities. In this perspective, we have developed several pipelines in R and Python to allow for hands-on illustration of and recommendations on missing values handling in various statistical tasks such as estimation and prediction, while ensuring reproducibility of the analyses.

Table of contents
Table des matières

9.1 – Context and motivation

Missing data are unavoidable as soon as collecting or acquiring data is involved. They occur for many reasons including: individuals choose not to answer survey questions, measurement devices fail, or data have simply not been recorded. Their presence becomes even more important as data are now obtained at increasing velocity and volume, and from heterogeneous sources not originally designed to be analyzed together. As pointed out by Zhu et al. [2019], "one of the ironies of working with Big Data is that missing data play an ever more significant role, and often present serious difficulties for analysis". Despite this, the approach most commonly implemented by default in software is to toss out cases with missing values. At best, this is inefficient because it wastes information from the partially observed cases. At worst, it results in biased estimates, particularly when the distributions of the missing values are systematically different from those of the observed values [e.g., Enders, 2010, Chap. 2].

However, handling missing data in a more efficient and relevant way (than limiting the analysis on solely the complete cases) has attracted a lot of attention in the literature in the last two decades. In particular, a number of reference books have

been published [Schafer and Graham, 2002, Little and Rubin, 2019, van Buuren, 2018, Carpenter and Kenward, 2013] and the topic is an active field of research [Josse and Reiter, 2018]. The diversity of the problems of missing data means there is great variety in the proposed and studied methods. They include model-based approaches, integrating likelihoods or posterior distributions over missing values, filling in missing values in a realistic way with single, or multiple imputations, or weighting of observations, appealing to ideas from the design-based literature in survey sampling. The multiplicity of the available solutions makes sense because there is no single solution or tool to manage missing data: the appropriate methodology to handle them depends on many features, such as the objective of the analysis, type of data, the type of missing data and their pattern. Some of these methods are available in various software solutions. As R [R Core Team, 2020] is one of the main softwares for statisticians and data scientists and as its development has started almost three decades ago [Ihaka, 1998], R is one of the language that offers the largest number of implemented approaches. This is also due to its ease to incorporate new methods and its modular packaging system. Currently, there are over 270 R packages on CRAN that mention missing data or imputation in their DESCRIPTION files. These packages serve many different applications, data types or types of analysis. More precisely, exploratory and visualization tools for missing data are available in packages like **naniar**, **VIM**, and **MissingDataGUI** [Tierney et al., Tierney and Cook, 2018, Kowarik and Templ, 2016, Cheng et al., 2015]. Imputation methods are included in packages like **mice**, **Amelia**, and **mi** [van Buuren and Groothuis-Oudshoorn, 2011, Honaker et al., 2011, Gelman and L., 2011]. Other packages focus on dealing with complex, heterogeneous (categorical, quantitative, ordinal variables) data or with large dimension multi-level data, such as **missMDA**, and **MixedDataImpute** [Josse et al., 2016a, Murray and Reiter, 2015]. To our knowledge, R is the programming language offering the largest variety of implemented methods. However, other languages such as Python [Van Rossum and Drake, 2009], which currently only have few publicly available implementations of methods that handle missing values in statistical tasks, offer more and more solutions. Two prominent examples are: 1) the **scikit-learn** library [Pedregosa et al., 2011] which has recently added a module for missing values imputation; and 2) the **DataWig** library [Biessmann et al., 2018] which provides a framework to learn to impute incomplete data tables.

Despite the large range of options, missing data are often not handled appropriately by practitioners. This may be for a few reasons. First, the plethora of options can be a double-edged sword, the sheer number of options making it challenging to navigate and find the best one. Second, the topic of missing data is often itself missing from many statistics and data science syllabuses, despite its relative omnipresence in data. So, when faced with missing data, practitioners are left powerless: quite possibly never having been taught about missing data, they do not have an idea of how to approach the problem, what are the dangers of mismanagement, navigate the methods, software, or choose the appropriate method or workflow for their problem.

To help promote better management and understanding of missing data, we have released R-miss-tastic, an open platform for missing values. The platform takes the

form of a reference website [1], which collects, organizes and produces material on missing data. It has been conceived by an infrastructure steering committee (ISC; its members are authors of this article) working group, which first provided a CRAN Task View [2] on missing data [3] that lists and organizes existing R packages on the topic. The "R-miss-tastic" platform extends and builds on the CRAN Task View by collecting and organizing articles, tutorials, documentation, and workflows for analyses with missing data.

The intent of this platform is easily extendable and well documented, so it can seamlessly incorporate future research in missing values. The intent of the platform is to foster a welcoming community, within and beyond the R community . "R-miss-tastic" has been designed to be accessible for a wide audience with different levels of prior knowledge, needs, and questions. This includes, for instance, students looking for course material to complement their studies, teachers and professors who can use a reference website for their own classes or refer to students, statisticians or researchers in a different fields using statistics searching for solutions or existing work to help with analysis, researchers wishing to understand or contribute information for specific research questions, or find collaborators.

In this perspective, the platform provides new tutorials, examples and pipelines of analyses that we have developed with missing data that span the entirety of an analysis. The latter have been developed in R and in Python, implementing standard methods for generating missing values and for analyzing them under different perspectives. These pipelines cover the entirety of a data analysis: starting with data preparation, they contain exploratory analyses of the data, the establishment of statistical models, analysis diagnostics, the application of machine learning methods, and finally an interpretation of the results obtained from incomplete data. We hope that these pipelines also serve as guidance when it comes to choosing a method to handle missing values in a specific context. Another important ingredient in statistical analyses (perhaps the most important) is data to which a proposed method or estimator are applied. We thus also reference publicly available datasets that are commonly used as benchmark for new missing values methodologies.

The remainder of the article is organized as follows: Section 9.2 describes the different components of the platform, the structure that has been chosen, and the targeted audience. The section is organized as the platform itself, starting by describing materials for less advanced users then materials for researchers and finally resources for practical implementation. Section 9.3 details the implementation and use-cases of the provided workflows, implemented both in R and in Python. Finally, in Section 9.4, we conclude with an overview of the planed future developments for the platform and of interesting areas in missing values research that we would like to bring to a broader audience.

1. https://rmisstastic.netlify.com/
2. https://CRAN.R-project.org/package=ctv
3. https://cran.r-project.org/web/views/MissingData.html

9.2 – Structure and content of the platform

The R-miss-tastic platform is released at https://rmisstastic.netlify.com/. It has been developed using the R package **blogdown** Xie et al. [2017] which generates static websites using Hugo [4]. Live examples have been included using the tool https://rdrr.io/snippets/ provided by the website "R Package Documentation". The source code and materials of the platform have been made publicly available on GitHub [5], which provides a transparent record of the platform's development, and facilitates contributions from the community.

We now discuss the structure of the R-miss-tastic platform, the aim and content of each subsection, and highlight key features of the platform.

9.2.1 Workflows

An important contribution and novelty of this work is the proposal of several workflows that allow for a hands-on illustration of classical analyses with missing values, both on simulated data and on publicly available real-world data. These workflows are provided both in R and in Python codes and cover the following topics:

— *How to generate missing values?* Generate missing values under different mechanisms, on complete or incomplete datasets. This is useful when performing simulations to compare methods that impute or handle missing data.

— *How to do statistical inference with missing values?* In particular, we focus on the different solutions (maximum likelihood or multiple imputation) that are available to estimate linear and logistic regression parameters with missing values in the covariates.

— *How to impute missing values?* We compare different single imputation/matrix completion methods (for instance using conditional models, low-rank models, etc.).

— *How to predict with missing values?* We consider establishing predictive models (for instance using random forests [Breiman, 2001]) on data with incomplete predictors. The workflows present different strategies to deal with the missing values in the covariates both in the training set and in the test set.

The aim of these workflows is threefold: 1) they provide a practical implementation of concepts and methods discussed in the lectures and bibliography sections of the platform (see Subsection 9.2.2 and Subsection 9.2.3 of the present article); 2) they are coded in a generic way, allowing for simple re-use on other datasets, for integration of other estimation or imputation methods; 3) the distinction between inference, imputation, and prediction lets the user keep in mind that the solutions are not the same in these cases.

Furthermore, the workflows allow for a transparent and open discussion about the proposed implementations, which can be followed on the project GitHub repository [6],

4. https://gohugo.io/
5. repository `R-miss-tastic/website`
6. https://github.com/R-miss-tastic/website

referencing proposals and discussions about practicable extensions of the workflows.

Additionally, a workflow on *How to do causal inference with incomplete covariates/attributes in R?* allows to use simple weighting and doubly robust estimators for treatment effect estimation using R language. This workflow is based on the R implementation of the work presented in Chapter 4.

We provide a more detailed view on the proposed workflows in Section 9.3, giving code examples and their corresponding tabular or graphical outputs as well as recommendations on how to interpret and leverage these outputs.

9.2.2 Lectures

For someone unfamiliar with missing data, it is a challenge to know where to begin the journey of understanding them, and the methods to address them. This challenge is being addressed with "R-miss-tastic", which makes the material to get started easily accessible.

Teaching and workshop material takes many forms – from slides, course notes, lab workshops, video tutorials and in-depth seminars. The material is of high quality, and has been generously contributed by numerous renowned researchers who investigate the problems of missing values, many of whom are professors having designed introductory and advanced classes for statistical analysis with missing data. This makes the material on the "R-miss-tastic" platform well suited for both beginners and more experienced users.

These teaching and workshop materials are described as "lectures", and are organized into five sections:

1. General lectures: introduction to statistical analyses with missing values; the role of visualization and exploratory data analysis for understanding missingness and guiding its handling; theory and concepts are covered, such as missing values mechanism, likelihood methods, and imputation.
2. Multiple imputation: introduction to popular methods of multiple imputation (joint modeling and fully conditional), how to correctly perform multiple imputation and limits of imputation methods.
3. Principal component methods: introduction to methods exploiting low-rank type structures in the data for visualization, imputation and estimation.
4. Specific data or applications types: lectures covering in details various sub-problems such as missing values in time series, in surveys, or in treatment effect estimation. Indeed, certain data types require adaptations of standard missing values methods (for instance handling the time dependence in time series [Moritz and Bartz-Beielstein, 2017]) or additional assumptions about the impact of missing values (such as the impact on confounded treatment effects in the causal inference context [Mayer et al., 2020]). But also more in-depth material, for instance video recordings from a virtual workshop on *Missing Data Challenges in Computation, Statistics and Applications*[7] held in 2020.

7. https://www.ias.edu/math/mdccsa

5. Implementations: a non-exhaustive list of detailed vignettes describing functionalities of R packages and of Python modules that implement some of the statistical analysis methods covered in the other lectures. For instance, the functionalities and possible applications of the **missMDA** R package are presented in a brief summary, allowing the reader to compare the main differences between this package and the **mice** package which is also summarized using the same summary format.

Figure 9.1 illustrates two views of the lectures page: Figure 9.1A shows a collapsed view presenting the different topics, Figure 9.1B shows an example of the expanded view of one topic (General tutorials), with a detailed description of one of the lecture (obtained by clicking on its title), "Analysis of missing values" by Jae-Kwang Kim. Each lecture can contain several documents (as is the case for this one) and is briefly described by a header presenting its purpose.

Lectures that we found very complete and thus recommend are:

— *Statistical Methods for Analysis with Missing Data* by Mauricio Sadinle (in "General tutorials")

— *Missing Values in Clinical Research – Multiple Imputation* by Nicole Erler (in "Multiple imputation")

— *Handling missing values in PCA and MCA* by François Husson. (in "Missing values and principal component methods")



(a) Collapsed view (b) Extract

Figure 9.1 – Lectures overview.

The purpose of these lectures is to provide either an introduction or a deeper understanding of the statistical problems and proposed solutions in terms of their (mathematical) derivation and theoretical scope. The focus is thus less on a practical illustration on real data or a systematic comparison of all methods for a same statistical problem. This aspect is covered by the workflows as will be explained in more detail in Section 9.3.

9.2.3 Bibliography

Complementary to the *Lectures* section, this part of the platform serves as a broad overview on the scientific literature discussing missing values taxonomies and mechanisms and statistical, machine learning methods to handle them. This overview covers both classical references with books, articles, etc. such as Schafer and Graham [2002], Little and Rubin [2019], van Buuren [2018], Carpenter and Kenward [2013] and more recent developments such as Josse et al. [2019], Gondara and Wang [2018], which study the consistency of supervised learning with missing values. The entire (non-exhaustive) bibliography can be browsed in two ways: 1) a complete list, filtered by publication type and year, with a search option for the authors or, 2) as a contextualized version. For 2), we classified the references into several domains of research or application, briefly discussing important aspects of each domain. This dual representation is shown in Figure 9.2 and allows for an extensive search in the existing literature, while providing some guidance for those focused on a specific topic. All references are also collected in a unique BibTex file made available in the GitHub repository [8]. This shared file allows external users to easily propose additions to the bibliography, which are then reviewed by the platform editorial and maintenance committee, composed of researchers with different focuses on the handling of missing values.



(a) Contextualized version

(b) Unordered version

Figure 9.2 – Bibliography overview.

8. in resources/rmisstastic_biblio.bib

9.2.4 Implementations

R packages As mentioned in the introduction, the platform development is based on the release of the *MissingData* CRAN Task View, which currently lists approximately 150 R packages. The CRAN Task View is continuously updated, adding new R packages, and removing obsolete ones. Packages are organized by topic: *exploration of missing data*, *likelihood based approaches*, *single imputation*, *multiple imputation*, *weighting methods*, *specific types of data*, *specific application fields*. We selected only those that were sufficiently mature and stable, and that were already published on CRAN or Bioconductor. This choice was made to ensure that all listed packages can easily be installed and used by practitioners.

Even though the Task View classifies packages into different sub-domains, it may still be a challenge for practitioners and researchers inexperienced with missing values to choose the most relevant package for their application. To address this challenge, we provide a partial and slightly more detailed overview of existing R packages, selecting the most popular and versatile ones. This overview is a blend of the Task View, and of the individual package description pages and vignettes as provided on CRAN or Bioconductor. For each selected package (7 at the date of writing of this article: **imputeTS**, **mice**, **missForest**, **missMDA**, **naniar**, **simputation** and **VIM**), we provided a category (in the style of the categorization in the Task View), a short description of use-cases, its description (as on CRAN), the usual CRAN statistics (number of monthly downloads, last update), the handled data formats (e.g., `data.frame`, `matrix`, `vector`), a list of implemented algorithms (e.g., k-means, PCA, decision tree), the list of available datasets, some references (such as articles and books), and a small chunk of code, ready for a direct execution on the platform via the *R package Documentation*[9]. Figure 9.3 shows the condensed view of the package page and the expanded description sheet of a given package (here **naniar**).

We believe shortlisting R packages is highly useful for practitioners new to the field, as it demonstrates data analysis that handles missing values in the data. We are aware that this selection is subjective, and we welcome external suggestions for other packages to add to this shortlist.

Python modules To the best of our knowledge, very few methods are already implemented for handling missing data in Python. However, one of the major libraries for machine learning and data analysis, **scikit-learn** [Pedregosa et al., 2011] has recently proposed a module for simple and multiple imputations, **sklearn.impute**. Also, as an alternative, the **statsmodels**[10] library also has an implementation module for multiple imputation in Python now. Additionally, the **missingno** toolset [Bilogur, 2018] allows to visualize missing values for exploratory data analyses. We regularly survey new Python implementations for handling missing values and, if pertinent from a theoretical and practical point of view, reference them on our platform. We expect this to promote their use but also additional assessment by practitioners and

9. https://rdrr.io/snippets/
10. https://www.statsmodels.org/stable/about.html



(a) Extract of global view

(b) Description sheet

Figure 9.3 – R packages overview.

researchers from the missing values (statistics/machine learning) community.

9.2.5 Datasets

Especially in methodology research, an important aspect is the comparison of different methods to assess their respective strengths and weaknesses. Several datasets are recurrent in the missing values literature but have not been referenced together yet. We gathered publicly available datasets that have recurrently been used for comparison or illustration purposes in publications, R packages and tutorials. Most of these datasets are already included in R packages but some are available in other data collections. Figure 9.4 shows how the datasets are presented, with a detailed description shown for one of the dataset ("Ozone", obtained by clicking on its name). The description follows the UCI Machine Learning Repository presentation [Dua and Graff, 2019], including a short description of the dataset, how to obtain it, external references describing the dataset in more details, and links to tutorials/lectures on our websites or to vignettes in R packages that use the dataset.

In addition, the *Datasets* section also references existing methods for generating missing data, given assumptions on their generation mechanisms (as in the R package **mice**).

Note, however, that the list of datasets gathered here is short compared to benchmark datasets for full data methods such as the UCI Machine Learning Repository. Therefore, our proposed list also serves as an invitation to tackle this lack of a wider variety of common benchmark datasets in the missing data community.

Incomplete data

The data sets listed below are either widely used in general in the missing data community or used for illustration of different methods handling missing values in the tutorials from the Tutorials and R packages sections. This presentation scheme is inspired by the UCI Machine Learning Repository.

Click on a table entry to obtain further information about the data set.

Name	Data Types	Attribute Types	# Instances	# Attributes	% Missing entries	Complete data available	Year
Airquality	Multivariate, Time Series	Real	154	6	7	No	1973
chorizonDL	Multivariate	Integer, Real	606	110	15	Yes	1998
Health Nutrition And Population Statistics	Multivariate, Time Series	Integer, Real	15,022	397	54	No	2017
NHANES	Multivariate	Categorical, Integer, Real	10,000	75	37	No	2012
oceanbuoys	Multivariate, Time Series	Real	736	8	3	No	1997
Ozone	Multivariate	Categorical, Integer, Real	366	13	6	No	1976

Los Angeles Ozone Pollution Data, 1976. This data set contains daily measurements of ozone concentration and meteorological quantities. It can be found in R in the `mlbench` package and is loaded by calling `data(Ozone)`.

More information on the dataset.

Tutorials illustrating methods on this data:

- Julie Josse's course on missing values imputation using PC methods.
- Julie Josse's and Nick Tierney's tutorial on handling missing values. Download the data set from this tutorial: ozoneNA.csv
- Nick Tierney's `naniar` vignette for missing data visualization.

pedestrian	Multivariate, Time series	Categorical, Integer	37,700	9	2	No	2016

Figure 9.4 – Datasets overview.

9.2.6 Additional content

This unified platform collects and edits the contributions of numerous individuals who have investigated missing values problems, and developed methods to handle them. To provide an overview of some of the main actors in this field, the list of all contributors who agreed to appear on this platform is given with links to their personal or to their research lab website.

We also provide links to other interesting websites or working groups, not necessarily working with R and Python [Van Rossum and Drake, 2009] but with other programming languages such as SAS/STAT® and STATA [StataCorp., 2019].

Two other features are finally provided to engage the community:

1. a regularly updated list of events such as conferences or summer schools with special focus on missing values problems, and
2. a list of recurring questions together with short answers and links for more details for every question (FAQ).

9.3 – Workflows

After this general introduction to the R-miss-tastic project and platform and the overview of its structure, we now turn to a more detailed presentation of the various workflows that we have developed and proposed on this platform.

To allow for both hands-on tutorials illustrating current practices and state-of-the-art and ready-to-use pipelines, we propose the workflows under different formats such as HTML, PDF, R Markdown (for R code) and IPython Notebook (for Python code). We encourage practitioners and researchers to use and adapt these workflows, in order to increase reproducibility and comparability of their work. Of course, we are aware that these workflows do not cover the entire spectrum of existing methods and data problems. The goal of the proposed workflows is rather to initiate a joint effort to create a larger spectrum of open-source workflows, and to encourage the use of standardized procedures to handle missing values.

With an incomplete dataset at hand, prior to embarking on an in-depth statistical analysis, a specific aim has to be defined in order to choose a specific method to use. An example of a method whose success crucially depends on the analyst's goal is *mean imputation*: this approach is strongly counter-indicated if the aim is to estimate parameters, but it can be consistent if the aim is to predict as well as possible [Josse et al., 2019]. Following this observation, our workflows are divided into different parts, defined by the objective of the statistical analysis. We have tried to present and compare the main implementations available both in R and Python for each objective. Currently there are seven workflows available on the platform and we present their scope and use below.

9.3.1 How to generate missing values?

The goal of this workflow is to propose functions to generate missing values under different mechanisms. The way in which the missing values are generated is crucial for comparing methods (and studies) in a fair manner and is often subject of debate [Seaman et al., 2013]. This code aims to unify classical solutions to do this. Indeed, a usual strategy to compare imputation or estimation strategies is to introduce (additional) missing values in the dataset, and use the ground truth for these missing values to evaluate the strategies.

Rubin [1976] classifies the cause for a lack of data into three missing data mechanisms. The missing data mechanism is said to be: (i) missing completely at random (MCAR) if the lack of data is totally independent of the data values, (ii) missing at random (MAR) if the process that causes the missing data only depends on the observed values and (iii) missing not at random (MNAR) if the unavailability of the data depends on the missing variables. More formally, let us define the matrix $R \in \mathbb{R}^{n \times p}$, which indicates the indices of the observed values in $X \in \mathbb{R}^{n \times p}$, i.e., $R_{ij} = 1$ if X_{ij} is observed and $R_{ij} = 0$ otherwise. The missing data mechanism is then the distribution of the indicator matrix R given the data X. If $X = (X^{\text{obs}}, X^{\text{mis}})$, with X^{obs} (resp. X^{mis}) the matrix formed by the observed variables (resp. the missing variables), the mechanism is (i) MCAR if $\mathbb{P}(R_1 = 0|X; \phi) = \mathbb{P}(R_1 = 0; \phi)$, (ii) MAR if $\mathbb{P}(R_1 = 0|X; \phi) = \mathbb{P}(R_1 = 0|X^{\text{obs}}; \phi)$ and (iii) MNAR otherwise.

In R In the R workflow, we have implemented the main function `produce_NA` [11] which allows to generate missing values under the three missing-data mechanisms outlined above. This function internally calls the `ampute` function of the **mice** package [van Buuren and Groothuis-Oudshoorn, 2011] but we chose to simplify its use while adding some additional options to specify the missing values generation. In addition, the original `ampute` function generates missing values only for complete datasets. In our workflow, the user can easily introduce (additional) missing values in a complete or incomplete dataset composed of quantitative, categorical or mixed variables. The three main arguments are the initial dataset (`data`) in which the missing values are introduced using a given missing data mechanism (`mechanism`) and a given percentage of missing values (`perc.missing`). For example, to introduce 20% of MCAR values in the dataset X, the code is detailed below.

```
X.miss.mcar <- produce_NA(data = X,
                          mechanism = "MCAR",
                          perc.missing = 0.2)
X.mcar <- X.miss.mcar$data.incomp
# incomplete matrix containing (additional) missing values
R.mcar <- X.miss.mcar$idx_newNA # indicator matrix
```

Listing 9.1 – Generating MCAR missing values in R.

The function returns the data matrix containing the new dataset with missing values (that also includes the missing values already present in the input data) and the indicator matrix R.

11. https://rmisstastic.netlify.app/how-to/generate/amputation.R

Several options are detailed and illustrated in the workflow to generate missing values under the MAR and MNAR mechanisms. For instance, if X contains three variables (fully observed) denoted as X_1, X_2, X_3, two options are available to generate MAR values:

1. the first option consists of generating missing values in X_1 by using a logistic model depending on (X_2, X_3), which are fully observed, i.e.

$$\mathbb{P}(R_1 = 0|X; \phi) = 1/(1 + \exp(-(\phi_2 X_2 + \phi_3 X_3)),$$

where $\phi = (\phi_2, \phi_3)$ is the parameter of the missing-data mechanism. In our function, ϕ is chosen so that the given percentage of missing values is reached. This allows to obtain missing values in the first variable X_1^{NA}. Then, the same strategy is performed to introduce missing values in X_2 and X_3, by using a logistic model depending on (X_1, X_3) (fully observed) and (X_1, X_2) (fully observed) respectively. To get the final matrix containing missing values, we concatenate X_1^{NA}, X_2^{NA} and X_3^{NA} by handling the rows containing only missing values. To use this option, the code is detailed below.

```
X.miss.mar <- produce_NA(data = X, mechanism = "MAR",
                         perc.missing = 0.2,
                         by.patterns = FALSE)
```

Listing 9.2 – Generating MAR values in R.

2. the second option consists in generating the missing values *by pattern*, i.e., by rows. In this case, the combinations of which variables are observed and missing are specified in a pattern matrix. For the MAR mechanism, in each pattern, at least one variable must be observed. An example (the choice by default) of such a pattern matrix is

$$\begin{pmatrix} 0 & 1 & 1 \\ 1 & 0 & 1 \\ 1 & 1 & 0 \end{pmatrix},$$

where 0 indicates that the variable should have missing values whereas 1 means that it should be observed. For example, the first pattern means that the process which causes the missingness of the first variable X_1 depends on the values of X_2 and X_3 that are observed. The code below allows to choose this option.

```
X.miss.marpat <- produce_NA(data = X, mechanism = "MAR",
                            perc.missing = 0.2,
                            by.patterns = TRUE)
```

Listing 9.3 – Generating MAR values by patterns in R.

We propose several ways to generate missing values, under the MNAR mechanism, including the most general one when the missingness depends on both the missing variables and the observed variables. A particular case of a MNAR mechanism is the self-masked mechanism, where the unavailability of the data only depends on their

values themselves. The following code allows to introduce such missing values using a quantile censorship for which the form is defined by the argument `self.mask`. The argument `idx.incomplete` is a binary indicator vector c where $c_j = 1$ indicates that for the jth variable in `X.complete`, self-masked MNAR values should be introduced (and analogously $c_k = 0$ means that no missing values are introduced for the kth variable).

```
X.miss.mnar <- produce_NA(X.complete, mechanism = "MNAR",
                          perc.missing = 0.2, self.mask = "lower",
                          idx.incomplete = c(1,1,1,1))
```

Listing 9.4 – Generating self-masked MNAR values in R.

The choice `self.mask = "lower"` in the above example specifies that the values are amputed based on a quantile from the lower tail of the empirical distribution chosen such that the target proportion of missing values is achieved.

In Python To our knowledge, there is no specific module in Python to generate missing values. The workflow that we present now has been developed to bridge this gap in collaboration with Boris Muzellec (post-doctoral reasearcher, Inria Paris). Similarly to the R workflow, we can obtain missing values under by different mechanisms and different percentage of missing values with the following command lines. The only difference with the R workflow is that the data set must be complete and can currently only contain quantitative variables.

```
X_miss_mcar = produce_NA(data = X, perc_missing = 0.2,
                         mechanism = "MCAR")
X_mcar = X_miss_mcar['X_incomp']
# incomplete matrix containing missing values
R_mcar = X_miss_mcar['mask'] #indicator matrix
```

Listing 9.5 – Generating MCAR values in Python.

The outputs of this function are the incomplete matrix with 20% MCAR values and the indicator matrix R.

For the MAR mechanism, by contrast with the R workflow, the Python code relies on the definition of Little and Rubin [2019]. For instance, if we have $X = (X_1, X_2, X_3)$, then at least one variable should be fully-observed (say X_3) and missing values in X_1 and X_2 are introduced with the following logistic model,

$$\mathbb{P}(R_1 = 0|X; \phi) = \mathbb{P}(R_2 = 0|X; \phi) = 1/(1 + \exp(-\phi_3 X_3),$$

with $\phi = \phi_3$ the parameter of the missing-data mechanism chosen to reach the given percentage of missing values. To introduce 20% missing values in each missing variable (i.e., X_1 and X_2), the following code can be used, with `p_obs` the proportion of fully observed variables.

```
X_miss_mar = produce_NA(data = X, perc_missing = 0.2,
                        mechanism = "MAR", p_obs = 0.3)
```

Listing 9.6 – Generating MAR values in Python.

For the MNAR mechanism, three main options are available, using a logistic model, a quantile censorship or a logistic model for a self-masked mechanism (for their exact definition, we refer to the workflow). For example, to introduce 20% of self-masked missing values (in all the variables), we can use the code below.

```
X_miss_selfmasked = produce_NA(data = X, perc_missing = 0.2,
                               mechanism = "MNAR",
                               opt = "selfmasked")
```

Listing 9.7 – Generating self-masked MNAR values in Python.

9.3.2 How to impute missing values?

There exists a vast literature on how to impute missing values. The aim of these workflows (in R and Python) is to compare the most classical imputation methods and to propose a reference pipeline for comparison on simulated and real datasets, which can be easily extended with other imputation methods. Different types of methods are included:

1. imputation by the mean, which serves as a naive baseline.
2. conditional models, if, roughly speaking, the imputation relies on the distributions of each variable given the others.
   - in R:
     - **mice** [van Buuren and Groothuis-Oudshoorn, 2011]: it allows to compute multiple imputations by chained equations and thus returns several imputed datasets. We use the predictive mean matching method (default method) and aggregate the complete datasets using the mean of the imputations to get a simple imputation.
     - **missForest** [Stekhoven and Bühlmann, 2012]: it imputes missing values iteratively by training random forests.
   - in Python:
     - **IterativeImputer** of scikit-learn library [Pedregosa et al., 2011]: this function is inspired by mice, but it uses (iterative) regularized imputation using conditional expectation and provides a simple imputation. We also use the **ExtraTreesRegressor** estimator of **IterativeImputer**, which trains iterative random forests.
3. low-rank based models, if the data matrix to impute is assumed to be low rank and the similarities between the variables (or the observations) may inform the imputation,
   - in R:
     - **softImpute** [Hastie et al., 2015]: it minimizes the re-weighted least squares error penalized by the nuclear norm.
     - **missMDA** [Josse et al., 2016a]: it minimizes the re-weighted least squares error penalized by a mix between the ℓ_2-norm and ℓ_0-norm.

  - in Python: **softImpute** (coded in Python by ourselves), which minimizes the re-weighted least squares error penalized by the nuclear norm.

4. machine learning methods (for the Python workflow only) using optimal transport or variational autoencoders, variables (or the observations) may inform the imputation,
   - in Python:
     - **MIWAE** [Mattei and Frellsen, 2019]: it imputes missing values with a deep latent variable model based on importance weighted variational inference.
     - **Sinkhorn** [Muzellec et al., 2020]: it randomly extracts several batches and consists in minimizing optimal transport distances between batches to impute missing values.

Other methods such as GAIN [Yoon et al., 2018b] which uses generative adversarial networks, have not yet been compared, as they are close to MIWAE, already being compared.

The metric that we chose to compare the methods is the mean squared error (MSE), which can be calculated if the ground truth of the missing values is known. More precisely, the procedure is the following one: (i) we have access to a complete dataset X, (ii) missing values are introduced in X and we get an incomplete dataset X^{NA}, (iii) this incomplete dataset is imputed and we obtain an imputed dataset X^{imp}. The MSE for X^{imp} is computed as follows:

$$MSE(X^{\text{imp}}, X) = \frac{1}{n_{\text{NA}}} \sum_i \sum_j 1_{\{X_{ij}^{\text{NA}}=\text{NA}\}} (X_{ij}^{\text{imp}} - X_{ij})^2$$

where $n_{\text{NA}} = \sum_i \sum_j 1_{\{X_{ij}^{\text{NA}}=\text{NA}\}}$ is the number of missing entries in X^{NA}. Note that this procedure can also be performed on an incomplete dataset by introducing additional missing values. However, for now, both R and Python workflows only consider complete datasets.

In R This workflow first presents the main imputation methods available in R, including **mice**, **missForest**, **softImpute** and **missMDA**.

We compare the methods on a simulated dataset $X \in \mathbb{R}^{n \times d}$ under the multivariate Gaussian law $X \sim \mathcal{N}(\mu, \Sigma)$, with μ the mean vector and Σ the covariance matrix. The function `how_to_impute` compares the imputation methods by introducing missing values in a complete dataset (`X`) using different percentages of missing values (`perc.list`) and missing data mechanisms (`mecha.list`). It returns the mean of the methods' MSEs for the different missing values settings by taking the average over `nbsim` repetitions. The code to use this function is given below. For the sake of clarity, in the workflow, all the code is detailed and commented. The output of this function and its associated plot are shown in Figure 9.5, for $n = 1000$, $d = 10$, $\mu_i = 1$, $\forall i \in \{1, \ldots, d\}$ and $\Sigma_{ij} = 0.5$ if $i \neq j \in \{1, \ldots, d\}$ and $\Sigma_{ij} = 1$ if $i = j$. For the MCAR mechanism, the methods perform well, while for the MNAR mechanism, the results are close to those of the naive imputation by the mean. As expected, most methods give worse results for high percentages of missing values.

```
perc.list = c(0.1, 0.3, 0.5)
#list of the percentages of missing values
mecha.list = c("MCAR", "MAR", "MNAR") #list of the missing-data
  mechanisms
res <- how_to_impute(X = X, perc.list = perc.list,
                     mecha.list = mecha.list, nbsim = 10)

```

Listing 9.8 – Code to compare imputation methods for different missing-values settings in R.

	0.1 MCAR	0.3 MCAR	0.5 MCAR	0.1 MAR	0.3 MAR	0.5 MAR	0.1 MNAR	0.3 MNAR	0.5 MNAR
X.pca	0.74	0.76	0.78	0.75	0.78	0.81	0.76	0.78	0.81
X.forest	0.77	0.8	0.86	0.78	0.81	0.87	0.78	0.81	0.88
X.mice	0.82	0.83	0.86	0.83	0.86	0.9	0.84	0.87	0.9
X.soft	0.93	0.86	0.87	0.97	1	1.1	1	1.1	1.1
X.mean	1	0.99	1	1.1	1.1	1.1	1.2	1.1	1.1

(a) Output of the function `how_to_impute` in R. The results are truncated to two digits.



(b) Example of plot for the MNAR mechanism (one plot per mechanism).

Figure 9.5 – Tabular and graphical outputs of the R function `how_to_impute`. The methods **mice**, **missForest**, **softImpute** and **missMDA** are compared with the naive imputation by the mean for several percentages of missing values (10%, 30%, 50%). The mean of the MSEs computed for several generations of missing values are given. In the table, the results are shown for several mechanisms (MCAR, MAR, MNAR) and the plot corresponds to the MNAR mechanism.

We also propose a function `how_to_impute_real` which gives the comparison of the imputation methods for a list of datasets (`datasets_list`) and for a given missing data mechanism (`mech`) and a given percentage of missing values (`perc`). This can be particularly useful for practitioners who would like to have an indication of which method might be the most suited for a given or for several specific datasets. This function returns a table containing the mean of the MSEs for the simulations performed and a table for the summary plot shown in Figure 9.6. An example of

how to use this function in practice is detailed below. Here, the real datasets are taken from the UCI repository.

```
datasets_list <- list(
                   wine_white = wine_white,
                   wine_red = wine_red,
                   slump = slump,
                   movement = movement,
                   decathlon = decathlon
                  ) # list of different datasets
names_dataset <- c("winequality-white", "winequality-red", "slump",
                   "movement", "decathlon")
                   # names of the different datasets
perc <- 0.2 # percentage of missing values to introduce
mecha <- "MCAR" # missing data mechanism to use
howimp_real <-  how_to_impute_real(
                   datasets_list = datasets_list ,
                   perc = perc,
                   mech = mecha,
                   nbsim = 10,
                   names_dataset = names_dataset
                 )
plotdf_fin <- howimp_real$plot
res <- howimp_real$res
```

Listing 9.9 – Code to compare imputation methods for different datasets in R.



Figure 9.6 – Graphical output of the R function `how_to_impute_real`. The methods **mice**, **missForest**, **softImpute** and **missMDA** for several real datasets in which 20% MCAR missing values have been introduced.

In Python The Python workflow is very similar to its R counterpart. The classical imputation methods that we consider are **softImpute**, **IterativeImputer** and we

compare them to very recent approaches using optimal transport with the **Sinkhorn** module and autoencoders with the **MIWAE** module. The code for the function Python `how_to_impute` is provided below.

```
perc_list = [0.1, 0.3, 0.5] # list of the percentages of missing
    values
mecha_list = ["MCAR", "MAR", "MNAR"] # list of the missing-data
    mechanisms
results_how_to_impute = how_to_impute(X = X ,
                                      perc_list=perc_list,
                                      mecha_list=mecha_list,
                                      nbsim=10)
```

Listing 9.10 – Code to compare imputation methods for different missing-values settings in Python.

Similarly, the following code for the function `how_to_impute_real` in Python can also be used. The graphical output of this code is given in Figure 9.7.

```
datasets_list = dict(wine_white=wine_white,
                     wine_red=wine_red,
                     slump=slump) # dictionary of different
    datasets
names_dataset = ['wine_white','wine_red','slump']
# names of the different datasets
perc = [0.1] # percentage of missing values to introduce
mecha = ["MCAR"] # missing-data mechanism to use
results_how_to_impute_real = how_to_impute_real(
                             datasets_list=datasets_list,
                             perc=perc, mecha=mecha, nbsim=10,
                             names_dataset=names_dataset)
```

Listing 9.11 – Code to compare imputation methods for different datasets in Python.



Figure 9.7 – Graphical output of the Python function `how_to_impute_real`. The methods **softImpute**, **IterativeImputer**, **Sinkhorn**, **MIWAE** and the imputation by the mean are compared for several real datasets in which 10% MCAR missing values have been introduced.

An additional workflow has been written by an external contributor, François Husson (Professor in Statistics at Agrocampus Ouest, France) and reviewed by us. It specifically compares imputation methods using variational and denoising autoencoders [Gondara and Wang, 2018, Mattei and Frellsen, 2019, Abiri et al., 2019] with classical methods such as the low-rank based method [Josse et al., 2016a]. These deep learning methods often require parameter tuning. In this workflow, an automatic tuning is implemented. In addition, the methods are compared for several simulation scenarios, when the variables of the dataset are linearly linked or not. In both cases, deep learning methods do not outperform the low-rank method, although they are known to be able to handle non-linear relationships. This workflow is available on our website [12].

9.3.3 How to estimate parameters with missing values in R?

This workflow is dedicated to a specific inferential framework when the aim is to estimate linear and logistic regression parameters for multivariate normal data. It is currently only available in R, as there are no analogous implementations available in Python to our knowledge.

In this workflow, two classical methods are compared, using available R implementations: the EM algorithm for logistic and linear regressions with the package **misaem** [Jiang et al., 2020] which uses the SAEM algorithm, Stochastic Approximation of EM algorithm [Delyon et al., 1999], and multiple imputation with the package **mice**. Both strategies are valid under the MAR missing data mechanism.

The EM algorithm [Dempster et al., 1977] allows to handle MAR missing values in maximum likelihood estimation by integrating over the missing values distribution, conditionally on the observed values. A drawback of this approach is that it requires a separate derivation of the expectation and maximization steps for each model and data type, such as linear regression and logistic regression on multivariate normal covariates. More particularly, multiple imputation allows any method to be applied once the imputation is done, whereas the EM algorithm requires a new variant of the algorithm for each statistical method. Besides, note that **mice** does not rely on parametric assumptions about the data distribution, whereas **misaem** assumes Gaussian covariates.

If we assume that we have a binary response variable `y` and incomplete covariate matrix `X_NA` composed of five covariates and whose full data counterpart follows a multivariate normal distribution and where the missing values are MAR, we can fit a logistic regression with missing values using the following lines of code.

```
df_NA <- data.frame(y, X_NA)
miss_list <- miss.glm(y~., data=df_NA)
```

Listing 9.12 – Code to fit a logistic regression model with incomplete covariates using the EM algorithm in R.

12. https://rmisstastic.netlify.app/how-to/external/comparison_imputation_deep_classical

This function `miss.glm` resembles the standard `glm` function both in terms of its signature and output. Below we provide an example of output obtained when applying the function `summary` to the output of the above call to `miss.glm`.

```
# Summary
print(summary(miss_list))
##
## Call:
## miss.glm(formula = y ~ ., data = df_NA)
##
## Coefficients:
##              Estimate  Std. Error
## (Intercept)   0.05128   0.31942
## X1            1.05798   0.35989
## X2           -0.99347   0.19620
## X3            1.07606   0.13937
## X4           -0.02258   0.06604
## X5           -1.01527   0.13353
## Log-likelihood: -132.14
```

Listing 9.13 – Summary of a fitted logistic regression model with incomplete covariates in R.

The rationale behind the popular multiple imputation approach is to create $M > 1$ complete datasets by imputing the missing values with "plausible" values, and then to estimate a parameter of interest θ on each of the imputed datasets. The multiple estimations of θ and their variability allow to reflect uncertainty due to the unknown missing values. The parameter estimation is performed by applying the analytic method that we would have used had the data been complete. We assume that this provides an estimate of the parameter θ and an estimate of the corresponding variance, for each imputed dataset. These quantities are finally "pooled" by using specific rules named "Rubin's rules" [Rubin, 2004], leading to a final point estimate with a corresponding estimation of its variance that takes into account the uncertainty due to the missing values. In the following, we will compare this method to EM and illustrate the bias and variance of estimation by an example with a simulated dataset.

Using the same example as for the EM algorithm, we can fit a logistic regression model using multiple imputation and inspect its summary as follows:

```
mi <- mice(data.frame(y, X_NA), m=20)  # imputation of 20 complete
   datasets
fit <- with(data = mi, exp = glm(y ~ X1+X2+X3+X4+X5, family =
   binomial)) # fit
beta.mi <- mice::pool(fit) # pool the results using Rubin's rules
summary(beta.mi)

##          term    estimate  std.error  statistic        df      p
   .value
## 1 (Intercept)  0.04006508 0.32034287  0.1250694 325.01965
   9.005460e-01
## 2          X1  0.85919319 0.35413092  2.4262021 178.92213
   1.625036e-02
```

```
## 3           X2 -0.85098985 0.19626265 -4.3359745 123.30329
   2.983626e-05
## 4           X3  0.99568077 0.14825886  6.7158263  85.76393
   1.934425e-09
## 5           X4 -0.04100766 0.06938153 -0.5910457 126.65685
   5.555431e-01
## 6           X5 -0.92834313 0.14636424 -6.3426908  65.36987
   2.423562e-08
```

Listing 9.14 – Code to fit a logistic regression model with incomplete covariates using multiple imputation in R.

For this simulated dataset, which follows a multivariate normal distribution, **misaem** gives less biased results than **mice**. This is expected as **misaem** is in perfect fit with the parametric assumptions here.

This workflow directly applies and compares these two approaches, using either a simulated dataset, or a custom dataset that the user believes will satisfy the above stated assumptions about the missing data mechanism and distribution of covariates.

9.3.4 How to predict in the presence of missing values?

A key task in supervised learning is prediction. Knowing how to predict in the presence of missing values is thus crucial for many practitioners. More precisely, we assume that the missing values occur in the covariates X and not in the outcome y. In this context, the goal is to predict an outcome variable y such that $y = f(X) + \epsilon$, where ϵ is a noise term. As a reminder, in supervised learning, the algorithms learn on a training set where the outcome variable is assumed to be known and the results of new (incomplete) observations in the test set are then predicted by applying this learning. Both R and Python workflows present different strategies to deal with the missing values in X (in the train set and in the test set). This task has been studied in detail by Josse et al. [2019]. The recommended method is to impute the training set and the test set with the same constant, such as the mean, and then to apply a universally consistent learner, i.e., very powerful and able to learn any function f (linear or not), such as gradient boosting. This method has been shown to be asymptotically consistent. Besides, when random forests are used to impute the missing values, the authors recommend to use the Missing Incorporated in Attributes method [Twala et al., 2008], which allows imputation and prediction to be performed in a single step.

In R This R workflow has been written by an external contributor of the website, Katarzyna Woźnica (PhD student at the Warsaw University of Technology, Poland). It assesses a popular strategy (two-step strategy) which consists of imputing the training set and the test set independently with the same imputation method and of using usual learning algorithms to predict a target variable. Several imputation methods are compared, such as **mice**, **missForest** and **softImpute**. This work is also available on our website. [13] Note that, until recently, using the popular **mice** package

13. https://rmisstastic.netlify.app/how-to/external/how_to_predict_in_r

for learning predictive models for incomplete data in R was hindered by the fact that it did not allow to use the same imputation model for the training and for the test set. This has, however, been addressed and the details of this recent extension can be found on GitHub. [14]

In Python The Python workflow proposes to compare two strategies when the aim is to predict a target variable and the covariates may contain missing values:

1. The *two-step* strategy consists in imputing the missing values both in the training and in the test set with a method like mean imputation or `IterativeImputer` of the **scikit-learn** library, and to apply usual learning algorithms (such as random forests, gradient boosting, linear regression) on the imputed dataset. This learning algorithm can be applied to the imputed dataset $\tilde{X}$ but also to a new variable made of the combination of the imputed covariates $\tilde{X}$ with the response pattern R: $[\tilde{X}, R]$.
2. The *one-step* strategy aims at predicting with learning methods adapted to the missing data without necessarily imputing them, such as the Missing Incorparated in Attributes (*MIA*) method [Twala et al., 2008].

We propose a function, `score_pred`, which compares these strategies in terms of prediction performances by introducing missing values in the covariates (`x_comp`) under a specific missing data mechanism (`mecha`) and a given percentage of missing values (`p`). This missing values generation is repeated several times, (`nbsim`), which leads to a stochasticity in the results. The dataset is then split into the training set and the test set (75% in the training set, 25% in the test set) and the methods presented below are applied by considering a specific learning algorithm (`learner`), e.g., random forests, gradient boosting, linear regression. The function then returns the prediction error on the test set, by comparing the ground truth (`y`) and the predicted outcome values on the test set for each simulation (i.e., each run for the generation of missing values) in a table (see Figure 9.8). The code for calling this function is given below, when the learning algorithm is the gradient boosting and 20% of MCAR values are introduced. The covariates $X \in \mathbb{R}^{1000\times 3}$ are generated under a multivariate Gaussian distribution, the parameter of the regression $\beta \in \mathbb{R}^3$ follows a random uniform distribution. The outcome y is generated according to a linear model such that $y = X\beta + \epsilon$, with ϵ a Gaussian noise.

```
learner = HistGradientBoostingRegressor() # learning algo. to use
p = 0.2
res = score_pred(x_comp=X, y = y, learner=learner , p=p,
                 nbsim=10, mecha="MCAR")
```

Listing 9.15 – Code to compare different strategies to predict an output variable in Python.

Figure 9.9 shows the graphical output of this function called for different learning algorithms and for different missing-data mechanisms. When the learner is the linear regression, the two-step methods with added mask, both for the MCAR mechanism and the MNAR mechanism, perform well. Since the simulated dataset is generated

14. https://github.com/amices/mice/issues/32

considering a linear regression, the linear regression is expected to give better results than the other learners. In addition, for the MNAR mechanism, the one-step strategy *MIA* (especially when the gradient boosting is performed) seems to be a good choice. Note that MIA or mean imputation are recommended asymptotically but when having limited data in the prediction setting, other methods such as multiple imputation can outperform these asymptotically consistent methods [Josse et al., 2019].

Mean	Iterative	Mean + Mask	Iterative + Mask	MIA
0.892	0.895	0.892	0.895	0.892
0.885	0.896	0.885	0.896	0.891
0.895	0.89	0.895	0.89	0.903
0.866	0.836	0.866	0.836	0.873
0.881	0.863	0.881	0.863	0.887
0.859	0.862	0.859	0.862	0.865
0.9	0.91	0.9	0.91	0.905
0.86	0.852	0.86	0.852	0.847
0.897	0.899	0.897	0.899	0.911
0.879	0.872	0.879	0.872	0.883

Figure 9.8 – Output of the function `score_pred` to compare different strategies when the aim is to predict in Python. 20% of missing values are introduced in a simulated dataset using the MCAR mechanism. The two-step strategies (**IterativeImputer** and the mean imputation) with or without adding a mask and the one-step strategy *MIA* are compared in terms of prediction error, and then a gradient boosting is performed. The closer the result is to 1, the more accurate the prediction is (1 corresponds to perfect prediction, 0 to the worst prediction). The results in the tabular correspond to the prediction error for several simulations (i.e., several runs for the generation of missing values).

Another function `plot_score_realdatasets` is specifically designed to handle datasets which already contain missing values. The main arguments are the dataset (`X`), the outcome variable (`y`) and the learning algorithm to use (`learner`). In this case, the stochasticity comes from the way we split the dataset into a training set and a test set. This splitting and subsequent learning is repeated several times.

```
learner = HistGradientBoostingRegressor() # learning algo. to use
p = plot_score_realdatasets(X = X, y = y, learner = learner)
```

Listing 9.16 – Code to compare different strategies for a real dataset to predict an output variable in Python.

This concludes the overview of the workflows which have been developed in this project and which we consider as an invitation to other practitioners and researchers to use them for better comparability between methodologies when suggesting new methodologies in research articles.



Figure 9.9 – Plot of the function `score_pred` to compare different strategies when the aim is to predict in Python. 20% of missing values are introduced in a simulated dataset using the MCAR mechanism or the MNAR mechanism. The two-step strategies (**IterativeImputer** and the mean imputation) with or without adding a mask and the one-step strategy *MIA* are compared in terms of prediction error, and several learners are performed (linear regression, random forests, gradient boosting). The closer the result is to 1, the more accurate the prediction is (1 corresponds to perfect prediction, 0 to the worst prediction).

9.4 – Perspectives and future extensions

By providing a platform and community to discuss missing data, software, approaches and workflows, the sharing of expertise on missing data can hopefully improve and extend more easily.

9.4.1 Towards uniformization and reproducibility

One way to promote and encourage practitioners and researchers in their work with missing values is to provide community benchmarks and workflows centered around missing data. As has been demonstrated with data competitions, involving the community brings forth many creative solutions and discussions that advance the field, and challenge existing strategies. We will continue working on our workflows and the corresponding source code. In doing so, we hope to encourage users to continue benchmarking new methods and to present the results in a clear and reproducible way. In addition, we plan to propose two types of data challenges: 1) imputation and estimation, and 2) analysis workflows. For the first challenge, the objective is to find the best imputation or estimation strategy. The community would be given a dataset with missing values, for which there is actually a hidden copy of the real values. The community is then tasked with creating imputed values, which are assessed against the original dataset with complete values, to determine which imputation is best. This is similar in spirit to the Netflix prize [Bennett et al., 2007] and the M4 challenge in the time series domain [Makridakis et al., 2018]. This benchmarking could be

extended to other areas, such as parameter estimation, and predictive modeling with missing data. Analysis workflows could form another community challenge, assessed in a similar way to existing "datathon" events where entries are assessed by an expert panel. Here the challenge could be to develop workflows and data visualizations from complex data. The data could have challenging features, and be combined from various data with complex structure, such as data with several types of missingness, images, text, data, longitudinal data, and time series.

9.4.2 Future extensions

Potential extensions that could be added in future releases of the platform and for which we welcome suggestions and contributions are the following: a workflow with a focus on MNAR data and different solutions that can handle such data (as diversity of existing solutions is large, such a unified workflow will be a consequential contribution); for more applied users, a comparison of computation times of different methods, benchmarked on various types of data. In addition, a more and more often encountered problem concerns missing values in data integration. Indeed, questions such as *what do I do when I have clinical data from multiple centers with different mechanisms of missing values or with systematically missing values in certain data?* or *what do I do when I have time series and missing values in one of the groups of variables?* would be also worth addressing in a new workflow.

9.4.3 Participation and interaction

This platform is aimed to be a venue for the community, in the sense that we welcome every comment and question, encourage submissions of new work, theoretical or practical, either through the provided contact form or directly via the GitHub project repository [15]. We have already received much useful feedback and contributions from outside, organized several remote calls and working sessions at statistics conferences. We are planning on regularly relaunching calls for new material for the platform, for instance through the R consortium blog [16], R-bloggers [17] and social media platforms. We also intend to use these channels to communicate more generally about the platform and the topic of missing values.

In order for the platform to be a reference to the community, it needs to provide regularly updated user friendly content. Proposing sustainable and accessible solutions for the maintenance of the R-miss-tastic platform is crucial to achieve this goal. We hope that the well documented code source of the platform invites contributions and community feedback on this project.

In conclusion, the aim of this platform is to go further than merely community participation, namely to seed meaningful community interactions, and make it a hub of communication among groups that rarely exchange, both within, and between academia and industry.

15. https://github.com/R-miss-tastic/website
16. https://www.r-consortium.org/news/blog
17. https://www.r-bloggers.com/

Acknowledgements This work has partially been funded by the R Consortium, Inc. We would like to thank Steffen Moritz and François Husson for their active support and feedback, all contributors who have generously made their course and tutorial materials available, as well as the contributors to the workflows in R and Python code.

Chapter 10

Tutorial: Causal inference with missing values in R

This chapter provides two tutorials on how to carry out treatment effect estimation on incomplete observational and experimental data. It is based on code published on my GitHub account.

Abstract

The objective of this tutorial is to illustrate how to perform treatment effect estimation with missing attributes from observational or experimental data, using the R programming language [R Core Team, 2020]. The methodology is illustrated on a simulated example or on a provided dataset of interest. These examples are based on implementations realized during the work that has led to the contribution of Chapter 4 and of Chapter 7.

Table of contents
Table des matières

10.1 – Treatment effect estimation from observational data using R

We start with a synthetic example with datasets generated under the different identifiability assumptions laid out in Chapter 4. The goal of this tutorial is to describe and provide intuitions about these assumptions on concrete examples, and to guide through the analysis from descriptive statistics to the final treatment effect estimation, based on a toy example with reusable lines of R code. All the code reported here is available as R files at https://github.com/imkemayer/causal-inference-missing. The models and assumptions from Chapter 4 are recalled in the following section and the reader may skip them to continue directly with the tutorial on the toy dataset.

10.1.1 Identifiability assumptions

In this paragraph we recall the two different sets of identifiability assumptions that can be considered in case of incomplete covariates as seen in Chapter 4. Standard results from the complete case state that the average treatment effect τ as defined in (1.2) is (non-parametrically) identifiable if the *ignorability* or *unconfoundedness* assumption holds, i.e., conditionally on confounders C, the treatment assignment is independent of the potential outcomes:

$$\{Y_i(1), Y_i(0)\} \perp\!\!\!\perp W_i \,|\, C_i, \qquad \text{for all } i; \tag{10.1}$$

and if the *overlap* assumption holds that stipulates the existence of some $\eta > 0$ such that $\eta < e(c) < 1 - \eta, \quad \text{for all } c \in \mathcal{C}$.

For the case of possible missing entries in the covariates, we denote the response pattern of the i-th sample as $R_i \in \{0,1\}^p$ such that $R_{ij} = 1$ if X_{ij} is observed and $R_{ij} = 0$ otherwise. The matrix of observed covariates can be written with $X_i^\star \triangleq X_i \odot R_i + \texttt{NA} \odot (\mathbf{1} - R_i)$, with $\odot$ the element-wise multiplication and $\mathbf{1}$ the matrix filled with 1, so that $X_i^\star$ takes its value in the half discrete space $\mathcal{X}^\star \triangleq (\mathbb{R} \cup \{\texttt{NA}\})^p$. We model R_i as a random vector and the (conditional) distribution of $1 - R_i$ is known as the missing values mechanism.

Now, the possibility to infer treatment effects with incomplete covariates, i.e., from observations $(Y_i, W_i, X_i^\star)_{i=1,\dots,n}$, depends on additional assumptions on the joint law of
$(Y_i(0), Y_i(1), W_i, X_i, R_i)_{i=1,\dots,n}$. These can be cast into two categories: (i) an adaptation of the unconfoundedness assumption (10.1) in order to identify the causal effect and (ii) additional assumptions that are well known in the inference literature with missing data or matrix completions and are based on assumptions about the processes that generate the missing data.

(i) Unconfoundedness despite missingness:

$$\{Y_i(1), Y_i(0)\} \perp\!\!\!\perp W_i \,|\, X_i^\star, \qquad \text{for all } i, \tag{10.2}$$

i.e., here we have $C = X^*$. This implies that if a covariate is not observed, it is not a confounder. The causal graph for this case is provided in Figure 10.1. In particular, observations can have different confounders depending on their pattern of missing data. This entails an adaption of the nuisance parameters, namely the generalized propensity score [Rosenbaum and Rubin, 1984]

$$\forall x^\star \in \mathcal{X}^\star, \quad e^\star(x^\star) \triangleq P(W_i = 1 \,|\, X_i^\star = x^\star)\,, \tag{10.3}$$

which is a balancing score under (10.2), and the generalized conditional response surfaces:

$$\forall (w, x^\star) \in \{0,1\} \times \mathcal{X}^\star\,, \quad \mu_w^\star(x^\star) \triangleq \mathbb{E}[Y_i(w) \,|\, X_i^\star = x^\star]\,. \tag{10.4}$$

(ii) Classical unconfoundedness + assumptions about the missingness mechanism: we assume the unconfoundedness holds in the complete case, i.e., equation

(10.1) holds for $C = X$, and additionally we assume that the missingness in X is missing at random conditionally on W and Y:

$$\forall r,\ P(R = r|X, W, Y) = P(R = r|X^{obs(r)}, W, Y) \tag{10.5}$$



Figure 10.1 – Unconfoundedness despite missingness. X represents the complete covariates, and R a missing data mechanism, X^* represents the observed incomplete covariates, confounding the treatment assignment. The formalism of Pearl [1995] and Richardson and Robins [2013] is used.

10.1.2 Generating the simulated data

We will generate two simple toy datasets with normally distributed confounders and missing values under the MCAR mechanism such that the first satisfies the unconfoundedness despite missingness assumption (10.2), while the second follows the classical unconfoundedness + assumptions about the missingness mechanism. For the generation of missing values, we use the R code from the R-miss-tastic platform (see Chapter 9) and fix the proportion of missing covariate values at 30%.

```
n <- 5000 # number of observations
p <- 5 # number of covariates
tau <- 1 # true value of the ATE
prop.NA <- 0.3 # proportion of missing values generated in the
    confounders
Sigma <- diag(p) + 0.3*upper.tri(diag(p)) + 0.3*lower.tri(diag(p))
    # correlation between covariates is constant to 0.3
X <- mvrnorm(n=n, mu=rep(1, p), Sigma=Sigma) # matrix of covariates
res.na <- produce_NA(X, mechanism="MCAR", perc.missing=perc.NA,
    seed=seed) # generation of missing values
X.na <- res.na$data.incomp # matrix of incomplete covariates
```

Listing 10.1 – Code to simulate X of first toy dataset.

The propensity model as well as the conditional response surfaces are taken to be non-linear in the covariates. The treatment effect is chosen to be constant, i.e., $\tau_i = \tau$, for all i.

```
# non-linear transformations of X
X.tmp <- X
for (j in 1:p){
  X.tmp[,j] <- (mod(j,5)==1)*((X.tmp[,j]<quantile(X.tmp[,j],0.7)) +
    (X.tmp[,j]> quantile(X.tmp[,j],0.2))) +
                (mod(j,5)==2)*(1/(0.001+exp(X.tmp[,j]*X.tmp[,1]))) +
                (mod(j,5)==3)*(-(X.tmp[,j])*(X.tmp[,2]>0)) +
                (mod(j,5)==4)*(-2.5*sqrt(abs(X.tmp[,j]))) +
```

```
                (mod(j,5)==0)*(X.tmp[,3]*X.tmp[,j])
}

# auxiliary definitions
expit <- function(x){ return(1/(1+exp(-x))) }
alpha <- array(c(-0.6, 0.6), dim=p)
epsilons <- rnorm(n, sd=0.2)
beta <- runif(p, -1, 1)

# propensity score for dataset 1
X.tmp.ps <- X.tmp
X.tmp.ps[res.na$idx_newNA] <- 0
prop.scores.na <- apply(data.frame(X.tmp), MARGIN=1,
                        FUN=function(z) expit(z%*%alpha))
prop.scores.na <- 0.01 + (pmin(0.98,prop.scores.na) - min(prop.
    scores.na))/
                  (max(prop.scores.na)-min(prop.scores.na))

# treatment assignment for dataset 1
W.na <- sapply(prop.scores.na,
               FUN=function(p) rbinom(n=1, size=1, prob=p))

# observed outcome for dataset 1
Y.na <- rep(0,n)
Y.na[which(W.na==1)] <- X.tmp[which(W.na==1),]%*%beta +
                        tau + epsilons[which(W.na==1)]
Y.na[which(!(W.na==1))] <- X.tmp[which(!(W.na==1)),]%*%beta +
                           epsilons[which(!(W.na==1))]

# stacked covariates, treatment assignment and outcome for dataset
    1
toy.data.1 <- list(X=X, X.na=X.na, W=W.na, Y=Y.na)
df.na.1 <- data.frame(cbind(X.na, W=W.na, Y=Y.na))
colnames(df.na.1) <- c(colnames(X), "W", "Y")
```

Listing 10.2 – Code to simulate W and Y of first toy dataset.

As we can read off from the code, we choose to generate the treatment assignment under the CIT assumption (4.3) by defining one model per observed response pattern, while we generate the outcome using the full covariates. As detailed in Chapter 4, this ensures that the data satisfies the unconfoundedness despite missingness assumption (10.2).

For the second toy dataset, satisfying the classical unconfoundedness assumption (10.1), we use the full covariates to generate W and Y according to our pre-specified models, but the observed covariates are also the incomplete observations X^* as for the first toy dataset.

```
# propensity score for dataset 2
X.tmp.ps <- X.tmp
prop.scores <- apply(data.frame(X.tmp), MARGIN=1,
                     FUN=function(z) expit(z%*%alpha))
prop.scores <- 0.01 + (pmin(0.98,prop.scores) - min(prop.scores))/
               (max(prop.scores)-min(prop.scores))

```

```
# treatment assignment for dataset 2
W <- sapply(prop.scores,
            FUN=function(p) rbinom(n=1, size=1, prob=p))

# observed outcome for dataset 2
Y <- rep(0,n)
Y[which(W==1)] <- X.tmp[which(W==1),]%*%beta +
                  tau + epsilons[which(W==1)]
Y[which(!(W==1))] <- X.tmp[which(!(W==1)),]%*%beta +
                     epsilons[which(!(W==1))]

# stacked covariates, treatment assignment and outcome for dataset
   2
toy.data.2 <- list(X=X, X.na=X.na, W=W, Y=Y)
df.na.2 <- data.frame(cbind(X.na, W=W, Y=Y))
colnames(df.na.2) <- c(colnames(X), "W", "Y")
```

Listing 10.3 – Code to simulate W and Y of second toy dataset.

An example of a resulting dataset is provided in Table 10.1, with the removed values highlighted in red which are missing values in the following analyses. Note that the treatment assignment vector W as well as the observed outcome Y are fully observed.

Table 10.1 – First six rows of the generated toy dataset 1. The red cells correspond to the values that are missing in the observed dataset.

X_1	X_2	X_3	X_4	X_5	W	Y
2.97	0.29	0.55	2.54	2.66	1	-0.70
0.44	0.22	1.63	0.88	0.91	0	-1.62
0.63	-0.27	0.37	0.96	-0.29	0	0.52
3.19	2.59	2.33	2.53	2.15	0	-3.81
1.10	-0.26	1.62	1.24	-0.13	0	-0.09
-0.86	-0.08	1.39	0.86	2.02	1	-0.16

In certain cases, not all covariates are necessarily confounders. Therefore it can be necessary to specify the subset of confounders among the set of covariates. Note however that in the present example we consider all covariates to be confounders. The remaining covariates are either only related to the treatment assignment, e.g., treatment eligibility and counter-indications, or only related to the outcome, e.g., baseline risk factors that allow for a more accurate modeling of the outcome.

```
covariate.names <- colnames(X)
confounder.names <- covariate.names
only.treatment.pred.names <- c()
only.outcome.pred.names <- setdiff(covariate.names,
                                   c(confounder.names, only.
   treatment.pred.names))
```

Listing 10.4 – Designation of confounders

10.1.3 Preliminary analyses

Before we dive into a more extensive analysis of the data at hand, we first compute the *unadjusted* ATE, i.e., computing the difference in means estimator (1.14) while ignoring the confounding factors. Since we assume that treatment assignment and the observed outcome are completely observed, this preliminary step does not require any handling of missing values. This gives us two biased results that underestimate the true ATE which is fixed at 1, for instance we obtain `ate.raw.1`≈ 0.79, and `ate.raw.2`≈ 0.82. We will detail all the following steps and associated R code illustrated on the toy dataset 1, but the same steps are applicable to the toy dataset 2 and any other dataset following the same tabular data format.

Missing values exploration Prior to handling missing values, it is important to explore the data and to take a look at the missing values which might exhibit certain patterns. An overview of the broad variety of existing methods and tools to assess missing values can be found in Mayer et al. [2019], corresponding to the work presented in Chapter 9. In general settings, we don not know how the missing values are generated. A look at the matrix plot of missing and observed values can help identifying whether there are variables that tend to be missing together. Since we consider the simple case of MCAR data, we do not expect to find any such groups of variables in such a plot. Additionally, if we suspect dependence structures between missing values, we can perform a multiple correspondence analysis (MCA) on the missing and non missing entries to corroborate the conclusions from the previous graphical analysis [Josse et al., 2011a]. Finally, a useful graph can be the barplot representing the proportion of missing values in each variable. In practice, this last graph is especially useful to identify (groups of) variables with important fractions missing values. However, this graph should certainly not serve as a basis to exclude *a priori* variables with large fractions of missing values. Indeed, as we have seen in most of the previous chapters, certain variables, namely confounding variables, are necessary for identifiability of causal estimands and in some cases their missingness pattern itself can be confounding. Thus, removing such variables due to their large proportion of unobserved values can potentially lead to non-identifiability of the quantity of interest and generally to an important bias of the final estimate.

```
# matrix plot of missing and non missing entries
matrixplot(toy.data.1[['X.na']], las = 2, cex.axis = 0.3)

# MCA on the missing and non missing entries
data.miss <- data.frame(is.na(toy.data.1[['X.na']]))
data.miss <- apply(X=data.miss, FUN=function(x) if(x) "m" else "o",
    MARGIN=c(1,2))
res.mca <- FactoMineR::MCA(data.miss, graph = FALSE)
plot(res.mca, invis = "ind", title = "MCA graph of the categories",
    cex =0.5)

# barplot of missing values proportions
na.data <- sapply(toy.data.1[['X.na']], function(x) sum(is.na(x)))
missing.data <- as.data.frame(cbind(variable.names, na.data),
   stringsAsFactors = FALSE)
```

```
missing.data[-1] <- apply(missing.data[-1], 1:2, function(x) as.
    numeric(as.character(x)))
rownames(missing.data) <- NULL
missing.data.reshaped <- reshape2::melt(missing.data, id.var="
    variable.names")
ggplot2::ggplot(missing.data.reshaped,
                aes(x = reorder(variable.names, value), y = (100 *
    value / n), fill=variable)) +
     geom_bar(stat = "identity",show.legend=F) +
     theme_minimal()+
     theme(axis.text.x= element_text(angle=65,hjust=1, size = 12),
           axis.text.y = element_text(face="bold",
                                      size=14)) +
     xlab("Variable") + ylab("Percentage")
```

Listing 10.5 – Missing values visualization for toy dataset 1

The resulting figures from these commands are provided in Figure 10.2.



(a) Matrixplot: columns are the different variables, rows are the different observations, red indicates a missing value.



(b) Barplot of missing values proportions.



(c) MCA from response pattern

Figure 10.2 – Graphical visualizations of missing values and missingness patterns.

Group and overlap assessment Even if the identifiability assumptions described earlier and in Chapter 1 cannot be tested using a statistical test, it is possible to

empirically assess the balancing between the treatment groups. These do not allow to conclude that two groups are indeed balanced but they are indicative in case of unbalance.

A common way of visualizing the balance between treatment groups is to use standardized mean differences (SMD). For a continuous variable X_j, the SMD is defined as:

$$SMD(X_j) = \frac{\mu_{j,(1)} - \mu_{j,(0)}}{\sqrt{\frac{(\sigma^2_{j,(1)} + \sigma^2_{j,(0)}}{2}}}, \tag{10.6}$$

where $\mu_{j,(w)}$ and $\sigma^2_{j,(w)}$ respectively denote the mean and variance of X_j in treatment group w. An estimator of (10.6) is given by

$$\widehat{SMD}(X_j) = \frac{\overline{X_{j,(1)}} - \overline{X_{j,(0)}}}{\sqrt{\frac{s^2_{j,(1)} + s^2_{j,(0)}}{2}}}.$$

The SMD can also be defined for binary variables; for a binary variable X_k the SMD can be estimated by:

$$\widehat{SMD}(X_k) = \frac{\widehat{p_{k,(1)}} - \widehat{p_{k,(0)}}}{\sqrt{\frac{\widehat{p_{k,(1)}}(1-\widehat{p_{k,(1)}}) + \widehat{p_{k,(0)}}(1-\widehat{p_{k,(0)}})}{2}}},$$

where $\widehat{p_{k,(w)}}$ corresponds to the mean of X_k in treatment group w [Flury and Riedwyl, 1986].

In practice, if the estimated SMD is larger than some threshold κ, for instance $\kappa = 0.1$, then this points towards non-random differences between the covariate distributions in the two groups: the treatment is likely not given uniformly at random for such data.

These SMDs can be computed prior to any causal analyses, but they can also be computed after re-weighting or matching of the data to assess the changes induced by these data manipulations.

Since the unconfoundedness despite missingness assumption states that the response pattern can also be a confounder, we can also compute SMDs for the response pattern to assess the balance of the response patterns.

Even though in the observational data case we generally do not have access to the true propensity scores, it can be helpful to visualize the estimated propensity scores to detect potential violations of the overlap assumption. For instance, if a (regularized) estimation approach predicts propensity scores close to 0 for the control group and close to 1 for the treated group, this can point towards a lack of overlap between these two groups.

We provide in Figure 10.3 the plot of the SMDs before and after re-weighting with MIA propensity scores $\widehat{e^*}(X_i)$ and the histogram of these estimated propensity scores for the toy dataset 1, obtained with the following lines of code.

```
weights <- W/w.hat + (1-W)/(1-w.hat) # w.hat contains the MIA
    estimated propensity scores

```

```
cobalt::bal.plot(x=data.frame(treat=W, propensity_score=w.hat,
    weights=weights),
                 var.name = "propensity_score", which = "both",
                 treat=W,
                 weights=weights,
                 type = "histogram", mirror = TRUE)

balance <- cobalt::bal.tab(X.na[, confounder_names], treat = W,
                           estimand="ATE",
                           continuous="std", weights = weights,
                           method = "weighting", un=TRUE)
cobalt::love.plot(x = balance, stat = "mean.diffs", abs = TRUE,
                  var.order = "unadjusted",
                  stars="raw",continuous="std", threshold = 0.1)
```

Listing 10.6 – Balance and overlap assessment for toy dataset 1



(a) Absolute standardized mean differences before and after re-weighting with MIA propensity scores $\hat{e}^*(X_i)$.

(b) Histograms of estimated propensity scores $\hat{e}^*(X_i)$ obtained with MIA random forest before and after re-weighting observations.

Figure 10.3 – Graphical visualizations of balance and overlap.

We note on the left part of Figure 10.3b that the control sample's propensity scores (in red) are overall lower than the propensity scores of the treated sample (turquoise), while after adjustment, the two empirical propensity scores distributions are similar between the two samples.

10.1.4 Imputation

As detailed in Chapter 4, under the classical unconfoundedness assumption with additional assumptions about the missingness mechanism, multiple imputation analysis is a valid strategy to estimate an ATE, provided that both the treatment assignment as well as the outcome are included in the imputation model [Seaman and White, 2014]. We know that the first toy dataset does not satisfy this assumption while the second does. We impute both of them, using the `mice` R package [van Buuren and Groothuis-Oudshoorn, 2011] with 10 imputations.

```
m <- 10
```

```
df.imp.mice.1 <- mice(df.na.1, m=m, seed=seed, printFlag=F)
```

Listing 10.7 – Multiple imputations for toy dataset 1.

10.1.5 Average treatment effect estimation

We are now at the core step of the analysis, the estimation of the ATE. The code below is also suited to estimate other estimands such as the ATT and ATC. The argument to change the estimand of interest is `target` which can be set to the following values:

- `target <- "all"` for the ATE,
- `target <- "treated"` for the ATT,
- `target <- "control"` for the ATC,
- `target <- "overlap"` for the ATE on the overlap population [Li et al., 2018].

Following the theory detailed in Chapter 4, we estimate the ATE using two different estimators (the IPW and doubly robust AIPW) and two possibilities to estimate nuisance parameters (i.e., the propensity scores and the conditional response surfaces). A classical choice for nuisance parameter estimation in causal inference applications is the use of generalized linear models (in practice, mostly logistic and linear models), which we use with the `glm` R function. And more recently, more complex and flexible models became available, such as generalized regression forest (grf) [Athey et al., 2019].

We recall the form of the (non-normalized) IPW estimator which has the following expression:

$$\hat{\tau}_{IPW} = \frac{1}{n}\sum_{i=1}^{n}\left(\frac{W_i Y_i}{\hat{e}(X_i)} - \frac{(1-X_i)Y_i}{1-\hat{e}(X_i)}\right),$$

and the doubly robust AIPW estimator can be written as follows:

$$\hat{\tau}_{DR} = \frac{1}{n}\sum_{i=1}^{n}\hat{\mu}_1(X_i) - \hat{\mu}_0(X_i) + W_i\frac{Y_i - \hat{\mu}_1(X_i)}{\hat{e}(X_i)} - (1-W_i)\frac{Y_i - \hat{\mu}_0(X_i)}{1-\hat{e}(X_i)}.$$

If X is incomplete (i.e., we effectively work with X^*), and we assume the unconfoundedness despite missingness assumption, then the nuisance parameters e, μ_0, μ_1 and their estimations in the above expressions are replaced by their generalized counterparts, e.g., $e^*(x^*) = \mathbb{P}[W_i = 1 | X_i^* = x^*]$.

In the published R code supporting the work presented in Chapter 4, a function `treatment_effect_estimates` allows to compute the normalized and non-normalized IPW estimator as well as the AIPW estimator for a given dataset and target estimand. The R code of this function as well as additional documentation and examples can also be found on the GitHub repository `causal-inference-missing`[1]. For the multiple imputation approach, the different estimations obtained for every imputed dataset are aggregated using Rubin's rules [Rubin, 2004].

1. https://github.com/imkemayer/causal-inference-missing

```
target <- "all"

# Toy dataset 1
res.tmp <- complete(df.imp.mice.1, "all") %>%
            lapply(treatment_effect_estimates,
                   target=target,
                   confounder_names=confounder.names,
                   only_treatment_pred_names=only.treatment.pred.
    names,
                   only_outcome_pred_names=only.treatment.pred.
    names)
res.val <- as.data.frame(do.call(rbind, lapply(res.tmp, "[", , "
    Value")))
res.se <- as.data.frame(do.call(rbind, lapply(res.tmp, "[", , "
    StandardError")))
results.mice.1 <- cbind(res.tmp[[1]][,1:2],
                        apply(res.val,2, mean),
                        sapply(1:dim(res.tmp[[1]])[1],
                               function(j) sqrt(mean(res.se[,j]^2*n
    )+
                               (1+1/m)*sum((res.val[,j]-mean(res.
    val[,j]))^2)/(m-1))/sqrt(n)))
colnames(results.mice.1) <- colnames(res.tmp[[1]])
```

Listing 10.8 – Treatment effect estimation using multiple imputation for toy dataset 1.

Using the "raw" data without pre-processing of the missing values, i.e., using the data with `NA`s indicating missing values in the covariates, we compute the IPW estimator with propensity scores estimated via generalized random forests with Missing Incorporated in Attributes (MIA) and the AIPW estimator with two generalized random forests with MIA.

```
# Toy dataset 1
results.mia.1 <- treatment_effect_estimates(df.na.1, target=target,
                                            confounder_names=
    confounder.names,
                                            only_treatment_pred_
    names=only.treatment.pred.names,
                                            only_outcome_pred_names
    =only.treatment.pred.names)
```

Listing 10.9 – Treatment effect estimation using MIA for toy dataset 1.

A summary of all values computed by the function `treatment_effect_estimates` is provided for toy dataset 1 in Table 10.2 and for toy dataset 2 in Table 10.3. We observe the expected behavior of the various estimators Table 10.2, namely the MIA-AIPW estimator which recovers well the true ATE $\tau = 1$ with small standard error, while the MICE estimators overestimate the ATE (with the exception of the MICE-AIPW estimator with non-parametric nuisance parameter estimation). Conversely, on Table 10.3, we observe a better performance of the MICE estimators (with non-parametric nuisance parameter estimation). The bad performance of the parametric MICE estimators is not surprising because we have generated W and Y using highly non-linear functions of X.

Table 10.2 – ATE estimation results for the toy dataset 1 generated under the unconfoundedness despite missingness assumption (10.2).

Approach	Nuisance parameter estimation	ATE estimate	Value	Standard Error
MICE	glm	IPW_{un}	1.69	0.13
		IPW_{norm}	1.71	0.15
		AIPW	1.31	0.12
	grf	IPW_{un}	1.19	0.07
		IPW_{norm}	1.14	0.06
		AIPW	0.92	0.03
MIA	grf	IPW_{un}	1.29	0.09
		IPW_{norm}	1.25	0.08
		AIPW	1.05	0.06

Table 10.3 – ATE estimation results for the toy dataset 2 generated under the classical unconfoundedness assumption (10.1).

Approach	Nuisance parameter estimation	ATE estimate	Value	Standard Error
MICE	glm	IPW_{un}	1.62	0.11
		IPW_{norm}	1.62	0.12
		AIPW	1.34	0.07
	grf	IPW_{un}	1.21	0.07
		IPW_{norm}	1.17	0.06
		AIPW	0.96	0.03
MIA	grf	IPW_{un}	1.29	0.08
		IPW_{norm}	1.25	0.08
		AIPW	1.03	0.05

10.1.6 Heterogeneous treatment effect estimation

We conclude this tutorial with a remark on heterogeneous treatment effect estimation. Indeed, the previously illustrated implementation is easily extentable for heterogeneous treatment effect estimation, i.e., estimation of the CATE function $\tau(\cdot)$.

Since we simulated data with a constant treatment effect τ, we do not expect to find any treatment effect heterogeneity in the data. We provide however the lines of code for estimating the CATE function on the observed data using the `grf` package to illustrate the straightforward extension of the ATE estimation to the CATE or HTE (heterogeneous treatment effect) estimation with missing attributes.

```
cf <- causal_forest(X = as.matrix(X.na[,confounder_names]),
                    Y = Y,
                    W = W)
oob_pred <- predict(cf, estimate.variance=TRUE)
```

```
hist(oob_pred$predictions,
    main="Causal forest: out-of-bag CATE")
```

Listing 10.10 – Heterogeneous treatment effect estimation with missing attributes using the `causal_forest` function.



Figure 10.4 – Histogram of estimated CATE function $\hat{\tau}(\cdot)$ evaluated at the observations X_i.

The histogram of the estimated CATE function evaluated at the observations X_i does not necessarily provide insights into the actual treatment heterogeneity. Indeed, in certain cases of insufficient data or information, e.g. an unobserved treatment effect modifier, the heterogeneity could be underestimated, while it can be overestimated due to important noise in the data. For valid assessments of treatment effect heterogeneity we refer to Chernozhukov et al. [2018b] in the case of experimental data and to Athey and Wager [2019] for observational studies.

10.2 – Generalizing treatment effects from experimental to observational data

In this section we detail the basic steps and lines of R code required to generalize estimated treatment effects from (incomplete) experimental to (incomplete) observational data, complementing the theoretical part of Chapter 7 that details the problem and proposed solutions. All the code reported here is available as R files at https://github.com/imkemayer/combined-incomplete-data.

For the following illustration, we use the same simulation setting as in Chapter 7, namely:

$$\text{logit}\left\{\pi_S(X)\right\} = -2.5 - 0.5X_1 - 0.3X_2 - 0.5X_3 - 0.4X_4,$$

where X is drawn from a multivariate normal distribution with mean 1 and covariance matrix Σ such that

$$\Sigma_{ij} = \begin{cases} 1 & \text{if } i = j \\ 0.6 & \text{if } i \neq j \end{cases}$$

This model specifies the trial selection, S.

The outcome is linear in the covariates X, with an interaction between X_1 and the treatment assignment W:

$$Y(w) = -100 + 27.4wX_1 + 13.7X_2 + 13.7X_3 + 13.7X_4 + \epsilon \quad \text{with } \epsilon \sim \mathcal{N}(0, \sigma_\varepsilon^2), \tag{10.7}$$

where σ_ε^2 is chosen such that the signal-to-noise ratio of Y corresponds to a chosen value SNR. The missing covariate values, indexed by the mask $M = 1 - R \in \{0,1\}^{n \times p}$, are sampled using one of the three missingness mechanisms detailed in Chapter 7.

We do not modify the treatment assignment mechanism since by assumption it is independent of everything and generally constant for all individuals ($e_1(x) = e_1 = 0.5$). Below, we compare the methods in the setting where we assume the classical ignorability from the full data case and make assumptions about the missing values mechanism, this corresponds to Section 7.3. In practice that means that the missing values occur after trial inclusion and treatment randomization.

10.2.1 Generating the simulated data

A generic function implemented for the simulation study presented in Chapter 7 allows to generate data satisfying various assumptions such as the transportability and positivity assumptions (7.14) and (7.13) and to specify the type of missing values to occur in the trial sample and the sample representative of the target population.

In our example we generate a trial sample of $n \approx 1000$ observations and a target population sample of $m = 10000$ observations, with 20% of MAR missing values in the trial sample and MAR missing values of different proportions in the target sample, such that the treatment effect modifier variable X_1 has 50% of missing values. We focus on the classical ignorability assumption (6.3.3) coupled with classical assumptions about the missingness mechanism, thus we expect the multiple imputation approach detailed in Section 7.3 to outperform all other estimators.

```
df <- simulate_continuous(n = 1000, m = 10000, snr=5,
                          link="linear", Sigma=Sigma, bs0=-3.1,
                          na_rct=list(mechanism="MAR",
                                      prop_miss=0.2,
                                      idx_incomplete=rep(1,4),
                                      cis=F, cio=F),
                          na_rwe=list(mechanism="MAR",
                                      prop_miss=c(0.5,0.1,0.1,0.1),
                                      idx_incomplete=rep(1,4),
                                      cio=F))
tau <- df
df <- df$DF
df$sample <- ifelse(df$V == 1, "RCT", "Observational")
```

Listing 10.11 – Generation of the incomplete dataset.

We can summarize the data to ensure that the proportions of missing values correspond to our specifications, as illustrated in Table 10.4.

Table 10.4 – Baseline characteristics of the simulated covariates with trial and target population samples.

	Observational (N = 10000)	RCT (**N = 1091**)	Total (**N = 11091**)
X1			
Mean (SD)	0.350 (0.854)	−0.223 (0.924)	0.262 (0.889)
Median [Min, Max]	0.319 [−2.47, 4.15]	−0.218 [−2.96, 2.57]	0.266 [−2.96, 4.15]
Missing	5015 (50.1%)	196 (18.0%)	5211 (47.0%)
X2			
Mean (SD)	0.861 (0.926)	−0.136 (0.927)	0.772 (0.969)
Median [Min, Max]	0.892 [−3.77, 4.95]	−0.176 [−2.96, 2.78]	0.819 [−3.77, 4.95]
Missing	1008 (10.1%)	208 (19.1%)	1216 (11.0%)
X3			
Mean (SD)	0.834 (0.916)	−0.187 (0.898)	0.743 (0.960)
Median [Min, Max]	0.873 [−2.87, 4.23]	−0.177 [−2.78, 2.45]	0.787 [−2.87, 4.23]
Missing	1024 (10.2%)	210 (19.2%)	1234 (11.1%)
X4			
Mean (SD)	0.848 (0.932)	−0.210 (0.882)	0.756 (0.975)
Median [Min, Max]	0.862 [−2.86, 5.85]	−0.171 [−2.79, 3.13]	0.788 [−2.86, 5.85]
Missing	993 (9.9%)	230 (21.1%)	1223 (11.0%)

10.2.2 Preliminary analyses

Similar to the previous tutorial, and more generally speaking as applicable for data analysis, we begin by examining the data using descriptive statistics and graphical tools. The graphical tools to assess missing values and patterns have been illustrated in the previous section, we thus focus on the distributional shift between the data sources.

From model (10.7) we know that only X_1 is a treatment effect modifier and that it is also relevant for trial selection, thus we visualize the distribution of X_1 in the two samples in Figure 10.5.



Figure 10.5 – Distribution shift between trial sample and observational target sample.

10.2.3 Estimating selection scores and assessing positivity

Since we assume we are in the the classical ignorability + classical missingness mechanism case, we will focus on the estimation of selection scores using the joint fixed effect multiple imputation strategy detailed in Section 7.3. We will compare two sets of selection scores, those obtained using a classical logistic regression model, and those obtained with generalized random forests.

```
df_tmp <- df[,1:7] # we keep the covariates X, the study indicator Q, treatment assignment W and outcome Y
nb_mi <- 10 # we use 10 imputations
m0 <- mice(df_tmp, maxit=0) # initialization of the argument predictorMatrix
predMatrix <- m0$pred
predMatrix[,c("W", "Y")] <- 0
#initialisation of the argument method
df_mice <- mice.par(df_tmp, predictorMatrix=predMatrix, m=nb_mi)
```

Listing 10.12 – Joint fixed effect multiple imputation of the incomplete dataset.

We can now estimate the odds via the estimation of $\pi_{\mathcal{R}}(X_i)$ using either the parametric or non-parametric regression approach. The results are respectively stored in the `alpha_hat_mi_glm` and `alpha_s_hat_mi_grf` variables.

```
res_tmp <- df_mice %>%
            mice::complete(1:nb_mi, mild=TRUE) %>%
            map(dplyr::select, c("X1", "X2", "X3", "X4", "Q")) %>%
            map(sampling_propensities,
                method="glm", seed=100)
alpha_s_hat_mi_glm <- matrix(apply(sapply(data.frame(do.call(rbind, res_tmp)), unlist),
                                   2, function(x) mean(x, na.rm=T))
    )

res_tmp <- df_mice %>%
            mice::complete(1:nb_mi, mild=TRUE) %>%
            map(dplyr::select, c("X1", "X2", "X3", "X4", "Q")) %>%
            map(sampling_propensities,
                method="grf", seed=100)
alpha_s_hat_mi_grf <- matrix(apply(sapply(data.frame(do.call(rbind, res_tmp)), unlist),
                                   2, function(x) mean(x, na.rm=T))
    )
```

Listing 10.13 – Selection score estimation on multiply imputed dataset.

In Figures 10.6a and 10.6b, we can the empirical distributions of these two sets of estimated selection scores to compare them.



(a) Distribution of estimated odds $\widehat{\alpha}^{glm}_{n,m}(X_i)$.



(b) Distribution of estimated odds $\widehat{\alpha}^{grf}_{n,m}(X_i)$



(c) Comparison of $\widehat{\alpha}^{glm}(X_i)$ and $\widehat{\alpha}^{grf}(X_i)$ by sample group.

Figure 10.6 – Comparisons of estimated odds using joint fixed effect multiple imputation. Top left: logistic regression; top right: generalized random forest; bottom: comparison of logistic regression and generalized random forest results.

We observe on Figures 10.6 that both approaches find relatively similar conditional odds, however, when comparing the different estimations of the conditional odds, we notice that the estimation differs especially for certain individuals from the RCT sample We recall the definition of α, conditional odds that an individual with covariates x is in the RCT or in the observational cohort:

$$\alpha(x) \triangleq \frac{P(i \in \mathcal{R} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)}{P(i \in \mathcal{O} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)} = \frac{\pi_{\mathcal{R}}(x)}{\pi_{\mathcal{O}}(x)} = \frac{\pi_{\mathcal{R}}(x)}{1 - \pi_{\mathcal{R}}(x)} .$$

10.2.4 Generalizing the treatment effect

We are now ready to undertake the final step of the primary analysis, namely generalizing the treatment effect from the RCT to the target population represented by the observational sample. [2]

The custom R function `compute_all` implements all estimators discussed in Chapter 7.

```
rct_ate <- df_mice %>%
             mice::complete(1:nb_mi, mild=TRUE) %>%
             map(filter, S == 1) %>%
             map(function(x) mean(x[which(x[,"W"] == 1), "Y"]) -
    mean(x[which(x[,"W"] == 0), "Y"])) %>%
             Reduce("+", .) / nb_mi

results <- c()
for (meth in c("glm", "grf")){
  res_tmp <- df_mice %>%
    mice::complete(1:nb_mi, mild=TRUE) %>%
    map(compute_all, outcome_name="Y", treatment_name="W",
        method=meth, nb_strat=1)
  res_mi <- data.frame(t(apply(sapply(data.frame(do.call(rbind,res_
    tmp)), unlist), 2, mean)))

  results <- rbind(results, data.frame("RCT"=rct_ate,
                                       "IPSW"=res_mi$ipsw_hat,
                                       "IPSW norm"=res_mi$ipsw.norm
    _hat,
                                       "G-formula"=res_mi$gformula_
    hat,
                                       "AIPSW"=res_mi$aipsw_hat,
                                       "CW"=res_mi$cw_hat,
                                       "tau"=tau,
                                       "method"=meth))
}
```

Listing 10.14 – Treatment effect generalization from RCT to target population.

The results of this computation for our toy dataset are reported in Table 10.5, where we denote by `glm` the results obtained using a logistic regression model for $\pi_{\mathcal{R}}$ and by `grf` those obtained using a generalized random forest.

Table 10.5 – Estimation results when generalizing the ATE from the RCT sample to the cohort sample. The true ATE τ is fixed at 27.4.

Estimation approach	$\hat{\tau}_1$	$\hat{\tau}_{IPSW}$	$\hat{\tau}_{IPSW.norm}$	$\hat{\tau}_g$ (or $\hat{\tau}_{CO}$)	$\hat{\tau}_{AIPSW}$	$\hat{\tau}_{CW}$
`glm`	0.16	18.2	27.2	23.5	23.6	22.5
`grf`		15.2	24.4	21.0	23.2	

2. For secondary analyses, in particular sensitivity analysis to assess the sensitivity to violations of the positivity and the ignorability assumptions in the case of systematic missing covariates, we refer to the recent work of Colnet et al. [2021].

Since we generated the data using logistic and linear models, we are not surprised to find that the `glm` estimators overall perform better than their `grf` counterpart. We also note that on this example, the two $\hat{\tau}_{IPSW.norm}$ estimators outperform their competitors within their respective estimation context (`glm` or `grf`).

Even though in this specific synthetic example, we obtain the best results with the simple (normalized) IPSW estimator, in more general cases where we do not know the underlying truth, both in terms of selection and outcome models and of the difference between τ_1 and τ, we recall the superior theoretical guarantees of the AIPSW (and also the ACW, see Subsubsection 6.3.2.3) estimator in terms of robustness to mis-specification and of data efficiency.

Conclusion

The objective of this thesis was twofold: to propose new data analysis tools in the context of causal inference, adapted to some of the challenges of modern data collection processes, namely missingness and heterogeneity; and to develop practical methodologies suited to assess questions of medical relevance and support decision making in a context of time and resource constraints, as it is the case for the chosen application of critical care management. New methodologies are developed at a great pace within this rather young discipline. Especially in recent years the concept of double machine learning has encouraged the use of more complex modern statistical learning methods for tackling causal problems. The task at hand now is to make use of the existing theory and apply them to the abundant data potential among the scientific fields. However a key factor lies in the gap between the classical statistical framework(s) and the collected data which do not always – or only partially – fit into the former. Additionally, a related limiting factor for the use of such methodologies concerns the implementations that often allow for astonishing performances under the correct theoretical assumptions about the data generating process – but that sometimes fail to even produce a result on data that is slightly diverging from these assumptions; in such cases the presence of missing values either produces an execution error or may induce the silent removal of all incomplete observations which, in unfavorable cases, can lead to other violations of the necessary assumptions and potentially misleading conclusions.

In the context of causal inference with observational data, as we have seen in Chapters 1 and 4-7 of this thesis, an additional set of assumptions underlies almost all methodologies and analysis tools, ensuring the identifiability of the causal estimand. When it comes to concrete problems however, e.g., in a clinical context, the extent to which these assumptions are satisfied by the data at hand, is a question of debate and requires sound expert knowledge to ensure the validity of the statistical analysis. Due to this important level of uncertainty related to these assumptions and especially the unconfoundedness assumption, sound and robust techniques that are both efficient and flexible with respect to the types of input become even more relevant for various fields of applications.

With this motivation we began with the problem of causal effect estimation with missing attributes in observational data in Chapter 4. We classified different cases of missing attributes and formulated associated assumptions that ensure identifiability of the average treatment effect. We proposed estimators suited for these different cases, in particular we proposed a doubly robust estimator handling MNAR missing values, based on work by [Josse et al., 2019] and [Athey et al., 2019]. This method

benefits from theoretical guarantees obtained by combining consistency results for supervised learning with missing values and for double machine learning, and it is conceptually and practically easy to use due to its integration into the broader `grf` R package environment. We demonstrated the applicability of this new methodology on a concrete open medical research question in Chapter 8. This question arose in the very recent and still ongoing COVID-19 pandemic calling for public health policies to be proposed and adapted in a context of limited and constantly evolving evidence. This admittedly unique context highlighted an issue that is however of more general relevance and interest, namely the question of combining observational and experimental studies in a way of mutually guiding further exploration and experiments as well as supporting decision making for populations that are potentially different from former study populations.

In Chapter 6 we proposed a systematic review of methods that consider the related issues of study generalizability and transportability of findings, using combined forces of experimental and observational studies. As we have seen, there already exist various approaches that leverage the duality of experimental and observational studies, exploiting internal validity of experimental data and external validity of observational data. The associated question of transportability or generalizability becomes more and more relevant, especially in pharmaceutical applications, but many related and interesting research problems still need to be addressed, on a theoretical side, e.g., questions of systematically missing variables, but also on a practical side, such as the large variety of data types and encodings which require clear communication between different study investigators to well align the different data sources. This remark also rejoins another important aspect highlighted by the application of Chapter 8, namely a complementary part to the statistical methodology research: the collaboration with domain experts who are crucial at every step of the statistical analysis, from the study design, to the data modeling and estimation and subsequent interpretation of the results. Thus, this work also contributes an example of fruitful and mutual value creation both in statistics and in clinical research.

An interesting extension of the work presented in this thesis would be a more precise formalization and methodology on how to combine domain expertise and automated causal discovery to leverage the available data and knowledge in an efficient way, while quantifying the levels of uncertainty both on the expert and the algorithm side. Such work might still not respond to a regular – and understandable – reproach to observational studies, namely their Achilles heel of untestable identifiability assumptions. As reviewed in the introduction to causal inference (Chapter 1) there exist sensitivity analyses and instrumental variable methods to partially answer these concerns. The latter are indeed popular in practice, especially in economic applications; however it has not been widely studied yet how missing values can impact these instrumental variable approaches theoretically and in practice. Thus an interesting direction would be to explore this class of methods from the angle of identifiability and estimation with missing (covariate) values.

In conclusion, despite the major advances made in causal inference since the first formalizations by Rubin [1974] and Pearl [1995], it is important to bear in mind the conclusion from Cochran [1972] that remains valid to date: "*In conclusion,*

observational studies are an interesting and challenging field which demands a good deal of humility, since we can claim only to be groping toward the truth." This remark is not to be understood as an appeal to refrain from further investigating novel and complex causal inference problems but rather as a cautious note on what we can or should expect from such work besides the scientific value of potentially strong theoretical results.

Finally, a transparent and robust way of answering a question by proposing "good" predictions also assumes that the method is appropriate for the question at hand and that the question, or more specifically the estimand, is appropriate for the problem of interest. Thus, asking the appropriate question and choosing or developing the appropriate tools to answer such questions based on the available data is an interdisciplinary task that requires a continuous exchange between practitioners and statisticians and analysts, and a mutual understanding for the respective challenges and limits. Such an exchange paved the path to formulating the issues addressed by and the results developed during this thesis and hopefully encourages future collaborations, addressing questions of dynamic treatment decisions and helping the promotion of data-assisted decision support in critical care and other applications.

Scientific production

Articles in peer-reviewed journals

— Treatment effect estimation with incomplete attributes, I. Mayer, E. Sverdrup, T. Gauss, J.-D. Moyer, S. Wager and J. Josse, *Annals of Applied Statistics*, 2020.

Submitted articles

— Causal inference methods for combining randomized trials and observational studies: a review, led by Bénédicte Colnet, and in collaboration with Guanhua Chen, Awa Dieng, Ruohong Li, Gaël Varoquaux, Jean-Philippe Vert, Julie Josse, Shu Yang.

— Generalizing treatment effects with incomplete covariates, in collaboration with Julie Josse and the Traumabase® Group.

— R-miss-tastic: a unified platform for missing values methods and workflows, in collaboration with Aude Sportisse, Julie Josse, Nathalie Vialaneix, Nicholas Tierney.

— Machine learning augmented causal inference to estimate the treatment effect of Tranexamic Acid in Traumatic Brain Injury, in collaboration with J.-D. Moyer, A. Dreyfus, M. Boutonnet, P-.J. Cungi, A. Foucrier, A. Harrois, A. James, J.-P. Nadal, J. Josse, T. Gauss.

Working papers

— Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France, in collaboration with E. Sbidian, J. Josse, G. Lemaitre, M. Bernaux, A. Gramfort, N. Lapidus, N. Paris, A. Neuraz, I. Lerner, N. Garcelon, B. Rance, O. Grisel, T. Moreau, A. Bellamine, P. Wolkenstein, G. Varoquaux, E. Caumes, M. Lavielle, A. Mekontso Dessap, E. Audureau.

— MissDeepCausal: Causal Inference from Incomplete Data Using Deep Latent Variable Models, initiated by Jean-Philippe Vert and Julie Josse.

Software

— R online platform R-miss-tastic (2019/2020).

Awards

— FSMP pre-doctoral research visit scholarship for four-months visit at Stanford University (2020).

— Google PhD fellowship (2020).

Appendix A

Appendix of Chapter 1

A.1 – Proofs for the results stated in Section 1.4

Asymptotic normality of $\hat{\tau}_{OLS}$ under linear specification for RCT data

Proof. We start by rewriting $\hat{\tau}_{OLS}$

$$\begin{aligned}\hat{\tau}_{OLS} &= \hat{c}_{(1)} - \hat{c}_{(0)} + \left(\frac{n_1}{n}\bar{X}_{(1)} + \frac{n_0}{n}\bar{X}_{(0)}\right)\left(\hat{\beta}_{(1)} - \hat{\beta}_{(0)}\right) \\ &= \overline{Y_1} - \overline{Y_0} - (\overline{X_1} - \overline{X_0})\left(\frac{n_0}{n}\hat{\beta}_{(1)} + \frac{n_1}{n}\hat{\beta}_{(0)}\right),\end{aligned}$$

where we used the standard result from OLS regression: $\hat{c}_{(w)} = \overline{Y_{(w)}} - \overline{X_{(w)}}\hat{\beta}_{(w)}$, for $w \in \{0, 1\}$.

Now, since we assume, w.l.o.g., that $\mathbb{E}[X] = 0$, we can write that

$$\begin{aligned}\hat{\tau}_{OLS} - \tau &= \overline{Y_1} - \overline{Y_0} - (\overline{X_1} - \overline{X_0})\left(\frac{n_0}{n}\hat{\beta}_{(1)} + \frac{n_1}{n}\hat{\beta}_{(0)}\right) - c_{(1)} - c_{(0)} \\ &= \underbrace{\left[\overline{Y_1} - (c_{(1)} + \overline{X_1}\beta_{(1)})\right] - \left[\overline{Y_0} - (c_{(0)} + \overline{X_0}\beta_{(0)})\right]}_{R_1} \\ &\quad - \underbrace{(\overline{X_1} - \overline{X_0})\left(\frac{n_0}{n}(\hat{\beta}_{(1)} - \beta_{(1)}) + \frac{n_1}{n}(\hat{\beta}_{(0)} - \beta_{(0)})\right)}_{R_2} \\ &\quad + \underbrace{\left(\frac{n_1}{n}\overline{X_1} + \frac{n_0}{n}\overline{X_0}\right)(\beta_{(1)} - \beta_{(0)})}_{R_3}\end{aligned}$$

Using the following list of remarks, we can show below that the variance of $\hat{\tau}_{OLS}$ can be split into several terms.

— For R_1, note that $\overline{Y_1} - (c_{(1)} + \overline{X_1}\beta_{(1)}) = \frac{1}{n_1}\sum_{i:W_i=1} Y_i - c_{(1)} - \frac{1}{n_1}\sum_{i:W_i=1} X_i\beta_{(1)} = \frac{1}{n_1}\sum_{i:W_i=1}\left(Y_i - c_{(1)} + X_i\beta_{(1)}\right)$. Hence R_1 is a function of the error terms ε_i. And R_2 and R_3 functions of the covariates X (by construction of $\hat{\beta}_{(w)}$ as OLS parameter estimates), hence $R_1 \perp\!\!\!\perp \{R_2, R_3\}$ because by assumption, the errors ε_i are independent of X.

— Using standard regression results, it can be shown that R_2 and R_3 are uncorrelated.

— Furthermore $\mathbb{E}[R_1] = 0$ (since we assume $\mathbb{E}[\varepsilon_i|X] = 0$) and $\mathbb{E}[R_2] = \mathbb{E}[R_3] = 0$ since $\mathbb{E}[\bar{X}] = 0$.

— And using standard regression results, we have that $R_2^2 = \mathcal{O}_P(\frac{1}{n^2})$.

It follows that

$$\begin{aligned}
\mathrm{Var}(\hat{\tau}_{OLS}) &= \mathbb{E}[R_1^2] + \mathbb{E}[R_2^2] + \mathbb{E}[R_3^2] \\
&= \mathbb{E}[\overline{\varepsilon(1)}^2 + \overline{\varepsilon(0)}^2] + \mathcal{O}_P(\frac{1}{n^2}) \\
&\quad + (\beta_{(1)} - \beta_{(0)})^T \left(\frac{n_1}{n} \mathrm{Var}(X_1) + \frac{n_0}{n} \mathrm{Var}(X_0) \right) (\beta_{(1)} - \beta_{(0)}) \\
&= \frac{\sigma^2}{n_1} + \frac{\sigma^2}{n_0} + \mathcal{O}_P\left(\frac{1}{n^2}\right) + \frac{1}{n} \left\| \beta_{(1)} - \beta_{(0)} \right\|_A^2
\end{aligned}$$

where we used that $\mathrm{Var}(X_1) = \mathrm{Var}(X_0) = \mathrm{Var}(X) = A$.
From the previous result and using a CLT result, we deduce that

$$\sqrt{n}(\hat{\tau}_{OLS} - \tau) \xrightarrow{d} \mathcal{N}(0, V_{OLS}),$$

where $V_{OLS} = \sigma^2 \left(\frac{n}{n_1} + \frac{n}{n_0} \right) + \left\| \beta_{(1)} - \beta_{(0)} \right\|_A^2$. Thus, in the special case where we assume $\frac{n_1}{n} = \frac{n_0}{n} = \frac{1}{2}$, $V_{OLS} = 4\sigma^2 + \left\| \beta_{(1)} - \beta_{(0)} \right\|_A^2$. □

Equivalent OLS estimator of τ under linear specification for RCT data

Proof. If we consider the two following least squares regression problems

$$(c_{(0)}^*,\, \beta_{(0)}^*) = \arg \min_{c_{(0)}, \beta_{(0)}} \mathbb{E}\left[(1 - W_i) \left(Y_i - c_{(0)} - (X_i - m_X)\beta_{(0)} \right)^2 \right]$$

and

$$(c_{(1)}^*,\, \beta_{(1)}^*) = \arg \min_{c_{(1)}, \beta_{(1)}} \mathbb{E}\left[W_i \left(Y_i - c_{(1)} - (X_i - m_X)\beta_{(1)} \right)^2 \right].$$

Using the n i.i.d. observations (Y_i, W_i, X_i), we note $\hat{c}_{(0)}, \hat{\beta}_{(0)}$, $\hat{c}_{(1)}, \hat{\beta}_{(1)}$ the respective estimators.
Then

$$\hat{\tau}_{OLS\_diff} = \frac{1}{n} \sum_{i=1}^{n} \left(\hat{c}_{(1)} + (X_i - \overline{X})\hat{\beta}_{(1)} - (\hat{c}_{(0)} + (X_i - \overline{X})\hat{\beta}_{(0)} \right) = \hat{c}_{(1)} - \hat{c}_{(0)}.$$

We rewrite the above minimization problems as a single minimization problem:

$$\begin{aligned}
(c_{(0)}^*, c_{(1)}^*, \beta_{(0)}^*, \beta_{(1)}^*) = \mathrm{argmin}_{c_{(0)}, \beta_{(0)}, c_{(1)}, \beta_{(1)}} \mathbb{E}\Big[&(1 - W_i) \left(Y_i - c_{(0)} - (X_i - m_X)\beta_{(0)} \right)^2 \\
&+ W_i \left(Y_i - c_{(1)} - (X_i - m_X)\beta_{(1)} \right)^2 \Big] \\
= \mathrm{argmin}_{c_{(0)}, \beta_{(0)}, c_{(1)}, \beta_{(1)}} \mathbb{E}\Big[&\Big(Y_i - c_{(0)} - (c_{(1)} - c_{(0)})W_i \\
&- (X_i - m_X)\beta_{(0)} - W_i(X_i - m_X)(\beta_{(1)} - \beta_{(0)}) \Big)^2 \Big]
\end{aligned}$$

where we used that

$$
\begin{aligned}
&(1-W_i)\left(Y_i - c_{(0)} - (X_i - m_X)\beta_{(0)}\right)^2 + W_i\left(Y_i - c_{(1)} - (X_i - m_X)\beta_{(1)}\right)^2 \\
&= Y_i^2 + (c_{(0)} + (X_i - m_X)\beta_{(0)})^2 + W_i\left((c_{(1)} + (X_i - m_X)\beta_{(1)})^2 - (c_{(0)} + (X_i - m_X)\beta_{(0)})^2\right) \\
&\quad - 2Y_i(\underbrace{c_{(0)}}_{e} + \underbrace{W_i(c_{(1)} - c_{(0)})}_{f} + \underbrace{(X_i - m_X)\beta_{(0)}}_{g} + \underbrace{W_i(X_i - m_X)(\beta_{(1)} - \beta_{(0)})}_{h}) \\
&= Y_i^2 + e^2 + g^2 + 2eg \\
&\quad + f^2 + 2W_i c_{(0)}c_{(1)} - 2W_i c_{(0)}^2 \\
&\quad + h^2 + 2W_i\beta_{(1)}^T(X_i - m_X)^T(X_i - m_X)\beta_{(0)} - 2W_i((X_i - m_X)\beta_{(0)})^T((X_i - m_X)\beta_{(0)}) \\
&\quad + 2ef + 2W_i c_{(0)}^2 - 2W_i c_{(0)}c_{(1)} \\
&\quad + 2eh - 2W_i c_{(0)}(X_i - m_X)\beta_{(1)} + 2W_i c_{(0)}(X_i - m_X)\beta_{(0)} \\
&\quad + 2fg - 2W_i c_{(1)}(X_i - m_X)\beta_{(0)} + 2W_i c_{(0)}(X_i - m_X)\beta_{(0)} \\
&\quad + 2fh + 2W_i c_{(1)}(X_i - m_X)\beta_{(0)} + 2W_i c_{(0)}(X_i - m_X)\beta_{(1)} - 4W_i c_{(0)}(X_i - m_X)\beta_{(0)} \\
&\quad + 2gh - 2W_i(X - m_X)\beta_{(1)}(X_i - m_X)\beta_{(0)} + 2W_i\beta_{(0)}^T(X_i - m_X)^T(X_i - m_X)\beta_{(0)} \\
&\quad - 2Y_i(e + f + g + h) \\
&= Y_i + (e + f + g + h)^2 - 2Y_i(e + f + g + h) = (Y - (e + f + g + h))^2.
\end{aligned}
$$

Thus we deduce the following re-parametrization:

$$[c,\, \beta,\, \tau,\, \gamma] = [c_{(0)} - m_X\beta_{(0)},\, \beta_{(0)},\, c_{(1)} - c_{(0)}, \beta_{(1)} - \beta_{(0)}],$$

(with inverse $[c_{(0)},\, \beta_{(0)},\, c_{(1)},\, \beta_{(1)}] = [c + m_X\beta,\, \beta,\, c + \tau + m_X\beta,\, \gamma + \beta]$), allowing us to write

$$(c^*, \tau^*, \beta^*, \gamma^*) = \arg\min_{c,\tau,\beta,\gamma} \mathbb{E}\left[(Y_i - c - \tau W_i - (X_i - m_X)\beta - W_i(X_i - m_X)\gamma)^2\right],$$

and the corresponding OLS estimates

$$
\begin{aligned}
&(\hat{c}_{OLS\_interact}, \hat{\tau}_{OLS\_interact}, \hat{\beta}_{OLS\_interact}, \hat{\gamma}_{OLS\_interact}) \\
&\quad = \arg\min_{c,\tau,\beta,\gamma} \sum_{i=1}^{n}\left(Y_i - c - \tau W_i - (X_i - \overline{X})\beta - W_i(X_i - \overline{X})\gamma\right)^2.
\end{aligned}
$$

Thus, we have that $\hat{\tau}_{OLS\_interact}\,(= \hat{c}_{(1),OLS\_diff} - \hat{c}_{(0),OLS\_diff})$ is a consistent estimator of τ. □

Appendix B
Appendix of Chapter 3

The following pages provide the entire graphical representation of the Traumabase® as presented in Chapter 3. The first four pages form the upper part of the graph in Figure 3.1, while the remaining four pages form the lower part.


Supplementary data
Base:
Ref, Center, Author, Filling.date, Filling, Work.shift, Discordance
Epidemiology:
DOB, Initials, Date.entry, Date.discharge, Weight, Size, BMI, Origin
Legend
Treatment
Measurement
Observation
Important for TBI
Important for HS
Deterministic/measurement filled par group
Correlations
Links between measurements repeated over time
Influence on treatment decision
Treatment target
Antiplatelet.treatment
Anticoagulant.treatment
EMS.city
Sex
Age
Intention
Origin
EMS.department
Announced.instable
Ante.pregnancy
Ante.ASA.PS
TA (Anamnesis)
TA.ischemia
TA.amputation
TA.pelvis.fracture
TA.burned.surface
TC.vehicle.ejection
TC.dead.passenger
TC.high.speed
TC.entrapment
TC.duration.entrapment
TC.crushed.projected
TC.fall
TC.blast
Mechanism
TC (Cause)
Helmet
Gloves
Cause of accident
Regulatory EMS
Mobile emergency medical unit
Epidemiology
Triage
Triage
Cause Anamnesis



Call

Resuscitation team

Triage
Treatment

Ambulance (ph)

Ambulance (ph).

Ambulance (ph)..



Resuscitation

Radiologist.

Hospital (admission) → Hospital → Hospital. → Hospital (max 30 min. after admission)


Troponin
Bicarbonate
Creatinine
Fibrinogen.1
Prothrombin
Platelets
Hemoglobin
ICPDelay.admission.initiation.monitoring
EVD
Therapeutic.hypothermiaDelay.admission.installation.EVD
ICP
Delay.admission.initiation.monitoring
CT-scan
Delay.departure.scan.or.surgery
Alcohol
Traumatic.brain.injury
AIS.head
TP.pourcentage
Plaquettes
Fibrinogene.1
RBCFFP
Platelets
Fibrinogen
->6h
AIS.abdomen
AIS.extremities
AIS.external
AIS.chest
AIS.face
ISS
Hemorrhagic.shock
CT scan, Surgical block, ICU
, Surgeons, Resuscitators
Hospital
(after CT scan)
Laboratory
after 6h


TCD.PI.max.24h.HICP
pH.min Lactate.max Creatinine.max.1
Ca.ionise.min BE.max Bicarbonate.min
Prothrombin.min.percentage Prothrombin.min.INR Fibrinogen.min Hb.min Platelets.min
Tranexamic.acid.Hemorrhagic.shock
CardiacArrest.2
SOFA.24h
IGS.II
Surgery.d0
Decompressive.craniectomy
Number.days.hospital
Sepsis.infection
Tracheotomy
Spinal.chord.recovery.ASIA.motor
Number.intubations
Number.days.MV
Reason.seconday.transfer
Deceased.in.ICU
Delay.DC
Cause.of.DC
Delay.cause.DC
Date.DC.hosp
Length.ICU.stay
HICP
Withdrawal.care
Epidemio. (details)
Geographical.location.traumatism
Type.of.location
Highest.education.level
Professional.situationLast.socio-pro.activity
Couple
RBCFFP
Platelets
Fibrinogen
->24h
Cristalloid Colloid 24h
Vasopressor.max
GCS.discharge
Renal.replacement.therapy Number.days.RRT
Total.number.RBC
Total.number.FFP
Total.number.PC
Delay.normal.BE
Delay.normal.lactate
Episode.diuresis.inf.500.mlperd
ARDS.severity
ECMO
Circulatory.failure
Coagulation.failure
Creatinine.max.2
Discharge
CPK.max
Episode.diuresis.inf.500.mlparj
Myoglobin.max
after 24h
Epidemiology
(details)
Resuscitation
(at discharge)

Appendix C

Appendix of Chapter 4

C.1 – Proof for consistency for treatment effect estimation with missing attributes

Below we provide the proof for the balancing property of the generalized propensity score (4.2).

Proof. We note that the distribution of W is fully specified by its mean. Therefore we need to prove that:

$$\mathbb{E}[W_i|\{Y_i(0), Y_i(1)\}, X_i^*] = \mathbb{E}[W_i|X_i^*] \Rightarrow \mathbb{E}[W_i|\{Y_i(0), Y_i(1)\}, e^*(X_i^*)] = \mathbb{E}[W_i|e^*(X_i^*)]$$

a) By the law of total expectation we have:

$$\mathbb{E}[W_i \,|\, e^*(X_i^*)] = \mathbb{E}[\mathbb{E}[W_i|X_i^*, e^*(X_i^*)] \,|\, e^*(X_i^*)] = \mathbb{E}[\mathbb{E}[W_i|X_i^*] \,|\, e^*(X_i^*)] = e^*(X_i^*)$$

b) And again using the law of total expectation we have the following:

$$\begin{aligned}
&\mathbb{E}[W_i \,|\, \{Y_i(0), Y_i(1)\}, e^*(X_i^*)] \\
&\quad = \mathbb{E}[\mathbb{E}[W_i \,|\, \{Y_i(0), Y_i(1)\}, X_i^*, e^*(X_i^*)] \,|\, \{Y_i(0), Y_i(1)\}, e^*(X_i^*)] \\
&\quad = \mathbb{E}[\mathbb{E}[W_i|\{Y_i(0), Y_i(1)\}, X_i^*] \,|\, \{Y_i(0), Y_i(1)\}, e^*(X_i^*)] \\
&\quad = \mathbb{E}[\mathbb{E}[W_i \,|\, X_i^*] \,|\, \{Y_i(0), Y_i(1)\}, e^*(X_i^*)] \qquad \text{(assuming (4.3))} \\
&\quad = \mathbb{E}[e^*(X_i^*) \,|\, \{Y_i(0), Y_i(1)\}, e^*(X_i^*)] = e^*(X_i^*)
\end{aligned}$$

□

C.2 – Procedures

In this section we give the details of all procedures omitted in the main article. The IPW counterparts to the Procedures presented in the main article and to Procedure 4 are obtained by simply dropping the regressions of Y on the (proxies for the) confounders and by estimating τ using expression (1.20) and its generalized extension

$$\hat{\tau}_{IPW^*} \triangleq \frac{1}{n}\sum_{i=1}^{n}\left(\frac{W_i Y_i}{\hat{e}^*(X_i)} - \frac{(1-W_i)Y_i}{1-\hat{e}^*(X_i)}\right), \tag{C.1}$$

instead of expressions (1.26) and (4.5).

Procedure 4: AIPW with matrix factorization pre-processing.
This algorithm provides an estimation for the average treatment effect τ using a matrix factorization pre-processing, given observed covariates with missing attributes, observed treatment assignment and outcome. We assume a low rank matrix factorization model for X and unconfoundedness (1.5) given the latent factors U as detailed in Section 4.2.2 and MCAR.

1. Estimate the latent factors U using SVD decomposition of X, choose the number of latent factors by cross-validation.
2. **Option 1** non-parametric regression.
   (a) Train a causal forest on $(\hat{U}, W, Y)$.
   (b) Take the average over the out-of-bag predictions of conditional average treatment effects $\tau(\hat{U}_i) = \mathbb{E}[Y_i(1) - Y_i(0)|\hat{U}_i]$ using the trained causal forest to obtain an estimation $\hat{\tau}$ for τ as in (1.26).

   Option 2 Parametric regression (we additionally assume logistic-linear model specification for $(e, \mu_{(0)}, \mu_{(1)})$).
   (a) Fit a logistic model to obtain predictions for the propensity score $e(\hat{U}_i)$
   (b) Fit two separate linear models on $(Y_{i:W_i=1}, \hat{U}_{i:W_i=1})$ and on $(Y_{i:W_i=1}, \hat{U}_{i:W_i=1})$ respectively to obtain predictions for $\mu_{(1)}(\hat{U}_i)$ and $\mu_{(0)}(\hat{U}_i)$ respectively.
   (c) Combine the predictions following (1.26) to obtain a doubly robust estimation $\hat{\tau}$ for τ.

C.3 – Simulation study on synthetic data

C.3.1 Interpretation and discussion of the results from Section 4.4.3

Figure 4.3a shows that if the data is MCAR and satisfies (4.1), *saem* works well as expected, i.e. it converges to the true value τ. Note however that the EM-based estimators fail in the small sample case ($(n, p) = (100, 10)$). This is likely due to the strong correlation in the covariates, leading to numerically singular variance-covariance estimates for low sample sizes. Note that *mia.grf* also converges but very slowly which is expected due to the smoothness of e^* and $\mu^*_{(w)}$ and as it does not use the strong parametric assumptions which are met in these simulations. The method *mean.grf* gives similar results than *mia.grf*, which is expected according to the results from Josse et al. [2019]. We observe that *mean.loglin* performs similarly to *saem*, in terms of convergence and behavior w.r.t. the unconfoundedness assumptions. Figure 4.3a shows as well that *mice* works under both unconfoundedness assumptions as expected [1]. In particular, when only (1.5) holds and (4.3) is violated, then all methods but multiple imputation give biased results.

In the general missingness case, Figure 4.3b, we only expect *mia.grf* and *mean.grf* to perform well as explained in Section 4.3.1.2. However their convergence seems to be very slow which again can be explained with the strong parametric and smooth models we defined with the attributes X and that are hard to estimate with random forests. The good performance of the others estimators in this general case can only be observed when the mask R is used in the estimation, otherwise these methods fail in this setting, as expected but not shown in Figure 4.3b.

Under Model 3, Figures 4.4 show that, as expected, if (4.1) is satisfied, our estimator *mia.grf* converges quickly to the true value τ while the other methods remain biased. With the exception of *mice*, all other methods fail if the "unconfoundedness despite missingness" assumption is violated, independently from the missingness mechanism. However *mia.grf* and *mean.grf* in AIPW-form seem to cope well even under the standard unconfoundedness (1.5).

Figures C.1a and C.1b show that under Model 4, *mia.grf* converges to the true value τ in all cases but rather slowly, provided assumption (4.1) is met. Even in the "simplest" MCAR case, the parametric observed-likelihood based approach, namely *saem*, fails under DLVM for small sample sizes ($n \in \{100, 500\}$). Indeed, while satisfying the necessary normality assumption, the observations X_i are not i.i.d. due to their (non-linear) dependence on the (latent) codes C_i. This behavior of *mia.grf* and *saem* is again in accordance with Section 4.3. The multiple imputation method yields some biased estimations in the MCAR case but performs well in the general case (with the mask). Note that the poor performance of the estimator based on low-rank matrix factorization (*mf*) is not surprising since the latency structure arises in the covariate generating process, but the confounders themselves are defined as the observed X rather than the latent factors (C or $\mu(C)$).

1. Note that the small remaining bias with multiple imputation is likely to vanish as the number of imputations increases.

For model 4, where treatment and outcome are unconfounded given some latent factors U, we observe on Figure 4.5 that the estimator based on low-rank matrix factorization in the MCAR performs well. This result is expected, since we assume confoundedness on to the latent factors U and not the partially observed covariates X. Hence the crucial point for recovering the treatment effect is the recovery of these latent factors U, as pointed out by Kallus et al. [2018a]. Interestingly, all methods—except *saem* which fails in the case of informative missingness—empirically perform well in this scenario scenario. This again, is only observed as long as the mask is used for estimation. Furthermore, our *mia.grf* and *mean.grf* seem to converge to the true value of τ despite the "wrong" unconfoundedness assumption.

C.3.2 Simulation results for a variant of Model 4

We start by reporting in Figure C.1 the simulation results for Model 4 omitted in the main manuscript.

The hierarchical data-generating model used in Section 4.4.2 can be modified in order to allow for correlation between covariates by defining the code-depending Gaussian parameters as

$$(\mu(c), \Sigma(c)) = (U(V \tanh(Wc + a) + b), U \exp(\gamma^T (Wc + a) + \delta) I_p U^T),$$

for some randomly generated orthonormal matrix U.

The difference in terms of bias and variability between the AIPW-type estimators and their IPW-type equivalent is clear in this scenario. However the difference in terms of bias w.r.t. the different unconfoundedness assumptions is less apparent. More precisely, *mia.grf* and *mean.grf* seem to approximate the true treatment effect τ for large sample sizes ($n \geq 500$) similarly in both scenarios (first and second line in Figure C.2a and C.2b). These observations require further investigations in the future.

C.4 – Details on the medical application (Traumabase)

C.4.1 Definition of the variables of the Traumabase® used in the analysis

Here we provide the names and short descriptions of the variables we use in our causal analysis. The moment at which the variable is first available is given in parentheses (ph = pre-hospital phase, h = hospital phase).

List of confounders:

— *Trauma.center* (categorical): name of the trauma center. (ph/h)

— *SBP.ph*, *DBP.ph*, *HR.ph* (continuous): systolic and diastolic arterial pressure and heart rate during pre-hospital phase (SBP.ph = min(SBP.min, SBP.MICU), etc.); MICU = mobile intensive care unit. (ph)



(a) MCAR (with 30% missing values in $X_{\cdot,1:10}$)



(b) Informative missing values (with 30% missing values in $X_{\cdot,1:5}$)

Figure C.1 – Model 4. IPW and AIPW estimations across simulation designs described in Section 4.4.2. We report results for all combinations of $n \in \{100, 500, 1000, 5000\}$, missing values mechanism $\in$ {MCAR, general} and unconfoundedness $\in \{\cdot$ despite missingness, complete data $\cdot\}$. Results are displayed for 100 runs of every setting.

— *Cardiac.arrest.ph* (categorical): cardiac arrest during pre-hospital phase. (ph)

— *HemoCue.init* (continuous): prehospital capillary hemoglobin concentration (the lower, the more the patient is probably bleeding and in shock); hemoglobin is an oxygen carrier molecule in the blood. (ph)

— *SpO2.min* (continuous): peripheral oxygen saturation, measured by pulse



(a) MCAR (with 30% missing values in $X_{\cdot,1:10}$)



(b) MNAR (with 30% missing values in $X_{\cdot,1:5}$)

Figure C.2 – Modified model 4 (dense covariance matrices). IPW and AIPW estimations across simulation designs described in Section 4.4.2. We report results for all combinations of $n \in \{100, 500, 1000, 5000\}$, missing values mechanism $\in$ {MCAR, general} and unconfoundedness $\in \{\cdot$ despite missingness, complete data $\cdot\}$. Results are displayed for 100 runs of every setting.

oxymetry, to estimate oxygen content in the blood ($95 - 100\%$: considered normal; $< 90\%$ critical and associated with considerable trauma, danger and mortality). (ph)

— *Vasopressor.therapy* (continuous): treatment with catecholamines in case of physical or emotional stress increasing heart rate, blood pressure, breathing

rate, muscle strength and mental alertness. (ph)

— *Cristalloid.volume* (continuous): total amount of prehospital administered cristalloid fluid resuscitation (volume expansion). (ph)

— *Colloid.volume* (continuous): total amount of prehospital administered colloid fluid resuscitation (volume expansion). (ph)

— *Shock.index.ph* (continuous): ratio of heart rate and systolic arterial pressure during pre-hospital phase. (ph)

— *AIS.external* (discrete, range: $[0, 6]$): Abbreviated Injury Score for external injuries, here it is assumed to be a proxy of information available/visible during pre-hospital phase. (ph/h)

— *Delta.hemoCue* (continuous): Difference of hemoglobin level between arrival at the hospital and arrival on the scene. (h)

— *Activation.HS.procedure* (categorical): activation of hemorragic shock procedure in case of HS suspicion. (h)

List of predictors of mortality and that are not associated with treatment assignment

— *Anticoagulant.therapy* (categorical): oral anticoagulant therapy before the accident. (ph)

— *Antiplatelet.therapy* (categorical): anti-platelet therapy before the accident. (ph)

— *GCS(.init)* (discrete, range: $[3, 15]$): Initial Glasgow Coma Scale (GCS) on arrival on scene of enhanced care team and on arrival at the hospital ($GCS = 3$: deep coma; $GCS = 15$: conscious and alert). (ph & h)

— *GCS.motor(.init)* (discrete, range: $[1, 6]$): Initial Glasgow Coma Scale motor score ($GCS.motor = 1$: no response; $GCS.motor = 6$: obeys command/purposeful movement). (ph & h)

— *Pupil.anomaly* (categorical): pupil dilation indicating brain herniation. (ph & h)

— *Osmotherapy* (categorical): administration of osmotherapy to alleviate compression of the brain (either Mannitol or hypertonic saline solution). (ph & h)

— *Improv.anomaly.osmo* (categorical): change of pupil anomaly after administration of osmotherapy. (ph)

— *Medcare.time.ph* (continuous): total duration of prehospital care team engaged (arrival on scene to arrival at hospital). (h)

— *FiO2* (discrete, range: $[0, 5]$): inspired concentration of oxygen on ventilatory support (the higher the more critical; $Ventilation = 0$: no ventilatory support). (h)

— *Temperature.min* (continuous): Minimal body temperature. (h)

— *TCD.PI.max* (continuous): pulsatility index (PI) measured by echodoppler sonographic examen of blood velocity in cerebral arteries ($PI > 1.2$: indicates altered blood flow maybe due to traumatic brain injury). (h)

— *IICP* (categorical): at least one episode of increased intracranial pressure; mainly in traumatic brain injury; usually associated with worse prognosis. (h)

— *EVD* (categorical): external ventricular drainage (EVD); mean to drain cerebrospinal fluid to reduce intracranial pressure. (h)

— *Decompressive.craniectomy* (categorical): surgical intervention to reduce intracranial hypertension. (h)

— *Neurosurgery.day0* (categorical): neurosurgical intervention performed on day of admission. (h)

— *AIS.head, AIS.face* (discrete, range: $[0, 6]$): Abbreviated Injury Score, describing and quantifying facial and head injuries ($AIS = 0$: no injury; the higher the more critical).(h)

— *ISS* (discrete, range: $[0, 108]$): Injury Severity Score, sum of squares of top three AIS scores. (h)

— *IGS.II* (continuous): Simplified Acute Physiology Score. (h)

C.4.2 Covariate balance on observed values and response pattern (mask)

Since the treatment assignment is not randomized in observational study, it is natural to observe important differences for instance in terms of standardized mean differences of the confounding variables between treatment and control groups. Indeed on Figure C.3 we observe that certain features such as the blood pressure variables differ considerably between the two groups. The treatment being prescribed for injuries that affect these hemostatic parameters, it is not surprising to see important differences for these parameters before adjustment. When comparing balance for the GRF and multiple imputation approach in terms of standardized mean differences, we note on Figure C.3 that both methods achieve similar balance on the observed values but, as expected, only GRF additionally achieves balance on the response pattern. This latter point is discussed in more detail in the main manuscript.

C.4.3 ATE estimation on the Traumabase® using overlap weights

An often raised concern with many medical observational data sets is the potential violation of the overlap assumption. For instance some patients might never get the treatment due to infrastructural circumstances or due to recommendations followed strictly by the entire medical staff. The overlap assumption however is needed for consistency of the treatment effect estimations and states that every patient has a non-zero probability of being in either treated or control group. Another way of describing this assumption is that the treatment groups are sufficiently comparable,



(a) GRF (b) MICE

Figure C.3 – Absolute standardized mean differences; circles: before adjustment, triangles: after adjustment.

otherwise the attempt of drawing causal inferences is doomed to failure from the beginning.

Given the important level of heterogeneity among trauma patients, especially among patients with traumatic brain injury, and the multi-level and multi-actor nature of the data, it cannot be ruled out that the treatment groups have only small overlap. As detailed in Section 4.6, a possible solution to deal with this potential situation is the use of overlap weights instead of the inverse propensity weights [Li et al., 2018]. In our case, when using the corresponding modified estimands and estimators, i.e., the average treatment effect on the overlap population, the results reported in Figure C.4 differ slightly from those from the normal average treatment effect estimation on the entire population (Figure 4.7) as they give evidence of an increase in mortality among traumatic brain injury patients. This result is not in contradiction with the clinical trial Shakur-Still et al. [2009] since the overlap population is not directly comparable to the trial population (isolated traumatic brain injury without major extracranial hemorrhage). The observed results on the overlap population could clinically make sense since the treatment increases the risk of developing arterial thromboembolic events (such as a stroke) [Medcalf, 2015]. Further discussions about the different findings on the entire population and the overlap population and their plausibility will be provided in a forthcoming medical publication.

2. Values on the x-axis are multiplied by 100 for better readability.



Figure C.4 – [
ATE estimations on overlap population of the Traumabase® data (solid: doubly robust estimates; dotted: IPW estimates; dashed vertical line: without adjustment; x-axis: $\hat{\tau}$ and asymptotic confidence intervals]ATE estimations on overlap population on Traumabase® data (solid: doubly robust estimates; dotted: IPW estimates; dashed vertical line: without adjustment; x-axis: $\hat{\tau}$ and asymptotic confidence intervals [2]).

Appendix D

Appendix of Chapter 6

D.1 – Identification formula

This part focuses on the non-nested design only, as it corresponds to the central design of this review.

Identification by the g-formula or regression formula in the target population

Proof.

$$\begin{aligned}
\mathbb{E}[Y(w)] &= \mathbb{E}[\mathbb{E}[Y(w) \mid X]] && \text{Law of total expectation} \\
&= \mathbb{E}[\mathbb{E}[Y(w) \mid X, S=1]] && \text{Assump. 6.3.4} \\
&= \mathbb{E}[\mathbb{E}[Y(w) \mid X, S=1, W=w]] && \text{Assump. 6.3.4} \\
&= \mathbb{E}[\mathbb{E}[Y \mid X, S=1, W=w]] && \text{Assump. 6.3.1}
\end{aligned}$$

□

This last quantity can be expressed as a function of the distribution of X in the target population:

$$\mathbb{E}[Y(w)] = \int \mathrm{E}[Y \mid X=x, S=1, W=w] df(x)\,,$$

where $f(X)$ denotes the distribution of X in the target population.

Identification by weighting

Proof.

$$\begin{aligned}
\tau &= \mathbb{E}[\tau(X)] && \text{Law of total expectation} \\
&= \mathbb{E}[\tau_1(X)] && \text{Assump. 6.3.3} \\
&= \mathbb{E}[\frac{f(X)}{f(X \mid S=1)} \tau_1(X) \mid S=1] && \text{Assump. 6.3.6.}
\end{aligned}$$

□

Using Bayes' rule, we note that

$$\frac{f(x)}{f(x \mid S=1)} = \frac{P(S=1)}{P(S=1 \mid X=x)} = \frac{P(S=1)}{\pi_S(x)}\,.$$

In this expression, however, it is important to notice that neither $\pi_S(x)$ nor $P(S=1)$ can be estimated from the data, because we do not observe the S indicator in the observational study (Figure 6.1). On the other hand, the conditional odds $\alpha(x)$ can be estimated by fitting a logistic regression model that discriminates RCT versus observational samples, and Bayes's rule gives:

$$\begin{aligned}\alpha(x) &= \frac{P(i \in \mathcal{R} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)}{P(i \in \mathcal{O} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)} \\ &= \frac{P(i \in \mathcal{R})}{P(i \in \mathcal{O})} \times \frac{P(X_i = x \mid i \in \mathcal{R})}{P(X_i = x \mid i \in \mathcal{O})} \\ &= \frac{n}{m} \times \frac{f(x \mid S=1)}{f(x)}\,,\end{aligned}$$

and therefore

$$\tau = \mathbb{E}[\frac{n}{m\alpha(X)}\tau_1(X) \mid S=1]\,.$$

This quantity can be further developed, underlying $\tau_1(X)$ identification as presented in proof D.1.

Proof.

$$\begin{aligned}\tau_1(x) &= \mathbb{E}[Y(1) - Y(0) \mid X=x, S=1] \\ &= \mathbb{E}[Y(1) \mid X=x, S=1] - \mathbb{E}[Y(0) \mid X=x, S=1] \\ &= \frac{\mathbb{E}[W \mid X=x, S=1]\mathbb{E}[Y(1) \mid X=x, S=1]}{e_1(x)} \\ &\qquad - \frac{\mathbb{E}[1-W \mid X=x, S=1]\mathbb{E}[Y(0) \mid X=x, S=1]}{1-e_1(x)} \\ &= \frac{\mathbb{E}[WY(1) \mid X=x, S=1]}{e_1(x)} - \frac{\mathbb{E}[(1-W)Y(0) \mid X=x, S=1]}{1-e_1(x)} && \text{Assump. 6.3.2} \\ &= \frac{\mathbb{E}[WY \mid X=x, S=1]}{e_1(x)} - \frac{\mathbb{E}[(1-W)Y \mid X=x, S=1]}{1-e_1(x)} && \text{Assump. 6.3.1} \\ &= \mathbb{E}[\frac{W}{e_1(x)}Y - \frac{1-W}{1-e_1(x)}Y \mid X=x, S=1]\,. && \square\end{aligned}$$

D.2 – Nested study design

The nested trial design has different impacts on the estimators expressions previously introduced, and even on the causal quantity of interest. In a nested trial design the randomized trial is embedded in a cohort (e.g. a large cohort - considered as a sample from the target population - in which eligible people are proposed to participate in the trial, but if they refuse they are still included in the cohort study). As a consequence, S is the binary indicator for trial participation, with $S = 1$ for participants and $S = 0$ for non-participants. Therefore the sampling probability of non-randomized individuals is known in nested trial designs [Buchanan et al., 2018, Dahabreh et al., 2019a]. Mathematically it means that the quantity $P(S = 1)$ is identifiable. In addition, two causal quantities can be identified: $\mathbb{E}[Y(1) - Y(0)]$ and $\mathbb{E}[Y(1) - Y(0) \mid S = 0]$. It is important to note that the second quantity can have a scientific interest in order to better understand heterogeneities within the cohort, and variables that influence the sampling selection and/or the treatment effect on the outcome.

D.2.1 When observational data have no outcome and treatment information

Main estimators, such as IPSW, g-formula, and doubly-robust estimators are presented for the specific case of nested trial design.

D.2.1.1 IPSW

In this design the weights in the IPSW estimators are different, because the quantity π_S can be estimated directly from the observed data as the indicator S is observed. This allows the IPSW formula to be closer to the classic IPW expression without the need to use the inverse odds to weight the data. The IPSW expression is the following:

$$\widehat{\tau}_{\text{IPSW-nested},n,m} \triangleq \frac{1}{n}\sum_{i=1}^{n} \frac{n}{n+m} \frac{W_i Y_i}{\widehat{\pi}_{S,n,m}(X_i)e_1(X_i)} - \frac{1}{n}\sum_{i=1}^{n} \frac{n}{n+m} \frac{(1-W_i)Y_i}{\widehat{\pi}_{S,n,m}(X_i)(1-e_1(X_i))}. \tag{D.1}$$

The normalized version is the following one:

$$\begin{aligned}\widehat{\tau}_{\text{IPSW-nested norm.},n,m} \triangleq & \frac{\sum_{i=1}^{n}(\widehat{\pi}_{S,n,m}(X_i)e_1(X_i))^{-1}W_i Y_i}{\sum_{i=1}^{n}(\widehat{\pi}_{S,n,m}(X_i)e_1(X_i))^{-1}W_i} \\ & - \frac{\sum_{i=1}^{n}(\widehat{\pi}_{S,n,m}(X_i)(1-e_1(X_i)))^{-1}(1-W_i)Y_i}{\sum_{i=1}^{n}(\widehat{\pi}_{S,n,m}(X_i)(1-e_1(X_i)))^{-1}(1-W_i)}.\end{aligned} \tag{D.2}$$

Proof.

$$
\begin{aligned}
\tau &= \mathbb{E}[\tau(X)] && \text{Law of total expectation} \\
&= \mathbb{E}[\tau_1(X)] && \text{Assump. 6.3.3} \\
&= \mathbb{E}[\frac{f(X)}{f(X \mid S=1)}\tau_1(X) \mid S=1] && \text{Assump. 6.3.6} \\
&= \mathbb{E}[\frac{P(S=1)}{\pi_S(X)}\tau_1(X) \mid S=1] && \text{Bayes law} \\
&= \mathbb{E}[\frac{n}{n+m}\pi_S(X_i)^{-1}\tau_1(X) \mid S=1] && P(S=1) = \frac{n}{n+m} \text{ in the nested design}
\end{aligned}
$$

□

Where π_S can be estimated directly using the randomized and the non randomized data. τ_1 is further derived as presented in proof D.1.

D.2.1.2 G-formula

The g-formula formulation in the case of nested trial design depends on the causal quantity of interest. When the target population is the causal quantity of interest, then the identification expression is the same as in the non-nested design. But, because $f \neq f_{.|S=0}$, the estimator's expression is slightly different:

$$
\widehat{\tau}_{G-nested,n,m} \triangleq \frac{1}{n+m}\sum_{i=1}^{n+m}\left(\widehat{\mu}_{1,1,n}(X_i) - \widehat{\mu}_{0,1,n}(X_i)\right), \tag{D.3}
$$

In the case where the population of interest is the non-randomized one, the identification of the causal quantity of interest is the following:

$$
\mathrm{E}\left[Y^w \mid S=0\right] = \mathrm{E}[\mathrm{E}[Y \mid X, S=1, W=w] \mid S=0] = \mathbb{E}[\mu_{1,1}(X) - \mu_{0,1}(X) \mid S=0] \tag{D.4}
$$

The Proof D.2.1.2 details the calculus. And the estimator is the same as presented in equation 6.5 as the integration is done on the law $f_{.|S=0}$.

Proof.

$$
\begin{aligned}
\mathbb{E}[Y(a)|S=0] &= \mathbb{E}[\mathbb{E}[Y(w) \mid X]|S=0] && \text{Law of total expectation} \\
&= \mathbb{E}[\mathbb{E}[Y(w) \mid X, S=1]|S=0] && \text{Assump. 6.3.4} \\
&= \mathbb{E}[\mathbb{E}[Y(w) \mid X, S=1, W=w]|S=0] && \text{Assump. 6.3.4} \\
&= \mathbb{E}[\mathbb{E}[Y \mid X, S=1, W=w]|S=0] && \text{Assump. 6.3.1}
\end{aligned}
$$

□

This last quantity can be expressed as a function of the distribution of X in the non-randomized population:

$$
\mathbb{E}[Y(w)] = \int \mathrm{E}[Y \mid X=x, S=1, W=w] f(x|S=0)dx
$$

where $f(X|S=0)$ denotes the density function of X in the non-randomized population.

D.2.1.3 Doubly-robust estimator

Similarly to the doubly-robust estimation in the non-nested case (Section 6.3.2.4), the g-formula and the IPSW methods can be leveraged into a doubly-robust estimator. The AIPSW expression for the nested case is the following:

$$\begin{aligned}\widehat{\tau}_{\text{AIPSW-nested},n,m} \triangleq & \frac{1}{n+m}\sum_{i=1}^{n+m}\frac{S_i W_i}{\widehat{\pi}_{S,n,m}(X_i)e_1(X_i)}(Y_i-\widehat{\mu}_{1,1,n}(X_i)) \\ & -\frac{1}{n+m}\sum_{i=1}^{n+m}\frac{S_i(1-W_i)}{\widehat{\pi}_{S,n,m}(X_i)(1-e_1(X_i))}(Y_i-\widehat{\mu}_{0,1,n}(X_i)) \\ & +\frac{1}{m+m}\sum_{i=1}^{m+n}\left\{\widehat{\mu}_{1,1,n}(X_i)-\widehat{\mu}_{0,1,n}(X_i)\right\}.\end{aligned} \tag{D.5}$$

D.2.2 Combining treatment-effect estimates from both sources of data

Under Assumptions 6.3.1, 6.3.2 and 6.3.5 for the RCT and Assumptions 6.4.1 and 6.4.2 for the observational data, separate estimators of the ATEs from the two data sources can be constructed. Lu et al. [2019] considered the ATEs for the comprehensive cohort studies (CCS) which include participants who would like to be randomized, constituting the RCT, and participants who would like to choose the treatment by their preference, constituting the observational sample. In particular, they considered the ATE over the CCS study population τ_2 and the ATE over the trial population τ_1. Note that τ_2 is different from τ in our setting because τ_2 is defined with respect to the combined RCT and observational sample; while τ is defined with respect to the observational sample only. In order to construct improved estimators by combining study-specific estimators, they derived the optimal influence functions for τ_1 and τ_2, which suggest that the efficient estimators of τ_1 and τ_2 can be obtained by

$$\begin{aligned}\widehat{\tau}_{1,\text{eff}} \triangleq \frac{1}{n}\sum_{i=1}^{n+m}\Bigg[&\frac{\widehat{\pi}_{S,n,m}(X_i)W_iY_i}{\widehat{e}_n(X_i)}+\left\{S_i-\frac{W_i\widehat{\pi}_{S,n,m}(X_i)}{\widehat{e}_n(X_i)}\right\}\widehat{\mu}_{1,n}(X_i) \\ &-\frac{\widehat{\pi}_{S,n,m}(X_i)(1-W_i)Y_i}{1-\widehat{e}_n(X_i)}-\left\{S_i-\frac{(1-W_i)\widehat{\pi}_{S,n,m}(X_i)}{1-\widehat{e}_n(X_i)}\right\}\widehat{\mu}_{0,n}(X_i)\Bigg],\end{aligned}$$

$$\widehat{\tau}_{2,\text{eff}} \triangleq \frac{1}{n+m}\sum_{i=n}^{n+m}\frac{W_i\{Y_i-\widehat{\mu}_{1,n}(X_i)\}}{\widehat{e}_n(X_i)}-\frac{(1-W_i)\{Y_i-\widehat{\mu}_{0,n}(X_i)\}}{1-\widehat{e}_n(X_i)}+\{\widehat{\mu}_{1,n}(X_i)-\widehat{\mu}_{0,n}(X_i)\},$$

where $\widehat{e}_{1,n}(X_i)$, $\widehat{\mu}_{0,1,n}(X_i)$, and $\widehat{\mu}_{1,1,n}(X_i)$ for units in the RCT are simplified as $\widehat{e}_n(X_i)$, $\widehat{\mu}_{0,n}(X_i)$, and $\widehat{\mu}_{1,n}(X_i)$.

D.2.3 Software: Examples of implementations

This part follows Section 6.6 and proposes specific examples of implementations for the nested design in the case of IPSW and G-formula.

D.2.3.1 IPSW

Te IPSW estimator can be implemented using the available code from Dahabreh et al. [2019c]. It requires as input a dataframe (here called `study`) which columns represent treatment, denoted by A (binary, this corresponds to the W from our notations), the RCT indicator, denoted as S (binary), the outcome as Y (continuous), and the quantitative covariates. The current available code for 3 quantitative covariates denoted X_1, X_2, X_3 is presented below. A first function `generate_weights()` estimates the sampling propensity score and the propensity score as logistic regressions, and compute the according weights to each data point. The variance is estimated with the `geex` library [Saul and Hudgens, 2020] through the `m_estimate` function which computes the empirical sandwich variance estimator.

```
# Compute selection score model and propensity score in the trial (
    logit)
weights <- generate_weights(Smod = S~X1+X2+X3, Amod = A~X1+X2+X3,
    study)

# Use these scores to compute IPSW
IOW1 <- IOW1_est(data = weights$dat)

# Compute the empirical sandwich variance
param_start_IOW1 <- c(coef(weights$Smod) , coef(weights$Amod),
                      m1 = IOW1$IOW1_1, m0 = IOW1$IOW1_0, ate =
    IOW1$IOW1)
IOW1_mest <- m_estimate( estFUN = IOW1_EE, data  = study,
root_control = setup_root_control(start = param_start_IOW1))

# Format the output
IOW1_ate <- extractEST(geex_output = IOW1_mest,
est_name ="ate",
param_start = param_start_IOW1)
```

The output is:

```
print(IOW1_ate)
>    ate         SE
>  -0.16961   0.02751
```

D.2.3.2 G-formula

The G-formula can also be implemented in the nested design using the available code from Dahabreh et al. [2019c]. It takes a similar entry as the IPSW previously presented. The variance is estimated with the `geex` library [Saul and Hudgens, 2020] through the `m_estimate` function which computes the empirical sandwich variance estimator.

```
# Linear regression cond. outcome mean as a function of covariates
    on the RCT
# Compute ATE on the observational data
OM <- OM_est(data = study)

# Compute the empirical sandwich variance
param_start_OM <- c(coef(OM$OM1mod), coef(OM$OM0mod),
                    m1=OM$OM_1, m0=OM$OM_0, ate=OM$OM)
OM_mest <- m_estimate( estFUN = OM_EE, data  = study,
  root_control = setup_root_control(start = param_start_OM))

# Format the output
OM_ate <- extractEST(geex_output = OM_mest, est_name = "ate",
param_start = param_start_OM)
```

The output is:

```
>    ate         SE
> -0.1934   0.0300
```

D.3 – Additional notations, assumptions and results in the Structural Causal Model

D.3.1 Notations and Assumptions

This supplementary introduction aims to provide an introduction to the whole SCM framework, and introduce the graphical representation, along with the do-calculus concepts and notations.

Structural Causal Models (SCM). Formally [Pearl, 2009c, p.203], an SCM is a 4-tuple $M = (U, V, F, P)$ where:

1. U is a set of *background* or *exogenous* variables, which are not explicitly modeled but which can affect relationships within the model.
2. $V = \{V_1, \ldots, V_n\}$ is a set of *endogenous* variables, that are deterministically determined by variables in $U \cup V$; in the setting of this paper, one typically chooses $V = \{X, W, Y\}$ or $V = \{X, W, Y, S\}$ to respectively model covariates, treatment, outcome and selection.
3. F is a set of functions $\{f_1, .., f_n\}$ such that each f_i uniquely determines the value of $V_i \in V$ by the so-called *structural equation* $v_i = f(pa_i, u_i)$, where $PA_i \subset V \backslash \{V_i\}$ are called the *parents* of V_i and $U_i \subset U$.

4. P is a probability distribution for U.

The *causal diagram* corresponding to an SCM is a graph with V as vertices, directed edges from each parent to its children, and undirected dotted edges between vertices V_i and V_j such that $U_i \cap U_j \neq \emptyset$. Alternatively, the U can be explicitly represented, with directed dotted edges from U_i to V_i, as in Figure D.1a which represents the SCM with $V = (X, W, Y)$, $U = (U_x, U_w, U_y)$, and structural equations:

$$\begin{aligned} x &\leftarrow f_x(u_x) \\ w &\leftarrow f_w(x, u_w), \\ y &\leftarrow f_y(w, x, u_y). \end{aligned}$$

Often, no parametric assumptions is made on F or P. The distribution $P(U)$ induces a distribution $P_M(V)$ through $V = F(U)$, and in the case where the causal diagram is a directed acyclic graph and variables in U are independent, then the distribution $P_M(V)$ is a Bayesian network. In particular, the causal diagram encodes the conditional independence relationships among variables in V.



(a) Example of an SCM M and corresponding DAG.

(b) Post-intervention graph of M for $do(W = w_0)$.

Figure D.1 – Examples of an SCM M with corresponding DAG and a post-intervention graph of M for $do(W = w_0)$.

Interventions. At the core of the SCM framework is the *do*-operator which enables the use of structural equations to represent causal effects and counterfactuals. The $do(W = w_0)$ operation marks the replacements of the mechanism f_w with a constant w_0, while keeping the rest of the model unchanged, resulting in the following post-treatment model for our toy example:

$$\begin{aligned} x &\leftarrow f_x(u_x) \\ w &\leftarrow w_0 \\ y &\leftarrow f_y(w, x, u_y) \end{aligned}$$

In the causal graph, this corresponds to deleting all incoming arrows in W (Figure D.1b).

We denote $Q = P(Y = y \mid do(W = w_0))$ the post-intervention distribution, i.e., the distribution of a random variable Y after a manipulation on W. From this distribution, the ATE can be written as:

$$\begin{aligned} \tau &= \mathbb{E}[Y \mid do(W = w_1)] - \mathbb{E}[Y \mid do(W = w_0)] \\ &= \sum_y y(P\{Y = y \mid do(W = w_1)\} - P\{Y = y \mid do(W = w_0)\}). \end{aligned}$$

Note that the post-intervention distribution can also be denoted in counterfactual notation as $P(Y = y \mid do(W = w)) = P(Y(w) = y)$. The distinction between $P(Y \mid W = w)$ and $P(Y \mid do(w))$ corresponds in the PO framework to the difference between $P(Y \mid W = w)$ and $P(Y(w))$.

D-separation. Conditional independences between variables can be read from the DAG induced by an SCM using a graphical criterion known as *d-separation*. This criterion will be useful in identifying the causal effect.

Definition D.3.1 (d-separation)**.** *A set X of nodes is said to block a path p if either*

- *p contains at least one arrow-emitting node that is in X, or*
- *p contains at least one collision node that is outside X and has no descendant in X.*

If X blocks all paths from set W to set Y, it is said to "d-separate W and Y" and then it can be shown that $W \perp\!\!\!\perp Y \mid X$. As an illustration, let us consider a path with $A \to D \leftarrow B \to C$. Since B emits arrows on that path, it blocks the path between A and C, and $A \perp\!\!\!\perp C \mid B$. D is a collider (two arrows incoming) and consequently it blocks the path without conditioning $A \perp\!\!\!\perp C$; but conditioning on D would open the path and thus would imply that $A \not\perp\!\!\!\perp C \mid D$. Furthermore, in the SCM framework it is generally assumed that *faithfulness* holds, i.e., that all conditional independences are encoded in the graph, allowing to infer dependencies from the graph structure [Peters et al., 2017]. In other words, if the Global Markov property (i.e., d-separation implies conditional independence), and faithfulness hold, then the resulting equivalence between conditional independences and d-separation allows to move back and forth between the graphical and the probabilistic model.

Identifiability We are interested in answering the *identifiability* question: *can the post-intervention distribution Q be estimated using observed data (such as pre-intervention distribution)?*

Definition D.3.2 (identifiability)**.** *A causal query Q is identifiable from distribution $P(y)$ compatible with a causal graph G, if for any two (fully specified) models M_1 and M_2 that satisfy the assumptions in G, we have*

$$P_1(V) = P_2(V) \implies Q(M_1) = Q(M_2).$$

Specifically, if a causal query Q in the form of a *do*-expression can be *reduced* to an expression no longer containing the *do-operator* (i.e, containing only estimable expressions using nonexperimental, observed data) by iteratively applying the inference rules of *do-calculus*, then Q is identifiable. The language of *do-calculus* is proved to be *complete* for queries in the form $Q = P(Y = y \mid do(W = w), X = x)$ meaning that if no reduction can be obtained using these rules, Q is not identifiable.

The application of previous rules and the backdoor criterion in the graph of Figure D.2 allows to list all possible admissible adjustment sets for identifying

$P(Y = y \mid do(W = w))$:

$$X = \{W_2\}, \{W_2, W_3\}, \{W_2, W_4\}, \{W_3, W_4\}, \{W_2, W_3, W_4\}, \{W_2, W_5\}, \{W_2, W_3, W_5\}, \{W_4, W_5\}, \{W_2, W_4, W_5\}, \{W_3, W_4, W_5\}, \{W_2, W_3, W_4, W_5\} \quad \text{(D.6)}$$

The analyst can select from this list which is preferable. Note that conditioning on W_1 would induce bias as it is a collider.



Figure D.2 – Application of the backdoor criterion in a larger graph. Based on the admissible set Definition D.3.3, (D.6) present all the following sets that are admissible and can be used for adjustment. For example, the set $\{W_2, W_3\}$ blocks all backdoor paths between W and Y. W_2 block the path $W \leftarrow W_2 \rightarrow W_3 \rightarrow W_5 \rightarrow Y$.

D.3.1.1 Confounding bias

In order to estimate the causal effect $P(Y = y \mid do(W = w))$ using only available observational data, following the observational distribution $P(W, X, Y)$, the idea is to identify—on the basis of the causal graph—a set of *admissible variables* such that measuring and adjusting for these variables removes any bias due to confounding. The *backdoor criterion* defined below provides a graphical method for selecting admissible sets for adjustment.

Definition D.3.3 (Admissible sets - the backdoor criterion)**.** *Given an ordered pair of treatment and outcome variables (W, Y) in a causal DAG G, a set X is backdoor admissible if it blocks every path between A and Y in the graph $G_{\underline{W}}$, with $G_{\underline{W}}$ the graph that is obtained when all edges emitted by node W are deleted in G.*

The backdoor criterion can be seen as the counterpart of unconfoundedness in Assumption 6.4.1: If a set X of variables satisfies the backdoor condition relative to (W, Y), then $Y(w) \perp\!\!\!\perp W \mid X$. Identifying backdoor admissible variables is important because it allows to estimate causal effects from observational data as follows:

Theorem D.3.1 (Backdoor adjustment criterion)**.** *If a set of variables satisfies the backdoor criterion relative to (W, Y), the causal effect of W on Y can be identified from observational data by the adjustment formula $P(Y = y \mid do(W = w)) = \sum_x P(Y = y \mid W = w, X = x)P(X = x)$.*

The adjustment formula can be seen as the counterpart of the identifiability formula in Equation 6.10.

The backdoor criterion is one of the graphical methods for identifying admissible sets. In cases where it is not applicable, an extended definition called the *frontdoor criterion* can be applied using mediators in the graph. Figure D.3 provides a summary of the identifiability conditions when the available data is either observational data or data from surrogate experiments.



Figure D.3 – Summary of identifiability results to control for confounding bias: If there exists a set of observed variables that satisfies the backdoor criterion, then the causal effect of W on Y can be identified using nonexperimental data alone. In the case where no set of observed variables satisfies the backdoor condition but the effect of W can be mediated by an observed variable M (mediator), if there exists a set of observed variables that satisfies the frontdoor criterion, then the causal effect if also identifiable from observational data alone. If none of these conditions holds, the query is not identifiable. If, in addition to observational data, RCTs through surrogate experiments are available, the z-identifiability condition is sufficient to determine if the query is identifiable or not.

D.3.1.2 Sample selection bias

To tackle sample selection bias, i.e., preferential selection of units, the authors consider an indicator variable S such that $S = 1$ identifies units in the sample. The data at hand can be seen as $P(W = w, Y = y, X = x \mid S = 1)$ and the target is $P(Y = y \mid do(W = w))$.



Figure D.4 – Examples of causal graphs with sample selection bias, reproducing figures from Bareinboim and Pearl [2016]: W is the treatment and Y the outcome, S is the selection process and the aim is to estimate $P(Y = y \mid do(W = w))$ when data available come from $P(W = w, Y = y \mid S = 1)$ in (a) and (b).

Figure D.4 (b) presents a case where the selection process is d-separated (definition in Appendix D.3) from Y by W, then $P(y \mid w) = P(y \mid w, S = 1)$; since A and Y are unconfounded, $P(y \mid do(w)) = P(y \mid w)$ so that the experimental distribution is recoverable from observed data. This is not the case for Figure D.4 (a) without further assumptions. When both confounding bias and selection bias are present in the data (Figure D.4 (c)), the graphical framework can help selecting among the list of adjustment sets, $\{W_1, W_2\}$, $\{W_1, W_2, X\}$, $\{W_1, X\}$, $\{W_2, X\}$, and X, (these sets control for confounding), the one that can be used as available from biased data; here it will be X as it is the only one separated from S, leading to $P(y \mid do(a)) = \sum_x P(y \mid a, x, S = 1)P(x \mid S = 1)$. This ability to select relevant covariates for identifiability is presented as an important advantage of the SCM framework.

Combined bias and unbiased data. Note that the previous examples in Figure D.4 concern only one set of data but the approach is extended to combine data, biased (with a selection) data, and unbiased data (for instance covariates from the target population) as follows. To do so, Bareinboim and Pearl [2016] define the **S-backdoor admissible criterion** which is a sufficient condition but not necessary. It states that if X is backdoor admissible, W and X block all paths between S and Y, i.e. $Y \perp\!\!\!\perp S \mid W, X$, and that X is measured in both population-level data and biased data, then, the causal effect can be identified as

$$P(Y = y \mid do(W = w)) = \sum_x P(Y = y \mid W = w, X = x, S = 1)P(X = x),$$

where $P(X = x)$ is the probability of the event $X = x$ in the target population. Whenever if the set X are post-treatment covariate, then this formula does not hold. Indeed S-ignorability is rarely satisfied in transportability problems by any set of covariates containing post-treatment covariates. Several examples are detailed in [Pearl, 2015]. This formula is called the post-stratification formula, to define this action of re-calibrate or re-weight [Pearl, 2015]. This expression shows that one can generalize what is observed on the selected sample by reweighting or recalibrating by $P(X = x)$ that is available from the target population (unbiased data). More complex setting can be handled, such as dealing with post-treatment variables. In

such a case, they show that generalizability can be obtained by another weighting strategy (not by $P(X = x)$), which can also be seen as a benefit of this framework.

D.3.2 Proof of the transport formula (Equation 6.13)

We compute:

$$\begin{aligned} P(Y \mid do(W = w)) &= \sum_x P(Y \mid do(W = w), X = x) P(X = x \mid do(W = w)) \\ &= \sum_x P(Y \mid do(W = w), X = x, S = 1) P(X = x \mid do(W = w)) \\ &= \sum_x P(Y \mid do(W = w), X = x, S = 1) P(X = x)\,, \end{aligned}$$

where the first equation follows by conditioning, the second one by S-admissibility assumption of X, and the third one from the fact X are pre-treatment variables.

D.4 – Additional simulation results

This section follows Section 6.6.3 and provides additional results for the simulations.

D.4.1 Distributional shift between RCT and observational samples

The simulation design proposed simulates a situation where the RCT data reveals a distributional shift with the observational sample. In the RCT all the covariates tend to have lower values than in the observational sample. Still, the overlap assumption (Assumption 6.4.2) is still valid as each individual in the target population has a non-zero probability to be included in the experimental sample. Quantitative results obtained for a simulation with ~ 1000 observations in the RCT and 10 000 observations in the observational sample is given on Figure D.5, in addition with an histogram illustrating overlaps and the distributional shift for the covariate X_1.

	Observational (N=10000)	RCT (N=1023)	Total (N=11023)
X1			
Mean (SD)	1.01 (0.996)	0.552 (0.980)	0.968 (1.00)
Median [Min, Max]	1.01 [-2.84, 4.43]	0.535 [-2.51, 3.62]	0.972 [-2.84, 4.43]
X2			
Mean (SD)	1.00 (0.984)	0.652 (0.991)	0.970 (0.990)
Median [Min, Max]	0.996 [-2.48, 5.02]	0.679 [-2.81, 3.49]	0.963 [-2.81, 5.02]
X3			
Mean (SD)	1.00 (1.01)	0.485 (1.02)	0.954 (1.02)
Median [Min, Max]	1.01 [-2.91, 5.05]	0.468 [-2.32, 3.88]	0.961 [-2.91, 5.05]
X4			
Mean (SD)	0.991 (1.00)	0.616 (1.01)	0.956 (1.01)
Median [Min, Max]	0.988 [-2.77, 4.94]	0.615 [-2.14, 4.17]	0.960 [-2.77, 4.94]



Figure D.5 – Covariate distributions differences between experimental sample and observational sample when simulating according to (6.15) as detailed in Section 6.6.3 (left), with a focus on the X_1 distributional shift with histograms overlap for the two samples (right).

D.4.2 Stratification

Within the weighted estimators, the stratification estimator (Section 6.3.2.1) supposes to choose an additional parameter being the number of strata used. Simulations are launched with the number of strata varying from 3 to 15, and the results are presented on Figure D.6. We observed that the number of strata has an impact on the results, the higher the number of strata used, the better the prediction.



Figure D.6 – Effect of strata number. Estimated ATE obtained while varying the number of strata $L \in \{3, 5, 7, 9, 11, 13, 15\}$ with 100 repetitions each time. All others simulation parameters being the same as the standard case described in 6.6.3 and in Figure 6.4.

D.4.3 Homogeneous treatment effect

It is always interesting to note that in the case of an homogeneous treatment effect the RCT sample contains all the information to estimate the population ATE, in other words τ_1 is a consistent estimator of the ATE. We performed simulation with an homogeneous treatment effect (results are presented on Figure (D.7)) such as:

$$Y(w) \mid X = -100 + X_1 + 13.7X_2 + 13.7X_3 + 13.7X_4 + 27.4w + \epsilon$$



Figure D.7 – Homogeneous treatment effect. Estimated ATE with a homogeneous treatment effect $Y(w) \mid X = -100 + X_1 + 13.7X_2 + 13.7X_3 + 13.7X_4 + 27.4w + \epsilon$. All others simulation parameters being the same as the standard case described in Subsection 6.6.3 and in Figure 6.4.

D.5 – Additional analysis for Traumabase® and CRASH-3

This part proposes additional analysis to the data analysis part (Section 6.7). We first propose additional visualization of the distributional shift between CRASH-3 and the Traumabase®, then we present a principal component analysis of the combined database. Propensity scores obtained either with the logistic regression or the forest are analyzed with histograms and scatter plots. A complementary analysis of the results (Figure 6.10) is proposed while estimating the generalized treatment effect from an imputed Traumabase® on Figure D.17. Finally, a focus on the different patients strata, based on the severity of the injury, is presented.

D.5.1 Distributional shift between CRASH-3 and Traumabase

Distributional shift between CRASH-3 and the Traumabase® data can be illustrated with histograms. Figures D.8 – D.12 presents the empirical distribution shift between the Traumabase® and CRASH-3 for age, Glasgow score, systolic blood pressure, sex and pupils reactivity (respectively). Differences can be observed, and for example the fact that the CRASH-3 study contains more young patients, while the Traumabase® contains more moderate case (corresponding to a high Glasgow score). It is interesting to notice that the overlaps assumption seems to hold in our situation.



Figure D.8 – Distributional shift of Age between the Traumabase® and the CRASH-3 studies.



Figure D.9 – Distributional shift of the Glasgow score between the Traumabase® and the CRASH-3 studies.



Figure D.10 – Distributional shift of the systolic blood pressure between the Traumabase® and the CRASH-3 studies.



Figure D.11 – Distributional shift of the sex between the Traumabase® and the CRASH-3 studies.



Figure D.12 – Distributional shift of the pupils reactivity between the Traumabase® and the CRASH-3 studies.

D.5.2 Principal component analysis

A principal component analysis is performed on the combined data for the Traumabase® and the CRASH-3 data using the `FactoMineR` package [Lê et al., 2008], results are presented on Figure D.13. As expected the Glasgow coma scale score and the pupils reactivity are related (paralysis of the cranial nerves leading to pupil anomalies being closely related to the presence of an intracranial lesion, itself linked to the state of consciousness encoded in the Glasgow.). Additionally, the link between age and systolic blood pressure can be explained by the fact that atherosclerosis of the arteries is the source of an increase in blood pressure and is related to age.



Figure D.13 – Principal Components Analysis (PCA) of the data set combining CRASH-3 and Traumabase® data.

D.5.3 Sampling propensity scores

The sampling propensity scores obtained while performing the generalization from the CRASH-3 patients to the observational data are presented on Figures D.14 (logistic regression) and D.15 (forest). We observe that extreme coefficient values are obtained, and that the forest `grf` strengthens this trend. We can further investigate the differences in between the two methods to infer the propensity scores noticing that the forest method uses the `NAs` from the Traumabase® to learn the propensity scores model. Figure D.16 shows that the `NAs` present in the systolic blood pressure covariate are used by the random forest to predict S, leading to more extreme values at the end. This importance of different missing values patterns when combining two data sets are of importance and highlight the need for a better understanding of

the impact of missing values in the present framework.



Figure D.14 – Sampling propensity scores histogram (`glm`) obtained with the `misaem` R package.



Figure D.15 – Sampling propensity scores histogram (`grf`) obtained with random forests.



Figure D.16 – Scatter plot of the two sampling propensity scores obtained with `glm` in x-axis and `grf` in the y-axis. Color is set according to the systolic blood pressure covariate values (while missing values are in grey).

D.5.4 Additional results with imputed Traumabase

As the Traumabase® presents missing values such that the estimators introduced in Chapter 6 (such as IPSW, G-formula, ...) have not been used directly but adapted using methods dealing missing values such as the logistic regression in case of missing values or random forests. Another method consists in imputing the Traumabase® and then carrying out the analysis with estimators introduced in Chapter 6 without further modifications. Results are presented on Figure D.17 with an imputation using `mice`. Similar conclusions on the treatment effect as the general case presented in Section 6.7 are obtained.



Figure D.17 – Juxtaposition of different estimation results for target population corresponding for all patients with ATE estimators computed on the **imputed** Traumabase® (observational data set), on the CRASH-3 trial (RCT), and transported from CRASH-3 to the Traumabase® target population. Number of variables used in each context is given in the legend.

D.5.5 Evidence on other patient strata

The data analysis part only focuses on all the patients from the two studies CRASH-3 and Traumabase®. This part proposes a focus on different patients type, based on the severity of the brain trauma (measured either with the Glasgow score or the pupils reactivity).

D.5.5.1 Traumabase®: evidence on different strata

When stratifying along different criteria of severity as in the CRASH-3 study, namely pupil reactivity and the Glasgow Coma Scale as illustrated in Table D.1 with Mild/moderate and Severe strata, the two studies provide different evidence: no average treatment effect in any of the strata for the Traumabase®, while the CRASH-3 study finds a beneficial effect for mild forms of TBI.

Table D.1 – ATE estimations from the Traumabase® for TBI-related 28-day mortality. Red cells conclude on deteriorating effect, white cells conclude on no effect.

	Multiple imputation (MICE)				MIA		Unadjusted ATE $\times 10^2$
	IPW (95% CI) $\times 10^2$		AIPW (95% CI) $\times 10^2$		IPW (95% CI) $\times 10^2$	AIPW (95% CI) $\times 10^2$	
	GLM	GRF	GLM	GRF			
Total ($n = 8248$)	15 (6.8, 23)	11 (6.0, 16)	3.4 (-9.0, 16)	-0.1 (-4.7, 4.4)	9.3 (4.0, 15)	-0.4 (-5.2, 4.4)	16
Mild/moderate ($GCS > 8$, $n = 5228$)	17 (-7.9, 42)	11 (3.3,18)	15 (-47, 77)	2.1 (-8.5, 13)	6.8 (2.6, 11)	-0.1 (-4.9, 4.7)	8.7
Severe ($GCS \leq 8$, $n = 2855$)	10 (-7.0, 27)	7.7 (-6.6, 22)	2.2 (-14, 18)	-1.3 (-14, 11)	7.1 (-1.0, 15)	-0.3 (-4.6, 4.0)	9.5

D.5.5.2 CRASH-3: evidence on different strata

The CRASH-3 trial presents a significant treatment effect only on some strata (in particular on less severe injured patients). As the brain-injury severity has an effect on the outcome—most patients with TBI with a GCS score of 3 (corresponding to a coma or unconsciousness state) and those with bilateral non-reactive pupils have a very poor prognosis regardless of treatment—, the treatment effect is likely to be biased towards the null. Therefore the CRASH-3 authors observe the maximal treatment effect and statistical strength on mild to moderate injured patients, which is what we retrieve from the data. This evidence is computed from the data, with a link between the risk ratio (RR) and the average treatment effect (ATE) on Table D.2.

Table D.2 – Results reproduction for CRASH-3, with four possible stratifications based on the severity level of the injury. Results are both presented as risk ratio (in accordance with Cap [2019]) and as ATE (in accordance with our framework, Section 6.2.1).

	Relative risk		Average Treatment Effect	
	RR	95% CI	ATE	95% CI
Total (within 3 hours)	0.94	(0.855, 1.02)	-0.12	$(-0.28, 0.004)$
$GCS > 3$ or at least 1 pupil reacts	0.90	(0.78, 1.01)	-0.02	$(-0.03, 0.0005)$
Mild/moderate ($GCS > 8$)	0.78	(0.59, 0.98)	-0.2	$(-0.03, -0.003)$
Severe ($GCS \leq 8$)	0.99	(0.91, 1.07)	-0.004	$(-0.04, 0.03)$
Both pupils react	0.87	(0.74, 1.00)	-0.015	$(-0.03, -0.001)$

Table D.3 – Sample sizes for both studies and different strata along the Glasgow Coma Scale. #maj.Ex corresponds to the number of patients with a major extracranial bleeding.

	Traumabase				CRASH-3			
	m	#treated	#death	#maj.Ex	n	#treated	#death	#maj.Ex
Total (within 3 hours)	8248	683	1411	5583	9168	4632	1745	5
Mild/moderate ($GCS > 8$)	5456	535	527	3392	5844	3075	600	0
Severe ($GCS \leq 8$)	3083	596	1322	2224	3717	1985	1601	5

D.5.5.3 Generalizing treatment effect on patient strata

As found by the CRASH-3 study, the group with potential benefit from TXA seems to be mild to moderate TBI patients (Table D.2), defined as patients with a Glasgow Coma Scale between 9 and 15, while the evidence obtained from the Traumabase® has not found a significant treatment effect for this group. However, in this stratum, for the CRASH-3 study, none of the patients has major extracranial bleeding, leading to a constant variable for this group. Conversely, in the Traumabase®, in this stratum, only four patients without major extracranial bleeding are treated (while 1867 are not treated with TXA). Since the practitioners are interested in the treatment effect transported on patients with mild to moderate TBI and with major extracranial bleeding, we cannot restrict the target population to those patients without major extracranial bleeding. The current methodology does not allow to satisfy the necessary assumptions for transporting the effect using the presented estimation strategies and defining a clinically relevant target population. Further methodological investigations are required to transport the effect on the stratified subpopulations (see Table D.3 for the corresponding sample sizes).

This issue does not apply to the complementary stratum of severe TBI patients (corresponding to a low Glasgow score ($GCS \leq 8$)). We can thus provide the results for this stratum in Figure D.18. We observe that on this strata discrepancies between the solely Traumabase® estimators and the generalized estimators are presents. The generalization supports either no-effect or a deleterious effect, while the RCT and the observational estimators support the no-effect hypothesis.



Figure D.18 – Juxtaposition of different estimation results for target population corresponding to the severe Traumabase® patients with ATE estimators computed on the Traumabase® (observational data set), on the CRASH-3 trial (RCT), and transported from CRASH-3 to the Traumabase® target population (severe TBI patients). Number of variables used in each context is given in the legend.

Appendix E

Appendix of Chapter 7

E.1 – Details on the estimation methods with missing values

E.1.1 Prediction on new incomplete observations with parametric model

As mentioned in Section 7.4, it is possible to predict the outcome y for new incomplete observations, using the regression model estimated via EM, by marginalizing over the distribution of missing data given the observed. More formally, in the logistic regression case, using a Monte Carlo approach and *maximum a posteriori* estimator, it is possible to predict the response y for a new observation x_i as follows:

1. Sample
$$\left(x_{\text{mis}}^{(s)}, 1 \leq s \leq S\right) \sim \text{p}\left(x_{\text{mis}} \mid x_{\text{obs}}\right)$$
2. Predict the response y by *maximum a posteriori*

$$\begin{aligned}\hat{y} = \arg\max_y \text{p}\left(y \mid x_{\text{obs}}\right) &= \arg\max_y \int \text{p}(y \mid x)\text{p}\left(x_{\text{mis}} \mid x_{\text{obs}}\right) dx_{\text{mis}} \\ &= \arg\max_y \mathbb{E}_{p_{z_{\text{mis}}|x_{obs}}} \text{p}(y \mid x) \\ &= \arg\max_y \sum_{s=1}^{S} \text{p}\left(y \mid x_{\text{obs}}, x_{\text{mis}}^{(s)}\right)\end{aligned}$$

For the linear case, the prediction proceeds in two steps:

1. Imputation of the new observation using the estimated variance-covariance matrix of the covariates $\widehat{\Sigma}$.
$$\hat{x}_{mis}^{new} = -\left[\widehat{\Sigma^{-1}}_{mis,mis}\right]^{-1} \widehat{\Sigma^{-1}}_{mis,obs} x_{obs}^{new}$$
2. Prediction of response y using the imputed observation $[x_{obs}^{new}, \hat{x}_{mis}^{new}]$.

E.2 – Details on the critical care management application

We have seen in Section 7.6 that the scores obtained using EM and MI suggest that the positivity assumption is satisfied, while the scores estimated via MIA however concentrate around 0 and 1 for the observational and RCT observations respectively, suggesting poor overlap under this model. This can be also observed in the scatter plots in Figure E.1, where we color the observations according to the values of the systolic blood pressure (SBP, a variable with an important fraction of missing values in the observational data, see Figure 7.8). We notice that MIA attributes a very low selection score to all observations with missing SBP value and thus selects the response indicator of the SBP variable to partly predict trial eligibility. This method has been studied more extensively in a regression framework and not in a classification framework and here we find that it predicts a class according to the presence of missing values and this is not necessarily what we intend when applying this method.



(a) x-axis: EM; y-axis: MIA.

(b) x-axis: EM; y-axis: joint fixed effect MI.

Figure E.1 – Scatter plots of different estimated selection scores. The point color is set according to the systolic blood pressure (SBP) covariate values (missing SBP values are indicated by gray points).

Appendix F

Appendix of Chapter 8

F.1 – Supplemental method

Descriptive statistics Descriptive results are given as medians [interquartile range (IQR)] for continuous variables, and counts (%) for categorical variables. Unadjusted between-groups comparisons were performed using the Chi-square test for comparing categorical variables, the Kruskal-Wallis (three-groups comparisons) and Mann–Whitney rank sum tests (pairwise comparisons, correcting for test multiplicity with the Benjamini-Hochberg procedure) for continuous variables, as appropriate. For time-to-event analyses, non-parametric Nelson–Aalen estimates of the cumulative cause-specific hazards were plotted for the occurrence of death or hospital discharge.

F.2 – Supplemental tables

Table F.1 – Definitions for comorbidities.

Diseases	**Natural language processing Key words**	**French hospital discharge database** (Programme de Médicatlisation des Systèmes d'Information, PMSI) **ICD 10th codes for hospitalization admissions**[1]
Comorbidities		
Smoker	'smoker', 'tabacco', 'pack-years'	
Obesity	'obesity'	
Hypertension	'hypertension', 'HBP'	I10
Diabetes	'diabetes'	E10, E11, E12, E13, E14, G59.0, G63.2, G73.0, G99.0, H28.0, H36.0, I79.2, L97, M14.2, M14.6, N08.3
Dyslipidemia	'hyperlipidemia', 'hypertriglyceridemia', 'dyslipidemia', 'hypercholesterolemia'	
Ischemic heart diseases	'heart attack', 'myocardiac infarction', 'MI', 'AMI', 'ischaemic heart disease', 'myocardium', 'angora', 'angina pectoris', 'coronary heart disease'	120-125
Rhythmic heart diseases	'arrhythmias', 'cardiac rhythm disorder', 'atrial fibrillation', 'flutter'	170, 173, 174
Chronic renal failure & Chronic end-stage kidney failure	'renal failure', 'kidney failure', 'renal insufficiency', 'chronic kidney disease','CKD', 'nephropathy'	N18
Transplantation	'transplant', 'graft'	
Chronic obstructive pulmonary diseases	'BPCO, pulmonary disease', 'pneumopathy', 'HTAP', 'chronic respiratory insufficiency', 'emphysama', 'Asthma', 'bronchospasms'	J40, J41, J42, J43, J44, J45, J46, J47, J96, J98
Hepatic failure	'Cirrhosis', 'portal hypertension'	K70, K76
Cancer	'cancer'	C00-C80
Hemopathies	'lymphoma', 'Leucemia', 'hematologic malignancy'	C81-C96

[1]Available for in-patients who had at least a previous hospital stay in one out of the 39 establishments of the AP-HP. Data from previous hospital stays were extracted from 2012 to the index date.

Table F.2 – Patients characteristics by treatment group after imputation of missing data using Factorial Analysis for Mixed Data model.

	HCQ alone, $n = 623$ N **(%)**	**HCQ plut AZI,** $n = 227$ N **(%)**	**Neither drug,** $n = 3,792$ N **(%)**
Demographic characteristics			
Age years, median (IQR)	63 (53-74)	61 (53-72)	69 (54-82)
Male sex, n (%)	413 (66.3)	158 (69.6)	2167 (57.1)
Comorbidities, n (%)			
Current smoker	178 (28.6)	65 (28.6)	914 (24.1)
Obesity	121 (19.4)	59 (26.0)	467 (12.3)
Hypertension	30 (4.82)	8 (3.52)	229 (6.04)
Diabetes	243 (39.0)	89 (39.2)	1237 (32.6)
Dyslipidemia	141 (22.6)	50 (22.0)	761 (20.1)
Ischemic heart disease	163 (26.2)	47 (20.7)	927 (24.4)
Rhythmic heart disease	60 (9.63)	23 (10.1)	488 (12.9)
Chronic renal failure Chronic end-stage kidney failure	142 (22.8)	26 (11.5)	770 (20.3)
Asthma	45 (7.22)	30 (13.2)	280 (7.38)
Chronic obstructive pulmonary diseases	27 (4.3)	19 (8.4)	173 (4.6)
Other chronic respiratory failure	19 (3.0)	8 (3.5)	87 (2.3)
Hepatic failure	35 (5.62)	25 (11.0)	160 (4.22)
Cancer	117 (18.8)	50 (22.0)	822 (21.7)
Hemopathies	35 (5.62)	15 (6.61)	210 (5.54)
Chemotherapy	96 (15.4)	42 (18.5)	679 (17.9)
Current steroid use	106 (17.0)	43 (18.9)	400 (10.5)
Biological parameters at baseline			
Oxygen saturation (%), median (IQR)	94.9 (92.0-97.0)	95.1 (92.5-97.0)	93.0 (89.8-96.0)
Partial pressure of oxygen (mmHg), median (IQR)	75.8 (63.3-92.5)	74.0 (61.1-88.5)	64.2 (50.5-80.7)
Partial pressure of carbon dioxide (mmHg), median (IQR)	35.3 (31.9-39.1)	35.2 (30.9-38.9)	31.9 (28.0-36.3)
Neutrophil count (/mm^3), median (IQR)	5.18 (3.74-6.75)	4.66 (3.47-6.51)	4.90 (3.39-6.94)
Lymphocytes (/mm^3), median (IQR)	0.93 (0.74-1.16)	1.00 (0.72-1.29)	0.96 (0.71-1.28)
Prothrombin time (%), median (IQR)	85.0 (76.8-93.0)	82.0 (73.0-89.0)	84.8 (76.7-93.0)
D-Dimer (µg/L), median (IQR)	903 (640-1230)	797 (572-1200)	975 (676-1400)
Creatine (mg/dL), median (IQR)	84.0 (69.0-112)	81.0 (66.0-99.0)	82.0 (65.0-112)
C reactive protein (mg/L), median (IQR)	76.0 (42.0-134)	79.0 (45.0-136)	61.0 (24.5-126)
Lacticodeshydrogenase (U/L), median (IQR)	373 (304-465)	380 (312-491)	352 (278-443)

Table F.3 – Within 24h-ICU transfer patients characteristics by treatment group.

	Missing data (%)	**HCQ alone,** $n = 94$ N **(%)**	**HCQ plut AZI,** $n = 70$ N **(%)**	**Neither drug,** $n = 621$ N **(%)**
Demographic characteristics				
Age years, median (IQR)		61.5 (53-68)	58.5 (53.2-64.8)	62 (53-69)
Male sex, n (%)		73 (77.7)	55 (78.6)	464 (74.7)
Comorbidities, n (%)				
Current smoker	18 (2.3)	30 (31.9)	18 (24.3)	142 (20.6)
Obesity	18 (2.3)	24 (25.5)	30 (42.9)	124 (20)
Hypertension	18 (2.3)	4 (4.3)	3 (4.3)	20 (3.3)
Diabetes	18 (2.3)	332 (34)	38 (54.3)	240 (38.6)
Dyslipidemia	18 (2.3)	19 (20.2)	187 (24.3)	128 (20.6)
Ischemic heart disease	18 (2.3)	20 (26.6)	13 (18.6)	148 (23.8)
Rhythmic heart disease	18 (2.3)	10 (10.6)	6 (8.6)	55 (8.9)
Chronic renal failure Chronic end-stage kidney failure	18 (2.3)	18 (19.1)	5 (7.1)	72 (11.6)
Asthma	18 (2.3)	5 (5.3)	5 (7.1)	45 (7.3)
Chronic obstructive pulmonary diseases	18 (2.3)	4 (4.3)	4 (5.7)	24 (3.9)
Hepatic failure	18 (2.3)	5 (5.3)	7 (10)	22 (3.5)
Cancer	18 (2.3)	11 (11.7)	12 (17.1)	83 (13.4)
Hemopathies	18 (2.3)	2 (2.1)	1 (1.4)	25 (4)
Chemotherapy	18 (2.3)	8 (8.5)	8 (11.4)	49 (7.9)
Current steroid use	18 (2.3)	17 (18.1)	11 (15.7)	59 (9.5)
Biological parameters at baseline				
Oxygen saturation (%), median (IQR)	75 (9.6)	94.4 (90.8-96.7)	95 (91.9-96.7)	95.1 (90.9-97.5)
Partial pressure of oxygen (mmHg), median (IQR)	66 (8.4)	72.2 (56.5-93.9)	73.2 (63.2-86.1)	75.3 (57.6-98)
Partial pressure of carbon dioxide (mmHg), median (IQR)	62 (7.9)	35 (32.3-39.4)	37 (31.8-39.5)	37 (31.8-39.5)
Neutrophil count (/mm^3), median (IQR)	59 (7.5)	6.58 (4.14-8.79)	5.31 (3.87-7.26)	6.57 (4.6-9.62)
Lymphocytes (/mm^3), median (IQR)	59 (7.5)	0.8 (0.55-1.16)	1.03 (0.69-1.31)	0.88 (0.65-1.23)
Prothrombin time (%), median (IQR)	38 (4.8)	82 (71-93)	79.5 (72-91.8)	83 (73-93)
D-Dimer (µg/L), median (IQR)	279 (35.5)	1032 (698-1618)	720 (513-1281)	1650 (941-3870)
Creatine (mg/dL), median (IQR)	4 (0.5)	86 (71-128)	84 (68.6-99.8)	88 (69-132)
C reactive protein (mg/L), median (IQR)	118 (15)	134 (77.5-192)	112 (66.3-163)	144 (71.4-236)
Lacticodeshydrogenase (U/L), median (IQR)	181 (23)	470 (311-627)	414 (332-606)	554 (410-752)
Outcomes				
Mortality		28 (29.8)	18 (25.4)	199 (32)
Time to death (days), median (IQR)		9.83 (6.18-16)	9.17 (7.47-133)	9.57 (5.02-16.4)
Hospital discharge		42 (44.7)	34 (48.6)	174 (28)

*Missing data correspond to censored patients who were transferred to other hospitals before Day 28 and lost to follow-up

Table F.4 – Not within 24h-ICU transfer patients characteristics by treatment group.

	Missing data (%)	**HCQ alone, $n = 529$ N (%)**	**HCQ plut AZI, $n = 204$ N (%)**	**Neither drug, $n = 3,171$ N (%)**
Demographic characteristics				
Age years, median (IQR)		63(53 − 76)	65(53 − 76)	71(55 − 84)
Male sex, n (%)		340(64.3)	137(67.2)	1703(53.7)
Comorbidities				
Current smoker	138(3.5)	148(28)	63(30.9)	771(24.3)
Obesity	138(3.5)	97(18.3)	39(19.1)	343(10.8)
Hypertension	138(3.5)	26(4.9)	7(3.4)	209(6.6)
Diabetes	138(3.5)	211(39.9)	73(35.8)	989(31.2)
Dyslipidemia	138(3.5)	122(23.1)	43(21.1)	633(20)
Ischaemic heart disease	138(3.5)	138(26.1)	45(22.1)	776(24.5)
Rhythmic heart diseases	138(3.5)	50(9.5)	23(11.3)	433(13.7)
Chronic renal failure Chronic end-stage kidney failure	138(3.5)	124(23.4)	30(14.7)	698(22)
Asthma	138(3.5)	40(7.6)	31(15.2)	235(7.4)
Chronic obstructive pulmonary diseases	138(3.5)	42(7.9)	28(13.7)	236(7.4)
Hepatic Failure	138(3.5)	30(5.7)	22(10.8)	138(4.4)
Cancer	138(3.5)	106(20)	44(21.6)	739(23.3)
Hemopathies	138(3.5)	33(6.2)	17(8.3)	185(5.8)
Chemotherapy	138(3.5)	88(16.6)	41(20.1)	630(19.9)
Current steroid use		89(16.8)	47(23)	341(10.8)
Biological parameters at baseline				
Oxygen saturation (%), median (IQR)	2039(52.2)	95.1(92.6-97.1)	95.3(93-97.2)	95(92.2-97.2)
Partial pressure of oxygen (mmHg), median (IQR)	1966 (50.4)	75.8(65.1-89.8)	73(57.5-88.5)	73(59.3-88.8)
Partial pressure of carbon dioxide (mmHg), median (IQR)	1945 (49.8)	35.3(31.8-39.1)	34.7 (29.4-38.4)	34.8(30-39)
Neutrophil count per mm^3, median (IQR)	593(15.2)	4.48(3.25-6.11)	4.44(3.31-6.51)	4.48(3.12-6.51)
Lymphocytes (/mm^3), median (IQR)	823(20.8)	0.96(0.67-1.32)	0.97(0.71-1.28)	0.98(0.7-1.36)
Prothrombin time (%), median (IQR)	1117(28.6)	87(77-96)	81(72.8-90)	87(76-97)
D-Dimer (μg/L), median (IQR)	2839 (71.7)	802(566-1390)	733(487-1260)	959 (568-1596)
Creatine (mg/dL), median (IQR)	396(10)	84(68 − 108)	79(63.2 − 99.8)	81(64 − 110)
C reactive protein (mg/L), median (IQR)	660(16.7)	72.8(38.8 − 123)	77(44.2 − 135)	55.4(20.7 − 112)
Lacticodeshydrogenase (U/L), median (IQR)	2296(58)	361(288 − 466)	402(314 − 549)	327(248 − 442)
Outcomes				
ICU entry		112(21.2)	48(23.5)	172(5.42)
Time to ICU transfer, days, median (IQR)		3.17(2.03 − 5.2)	2.93(2.1 − 4.5)	2.8(1.7 − 5.1)
Mortality		98(18.5)	47(23)	666(21)
Time to death, days, median (IQR)		8.35(4.41 − 15.2)	6.54(3.87 − 11.9)	7.3(3.7 − 11.9)
Hospital Discharge		321(60.7)	106(52)	1,371(43.2)

*Missing data correspond to censored patients who were transferred to other hospitals before Day 28 and lost to follow-up

Table F.5 – 28-day mortality analysis considering the outcome as a binary endpoint at a fixed time point.

		HCQ alone vs. neither drug		**HCQ plus AZI vs. neither drug**	
		Raw Estimate (95% CI)	AIPTW Estimate* (95% CI)	Raw Estimate (95% CI)	AIPTW Estimate* (95% CI)
Whole population					
28-day mortality	ATE	-5.80% (-9.3 to -2.3)	-2.16% (-6.5 to 2.1)	1.76% (-4.5 to 8)	1.19% (-4.4 to 6.8)
Population who were transferred to ICU within the first 24h					
28-day mortality	ATE	-5.45% (-9.4 to -1.5)	-2.46% (-11.5 to 6.5)	-2.12% (-8.8 to 4.5)	2.04% (-7.9 to 12)
Population who were not transferred to ICU within the first 24h					
28-day mortality	ATE	-5.54% (-8.9 to -2.1)	-1.09% (-5.8 to 3.6)	1.52% (-4.6 to 7.6)	-0.08% (-6.5 to 6.4)

* AIPTW: Augmented inverse probability of treatment weight estimator for doubly robust inference of the average treatment effect conditional on baseline covariates, derived from causal forest implementation based on the generalized random forests method; GRF-MIA method was used for handling missing data; 95%CI: 95% confidence interval.

ATE: average treatment effect

Baseline covariables considered for adjustment were sex, age, current smoker, diabetes, obesity, hypertension, dyslipidemia, ischemic heart disease, rhythmic heart diseases, chronic renal failure & chronic end-stage kidney failure, any chronic lung disease, hepatic failure, cancer, hemopathies, chemotherapy, current steroid use, oxygen saturation, partial pressure of oxygen, paCO2, lymphocytes, neutrophils, d-dimer, creatine, C reactive protein, dehydrogenase lactate, prothrombin time.

Table F.6 – Balance statistics between treated and control groups according to analysis populations: HCQ vs neither drug comparison.

	Original population			IPT-weighted population			Matched population		
	Mean Treated (N=623)	Mean Controls (N=3792)	zed Mean difference	Mean Treated (N=623)	Mean Controls (N=3792)	zed Mean difference	Mean Treated (N=623)	Mean Controls (N=623)	zed Mean difference
Demographic characteristics									
Age, years	63.2	66.8	-0.24	64.8	66.3	-0.09	63.2	62.7	0.03
Male sex, %	66.3	57.2	0.19	56.9	58.5	-0.02	66.3	66.3	0.00
Comorbidities, %									
Obesity, %	19.4	12.3	0.18	15.3	13.5	0.02	19.4	18.5	0.02
Weight, kg	80.4	74.6	0.35	76.2	75.5	0.04	80.4	80.5	-0.01
Hypertension, %	4.8	6.0	-0.06	6.0	5.8	0.00	4.8	4.2	0.03
Diabetes, %	39.0	32.6	0.13	39.2	33.7	0.06	39.0	38.4	0.01
Ischaemic heart disease, %	26.2	24.5	0.04	27.4	24.8	0.03	26.2	24.7	0.03
Rhythmic heart disease, %	9.6	12.9	-0.11	13.2	12.4	0.01	9.6	10.8	-0.04
Chronic renal failure &Chronic end-stage kidney failure, %	22.8	20.3	0.06	18.7	20.6	-0.02	22.8	21.5	0.03
Asthma, %	7.2	7.4	-0.01	8.6	7.4	0.01	7.2	6.4	0.03
Chronic obstructive pulmonary diseases, %	4.3	4.6	-0.01	3.7	4.5	-0.01	4.3	4.3	0.00
Other chronic respiratory failure, %	3.1	2.3	0.04	1.5	2.4	-0.01	3.1	3.4	-0.02
Hepatic failure, %	5.6	4.2	0.06	4.1	4.4	0.00	5.6	5.9	-0.01
Cancer, %	18.8	21.7	-0.07	21.1	21.3	0.00	18.8	19.4	-0.02
Hemopathies, %	5.6	5.5	0.00	5.2	5.6	0.00	5.6	6.7	-0.05
Chemotherapy, %	15.4	17.9	-0.07	19.0	17.6	0.01	15.4	14.9	0.01
Biological parameters at baseline									
Oxygen saturation, %	93.2	92.0	0.15	92.4	92.2	0.03	93.2	93.5	-0.04
PaO2, mmH	81.0	69.9	0.33	71.3	71.7	-0.01	81.0	80.4	0.02
PaCO2, mmHg	35.3	31.8	0.51	32.3	32.3	-0.01	35.3	35.3	0.00
Neutrophil, count per mm^3	5.7	5.6	0.01	6.2	5.6	0.13	5.7	5.7	-0.01
Lymphocyte, count per mm^3	1.0	1.1	-0.12	1.1	1.1	-0.01	1.0	1.1	-0.07
Prothrombin time, %	83.2	82.6	0.04	82.8	82.7	0.00	83.2	83.7	-0.03
D-Dimer, μg/L	1172.7	1376.2	-0.17	1573.2	1351.3	0.11	1172.7	1141.3	0.03
Creatine, mg/dL	113.2	111.5	0.01	119.8	112.0	0.06	113.2	111.6	0.01
C reactive protein, mg/L	99.4	89.7	0.12	89.3	91.3	-0.02	99.4	95.1	0.05
Dehydrogenase lactate, U/liter	409.4	391.7	0.11	407.1	395.6	0.07	409.4	411.8	-0.02

Standardized difference in means for continuous data; standardized difference in proportions for binary data.

Table F.7 – Balance statistics between treated and control groups according to analysis populations: HCQ+AZI vs neither drug comparison.

	Original population			IPT-weighted population			Matched population		
	Mean Treated (N=274)	Mean Controls (N=3792)	zed Mean difference	Mean Treated (N=274)	Mean Controls (N=3792)	zed Mean difference	Mean Treated (N=274)	Mean Controls (N=274)	zed Mean difference
Demographic characteristics									
Age, years	61.3	66.8	-0.36	64.6	66.5	-0.12	61.3	61.8	-0.03
Male sex, %	69.9	57.2	0.27	62.3	57.9	0.04	69.6	69.6	0.00
Comorbidities									
Obesity, %	26.0	12.3	0.31	16.4	13.0	0.03	26.0	30.0	-0.09
Weight, kg	82.6	74.6	0.37	78.8	75.1	0.15	82.6	82.8	-0.01
Hypertension, %	3.5	6.0	-0.14	1.4	5.9	-0.04	3.5	3.1	0.02
Diabetes, %	39.2	32.6	0.13	39.8	33.0	0.07	39.2	35.2	0.08
Ischaemic heart disease, %	20.7	24.5	-0.09	21.1	24.3	-0.03	20.7	22.9	-0.05
Rhythmic heart disease, %	10.1	12.9	-0.09	15.8	12.7	0.03	10.1	11.0	-0.03
Chronic renal failure &Chronic end-stage kidney failure, %	11.5	20.3	-0.28	23.7	19.8	0.04	11.5	9.7	0.06
Asthma, %	13.2	7.4	0.17	7.9	7.7	0.00	13.2	15.9	-0.08
Chronic obstructive pulmonary diseases, %	8.4	4.6	0.14	2.5	4.7	-0.02	8.4	8.4	0.00
Other chronic respiratory failure, %	3.5	2.3	0.07	1.3	2.4	-0.01	3.5	3.1	0.02
Hepatic failure, %	11.0	4.2	0.22	4.6	4.6	0.00	11.0	7.9	0.10
Cancer, %	22.0	21.7	0.01	25.3	21.8	0.03	22.0	22.0	0.00
Hemopathies, %	6.6	5.5	0.04	3.1	5.6	-0.03	6.6	4.9	0.07
Chemotherapy, %	18.5	17.9	0.02	27.0	18.0	0.09	18.5	16.7	0.05
Biological parameters at baseline									
Oxygen saturation, %	93.1	92.0	0.12	92.3	92.1	0.03	93.1	93.1	-0.01
PaO2, mmH	75.3	69.9	0.16	72.0	70.3	0.05	75.3	78.1	-0.09
PaCO2, mmHg	33.2	31.8	0.13	32.5	31.9	0.07	33.2	33.8	-0.06
Neutrophil, count per mm^3	5.3	5.6	-0.14	6.0	5.6	0.15	5.3	5.4	-0.07
Lymphocyte, count per mm^3	1.1	1.1	0.00	1.1	1.1	0.02	1.1	1.2	-0.12
Prothrombin time, %	80.1	82.6	-0.16	83.8	82.5	0.09	80.1	80.3	-0.01
D-Dimer, μg/L	1055.7	1376.2	-0.32	1562.2	1359.0	0.10	1055.7	1207.9	-0.15
Creatine, mg/dL	89.5	111.5	-0.53	109.3	110.4	-0.01	89.5	90.0	-0.01
C reactive protein, mg/L	103.0	89.7	0.16	98.4	90.5	0.10	103.0	103.8	-0.01
Dehydrogenase lactate, U/liter	424.2	391.7	0.18	404.4	393.8	0.06	424.2	440.5	-0.09

Standardized difference in means for continuous data; standardized difference in proportions for binary data.

F.3 – Supplemental figures



Figure F.1 – Causal graph of the observational study (generated using DAGitty [Textor et al., 2011]).



Figure F.2 – Death and discharge cumulative incidence curves: results from the HCQ vs. neither drug comparison by Fine-Gray competing risks analysis.



Figure F.3 – Death and discharge cumulative incidence curves: results from the HCQ+AZI vs. neither drug comparison by Fine-Gray competing risks analysis.

Appendix G

Machine learning augmented causal inference to estimate the treatment effect of Tranexamic Acid in Traumatic Brain Injury

This chapter is a work submitted to *BMC Medical Research Methodology* and which has been carried out in collaboration with Jean-Pierre Nadal, Julie Josse and the medical doctors Jean-Denis Moyer, Aliénor Dreyfus, Mathieu Boutonnet, Pierre-Julien Cungi, Arnaud Foucrier, Anatole Harrois, Arthur James, and Tobias Gauss. It provides a medical study that applies the methodology proposed in Chapter 4

Abstract

Importance: The CRASH-3 trial provides a high level of evidence on the question whether to administer Tranexamic Acid (TXA) for Traumatic brain injury (TBI). For numerous other research questions, the available evidence will not correspond to such a level of evidence and will rely on observational evidence only Objective: The development of methodological alternatives to analyze observational data is necessary. The Crash-3trial provided the opportunity to explore the effect of TXA on TBI mortality with two distinct causal inference methods using incomplete observational data.

Methods: Two causal inference techniques, inverse propensity weighting (IPW) and doubly robust method (DR), associated with machine learning method techniques to handle missing data, explored the effect of TXA administration on 30-day head injury related death expressed in registry data. The effect was expressed as Average Treatment Effect (ATE). TBI was defined as a head Abbreviated Injury Score > 2. The hypothesis expected the results to concur with the results obtained with the CRASH-3 benchmark trial.

Results: Between September 2010 and February 2019, from a total of 20037 registry cases 8269 corresponded to the definition of TBI. A total of 683 received TXA and 7565 did not. The observed head-injury related 30-day hospital mortality rate in the group TXA was 30% (205/683) compared to 15% in the group no-TXA (1102/7565, $p < 0.001$). Causal inference with the IPW approach indicates an ATE with a higher mortality after TXA independently of the approach applied to manage missing data (ATE 0.10 (95% IC [0.06, 0.14]) or 0.09 (95% IC [0.03, 0.15])). ATE obtained with

DR did not show any effect on mortality independently of the approach applied to missing data (ATE -0.01 (95% IC [-0.05, 0.03]) or -0.01 (95% IC [-0.07, 0.05])). No effect was observed in predefined subgroups.
Conclusion: This study demonstrated the feasibility to apply causal inference techniques in incomplete observational data. DR based on a stronger theoretical background compared to IPW, did not show a significant association of TXA administration with in-hospital mortality. This result provides a strong incentive to explore augmented causal inference techniques on incomplete observational data coupled with techniques to handle missing values.

Table of contents
Table des matières

G.1 – Introduction

Severe traumatic brain injury (TBI) remains a major global public health challenge. The global incidence is expected to rise, due to increased road traffic in the developing world and a higher proportion elderly in all populations [James et al., 2019]. The CRASH-3 landmark trial examined the use of Tranexamic Acid (TXA) to tackle the challenge of TBI with exemplary methodological rigor [Cap, 2019]. The trial demonstrated no reduction in overall head injury-related 28-day mortality, but a reduction in the pre-specified subgroup of mild to moderate TBI (GCS 9-13).

Despite the conclusion of two recent studies [Rowell et al., 2020, Bossers et al., 2021], one randomized, and a meta-analysis incorporating several other underpowered RCT's [Al Lawati et al., 2020] the result of CRASH-3 remains the most reliable evidence on TXA use in TBI with a beneficial risk benefit ratio [Maas et al., 2020].

In contrast, to the administration for TXA in TBI, for many research questions, the medical community does not and will not dispose of results from prospective and randomized trials but rely on observational data only. Alternatives are needed to improve inference from observational data. Causal inference attempts to determine the independent influence of an effector as a component of a complex system. Causal inference from observational data differs from association by analyzing the response of an effector variable when a cause of the effect variable is changed. Methods from this family of approaches, for instance propensity weighting or matching, have

been successfully applied by physics, climate research, econometrics and cognitive science [Harhay et al., 2014, Dreyfuss, 2005]. Augmented causal inference and related techniques appear more reliable than conventional observational and pathophysiological research [Lederer et al., 2019] and help to develop more robust hypotheses for prospective research. Augmented Causal inference for observational data is not meant not become a substitute for randomized controlled trials but a useful addition to the methodological arsenal. To learn about and familiarize with this concept in reference to high level evidence such as provided by the CRASH-3 trial appears necessary.

Based on this rationale the present study investigated the capacity of two causal inference approaches (inverse propensity weighting and doubly robust method) combined with handling of missing data and to interpret the results into the context of the available clinical evidence [Al Lawati et al., 2020]. The hypothesis expected the results to concur with the results obtained with the CRASH-3 benchmark trial.

G.2 – Material and Methods

This observational study is based on data from a prospective multicenter regional trauma registry, the TraumaBase® (TB). This registry has obtained approval from the Institutional Review Board (Comité de Protection des Personnes, Paris VI and Clermont-Ferrand) from the Advisory Committee for Information Processing in Health Research (Comite Consultatif Pour le Traitement de l'information en matière de recherche dans le domaine de la santé CCTIRS, 11.305bis) and from the National Data Protection Agency (Commission Nationale de l'Informatique et des Libertés CNIL, 911461), waiving the need for informed consent. The registry disposes of algorithms for consistency and coherence and professional data monitoring. Data monitoring for the TraumaBase® is assured by the Biostatistics Laboratory of Paris 7.

G.2.1 Setting and Cohort

All consecutive trauma patients admitted to one of the 14 participating trauma centers were screened for inclusion. Table G.1 provides the complete list of variables that were recorded for each patient according to the revised Utstein major trauma template [Utstein TCD expert panel et al., 2008]. The trauma system in participating trauma centers have been previously described [Gauss et al., 2019, Hamada et al., 2014, 2019]; management was left to the discretion of the responsible physician based on national triage [Riou et al., 2002] and TBI management guidelines [Geeraerts et al., 2018]. The corresponding Strobe checklist is provided in Appendix H.1.

G.2.2 Inclusion criteria

The traumatic brain injury was defined as cerebral injury identified on a brain CT scan on admission corresponding to and Abbreviated Injury Score > 2.

G.2.3 Exclusion criteria

Patients were excluded if their age was < 16 years old or the patient was admitted to a center with less than 20 traumatic brain injuries (TBI) over the entire inclusion period.

G.2.4 Administration of Tranexamic Acid (TXA)

TXA administration followed the CRASH-2 protocol, an intravenous dose of 1 gram over 10 minutes, followed immediately by a second intravenous dose of 1 gram over 8 hours. For the purpose of the study, the authors considered, that all administration occurred within three hours of injury.

G.2.5 Data extraction

A complete list of collected data can be found in Appendix H.

G.2.6 Analysis

The objective was to evaluate the effect of TXA on 30-day head-injury related mortality in a cohort of traumatic brain injured patients by causal inference. The study cohort was stratified into predefined subgroups in accordance with the CRASH-3 trial: GCS 9-12 and less than 8 and pupil anomaly. Other outcomes reported are all cause 30-day mortality and all-cause mortality as well as all head-injury related deaths to allow comparison with other studies. Data are presented as absolute count and percentages (n, %) for categorical and median (interquartile range) for numerical data. Categorical data were compared using a Chi-2 or Fisher Exact Test, numerical data using a Mann-Whitney Test. The analysis was performed on the whole cohort stratified into "TXA administration" and "no TXA administration". A p value < 0.05 was considered as significant. The statistical package R version 3.6.2 was used for the entire analysis of this study [R Core Team, 2020].

G.2.6.1 Adopted Causal Inference approach

A detailed description and essential theoretical concepts can be found in Appendix H.2.

G.2.6.2 Exposure variable and outcome criteria

Traumatic Brain Injury (TBI) was defined as stated above. The exposure variable was administration of tranexamic acid (TXA) during prehospital care or on admission to the resuscitation room and considered to have occurred within three hours of the initial trauma. TXA administration followed the CRASH-2 protocol. The main outcome of interest was all cause in-hospital mortality. Patients who died within 24 hours were retained in the analysis to minimize survivor bias.

G.2.6.3 Measure of Impact

The measure of impact was the average treatment effect (ATE) and corresponded to the difference in mortality between TBI patients exposed to TXA compared to patients not exposed. The ATE and the corresponding 95% confidence interval (95% CI) were calculated for the entire cohort and pre-defined subgroups: TBI severity (mild/moderate, severe) and pupil reactivity (normal, reactive, non-reactive). ATE corresponds to the estimation of the average effect of the treatment to reduce mortality, expressed in % points difference between the two groups (see Appendix H.2 for the CRASH-3 results expressed as ATE). ATE was considered in favor of a causal relationship if the 95%CI did not include 0. All 95%CI were calculated with a non-parametric Bootstrap method.

G.2.6.4 Identification of confounding factors

Potential confounders were identified by a Delphi process consulting with a group of 10 experts in TBI [Dalkey and Helmer, 1963]. Pre-intervention (prior to the administration of TXA) variables identified by the Delphi process concerned factors that would influence the clinician to administer TXA (e.g. hemorrhage, see Figure G.1). In the final model (see Appendix H.2) all variables associated to the severity of the TBI and hospital mortality (e.g. GCS) as well as criteria associated with the treatment administration were mapped with the program dagitty [Textor et al., 2011] into a Directed Acyclic Graph (DAG, Figure G.1) as recommended [Lederer et al., 2019].

0. ph=prehospital; init=initial, SBP/DBP=systolic/diastolic blood pressure; HR=heart rate; SpO2.min=minimal peripheral oxygen saturation in prehospital phase; HemoCue=capillary hemoglobin concentration; delta HemoCue=difference prehospital and admission capillary hemoglobin; Activation HS procedure=activation of hemorrhagic shock procedure; TCD.PI.max=maximal pulsatility index measured with transcranial doppler, EVD=external ventricular drain, IICP=at least one episode of increased PI, GCS=Glasgow Coma Scale, ISS=Injury Severity Score, AIS=Abbreviated Injury Score, IGS.II=Simplified acute physiology score.



Figure G.1 – Directed Acyclic Graph (DAG): a) Pre-intervention variables associated with the decision to administer Tranexamic Acid (TXA) in purple; arrows point toward TXA administration or death if the same variables are associated with death. b) Explicative variables associated with the main outcome death (blue arrows) independent from treatment administration. [1]

G.2.6.5 Balancing

In order to estimate the average treatment effect (ATE), deconfounding or balancing of the groups was achieved by reweighting observations and consequently comparing the standardized mean differences; the differences were not to exceed a 20% threshold.

G.2.6.6 Effect estimation

The ATE was estimated by

1. Inverse propensity score weighting, requiring a model capturing the confounding factors to debias the treatment assignment and
2. Doubly robust approach requiring a model capturing the confounding factors to debias the treatment assignment and a model that relates the confounding factors to the outcome, the outcome model.

For more details, refer to Appendix H.2.

G.2.6.7 Sensitivity analysis (see Appendix H)

After estimation of the treatment effects, a sensitivity analysis was performed to assess how much the final results would change if one or more of the working assumptions such as unconfoundedness and expert based plausibility were violated.

G.2.6.8 Management of missing data

Missing data were managed with two distinct methods (Appendix H.3):

— MICE, multiple imputation with chained equations

— MIA, missing incorporated in attributes

MICE, and multiple imputation in general, is a probabilistic imputation method exploiting the correlation between different variables replacing missing values with several plausible values [van Buuren, 2018]. MIA uses random forests algorithms to learn complex relationships between predictive factors and treatment allocation/outcome and additionally about the information in the missing values patterns in the data.

G.3 – Results

G.3.1 Cohort and propensity score weighting

Between September 2010 and February 2019, a total of 20037 separate trauma cases have been incorporated into the Traumabase® registry in 14 participating centers (Flowchart in Appendix H.1). Among this sample, 8269 corresponded to the definition of TBI. A total of 683 received TXA and 7565 did not receive TXA. Table G.1 illustrates that the clinical characteristics of the two groups before propensity score adjustment differed significantly. Patients with administration of TXA were more severely injured, showed higher SAPS II scores, and were more often in shock or required more often neurosurgery and neurocritical care.

Table G.1 – Cohort characteristics.

Variable	TXA group (n = 683)	Control group (n = 7565)	p
Gender = male, n (%)	460 (67)	5817 (77)	<0.001
Age (years)	39 [26-55]	40 [26-58]	0.099
<25, n (%)	139 (20)	1654 (22)	0.004
25-44, n (%)	275 (40)	2551 (34)	0.004
45-64, n (%)	172 (25)	2000 (27)	0.004
≥ 65, n (%)	97 (14)	1338 (18)	0.004
Anticoagulant therapy, n (%)	24 (4)	395 (5)	0.084
Antiplatelet therapy, n (%)	33 (5)	363 (5)	0.703
Initial GCS in pre-hospital phase	7 [3-14]	13 [6-15]	<0.001
Initial GCS = 3, n (%)	227 (34)	1042 (14)	<0.001
Initial GCS = 3 or bilateral mydriasis in pre-hospital phase, n (%)	240 (36)	1146 (16)	<0.001
AIS			
Head	3 [3-5]	3 [2-5]	<0.001
Face	0 [0-2]	0 [0-1]	<0.001
External	0 [0-0]	0 [0-0]	0.193
ISS	38 [29-50]	21 [13-29]	<0.001
Pupil anomaly in pre-hospital phase			
Anisocoria, n (%)	93 (14)	689 (9)	<0.001
Bilateral mydriasis, n (%)	163 (24)	605 (8)	<0.001
None, n (%)	418 (61)	6142 (81)	<0.001
Not specified, n (%)	9 (1)	129 (2)	<0.001
Osmotherapy in pre-hospital phase			
Mannitol, n (%)	122 (18)	822 (11)	<0.001
Hypertonic saline serum, n (%)	20 (3)	134 (2)	<0.001
None, n (%)	113 (17)	514 (7)	<0.001
Improvement of pupil anomaly after osmotherapy			
Yes, n (%)	35 (5)	346 (5)	<0.001
No, n (%)	142 (21)	765 (10)	<0.001
Blood pressure in pre-hospital phase			
Systolic	105 [80-125]	130 [116-148]	<0.001
Diastolic	62 [45-80]	80 [68-90]	<0.001
Heart rate in pre-hospital phase	108 [78-127]	87 [72-101]	<0.001
Shock index in pre-hospital phase	0.96 [0.69-1.3]	0.66 [0.53-0.81]	<0.001
Minimal SpO2 in pre-hospital phase	95 [87-99]	97 [95-99]	<0.001
Activation of hemorrhagic shock procedure, n (%)	96 (14)	1261 (17)	0.087
Cardiac arrest in pre-hospital phase, n (%)	131 (19)	358 (5)	<0.001
Cristalloid volume (mL)	1000 [750-1500]	500 [500-1000]	<0.001
Colloid volume (mL)	0 [0-500]	0 [0-0]	<0.001
Vasopressor therapy, n (%)	397 (58)	1064 (14)	<0.001
GCS at hospital admission	13 [3-15]	15 [13-15]	<0.001
Pupil anomaly at hospital admission			
Anisocoria, n (%)	93 (14)	689 (9)	<0.001
Bilateral mydriasis, n (%)	163 (24)	605 (9)	<0.001
None, n (%)	418 (61)	6142 (81)	<0.001
Osmotherapy at hospital admission			
Mannitol, n (%)	122 (18)	922 (12)	<0.001
Hypertonic saline serum, n (%)	127 (19)	599 (8)	<0.001
None, n (%)	434 (64)	6044 (80)	<0.001
IGS II	60 [45-75]	30 [17-49]	<0.001
Maximal PI with transcranial Doppler	1.2 [0.9-1.6]	1.1 [0.9-1.4]	0.003
TBI on brain scan	479 (70)	4999 (66)	0.035

Inverse propensity weighting (IPW) generated two comparable groups as demonstrated in Figure G.2. The distribution of missing data was equally weighted to acknowledge for distinct distribution in each group (see Appendix H.3).



Figure G.2 – Effect of inverse propensity weighting (IPW) on Mean Standardized Differences (MSD) in absolute values. Black dots represent absolute values of the MSD before inverse propensity weighting. Blue dots represent absolute values of the MSD after inverse propensity weighting. All confounding factors demonstrated an MSD $< 20\%$ after IPW except for capillary hemoglobine (=Hemocue); blue points =adjusted after IPW, black points =unadjusted before IPW.

G.3.2 Main outcome criterion

Before application of the causal inference approach the observed head-injury related 30-day mortality in the group TXA was 30% (205/683) compared to 15% in the group no-TXA (1102/7565), p<0.001. Figure G.3 illustrates results obtained with causal inference for the main outcome. The Average Treatment Effect (ATE) indicates the mortality difference in the group TXA versus the group without TXA. Causal inference according to IPW indicates an ATE suggesting an objective association with a higher 30-day head-injury related mortality after TXA administration independently of the approach applied to estimate missing data (ATE MICE: 0.10 (95% IC [0.06, 0.14]); ATE MIA: 0.09 (95% IC [0.03, 0.15])). Results obtained with doubly robust method did not show any effect of the treatment on 30-day head-injury related mortality (ATE MICE: -0.01 (95% IC [-0.05, 0.03]); ATE MIA: -0.01 (95% IC [-0.07, 0.05])).



Figure G.3 – Estimation of ATE (Average treatment effect) on 30-day head injury related death after application of causal inference with inverse propensity weighting (IPW) and doubly robust method (DR). In dotted lines estimation by IPW, in uninterrupted lines estimation by DR; in orange imputation of missing data with MICE; in purple estimation of missing data with MIA. In cyan dashed line the unadjusted ATE (without reweighting of the treatment groups). A negative ATE excluding zero favors the TXA group over the group without TXA.

G.3.3 Subgroup Analysis

Table G.2 exposes the results after stratification of the two groups according to TBI severity (severe GCS $\leq$ 8, moderate/mild GCS 9-15), pupil reaction (reactive versus non-reactive). IPW estimates an ATE in favor of an increased mortality in mild TBI patients (mild/moderate GCS or reactive pupils) no matter which imputation technique is applied compared to DR. For severe patients (severe GCS or non-reactive pupils) both approaches, IPW and DR, agree on a non-significant effect, independently of the imputation technique. Appendix H provides all-cause mortality and 30-day all-cause mortality and all head-injury related mortality and the corresponding ATE including subgroups. Independently of the definition applied, no mortality definition and in no subgroup we could show a causal relationship between TXA and mortality.

Table G.2 – Head injury related 30d death stratified into subgroups according to GCS and pupil response.

Inverse propensity weighting	**ATE with MICE imputation**	**ATE with MIA estimation**
GCS = 9-15	0.10 (95% IC [0.02, 0.18])	0.07 (95% IC [0.03, 0.11])
GCS $\leq$ 8	0.07 (95% IC [-0.07, 0.21])	0.07 (95% IC [-0.01, 0.15])
Reactive pupils	0.13 (95% IC [0.07, 0.19])	0.11 (95% IC [0.05, 0.17])
Non reactive pupils	0.01 (95% IC [-0.28, 0.30])	0.01 (95% IC [-0.11, 0.13])
Doubly robust method	**ATE with MICE imputation**	**ATE with MIA estimation**
GCS = 9-15	0.02 (95% IC [-0.08, 0.12])	0.00 (95% IC [-0.06, 0.06])
GCS $\leq$ 8	-0.02 (95% IC [-0.16, 0.12])	-0.01 (95% IC [-0.05, 0.03])
Reactive pupils	0.05 (95% IC [-0.01, 0.11])	0.00 (95% IC [-0.06, 0.06])
Non reactive pupils	-0.11 (95% IC [-0.38, 0.16])	-0.01 (95% IC [-0.07, 0.05])

G.4 – Discussion

This study applied two causal inference techniques, inverse propensity weighting (IPW) and doubly robust method (DR), combined with handling of missing data to estimate the effect of TXA on patients with TBI from observational data. Based on the present large observational database, IPW seems to overestimate a harmful effect of TXA on mortality when compared to the CRASH-3 reference. By contrast, the estimation based on Doubly Robust (DR) suggests that TXA administration after TBI does not exert any effect on mortality.

How do these results relate to the available evidence? First, the present study truly does not compare to the available prospective evidence. Any evaluation between the presented results and prospective evidence in particular CRASH-3 only serves the purpose to appreciate the performance of the deployed statistical (or analysis) techniques. Second, prospective studies diverge in crucial points such as power, outcome criteria (28-day mortality versus 30-day or all cause mortality), pre-hospital or intrahospital TXA administration, excluding extracranial hemorrhage, administration protocols.

The results for ATE in % of risk of head injury related death for the Doubly Robust method ranged from a 7% decrease to a 5% increase depending on the method to estimate the missing values (MICE of MIA) and 3% to 15% increase with IPW. In comparison, CRASH-3 risk of head injury related death in the overall cohort ranged from a 14% decrease to a 2% increase with a mean of a 1.3% decrease [Cap, 2019]. Rowell et al. [2020] showed a range from a 8% decrease for 28-day mortality to a 2% increase, with a mean of 3% decrease. The meta-analysis by Al Lawati et al. [2020] concluded to a 3% decrease to a 1% increase in overall mortality.

The main challenge in any causal inference approach from observational data is the control of confounders. Bossers et al. [2021], a registry based observational study, showed an increase in 28-day mortality concurring with the ATE estimation by IPW. Bossers et al. [2021] established the association through unadjusted logistic regression,

then adjusted for confounders in contrast the present study based on expert knowledge and directed acyclic graphs as recommended9. The results discordant from CRASH-3 obtained by Bossers et al. [2021] and IPW may however pertain to the same difficulty to obtain sufficient control for confounding.

When comparing observational data from two very disparate groups, standard propensity scores methods tend to under-correct for the observed difference, either due to model mis-specification (in the case of logistic regression) or insufficient sample size (in case of random forest regression). In consequence the estimation of the treatment effect becomes erroneous. In the present case IPW seems not to have sufficiently corrected for the treatment bias, probably because it struggles to achieve sufficient control of confounders. IPW and DR require both a sufficient knowledge of all confounding factors. DR however provides better control of potential bias and smaller variability than IPW, integrating at the same time a prediction of mortality and of treatment allocation. This dual modeling of mortality and treatment allocation optimally exploits the available data and protects against mis-specification of either one of the models, making it more robust than IPW. Furthermore, the flexibility of random forests in the doubly robust method engenders a more powerful model capturing complex relationships and is suited for application to a large cohort. The first take-away from the present work is therefore when employing causal inference, DR is preferable to IPW. This study also shares an important innovation, since it is the first to combine DR with two advanced methods to handle missing data and both generate concordant results.

Trials in critical care in the last fifteen years often produced negative results and were regularly underpowered to detect frequently unattainable outcome targets [Harhay et al., 2014]. Mortality as the most certified outcome criterion often falls short to picture heterogeneous effects of complex interventions in complex disease [Dreyfuss, 2005]. Furthermore, RCTs consume precious human, financial, organizational and time resources. Benchmark trials such as CRASH-3 result from exemplar international research efforts, not applicable or reproducible to many research questions. Not only because of resource constraints, but the necessary recruitment remains unobtainable in an appropriate timeframe. Recruitment is not facilitated by the increasingly small marginal benefits bestowed by ever more complex interventions. Despite a strong rationale, CRASH-3 required more than 12000 patients.

Augmented causal inference does not aspire to become a substitute for randomized controlled trials but is capable to upgrade conventional observational in particular in the era of big data and physiological research and to provide a better rationales for RCTs [Lederer et al., 2019]. The approach could become a reference to prepare RCTs, explore the association of different interventions or bundles in different subgroups. This customized preparation would funnel research resources to the most promising RCTs. For this reason, the results of this study using augmented causal inference appear promising and should be further explored. An association of prospective, randomized data and parallel augmented causal inference on observational dataset could be feasible.

The study imparts specific limitations. The inclusion period spans from 2010 to 2019, over this long period it is likely that management and epidemiology have

evolved. The study group considered all TXA to be administered within three hours of injury. Furthermore, TXA was administered for suspected hemorrhage and not TBI, making the effect on isolated TBI difficult to assess; the association of hemorrhage and TBI might have affected the outcome prediction, although this was accounted for in the model. Among the patients included with TBI, 842 presented with severe acute hemorrhage (received at least 4 red blood cell packs within the first six hours). The choice of confounders and treatment allocation variables was based on expert advice and could be a possible source of bias. Even experts may fail to perceive alternative explicative patterns and risk to appreciate only the patterns they know and are prone to inherent cognitive bias. Despite use of a Delphi and DAG to map possible confounders to account for these in the final model, some variables might still escape sufficient control. Collected data can be imprecise (for example blood pressure measurements) and are only a fragmented surrogate for a complex physiological process (a few blood pressure measurements at various time points versus continuous data). Missing data constitute an inherent limitation of any work based on off-the-shelf observational data; missingness of data is impossible to prevent in particular in registry data and all the more so in a clinical context of emergency. Fully aware of this intrinsic limitation of registry data, the study group set out to purposefully integrate and advance management of missing data, testing two different methods for imputation of missing data. With all these imperfections, control for confounding in causal inference of observational data remains a formidable challenge. Future studies need to address this challenge including the quality and mapping capacity of observational data. Finally, the chosen threshold of a Mean Standardized Difference of 20% as accepted might seem important, in particular since mortality differences between the groups are <20%.

G.5 – Conclusion

This study explored the feasibility to estimate the effect of TXA administration on TBI in relationship to available prospective evidence, in particular an international benchmark trial combined with an innovative approach to handle missing data. In comparison to the IPW approach, the doubly robust method provides a better estimate of the effect of TXA. Possibly IPW provides insufficient control of confounding. This result provides a strong incentive to explore augmented causal inference techniques on observational data as an alternative to situations where randomized controlled trials are impossible or in the preparation of RCTs.

Appendix H

Additional results for Appendix G

H.1 – Baseline information

H.1.1 Strobe checklist for observational studies

Table H.1 – Strobe checklist for observational studies (N.A.=not applicable).

		Item N°	Recommendation	
	Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Done
			(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Done
Introduction	Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Done
	Objectives	3	State specific objectives, including any prespecified hypotheses	Done
Methods	Study design	4	Present key elements of study design early in the paper	Done
	Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Done
	Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Done
			(b) For matched studies, give matching criteria and number of exposed and unexposed	Done
	Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Done
	Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Done
	Bias	9	Describe any efforts to address potential sources of bias	Done
	Study size	10	Explain how the study size was arrived at	N.A.
	Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Done
	Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Done
			(b) Describe any methods used to examine subgroups and interactions	Done
			(c) Explain how missing data were addressed	Done
			(d) If applicable, explain how loss to follow-up was addressed	N.A.
			(e) Describe any sensitivity analyses	Done
Results	Participants	13*	(a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	Done
			(b) Give reasons for non-participation at each stage	Done
			(c) Consider use of a flow diagram	Done
	Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	Done
			(b) Indicate number of participants with missing data for each variable of interest	Done
			(c) Summarize follow-up time (e.g., average and total amount)	Done
	Outcome data	15*	Report numbers of outcome events or summary measures over time	Done
	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Done
			Make clear which confounders were adjusted for and why they were included	Done
			(b) Report category boundaries when continuous variables were categorized	Done
			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N.A.
	Other analyses	17	Report other analyses done–e.g. analyses of subgroups and interactions, and sensitivity analyses	Done
Discussion	Key results	18	Summarize key results with reference to study objectives	Done
	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	Done
			Discuss both direction and magnitude of any potential bias	Done
	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
	Generalizability	21	Discuss the generalizability (external validity) of the study results	Done
	Other information: Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Done

H.1.2 Study flowchart



Figure H.1 – Flowchart of the observational study based on the Traumabase® registry.

H.2 – Theoretical principles

H.2.1 Observational data and principles of causal inference

A fundamental difference between experimental and observational studies consists in the randomization of treatment assignment for the former and absence thereof in the latter. In the absence of an experimental design, estimating a treatment effect with heterogeneous observational data the risk of bias and inconsistencies. In critical care, or more generally in health care, if an observational study compares two groups of patients, the group receiving the treatment associates most often with a higher level of severity and thus carry a higher probability to receive the treatment. The control of confounding factors that at the same time attribute administration of the treatment and/or influence the outcome becomes crucial in order to balance these factors between the two groups in the absence of randomization.

Causal inference estimates the connecting relationship between an exposition, such as a treatment, and an effect, such as mortality. The identification of principal confounding factors culminates in the construction of a causal relationship model. These confounding factors are defined by an association to the outcome criterion but are not supposed to contribute to the causal pathway between the exposition variable and the outcome [Lederer et al., 2019]. The causal model summarizes the various hypotheses about the eventual causal relationships to define the analysis plan based on the available scientific knowledge.

For a causal analysis to estimate the average treatment effect, this list of features must contain at least the outcome of interest and the treatment assignment.

It is recommended to map these relationships and interactions in a *Directed Acyclic Graph* (DAG). Within a DAG unidirectional arrows indicate graphic representation of these relationships and interactions. Figure H.2 illustrates an example of a DAG.



Figure H.2 – DAG, predictors of exposition (node T), pictured in green, predictors of the outcome criterion (node Y), pictured in blue, confounding factors pictured in red.

H.2.2 Identifiability and unconfoundedness

Given the major drawback of observational data with the lack of a randomized treatment assignment, an essential assumption is required to "transform" the data in a way to emulate this property and estimate the average treatment effect. The key aspect of this assumption is known as *ignorability* or *unconfoundedness*. In order to estimate the ATE from the present data set, a correction is required to compensate for the lack of randomization of the treatment assignment (in the present example TXA or no TXA). The information contained in the data set allows this compensation in order to emulate an experiment by reversing or retracing the treatment assignment process. This assumption can be translated as "there is sufficient information about the treatment assignment decision process captured in the describing features" (e.g., the patient's pre-treatment state and baseline characteristics), so that conditionally on every possible patient description, we have a random treatment assignment. This ensures independence between potential outcomes and treatment assignment. Defining the correct set of such describing features requires domain-specific knowledge. The information required should allow to emulate an experiment by reversing or retracing the treatment assignment process. For instance, if a treatment is prescribed as soon as at least two out of three conditions A, B and C are satisfied, then it is possible to retrospectively retrace this assignment as long as information on conditions A, B and C is recorded. The assumption that this correction is possible from the available data is referred to as *unconfoundedness* or *ignorability*. This process of correcting for the nonrandomized treatment assignment is also called *deconfounding*

H.2.3 Deconfounding or balancing

The key step in estimating treatment effects from observational data is the *deconfounding*, sometimes also referred to as balancing of the treatment groups. The balancing can be achieved by different means, namely by matching or re-weighting methods. The quality of this balancing can be assessed in different ways using for instance different statistical tests reference, but the most popular approach is to compare standardized mean differences before and after the balancing. If these differences fall beyond some small threshold, usually 10%, for all confounding factors, the balancing step is considered successful. If the balancing step is however failing or insufficient, then the balancing method or the propensity model need to be revisited.

H.2.4 Model choice

A popular choice for the propensity model, i.e., the model that describes the treatment decision, is logistic regression allowing to relate the confounding factors to the binary treatment assignment. Note that it is possible to handle uninformative missing values in the logistic regression [Jiang et al., 2020]. Other possible models are decision trees or their generalization, such as random forests. These can account for interactions between multiple covariates [Breiman, 2001, Wager and Athey, 2018].

H.2.5 Treatment effect estimation

After completion of these previous steps, it is possible to estimate the average treatment effect from the data set. Balancing renders the treatment groups comparable and enables methods similar to those employed in experimental studies, such as for the estimation of ATE, to analyze the difference of the average outcomes from the balanced groups. Two popular approaches to treatment effect estimation with observational data under the unconfoundedness assumption are propensity score matching and inverse propensity weighting.

A propensity score is based on the propensity model, i.e., a model relating the treatment administration to the list of baseline factors, estimating the probability to receive the treatment depending on a number of confounders. This score ranges from 0 to 1. Although common, matching pairs of patients from both treatment groups reduces the number of available patients in the study and thus reduce power and may also induce a selection bias [Rosenbaum, 2002]. To navigate this difficulty an alternative approach exists, the inverse propensity score weighting (IPW). IPW allows to include all patients of the cohort by applying a weighting factor to each patient. To obtain two comparable groups, the contribution of each patient to the treatment effect is estimated with the following formula:

(i) $1/$ propensity score, for a treated patient;

(ii) $1/(1-$ propensity score), for a non-treated patient

Patients with an intermediate propensity score around 0.5 have the same probability to receive the treatment or not to receive the treatment. The propensity of these patients can be considered as equivalent to inclusion in a randomized controlled

trial, since their profile does not determine the administration of the intervention. The IPW approach attributes these patients and the corresponding assignment uncertainty more weight, while keeping patients with propensity score close to the boundaries and with small weights. The potentially high variance of the IPW and its pitfalls related to model mis-specification call for an alternative, which has been first proposed by Robins et al. [1994], the augmented IPW or doubly robust method.

The doubly robust method disposes of superior statistical characteristics compared to a propensity score or inverse proportional weighting [Bang and Robins, 2005, Lunceford and Davidian, 2004]. IPW only takes into account the predictive effect of confounding variables on treatment allocation (an analogous approach exists that only considers the predictive effect on the outcome). The doubly robust method considers the dual aspect of predictors: treatment allocation and outcome. This concept allows for a more efficient alternative to propensity score matching and IPW: it optimally exploits the entire data. Not only is this approach more data-efficient, it is also robust to "bad", i.e., inaccurate, modeling of either the propensity or outcome model. Note that this method requires specification of both the outcome and propensity model. Another advantage of the Doubly Robust Method lies its compatibility with modern machine learning algorithms as applied in the present study.

Additionally, in the case of our specific TXA question, this estimator is most attractive, since it allows us to incorporate information both about the hemorrhage state of the patient – necessary to adjust for the treatment bias – and about the severity of the brain injury.

H.3 – Missing data

In almost all data set are contaminated by missing values [Josse and Reiter, 2018, Mayer et al., 2019]. Before proceeding to the actual data analysis, it is essential to assess the data quality, in particular the level of missing data or missingness, i.e., how many observations are available. It is important to understand that it is not necessarily the amount of missing data that can lead to problems in subsequent analyses but rather the source or the mechanism behind missing values. In the statistical literature, a classical taxonomy for the missingness mechanisms basically distinguishes uninformative and informative missing values [Rubin, 1976]. The former characterizes cases where the missingness mechanism is either completely at random or only depends on observed information, while the latter contains all other cases. For instance, missing values due to a defective measurement device (blood pressure cuff not working) are noninformative. If a value is missing because the measured value exceeds the range of the measurement device, then the missingness is due to the missing value itself. This is an example of informative missingness. In the context of this study, the Glasgow Coma Scale is difficult to assess in an intubated and sedated patient, hence the information is missing but for a specific reason. As any registry, the Traumabase® contains missing values, some of which are explicitly encoded as being informative missing values. Figure 4.1 (Chapter 4) depicts the percentages

of missing values in the Traumabase® according to the type and mechanism of missingness; Table H.2 give the proportions of missing values in each treatment arm. It is important to distinguish the mechanism behind missing data, since the choice of the statistical analysis tool(s) and imputation approach depends on the detected or assumed missingness mechanism.

Table H.2 – Description of missing data by treatment group.

Variable	**TXA group**	**Control group**	**p**
Gender=male, n (%)	0 (0)	64 (1)	<0.001
Anticoagulant treatment, n (%)	35 (5)	316 (4)	0.235
Antiplatelet treatment, n (%)	3 (5)	325 (4)	0.379
Initial GCS in pre-hospital phase, n (%)	8 (1)	157 (2)	0.116
AIS, n (%)			
Head	10 (2)	128 (2)	0.757
Face	10 (2)	128 (2)	0.757
External	10 (2)	128 (2)	0.757
ISS, n (%)	10 (2)	122 (2)	0.874
Pupil anomaly in pre-hospital phase, n (%)	10 (2)	151 (2)	0.388
Osmotherapy in pre-hospital phase, n (%)	7 (1)	133 (2)	0.213
Improvement of pupil anomaly after osmotherapy, n %	506 (74)	6454 (85)	<0.001
Blood pressure un pre-hospital phase, n (%)			
Systolic	208 (31)	2209 (29)	0.510
Diastolic	209 (31)	2230 (30)	0.540
Heart rate in pre-hospital phase, n (%)	187 (27)	2248 (30)	0.204
Shock index in pre-hospital phase, n (%)	219 (32)	2297 (30)	0.362
Minmal SpO2 in pre-hospital phase, n (%)	111 (16)	855 (11)	<0.001
Activation of hemorragic shock procedure, n (%)	28 (4)	281 (4)	0.599
Cardiac arrest in pre-hospital phase, n (%)	3 (0)	187 (3)	<0.001
Initial HemoCue®, n (%)	118 (17)	2760 (37)	<0.001
Delta HemoCue®, n (%)	129 (19)	2940 (39)	<.001
Cristalloid volume (mL), n (%)	68 (10)	2405 (32)	<0.001
Colloid volume (mL), n (%)	84 (12)	2495 (33)	<0.001
Vasopressor therapy, n (%)	0 (0)	0 (0)	1
GCS at hospital admission, n (%)	424 (62)	3050 (40)	<0.001
Pupil anomaly at hospital admission, n (%)	9 (1)	129 (2)	0.535
Osmotherapy at hospital admission, n (%)	0 (0)	0 (0)	1
IGS II, n (%)	13 (2)	156 (2)	0.888
Maximal PI with transcranial Doppler, n (%)	362 (53)	3857 (51)	0.318
TBI on brain scan, n (%)	0 (0)	0 (0)	1

In the context of treatment effect estimation, applying straightforward imputation techniques can lead to heavy bias in the final treatment effect estimates [Leyrat et al., 2019]. For a review on different approaches for handling missing values in the context of treatment effect estimation, we refer the reader to and how to combine these with a Doubly Robust Method please refer to Mayer et al. [2020].

The two techniques adopted in this work are Multiple imputation with chained, MICE, and Missing incorporated in attributes, MIA.

H.3.1 Multiple imputation by chained equations (MICE)

Multiple Imputation with chained equations (MICE) exploits the correlation between various variables and variable patterns replacing missing values with plausible values. In the given example of a TBI cohort, patients with a GCS of 3 is more likely to have a pupil anomaly. MICE is a probabilistic approach taking to a certain extent into account the level of uncertainty associated with estimating missing values. Figure H.3 illustrates the approach. For every missing value represented by a "?" five plausible values are suggested by the automatic imputation algorithm based on the correlation patterns of various variables. Five copies of the initial data set are created. In each new set missing values are replaced by plausible values. The ATE (average treatment effect) is then calculated for every completed data set. The final ATE corresponds to the mean of all ATE for every imputed data set.



Figure H.3 – Illustration of multiple imputation principle.

H.3.2 Missing incorporated in attributes (MIA)

The method Missing Incorporated in Attributes applies a so-called machine learning component by automatic learning and does not correspond to a classical imputation technique. The method employs random decision forests algorithms learning autonomously and empirically by filtering through the data set. These algorithms train repetitively on multiple examples in the data set and develop mathematical and statistical patterns that are repetitively applied and improved by new and increasing amount of data; hence the concept of learning. This corresponds to a generalization of the regression line within a cloud of data points to indicate the relationship between patients and the indication for a treatment. For example, the algorithm will identify sub-groups of patients based on their capillary hemoglobin pattern and attribute a level of possible shock or hemorrhage to this value given the data profile of the patient. If the capillary hemoglobin is missing in another patient, the algorithm will complete the missing value with the most frequently one

encountered in patients with a corresponding profile. The method is capable of integrating numerous variables and their interaction. To predict whether a patient will receive the treatment, the algorithm will estimate an the most likely answer based on the sample of patients in the cohort and approximate the profile identified in the random forest (see Figure H.4).



Figure H.4 – Illustration of missing incorporated in attributes principle.

Bibliography

Alberto Abadie and Guido W. Imbens. Matching on the estimated propensity score. *Econometrica*, 84(2):781–807, 2016.

Alberto Abadie, Alexis Diamond, and Jens Hainmueller. Synthetic control methods for comparative case studies: Estimating the effect of california's tobacco control program. *Journal of the American statistical Association*, 105(490):493–505, 2010.

Najmeh Abiri, Björn Linse, Patrik Edén, and Mattias Ohlsson. Establishing strong imputation performance of a denoising autoencoder in a wide range of missing data problems. *Neurocomputing*, 365:137–146, 2019.

Benjamin Ackerman, Catherine R. Lesko, Juned Siddique, Ryoko Susukida, and Elizabeth A. Stuart. Generalizing randomized trial findings to a target population using complex survey population data. *arXiv:2003.07500*, 2020.

Abdelmonem A. Afifi and Robert M. Elashoff. Missing observations in multivariate statistics i. review of the literature. *Journal of the American Statistical Association*, 61(315):595–604, 1966.

Kumait Al Lawati, Sameer Sharif, Said Al Maqbali, Hussein Al Rimawi, Andrew Petrosoniak, Emilie P Belley-Cote, Sunjay V Sharma, Justin Morgenstern, Shannon M Fernando, Julian J Owen, et al. Efficacy and safety of tranexamic acid in acute traumatic brain injury: a systematic review and meta-analysis of randomized-controlled trials. *Intensive Care Medicine*, pages 1–14, 2020.

Theodore W. Anderson. Maximum likelihood estimates for a multivariate normal distribution when some observations are missing. *Journal of the american Statistical Association*, 52(278):200–203, 1957.

Rebecca R. Andridge. Quantifying the impact of fixed effects modeling of clusters in multiple imputation for cluster randomized trials. *Biometrical journal*, 53(1): 57–74, 2011.

Joshua D. Angrist, Guido W. Imbens, and Donald B. Rubin. Identification of causal effects using instrumental variables. *Journal of the American statistical Association*, 91(434):444–455, 1996.

Dmitry Arkhangelsky, Susan Athey, David A. Hirshberg, Guido W. Imbens, and Stefan Wager. Synthetic difference in differences. Technical report, National Bureau of Economic Research, 2019.

Susan Athey and Guido W. Imbens. Recursive partitioning for heterogeneous causal effects. *Proceedings of the National Academy of Sciences*, 113(27):7353–7360, 2016.

Susan Athey and Stefan Wager. Efficient policy learning. *arXiv preprint arXiv:1702.02896*, 2017.

Susan Athey and Stefan Wager. Estimating treatment effects with causal forests: An application. *Observational Studies*, 5, 2019.

Susan Athey and Stefan Wager. Policy learning with observational data. *Econometrica*, 89(1):133–161, 2021.

Susan Athey, Guido W. Imbens, and Stefan Wager. Approximate residual balancing: debiased inference of average treatment effects in high dimensions. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 80(4):597–623, 2018.

Susan Athey, Julie Tibshirani, and Stefan Wager. Generalized random forests. *The Annals of Statistics*, 47(2):1148–1178, 2019.

Susan Athey, Raj Chetty, and Guido W. Imbens. Combining experimental and observational data to estimate treatment effects on long term outcomes. *arXiv preprint arXiv:2006.09676*, 2020a.

Susan Athey, Raj Chetty, Guido W. Imbens, and Hyunseung Kang. Estimating treatment effects using multiple surrogates: The role of the surrogate score and the surrogate index. 2020b.

Susan Athey, Mohsen Bayati, Nikolay Doudchenko, Guido Imbens, and Khashayar Khosravi. Matrix completion methods for causal panel data models. *Journal of the American Statistical Association*, pages 1–41, 2021.

Anthony B. Atkinson, Thomas Piketty, and Emmanuel Saez. Top incomes in the long run of history. *Journal of economic literature*, 49(1):3–71, 2011.

Vincent Audigier, François Husson, and Julie Josse. A principal component method to impute missing values for mixed data. *Advances in Data Analysis and Classification*, 10(1):5–26, 2016.

Vincent Audigier, François Husson, and Julie Josse. MIMCA: multiple imputation for categorical variables with multiple correspondence analysis. *Statistics and computing*, 27(2):501–518, 2017.

Vincent Audigier, Ian R. White, Shahab Jolani, Thomas P.A. Debray, Matteo Quartagno, James R. Carpenter, Stef Van Buuren, Matthieu Resche-Rigon, et al. Multiple imputation for multilevel data with continuous and binary variables. *Statistical Science*, 33(2):160–183, 2018.

Peter C. Austin. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behavioral Research*, 46:399–424, 2011.

Peter C Austin and Elizabeth A. Stuart. Moving towards best practice when using inverse probability of treatment weighting (iptw) using the propensity score to estimate causal treatment effects in observational studies. *Statistics in medicine*, 34(28):3661–3679, 2015.

Michael Baiocchi, Jing Cheng, and Dylan S Small. Instrumental variable methods for causal inference. *Statistics in medicine*, 33(13):2297–2340, 2014.

Heejung Bang and James M. Robins. Doubly robust estimation in missing data and causal inference models. *Biometrics*, 61:962–973, 2005.

Elias Bareinboim and Judea Pearl. Controlling selection bias in causal inference. In Neil D. Lawrence and Mark Girolami, editors, *Proceedings of the Fifteenth International Conference on Artificial Intelligence and Statistics*, volume 22 of *Proceedings of Machine Learning Research*, pages 100–108, La Palma, Canary Islands, 2012a. PMLR.

Elias Bareinboim and Judea Pearl. Transportability of causal effects: Completeness results. In *Proceedings of the Twenty-Sixth AAAI Conference on Artificial Intelligence*, AAAI'12, page 698–704. AAAI Press, 2012b.

Elias Bareinboim and Judea Pearl. A general algorithm for deciding transportability of experimental results. *Journal of Causal Inference*, 1(1):107–134, 2013. doi: doi:10.1515/jci-2012-0004. URL https://doi.org/10.1515/jci-2012-0004.

Elias Bareinboim and Judea Pearl. Causal inference and the data-fusion problem. *Proceedings of the National Academy of Sciences*, 113:7345–7352, 2016.

Jeremy Hugh Baron. Sailors' scurvy before and after james lind–a reassessment. *Nutrition reviews*, 67(6):315–332, 2009.

Reuben M. Baron and David A. Kenny. The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. *Journal of personality and social psychology*, 51(6):1173, 1986.

Jonathan W. Bartlett, Ofer Harel, and James R. Carpenter. Asymptotically unbiased estimation of exposure odds ratios in complete records logistic regression. *American journal of epidemiology*, 182(8):730–736, 2015. doi: 10.1093/aje/kwv114.

Jacques Benichou and Mitchell H Gail. Estimates of absolute cause-specific risk in cohort studies. *Biometrics*, pages 813–826, 1990.

Andrew Bennett and Nathan Kallus. Policy evaluation with latent confounders via optimal balance. In *Advances in Neural Information Processing Systems*, pages 4826–4836, 2019.

James Bennett, Stan Lanning, et al. The netflix prize. In *Proceedings of KDD cup and workshop*, volume 2007, page 35. Citeseer, 2007.

Rohit Bhattacharya, Razieh Nabi, Ilya Shpitser, and James M. Robins. Identification in missing data models represented by directed acyclic graphs. In *Uncertainty in artificial intelligence: proceedings of the... conference. Conference on Uncertainty in Artificial Intelligence*, volume 2019. NIH Public Access, 2019.

Rohit Bhattacharya, Razieh Nabi, and Ilya Shpitser. Semiparametric inference for causal effects in graphical models with hidden variables. *arXiv preprint arXiv:2003.12659*, 2020.

Felix Biessmann, David Salinas, Sebastian Schelter, Philipp Schmidt, and Dustin Lange. "deep" learning for missing value imputationin tables with non-numerical data. In *Proceedings of the 27th ACM International Conference on Information and Knowledge Management*, CIKM '18, pages 2017–2025, 2018. ISBN 978-1-4503-6014-2. doi: 10.1145/3269206.3272005. URL http://doi.acm.org/10.1145/3269206.3272005.

Aleksey Bilogur. Missingno: a missing data visualization suite. *Journal of Open Source Software*, 3(22):547, 2018. doi: 10.21105/joss.00547. URL https://doi.org/10.21105/joss.00547.

Helen A. Blake, Clémence Leyrat, Kathryn E. Mansfield, Laurie A. Tomlinson, James R. Carpenter, and Elizabeth J. Williamson. Estimating treatment effects with partially observed covariates using outcome regression with missing indicators. *Biometrical Journal*, 62(2):428–443, 2020.

Matteo Bonvini and Edward H. Kennedy. Sensitivity analysis via the proportion of unmeasured confounding. *Journal of the American Statistical Association*, pages 1–11, 2021.

Sebastiaan M. Bossers, Stephan A. Loer, Frank W. Bloemers, Dennis Den Hartog, Esther M.M. Van Lieshout, Nico Hoogerwerf, Joukje van der Naalt, Anthony R. Absalom, Saskia M. Peerdeman, Lothar A. Schwarte, et al. Association between prehospital tranexamic acid administration and outcomes of severe traumatic brain injury. *Jama neurology*, 78(3):338–345, 2021.

Gabriel A. Brat, Griffin M. Weber, Nils Gehlenborg, Paul Avillach, Nathan P. Palmer, Luca Chiovato, James Cimino, Lemuel R. Waitman, Gilbert S. Omenn, Alberto Malovini, et al. International electronic health record-derived covid-19 clinical course profiles: the 4ce consortium. *Npj Digital Medicine*, 3(1):1–9, 2020 (cited on 2020-07-17).

Leo Breiman. Random forests. *Machine learning*, 45(1):5–32, 2001.

Leo Breiman, Jerome H. Friedman, Richard A. Olshen, and Charles J. Stone. Classification and regression trees. 1984.

K Alexander Brownlee. Statistics of the 1954 polio vaccine trials. *Journal of the American Statistical Association*, 50(272):1005–1013, 1955.

Ashley L Buchanan, Michael G Hudgens, Stephen R Cole, Katie R Mollan, Paul E Sax, Eric S Daar, Adaora A Adimora, Joseph J Eron, and Michael J Mugavero. Generalizing evidence from randomized trials using inverse probability of sampling weights. *J. R. Statist. Soc. A*, page doi: 10.1111/rssa.12357, 2018.

Stephen Burgess, Ian R. White, Matthieu Resche-Rigon, and Angela M. Wood. Combining multiple imputation and meta-analysis with individual participant data. *Statistics in medicine*, 32(26):4499–4514, 2013.

David P. Byar. Assessing apparent treatment—covariate interactions in randomized clinical trials. *Statistics in medicine*, 4(3):255–263, 1985.

Alison Callahan, Nigam H. Shah, and Jonathan H Chen. Research and reporting considerations for observational studies using electronic health record data. *Annals of internal medicine*, 172(11_Supplement):S79–S84, 2020.

Donald T. Campbell. Factors relevant to the validity of experiments in social settings. *Psychological Bulletin*, 54(4):297–312, 1957. doi: 10.1037/h0040950. URL https://app.dimensions.ai/details/publication/pub.1006899002.

Marta Camprubí-Rimblas, Neus Tantinyà, Josep Bringué, Raquel Guillamat-Prats, and Antonio Artigas. Anticoagulant therapy in acute respiratory distress syndrome. *Annals of translational medicine*, 6(2), 2018.

Emmanuel J. Candès and Yaniv Plan. Matrix completion with noise. *Proceedings of the IEEE*, 98(6):925–936, 2010.

Andrew P Cap. Crash-3: a win for patients with traumatic brain injury. *The Lancet*, 394(10210):1687 – 1688, 2019. ISSN 0140-6736. doi: 10.1016/S0140-6736(19)32312-8. URL http://www.sciencedirect.com/science/article/pii/S0140673619323128.

David Card and Alan B. Krueger. Minimum wages and employment: A case study of the fast-food industry in new jersey and pennsylvania. *The American Economic Review*, 84(4):772–793, 1994.

James R. Carpenter and Michael G. Kenward. Missing data in randomised controlled trials: a practical guide, 2007.

James R. Carpenter and Michael G. Kenward. *Multiple Imputation and its Application*. Wiley, Chichester, West Sussex, UK, 2013. ISBN 9780470740521. doi: 10.1002/9781119942283.

Raymond J. Carroll, David Ruppert, Leonard A. Stefanski, and Ciprian M. Crainiceanu. *Measurement error in nonlinear models: a modern perspective*. CRC press, 2006.

Clive R. Charig, David R. Webb, Stephen Richard Payne, and John E. Wickham. Comparison of treatment of renal calculi by open surgery, percutaneous nephrolithotomy, and extracorporeal shockwave lithotripsy. *Br Med J (Clin Res Ed)*, 292 (6524):879–882, 1986.

Rui Chen, Guanhua Chen, and Menggang Yu. A generalizability score for aggregate causal effect. *arXiv preprint arXiv:2106.14243*, 2021.

Shuai Chen, Lu Tian, Tianxi Cai, and Menggang Yu. A general statistical framework for subgroup identification and comparative treatment scoring. *Biometrics*, 73(4): 1199–1209, 2017.

Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, and Zhan Zhang. Efficacy of hydroxychloroquine in patients with covid-19: results of a randomized clinical trial. *medrxiv*, 2020.

Xiaoyue Cheng, Dianne Cook, and Heike Hofmann. Visually exploring missing values in multivariable data using a graphical user interface. *Journal of statistical software*, 68(1):1–23, 2015.

Victor Chernozhukov, Denis Chetverikov, Mert Demirer, Esther Duflo, Christian Hansen, Whitney Newey, and James Robins. Double/debiased machine learning for treatment and structural parameters. *The Econometrics Journal*, 21(1):C1–C68, 2018a.

Victor Chernozhukov, Mert Demirer, Esther Duflo, and Ivan Fernandez-Val. Generic machine learning inference on heterogenous treatment effects in randomized experiments. Technical report, National Bureau of Economic Research, 2018b.

David Maxwell Chickering. Optimal structure identification with greedy search. *Journal of machine learning research*, 3(Nov):507–554, 2002.

Hugh A. Chipman, Edward I. George, Robert E. McCulloch, et al. Bart: Bayesian additive regression trees. *The Annals of Applied Statistics*, 4(1):266–298, 2010.

Carlos Cinelli and Chad Hazlett. Making sense of sensitivity: extending omitted variable bias. 82(1):39–67, 2020. doi: 10.1111/rssb.12348. URL https://ideas.repec.org/a/bla/jorssb/v82y2020i1p39-67.html.

Carlos Cinelli and Judea Pearl. Generalizing experimental results by leveraging knowledge of mechanisms. *European Journal of Epidemiology*, 2020.

William G. Cochran. Analysis of covariance: its nature and uses. *Biometrics*, 13(3): 261–281, 1957.

William G. Cochran. The effectiveness of adjustment by subclassification in removing bias in observational studies. *Biometrics*, 24:295–313, 1968.

William G. Cochran. Observational studies. *Statistical PApers in Honor of George W. Snedecor*, pages 70–90, 1972.

Archibald Leman Cochrane et al. *Effectiveness and efficiency: random reflections on health services*, volume 900574178. Nuffield Provincial Hospitals Trust London, 1972.

Stephen R Cole and Elizabeth A Stuart. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. *American Journal of Epidemiology*, 172:107–115, 2010.

Bénédicte Colnet, Imke Mayer, Guanhua Chen, Awa Dieng, Ruohong Li, Gaël Varoquaux, Jean-Philippe Vert, Julie Josse, and Shu Yang. Causal inference methods for combining randomized trials and observational studies: a review. *arXiv preprint arXiv:2011.08047*, 2020.

Bénédicte Colnet, Julie Josse, Erwan Scornet, and Gaël Varoquaux. Generalizing a causal effect: sensitivity analysis and missing covariates. *arXiv preprint arXiv:2105.06435*, 2021.

John Concato and Ralph I. Horwitz. Beyond randomised versus observational studies. *Lancet (London, England)*, 363(9422):1660–1661, 2004.

John Concato, Nirav Shah, and Ralph Horwitz. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *The New England journal of medicine*, 342:1887–1892, 2000. doi: 10.1056/NEJM200006223422507.

G Cooper. Causal discovery from data in the presence of selection bias. In *Proceedings of the Fifth International Workshop on Artificial Intelligence and Statistics*, pages 140–150, 1995.

Jerome Cornfield, William Haenszel, E. Cuyler Hammond, Abraham M. Lilienfeld, Michael B. Shimkin, and Ernst L. Wynder. Smoking and Lung Cancer: Recent Evidence and a Discussion of Some Questions. 22(1):173–203, 1959. ISSN 0027-8874. doi: 10.1093/jnci/22.1.173. URL https://doi.org/10.1093/jnci/22.1.173.

Juan D. Correa, Jin Tian, and Elias Bareinboim. Generalized adjustment under confounding and selection biases. In *Thirty-Second AAAI Conference on Artificial Intelligence*, 2018.

David R. Cox. *Planning of experiments*. Wiley & Sons, New York, 1958. ISBN 0471574295.

CRASH-2 Collaborators et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the crash-2 randomised controlled trial. *The Lancet*, 377(9771):1096–1101, 2011.

Suzie Cro, Tim P. Morris, Brennan C. Kahan, Victoria R. Cornelius, and James R. Carpenter. A four-step strategy for handling missing outcome data in randomised trials affected by a pandemic. *BMC medical research methodology*, 20(1):1–12, 2020.

Richard K. Crump, V. Joseph Hotz, Guido W. Imbens, and Oscar A. Mitnik. Dealing with limited overlap in estimation of average treatment effects. *Biometrika*, 96(1): 187–199, 2009.

Yifan Cui, Michael R Kosorok, Erik Sverdrup, Stefan Wager, and Ruoqing Zhu. Estimating heterogeneous treatment effects with right-censored data via causal survival forests. *arXiv preprint arXiv:2001.09887*, 2020.

Noa Dagan, Noam Barda, Eldad Kepten, Oren Miron, Shay Perchik, Mark A Katz, Miguel A Hernán, Marc Lipsitch, Ben Reis, and Ran D Balicer. Bnt162b2 mrna covid-19 vaccine in a nationwide mass vaccination setting. *New England Journal of Medicine*, 384(15):1412–1423, 2021.

Ralph B. D'Agostino, Jr and Donald B. Rubin. Estimating and using propensity scores with partially missing data. *Journal of the American Statistical Association*, 95(451):749–759, 2000. doi: 10.2307/2669455.

Ralph B. D'Agostino, Jr, Wei Lang, Michael Walkup, Timothy Morgan, and Andrew Karter. Examining the impact of missing data on propensity score estimation in determining the effectiveness of self-monitoring of blood glucose (SMBG). *Health Services and Outcomes Research Methodology*, 2(3-4):291–315, 2001. doi: 10.1023/A:102037541.

Issa J. Dahabreh and Miguel A. Hernán. Extending inferences from a randomized trial to a target population. *European Journal of Epidemiology*, 34(8):719–722, 2019.

Issa J. Dahabreh, Sebastien J. P. Haneuse, James M. Robins, Sarah E. Robertson, Ashley L. Buchanan, Elizabeth A. Stuart, and Miguel A. Hernán. Study designs for extending causal inferences from a randomized trial to a target population. *arXiv preprint arXiv:1905.07764*, 2019a.

Issa J. Dahabreh, Sarah E. Robertson, and Miguel A. Hernán. On the relation between g-formula and inverse probability weighting estimators for generalizing trial results. *Epidemiology*, 30(6):807–812, 2019b.

Issa J. Dahabreh, Sarah E. Robertson, Eric J. Tchetgen Tchetgen, Elizabeth A. Stuart, and Miguel A. Hernán. Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals. *Biometrics*, 75:685–694, 2019c.

Issa J. Dahabreh, James M. Robins, and Miguel A. Hernán. Benchmarking observational methods by comparing randomized trials and their emulations. *Epidemiology*, 31(5):614–619, 2020.

Norman Dalkey and Olaf Helmer. An experimental application of the delphi method to the use of experts. *Management science*, 9(3):458–467, 1963.

Alexander D'Amour. On multi-cause approaches to causal inference with unobserved confounding: Two cautionary failure cases and a promising alternative. In *Proceedings of Machine Learning Research*, volume 89 of *Proceedings of Machine Learning Research*, pages 3478–3486. PMLR, 16–18 Apr 2019. URL http://proceedings.mlr.press/v89/d-amour19a.html.

Huw Talfryn Oakley Davies, Iain Kinloch Crombie, and Manouche Tavakoli. When can odds ratios mislead? *BMJ*, 316(7136):989–991, 1998.

Philip Dawid, Macartan Humphreys, and Monica Musio. Bounding causes of effects with mediators. Technical Report 1907.00399, arXiv, 2019.

Angus Deaton and Nancy Cartwright. Understanding and misunderstanding randomized controlled trials. *Social Science & Medicine*, 210:2–21, 2018.

Angus Deaton, Shoumitro Chatterjee Case, Nicolas Côté, Jean Drèze, William Easterly, Reetika Khera, Lant Pritchett, and C Rammanohar Reddy. Randomization in the tropics revisited: a theme and eleven variations. *Randomized controlled trials in the field of development: A critical perspective. Oxford University Press. Forthcoming*, 2019.

Irina Degtiar and Sherri Rose. A review of generalizability and transportability. *arXiv preprint arXiv:2102.11904*, 2021.

Bernard Delyon, Marc Lavielle, Eric Moulines, et al. Convergence of a stochastic approximation version of the em algorithm. *The Annals of Statistics*, 27(1):94–128, 1999.

Policarpo C. deMattos, Daniel M. Miller, and Eui H. Park. Decision making in trauma centers from the standpoint of complex adaptive systems. *Management Decision*, 50(9):1549–1569, 2012.

Arthur P. Dempster, Nan M. Laird, and Donald B. Rubin. Maximum likelihood from incomplete data via the em algorithm. *Journal of the Royal Statistical Society: Series B (Methodological)*, 39(1):1–22, 1977. doi: 10.1111/j.2517-6161.1977.tb01600.x.

Yashbir Dewan, Edward Komolafe, Jorge Mejìa-Mantilla, Pablo Perel, Ian Roberts, and Haleema Shakur-Still. CRASH-3: Tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. *Trials*, 13:87, 06 2012. doi: 10.1186/1745-6215-13-87.

Vanessa Didelez, Svend Kreiner, and Niels Keiding. Graphical Models for Inference Under Outcome-Dependent Sampling. *Statistical Science*, 25(3):368 – 387, 2010.

Peng Ding and Fan Li. Causal inference: A missing data perspective. *Statistical Science*, 33(2):214–237, 2018. doi: 10.1214/18-STS645.

Dennis O. Dixon and Richard Simon. Bayesian subset analysis. *Biometrics*, pages 871–881, 1991.

Richard Doll and A Bradford Hill. Smoking and carcinoma of the lung. *British medical journal*, 2(4682):739, 1950.

Lin Dong, Shu Yang, Xiaofei Wang, Donglin Zeng, and Jianwen Cai. Integrative analysis of randomized clinical trials with real world evidence studies. *arXiv preprint arXiv:2003.01242*, 2020.

Vincent Dorie, Masataka Harada, Nicole Bohme Carnegie, and Jennifer Hill. A flexible, interpretable framework for assessing sensitivity to unmeasured confounding. *Statistics in medicine*, 35(20):3453–3470, 2016.

Vincent Dorie, Jennifer Hill, Uri Shalit, Marc Scott, Dan Cervone, et al. Automated versus do-it-yourself methods for causal inference: Lessons learned from a data analysis competition. *Statistical Science*, 34(1):43–68, 2019.

Nikolay Doudchenko and Guido W. Imbens. Balancing, regression, difference-in-differences and synthetic control methods: A synthesis. Technical report, National Bureau of Economic Research, 2016.

Didier Dreyfuss. Faut-il continuer à faire des études randomisées? *Revue des maladies respiratoires*, 22(3):381–385, 2005. doi: 10.1016/S0761-8425(05)85563-9.

Dheeru Dua and Casey Graff. UCI machine learning repository, 2019. URL http://archive.ics.uci.edu/ml.

Esther Duflo, Rema Hanna, and Stephen P Ryan. Incentives work: Getting teachers to come to school. *American Economic Review*, 102(4):1241–78, 2012.

Bradley Efron. Prediction, estimation, and attribution. *International Statistical Review*, 88:S28–S59, 2020.

Bradley Efron and Robert Tibshirani. *An introduction to the bootstrap*. CRC press, 1994.

Craig K. Enders. *Applied missing data analysis*. Guilford press, 2010.

FDA. Framework for fda's real-world evidence program. December 2018.

Ronald A. Fisher. Design of experiments. *British Medical Journal*, 1(3923):554, 1936.

Brian R. Flay. Efficacy and effectiveness trials (and other phases of research) in the development of health promotion programs. *Preventive medicine*, 15(5):451–474, 1986.

Bernhard K. Flury and Hans Riedwyl. Standard distance in univariate and multivariate analysis. *The American Statistician*, 40(3):249–251, 1986.

David B. Fogel. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. *Contemporary clinical trials communications*, 11:156–164, 2018.

Alexander M. Franks, Edoardo M. Airoldi, and Donald B. Rubin. Non-standard conditionally specified models for non-ignorable missing data. *arXiv preprint arXiv:1603.06045*, 2016.

Alexander M. Franks, Alexander D'Amour, and Avi Feller. Flexible sensitivity analysis for observational studies without observable implications. *Journal of the American Statistical Association*, pages 1–33, 2019. doi: 10.1080/01621459.2019.1604369.

Thomas Frieden. Evidence for health decision making - beyond randomized, controlled trials. *New England Journal of Medicine*, 377:465–475, 08 2017. doi: 10.1056/NEJMra1614394.

Benjamin Frot, Preetam Nandy, and Marloes H Maathuis. Robust causal structure learning with some hidden variables. *arXiv preprint arXiv:1708.01151*, 2017.

Michele J. Funk, D. Westreich, C. Wiesen, T. Stürmer, M. A. Brookhart, and M. Davidian. Doubly robust estimation of causal effects. *American Journal of Epidemiology*, 173(7):761–767, 2011. doi: 10.1093/aje/kwq439.

Tobias Gauss, François-Xavier Ageron, Marie-Laure Devaud, Guillaume Debaty, Stéphane Travers, Delphine Garrigue, Mathieu Raux, Anatole Harrois, Pierre Bouzat, French Trauma Research Initiative, et al. Association of prehospital time to in-hospital trauma mortality in a physician-staffed emergency medicine system. *JAMA surgery*, 154(12):1117–1124, 2019.

Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Line Meddeb, Morgane Mailhe, Barbara Doudier, Johan Courjon, Valérie Giordanengo, Vera Esteves Vieira, Hervé Tissot Dupont, et al. Hydroxychloroquine and azithromycin as a treatment of covid-19: results of an open-label non-randomized clinical trial. *International journal of antimicrobial agents*, 56(1):105949, 2020a.

Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Line Meddeb, Jacques Sevestre, Morgane Mailhe, Barbara Doudier, Camille Aubry, Sophie Amrane, Piseth Seng, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 covid-19 patients with at least a six-day follow up: a pilot observational study. *Travel medicine and infectious disease*, 34:101663, 2020b.

Thomas Geeraerts, Lionel Velly, Lamine Abdennour, Karim Asehnoune, Gérard Audibert, Pierre Bouzat, Nicolas Bruder, Romain Carrillon, Vincent Cottenceau, François Cotton, et al. Management of severe traumatic brain injury (first 24 hours). *Anaesthesia Critical Care & Pain Medicine*, 37(2):171–186, 2018. doi: 10.1016/j.accpm.2017.12.001.

Joshua Geleris, Yifei Sun, Jonathan Platt, Jason Zucker, Matthew Baldwin, George Hripcsak, Angelena Labella, Daniel K Manson, Christine Kubin, R Graham Barr, et al. Observational study of hydroxychloroquine in hospitalized patients with covid-19. *New England Journal of Medicine*, 382(25):2411–2418, 2020.

Andrew Gelman and Jennifer Hill L. Opening windows to the black box. *Journal of Statistical Software*, 40, 2011.

Sara Geneletti, Sylvia Richardson, and Nicky Best. Adjusting for selection bias in retrospective, case–control studies. *Biostatistics*, 10(1):17–31, 05 2008.

M. Maria Glymour and Rita Hamad. Causal thinking as a critical tool for eliminating social inequalities in health, 2018.

Lovedeep Gondara and Ke Wang. MIDA: Multiple imputation using denoising autoencoders. In D. Phung, V. Tseng, G. Webb, B. Ho, M. Ganji, and L. Rashidi, editors, *Proceedings of the 22nd Pacific-Asia Conference on Knowledge Discovery and Data Mining (PAKDD 2018)*, Lecture Notes in Computer Science, pages 260–272. Springer International Publishing, 2018. ISBN 3319930404. doi: 10.1007/978-3-319-93040-4_21. URL https://arxiv.org/abs/1705.02737.

Brett R. Gordon, Florian Zettelmeyer, Neha Bhargava, and Dan Chapsky. A Comparison of Approaches to Advertising Measurement: Evidence from Big Field Experiments at Facebook. *Marketing Science*, 38(2):193–225, March 2019. doi: 10.1287/mksc.2018.1135. URL https://ideas.repec.org/a/inm/ormksc/v38y2019i2p193-225.html.

Parag Goyal, Justin J. Choi, Laura C. Pinheiro, Edward J. Schenck, Ruijun Chen, Assem Jabri, Michael J. Satlin, Thomas R. Campion Jr, Musarrat Nahid, Joanna B. Ringel, et al. Clinical characteristics of covid-19 in new york city. *New England Journal of Medicine*, 382(24):2372–2374, 04 2020.

Lawrence Green and Russell Glasgow. Evaluating the relevance, generalization, and applicability of research issues in external validation and translation methodology. *Evaluation & the health professions*, 29:126–53, 04 2006. doi: 10.1177/0163278705284445.

Justin Grimmer, Dean Knox, and Brandon M. Stewart. Naïve regression requires weaker assumptions than factor models to adjust for multiple cause confounding. 2020.

Wei-jie Guan, Zheng-yi Ni, Yu Hu, Wen-hua Liang, Chun-quan Ou, Jian-xing He, Lei Liu, Hong Shan, Chun-liang Lei, David SC Hui, et al. Clinical characteristics of coronavirus disease 2019 in china. *New England journal of medicine*, 382(18): 1708–1720, 2020.

F. Richard Guo and Emilija Perković. Efficient least squares for estimating total effects under linearity and causal sufficiency. *arXiv preprint arXiv:2008.03481*, 2020.

Ruocheng Guo, Lu Cheng, Jundong Li, Paul Richard Hahn, and Huan Liu. A survey of learning causality with data: Problems and methods. *arXiv preprint arXiv:1809.09337*, 2019.

Wenshuo Guo, Serena Wang, Peng Ding, Yixin Wang, and Michael I Jordan. Multi-source causal inference using control variates. *arXiv preprint arXiv:2103.16689*, 2021.

Jinyong Hahn. On the role of the propensity score in efficient semiparametric estimation of average treatment effects. *Econometrica*, 66:315–331, 1998.

Paul Richard Hahn, Jared S. Murray, Carlos M. Carvalho, et al. Bayesian regression tree models for causal inference: regularization, confounding, and heterogeneous effects. *Bayesian Analysis*, 2020.

Jens Hainmueller. Entropy balancing for causal effects: A multivariate reweighting method to produce balanced samples in observational studies. *Political Analysis*, 20:25–46, 2012.

Jaroslav Hájek. Comment on "an essay on the logical foundations of survey sampling, part one" by d. basu. *Foundations of Statistical Inference*, page 236, 1971.

Sophie R. Hamada. *Analyse de la prise en charge des patients traumatisés sévères dans le contexte français: processus de triage et processus de soin.* PhD thesis, Université Paris-Saclay, 2019.

Sophie R. Hamada, Tobias Gauss, François-Xavier Duchateau, Jennifer Truchot, Anatole Harrois, Mathieu Raux, Jacques Duranteau, Jean Mantz, and Catherine Paugam-Burtz. Evaluation of the performance of french physician-staffed emergency medical service in the triage of major trauma patients. *Journal of Trauma and Acute Care Surgery*, 76(6):1476–1483, 2014.

Sophie R. Hamada, Tobias Gauss, Jakob Pann, Martin Dünser, Marc Leone, and Jacques Duranteau. European trauma guideline compliance assessment: the etrauss study. *Critical Care*, 19(1):423, 2015.

Sophie R. Hamada, Anne Rosa, Tobias Gauss, Jean-Philippe Desclefs, Mathieu Raux, Anatole Harrois, Arnaud Follin, Fabrice Cook, Mathieu Boutonnet, Arie Attias, et al. Development and validation of a pre-hospital “red flag” alert for activation of intra-hospital haemorrhage control response in blunt trauma. *Critical Care*, 22 (1):1–12, 2018.

Sophie R. Hamada, Nathalie Delhaye, Samuel Degoul, Tobias Gauss, Mathieu Raux, Marie-Laure Devaud, Johan Amani, Fabrice Cook, Camille Hego, Jacques Duranteau, et al. Direct transport vs secondary transfer to level i trauma centers in a french exclusive trauma system: Impact on mortality and determinants of triage on road-traffic victims. *PloS one*, 14(11):e0223809, 2019.

Thierry Hamon and Natalia Grabar. Linguistic approach for identification of medication names and related information in clinical narratives. *Journal of the American Medical Informatics Association*, 17(5):549–554, 2010.

Michael O. Harhay, Jason Wagner, Sarah J. Ratcliffe, Rachel S. Bronheim, Anand Gopal, Sydney Green, Elizabeth Cooney, Mark E. Mikkelsen, Meeta Prasad Kerlin, Dylan S. Small, et al. Outcomes and statistical power in adult critical care randomized trials. *American journal of respiratory and critical care medicine*, 189 (12):1469–1478, 2014.

Trevor Hastie and Rahul Mazumder. *softImpute: Matrix Completion via Iterative Soft-Thresholded SVD*, 2015. URL https://CRAN.R-project.org/package=softImpute. R package version 1.4.

Trevor Hastie, Robert Tibshirani, and Jerome Friedman. *The Elements of Statistical Learning*, volume 2. Springer, 2009.

Trevor Hastie, Rahul Mazumder, Jason D. Lee, and Reza Zadeh. Matrix completion and low-rank SVD via fast alternating least squares. *The Journal of Machine Learning Research*, 16(1):3367–3402, 2015.

Simon I. Hay, Amanuel Alemu Abajobir, Kalkidan Hassen Abate, Cristiana Abbafati, Kaja M. Abbas, Foad Abd-Allah, Rizwan Suliankatchi Abdulkader, Abdishakur M. Abdulle, Teshome Abuka Abebo, Semaw Ferede Abera, et al. Global, regional, and national disability-adjusted life-years (dalys) for 333 diseases and injuries and healthy life expectancy (hale) for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. *The Lancet*, 390 (10100):1260–1344, 2017.

Zhe He, Xiang Tang, Xi Yang, Yi Guo, Thomas George, Neil Charness, Kelsa Hem, William Hogan, and Jiang Bian. Clinical trial generalizability assessment in the big data era: A review. *Clinical and Translational Science*, 13, 02 2020. doi: 10.1111/cts.12764.

Steven G. Heeringa, Brady T. West, and Patricia A. Berglund. *Applied survey data analysis*. chapman and hall/CRC, 2010.

Christina Heinze-Deml, Jonas Peters, and Nicolai Meinshausen. Invariant causal prediction for nonlinear models. *Journal of Causal Inference*, 6(2), 2018.

Miguel A. Hernán. The c-word: Scientific euphemisms do not improve causal inference from observational data. *American Journal of Public Health*, 108(5): 616–619, 2018. doi: 10.2105/AJPH.2018.304337. URL https://doi.org/10.2105/AJPH.2018.304337. PMID: 29565659.

Miguel A. Hernán and James M. Robins. Instruments for causal inference: an epidemiologist's dream? *Epidemiology*, 17:360–372, 2006.

Miguel A Hernán and James M. Robins. Using big data to emulate a target trial when a randomized trial is not available. *American journal of epidemiology*, 183 (8):758–764, 2016.

Miguel A. Hernán and James M. Robins. *Causal Inference: What If*. Boca Raton: Chapman & Hall/CRC, 2020.

Miguel A. Hernán and Tyler J. VanderWeele. Compound treatments and transportability of causal inference. *Epidemiology*, 22:368–77, 2011.

Miguel A. Hernán, Stephen R Cole, Joseph Margolick, Mardge Cohen, and James M. Robins. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. *Pharmacoepidemiology and Drug Safety*, 14:477–491, 2005.

Miguel A. Hernán, Brian Sauer, Sonia Hernández-Diaz, Robert Platt, and Ian Shrier. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *Journal of Clinical Epidemiology*, 79, 05 2016. doi: 10.1016/j.jclinepi.2016.04.014.

Nuha Hijazi, Rami Abu Fanne, Rinat Abramovitch, Serge Yarovoi, Muhamed Higazi, Suhair Abdeen, Maamon Basheer, Emad Maraga, Douglas B Cines, and Abd Al-Roof Higazi. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. *Blood, The Journal of the American Society of Hematology*, 125(16):2558–2567, 2015.

Jennifer L. Hill. Bayesian nonparametric modeling for causal inference. *Journal of Computational and Graphical Statistics*, 20(1):217–240, 2011.

Jennifer L. Hill, Christopher Weiss, and Fuhua Zhai. Challenges with propensity score strategies in a high-dimensional setting and a potential alternative. *Multivariate Behavioral Research*, 46(3):477–513, 2011.

Paul T. von Hippel. How to impute interactions, squares, and other transformed variables. *Sociological Methodology*, 39(1):265–291, 2009.

Keisuke Hirano and Guido W. Imbens. The propensity score with continuous treatments. *Applied Bayesian modeling and causal inference from incomplete-data perspectives*, 22:73–84, 2004.

Keisuke Hirano, Guido W. Imbens, and Geert Ridder. Efficient estimation of average treatment effects using the estimated propensity score. *Econometrica*, 71:1161–1189, 2003.

Daniel E. Ho, Kosuke Imai, Gary King, and Elizabeth A. Stuart. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. *Political analysis*, 15(3):199–236, 2007.

Brian P. Hobbs, Daniel J. Sargent, and Bradley P. Carlin. Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. *Bayesian Analysis*, 7(3):639 – 674, 2012. doi: 10.1214/12-BA722. URL https://doi.org/10.1214/12-BA722.

Paul W. Holland. Statistics and causal inference. *Journal of the American Statistical Association*, 81(396):945–960, 1986.

James Honaker, Gary King, and Matthew Blackwell. Amelia II: A program for missing data. *Journal of Statistical Software*, 45(7):1–47, 2011. URL http://www.jstatsoft.org/v45/i07/.

Peter Horby, Marion Mafham, Louise Linsell, Jennifer L. Bell, Natalie Staplin, Jonathan R Emberson, Martin Wiselka, Andrew Ustianowski, Einas Elmahi, Benjamin Prudon, et al. Effect of hydroxychloroquine in hospitalized patients with covid-19: Preliminary results from a multi-centre, randomized, controlled trial. *MedRxiv*, 2020.

Daniel G. Horvitz and Donovan J. Thompson. A generalization of sampling without replacement from a finite universe. *Journal of the American statistical Association*, 47(260):663–685, 1952. doi: 10.1080/01621459.1952.10483446.

Chanelle J. Howe, Stephen R. Cole, Bryan Lau, Sonia Napravnik, and Joseph J. Eron Jr. Selection bias due to loss to follow up in cohort studies. *Epidemiology (Cambridge, Mass.)*, 27(1):91, 2016.

Yimin Huang and Marco Valtorta. Pearl's calculus of intervention is complete. In *Proceedings of the Twenty-Second Conference on Uncertainty in Artificial Intelligence*, UAI'06, pages 217–224, Arlington, Virginia, USA, 2006. AUAI Press. ISBN 0974903922.

Paul Hünermund and Elias Bareinboim. Causal inference and data-fusion in econometrics. *arXiv preprint arXiv:1912.09104*, 2019.

Thomas J. Hwang, Daniel Carpenter, Julie C. Lauffenburger, Bo Wang, Jessica M. Franklin, and Aaron S. Kesselheim. Failure of investigational drugs in late-stage clinical development and publication of trial results. *JAMA internal medicine*, 176 (12):1826–1833, 2016.

Stefano M. Iacus, Gary King, and Giuseppe Porro. Causal inference without balance checking: Coarsened exact matching. *Political Analysis*, 20(1):1–24, 2012. doi: 10.1093/pan/mpr013.

Andrea Ichino, Tommaso Nannicini, and Fabrizia Mealli. From temporary help jobs to permanent employment: What can we learn from matching estimators and their sensitivity? 23:305–327, 2008. doi: 10.1002/jae.998.

Ross Ihaka. R: Past and future history. *Computing Science and Statistics*, 392396, 1998.

Kosuke Imai and Zhichao Jiang. Comment: The challenges of multiple causes. *Journal of the American Statistical Association*, 114(528):1605–1610, 2019.

Kosuke Imai and Marc Ratkovic. Estimating treatment effect heterogeneity in randomized program evaluation. *The Annals of Applied Statistics*, 7(1):443–470, 2013.

Kosuke Imai, Luke Keele, and Teppei Yamamoto. Identification, inference and sensitivity analysis for causal mediation effects. *Statistical science*, pages 51–71, 2010.

Guido Imbens. Sensitivity to exogeneity assumptions in program evaluation. 2003.

Guido W. Imbens. The role of the propensity score in estimating dose-response functions. *Biometrika*, 87(3):706–710, 2000. doi: 10.1093/biomet/87.3.706.

Guido W. Imbens. Nonparametric estimation of average treatment effects under exogeneity: A review. *Review of Economics and statistics*, 86(1):4–29, 2004.

Guido W. Imbens. Instrumental variables: an econometrician's perspective. Technical report, National Bureau of Economic Research, 2014.

Guido W. Imbens. Potential outcome and directed acyclic graph approaches to causality: Relevance for empirical practice in economics. Technical report, National Bureau of Economic Research, 2019.

Guido W. Imbens and Donald B. Rubin. *Causal Inference in Statistics, Social, and Biomedical Sciences*. Cambridge University Press, 2015.

Spencer L. James, Alice Theadom, Richard G. Ellenbogen, Marlena S. Bannick, Wcliff Montjoy-Venning, Lydia R. Lucchesi, Nooshin Abbasi, Rizwan Abdulkader, Haftom Niguse Abraha, Jose C. Adsuar, et al. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the global burden of disease study 2016. *The Lancet Neurology*, 18(1): 56–87, 2019.

Wei Jiang. *misaem: Logistic Regression with Missing Covariates*, 2019. URL https://CRAN.R-project.org/package=misaem. R package version 0.9.1.

Wei Jiang, Julie Josse, Marc Lavielle, and TraumaBase Group. Logistic regression with missing covariates—parameter estimation, model selection and prediction within a joint-modeling framework. *Computational Statistics & Data Analysis*, 145:106907, 2020.

Fredrik D. Johansson, Uri Shalit, and David Sontag. Learning representations for counterfactual inference. In *International conference on machine learning*, pages 3020–3029, 2016.

Jeremy Jones and Duncan Hunter. Consensus methods for medical and health services research. *BMJ: British Medical Journal*, 311(7001):376, 1995.

Kevin P. Josey, Seth A. Berkowitz, Debashis Ghosh, and Sridharan Raghavan. Transporting experimental results with entropy balancing. *Statistics in Medicine*, 40(19):4310–4326, May 2021. ISSN 1097-0258. doi: 10.1002/sim.9031. URL http://dx.doi.org/10.1002/sim.9031.

Julie Josse and Jerome P. Reiter. Introduction to the special section on missing data. *Statistical Science*, 33(2):139–141, 2018. doi: 10.1214/18-STS332IN.

Julie Josse, François Husson, Marie Chavent, and Benoit Liquet. Multiple correspondence analysis with missing values. In *DAGM, GfKI conference*, 2011a.

Julie Josse, Jérôme Pagès, and François Husson. Multiple imputation in principal component analysis. *Advances in Data Analysis and Classification*, 5(3):231–246, 2011b. doi: 10.1007/s11634-011-0086-7.

Julie Josse, François Husson, et al. missMDA: a package for handling missing values in multivariate data analysis. *Journal of Statistical Software*, 70(1):1–31, 2016a.

Julie Josse, Sylvain Sardy, and Stefan Wager. denoiser: A package for low rank matrix estimation. *arXiv preprint arXiv:1602.01206*, 2016b.

Julie Josse, Nicolas Prost, Erwan Scornet, and Gaël Varoquaux. On the consistency of supervised learning with missing values. *arXiv preprint*, 2019.

Charles M. Judd and David A Kenny. Process analysis: Estimating mediation in treatment evaluations. *Evaluation review*, 5(5):602–619, 1981.

Yonghan Jung, Jin Tian, and Elias Bareinboim. Learning causal effects via weighted empirical risk minimization. In H. Larochelle, M. Ranzato, R. Hadsell, M. F. Balcan, and H. Lin, editors, *Advances in Neural Information Processing Systems*, volume 33, pages 12697–12709. Curran Associates, Inc., 2020a. URL https://proceedings.neurips.cc/paper/2020/file/95a6fc111fa11c3ab209a0ed1b9abeb6-Paper.pdf.

Yonghan Jung, Jin Tian, and Elias Bareinboim. Estimating causal effects using weighting-based estimators. In *Proceedings of the AAAI Conference on Artificial Intelligence*, volume 34, pages 10186–10193, 2020b.

Nathan Kallus, Xiaojie Mao, and Madeleine Udell. Causal inference with noisy and missing covariates via matrix factorization. In *Advances in Neural Information Processing Systems*, pages 6921–6932, 2018a.

Nathan Kallus, Aahlad Manas Puli, and Uri Shalit. Removing hidden confounding by experimental grounding. In *Advances in neural information processing systems*, pages 10888–10897, 2018b.

Joseph D.Y. Kang, Joseph L. Schafer, et al. Demystifying double robustness: A comparison of alternative strategies for estimating a population mean from incomplete data. *Statistical science*, 22(4):523–539, 2007. doi: 10.1214/07-STS227.

Edward L. Kaplan and Paul Meier. Nonparametric estimation from incomplete observations. *Journal of the American statistical association*, 53(282):457–481, 1958.

Juha Karvanen, Santtu Tikka, and Antti Hyttinen. Do-search: A tool for causal inference and study design with multiple data sources. *Epidemiology*, 32(1):111–119, 2020.

Niels Keiding and Thomas A. Louis. Perils and potentials of self-selected entry to epidemiological studies and surveys. *J. R. Statist. Soc. A*, 179:319–376, 2016.

Michael G. Kenward. The handling of missing data in clinical trials. *Clinical Investigation*, 3(3):241–250, 2013.

Holger L. Kern, Elizabeth A. Stuart, Jennifer L. Hill, and Donald P Green. Assessing methods for generalizing experimental impact estimates to target populations. *Journal of research on educational effectiveness*, 9(1):103–127, 2016.

Ilyes Khemakhem, Diederik P. Kingma, Ricardo Monti, and Aapo Hyvarinen. Variational autoencoders and nonlinear ica: A unifying framework. In *International Conference on Artificial Intelligence and Statistics*, pages 2207–2217, 2020.

Jae Kwang Kim and David Haziza. Doubly robust inference with missing data in survey sampling. In *Statistica Sinica*, volume 24, pages 375–394, 2013.

Jae Kwang Kim and Jun Shao. *Statistical methods for handling incomplete Data*. CRC Press, 2013.

Jerome Kim, Florian Marks, and John Clemens. Looking beyond covid-19 vaccine phase 3 trials. *Nature Medicine*, 27, 01 2021. doi: 10.1038/s41591-021-01230-y.

Diederik P. Kingma and Max Welling. Auto-encoding variational bayes. In *International Conference on Learning Representations*, 2014a.

Diederik P. Kingma and Max Welling. Stochastic gradient vb and the variational auto-encoder. In *Second International Conference on Learning Representations, ICLR*, 2014b.

Toru Kitagawa and Aleksey Tetenov. Who should be treated? empirical welfare maximization methods for treatment choice. *Econometrica*, 86(2):591–616, 2018.

John P. Klein and Melvin L. Moeschberger. *Survival analysis: techniques for censored and truncated data*, volume 1230. Springer, 2003.

Michael C Knaus, Michael Lechner, and Anthony Strittmatter. Machine learning estimation of heterogeneous causal effects: Empirical monte carlo evidence. *The Econometrics Journal*, 24(1):134–161, 2021.

Dehan Kong, Shu Yang, and Linbo Wang. Multi-cause causal inference with unmeasured confounding and binary outcome. *Biometrika*, (in press), 2021.

Alexander Kowarik and Matthias Templ. Imputation with the R package VIM. *Journal of Statistical Software*, 74(7):1–16, 2016. doi: 10.18637/jss.v074.i07.

Sören R. Künzel, Simon J.S. Walter, and Jasjeet S. Sekhon. Causaltoolbox—estimator stability for heterogeneous treatment effects. *arXiv preprint arXiv:1811.02833*, 2018.

Sören R Künzel, Jasjeet S Sekhon, Peter J Bickel, and Bin Yu. Metalearners for estimating heterogeneous treatment effects using machine learning. *Proceedings of the national academy of sciences*, 116(10):4156–4165, 2019.

Manabu Kuroki and Judea Pearl. Measurement bias and effect restoration in causal inference. *Biometrika*, 101(2):423–437, 2014.

Tor Lattimore and Csaba Szepesvári. *Bandit algorithms*. Cambridge University Press, 2020.

S. L. Lauritzen and T. S. Richardson. Discussion of mccullagh: Sampling bias and logistic models. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 70(4):671, 2008.

Sébastien Lê, Julie Josse, and François Husson. FactoMineR: A package for multivariate analysis. *Journal of Statistical Software*, 25(1):1–18, 2008. doi: 10.18637/jss.v025.i01.

Marine Le Morvan, Julie Josse, Thomas Moreau, Erwan Scornet, and Gaël Varoquaux. Neumiss networks: differential programming for supervised learning with missing values. In *Advances in Neural Information Processing Systems 33*, 2020a.

Marine Le Morvan, Nicolas Prost, Julie Josse, Erwan Scornet, and Gaël Varoquaux. Linear predictor on linearly-generated data with missing values: non consistency and solutions. In *International Conference on Artificial Intelligence and Statistics*, pages 3165–3174. PMLR, 2020b.

David J. Lederer, Scott C. Bell, Richard D. Branson, James D. Chalmers, Rachel Marshall, David M. Maslove, David E. Ost, Naresh M. Punjabi, Michael Schatz, Alan R. Smyth, et al. Control of confounding and reporting of results in causal inference studies. guidance for authors from editors of respiratory, sleep, and critical care journals. *Annals of the American Thoracic Society*, 16(1):22–28, 2019.

Sanghack Lee, Juan Correa, and Elias Bareinboim. General transportability - synthesizing observations and experiments from heterogeneous domains. *Proceedings of the AAAI Conference on Artificial Intelligence*, 34(06):10210–10217, 2020. doi: 10.1609/aaai.v34i06.6582. URL https://ojs.aaai.org/index.php/AAAI/article/view/6582.

Catherine R. Lesko, Stephen R. Cole, H. Irene Hall, Daniel Westreich, William C. Miller, Joseph J. Eron, Jianmin Li, Michael J. Mugavero, and for the CNICS Investigators. The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11. *International Journal of Epidemiology*, 45(1):140–150, 01 2016. ISSN 0300-5771. doi: 10.1093/ije/dyv352. URL https://doi.org/10.1093/ije/dyv352.

Catherine R. Lesko, Ashley L. Buchanan, Daniel Westreich, Jessie K. Edwards, Michael G. Hudgens, and Stephen R. Cole. Generalizing study results: a potential outcomes perspective. *Epidemiology*, 28:553–561, 2017.

Clémence Leyrat, Shaun R. Seaman, Ian R. White, Ian Douglas, Liam Smeeth, Joseph Kim, Matthieu Resche-Rigon, James R. Carpenter, and Elizabeth J. Williamson. Propensity score analysis with partially observed covariates: How should multiple

imputation be used? *Statistical methods in medical research*, 28(1):3–19, 2019. doi: 10.1177/0962280217713032.

Fan Li, Kari Lock Morgan, and Alan M. Zaslavsky. Balancing covariates via propensity score weighting. *Journal of the American Statistical Association*, 113 (521):390–400, 2018. doi: 10.1080/01621459.2016.1260466.

Fan Li, Ashley L. Buchanan, and Stephen R. Cole. Generalizing trial evidence to target populations in non-nested designs: Applications to aids clinical trials, 2021.

Peng Li and Elizabeth A Stuart. Best (but oft-forgotten) practices: missing data methods in randomized controlled nutrition trials. *The American journal of clinical nutrition*, 109(3):504–508, 2019.

Winston Lin et al. Agnostic notes on regression adjustments to experimental data: Reexamining freedman's critique. *Annals of Applied Statistics*, 7(1):295–318, 2013.

James Lind. *A treatise on the scurvy: in three parts. Containing an inquiry into the nature, causes, and cure, of that disease. Together with a critical and chronological view of what has been published on the subject*. S. Crowder, 1772.

Antonio R. Linero and Michael J. Daniels. Bayesian approaches for missing not at random outcome data: The role of identifying restrictions. *Statistical science: a review journal of the Institute of Mathematical Statistics*, 33(2):198, 2018.

Roderick J. A. Little and Donald B. Rubin. *Statistical Analysis with Missing Data*. John Wiley & Sons, 2019. ISBN 0470526798. doi: 10.1002/9781119482260.

Sara Lodi, Andrew Phillips, Jens Lundgren, Roger Logan, Shweta Sharma, Stephen Cole, Abdel Babiker, Matthew Law, Haitao Chu, Dana Byrne, Andrzej Horban, Jonathan Sterne, Kholoud Porter, Caroline Sabin, Dominique Costagliola, Sophie Abgrall, Michael Gill, Giota Touloumi, Antonio Pacheco, and Miguel Hernán. Effect estimates in randomized trials and observational studies: Comparing apples with apples. *American Journal of Epidemiology*, 188, 05 2019. doi: 10.1093/aje/kwz100.

Thomas A. Louis. Finding the observed information matrix when using the em algorithm. *Journal of the Royal Statistical Society. Series B (Methodological)*, 44 (2):226–233, 1982. ISSN 00359246. URL http://www.jstor.org/stable/2345828.

Christos Louizos, Uri Shalit, Joris M Mooij, David Sontag, Richard Zemel, and Max Welling. Causal effect inference with deep latent-variable models. In *Advances in Neural Information Processing Systems*, pages 6446–6456, 2017.

Yi Lu, Daniel O. Scharfstein, Maria M. Brooks, Kevin Quach, and Edward H. Kennedy. Causal inference for comprehensive cohort studies. *arXiv preprint arXiv:1910.03531*, 2019.

Alexander R. Luedtke and Mark J. Van Der Laan. Statistical inference for the mean outcome under a possibly non-unique optimal treatment strategy. *Annals of statistics*, 44(2):713, 2016.

Alexander R. Luedtke, Ivan Diaz, and Mark J. van der Laan. The statistics of sensitivity analyses. 2015.

Jared K. Lunceford and Marie Davidian. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. *Statistics in medicine*, 23(19):2937–2960, 2004. doi: 10.1002/sim.1903.

Andrew IR Maas, Ewout W Steyerberg, and Giuseppe Citerio. Tranexamic acid in traumatic brain injury: systematic review and meta-analysis trumps a large clinical trial?, 2020.

Joseph Magagnoli, Siddharth Narendran, Felipe Pereira, Tammy H Cummings, James W Hardin, S Scott Sutton, and Jayakrishna Ambati. Outcomes of hydroxychloroquine usage in united states veterans hospitalized with covid-19. *Med*, 1(1): 114–127, 2020.

Matthieu Mahévas, Viet-Thi Tran, Mathilde Roumier, Amélie Chabrol, Romain Paule, Constance Guillaud, Elena Fois, Raphael Lepeule, Tali-Anne Szwebel, François-Xavier Lescure, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. *Bmj*, 369, 2020.

Spyros Makridakis, Evangelos Spiliotis, and Vassilios Assimakopoulos. The m4 competition: Results, findings, conclusion and way forward. *International Journal of Forecasting*, 34(4):802–808, 2018.

Fernando Martel Garcia and Leonard Wantchekon. Theory, external validity, and experimental inference: Some conjectures. *The ANNALS of the American Academy of Political and Social Science*, 628(1):132–147, 2010.

Alessandra Mattei and Fabrizia Mealli. Estimating and using propensity score in presence of missing background data: an application to assess the impact of childbearing on wellbeing. *Statistical Methods and Applications*, 18(2):257–273, 2009. doi: 10.1007/s10260-007-0086-0.

Pierre-Alexandre Mattei and Jes Frellsen. MIWAE: Deep generative modelling and imputation of incomplete data sets. In Kamalika Chaudhuri and Ruslan Salakhutdinov, editors, *Proceedings of the 36th International Conference on Machine Learning*, volume 97 of *Proceedings of Machine Learning Research*, pages 4413–4423, Long Beach, California, USA, 09–15 Jun 2019. PMLR.

Imke Mayer, Aude Sportisse, Julie Josse, Nicholas J. Tierney, and Nathalie Vialaneix. R-miss-tastic: a unified platform for missing values methods and workflows. *arXiv preprint arXiv:1908.04822*, 2019.

Imke Mayer, Erik Sverdrup, Tobias Gauss, Jean-Denis Moyer, Stefan Wager, and Julie Josse. Doubly robust treatment effect estimation with missing attributes. *Ann. Appl. Statist.*, 14(3):1409–1431, 2020. ISSN 1932-6157. doi: 10.1214/20-AOAS1356.

Robert L. Medcalf. The traumatic side of fibrinolysis. *Blood, The Journal of the American Society of Hematology*, 125(16):2457–2458, 2015.

Medical Research Council Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. *BMJ*, 2(4582):769–782, 1948. ISSN 0007-1447. doi: 10.1136/bmj.2.4582.769. URL https://www.bmj.com/content/2/4582/769.

Xiao-Li Meng and Donald B. Rubin. Using EM to obtain asymptotic variance-covariance matrices: the SEM algorithm. *Journal of the American Statistical Association*, 86(416):899–909, 1991. ISSN 1537274X. doi: 10.1080/01621459.1991.10475130.

Nicholas J. Mercuro, Christina F. Yen, David J. Shim, Timothy R. Maher, Christopher M. McCoy, Peter J. Zimetbaum, and Howard S. Gold. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (covid-19). *JAMA cardiology*, 5(9):1036–1041, 2020 (cited on 2020-05-26).

Franz H. Messerli. Chocolate consumption, cognitive function, and nobel laureates. *The New England Journal of Medicine*, (367):1562–1564, 2012. doi: 10.1056/NEJMon1211064.

Wang Miao, Zhi Geng, and Eric J. Tchetgen Tchetgen. Identifying causal effects with proxy variables of an unmeasured confounder. *Biometrika*, 105(4):987–993, 2018.

Microsoft Research. EconML: A Python Package for ML-Based Heterogeneous Treatment Effects Estimation. https://github.com/microsoft/EconML, 2019. Version 0.x.

Olli S. Miettinen. *Theoretical epidemiology: principles of occurrence research*. John Wiley & Sons, New York, 1985. ISBN 0827343132.

Takahisa Mikami, Hirotaka Miyashita, Takayuki Yamada, Matthew Harrington, Daniel Steinberg, Andrew Dunn, and Evan Siau. Risk factors for mortality in patients with covid-19 in new york city. *Journal of general internal medicine*, 36 (1):17–26, 2021.

Matthieu Million, Jean-Christophe Lagier, Philippe Gautret, Philippe Colson, Pierre-Edouard Fournier, Sophie Amrane, Marie Hocquart, Morgane Mailhe, Vera Esteves-Vieira, Barbara Doudier, et al. Early treatment of covid-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in marseille, france. *Travel medicine and infectious disease*, 35:101738, 2020.

Robin Mitra and Jerome P. Reiter. Estimating propensity scores with missing covariate data using general location mixture models. *Statistics in Medicine*, 30: 627–641, 2011.

Geert Molenberghs, Garrett Fitzmaurice, Michael G. Kenward, Anastasios Tsiatis, and Geert Verbeke. *Handbook of missing data methodology*. CRC Press, 2014.

Steffen Moritz and Thomas Bartz-Beielstein. imputeTS: Time Series Missing Value Imputation in R. *The R Journal*, 9(1):207–218, 2017. doi: 10.32614/RJ-2017-009.

Tim P Morris, Ian R White, and Michael J Crowther. Using simulation studies to evaluate statistical methods. *Statistics in medicine*, 38(11):2074–2102, 2019.

Travis B. Murdoch and Allan S. Detsky. The inevitable application of big data to health care. *Jama*, 309(13):1351–1352, 2013.

Susan A. Murphy. Optimal dynamic treatment regimes. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 65(2):331–355, 2003.

Susan A. Murphy, Mark J. van der Laan, and James M. Robins. Marginal mean models for dynamic regimes. *Journal of the American Statistical Association*, 96: 1410–1423, 2001.

Jared S. Murray and Jerome P. Reiter. Multiple imputation of missing categorical and continuous values via bayesian mixture models with local dependence, 2015. URL http://arxiv.org/abs/1410.0438.

Boris Muzellec, Julie Josse, Claire Boyer, and Marco Cuturi. Missing data imputation using optimal transport. In *International Conference on Machine Learning*, pages 7130–7140. PMLR, 2020.

National Research Council. *The Prevention and Treatment of Missing Data in Clinical Trials*. Number 14. 2010.

Ushma S. Neill et al. All data are not created equal. *The Journal of clinical investigation*, 119(3):424–424, 2009.

Trang Nguyen, Benjamin Ackerman, Ian Schmid, Stephen R. Cole, and Elizabeth A. Stuart. Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details. 13: e0208795, a. doi: 10.1371/journal.pone.0208795.

Trang Quynh Nguyen, Cyrus Ebnesajjad, Stephen R. Cole, Elizabeth A. Stuart, et al. Sensitivity analysis for an unobserved moderator in rct-to-target-population generalization of treatment effects. 11(1):225–247, b.

Xinkun Nie and Stefan Wager. Quasi-oracle estimation of heterogeneous treatment effects. *arXiv preprint arXiv:1712.04912*, 2017.

Michael O'Kelly and Bohdana Ratitch. *Clinical trials with missing data: a guide for practitioners*. John Wiley & Sons, 2014.

Manfred Olschewski and H Scheurlen. Comprehensive cohort study: an alternative to randomized consent design in a breast preservation trial. *Methods of Information in Medicine*, 24(3):131–134, 1985.

Colm O'Muircheartaigh and Larry V Hedges. Generalizing from unrepresentative experiments: a stratified propensity score approach. *J. R. Statist. Soc. C*, 63: 195–210, 2014.

Brice Maxime Hugues Ozenne, Thomas Harder Scheike, Laila Stærk, and Thomas Alexander Gerds. On the estimation of average treatment effects with right-censored time to event outcome and competing risks. *Biometrical Journal*, 62(3):751–763, 2020.

Jay JH Park, Robin Mogg, Gerald E Smith, Etheldreda Nakimuli-Mpungu, Fyezah Jehan, Craig R Rayner, Jeanine Condo, Eric H Decloedt, Jean B Nachega, Gilmar Reis, et al. How covid-19 has fundamentally changed clinical research in global health. *The Lancet Global Health*, 9(5):e711–e720, 2021.

Judea Pearl. *Reverend Bayes on inference engines: A distributed hierarchical approach*. Cognitive Systems Laboratory, School of Engineering and Applied Science, 1982.

Judea Pearl. Bayesian analysis in expert systems – comment: graphical models, causality and intervention. *Statistical Science*, 8(3):266–269, 1993.

Judea Pearl. Causal diagrams for empirical research. *Biometrika*, 82(4):669–688, 1995.

Judea Pearl. Direct and indirect effects. In *Proceedings of the Seventeenth conference on Uncertainty in artificial intelligence*, pages 411–420, 2001.

Judea Pearl. Letter to the editor: Remarks on the method of propensity score. *Statistics in Medicine*, 28:1420–1423, 2009a.

Judea Pearl. Causal inference in statistics: An overview. *Statistics Surveys*, 3:96 – 146, 2009b. doi: 10.1214/09-SS057. URL https://doi.org/10.1214/09-SS057.

Judea Pearl. *Causality*. Cambridge: Cambridge University Press, 2 edition, 2009c.

Judea Pearl. Generalizing experimental findings. *Journal of Causal Inference*, 3(2): 259–266, 2015. doi: doi:10.1515/jci-2015-0025. URL https://doi.org/10.1515/jci-2015-0025.

Judea Pearl and Elias Bareinboim. Transportability of causal and statistical relations: A formal approach. In *Data Mining Workshops (ICDMW), 2011 IEEE 11th International Conference on*, pages 540–547. IEEE, 2011.

Judea Pearl and Elias Bareinboim. External Validity: From Do-Calculus to Transportability Across Populations. *Statistical Science*, 29(4):579 – 595, 2014. doi: 10.1214/14-STS486. URL https://doi.org/10.1214/14-STS486.

Judea Pearl and Dana Mackenzie. *The book of why: the new science of cause and effect*. Basic books, 2018.

Judea Pearl and Thomas S Verma. A statistical semantics for causation. *Statistics and Computing*, 2(2):91–95, 1992.

Fabian Pedregosa, Gaël Varoquaux, Alexandre Gramfort, Vincent Michel, Bertrand Thirion, Olivier Grisel, Mathieu Blondel, Peter Prettenhofer, Ron Weiss, Vincent Dubourg, et al. Scikit-learn: Machine learning in python. *the Journal of machine Learning research*, 12:2825–2830, 2011.

Jonas Peters, Peter Bühlmann, and Nicolai Meinshausen. Causal inference by using invariant prediction: identification and confidence intervals. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 78(5):947–1012, 2016.

Jonas Peters, Dominik Janzing, and Bernhard Schölkopf. *Elements of causal inference: foundations and learning algorithms*. MIT press, 2017.

Maya L. Petersen, Sandra E. Sinisi, and Mark J. van der Laan. Estimation of direct causal effects. *Epidemiology*, pages 276–284, 2006.

Alexander Peysakhovich and Akos Lada. Combining observational and experimental data to find heterogeneous treatment effects. *arXiv preprint arXiv:1611.02385*, 2016.

Stuart J. Pocock. The combination of randomized and historical controls in clinical trials. *Journal of Chronic Diseases*, 29(3):175–188, 1976. ISSN 0021-9681. doi: https://doi.org/10.1016/0021-9681(76)90044-8. URL https://www.sciencedirect.com/science/article/pii/0021968176900448.

Eric Polley, Erin LeDell, Chris Kennedy, Sam Lendle, and Mark J. van der Laan. Package 'superlearner', 2019.

Eric C. Polley and Mark J. Van der Laan. Super learner in prediction. 2010.

Scott Powers, Junyang Qian, Kenneth Jung, Alejandro Schuler, Nigam H. Shah, Trevor Hastie, and Robert Tibshirani. Some methods for heterogeneous treatment effect estimation in high dimensions. *Statistics in medicine*, 37(11):1767–1787, 2018.

Ross Prentice and Garnet Anderson. The women's health initiative: Lessons learned. *Annual review of public health*, 29:131–50, 02 2008. doi: 10.1146/annurev.publhealth.29.020907.090947.

Yongming Qu and Ilya Lipkovich. Propensity score estimation with missing values using a multiple imputation missingness pattern (mimp) approach. *Statistics in Medicine*, 28(9):1402–1414, 2009.

R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2020. URL https://www.R-project.org.

Mathieu Raux, Anatole Harrois, Tobias Gauss, and Sophie R. Hamada. De la nécessité de registres français en traumatologie. *Annales françaises de médecine d'urgence*, 2(3):153–155, 2012.

Danilo Jimenez Rezende, Shakir Mohamed, and Daan Wierstra. Stochastic backpropagation and approximate inference in deep generative models. In *31st International Conference on Machine Learning*, pages 1278–1286, 2014.

Todd W. Rice, Stephen Morris, Bartholomew J. Tortella, Arthur P. Wheeler, and Michael C. Christensen. Deviations from evidence-based clinical management guidelines increase mortality in critically injured trauma patients. *Critical care medicine*, 40(3):778–786, 2012.

Thomas S. Richardson and James M. Robins. Single world intervention graphs (SWIGs): A unification of the counterfactual and graphical approaches to causality. Technical report, Center for Statistics and the Social Sciences, University of Washington, 2013.

Bruno Riou, M. Thicoïpé, P. Atain-Kouadio, and P. Carli. Comment évaluer la gravité. *Le traumatisé grave*, pages 113–128, 2002.

James M. Robins. A new approach to causal inference in mortality studies with a sustained exposure period–application to control of the healthy worker survivor effect. *Mathematical Modelling*, 7:1393–1512, 1986.

James M. Robins. Marginal structural models versus structural nested models as tools for causal inference. In *Statistical Models in Epidemiology, the Environment, and Clinical Trials*, pages 95–133. Springer, New York, 2000.

James M. Robins. Semantics of causal dag models and the identification of direct and indirect effects. *Oxford Statistical Science Series*, pages 70–82, 2003.

James M. Robins and Dianne M. Finkelstein. Correcting for noncompliance and dependent censoring in an aids clinical trial with inverse probability of censoring weighted (ipcw) log-rank tests. *Biometrics*, 56(3):779–788, 2000.

James M. Robins and Sander Greenland. Identifiability and exchangeability for direct and indirect effects. *Epidemiology*, 3:143–155, 1992.

James M. Robins and Andrea Rotnitzky. Recovery of information and adjustment for dependent censoring using surrogate markers. In *AIDS epidemiology*, pages 297–331. Springer, 1992.

James M. Robins and Naisyin Wang. Inference for imputation estimators. *Biometrika*, 87(1):113–124, 2000a. doi: 10.1093/biomet/87.1.113.

James M. Robins and Naisyin Wang. Inference for imputation estimators. *Biometrika*, 87(1):113–124, 2000b. doi: 10.1093/biomet/87.1.113.

James M. Robins, Andrea Rotnitzky, and Lue P. Zhao. Estimation of regression coefficients when some regressors are not always observed. *Journal of the American Statistical Association*, 89(427):846–866, 1994. doi: 10.1080/01621459.1994.10476818.

Peter M. Robinson. Root-n-consistent semiparametric regression. *Econometrica: Journal of the Econometric Society*, pages 931–954, 1988.

Dan M. Roden. Drug-induced prolongation of the qt interval. *New England Journal of Medicine*, 350(10):1013–1022, 2004.

Paul R. Rosenbaum. Model-based direct adjustment. *Journal of the American Statistical Association*, 82(398):387–394, 1987.

Paul R. Rosenbaum. Covariance adjustment in randomized experiments and observational studies. *Statistical Science*, 17(3):286–327, 2002.

Paul R. Rosenbaum. *Sensitivity Analysis in Observational Studies*, volume 4. 2005. ISBN 9780470013199. doi: 10.1002/0470013192.bsa606.

Paul R. Rosenbaum. *Design of observational studies*, volume 10. Springer, springer series in statistics edition, 2010. ISBN 9781441912138. doi: 10.1007/978-1-4419-1213-8.

Paul R. Rosenbaum and Donald B. Rubin. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. *Journal of the Royal Statistical Society: Series B (Methodological)*, 45(2):212–218, 1983a.

Paul R. Rosenbaum and Donald B. Rubin. The central role of the propensity score in observational studies for causal effects. *Biometrika*, 70(1):41–55, 1983b. doi: 10.1093/biomet/70.1.41.

Paul R. Rosenbaum and Donald B. Rubin. Reducing bias in observational studies using subclassification on the propensity score. *Journal of the American Statistical Association*, 79(387):516–524, 1984. doi: 10.2307/2288398.

Paul R. Rosenbaum and Donald B. Rubin. The bias due to incomplete matching. *Biometrics*, 41(1):103–116, 1985. doi: 10.2307/2530647.

Eli S. Rosenberg, Elizabeth M. Dufort, Tomoko Udo, Larissa A. Wilberschied, Jessica Kumar, James Tesoriero, Patti Weinberg, James Kirkwood, Alison Muse, Jack DeHovitz, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with covid-19 in new york state. *Jama*, 323 (24):2493–2502, 2020.

Dominik Rothenhäusler, Nicolai Meinshausen, Peter Bühlmann, and Jonas Peters. Anchor regression: Heterogeneous data meet causality. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 83(2):215–246, 2021.

Kenneth J. Rothman, Sander Greenland, and Timothy L. Lash. *Modern epidemiology*. Lippincott Williams & Wilkins, 2008.

Kenneth J. Rothman, John E.J. Gallacher, and Elizabeth E. Hatch. Why representativeness should be avoided. *International Journal of Epidemiology*, 42 (4):1012–1014, 08 2013. ISSN 0300-5771. doi: 10.1093/ije/dys223. URL https://doi.org/10.1093/ije/dys223.

Peter M. Rothwell. External validity of randomised controlled trials: "to whom do the results of this trial apply?". *The Lancet*, 365:82–93, 2005.

Andrea Rotnitzky and Ezequiel Smucler. Efficient adjustment sets for population average treatment effect estimation in non-parametric causal graphical models. *arXiv preprint arXiv:1912.00306*, 2019.

Susan E. Rowell, Eric N. Meier, Barbara McKnight, Delores Kannas, Susanne May, Kellie Sheehan, Eileen M. Bulger, Ahamed H. Idris, Jim Christenson, Laurie J. Morrison, et al. Effect of out-of-hospital tranexamic acid vs placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury. *Jama*, 324(10):961–974, 2020.

Daniel Rubin and Mark J. van der Laan. A doubly robust censoring unbiased transformation. *The international journal of biostatistics*, 3(1), 2007.

Donald B. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology*, 66(5):688–701, 1974. doi: 10.1037/h0037350.

Donald B. Rubin. Inference and missing data. *Biometrika*, 63(3):581–592, 1976.

Donald B. Rubin. Multiple imputations in sample surveys-a phenomenological bayesian approach to nonresponse. In *Proceedings of the survey research methods section of the American Statistical Association*, volume 1, pages 20–34. American Statistical Association, 1978a.

Donald B. Rubin. Bayesian inference for causal effects: The role of randomization. *The Annals of statistics*, pages 34–58, 1978b. doi: 10.1214/aos/1176344064.

Donald B. Rubin. Using multivariate matched sampling and regression adjustment to control bias in observational studies. *Journal of the American Statistical Association*, 74(366a):318–328, 1979. doi: 10.1080/01621459.1979.10482513.

Donald B. Rubin. *Multlipe Imputation for Nonresponse in Surveys*, volume 81. John Wiley & Sons, Hoboken, NJ, USA, 2004. ISBN 9780471655740.

Kara E. Rudolph and Mark J. van der Laan. Robust estimation of encouragement design intervention effects transported across sites. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 79:1509–1525, 2017.

Mojdeh Saadati and Jin Tian. Adjustment criteria for recovering causal effects from missing data. In *Joint European Conference on Machine Learning and Knowledge Discovery in Databases*, pages 561–577. Springer, 2019.

Jonas E. Salk. Considerations in the preparation and use of poliomyelitis virus vaccine. *Journal of the American Medical Association*, 158(14):1239–1248, 1955.

Gilbert Saporta. *Probabilités, analyse des données et statistique*. Editions Technip, 2006.

Bradley C. Saul and Michael G. Hudgens. The calculus of m-estimation in R with geex. *Journal of Statistical Software*, 92(2):1–15, 2020. doi: 10.18637/jss.v092.i02.

Joseph L. Schafer. *Analysis of Incomplete Multivariate Data*. CRC Monographs on Statistics & Applied Probability. Chapman and Hall/CRC, Boca Raton, FL, USA, 1997. ISBN 0412040611.

Joseph L. Schafer and John W. Graham. Missing data: our view of the state of the art. *Psychological methods*, 7(2):147–177, June 2002.

Edna Schechtman. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat—which of these should we use? *Value in health*, 5(5):431–436, 2002.

Heinz Schmidli, Sandro Gsteiger, Satrajit Roychoudhury, Anthony O'Hagan, David Spiegelhalter, and Beat Neuenschwander. Robust meta-analytic-predictive priors in clinical trials with historical control information. *Biometrics*, 70(4):1023—1032, December 2014. ISSN 0006-341X. doi: 10.1111/biom.12242. URL https://doi.org/10.1111/biom.12242.

Erwan Scornet, Gérard Biau, Jean-Philippe Vert, et al. Consistency of random forests. *The Annals of Statistics*, 43(4):1716–1741, 2015.

Shaun R. Seaman and Ian R. White. Inverse probability weighting with missing predictors of treatment assignment or missingness. *Communications in Statistics-Theory and Methods*, 43(16):3499–3515, 2014. doi: 10.1080/03610926.2012.700371.

Shaun R. Seaman, John Galati, Dan Jackson, John Carlin, et al. What is meant by "missing at random"? *Statistical Science*, 28(2):257–268, 2013.

William R Shadish, Thomas D Cook, Donald Thomas Campbell, et al. *Experimental and quasi-experimental designs for generalized causal inference/William R. Shedish, Thomas D. Cook, Donald T. Campbell*. Boston: Houghton Mifflin„ 2002.

Haleema Shakur-Still, I. Roberts, R. Bautista, Jose Caballero, T. Coats, Yashbir Dewan, Hesham El-Sayed, Gogichaishvili Tamar, S. Gupta, J. Herrera, B. Hunt, P. Iribhogbe, Mario Izurieta, H. Khamis, Edward Komolafe, MA Marrero, Jorge Mejía-Mantilla, J. Jaime Miranda, Carlos Uribe, and Surakrant Yutthakasemsunt. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. *Lancet*, 376:23–32, 11 2009.

Uri Shalit, Fredrik D. Johansson, and David Sontag. Estimating individual treatment effect: generalization bounds and algorithms. In *Proceedings of the 34th International Conference on Machine Learning-Volume 70*, pages 3076–3085. JMLR. org, 2017.

Amit Sharma, Emre Kiciman, et al. DoWhy: A Python package for causal inference. https://github.com/microsoft/dowhy, 2019.

Changyu Shen, Xiaochun Li, Lingling Li, and Martin C Were. Sensitivity analysis for causal inference using inverse probability weighting. *Biometrical journal*, 53 (5):822–837, 2011.

Claudia Shi, David Blei, and Victor Veitch. Adapting neural networks for the estimation of treatment effects. In *Advances in Neural Information Processing Systems*, pages 2503–2513, 2019.

Xu Shi, Wang Miao, Jennifer C. Nelson, and Eric J. Tchetgen Tchetgen. Multiply robust causal inference with double-negative control adjustment for categorical unmeasured confounding. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 2020.

Ilya Shpitser and Judea Pearl. Identification of joint interventional distributions in recursive semi-markovian causal models. In *Proceedings of the 21st National Conference on Artificial Intelligence - Volume 2*, AAAI'06, page 1219–1226. AAAI Press, 2006. ISBN 9781577352815.

Edward H. Simpson. The interpretation of interaction in contingency tables. *Journal of the Royal Statistical Society: Series B (Methodological)*, 13(2):238–241, 1951.

Gordon C.S. Smith and Jill P. Pell. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. *Bmj*, 327(7429):1459–1461, 2003.

Peter Spirtes and Clark N. Glymour. An algorithm for fast recovery of sparse causal graphs. *Social science computer review*, 9(1):62–72, 1991.

Peter Spirtes, Clark N. Glymour, Richard Scheines, and David Heckerman. *Causation, prediction, and search*. MIT press, 2000.

Jerzy Splawa-Neyman, Dorota M Dabrowska, and TP Speed. On the application of probability theory to agricultural experiments. essay on principles. section 9. 1929.

StataCorp. *Stata Statistical Software: Release 16*. StataCorp LLC., College Station, TX, 2019.

Daniel J. Stekhoven and Peter Bühlmann. Missforest – non-parametric missing value imputation for mixed-type data. *Bioinformatics*, 28(1):112–118, 2012.

Elizabeth A. Stuart. Matching methods for causal inference: A review and a look forward. *Statistical Science*, 25:1–21, 2010.

Elizabeth A. Stuart, Stephen R. Cole, Catherine P. Bradshaw, and Philip J. Leaf. The use of propensity scores to assess the generalizability of results from randomized trials. *J. R. Statist. Soc. A*, 174:369–386, 2011.

Elizabeth A. Stuart, Catherine P Bradshaw, and Philip J Leaf. Assessing the generalizability of randomized trial results to target populations. *Prevention Science*, 16:475–485, 2015.

Elizabeth A. Stuart, Benjamin Ackerman, and Daniel Westreich. Generalizability of randomized trial results to target populations: Design and analysis possibilities. *Research on social work practice*, 28(5):532–537, 2018.

Adarsh Subbaswamy and Suchi Saria. Counterfactual normalization: Proactively addressing dataset shift and improving reliability using causal mechanisms. *arXiv preprint arXiv:1808.03253*, 2018.

Masashi Sugiyama and Motoaki Kawanabe. *Machine Learning in Non-stationary Environments: Introduction to Covariate Shift Adaptation*. MIT press, 2012.

Ryoko Susukida, Rosa Crum, Elizabeth A. Stuart, Cyrus Ebnesajjad, and Ramin Mojtabai. Assessing sample representativeness in randomized control trials: Application to the national institute of drug abuse clinical trials network. *Addiction*, 111:n/a–n/a, 01 2016. doi: 10.1111/add.13327.

Zhiqiang Tan. A distributional approach for causal inference using propensity scores. *Journal of the American Statistical Association*, 101:1619–1637, 2006.

Martin Abba Tanner and Wing Hung Wong. Data-based nonparametric estimation of the hazard function with applications to model diagnostics and exploratory analysis. *Journal of the american Statistical association*, 79(385):174–182, 1984.

Eric J. Tchetgen Tchetgen and Ilya Shpitser. Semiparametric theory for causal mediation analysis: efficiency bounds, multiple robustness, and sensitivity analysis. *Annals of statistics*, 40(3):1816, 2012.

Johannes Textor, Juliane Hardt, and Sven Knüppel. Dagitty: a graphical tool for analyzing causal diagrams. *Epidemiology*, 22(5):745, 2011.

William R. Thompson. On the likelihood that one unknown probability exceeds another in view of the evidence of two samples. *Biometrika*, 25(3/4):285–294, 1933.

Jin Tian and Judea Pearl. Probabilities of causation: Bounds and identification. *Annals of Mathematics and Artificial Intelligence*, 28(1):287–313, 2000. doi: 10.1023/A:1018912507879. URL https://doi.org/10.1023/A:1018912507879.

Lu Tian, Ash A Alizadeh, Andrew J Gentles, and Robert Tibshirani. A simple method for estimating interactions between a treatment and a large number of covariates. *Journal of the American Statistical Association*, 109(508):1517–1532, 2014.

Julie Tibshirani, Susan Athey, Rina Friedberg, Vitor Hadad, David A. Hirshberg, Luke Miner, Erik Sverdrup, Stefan Wager, and Marvin Wright. *grf: Generalized Random Forests*, 2020. URL https://github.com/grf-labs/grf. R package version 1.1.0.

Nicholas J. Tierney and Dianne H. Cook. Expanding tidy data principles to facilitate missing data exploration, visualization and assessment of imputations. *arXiv preprint arXiv:1809.02264*, 2018.

Nicholas J. Tierney, Dianne H. Cook, Miles McBain, and Colin Fay. *naniar: Data Structures, Summaries, and Visualisations for Missing Data*. URL https://github.com/njtierney/naniar. R package version 0.2.0.

Santtu Tikka and Juha Karvanen. Identifying causal effects with the R package causaleffect. *Journal of Statistical Software*, 76(12):1–30, 2017. doi: 10.18637/jss.v076.i12.

Santtu Tikka, Antti Hyttinen, and Juha Karvanen. Causal effect identification from multiple incomplete data sources: A general search-based approach. *arXiv preprint arXiv:1902.01073*, 2019.

Elizabeth Tipton. Improving generalizations from experiments using propensity score subclassification: Assumptions, properties, and contexts. *Journal of Educational and Behavioral Statistics*, 38:239–266, 2013.

Elizabeth Tipton, Kelly Hallberg, Larry Hedges, and Wendy Chan. Implications of small samples for generalization: Adjustments and rules of thumb. *Evaluation Review*, 41, 07 2016. doi: 10.1177/0193841X16655665.

Ingrid Torjesen. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, uk trial finds. *BMJ: British Medical Journal (Online)*, 369, 2020 (cited on 2020-06-16).

Traumabase Group. Traumabase, 2012, accessed on 2021-04-07. URL www.traumabase.eu.

Anastasios Tsiatis. *Semiparametric theory and missing data*. Springer Science & Business Media, 2007.

Anastasios A Tsiatis, Marie Davidian, Shannon T Holloway, and Eric B Laber. *Dynamic Treatment Regimes: Statistical Methods for Precision Medicine*. CRC press, 2019.

BETH Twala, MC Jones, and David J Hand. Good methods for coping with missing data in decision trees. *Pattern Recognition Letters*, 29(7):950–956, 2008.

Utstein TCD expert panel, K.G. Ringdal, T.J. Coats, R. Lefering, S. Di Bartolomeo, P.A. Steen, O. Røise, L. Handolin, and H.M. Lossius. The utstein template for uniform reporting of data following major trauma: a joint revision by SCANTEM,

TARN, DGU-TR and RITG. *Scand J Trauma Resusc Emerg Med*, 16(7), 08 2008. doi: 10.1186/1757-7241-16-7.

Stef van Buuren. *Flexible Imputation of Missing Data. Second Edition*. Chapman and Hall/CRC, Boca Raton, FL, 2018. URL https://stefvanbuuren.name/fimd/.

Stef van Buuren and Karin Groothuis-Oudshoorn. mice: Multivariate imputation by chained equations in r. *Journal of Statistical Software*, 45(3):1–67, 2011. URL https://www.jstatsoft.org/v45/i03/.

Sara Van de Geer, Peter Bühlmann, et al. ℓ_0-penalized maximum likelihood for sparse directed acyclic graphs. *Annals of Statistics*, 41(2):536–567, 2013.

Mark J Van der Laan and Sherri Rose. *Targeted learning: causal inference for observational and experimental data*. Springer Science & Business Media, 2011.

Mark J. Van Der Laan and Daniel Rubin. Targeted maximum likelihood learning. *The international journal of biostatistics*, 2(1), 2006.

Guido Van Rossum and Fred L. Drake. *Python 3 Reference Manual*. CreateSpace, Scotts Valley, CA, 2009. ISBN 1441412697.

Jan Vandenbroucke. The hrt controversy: Observational studies and rcts fall in line. *Lancet*, 373:1233–5, 05 2009. doi: 10.1016/S0140-6736(09)60708-X.

Tyler J. VanderWeele. Marginal structural models for the estimation of direct and indirect effects. *Epidemiology*, pages 18–26, 2009.

Stijn Vansteelandt, Maarten Bekaert, and Theis Lange. Imputation strategies for the estimation of natural direct and indirect effects. *Epidemiologic Methods*, 1(1): 131–158, 2012.

Victor Veitch and Anisha Zaveri. Sense and sensitivity analysis: Simple post-hoc analysis of bias due to unobserved confounding. *arXiv preprint arXiv:2003.01747*, 2020.

Thomas Verma and Judea Pearl. Causal networks: Semantics and expressiveness. In *Machine intelligence and pattern recognition*, volume 9, pages 69–76. Elsevier, 1990.

Jesús Villar, Carlos Ferrando, Domingo Martínez, Alfonso Ambrós, Tomás Muñoz, Juan A Soler, Gerardo Aguilar, Francisco Alba, Elena González-Higueras, Luís A Conesa, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *The Lancet Respiratory Medicine*, 8(3): 267–276, 2020.

Stefan Wager. Stats 361: Causal inference. 2020.

Stefan Wager and Susan Athey. Estimation and inference of heterogeneous treatment effects using random forests. *Journal of the American Statistical Association*, 113 (523):1228–1242, 2018.

Stefan Wager and Guenther Walther. Adaptive concentration of regression trees, with application to random forests. *arXiv preprint arXiv:1503.06388*, 2015.

Yixin Wang and David M. Blei. Towards clarifying the theory of the deconfounder.

Yixin Wang and David M. Blei. The blessings of multiple causes. *Journal of the American Statistical Association*, 114(528):1574–1596, 2019.

T Wendling, K Jung, A Callahan, A Schuler, NH Shah, and B Gallego. Comparing methods for estimation of heterogeneous treatment effects using observational data from health care databases. *Statistics in medicine*, 37(23):3309–3324, 2018.

Daniel Westreich, Jessie K. Edwards, Catherine R. Lesko, Elizabeth A. Stuart, and Stephen R. Cole. Transportability of trial results using inverse odds of sampling weights. *American journal of epidemiology*, 186(8):1010–1014, 2017.

Daniel Westreich, Jessie K Edwards, Catherine R Lesko, Stephen R Cole, and Elizabeth A Stuart. Target Validity and the Hierarchy of Study Designs. *American Journal of Epidemiology*, 188(2):438–443, 10 2018. ISSN 0002-9262. doi: 10.1093/aje/kwy228. URL https://doi.org/10.1093/aje/kwy228.

Janine Witte, Leonard Henckel, Marloes H Maathuis, and Vanessa Didelez. On efficient adjustment in causal graphs. *Journal of Machine Learning Research*, 21 (246):1–45, 2020.

Jeffrey M. Wooldridge. *Econometric analysis of cross section and panel data*. MIT press, 2010.

Yihui Xie, Alison Presmanes Hill, and Amber Thomas. *blogdown: Creating Websites with R Markdow*. The R Series. Chapman and Hall/CRC, 2017. ISBN 978-0815363729.

Steve Yadlowsky, Hongseok Namkoong, Sanjay Basu, John Duchi, and Lu Tian. Bounds on the conditional and average treatment effect with unobserved confounding factors. *arXiv preprint arXiv:1808.09521*, 2018.

Steve Yadlowsky, Fabio Pellegrini, Federica Lionetto, Stefan Braune, and Lu Tian. Estimation and validation of a class of conditional average treatment effects using observational data. *arXiv preprint arXiv:1912.06977*, 2019.

Shu Yang and Peng Ding. Combining multiple observational data sources to estimate causal effects. *Journal of the American Statistical Association*, (just-accepted): 1–46, 2019.

Shu Yang, Linbo Wang, and Peng Ding. Causal inference with confounders missing not at random. *Biometrika*, 106(4):875–888, 2019.

Shu Yang, Xiaofei Wang, and Donglin Zeng. Elastic integrative analysis of randomized trial and real-world data for treatment heterogeneity estimation. *arXiv preprint arXiv:2005.10579*, 2020a.

Shu Yang, Donglin Zeng, and Xiaofei Wang. Improved inference for heterogeneous treatment effects using real-world data subject to hidden confounding. *arXiv preprint arXiv:2007.12922*, 2020b.

Liuyi Yao, Zhixuan Chu, Sheng Li, Yaliang Li, Jing Gao, and Aidong Zhang. A survey on causal inference. *arXiv preprint arXiv:2002.02770*, 2020a.

Xueting Yao, Fei Ye, Miao Zhang, Cheng Cui, Baoying Huang, Peihua Niu, Xu Liu, Li Zhao, Erdan Dong, Chunli Song, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2). *Clinical infectious diseases*, 71 (15):732–739, 2020b.

Jinsung Yoon, James Jordon, and Mihaela van der Schaar. GANITE: Estimation of individualized treatment effects using generative adversarial nets. In *International Conference on Learning Representations*, 2018a.

Jinsung Yoon, James Jordon, and Mihaela van der Schaar. GAIN: Missing data imputation using generative adversarial nets. In J. Dy and A. Krause, editors, *Proceedings of the 35th International Conference on Machine Learning*, volume 80 of *Proceedings of Machine Learning Research*, pages 5689–5698, Stockholmsmässan, Stockholm Sweden, 2018b. PMLR. URL http://proceedings.mlr.press/v80/yoon18a.html.

Jiaxuan You, Xiaobai Ma, Daisy Yi Ding, Mykel Kochenderfer, and Jure Leskovec. Handling missing data with graph representation learning. *arXiv preprint arXiv:2010.16418*, 2020.

Baqun Zhang, Anastasios A Tsiatis, Marie Davidian, Min Zhang, and Eric Laber. Estimating optimal treatment regimes from a classification perspective. *Stat*, 1(1): 103–114, 2012.

Bo Zhang and Eric J. Tchetgen Tchetgen. A semiparametric approach to model-based sensitivity analysis in observational studies. *arXiv preprint arXiv:1910.14130*, 2019.

Qingyuan Zhao, Dylan S Small, and Bhaswar B Bhattacharya. Sensitivity analysis for inverse probability weighting estimators via the percentile bootstrap. *arXiv preprint arXiv:1711.11286*, 2017.

Ying-Qi Zhao, Donglin Zeng, A. John Rush, and Michael R. Kosorok. Estimating individualized treatment rules using outcome weighted learning. *Journal of the American Statistical Association*, 107(499):1106–1118, 2012.

Ying-Qi Zhao, Donglin Zeng, Eric B. Laber, Rui Song, Ming Yuan, and Michael R. Kosorok. Doubly robust learning for estimating individualized treatment with censored data. *Biometrika*, 102(1):151–168, 2015.

Wenjing Zheng and Mark J. van der Laan. Cross-validated targeted minimum-loss-based estimation. In *Targeted Learning*, pages 459–474. Springer, 2011.

Ziwei Zhu, Tengyao Wang, and Richard J Samworth. High-dimensional principal component analysis with heterogeneous missingness. *arXiv preprint arXiv:1906.12125*, 2019.

Corwin Matthew Zigler. The central role of Bayes' theorem for joint estimation of causal effects and propensity scores. *The American Statistician*, 70(1):47–54, 2016.

José R. Zubizarreta. Using mixed integer programming for matching in an observational study of kidney failure after surgery. *Journal of the American Statistical Association*, 107(500):1360–1371, 2012.

José R. Zubizarreta. Stable weights that balance covariates for estimation with incomplete outcome data. *Journal of the American Statistical Association*, 110 (511):910–922, 2015. doi: 10.1080/01621459.2015.1023805.